0000917520-23-000015.txt : 20230222 0000917520-23-000015.hdr.sgml : 20230222 20230222161243 ACCESSION NUMBER: 0000917520-23-000015 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 130 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230222 DATE AS OF CHANGE: 20230222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTEGRA LIFESCIENCES HOLDINGS CORP CENTRAL INDEX KEY: 0000917520 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 510317849 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26224 FILM NUMBER: 23653241 BUSINESS ADDRESS: STREET 1: 1100 CAMPUS ROAD CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 6092750500 MAIL ADDRESS: STREET 1: 1100 CAMPUS ROAD CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: INTEGRA LIFESCIENCES CORP DATE OF NAME CHANGE: 19950614 10-K 1 iart-20221231.htm 10-K iart-20221231
false2022FY0000917520http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201613Memberhttp://integralife.com/20221231#AccountingStandardUpdate202006MemberP1YP1YP1YP1YP1YP1Y0.0135739P6YP10Y——————00009175202022-01-012022-12-3100009175202022-06-30iso4217:USD00009175202023-02-21xbrli:shares00009175202021-01-012021-12-3100009175202020-01-012020-12-31iso4217:USDxbrli:shares00009175202022-12-3100009175202021-12-3100009175202020-12-3100009175202019-12-310000917520us-gaap:CommonStockMember2019-12-310000917520us-gaap:TreasuryStockMember2019-12-310000917520us-gaap:AdditionalPaidInCapitalMember2019-12-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000917520us-gaap:RetainedEarningsMember2019-12-310000917520us-gaap:RetainedEarningsMember2020-01-012020-12-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310000917520us-gaap:CommonStockMember2020-01-012020-12-310000917520us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310000917520us-gaap:TreasuryStockMember2020-01-012020-12-3100009175202019-01-012019-12-310000917520us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310000917520srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310000917520us-gaap:CommonStockMember2020-12-310000917520us-gaap:TreasuryStockMember2020-12-310000917520us-gaap:AdditionalPaidInCapitalMember2020-12-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000917520us-gaap:RetainedEarningsMember2020-12-310000917520us-gaap:RetainedEarningsMember2021-01-012021-12-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310000917520us-gaap:CommonStockMember2021-01-012021-12-310000917520us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310000917520us-gaap:TreasuryStockMember2021-01-012021-12-310000917520us-gaap:AdditionalPaidInCapitalMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-12-310000917520us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-12-310000917520srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2020-12-310000917520us-gaap:CommonStockMember2021-12-310000917520us-gaap:TreasuryStockMember2021-12-310000917520us-gaap:AdditionalPaidInCapitalMember2021-12-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000917520us-gaap:RetainedEarningsMember2021-12-310000917520us-gaap:RetainedEarningsMember2022-01-012022-12-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000917520us-gaap:CommonStockMember2022-01-012022-12-310000917520us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310000917520us-gaap:TreasuryStockMember2022-01-012022-12-310000917520us-gaap:CommonStockMember2022-12-310000917520us-gaap:TreasuryStockMember2022-12-310000917520us-gaap:AdditionalPaidInCapitalMember2022-12-310000917520us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000917520us-gaap:RetainedEarningsMember2022-12-310000917520us-gaap:AllowanceForCreditLossMember2021-12-310000917520us-gaap:AllowanceForCreditLossMember2022-01-012022-12-310000917520us-gaap:AllowanceForCreditLossMember2022-12-310000917520us-gaap:AllowanceForCreditLossMember2020-12-310000917520us-gaap:AllowanceForCreditLossMember2021-01-012021-12-310000917520us-gaap:AllowanceForCreditLossMember2019-12-310000917520us-gaap:AllowanceForCreditLossMember2020-01-012020-12-310000917520us-gaap:LandMember2022-12-310000917520us-gaap:LandMember2021-12-310000917520us-gaap:BuildingAndBuildingImprovementsMember2022-12-310000917520us-gaap:BuildingAndBuildingImprovementsMember2021-12-310000917520srt:MinimumMemberus-gaap:BuildingAndBuildingImprovementsMember2022-01-012022-12-310000917520us-gaap:BuildingAndBuildingImprovementsMembersrt:MaximumMember2022-01-012022-12-310000917520us-gaap:LeaseholdImprovementsMember2022-12-310000917520us-gaap:LeaseholdImprovementsMember2021-12-310000917520srt:MinimumMemberus-gaap:LeaseholdImprovementsMember2022-01-012022-12-310000917520us-gaap:LeaseholdImprovementsMembersrt:MaximumMember2022-01-012022-12-310000917520us-gaap:MachineryAndEquipmentMember2022-12-310000917520us-gaap:MachineryAndEquipmentMember2021-12-310000917520srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2022-01-012022-12-310000917520srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2022-01-012022-12-310000917520iart:DemonstrationEquipmentMember2022-12-310000917520iart:DemonstrationEquipmentMember2021-12-310000917520srt:MinimumMemberiart:DemonstrationEquipmentMember2022-01-012022-12-310000917520iart:DemonstrationEquipmentMembersrt:MaximumMember2022-01-012022-12-310000917520iart:InformationSystemsandHardwareMember2022-12-310000917520iart:InformationSystemsandHardwareMember2021-12-310000917520iart:InformationSystemsandHardwareMembersrt:MinimumMember2022-01-012022-12-310000917520iart:InformationSystemsandHardwareMembersrt:MaximumMember2022-01-012022-12-310000917520us-gaap:FurnitureAndFixturesMember2022-12-310000917520us-gaap:FurnitureAndFixturesMember2021-12-310000917520srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2022-01-012022-12-310000917520us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2022-01-012022-12-310000917520us-gaap:ConstructionInProgressMember2022-12-310000917520us-gaap:ConstructionInProgressMember2021-12-31iart:Segmentiart:reporting_unit0000917520srt:MinimumMember2022-01-012022-12-310000917520srt:MaximumMember2022-01-012022-12-310000917520us-gaap:CostOfSalesMember2022-01-012022-12-310000917520us-gaap:CostOfSalesMember2021-01-012021-12-310000917520us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310000917520us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310000917520us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-310000917520us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-310000917520iart:ClosureOfFacilityMember2022-12-310000917520iart:ReorganizationProjectsMember2022-12-310000917520iart:ClosureOfFacilityMember2021-12-31xbrli:pure0000917520us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-12-31iart:Customer0000917520us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-12-310000917520us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-12-310000917520iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember2020-02-040000917520us-gaap:ConvertibleDebtMemberiart:TwoThousandTwentyFiveSeniorConvertibleNotesMember2020-02-040000917520iart:CumulativeEffectPeriodOfAdoptionAdjustmentDebtDiscountReclassificationMember2020-12-310000917520iart:CumulativeEffectPeriodOfAdoptionAdjustmentDebtDiscountAmortizationAndEquityCostsReclassificationMember2020-12-310000917520iart:ReboundTherapeuticsCorporationMember2021-12-310000917520iart:ReboundTherapeuticsCorporationMember2020-12-3100009175202023-01-012022-12-3100009175202024-01-012022-12-3100009175202025-01-012022-12-3100009175202026-01-012022-12-3100009175202027-01-012022-12-3100009175202028-01-012022-12-310000917520iart:CodmanSpecialtySurgicalMemberiart:NeurosurgeryMember2022-01-012022-12-310000917520iart:CodmanSpecialtySurgicalMemberiart:NeurosurgeryMember2021-01-012021-12-310000917520iart:CodmanSpecialtySurgicalMemberiart:NeurosurgeryMember2020-01-012020-12-310000917520iart:InstrumentsMemberiart:CodmanSpecialtySurgicalMember2022-01-012022-12-310000917520iart:InstrumentsMemberiart:CodmanSpecialtySurgicalMember2021-01-012021-12-310000917520iart:InstrumentsMemberiart:CodmanSpecialtySurgicalMember2020-01-012020-12-310000917520iart:CodmanSpecialtySurgicalMember2022-01-012022-12-310000917520iart:CodmanSpecialtySurgicalMember2021-01-012021-12-310000917520iart:CodmanSpecialtySurgicalMember2020-01-012020-12-310000917520iart:RegenerativeSkinAndWoundMemberiart:TissueTechnologiesMember2022-01-012022-12-310000917520iart:RegenerativeSkinAndWoundMemberiart:TissueTechnologiesMember2021-01-012021-12-310000917520iart:RegenerativeSkinAndWoundMemberiart:TissueTechnologiesMember2020-01-012020-12-310000917520iart:TissueTechnologiesMemberiart:ExtremityOrthopedicsMember2022-01-012022-12-310000917520iart:TissueTechnologiesMemberiart:ExtremityOrthopedicsMember2021-01-012021-12-310000917520iart:TissueTechnologiesMemberiart:ExtremityOrthopedicsMember2020-01-012020-12-310000917520iart:PrivateLabelMemberiart:TissueTechnologiesMember2022-01-012022-12-310000917520iart:PrivateLabelMemberiart:TissueTechnologiesMember2021-01-012021-12-310000917520iart:PrivateLabelMemberiart:TissueTechnologiesMember2020-01-012020-12-310000917520iart:TissueTechnologiesMember2022-01-012022-12-310000917520iart:TissueTechnologiesMember2021-01-012021-12-310000917520iart:TissueTechnologiesMember2020-01-012020-12-310000917520iart:SurgicalInnovationAssociatesIncMember2022-12-062022-12-060000917520iart:SurgicalInnovationAssociatesIncMemberiart:RevenueBasedPerformanceMilestonesMember2022-12-060000917520iart:SurgicalInnovationAssociatesIncMemberiart:FDAApprovalOfPremarketApprovalMember2022-12-060000917520iart:SurgicalInnovationAssociatesIncMember2022-12-06iart:contingentLiability0000917520us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberiart:TraditionalWoundCareMember2022-08-310000917520us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberiart:TraditionalWoundCareMember2022-08-312022-08-310000917520us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberiart:TraditionalWoundCareMember2022-01-012022-12-310000917520us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberiart:TraditionalWoundCareMember2022-12-310000917520us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberiart:ExtremityOrthopedicsMember2021-01-040000917520us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberiart:ExtremityOrthopedicsMemberiart:ConsortiumofFocusedOrthopedistsLLCMember2021-01-042021-01-040000917520us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberiart:ExtremityOrthopedicsMember2020-12-310000917520us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberiart:ExtremityOrthopedicsMember2021-01-012021-12-310000917520us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberiart:ExtremityOrthopedicsMember2022-12-310000917520iart:ACellIncMember2021-01-202021-01-200000917520iart:ACellIncMember2021-01-200000917520iart:ACellIncMember2021-06-300000917520srt:MinimumMemberiart:ACellIncMember2021-01-202021-01-200000917520srt:MaximumMemberiart:ACellIncMember2021-01-202021-01-200000917520iart:ACellIncMember2022-12-310000917520iart:ACellIncMember2021-12-310000917520iart:SeniorCreditFacilityMember2020-02-030000917520iart:TermLoanFacilityMemberus-gaap:SecuredDebtMember2020-02-030000917520us-gaap:RevolvingCreditFacilityMember2020-02-030000917520us-gaap:StandbyLettersOfCreditMember2020-02-030000917520iart:SwinglineLoanMember2020-02-030000917520iart:DebtCovenantPeriod3Memberiart:SeniorCreditFacilityMember2020-07-140000917520iart:DebtCovenantPeriod4Memberiart:SeniorCreditFacilityMember2020-07-140000917520us-gaap:EurodollarMembersrt:MinimumMemberiart:SeniorCreditFacilityMember2022-01-012022-12-310000917520us-gaap:EurodollarMembersrt:MaximumMemberiart:SeniorCreditFacilityMember2022-01-012022-12-310000917520us-gaap:FederalFundsEffectiveSwapRateMemberiart:SeniorCreditFacilityMember2022-01-012022-12-310000917520iart:OneMonthEurodollarRateMemberiart:SeniorCreditFacilityMember2022-01-012022-12-310000917520srt:MinimumMemberiart:SeniorCreditFacilityMember2022-01-012022-12-310000917520iart:SeniorCreditFacilityMembersrt:MaximumMember2022-01-012022-12-310000917520iart:SeniorCreditFacilityMember2020-01-012020-03-310000917520iart:SeniorCreditFacilityMember2020-07-012020-09-300000917520us-gaap:RevolvingCreditFacilityMember2022-12-310000917520us-gaap:RevolvingCreditFacilityMember2021-12-310000917520iart:TermLoanFacilityMemberus-gaap:SecuredDebtMember2022-12-310000917520iart:TermLoanFacilityMemberus-gaap:SecuredDebtMember2021-12-310000917520us-gaap:FairValueInputsLevel2Memberiart:TermLoanFacilityMemberus-gaap:SecuredDebtMember2022-12-310000917520us-gaap:StandbyLettersOfCreditMemberiart:SeniorCreditFacilityMember2021-12-310000917520us-gaap:StandbyLettersOfCreditMemberiart:SeniorCreditFacilityMember2022-12-310000917520us-gaap:ConvertibleDebtMemberiart:TwoThousandTwentyFiveSeniorConvertibleNotesMember2020-02-042020-02-040000917520us-gaap:ConvertibleDebtMemberiart:TwoThousandTwentyFiveSeniorConvertibleNotesMember2020-12-090000917520us-gaap:CallOptionMemberus-gaap:ConvertibleDebtMemberiart:TwoThousandTwentyFiveSeniorConvertibleNotesMember2020-02-042020-02-040000917520us-gaap:ConvertibleDebtMemberiart:TwoThousandTwentyFiveSeniorConvertibleNotesMember2022-12-310000917520us-gaap:ConvertibleDebtMemberiart:TwoThousandTwentyFiveSeniorConvertibleNotesMember2021-01-012021-12-310000917520us-gaap:ConvertibleDebtMemberiart:TwoThousandTwentyFiveSeniorConvertibleNotesMember2022-01-012022-12-310000917520us-gaap:FairValueInputsLevel2Member2022-12-310000917520us-gaap:CashFlowHedgingMemberiart:OneMonthUSDLIBORMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:InterestRateSwapDesignatedDecember132017Tranche1Member2022-12-310000917520us-gaap:CashFlowHedgingMemberiart:OneMonthUSDLIBORMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:InterestRateSwapDesignatedDecember132017Tranche1Member2021-12-310000917520us-gaap:CashFlowHedgingMemberiart:OneMonthUSDLIBORMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:InterestRateSwapDesignatedDecember132017Tranche2Member2022-12-310000917520us-gaap:CashFlowHedgingMemberiart:OneMonthUSDLIBORMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:InterestRateSwapDesignatedDecember132017Tranche2Member2021-12-310000917520us-gaap:CashFlowHedgingMemberiart:OneMonthUSDLIBORMemberiart:InterestRateSwapDesignatedDecember132017Tranche3Memberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000917520us-gaap:CashFlowHedgingMemberiart:OneMonthUSDLIBORMemberiart:InterestRateSwapDesignatedDecember132017Tranche3Memberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000917520iart:InterestRateSwapDesignatedOctober102018Tranche1Memberus-gaap:CashFlowHedgingMemberiart:OneMonthUSDLIBORMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000917520iart:InterestRateSwapDesignatedOctober102018Tranche1Memberus-gaap:CashFlowHedgingMemberiart:OneMonthUSDLIBORMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000917520us-gaap:CashFlowHedgingMemberiart:OneMonthUSDLIBORMemberiart:InterestRateSwapDesignatedOctober102018Tranche2Memberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000917520us-gaap:CashFlowHedgingMemberiart:OneMonthUSDLIBORMemberiart:InterestRateSwapDesignatedOctober102018Tranche2Memberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000917520us-gaap:CashFlowHedgingMemberiart:OneMonthUSDLIBORMemberiart:InterestRateSwapDesignatedOctober102018Tranche3Memberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000917520us-gaap:CashFlowHedgingMemberiart:OneMonthUSDLIBORMemberiart:InterestRateSwapDesignatedOctober102018Tranche3Memberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000917520us-gaap:CashFlowHedgingMemberiart:OneMonthUSDLIBORMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:InterestRateSwapDesignatedDecember182018Tranche1Member2022-12-310000917520us-gaap:CashFlowHedgingMemberiart:OneMonthUSDLIBORMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:InterestRateSwapDesignatedDecember182018Tranche1Member2021-12-310000917520us-gaap:CashFlowHedgingMemberiart:OneMonthUSDLIBORMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:InterestRateSwapDesignatedDecember182018Tranche2Member2022-12-310000917520us-gaap:CashFlowHedgingMemberiart:OneMonthUSDLIBORMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:InterestRateSwapDesignatedDecember182018Tranche2Member2021-12-310000917520us-gaap:CashFlowHedgingMemberiart:OneMonthUSDLIBORMemberiart:InterestRateSwapDesignatedDecember152020Tranche1Memberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000917520us-gaap:CashFlowHedgingMemberiart:OneMonthUSDLIBORMemberiart:InterestRateSwapDesignatedDecember152020Tranche1Memberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000917520us-gaap:CashFlowHedgingMemberiart:OneMonthUSDLIBORMemberiart:InterestRateSwapDesignatedDecember152020Tranche2Memberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000917520us-gaap:CashFlowHedgingMemberiart:OneMonthUSDLIBORMemberiart:InterestRateSwapDesignatedDecember152020Tranche2Memberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000917520us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:ShortMember2017-10-020000917520us-gaap:LongMemberus-gaap:CrossCurrencyInterestRateContractMember2017-10-02iso4217:CHF0000917520iart:CodmanMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:ShortMember2022-09-260000917520iart:CodmanMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:ShortMember2022-12-310000917520us-gaap:CrossCurrencyInterestRateContractMember2020-12-210000917520us-gaap:CrossCurrencyInterestRateContractMember2022-01-012022-12-310000917520us-gaap:LongMemberus-gaap:CashFlowHedgingMemberiart:CrossCurrencyInterestRateSwapContractTwoMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000917520us-gaap:LongMemberus-gaap:CashFlowHedgingMemberiart:CrossCurrencyInterestRateSwapContractTwoMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000917520us-gaap:CashFlowHedgingMemberiart:CrossCurrencyInterestRateSwapContractTwoMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000917520us-gaap:CashFlowHedgingMemberiart:CrossCurrencyInterestRateSwapContractTwoMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000917520us-gaap:CashFlowHedgingMemberiart:CrossCurrencyInterestRateSwapContractTwoMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ShortMember2022-12-310000917520us-gaap:CashFlowHedgingMemberiart:CrossCurrencyInterestRateSwapContractTwoMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ShortMember2021-12-310000917520us-gaap:LongMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateSwapContractThreeMember2022-12-310000917520us-gaap:LongMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateSwapContractThreeMember2021-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateSwapContractThreeMember2022-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateSwapContractThreeMember2021-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ShortMemberiart:CrossCurrencyInterestRateSwapContractThreeMember2022-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ShortMemberiart:CrossCurrencyInterestRateSwapContractThreeMember2021-12-310000917520us-gaap:LongMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateSwapContractOneMember2022-12-310000917520us-gaap:LongMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateSwapContractOneMember2021-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateSwapContractOneMember2022-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateSwapContractOneMember2021-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ShortMemberiart:CrossCurrencyInterestRateSwapContractOneMember2022-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ShortMemberiart:CrossCurrencyInterestRateSwapContractOneMember2021-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2022-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2021-12-310000917520iart:CodmanMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:ShortMember2022-10-030000917520us-gaap:CrossCurrencyInterestRateContractMember2022-10-032022-10-030000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2021-10-040000917520us-gaap:LongMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateContractOneMember2022-12-31iso4217:EUR0000917520us-gaap:LongMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateContractOneMember2021-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateContractOneMember2022-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateContractOneMember2021-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ShortMemberiart:CrossCurrencyInterestRateContractOneMember2022-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ShortMemberiart:CrossCurrencyInterestRateContractOneMember2021-12-310000917520us-gaap:LongMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateContractTwoMember2022-12-310000917520us-gaap:LongMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateContractTwoMember2021-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateContractTwoMember2022-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateContractTwoMember2021-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateContractTwoMemberus-gaap:ShortMember2022-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateContractTwoMemberus-gaap:ShortMember2021-12-310000917520us-gaap:LongMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateContractThreeMember2022-12-310000917520us-gaap:LongMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateContractThreeMember2021-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateContractThreeMember2022-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateContractThreeMember2021-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateContractThreeMemberus-gaap:ShortMember2022-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberiart:CrossCurrencyInterestRateContractThreeMemberus-gaap:ShortMember2021-12-310000917520us-gaap:LongMemberiart:CrossCurrencyInterestRateContractFourMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000917520us-gaap:LongMemberiart:CrossCurrencyInterestRateContractFourMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000917520iart:CrossCurrencyInterestRateContractFourMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000917520iart:CrossCurrencyInterestRateContractFourMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000917520iart:CrossCurrencyInterestRateContractFourMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ShortMember2022-12-310000917520iart:CrossCurrencyInterestRateContractFourMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ShortMember2021-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2022-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2021-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2022-05-260000917520us-gaap:CrossCurrencyInterestRateContractMember2022-05-262022-05-260000917520us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2022-05-260000917520us-gaap:NetInvestmentHedgingMemberus-gaap:CrossCurrencyInterestRateContractMember2021-09-300000917520us-gaap:NetInvestmentHedgingMemberus-gaap:CrossCurrencyInterestRateContractMember2021-09-302021-09-300000917520us-gaap:CashFlowHedgingMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2022-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2021-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-12-310000917520us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2022-12-310000917520us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2021-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:OtherAssetsMember2022-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:OtherAssetsMember2021-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:OtherAssetsMember2022-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:OtherAssetsMember2021-12-310000917520us-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000917520us-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000917520us-gaap:CashFlowHedgingMemberiart:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-12-310000917520us-gaap:CashFlowHedgingMemberiart:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-12-310000917520us-gaap:CashFlowHedgingMemberiart:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2022-12-310000917520us-gaap:CashFlowHedgingMemberiart:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2021-12-310000917520iart:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2022-12-310000917520iart:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2021-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:OtherLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:OtherLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:OtherLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2022-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:OtherLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2021-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:OtherLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2022-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:OtherLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2021-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2022-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2021-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2021-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2022-01-012022-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2022-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-01-012022-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:InterestIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2021-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:InterestIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2022-01-012022-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:InterestIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2022-12-310000917520us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000917520us-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-12-310000917520us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2020-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:InterestExpenseMember2021-01-012021-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:OtherNonoperatingIncomeExpenseMember2020-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-01-012021-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:InterestIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2020-12-310000917520us-gaap:NetInvestmentHedgingMemberus-gaap:InterestIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2021-01-012021-12-310000917520us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000917520us-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2022-01-012022-12-310000917520us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CrossCurrencyInterestRateContractMember2021-01-012021-12-310000917520us-gaap:CrossCurrencyInterestRateContractMember2021-01-012021-12-310000917520us-gaap:CrossCurrencyInterestRateContractMember2022-12-310000917520us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2020-12-310000917520us-gaap:NondesignatedMemberus-gaap:CurrencySwapMember2021-06-300000917520us-gaap:NondesignatedMemberus-gaap:CurrencySwapMember2021-09-300000917520us-gaap:ForeignExchangeForwardMember2022-01-012022-12-310000917520us-gaap:ForeignExchangeForwardMember2021-01-012021-12-310000917520us-gaap:CurrencySwapMember2022-01-012022-12-310000917520us-gaap:CurrencySwapMember2021-01-012021-12-310000917520iart:CodmanSpecialtySurgicalMember2020-12-310000917520iart:TissueTechnologiesMember2020-12-310000917520iart:CodmanSpecialtySurgicalMemberiart:ACellIncMember2021-01-012021-12-310000917520iart:TissueTechnologiesMemberiart:ACellIncMember2021-01-012021-12-310000917520iart:ACellIncMember2021-01-012021-12-310000917520iart:CodmanSpecialtySurgicalMember2021-12-310000917520iart:TissueTechnologiesMember2021-12-310000917520iart:CodmanSpecialtySurgicalMemberiart:SurgicalInnovationAssociatesIncMember2022-01-012022-12-310000917520iart:SurgicalInnovationAssociatesIncMemberiart:TissueTechnologiesMember2022-01-012022-12-310000917520iart:SurgicalInnovationAssociatesIncMember2022-01-012022-12-310000917520iart:CodmanSpecialtySurgicalMember2022-12-310000917520iart:TissueTechnologiesMember2022-12-310000917520iart:CompletedTechnologyMember2022-01-012022-12-310000917520iart:CompletedTechnologyMember2022-12-310000917520us-gaap:CustomerRelationshipsMember2022-01-012022-12-310000917520us-gaap:CustomerRelationshipsMember2022-12-310000917520iart:TrademarksBrandNamesMember2022-01-012022-12-310000917520iart:TrademarksBrandNamesMember2022-12-310000917520us-gaap:TradeNamesMember2022-12-310000917520iart:SupplierRelationShipsMember2022-01-012022-12-310000917520iart:SupplierRelationShipsMember2022-12-310000917520iart:AllOtherMember2022-01-012022-12-310000917520iart:AllOtherMember2022-12-310000917520iart:CompletedTechnologyMember2021-01-012021-12-310000917520iart:CompletedTechnologyMember2021-12-310000917520us-gaap:CustomerRelationshipsMember2021-01-012021-12-310000917520us-gaap:CustomerRelationshipsMember2021-12-310000917520iart:TrademarksBrandNamesMember2021-01-012021-12-310000917520iart:TrademarksBrandNamesMember2021-12-310000917520us-gaap:TradeNamesMember2021-12-310000917520iart:SupplierRelationShipsMember2021-01-012021-12-310000917520iart:SupplierRelationShipsMember2021-12-310000917520iart:AllOtherMember2021-01-012021-12-310000917520iart:AllOtherMember2021-12-310000917520us-gaap:SubsequentEventMember2023-01-260000917520us-gaap:SubsequentEventMember2023-01-262023-01-2600009175202022-04-2600009175202022-01-1200009175202022-01-122022-01-1200009175202022-03-240000917520us-gaap:CostOfSalesMember2020-01-012020-12-310000917520us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310000917520us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-310000917520us-gaap:EmployeeStockMember2022-12-310000917520us-gaap:EmployeeStockMember2022-01-012022-12-310000917520us-gaap:EmployeeStockMember2021-01-012021-12-310000917520us-gaap:EmployeeStockMember2020-01-012020-12-310000917520iart:TwoThousandThreePlanMember2010-05-012010-05-310000917520iart:TwoThousandThreePlanMember2017-05-012017-05-310000917520iart:TwoThousandOnePlanMember2022-12-310000917520iart:TwoThousandPlanMember2022-12-310000917520iart:TwoThousandThreePlanMember2022-12-310000917520us-gaap:EmployeeStockOptionMember2022-01-012022-12-310000917520srt:DirectorMemberus-gaap:EmployeeStockOptionMember2022-01-012022-12-310000917520us-gaap:EmployeeStockOptionMemberiart:EmployeeMember2022-01-012022-12-310000917520iart:DirectorsandCertainExecutiveOfficersMembersrt:MinimumMemberus-gaap:EmployeeStockOptionMember2022-01-012022-12-310000917520iart:DirectorsandCertainExecutiveOfficersMemberus-gaap:EmployeeStockOptionMembersrt:MaximumMember2022-01-012022-12-310000917520us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310000917520us-gaap:EmployeeStockOptionMember2021-01-012021-12-310000917520us-gaap:EmployeeStockOptionMember2020-01-012020-12-310000917520us-gaap:EmployeeStockOptionMember2022-12-310000917520us-gaap:RestrictedStockMember2021-12-310000917520iart:PerformanceStockandContractStockMember2021-12-310000917520us-gaap:RestrictedStockMember2022-01-012022-12-310000917520iart:PerformanceStockandContractStockMember2022-01-012022-12-310000917520us-gaap:RestrictedStockMember2022-12-310000917520iart:PerformanceStockandContractStockMember2022-12-310000917520iart:RestrictedStockPerformanceStockAndContractStockMember2022-01-012022-12-310000917520iart:RestrictedStockPerformanceStockAndContractStockMember2021-01-012021-12-310000917520iart:RestrictedStockPerformanceStockAndContractStockMember2020-01-012020-12-310000917520us-gaap:PerformanceSharesMember2022-12-310000917520iart:RestrictedStockPerformanceStockAndContractStockMember2022-12-310000917520country:FR2022-12-310000917520country:DE2022-12-3100009175202019-05-012019-05-31iart:renewal_option0000917520srt:AffiliatedEntityMember2021-01-012021-12-310000917520srt:AffiliatedEntityMember2022-01-012022-12-310000917520us-gaap:BuildingMember2022-12-310000917520us-gaap:BuildingMember2021-12-310000917520us-gaap:VehiclesMember2022-12-310000917520us-gaap:VehiclesMember2021-12-310000917520iart:RelatedPartiesMember2022-12-310000917520iart:ThirdPartiesMember2022-12-310000917520srt:AffiliatedEntityMemberiart:FiveYearOptionLeasePeriodOneMember2022-01-012022-12-310000917520iart:FiveYearLeasePeriodTwoMembersrt:AffiliatedEntityMember2022-01-012022-12-310000917520iart:ExtremityOrthopedicsMember2021-01-012021-12-310000917520us-gaap:SwissFederalTaxAdministrationFTAMemberus-gaap:ForeignCountryMember2020-12-012020-12-310000917520us-gaap:DomesticCountryMember2022-12-310000917520us-gaap:ForeignCountryMember2022-12-310000917520us-gaap:StateAndLocalJurisdictionMember2022-12-310000917520us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2021-12-310000917520us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2021-01-012021-12-310000917520us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2022-12-310000917520us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2020-12-310000917520us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2020-01-012020-12-310000917520us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2019-12-310000917520us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2019-01-012019-12-310000917520us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000917520us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310000917520us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000917520us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-12-310000917520us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-12-310000917520us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-12-310000917520us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000917520us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000917520us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000917520us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-12-310000917520us-gaap:OtherCurrentLiabilitiesMemberiart:ArkisBioSciencesInc.Memberiart:ContingentConsiderationLiabilityMemberus-gaap:FairValueInputsLevel3Member2021-12-310000917520iart:ArkisBioSciencesInc.Memberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310000917520iart:ContingentConsiderationLiabilityMemberiart:DermaSciencesMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310000917520us-gaap:OtherCurrentLiabilitiesMemberiart:ContingentConsiderationLiabilityMemberiart:ACellMemberus-gaap:FairValueInputsLevel3Member2021-12-310000917520iart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMemberiart:ACellMemberus-gaap:FairValueInputsLevel3Member2021-12-310000917520iart:SurgicalInnovationAssociatesIncMemberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310000917520us-gaap:OtherCurrentLiabilitiesMemberiart:ArkisBioSciencesInc.Memberiart:ContingentConsiderationLiabilityMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-12-310000917520iart:ArkisBioSciencesInc.Memberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-12-310000917520iart:ContingentConsiderationLiabilityMemberiart:DermaSciencesMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-12-310000917520us-gaap:OtherCurrentLiabilitiesMemberiart:ContingentConsiderationLiabilityMemberiart:ACellMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-12-310000917520iart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMemberiart:ACellMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-12-310000917520iart:SurgicalInnovationAssociatesIncMemberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-12-310000917520us-gaap:OtherCurrentLiabilitiesMemberiart:ArkisBioSciencesInc.Memberiart:ContingentConsiderationLiabilityMemberus-gaap:FairValueInputsLevel3Member2022-12-310000917520iart:ArkisBioSciencesInc.Memberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310000917520iart:ContingentConsiderationLiabilityMemberiart:DermaSciencesMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310000917520us-gaap:OtherCurrentLiabilitiesMemberiart:ContingentConsiderationLiabilityMemberiart:ACellMemberus-gaap:FairValueInputsLevel3Member2022-12-310000917520iart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMemberiart:ACellMemberus-gaap:FairValueInputsLevel3Member2022-12-310000917520iart:SurgicalInnovationAssociatesIncMemberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310000917520us-gaap:OtherCurrentLiabilitiesMemberiart:ArkisBioSciencesInc.Memberiart:ContingentConsiderationLiabilityMemberus-gaap:FairValueInputsLevel3Member2020-12-310000917520iart:ArkisBioSciencesInc.Memberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2020-12-310000917520iart:ContingentConsiderationLiabilityMemberiart:DermaSciencesMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2020-12-310000917520iart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMemberiart:ACellMemberus-gaap:FairValueInputsLevel3Member2020-12-310000917520us-gaap:OtherCurrentLiabilitiesMemberiart:ArkisBioSciencesInc.Memberiart:ContingentConsiderationLiabilityMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-12-310000917520iart:ArkisBioSciencesInc.Memberiart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-12-310000917520iart:ContingentConsiderationLiabilityMemberiart:DermaSciencesMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-12-310000917520iart:ContingentConsiderationLiabilityMemberus-gaap:OtherNoncurrentLiabilitiesMemberiart:ACellMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-12-310000917520iart:DermaSciencesMemberiart:BioDEarnoutPaymentsandMedihoneyEarnoutPaymentsMember2022-01-012022-12-310000917520iart:DermaSciencesMember2022-12-31iart:liability0000917520iart:DermaSciencesMemberus-gaap:FairValueInputsLevel3Member2022-12-310000917520iart:DermaSciencesMemberus-gaap:FairValueInputsLevel3Member2021-12-310000917520iart:ArkisBioSciencesInc.Member2019-07-290000917520iart:ArkisBioSciencesInc.Memberiart:MilestonePaymentOneMember2019-07-290000917520iart:ArkisBioSciencesInc.Memberiart:MilestonePaymentTwoMember2019-07-290000917520iart:ArkisBioSciencesInc.Member2022-12-31iart:product0000917520us-gaap:OperatingSegmentsMemberiart:CodmanSpecialtySurgicalMember2022-01-012022-12-310000917520us-gaap:OperatingSegmentsMemberiart:CodmanSpecialtySurgicalMember2021-01-012021-12-310000917520us-gaap:OperatingSegmentsMemberiart:CodmanSpecialtySurgicalMember2020-01-012020-12-310000917520us-gaap:OperatingSegmentsMemberiart:TissueTechnologiesMember2022-01-012022-12-310000917520us-gaap:OperatingSegmentsMemberiart:TissueTechnologiesMember2021-01-012021-12-310000917520us-gaap:OperatingSegmentsMemberiart:TissueTechnologiesMember2020-01-012020-12-310000917520us-gaap:OperatingSegmentsMember2022-01-012022-12-310000917520us-gaap:OperatingSegmentsMember2021-01-012021-12-310000917520us-gaap:OperatingSegmentsMember2020-01-012020-12-310000917520us-gaap:CorporateNonSegmentMember2022-01-012022-12-310000917520us-gaap:CorporateNonSegmentMember2021-01-012021-12-310000917520us-gaap:CorporateNonSegmentMember2020-01-012020-12-310000917520country:US2022-01-012022-12-310000917520srt:EuropeMember2022-01-012022-12-310000917520srt:AsiaPacificMember2022-01-012022-12-310000917520iart:RestOfWorldMember2022-01-012022-12-310000917520country:US2021-01-012021-12-310000917520srt:EuropeMember2021-01-012021-12-310000917520srt:AsiaPacificMember2021-01-012021-12-310000917520iart:RestOfWorldMember2021-01-012021-12-310000917520country:US2020-01-012020-12-310000917520srt:EuropeMember2020-01-012020-12-310000917520srt:AsiaPacificMember2020-01-012020-12-310000917520iart:RestOfWorldMember2020-01-012020-12-310000917520country:US2022-12-310000917520srt:EuropeMember2022-12-310000917520srt:AsiaPacificMember2022-12-310000917520iart:RestOfWorldMember2022-12-310000917520country:US2021-12-310000917520srt:EuropeMember2021-12-310000917520srt:AsiaPacificMember2021-12-310000917520iart:RestOfWorldMember2021-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 10-K
 
(Mark One)
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2022
 or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             
COMMISSION FILE NO. 000-26224
 
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
 
Delaware 51-0317849
(STATE OR OTHER JURISDICTION OF
INCORPORATION OR ORGANIZATION)		 (I.R.S. EMPLOYER
IDENTIFICATION NO.)
1100 Campus Road 08540
Princeton,New Jersey(ZIP CODE)
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) 

REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE: (609) 275-0500
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:
Title of Each ClassTrading SymbolName of Exchange on Which Registered
Common Stock, Par Value $.01 Per ShareIARTNasdaq Global Select Market
SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:
NONE
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  ☒    No  ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act. Yes  ☐
 No  ☒
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
1

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check if the registrant has elected not to use the extended transition period for complying with any new revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐ No  ☒
As of June 30, 2022, the aggregate market value of the registrant’s common stock held by non-affiliates was approximately $3,916.0 million based upon the closing sales price of the registrant’s common stock on The Nasdaq Global Select Market on such date. The number of shares of the registrant’s Common Stock, $0.01 par value, outstanding as of February 21, 2023 was 81,636,066.

DOCUMENTS INCORPORATED BY REFERENCE:
Certain portions of the registrant’s definitive proxy statement relating to its scheduled May 12, 2023 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission, are incorporated by reference in Part III of this Annual Report on Form 10-K.


2

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
TABLE OF CONTENTS 
 Page
           Item 1. Business
           Item 1A. Risk Factors
           Item 1B. Unresolved Staff Comments
           Item 2. Properties
           Item 3. Legal Proceedings
           Item 4. Mine Safety Disclosures
            Item 6. [Reserved]
            Item 9A. Controls and Procedures
            Item 9B. Other Information
            Item 11. Executive Compensation
            Item 16. Form 10-K Summary

3

PART I
ITEM 1. BUSINESS
OVERVIEW
The terms “we,” “our,” “us,” “Company,” "Integra LifeSciences," and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries, unless the context suggests otherwise.
Integra LifeSciences is a global leader in regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians so they can focus on providing the best patient care. Founded in 1989 with the acquisition of an engineered collagen technology platform used to repair and regenerate tissue, Integra LifeSciences Holdings Corporation common stock trades on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “IART.” Integra has developed numerous product lines from this technology for applications ranging from burn and deep tissue wounds to the repair of dura mater in the brain, as well as nerves and tendons. The Company has expanded its base regenerative technology business to include surgical instruments, neurosurgical products and advanced wound care through global acquisitions and product development to meet the evolving needs of its customers and enhance patient care.
Integra products are sold in more than 130 countries through a direct sales force as well as distributors and wholesalers. We manufacture and sell medical technologies and products in two reportable business segments: Codman Specialty Surgical ("CSS") and Tissue Technologies ("TT"). The CSS segment, which represents approximately two-thirds of our total revenue, consists of market-leading technologies and instrumentation used for a wide range of specialties, such as neurosurgery, neurocritical care and otolaryngology. We are the world leader in neurosurgery and one of the top three providers in instruments used in precision, specialty, and general surgical procedures. Our TT segment generates about one-third of our overall revenue and focuses on three main areas: complex wound surgery, surgical reconstruction, and peripheral nerve repair.
We have key manufacturing and research facilities located in California, Indiana, Maryland, Massachusetts, New Jersey, Ohio, Puerto Rico, Tennessee, Utah, France, Germany, Ireland and Switzerland. We source most of our handheld surgical instruments and dural sealant products through specialized third-party vendors.
Vision
We aspire to continue to be a worldwide leader in neurosurgery and reconstructive surgery with a portfolio of leading businesses that delivers outstanding customer experiences through innovation, execution and teamwork to positively impact the lives of millions of patients and their families.
Strategy
Integra is committed to delivering high quality products that positively impact the lives of millions of patients and their families. We focus on four key pillars of our strategy: 1) enabling an execution-focused culture, 2) optimizing relevant scale, 3) advancing innovation and agility, and 4) leading in customer experience. We believe that by sharpening our focus on these areas through improved planning and communication, optimization of our infrastructure, and strategically aligned acquisitions, we can build scale, increase competitiveness and achieve our long-term goals.
To this end, the executive leadership team has established the following key priorities aligned to the following areas of focus:
Strategic Acquisitions. An important part of the our strategy is pursuing strategic transactions and licensing agreements that increase relevant scale in the clinical areas in which Integra competes. Our growth strategy includes the acquisition of businesses, assets or products lines to increase the breadth of our offerings, the reach of our product portfolios and drive relevant scale to our customers. On December 6, 2022, the Company completed the acquisition of Surgical Innovation Associates, Inc. ("SIA"), which develops, markets and sells DuraSorb®, a resorbable synthetic matrix for plastic and reconstructive surgery. This acquisition will advance Integra’s global strategy in breast reconstruction, expanding plans to access the U.S. market where SIA is pursuing pre-market approval for use in implant-based breast reconstruction ("IBBR"). We also continued to expand our product offering of regenerative technologies from our 2021 acquisition of ACell, Inc. ("ACell"), an innovative regenerative medicine company specializing in the manufacturing of porcine urinary bladder extracellular matrices. See Note 4, Acquisitions and Divestitures, to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K) for additional details.
New Product Introductions and Portfolio Optimization. We are investing in innovative product development to drive a multi-generational pipeline for our key product franchises. Our product development efforts span across our key global franchises focused on potential technological innovations for significant returns on investment. In addition to new product development, we are funding studies to gather clinical evidence to support launches, ensure market access and improve reimbursement for existing products. In addition to acquisitions and organic reinvestment, we continually look to optimize our portfolio towards higher growth and higher margin businesses.
As such, we may opportunistically divest businesses or discontinue products where we see limited runway for future value creation in line with our aspirations due in part to changes in the market, business fundamentals or the regulatory environment.
4

In August 2022, we completed the sale of our non-core traditional wound care ("TWC") business to Gentell, LLC ("Gentall") for $28.8 million, which consists of $27.8 million in cash plus $1.0 million in contingent consideration which may be received upon the achievement of certain revenue-based performance milestones. In January 2021, we completed the sale of our Extremity Orthopedics business to Smith & Nephew USD Limited ("Smith & Nephew"), a subsidiary of Smith & Nephew plc, for approximately $240 million in cash. Our portfolio optimization actions over the past two years have allowed us to increase our focus on Integra’s core portfolio of market-leading products in neurosurgery, surgical instrumentation and regenerative tissue and moves us closer to achieving our long-term organic growth and profitability targets. See Note 4, Acquisitions and Divestitures, to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K) for additional details.
Commercial Channel Investments. Investing in our sales channels is a core part of our strategy to create specialization and greater focus on reaching new and existing customers and addressing their needs. To support our commercial efforts in Tissue Technologies, we utilize a two-tier specialist model to increase our presence in focused segments to help serve the evolving needs of our customers. In addition, we continue to build upon our leadership brands across our product franchises in both CSS and TT to engage customers through enterprise-wide contracts with leading hospitals, integrated delivery networks and global purchasing organizations in the United States. Internationally, we have increased our commercial resources significantly in key emerging markets and are making investments to support our sales organization and maximize our commercial opportunities. Domestically, we have also increased our TT sales force in the United States to support the expanded regenerative tissue product portfolio that includes ACell products. These investments in our international and domestic sales channel position us well for expansion and long-term growth.
Customer Experience. We aspire to be ranked as a best-in-class provider and are committed to strengthening our relationships with all customers. We continue to invest in technologies, systems and processes to enhance the customer experience. In 2022, we outsourced certain transactional back-office finance and customer service activities to enhance customer quality, build scale for future growth, and capture cost efficiencies. We also launched digital tools and programs, resources and virtual product training to drive continued customer familiarity with our growing portfolio of medical technologies globally. .
BUSINESS SEGMENTS
Integra currently manufactures and sells our products and technologies in the following two global reportable business segments: Codman Specialty Surgical and Tissue Technologies. We include financial information regarding our reportable business segments and certain geographic information under "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" and Note 16, Segment and Geographic Information to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K).
Codman Specialty Surgical
The Codman Specialty Surgical business consists of a broad portfolio of market-leading brands, such as Codman®, DuraGen®, DuraSeal®, CUSA®, Mayfield®,Bactiseal®, and Certas® Plus,which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The growth in this business in the recent years has been fueled by geographic expansion and new product registrations in markets, such as China, Japan, and Europe, which we expect to continue in the near-to-long term.
In 2022, we made progress to several enhancements to our CUSA Clarity Tissue Ablation System. The extended laparoscopic tip was launched in the U.S. to enhance laparoscopic liver procedures. In addition, a single-sided bone tip received 510(k) clearance. Commercial launch is expected in the first quarter of 2023. We continue to update our CUSA Clarity platform by incorporating new ultrasonic handpiece and integrated electrosurgical capabilities.
Moreover, we are expanding into minimally invasive surgery ("MIS") and the surgical management of intracerebral hemorrhages ("ICH"), with the 2021 clinical launch of Aurora® Surgiscope®, a proprietary surgical solution with integrated visualization and capabilities designed specifically for use in deep-seated brain lesions. We continue to gather clinical evidence using this same technology for early surgical intervention of ICH. We believe this technology offers the promise of transforming the standard of care in neurosurgery. In 2022, we launched the Aurora® Evacuator with Coagulation device in the U.S., designed to be used in conjunction with our Aurora Surgiscope to safely address and evacuate blood in the brain caused by hemorrhagic stroke. 
Rounding out the portfolio is a catalog of surgical headlamps and surgical instrumentation, as well as after-market service. With thousands of surgical instrument products, including specialty surgical instruments, we call on the central sterile processing unit of hospitals and acute care surgical centers. Additionally, through a strong U.S. distribution model, we serve the needs of hundreds of medical offices.
We also expanded our product offerings in 2021 with the launch of our new intracranial pressure ("ICP") monitoring system, CereLink® in the U.S. and Europe and continued the global rollout in the first half of 2022. See additional discussion regarding certain matters with CereLink under "Item 1A. Risk Factors" under the heading Risks Related to our Regulatory Environment
5

and under "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations - General - FDA Matters" of this Annual Report on Form 10-K.
Our global commercial network includes clinical specialists, a large direct global sales force and strategic partnerships and distributors that serve hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers and health care providers.
Tissue Technologies
The Tissue Technologies segment consists of five unique regenerative technology areas - highly engineered bovine collagen, bovine dermis, porcine urinary bladder, human amniotic tissue, and resorbable synthetic mesh. This broad regenerative platform, which includes multiple leading brands such as Integra® Dermal Matrices, AmnioExcel®, SurgiMend®, MicroMatrix® and NeuraGen®, primarily addresses the needs of plastic, reconstructive and general surgeons focused on the treatment of acute wounds, such as burns, chronic wounds, including diabetic foot ulcers, and surgical tissue repair, such as hernia, tendon, peripheral nerve repair and protection. During 2022, we completed the acquisition of Surgical Innovation Associates, Inc. ("SIA"), which is seeking approval by the U.S Food and Drug Administration ("FDA") of the PMA application for its core technology, DuraSorb, for use in IBBR.
We have a specialized sales organization composed of directly employed sales representatives, as well as specialty distributors, organized based upon their call point. Our wound reconstruction sales representatives call on surgeons doing procedures in limb salvage, trauma, wound reconstruction and burns, chronic wounds primarily in the inpatient wound care clinic setting. We also have a dedicated surgical reconstruction sales team focused on plastic and reconstructive surgery and hernia procedures with differentiated products. Finally, we have a distributor network focused on biologics. Outside the U.S., we have a combination of direct and indirect sales channels in international markets to sell certain product lines.
This business segment also includes private-label sales of a broad set of our regenerative and wound care technologies. Our customers are other medical technology companies that sell to end markets primarily in spine, surgical and wound care.
We anticipate new product introductions and new clinical indications will continue to contribute to the growth of the segment. In 2022, we launched NeuraGen® 3D Nerve Guide Matrix, a resorbable implant for repair of peripheral nerve discontinuities and engineered to create an optimized environment for nerve regeneration. In the third quarter of 2021, we filed the PMA application for a specific indication for SurgiMend in the use of post-mastectomy breast reconstruction, for which we hope to obtain FDA approval in 2024.
COMPETITION
Our competitors for CSS are Medtronic, Inc., Stryker Corporation, Becton Dickinson and Company, and B. Braun Medical, Inc. In addition, we compete with many smaller specialized companies and larger companies that do not otherwise focus on the offerings of Codman Specialty Surgical technologies. We rely on the depth and breadth of our sales and marketing organization, our innovative technologies, and our procurement and manufacturing operations to maintain our competitive position.
Our competition for TT includes Smith & Nephew plc, Organogenesis Holdings Inc., MiMedx Group, Inc., Allergan PLC, Becton Dickinson and Company, and Axogen, Inc. We compete with many additional companies who partially participate in soft tissue reconstruction of complex wounds, peripheral nerve repair and surgical reconstruction. In addition, our products also compete against medical practices that treat a condition without using a medical device or any particular product, such as medical practices that utilize autograft tissue instead of our dermal regeneration products, duraplasty products and nerve repair products. Depending on the product line, we compete based on our products' features, strength of our sales force or distributors, sophistication of our technology and cost effectiveness of our solution.
RESEARCH AND DEVELOPMENT STRATEGY
Our research and development activities focus on identifying unmet surgical needs and addressing those needs with innovative solutions and products. We apply our core competency in regenerative technology to innovate products for neurosurgical, wound applications, plastic surgery, and reconstructive surgery and we have extensive R&D development programs for our core platforms of electromechanical technologies. Additionally, we conduct products and clinical studies to generate efficacy and health economic evidence.
Regenerative Technologies. Integra was the first company to receive a FDA claim for regeneration of dermal tissue and is a world leader in regenerative technology. Because regenerative technology products represent a fast-growing, high-margin opportunity for us, we allocate a large portion of our research and development budget to these projects. Our regenerative technology development program applies our expertise in bioengineering to a range of biomaterials including natural materials such as purified collagen, intact human or animal tissues, honey as well as resorbable synthetic polymers with our DuraSorb and DuraSeal product lines. These unique product designs are used for neurosurgical and reconstructive surgical applications, as well as dermal regeneration, including the healing of chronic and acute wounds, tendon and nerve repair. Our regenerative
6

technology platform includes our legacy Integra® Dermal Regeneration Template ("IDRT") products and complementary technologies that we have acquired. Our collagen manufacturing capability, combined with our history of innovation, including our launch of NeuraGen 3D, provides us with strong platform technologies for multiple indications.
In 2020, we announced positive clinical and economic data on Integra® Bilayer Wound Matrix ("IBWM") in complex lower extremity reconstruction based on two retrospective studies recently published in Plastic and Reconstructive Surgery, the official journal of the American Society of Plastic Surgeons. As surgeons look for ways to efficiently and effectively repair and close wounds, IBWM helps address the efficiency needed in operating rooms by reducing both the operating time and costs to hospitals and patients. In 2021, we completed one of the largest diabetic foot ulcers ("DFU"), randomized controlled trials of the PriMatrix® Dermal Repair Scaffold for the management of DFU. This multi-center study enrolled more than 225 patients with chronic DFU's over the course of 12-week treatments and 4-week follow-up phases. The results of this study, which was published in the Journal of Wound Care, demonstrated that PriMatrix plus standard of care ("SOC") consisting of sharp debridement, infection elimination, use of dressings and offloading was significantly more likely to achieve complete wound closure compared with SOC alone, with a median number of one application of the product. Integra is currently pursuing pre-market approval for implant-based breast reconstruction with our Surgimend product. In 2022, we acquired SIA, which is also pursuing a pre-market approval for IBBR. By offering two distinct product solutions, we believe we have the opportunity to build a leading position in the market. We completed design control activities in 2022 for a Q1 2023 launch of Cytal and MicroMatrix in Europe and a pilot launch of the Cardion Pericardial Patch to gain clinical experience for finding a private label partner for that product.
Electromechanical Technologies and Instrumentation. Because our electromechanical products and instruments address significant needs in surgical procedures and limit uncertainty for surgeons, we continue to invest in approvals for new indications and next generation improvements to our market-leading products. We have several active programs focused on life cycle management and innovation for capital and disposable products in our portfolio. Our product development efforts are focused on core clinical applications in cerebrospinal fluid ("CSF") management, neuro-critical care monitoring, minimally invasive instruments and electrosurgery and ultrasonic medical technologies, as well as our ambition to transform the standard of care in neurosurgery with product advancements in MIS and ICH. Our lighting franchise is among the most dynamic in the industry.
We are focused on the development of core clinical applications in our electromechanical technologies portfolio. In 2022, we made progress to several enhancements to our CUSA Clarity Tissue Ablation System. The extended laparoscopic tip was launched in the U.S. to enhance laparoscopic liver procedures. In addition, a single-sided bone tip received 510(k) approval. Commercial launch is expected in the first quarter of 2023. We continue to update our CUSA Clarity platform by incorporating new ultrasonic handpiece and integrated electrosurgical capabilities. We continue to work with several instrument partners to bring new surgical instrument platforms to the market.
We are focused on the development of core clinical applications in our electromechanical technologies portfolio. In June 2022, we launched the Neutus® EVD system, our first external ventricular drain (“EVD") in China. The Neutus EVD system is manufactured in China by Shanghai Haoju Medical Technology Co., Ltd. under an exclusive distribution arrangement. The device is used in the management of cerebrospinal fluid and is highly complementary to our Bactiseal® catheter and advanced intercranial pressure monitoring products.
In the third quarter of 2021, we launched our CereLink ICP Monitor System in the U.S. and Europe and continued the global rollout in the first half of 2022. On August 18, 2022, the Company, after consultation with the FDA and other regulatory authorities outside of the United States, initiated an immediate voluntary global product removal of all CereLink® intracranial pressure monitors. See Item 1A. Risk Factors, under the heading Risks Related to our Regulatory Environment and under Item 7. General Management's Discussion and Analysis of Financial Condition and Results of Operations - FDA Matters of this Annual Report on Form 10-K for further discussion.
In 2022, we continued to advance the early-stage technology platforms we acquired in 2019. Through the acquisition of Arkis Biosciences, Inc. ("Arkis") we added a platform technology, CerebroFlo® external ventricular drainage ("EVD"), catheter with Endexo® technology, a permanent additive designed to reduce the potential for catheter obstruction due to thrombus formation. The CerebroFlo EVD Catheter has demonstrated an average of 99% less thrombus accumulation onto its surface, in vitro, compared to a market leading EVD catheter. Our work to combine our bactiseal antimicrobial technology with the Endexo anti-occlusive technology obtained through our 2019 acquisition of Arkis continues to progress for both a silicone-based hydrocephalus and EVD project.

In 2019, we also acquired Rebound Therapeutics Corporation ("Rebound Therapeutics"), a company that specialized in single-use medical device, known as Aurora Surgiscope, which is the only tubular retractor system designed for cranial surgery with an integrated access channel, camera and lighting. In the third quarter of 2021, we conducted a limited clinical launch of the Aurora Surgiscope for use in minimally invasive neurosurgery as well as initiated a registry called MIRROR to collect data on early surgical intervention using this same technology platform for the treatment of ICH. In 2022, we launched the Aurora®
7

Evacuator with Coagulation device in the U.S., designed to be used in conjunction with our Aurora Surgiscope to safely address and evacuate blood in the brain caused by hemorrhagic stroke. 

RESOURCES
In general, raw materials essential to our businesses are readily available from multiple sources. For reasons of quality assurance, availability, or cost effectiveness, certain components and raw materials are available only from a sole supplier. Our practice is to maintain sufficient inventory of components so that our production will not be significantly disrupted even if a particular component or material is not available for a period of time.
Certain of our products, including but not limited to our dermal regeneration products, duraplasty products, wound care products, and nerve and tendon repair products, contain material derived from bovine tissue. We take great care to provide products that are safe and free of agents that can cause disease. In particular, the collagen used in the products that we manufacture is derived from the deep flexor tendon of cattle less than 24 months old from New Zealand, a country that has never had a reported case of bovine spongiform encephalopathy ("BSE") (otherwise known as mad cow disease), from the U.S. or from fetal bovine dermis. The World Health Organization classifies different types of cattle tissue for relative risk of BSE transmission. Deep flexor tendon and fetal bovine skin are in the lowest-risk category for BSE transmission, and therefore considered to have a negligible risk of containing the agent that causes BSE.
INTELLECTUAL PROPERTY
We seek patent and trademark protection for our key technology, products and product improvements, both in the U.S. and in selected foreign countries. When determined appropriate, we have enforced and plan to continue to enforce and defend our patent and trademark rights. In general, however, we do not rely solely on our patent and trademark estate to provide us with any significant competitive advantages as it relates to our existing product lines. We also rely upon trade secrets and continuing technological innovations to develop and maintain our competitive position. In an effort to protect our trade secrets, we have a policy requiring our employees, consultants and advisors to execute proprietary information and invention assignment agreements upon commencement of employment or consulting relationships with us. These agreements also provide that all confidential information developed or made known to the individual during the course of their relationship with us must be kept confidential, except in specified circumstances.
AccuDrain®, AmnioExcel®, Aquasonic®, Auragen®, Aurora® Surgiscope®, Bactiseal®, BioDFence®, BioDOptix®, Brainet®, Budde®, Buzz™, CereLink®, CerebroFlo® EVD Catheter with Endexo® Technology, Codman®, Codman Accu-Flo®, Codman Bicol®, Codman® Certas® Plus, Codman® Hakim®Programmable valve, Codman Holter®, Codman ICP Express®, Codman Microsensor®, Codman VersaTru®, Codman VPV®, Contour-Flex®, Cranioplastic®, CRW®, CRW Precision™, Ctherm™, CUSA®, Cytal®, DirectLink®, DuraGen®, DuraSeal®, DuraSorb®, Gentrix®, HeliCote®, HeliPlug®, HeliTape®, HeliMend®, Helistat®, Helitene®, Hermetic™, Hy-Tape®, Integra®, IntegraLink®, Isocool®, Jarit®, Lead-Lok™, Licox®, LimiTorr™, Luxtec®, Mayfield®, MatriStem UBM™, MediHoney®, MicroFrance®, MicroMatrix®, Miltex®, Mischler™, MoniTorr ICP™, Natus®, NeuraGen®, NeuraWrap™, Nicolet®, Omnigraft®, Omni-Tract®, OSV II®, Padgett®, PriMatrix®, Pureflow™, Q-Snor™, Redmond™, Revize™, Ruggles®, Signacreme®, SurgiMend®, TCC-EZ®, TenoGlide®, TissueMend®, Ultra VS™, VersaTru®, Xtrasorb®, zRIP™, and the Integra logo are some of the material trademarks of Integra LifeSciences Corporation and its subsidiaries. MAYFIELD® is a registered trademark of SM USA, Inc., and is used by Integra under license.
SEASONALITY
Revenues during our fourth quarter tend to be stronger than other quarters because many hospitals increase their purchases of our products during the fourth quarter to coincide with the end of their budget cycles in the U.S. In general, our first quarter usually has lower revenues than the preceding fourth quarter, the second and third quarters have higher revenues than the first quarter, and the fourth quarter revenues are the highest in the year. The main exceptions to this pattern occur because of material acquisitions as well as impacts of the COVID-19 pandemic.
GOVERNMENT REGULATION AND COMPLIANCE
We are a manufacturer and marketer of medical devices and Human Tissue and Cell Based Products ("HCT/Ps") and therefore are subject to extensive regulation by the FDA, the Center for Medicare Services of the U.S. Department of Health and Human Services, other federal governmental agencies and, in some jurisdictions, by state and foreign governmental authorities. These regulations govern the introduction of new medical devices and HCT/Ps, the observance of certain standards with respect to the design, manufacture, testing, labeling, promotion and sales of the products, the maintenance of certain records, the ability to track devices, the reporting of potential product defects, the import and export of products, and other matters.
8

United States Food and Drug Administration
Our products are subject to extensive regulation particularly as to safety, efficacy and adherence to FDA Quality System Regulation, and related manufacturing standards. Medical device products are subject to rigorous FDA and other governmental agency regulations in the United States and similar regulations of foreign agencies abroad. The FDA regulates the design, development, research, preclinical and clinical testing, introduction, manufacture, advertising, labeling, packaging, marketing, distribution, import and export, and record keeping for such products, in order to ensure that medical products distributed in the United States are safe and effective for their intended use. In addition, the FDA is authorized to establish special controls to provide reasonable assurance of the safety and effectiveness of most devices. Non-compliance with applicable requirements can result in import detentions, fines, civil and administrative penalties, injunctions, suspensions or losses of regulatory approvals, recall or seizure of products, operating restrictions, refusal of the government to approve product export applications or allow us to enter into supply contracts, and criminal prosecution. The regulatory process for obtaining product approvals and clearances can be onerous and costly. The FDA requires, as a condition to marketing a medical device in the U.S., that we secure a Premarket Notification clearance pursuant to Section 510(k) of the Federal Food, Drug and Cosmetic Act (the "FD&C Act"), or an approved PMA application (or supplemental PMA application). Obtaining these approvals and clearances can take up to several years and may involve preclinical studies and clinical trials. The FDA also may require a post-approval clinical study as a condition of approval. To perform clinical trials for significant risk devices in the U.S. on an unapproved product, we are required to obtain an Investigational Device Exemption from the FDA. The FDA also may require a filing for approval prior to marketing products that are modifications of existing products or new indications for existing products. Moreover, after clearance/approval is given, if the product is shown to be hazardous or defective, the FDA and foreign regulatory agencies have the power to withdraw the clearance or approval, as the case may be, or require us to change the device, its manufacturing process or its labeling, to supply additional proof of its safety and effectiveness or to recall, repair, replace or refund the cost of the medical device. Because we currently export medical devices manufactured in the U.S. that have not been approved by the FDA for distribution in the U.S., we are required to obtain approval/registration in the country to which we are exporting and maintain certain records relating to exports and make these available to the FDA for inspection, if required.
Human Cells, Tissues and Cellular and Tissue-Based Products
Integra, through its wholly-owned subsidiary BioD LLC ("BioD"), is involved with the recovery, processing, storage, transportation and distribution of donated amniotic tissue. The FDA has specific regulations governing HCT/Ps. An HCT/P is a product containing, or consisting of, human cells or tissue intended for transplantation into a human patient. Examples of HCT/Ps include bone, ligament, skin and cornea.
Some HCT/Ps fall within the definition of a biological product, medical device or drug regulated under the FD&C Act. These biologic, device or drug HCT/Ps must comply both with the requirements exclusively applicable to HCT/Ps and, in addition, with requirements applicable to biologics, devices or drugs, including premarket clearance or approval from the FDA.
Section 361 of the Public Health Service Act ("Section 361") authorizes the FDA to issue regulations to prevent the introduction, transmission or spread of communicable disease. HCT/Ps regulated as “361” HCT/Ps are subject to requirements relating to registering facilities and listing products with the FDA, screening and testing for tissue donor eligibility, and Good Tissue Practices when processing, storing, labeling, and distributing HCT/Ps, including required labeling information, stringent record keeping, and adverse event reporting.
The American Association of Tissue Banks ("AATB") has issued operating standards for tissue banking. Compliance with these standards is a requirement in order to become an AATB-accredited tissue establishment. In addition, some states have their own tissue banking regulations. We are licensed or have permits for tissue banking in California, Delaware, Illinois, Maryland, New York, Oregon, and Tennessee. In Tennessee, we are registered with the FDA Center for Biological Evaluations and Research.
Procurement of certain human organs and tissue for transplantation is subject to the restrictions of the National Organ Transplant Act, which prohibits the transfer of certain human organs, including skin and related tissue for valuable consideration, but permits the reasonable payment associated with the removal, transportation, implantation, processing, preservation, quality control and storage of human tissue and skin. BioD is a registered Tissue Bank and is involved with the recovery, storage and transportation of donated human amniotic tissue.
On June 22, 2015, the FDA issued an Untitled Letter (the "Untitled Letter") alleging that BioD's morselized amniotic membrane tissue-based products do not meet the criteria for regulation as HCT/Ps solely under Section 361 and that, as a result, BioD would need a biologics license to lawfully market those morselized products. Since the issuance of the Untitled Letter, BioD and the Company has made known to the FDA their disagreement with the FDA’s assertion that certain products are more than minimally manipulated. The FDA has not changed its position that certain of the BioD acquired products are not eligible for marketing solely under Section 361. In July 2020, the FDA issued the final guidance document related to human tissue titled, “Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use” (the “2020 HCT/P Final Guidance”). The 2020 HCT/P Final Guidance document supersedes the November 2017 guidance by the same title.
9

The HCT/P Final Guidance maintains the FDA’s position that products such as the Company’s morselized amniotic membrane tissue-based products do not meet the criteria for regulation solely as HCT/Ps. In addition, in the November 2017 guidance, the FDA articulated a risk-based approach to enforcement and, while some uses for amniotic membrane tissue-based products would have as much as thirty-six months of enforcement discretion, other high risk uses could be subject to immediate enforcement action. The 2020 HCT/P Final Guidance maintained this approach and extended the discretionary enforcement period to May 31, 2021.
Considering the risk of enforcement action, the Company discontinued the manufacturing of all morselized amniotic membrane tissue-based products prior to May 31, 2021. We no longer distribute these products. As of December 31, 2022, the Company has not received any further notice of enforcement action from the FDA regarding its morselized amniotic membrane tissue-based products.
Medical Device Regulations
Unless an exemption applies, the FDA requires that a manufacturer introducing a new medical device or a new indication for use of an existing medical device obtain either a Section 510(k) premarket notification clearance or a PMA, before introducing it into the U.S. market. The type of marketing authorization is generally linked to the classification of the device. The FDA classifies medical devices into one of three classes (Class I, II or III) based on the degree of risk the FDA determines to be associated with a device and the level of regulatory control deemed necessary to ensure the device’s safety and effectiveness.
The process of obtaining a Section 510(k) clearance generally requires the submission of performance data and often clinical data, which in some cases can be extensive, to demonstrate that the device is “substantially equivalent” to a device that was on the market before 1976 or to a device that has been found by the FDA to be “substantially equivalent” to such a pre-1976 device, a predecessor device is referred to as “predicate device.” As a result, FDA clearance requirements may extend the development process for a considerable length of time. In addition, in some cases, the FDA may require additional review by an advisory panel, which can further lengthen the process. The PMA process, which is reserved for new devices that are not substantially equivalent to any predicate device and for high-risk devices or those that are used to support or sustain human life, may take several years and requires the submission of extensive performance and clinical information.
Medical devices can be marketed only for the indications for which they are cleared or approved. After a device has received 510(k) clearance for a specific intended use, any change or modification that significantly affects its safety or effectiveness, such as a significant change in the design, materials, method of manufacture or intended use, may require a new 510(k) clearance or PMA approval and payment of an FDA user fee. The determination as to whether or not a modification could significantly affect the device’s safety or effectiveness is initially left to the manufacturer using available FDA guidance; however, the FDA may review this determination to evaluate the regulatory status of the modified product at any time and may require the manufacturer to cease marketing and recall the modified device until 510(k) clearance or PMA approval is obtained. The manufacturer may also be subject to significant regulatory fines or penalties.
We also are required to register with the FDA as a medical device manufacturer and any devices we manufacture and distribute pursuant to clearance or approval by the FDA are subject to pervasive and continuing regulation by the FDA and certain state agencies. These include product listing and establishment registration requirements, which help facilitate FDA inspections and other regulatory actions, and our manufacturing sites are subject to periodic inspection by the FDA for compliance with the FDA's Quality System Regulations. These regulations require that we manufacture our products and maintain our documents in a prescribed manner with respect to design, manufacturing, testing and control activities. Further, we are required to comply with various FDA requirements and other legal requirements for labeling and promotion. If the FDA believes that a company is not in compliance with applicable regulations, it may issue a warning letter, institute proceedings to detain or seize products, issue a recall order, impose operating restrictions, enjoin future violations and assess civil penalties against that company, its officers or its employees and may recommend criminal prosecution to the U.S. Department of Justice. All Integra manufacturing facilities participate in the Medical Device Single Audit Program and are audited annually for compliance with the Quality System for US FDA, Canada, Australia, Brazil, and Japan.
Medical device regulations also are in effect in many of the countries in which we do business outside the U.S. In the European Economic Area ("EEA"), which is comprised of the 27 member states of the European Union plus Norway, Iceland and Liechtenstein, medical devices need to comply with specific requirements. These requirements were previously known as "Essential Requirements" under the former EU Medical Devices Directive (Council Directive 93/42/EEC, or MDD) and are now defined "General Safety and Performance Requirements (GSPR)" under the new EU Medical Devices Regulation (Regulation (EU) 2017/745, or "EU MDR"). Although the requirements set forth in the EU MDR are generally consistent with those laid out in the MDD (with a few exceptions), the EU MDR is intended, among other things, to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical devices and ensure a high level of safety and health while supporting innovation. These laws range from comprehensive medical device approval and Quality System requirements for some or all of our medical device products to simpler requests for product data or certifications. Under the European Union Medical Device Directive, medical devices must meet the Medical Device Directive standards and receive
10

CE Mark Certification prior to marketing in the EEA. Although we continue to transition our certification profile to meet the new EU MDR requirements, these stricter regulations set forth in the EU MDR may pose additional challenges for Integra to continue marketing products in the EU as these regulations come into force. See “Item 1A. Risk Factors - We are subject to stringent domestic and foreign medical device regulations and oversight and any adverse action may adversely affect our ability to compete in the marketplace and our financial condition and business operations” of this Annual Report on Form 10-K.
CE Mark Certification requires a comprehensive quality system program, technical documentation, clinical evaluation and data on the product which are then reviewed, by a Notified Body. A Notified Body is an organization designated by the national governments of the EU member states to make independent judgments about whether a product complies with the requirements established by each CE marking directive. The Medical Device Directive, Medical Device Regulation, ISO 9000 series and ISO 13485 are recognized international quality standards that are designed to ensure that we develop and manufacture quality medical devices. Other countries are also instituting regulations regarding medical devices or interpreting and enforcing existing regulations more strictly. Compliance with these regulations requires extensive documentation and clinical reports for our products, revisions to labeling, and other requirements such as facility inspections to comply with the registration requirements. A recognized Notified Body audits our facilities annually to verify our compliance with the ISO 13485 Quality System standard.
Certain countries, as well as the EU, have issued regulations that govern products that contain materials derived from animal sources. Regulatory authorities are particularly concerned with materials infected with the agent that causes BSE. These regulations affect our dermal regeneration products, duraplasty products, hernia repair products, biomaterial products for the spine, nerve and tendon repair products and certain other products, all of which contain material derived from bovine tissue. Although we take great care to provide that our products are safe and free of agents that can cause disease, products that contain materials derived from animals, including our products, may become subject to additional regulation, or even be banned in certain countries, because of concern over the potential for prion transmission. Significant new regulations, a ban of our products, or a movement away from bovine-derived products because of an outbreak of BSE could have a material, adverse effect on our current business or our ability to expand our business. See “Item 1A. Risk Factors – Risks Related to our Regulatory Environment" of this Annual Report on Form 10-K.
Postmarket Requirements. After a device is cleared or approved for commercial distribution, numerous regulatory requirements apply. These include the FDA Quality System Regulations which cover the procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of medical devices; the FDA's general prohibition against promoting products for unapproved or 'off-label' uses; the Medical Device Reporting regulation, which requires that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur; and the Reports of Corrections and Removals regulation, which require manufacturers to report recalls and field corrective actions to the FDA if initiated to reduce a risk to health posed by the device or to remedy a violation of the FD&C Act. Postmarket requirements are also followed globally where our products are registered and approved. These foreign jurisdictions have similar requirements to the FDA which include reporting requirements such as adverse events and recalls.
Other regulations
Anti-Bribery Laws. In the U.S., we are subject to laws and regulations pertaining to healthcare fraud and abuse, including anti-kickback laws and physician self-referral laws that regulate the means by which companies in the health care industry may market their products to hospitals and health care professionals and may compete by discounting the prices of their products. Similar anti-bribery laws exist in many of the countries in which we sell our products outside the U.S., as well as the United States Foreign Corrupt Practices Act (which addresses the activities of U.S. companies in foreign markets). Our products also are subject to regulation regarding reimbursement, and U.S. healthcare laws apply when a customer submits a claim for a product that is reimbursed under a federally funded healthcare program. These global laws require that we exercise care in designing our sales and marketing practices, including interactions with healthcare professionals, and customer discount arrangements. See “Item 1A. Risk Factors – We are exposed to a variety of risks relating to our international sales and operations” of this Annual Report on Form 10-K for further details.
Import-export. Our international operations subject us to laws regarding sanctioned countries, entities and persons, customs, and import-export. Among other things, these laws restrict, and in some cases can prevent, U.S. companies from directly or indirectly selling goods, technology or services to people or entities in certain countries. In addition, these laws require that we exercise care in our business dealings with entities in and from foreign countries.
Hazardous materials. Our research, development and manufacturing processes involve the controlled use of certain hazardous materials. We are subject to country-specific, federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these materials and certain waste products. We believe that our environmental, health and safety procedures for handling and disposing of these materials comply with the standards prescribed by the controlling laws and regulations. However, risk of accidental releases or injury from these materials is possible. These risks are managed to minimize or eliminate associated business impacts. In the event of this type of accident, we could be held liable for damages
11

and face a liability that could exceed our resources. We could be subject to a regulatory shutdown of a facility that could prevent the distribution and sale of products manufactured there for a significant period of time, and we could suffer a casualty loss that could require a shutdown of the facility in order to repair it, any of which could have a material, adverse effect on our business. Although we continuously strive to maintain full compliance with respect to all applicable global environmental, health and safety laws and regulations, we could incur substantial costs to fully comply with future laws and regulations, and our operations, business or assets may be negatively affected. Furthermore, global environmental, health and safety compliance is an ongoing process. Integra has compliance procedures in place for compliance with Employee Health & Safety laws, driven by a centrally led organizational structure that ensures proper implementation, which is essential to our overall business objectives.
In addition to the above regulations, we are, and may be, subject to regulation under country-specific federal and state laws, including, but not limited to, requirements regarding record keeping, and the maintenance of personal information, including personal health information. As a public Company, we are subject to the securities laws and regulations, including the Sarbanes-Oxley Act of 2002. We also are subject to other present and could be subject to possible future, local, state, federal and foreign regulations.
Third-Party Reimbursement. Healthcare providers that purchase medical devices generally rely on third-party payors, including, in the U.S., the Medicare and Medicaid programs and private payors, such as indemnity insurers, employer group health insurance programs and managed care plans, to reimburse all or part of the cost of the products. As a result, demand for our products is and will continue to be dependent in part on the coverage and reimbursement policies of these payors. The manner in which reimbursement is sought and obtained varies based upon the type of payor involved and the setting in which the product is furnished and utilized. Reimbursement from Medicare, Medicaid and other third-party payors may be subject to periodic adjustments as a result of legislative, regulatory and policy changes, as well as budgetary pressures. Possible reductions in, or eliminations of, coverage or reimbursement by third-party payors, or denial of, or provision of uneconomical reimbursement for new products may affect our customers' revenue and ability to purchase our products. Any changes in the healthcare regulatory, payment or enforcement landscape relative to our customers' healthcare services have the potential to significantly affect our operations and revenue.
Data Privacy and Cybersecurity Laws and Regulations. As a business with a significant global footprint, compliance with evolving regulations and standards in data privacy and cybersecurity (relating to the confidentiality and security of our information technology systems, products such as medical devices, and other services provided by us) may result in increased costs, lower revenue, new complexities in compliance, new challenges for competition, and the threat of increased regulatory enforcement activity. Our business relies on the secure electronic transmission, storage and hosting of sensitive information, including personal information, financial information, intellectual property, and other sensitive information related to our customers and workforce.
For example, in the U.S., the collection, maintenance, protection, use, transmission, disclosure and disposal of certain personal information and the security of medical devices are regulated at the U.S. federal and state, and industry levels. U.S. federal and state laws protect the confidentiality of certain patient health information, including patient medical records, and restrict the use and disclosure of patient health information by health care providers. For example, in the U.S. we are obligated to comply with the requirements of the Health Insurance and Portability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (collectively, “HIPPA”). Under HIPAA, the Department of Health and Human Services has issued regulations, including the HIPAA Privacy, Security and Breach Notification Rules, to protect the privacy and security of protected health information used or disclosed by covered entities including health care providers and their business associates, as well as covered subcontractors. HIPAA also regulates standardization of data content, codes and formats used in health care transactions and standardization of identifiers for health plans and providers. Penalties for violations of HIPAA regulations include significant civil and criminal penalties for each violation. In addition, the FDA has issued guidance advising manufacturers to take cybersecurity risks into account in product design for connected medical devices and systems, to assure that appropriate safeguards are in place to reduce the risk of unauthorized access or modification to medical devices that contain software and reduce the risk of introducing threats into hospital systems that are connected to such devices. The FDA also issued guidance on post market management of cyber security in medical devices.
Outside the U.S., we are impacted by the privacy and data security requirements at the international, national and regional level, and on an industry specific basis. Legal requirements in these countries relating to the collection, storage, handling and transfer of personal data and, potentially, intellectual property continue to evolve with increasingly strict enforcement regimes. In Europe, for example, we are subject to EU General Data Protection Regulation ("GDPR") which requires member states to impose minimum restrictions on the collection, use and transfer of personal data and includes, among other things, a requirement for prompt notice of data breaches to data subjects and supervisory authorities in certain circumstances and significant fines for non-compliance. The GDPR also requires companies processing personal data of individuals residing in the EU to comply with EU privacy and data protection rules.
12

Please refer to “Item 1A. Risk Factors – We are subject to requirements relating to information technology which could adversely affect our business” of this Annual Report on Form 10-K for additional discussion of the risks accompanying compliance with data privacy and cybersecurity laws and regulations.
These laws and regulations impact the ways in which we use and manage personal data, protected health information, and our information technology systems. They also impact our ability to move, store, and access data across geographic boundaries. Compliance with these requirements may require changes in business practices, complicate our operations, and add complexity and additional management and oversight needs. They also may complicate our clinical research activities, as well as product offerings that involve transmission or use of clinical data.
HUMAN CAPITAL
Workforce Demographics
As of December 31, 2022, we had approximately 3,722 regular full and part time employees and 874 contingent, subcontracted, and outsourced partners.
70% of our employees are located in the United States, 21% in Europe, 2% in Latin America and Canada and 7% in Asia Pacific which includes Australia and New Zealand.

iart-20221231_g1.jpg

Diversity and Inclusion
A diverse workforce and an inclusive culture and work environment is a business priority and a key to our long-term success. Our commitment to diversity and inclusion starts at the top with our Board of Directors and CEO. At all levels of the Company, we focus on attracting, retaining, and developing our diverse talent.

Leadership Commitment and Accountability

Executive leadership set diversity and inclusion goals for the Company on an annual basis. Advancing diversity and inclusion initiatives to build stronger teams has been a company-wide goal and the direct engagement of executive leadership in advancing diversity and inclusion initiatives helps to promote awareness throughout the Company.

Leadership Councils, Employee Resource Groups and External Partnerships

We are accountable to our diversity commitment through our leadership councils, employee resource groups, and external partnerships.
•The Women’s Leadership Council, established in 2017 and chaired by our President & Chief Executive Officer, Jan De Witte, is a results-oriented advisory group comprised of ten of our senior women leaders across Integra. The
13

specific charter of the Council is to work together to identify ways to continue to attract and retain female talent, advance the development of our women into leadership roles, increase the cultural awareness of the value of inclusion and diversity in our Company, and create specific development forums for our high performing women at Integra.

•Employee Resources Groups encourage a culture of awareness and inclusion, assist in the attraction and retention of diverse talent, and help colleagues develop leadership skills. Members of the Executive Leadership Team serve as sponsors for each of Integra’s employee resource groups. Integra currently has six Employee Resources Groups:
◦Women of Integra Networks (WIN) with 20+ chapters globally
◦African American Affinity Group
◦Veteran Employee Resource Group
◦Indian American Network
◦Asian American and Pacific Islander Network
◦Integra PRIDE (LGBTQ+ Employee Resource Group)

•We reinforce our commitment to diversity by partnering with other organizations focused on driving inclusion in the workplace including the CEO Action for Diversity & Inclusion, the largest CEO-driven business commitment to advance diversity and inclusion in the work place and Healthcare Businesswomen’s Association, an association dedicated to further the advancement and impact of women in the business of healthcare.

Promoting an inclusive culture through learning opportunities

To help drive our culture of inclusion, our colleagues participate in programs focused on how to manage bias, value differences, and develop inclusive leadership skills.
•Members of our executive leadership, senior management team, and larger scope leaders participated in a ½ day Microinequities training. The content includes understanding unconscious bias and microinequities, how to identify microinequities in day-to-day decisions and actions as leaders, and ways to mitigate microinequities on an individual and organizational level.
•In 2020, we launched two foundational programs to promote diversity and inclusion: Introduction to Managing Unconscious Bias, a course that creates awareness of unconscious biases in the workplaces and tools to build-bias breaking skills and Practicing Inclusion which examines what practicing inclusion in the workplace looks like. These trainings are now mandatory for all new Integra hires.
•We regularly provide educational content and resources to aid our colleagues as they build cultural competency and inclusive leadership skills

Gender Diversity

We believe that our company is stronger and will deliver strong operating results, when we build diverse teams and leverage broad perspectives to meet the needs of our shareholders, customers, colleagues, and communities we serve.

The breakout of our colleagues by gender:

48% of Integra’s overall population is female, 52% male. We continue to strive to ensure our diversity in our leadership ranks is representative of our overall population. Through mentorship, sponsorship, recruitment efforts, and development programs we look to continue to grow our population of females in leadership roles at Integra. Currently, 38% of our executive leaders and 43% of senior leaders (non-executive vice presidents) are female.
14

iart-20221231_g2.jpg
In partnership with Leadership Edge, a company founded by women leaders and dedicated to growing and mentoring women. Integra sponsors the Excel Women’s Leadership Program. The program is designed to accelerate the development and advancement of high potential, mid-career female leaders into senior leadership roles. The program has assisted in further building our pipeline of women leaders with 60% of the program’s graduates being promoted into roles with increased responsibility.

Compensation and Benefits

Our compensation philosophy is designed to reinforce and align with our mission, business strategy, and financial needs. We invest in the physical, emotional and financial well-being of our employees through our robust compensation and benefit programs. We provide market-competitive compensation and benefits based on benchmarking surveys we conduct regularly for all position levels against relevant peer companies. Our annual and long-term incentive packages are linked directly to business and individual performance, with a balance of short- and long-term financial and strategic objectives. We have an employee stock purchase plan. Eligibility for non-salary benefits such as salary continuance, life insurance, health insurance, and similar benefits, follows local regulations and practices.

Integra is a pay-for-performance company committed to fair pay. All compensation decisions are made without regard to personal characteristics such as, but not limited to, gender, race, color, national or ethnic origin, age, disability, sexual orientation, gender identity or expression, genetic information, religion, or veteran status. As part of our commitment to compensation equity, Integra regularly conducts a pay equity analysis, reviewing how our organization compensates employees against external and internal data in conjunction with the role and scope of each position and making adjustments if necessary.

Talent Development and Retention

We have comprehensive and effective human capital development programs in place because we believe that the personal success of our employees is critical to the overall success of our business. To build a diverse and talented organization, we have invested in honing our recruiting and hiring processes to attract top talent and engage new hires from the very beginning of their experience at Integra.

We offer a variety of opportunities for our employees to learn and grow. Continued learning and development is a critical component of employee job satisfaction, retention, and career advancement—and ultimately, a driver of business success. We encourage and promote experiential, collaborative, and formal learning programs. Employees are also encouraged to discuss with their managers the skills, training, and experience needed to grow and develop. In addition to several skills-based trainings
15

available (technical, sales, leadership ability) to all employees, managers may recommend external job-specific development programs to employees. These programs are paid for directly by Integra.
Employee Health and Safety:
Integra is committed to providing a safe environment for all employees and visitors. We rely on our environmental, health and safety management systems as well as entrusting our managers to oversee and ensure health and safety at their respective sites and foster a workplace culture to achieve that end. We implement our approach globally by our systems and support at regional and country levels from colleagues that implement proper safety protocols, identify and correct hazards, and remain safety conscious at all times. Managers are expected to enforce health and safety regulations, including compliance with applicable federal, state and local laws. Our Environmental Health and Safety ("EH&S") organizational structure incorporates both workplace EH&S coordinators and compliance teams. We have developed an Incident Procedure Policy and General Safety Rules that guide our colleagues to improve our workplace environment, improve safety, and reduce risk and costs.

Throughout the COVID-19 pandemic, we have placed a high priority on employee health, providing resources to support our workforce. At the outset of the pandemic, we sought to protect the health and safety of our employees unable to work remotely, including those in research and development, quality, manufacturing, distribution and sales roles. Such measures included the institution of robust hygiene practices, distribution of personal protective equipment, and the adoption of increased sanitation and social distancing protocols. We continue to actively monitor the COVID-19 pandemic and its variants and respond based on guidance from U.S. and global health organizations, relevant governmental guidance, and evolving practices.

Employee Engagement & Wellbeing
We regularly seek employee feedback and sentiment about our workplace through global engagement surveys conducted on a bi-annual basis. After each survey is complete, we share detailed results with senior management and all employees within each department. Each function or division appoints survey administrators who work with their respective teams to understand the feedback and establish action items. We believe this process enables us to monitor employee engagement and create a continuously improving, satisfying work environment for our employees.

We are committed to improving the quality of life of our employees and their families. Our health and wellbeing programs differ by country and typical benefits include comprehensive health insurance, disability coverage, workplace accommodations, parental leave and other leaves of absence based on health or life events (e.g., bereavement), employee assistance programs, fitness reimbursement, and flu shots. We also provide on-demand health advocates to help employees navigate the health insurance system, access to digital health solutions, a weight management program, smoking cessation assistance, a substance use disorder helpline, a diabetes health program and other similar programs to drive healthy behaviors and awareness.

FINANCIAL INFORMATION ABOUT GEOGRAPHIC AREAS
Financial information about our geographical areas is set forth in our financial statements Note 16, Segment and Geographic Information, to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K).
AVAILABLE INFORMATION
We are subject to the informational requirements of the Securities Exchange Act of 1934, as amended, (the “Exchange Act"). In accordance with the Exchange Act, we file annual, quarterly and special reports, proxy statements and other information with the Securities and Exchange Commission, ("the SEC"). Our financial information may be viewed, including the information contained in this report, and other reports we file with the SEC, on the Internet, without charge as soon as reasonably practicable after we file them with the SEC, in the “SEC Filings” page of the Investor Relations section of our website at www.integralife.com. A copy may also be obtained for any of these reports, without charge, from our Investor Relations department, 1100 Campus Road, Princeton, NJ 08540. Alternatively, reports filed may be viewed or obtained through the SEC's website at www.sec.gov.
 
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
We have made statements in this report, including statements under “Business” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, ("the Securities Act"), and Section 21E of the Exchange Act. These forward-looking statements are subject to a number of risks, uncertainties and assumptions about us including, among other things:
•the on-going and possible future effects of the COVID-19 pandemic and associated economic disruptions, including supply chain constraints and inflation, on our business, financial condition, results of operations and cash flows;
•general economic and business conditions, both nationally and in our international markets, including the effect of the continuing worldwide macroeconomic uncertainty;
16

•our expectations and estimates concerning future financial performance, financing plans and the impact of competition;
•anticipated trends in our business;
•anticipated demand for our products, particularly capital equipment;
•our ability to produce and deliver products in sufficient quantities to meet sales demands;
•our expectations concerning our ongoing restructuring, integration and manufacturing transfer and expansion activities;
•existing and future regulations affecting our business, and enforcement of those regulations;
•our failure to comply with the substantial regulation related to quality standards applicable to our manufacturing and quality processes could have an adverse effect on our business, financial condition, or results of operations;
•our ability to obtain additional debt and equity financing to fund capital expenditures, working capital requirements and acquisitions;
•physicians' willingness to adopt our recently launched and planned products, third-party payors' willingness to provide or continue reimbursement for any of our products and our ability to secure regulatory approval for products in development;
•initiatives launched by our competitors;
•our ability to protect our intellectual property, including trade secrets;
•our ability to complete acquisitions, integrate operations post-acquisition and maintain relationships with customers of acquired entities;
•our ability to remediate all matters identified in FDA observations and warning letters that we received or may receive; and
•other risk factors described in Item 1A. "Risk Factors" in this Annual Report on Form 10-K.
Forward-looking statements can be identified by forward-looking words such as “believe,” “may,” “could,” “might,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “seek,” “plan,” “expect,” “should,” “would” and similar expressions in this report. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.
ITEM 1A. RISK FACTORS
GLOBAL CHALLENGES AND MACROECONOMIC CONDITIONS
The continuing worldwide macroeconomic and geopolitical uncertainty may adversely affect our business and prospects.
Global economic disruptions, including the COVID-19 pandemic, have continued to impact the global supply chain, primarily through constraints on raw materials and electronic components. Additionally, we have observed a reduction in both inbound and outbound transportation capacity as a result of port closures and delays associated with the pandemic, which is causing longer lead times in receiving raw materials, as well as increased freight costs. These highly competitive and constrained supply chain conditions are increasing our cost of sales, which has and may continue to adversely impact our profitability. Given the ongoing uncertainty regarding the duration and extent of the COVID-19 pandemic, we are uncertain as to the duration and extent of constraint on our supply chain and are unable to predict the extent to which it will affect our global operations.
Continued concerns about the systemic impact of potential long-term and wide-spread recession and geopolitical issues, including the war in Ukraine, have contributed to increased market volatility and diminished expectations for economic growth in the world. Our business and results of operations have been and may continue to be adversely impacted by changes in macroeconomic conditions, including inflation, rising interest rates and the accessibility of capital markets. Uncertainty about global economic conditions may also cause decreased demand for our products and services and increased competition, which could result in lower sales volume and downward pressure on the prices for our products, longer sales cycles, and slower adoption of new technologies. A weakening of macroeconomic conditions may also adversely affect our suppliers, which could result in interruptions in supply.
Market acceptance of our medical products in the U.S. and other countries is dependent upon the medical equipment purchasing and procurement practices of our customers, patient need for our products and procedures and the reimbursement of patients' medical expenses by government healthcare programs and third-party payors. The continuing uncertainty surrounding global economic conditions and financial markets may cause the purchasers of medical equipment to decrease their procurement activities. Economic uncertainty, an increase in unemployment rates, as well as increasing health insurance premiums, co-payments and deductibles may adversely affect demand for our products and procedures. Furthermore, governments and other third-party payors around the world facing tightening budgets could move to further reduce the reimbursement rates or the scope of coverage offered, which could adversely affect sales of our products.
Public health crises, such as the COVID-19 pandemic, have had, and could in the future have, a negative effect on our business.
17

Our global operations and interactions with healthcare systems, providers and patients around the world expose us to risks associated with public health crises, including epidemics and pandemics such as COVID-19. In particular, the COVID-19 pandemic continues to cause significant volatility and uncertainty in the global and regional economies, leading to changes in consumer and business behavior, market fluctuations, materials and product shortages and restrictions on business and individual activities, all of which are materially impacting supply and demand in broad sectors of the world markets. Additionally, the COVID-19 pandemic, together with general macroeconomic conditions, have led to disruptions in the global supply chain, primarily through a lack of availability of raw materials and electronic components. We have experienced challenges associated with material and component availability for certain product lines, longer shipping and delivery times for raw materials and components, constrained logistics capacity related to the movement of our products, availability of skilled labor and increased costs of raw materials, components, labor, and freight and courier services. Regional COVID-19 case volumes (including those related to subsequent variants), actions taken by governmental authorities, private businesses and individuals, such as “shelter-in-place” orders and restrictions on travel and access to our customers or temporary closures of our facilities or the facilities of our suppliers, disruption and/or higher costs to the Company’s supply chain, staffing shortages in hospitals and labor constraints in our facilities, could further impact our gross margins and our ability to ship our products and supply our customers.
The emergence of new variants, vaccinations and public health measures are driving the pace of economic recovery unevenly in various regions. The direct and indirect disruptions caused by the pandemic and the responses of both governments and individuals could negatively impact the number of surgical and medical intervention procedures performed and have a material adverse effect on our business, financial condition, results of operations, or cash flows. The extent to which fear of exposure to or actual effects of COVID-19, new variants, disease outbreak, epidemic or a similar widespread health concern impacts our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the speed and extent of geographic spread of the disease, the duration of the outbreak, travel restrictions, the efficacy of vaccination and treatment; impact on the U.S. and international healthcare systems, the U.S. economy and worldwide economy; the timing, scope and effectiveness of U.S. and international governmental response; and the impact on the health, well-being and productivity of our employees.
RISKS RELATING TO OUR BUSINESS
Our operating results may fluctuate.
Our operating results, including components of operating results such as gross margin and operating expenses, may fluctuate from time to time, and such fluctuations could affect our stock price. Our operating results have fluctuated in the past and can be expected to do so from time to time in the future. Some of the factors that may cause these fluctuations include:
•economic conditions worldwide, which could affect the ability of hospitals and other customers to purchase our products and could result in a reduction in elective and non-reimbursed operative procedures;
•the impact of acquisitions, our ability to integrate acquisitions, and our restructuring activities including portfolio rationalization, and divestitures;
•risks related to COVID-19 and other epidemics or similar widespread health concerns;
•expenditures for major initiatives, including acquired businesses and integrations thereof and restructuring;
•the timing of significant customer orders, which tend to increase in the fourth quarter coinciding with the end of budget cycles;
•increased competition for a wide range of customers across all our product lines in the markets our products are sold;
•market acceptance of our existing products, as well as products in development;
•retention of current employees and recruiting of new employees in light of market competition for talent and relevant skills;
•the timing of regulatory approvals as well as changes in country-specific regulatory requirements;
•changes in the exchange rates between the U.S. dollar and foreign currencies of countries in which we do business;
•changes in the variable interest rates of our debt instruments which could impact debt service requirements;
•potential backorders, lost sales and expenses incurred in connection with product recalls or field corrective actions;
•disruption of our operations and sales resulting from extreme weather conditions or natural disasters that damage our manufacturing, distribution, or infrastructure of those facilities, or the suppliers and service providers for those facilities;
•our ability to manufacture and ship our products efficiently or in sufficient quantities to meet sales demands;
•changes in the cost or decreases in the supply of raw materials and services, including sterilization, energy, steel and honey;
•the timing of our research and development expenditures;
•reimbursement for our products by third-party payors such as Medicare, Medicaid, private and public health insurers and foreign governmental health systems;
•the ability to maintain existing distribution rights to and from certain third parties;
•the ability to maintain business if or when we opt to convert such business from distributors to a direct sales model;
•the ability of our commercial sales representatives to obtain sales targets in a reasonable time frame;
18

•the impact of changes to our sales organization, continued channel expansion, including increased specialization;
•peer-reviewed publications discussing the clinical effectiveness of the products we sell;
•inspections of our manufacturing facilities for compliance with Quality System Regulations (Good Manufacturing Practices), which could result in Form 483 observations, warning letters, injunctions or other adverse findings from the FDA or from equivalent regulatory bodies, and corrective actions, procedural changes and other actions that we determine are necessary or appropriate to address the results of those inspections, any of which may affect production and our ability to supply our customers with our products;
•changes in regulations or guidelines that impact the sales and marketing practices for products that we sell;
•the increased regulatory scrutiny of certain of our products, including products which we manufacture for others, could result in removal from the market or involve field corrective actions that could affect the marketability of our products;
•enforcement or defense of intellectual property rights;
•changes in tax laws, or their interpretations; and
•the impact of goodwill and intangible asset impairment charges if future operating results of the acquired businesses are significantly less than the results anticipated at the time of the acquisitions.
The industry and market segments in which we operate are highly competitive, and we may be unable to compete effectively with other companies.
There is intense competition among medical device companies. We compete with established medical technology companies in many of our product areas. Competition also comes from early-stage companies, universities, research institutions and other non-profit entities. In certain cases, our products compete primarily against medical practices that treat a condition without using a device or any particular product, such as the medical practices that use autograft tissue instead of our dermal regeneration products, duraplasty products and nerve repair products, or that use other technologies that cost less than our products. Many of our competitors have access to greater financial, technical, research and development, marketing, manufacturing, sales, distribution, administrative, consulting and other resources than we do. Our competitors may be more effective at developing commercial products or navigating the regulatory approval process in the markets in which we operate. They may be able to gain market share by offering lower-cost products or products that enjoy better reimbursement from third-party payors and foreign governmental health systems.
Our competitive position depends on our ability to achieve market acceptance for our products, develop new products, implement marketing plans, secure regulatory approval for products under development, demonstrate clinical and economic effectiveness, obtain and maintain reimbursement coverage and funding under third-party payors and foreign governmental health systems, obtain patent protection and produce products consistently in sufficient quantities to meet demand. We may need to develop new applications for our products to remain competitive. Technological advances by one or more of our current or future competitors or their achievement of superior reimbursement from third-party payors and foreign governmental health systems could render our present or future products obsolete or uneconomical. Our future success will depend upon our ability to compete effectively against current technology as well as to respond effectively to technological advances, changes in customers' requirements or in payor or regulatory evidence requirements. Additionally, purchasing decisions of our customers may be based on clinical evidence or comparative effectiveness studies and, because of our vast array of products, we might not be able to fund the studies necessary to gain entry or maintain our position or provide the required information to compete effectively. Other companies may have more resources available to fund such studies. For example, competitors have launched and are developing products to compete with our dural repair products, regenerative skin, neuro critical care monitors and ultrasonic tissue ablation devices, among others. In the current environment of managed care, consolidation among health care providers, increased competition, and declining reimbursement rates, we have been increasingly required to compete on the basis of price. Competitive pressures could adversely affect our profitability. Given these factors, we cannot guarantee that we will be able to compete effectively or continue our level of success in the areas in which we compete.
Changes in the healthcare industry may require us to decrease the selling price for our products, may reduce the size of the market for our products, or may eliminate a market, any of which could have a negative impact on our financial performance.
Trends toward managed care, healthcare cost containment and other changes in government and private sector initiatives in the U.S. and other countries in which we do business are placing increased emphasis on the delivery of more cost-effective medical therapies that could adversely affect the sale and/or the prices of our products. For example:
•third-party payors of hospital services and hospital outpatient services, including Medicare, Medicaid, private and public health insurers and foreign governmental health systems, annually revise their payment methodologies, which can result in stricter standards for reimbursement of hospital charges for certain medical procedures or the elimination of reimbursement;
•several foreign countries have implemented reforms of their respective healthcare sectors in an effort to reduce healthcare spending, including restricting funding to only those medical technologies and procedures with proven effectiveness, increasing patient co-payments and providing for payback measures. Governmental health systems have revised and continue to consider revisions of healthcare budgets, which could result in stricter standards for implementing certain medical procedures, increased scrutiny of medical devices, and downward pricing pressure;
19

•Medicare, Medicaid, private and public health insurer and foreign governmental cutbacks could create downward pricing pressure on our products;
•in the U.S., Medicare and Medicaid coverage as well as commercial payor coverage determinations could reduce or eliminate reimbursement or coverage for certain of our wound matrix, amniotic, surgical reconstruction and advanced wound dressing products as well as other products in most regions, negatively affecting our market for these products, and future determinations could reduce or eliminate reimbursement or coverage for these products in other regions and could reduce or eliminate reimbursement or coverage for other products;
•there has been a consolidation among healthcare facilities and purchasers of medical devices in the U.S., some of whom prefer to limit the number of suppliers from whom they purchase medical products, and these entities may decide to stop purchasing our products or demand discounts on our prices;
•in the U.S., we are party to contracts with group purchasing organizations, which negotiate pricing for many member hospitals, require us to discount our prices for certain of our products and limit our ability to raise prices for certain of our products, particularly surgical instruments;
•there is economic pressure to contain healthcare costs in domestic and international markets, and, regardless of the consolidation discussed above, providers generally are exploring ways to cut costs by eliminating purchases or driving reductions in the prices that they pay for medical devices, or increasing clinical or economic evidence thresholds for product formularies;
•there are proposed and existing laws, regulations and industry policies in domestic and international markets regulating the sales and marketing practices and the pricing and profitability of companies in the healthcare industry;
•proposed laws or regulations may permit hospitals to provide financial incentives to doctors for reducing hospital costs, will award physician efficiency, and will encourage partnerships with healthcare service and goods providers to reduce prices; and
•there have been initiatives by third-party payors and foreign governmental health systems to challenge the prices charged for medical products that could affect our ability to sell products on a competitive basis.
Any and all of the above factors could materially and adversely affect our levels of revenue and our profitability.
Our current strategy involves growth through acquisitions, which requires us to incur substantial costs and potential liabilities for which we may never realize the anticipated benefits, and also requires us to successfully integrate acquired businesses into our business operations in order to avoid our business being materially and adversely affected.
In addition to internally generated growth, our current strategy involves growth through acquisitions. Between January 1, 2020 and December 31, 2022, we have acquired two businesses at a total cost of approximately $358.4 million which amount includes our acquisition of ACell, Inc. in January 2021 for $306.9 million and our acquisition of Surgical Innovation Associates, Inc. for $51.5 million in December 2022. Both of these acquisitions added products to our complex wound management and plastic and reconstructive surgery product portfolios, respectively, and provides additional growth opportunities for our TT segment.
We may be unable to continue to implement our growth strategy and it may ultimately be unsuccessful. A significant portion of our growth in revenues has resulted from, and is expected to continue to result from, the acquisition of businesses or products complementary to our own. We engage in evaluations of potential acquisitions and are in various stages of discussion regarding possible acquisitions, certain of which, if consummated, could be significant to us. Any new acquisition could result in material transaction expenses, increased operating, amortization and interest expenses, and possible in-process research and development charges for acquisitions that do not meet the definition of a “business,” any of which could have a material, adverse effect on our operating results. Certain businesses that we acquire may not have adequate financial, disclosure, regulatory, quality or other compliance controls at the time we acquire them and could require significant expenditures to address those controls or subject us to increased risk. As we grow by acquisition, we must manage and integrate the new businesses to bring them into our systems for financial, disclosure, compliance, regulatory and quality control, realize economies of scale, and control costs. Failure to integrate acquired businesses and operations (including acquired employees and systems), retain key customers and suppliers of any acquired business or manage the cost of providing our products or price our products appropriately could preclude realization of the full benefits that we expect from there transactions. Our failure to meet the challenges involved in integrating the business in order to realize the anticipated benefits of the acquisitions could cause an interruption of, or loss of momentum in, our activities and could materially and adversely affect our results of operations. In addition, acquisitions involve other risks, including diversion of management resources otherwise available for the running of our business and the development of our business as well as risks associated with entering markets in which our marketing teams and sales force has limited experience or where experienced distribution alliances are not available. Some acquisitions may include the need for ongoing product development to occur consistent with time sensitive milestones in order for the Company to achieve its commercial projections for the acquisition. Our future profitability will depend in part upon our ability to develop our resources to adapt to these new products or business areas and to identify and enter into or maintain satisfactory distribution networks. As a result of our acquisitions of other healthcare businesses, we may be subject to the risk of unanticipated business uncertainties, regulatory and other compliance matters or legal liabilities relating to those acquired businesses for which the sellers of the acquired businesses may not indemnify us, for which we may not be able to obtain insurance (or adequate insurance), or for which the indemnification may not be sufficient to cover the ultimate liabilities. We
20

may not be able to identify suitable acquisition candidates in the future, obtain acceptable financing or consummate any future acquisitions. Certain potential acquisitions are subject to antitrust and competition laws, which laws could impact our ability to pursue strategic acquisitions and could result in mandated divestitures. If we are unsuccessful in our acquisition strategy, we may be unable to meet our financial targets and our financial performance could be materially and adversely affected.
These risks may be heightened in cases where the majority of the former businesses’ operations, employees and customers are located outside the U.S. Any one or all of these factors could increase operating costs or lower anticipated financial performance. Many of these factors are also outside of our control. In addition, dispositions of certain key products, technologies and other rights, including pursuant to conditions imposed on us to obtain regulatory approvals, may affect our business operations.
Even if the operations of the businesses are integrated successfully, we may not realize the full benefits of the acquisition, including the synergies, cost savings or sales or growth opportunities that we expect. These benefits may not be achieved within the anticipated time frame, or at all. Additional unanticipated costs could be incurred in the integration of the businesses. All of these factors could cause a reduction to our earnings per share, decrease or delay the expected accretive effect of the transaction, and negatively impact the price of our common stock.
Our future financial results could be adversely affected by impairments or other charges.
We are required to test both goodwill and indefinite-lived intangible assets for impairment on an annual basis based upon a fair value approach, rather than amortizing them over time. We are also required to test goodwill and indefinite-lived intangible assets for impairment between annual tests if an event occurs such as a significant decline in revenues or cash flows for certain products, or the discount rates used in the calculations of discounted cash flows change significantly, or circumstances change that would more likely than not reduce our enterprise fair value below its book value. If such a decline, rate change or circumstance were to materialize, we may record an impairment of these intangible assets that could be material to the financial statements. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Estimates” of this report.
The guidance on long-lived assets requires that we assess the impairment of our long-lived assets, including finite-lived intangible assets, whenever events or changes in circumstances indicate that the carrying value may not be recoverable as measured by the sum of the expected future undiscounted cash flows.
Also, Company decisions and other economic factors relating to our trade names may occur over time. For instance, we may discontinue certain products in the future as we continue to assess the profitability of our product lines. As a result, we may need to record impairment charges or accelerate amortization on certain trade names or technology-related intangible assets in the future.
The value of a medical device business is often volatile, and the assumptions underlying our estimates made in connection with our assessments under the guidance may change as a result of that volatility or other factors outside our control and may result in impairment charges. The amount of any such impairment charges could be significant and have a material, adverse effect on our reported financial results for the period in which the charge is taken and could have an adverse effect on the market price of our securities, including the notes and the common stock into which they may be converted.
Lack of market acceptance for our products or market preference for technologies that compete with our products could reduce our revenues and profitability.
Market acceptance of our products depends on many factors, including our ability to convince prospective customers that our technology is an attractive alternative to other technologies, to manufacture products in sufficient quantities and at acceptable costs, and to supply and service sufficient quantities of our products directly or through our distribution alliances. For example, the use of autograft tissue is a well-established means for repairing the dermis, and it competes for acceptance in the market with our collagen-based wound care products. In addition, unfavorable payment amounts or adverse coverage determinations of third-party payors, including Medicare, Medicaid, private and public health insurers, and foreign governmental health systems, regarding our products or third-party determinations that favor a competitor’s product over ours, could harm acceptance or continued use of our products. For example, greater market acceptance of our wound graft products may ultimately depend on our ability to demonstrate that coverage and reimbursement are available and favorable, or because they are an attractive, cost-effective alternative to other treatment options.
If there are negative events in the healthcare industry, whether real or perceived, there could be a negative impact on the industry as a whole. The industry is subject to rapid and continuous change arising from, among other things, consolidation, technological improvements, the pressure on governments, third-party payors and providers to reduce healthcare costs, and healthcare reform legislation and initiatives domestically and internationally. In addition, our future success depends, in part, on our ability to license and develop additional products. Even if we determine that a product candidate has medical benefits, the cost of commercializing, either through internal development or payments associated with licensing arrangements, could be too high to justify development and we could ultimately face competitors with more effective products and better reimbursement status that cost less and are ready for commercial introduction before our products. If we are unable to develop additional commercially viable products, our future prospects could be materially and adversely affected.
21

One or more of these factors could vary unpredictably, and such variations could have a material, adverse effect on our competitive position. We may not be able to adjust our contemplated plan of development to meet changing market demands.
It could be difficult to replace some of our suppliers.
Outside vendors, some of whom are sole-source suppliers, provide key components and raw materials used in the manufacture of our products. Although we believe that alternative sources for many of these components and raw materials are available, any interruption in supply of a limited or sole-source component or raw material could harm our ability to manufacture our products until a new or alternative source of supply is identified and qualified. In addition, an uncorrected defect or supplier’s variation in a component or raw material, either unknown to us or incompatible with our manufacturing process, could harm our ability to manufacture products. We may not be able to find a sufficient alternative supplier in a reasonable time period, or on commercially reasonable terms, if at all, and our ability to produce and supply our products could be impaired. We believe that these factors are most likely to affect the following products that we sell:
•our collagen-based products and bovine-based products, such as the Integra Dermal Regeneration Template and wound matrix products, the DuraGen® family of products, our Absorbable Collagen Sponges, PriMatrix® and SurgiMend products;
•our products made from silicone, such as our neurosurgical shunts and drainage systems and hemodynamic shunts;
•products which use many different specialty parts, electrical components, or chemicals from numerous suppliers, such as our intracranial monitors, shunts, catheters, tissue ablation, and headlights;
•our biosynthetic products, including the DuraSeal sealant system and DuraSorb biosynthetic mesh scaffold;
•products which are amniotic tissue-based
•products which are porcine tissue-based;
•products that use medical grade leptospermum honey, such as our Medihoney products; and
•our TCC-EZ® total contact cast system products.
The availability of amniotic tissue-based products depends upon, among other factors, the availability of tissue from human donors. Access to donated amniotic tissue could also be adversely impacted by regulatory changes or evolving public perceptions of the donor process.
Additionally, many of our products require sterilization by third-party suppliers. To the extent these suppliers are unable to provide sterilization services, whether due to lack of capacity, regulatory requirements, environmental concerns such as those relating to ethylene oxide or otherwise, we may be unable to transition sterilization to other suppliers in a timely or cost effective manner, or at all, which could have an adverse impact on our operating results.
Our supply chain and our cost of goods also may be negatively impacted by unanticipated price increases due to factors such as global economic disruptions, electronic component shortages, fear of future or ongoing pandemics, inflation, including wage inflation, recessionary conditions and geopolitical events, including the war in Ukraine, all of which are beyond our control or the control of our suppliers.
While it is our policy to maintain sufficient inventory of components so that our production will not be significantly disrupted even if a particular component or material is not available for a period of time, we remain at risk that we will not be able to qualify new components or materials quickly enough to prevent a disruption if one or more of our suppliers ceases production of important components or materials.
We may experience difficulties, delays, performance impact or unexpected costs from consolidation of facilities and transfer of manufacturing facilities.
In recent years, we consolidated several facilities or transferred manufacturing operations from third parties to our existing internal manufacturing facilities and may further undertake similar consolidations or transfers in the future in order to improve our cost structure, achieve increased operating efficiencies, and improve our competitive standing or results of operations and/or to address unfavorable economic conditions. As part of these initiatives, we may also lose favorable tax incentives or not be able to renew leases on acceptable terms. We may further reduce staff, make changes to certain capital projects, close certain production operations and abandon leases for certain facilities that will not be used in our operations. In conjunction with any actions, we will continue to make significant investments and build the framework for our future growth. We may not realize, in full or in part, the anticipated benefits and savings from these efforts because of unforeseen difficulties, delays, implementation issues or unexpected costs. If we are unable to achieve or maintain all of the resulting savings or benefits to our business or other unforeseen events occur, our business and results of operations may be adversely affected.

We may have significant product liability exposure and our insurance may not cover all potential claims.
We are exposed to product liability and other claims if our technologies or products are alleged to have caused harm. We may not be able to obtain insurance for the potential liability on acceptable terms with adequate coverage or at reasonable costs. Any potential product liability claims could exceed the amount of our insurance coverage or may be excluded from coverage under the terms of the policy. Our insurance may not be renewed at a cost and level of coverage comparable to that then in effect.
22

Economic and political instability around the world could adversely affect the ability of hospitals, other customers, suppliers and distributors to access funds or otherwise have available liquidity, which could reduce orders for our products or interrupt our production or distribution or result in a reduction in elective and non-reimbursed operative procedures.
Economic and political instability around the world could adversely affect the ability of hospitals and other customers to access funds to enable them to fund their operating and capital budgets. As a result, hospitals and other customers could reduce budgets or put all or part of their budgets on hold or close their operations, which could have a negative effect on our sales, particularly the sales of capital equipment such as our ultrasonic surgical aspirators, neuromonitors and cranial stabilization products, or result in a reduction in elective and non-reimbursed procedures. The occurrence of those economic conditions could make it more difficult for us to accurately forecast and plan our future business activities and depending on their severity, could have a material, adverse effect on our business, financial condition and results of operations.
Our private-label product lines depend significantly on key relationships with third parties, which we could be unable to establish and maintain.
Our private-label business depends in part on entering into and maintaining long-term supply agreements with third parties. The third parties with whom we have entered into agreements might terminate these agreements for a variety of reasons, including developing other sources for the products that we supply. Termination of our most important relationships could adversely affect our expectations for the growth of private-label products.
RISKS RELATED TO OUR REGULATORY ENVIRONMENT
The adoption of healthcare reform in the U.S. and initiatives sponsored by other governments may adversely affect our business, results of operations and/or financial condition.
Our operations may be substantially affected by potential fundamental changes in the global political, economic and regulatory landscape of the healthcare industry. Government and private sector initiatives to limit the growth of healthcare costs are continuing in the U.S., and in many other countries in which we do business, causing the marketplace to put increased emphasis on the delivery of more cost-effective treatments. These initiatives include price regulation, competitive pricing, coverage and payment policies, comparative effectiveness of therapies, technology assessments and managed-care arrangements. The adoption of some or all of these initiatives could have a material, adverse effect on our financial condition and results of operations.
In the United States, the Patient Protection and Affordable Care Act (the “ACA”), signed into law in March 2010, includes several provisions that impact our businesses in the U.S. The ACA includes provisions that, among other things, reduce and/or limit Medicare reimbursement, require all individuals to have health insurance (with limited exceptions), and require detailed disclosure of transfers of value made to healthcare professionals. Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted, including The Budget Control Act of 2011, The American Taxpayer Relief Act of 2012 and Medicare Access and CHIP Reauthorization Act of 2015, which, among other things, have reduced payments under Medicare and Medicaid to certain healthcare providers or altered the formula by which Medicare makes annual payment adjustments. Congress also drafts and introduces, from time to time, legislation that could significantly change the statutory provisions governing the regulation of medical devices. In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval or clearance of our future products under development or impact our ability to modify our currently cleared products on a timely basis. For example, over the last several years, the FDA has proposed reforms to its 510(k) clearance process, and such proposals could include increased requirements for clinical data and a longer review period, or could make it more difficult for manufacturers to utilize the 510(k) clearance process for their products.
We cannot predict what impact ongoing uncertainty regarding federal and state health reform proposals, including the implementation or repeal of the ACA, judicial review and interpretation of the ACA and other healthcare laws, instability of the insurance markets, changes in the U.S. administration and policy, an expansion in government’s role in and/or additional proposals and/or changes to the U.S. health care system or its legislation will have on our customer’s purchasing decisions and/or reimbursement which could have a material adverse effect on our business. We expect that additional state and federal health care reform measures will be adopted in the future, including those initiatives affecting coverage and reimbursement for our products, any of which could limit the amounts that federal and state governments will pay for health care products and services, which could adversely affect the growth of the market for our products or demand for our products, or result in additional pricing pressures. We cannot predict the ultimate content, timing or effect of any healthcare reform legislation or the impact of potential legislation on us. We continue to monitor the implementation of such legislation and, to the extent new market or industry trends or new governmental programs evolve, we will consider implementing or implement programs in response.

We are subject to stringent domestic and foreign medical device regulations and oversight and any adverse action may adversely affect our ability to compete in the marketplace and our financial condition and business operations.
Our products, development activities and manufacturing processes are subject to extensive and rigorous regulation by numerous government agencies, including the FDA and comparable foreign agencies, as discussed in “Part 1, Item 1. Business –
23

Government Regulation.” To varying degrees, each of these agencies monitors and enforces our compliance with laws and regulations governing the development, testing, manufacturing, labeling, marketing and distribution of our medical devices. We are also subject to regulations that may apply to certain of our products that are Drug/Device Combination products or are considered to be subject to pharmaceutical regulations outside the U.S. The process of obtaining marketing approval or clearance from the FDA and comparable foreign regulatory agencies for new products, or for enhancements or modifications to existing products could be costly, time consuming and burdensome, lead to failed clinical trials or weakened clinical evidence, involve modifications, repairs or replacements of our products and result in limitations on the indicated use of our products, which may negatively impact our ability to market our products and services, result in delays or prevent full commercial realization of future products or service. Furthermore, failure to obtain timely approvals or renewals may result in significant penalties and fines. Additional regulations govern the approval, initiation, conduct, monitoring, documentation and reporting of clinical studies to regulatory agencies in the countries or regions in which they are conducted. Failure to comply, could subject us to significant enforcement actions and sanctions, including halting the study, rejection of data generated in the study, seizure of investigational devices or data, sanctions against investigators, civil or criminal penalties, and other actions. In addition, without the data from one or more clinical studies, it may not be possible for us to secure the data necessary to support certain regulatory submissions, to secure reimbursement or demonstrate other requirements. We cannot assure that access to clinical investigators, sites and subjects, documentation and data will be available on the terms and timeframes necessary.
We are subject to extensive complex regulatory requirements by domestic and foreign government agencies and any failure to comply with our ongoing responsibilities under their applicable laws and regulations could result in a material adverse impact on our business. Failure to comply with applicable regulations could result in future product recalls, injunctions preventing the shipment of products or other enforcement actions that could have a material adverse effect on our business.
We also are subject to the European Medical Device Regulation, which was adopted by the European Union (“EU”) as a common legal framework for all EU member states. The implementation for Class I products occurred on May 26, 2021 and the EUDAMED Database was implemented on May 26, 2022. Under this regulation, companies that wish to manufacture and distribute medical devices in EU member states must meet certain quality system, and safety requirements as well as ongoing product monitoring responsibilities. Companies must also obtain a “CE” marking (i.e., a mandatory conformity marking for certain products sold within the European Economic Area) for their products. Complying with the requirements of these regulations may require us to incur significant expenditures. Expenditures for European Union Medical Device Regulation compliance activities amounted to $45.1 million for the year ended December 31, 2022 and we anticipate incurring additional expenditures in connection with our on-going efforts to obtain certification for our products under the European Medical Device Regulation. Various penalties exist for non-compliance with the laws implementing the European Medical Device Regulations which if incurred, could have a material adverse impact on our business, results of operations and cash flows.
Further, the regulatory environment in China continues to evolve, and officials in the Chinese government exercise broad discretion in deciding how to interpret and apply regulations. It is possible that the Chinese government's current or future interpretation and application of existing or new regulations will negatively impact our China operations, result in regulatory investigations or lead to fines or penalties.
In addition, we are subject to laws and regulations that govern the means by which companies in the healthcare industry may market their products to healthcare professionals and may compete by discounting the prices of their products, including for example, the federal Anti-Kickback Statute, the federal False Claims Act, the federal Health Insurance Portability and Accountability Act of 1996, state law equivalents to these federal laws that are meant to protect against fraud and abuse and analogous laws in foreign countries. Violations of these laws are punishable by criminal and civil sanctions, including, but not limited to, in some instances civil and criminal penalties, damages, fines, and exclusion from participation in federal and state healthcare programs, including Medicare and Medicaid. Although we exercise care in structuring our sales and marketing practices and customer discount arrangements to comply with those laws and regulations, we cannot assure that:
•government officials charged with responsibility for enforcing those laws will not assert that our sales and marketing practices or customer discount arrangements are in violation of those laws or regulations; or
•government regulators or courts will interpret those laws or regulations in a manner consistent with our interpretation.
We have in place policies and procedures for compliance that we believe are at least as stringent as those set forth in the AdvaMed Code of Ethics which was developed by AdvaMed, a trade association that represents the medical device industry, and which is intended to represent best practices with respect to medical device companies' interactions with healthcare providers. We regularly train our sales and marketing personnel on our policies regarding sales and marketing practices. Pursuant to the AdvaMed Code, we have certified our adoption of the AdvaMed Code. The sales and marketing practices of our industry have been the subject of increased scrutiny from federal and state government agencies, and we believe that this trend will continue. Various hospital organizations, medical societies and trade associations are establishing their own practices that may require detailed disclosures of relationships between healthcare professionals and medical device companies or ban or restrict certain marketing and sales practices such as gifts and business meals. Since these laws, regulations and ultimate enforcement continue to evolve, we cannot predict with certainty, what, if any, impact, changes to them may have on our business or our customers.
24

Outside of the U.S. we are subject to privacy and data security regulations at the international, national and regional level, as well as on an industry specific basis. For example, in Europe, we are subject to the EU General Data Protection Regulation ("GDPR") which is related to the collection, processing, storage, transfer and use of personal data. In the U.S., we are subject to the California Consumer Privacy Act of 2018 (“CCPA”) and other similar laws in the United States, at both the federal and state level. Noncompliance with GDPR could trigger fines of up to 4% of global annual revenues. In addition, we are subject to the new China Personal Information Protection Law that went into effect November 1, 2021 which focuses on protecting personal information and cross border transfers of the information. Compliance with these requirements, either individually or in the aggregate, may require changes in business practices added complexity and additional management oversight. They also may complicate our clinical research activities, as well as product offerings that involve transmission or use of clinical data. Non-compliance may result in proceedings against us by governmental or other entities and/or significant fines which could negatively impact our reputation and adversely affect our business.
Should we delay or fail to comply with one or more of the regulatory requirements we could have reduced sales, increased costs, delays to new product introductions, enhancements or our strategic plans, or harm to our reputation or competitiveness, which could have a material adverse effect on our business and financial results.
Our medical device products are subject to reporting requirements and recalls, even after receiving regulatory clearance, approval or certification, which could harm our reputation, business and financial results.
After a device is placed on the market, numerous regulatory requirements apply, which require manufacturers to follow, among other things, design, testing, production, control, documentation and other quality assurance procedures during the manufacturing process; labeling regulations, which prohibit the promotion of products for unapproved or “off-label” uses and impose other restrictions on labeling; and medical device reporting regulations that require us to report to FDA or similar governmental bodies in other countries if our products may have caused or contributed to a death or serious injury or malfunction in a way that would be reasonably likely to contribute to death or serious injury if the malfunction were to recur. The FDA and similar governmental bodies in other countries have the authority to require the recall of our products in the event of material deficiencies or defects in design or manufacture or in the event that a product poses an unacceptable risk to health. We may, under own initiative, recall a product if a reasonable possibility of serious injury or any material deficiency in a device is found, or withdraw a product to improve device performance or for other reasons.
Recalls of any of our products may divert managerial and financial resources and have an adverse effect on our financial condition and results of operations. A recall could harm our reputation with customers and consumers which could reduce the sales of our products. In addition, the FDA or other foreign governmental agencies may implement enforcement actions in connection with a recall which could impair our product offerings and be harmful to our business and financial results.
Certain of our products contain materials derived from animal sources and may become subject to additional regulation.
Certain of our products are derived from bovine or porcine tissue sources. As a result, we may experience difficulties in processing and producing our bovine and porcine tissue products at scale, including problems related to yields, quality control and assurance, tissue availability, adequacy of control policies and procedures and availability of skilled personnel.
With respect to bovine, among other products, our dermal regeneration products, duraplasty products, wound care products, bone void fillers, nerve and tendon repair products and certain other products, contain material derived from bovine tissue. In 2022, 43.3% of our revenues derived from products containing material derived from bovine tissue. Products that contain materials derived from animal sources, including food, pharmaceuticals and medical devices, are subject to scrutiny in the media and by regulatory authorities. Regulatory authorities are concerned about the potential for the transmission of disease from animals to humans via those materials. This public scrutiny has been particularly acute in Japan and Western Europe with respect to products derived from animal sources, because of concern that materials infected with the agent that causes bovine spongiform encephalopathy, otherwise known as BSE or mad cow disease, may, if ingested or implanted, cause a variant of the human Creutzfeldt-Jakob Disease, an ultimately fatal disease with no known cure. The World Organization for Animal Health recognizes the U.S. as having a negligible risk for BSE, which is the highest status available.
We take care to provide that our products are safe and free of agents that can cause disease. In particular, we qualified a source of collagen from a country outside the U.S. that is considered BSE/TSE-free. The World Health Organization classifies different types of bovine tissue for relative risk of BSE transmission. Deep flexor tendon and bovine fetal skin, which are used in our products, are in the lowest-risk categories for BSE transmission and are therefore considered to have a negligible risk of containing the agent that causes BSE (an improperly folded protein known as a prion). Nevertheless, products that contain materials derived from animals, including our products, could become subject to additional regulation, or even be banned in certain countries, because of concern over the potential for the transmission of prions. Significant new regulations, or a ban of our products, could have a material, adverse effect on our current business or our ability to expand our business.

Certain countries, such as Japan, China, Taiwan and Argentina, have issued regulations that require our collagen products be sourced from countries where no cases of BSE have occurred, and the EU has requested that our dural replacement products and other products that are used in neurological tissue be sourced from a country where no cases of BSE have occurred. Currently, we source bovine fetal hides from the U.S. and purchase tendon from the U.S. and New Zealand. New Zealand has
25

never had a case of BSE. We received approval in the U.S., the EU, Japan, Taiwan, China, Argentina as well as other countries for the use of New Zealand-sourced tendon in the manufacturing of our products. If we cannot continue to use or qualify a source of tendon from New Zealand or another country that has never had a case of BSE, we could be prohibited from selling our collagen products in certain countries.
We are subject to current and potential future requirements relating to protection of the environment, such as hazardous materials regulations, which may impose significant compliance or other costs on us.
Certain of our processes in manufacturing and research and development involve the controlled use of certain hazardous materials. In addition, we own and/or lease a number of facilities at which hazardous materials have been used in the past. Finally, we have acquired various companies that historically have used certain hazardous materials and that have owned and/or leased facilities at which hazardous materials have been used. For all of these reasons, we are subject to federal, state, foreign, and local laws and regulations governing the use, manufacture, storage, transportation, handling, treatment, remediation, and disposal of hazardous materials and certain waste products (“Environmental, Health, Safety and Transportation Laws”). Although we believe that our procedures for handling, transporting, and disposing of hazardous materials comply with the Environmental, Health, Safety and Transportation Laws, such laws may be amended in ways that increase our cost of compliance, perhaps materially.
Furthermore, the potential risk of accidental contamination or injury from these materials cannot be eliminated, and there is also a risk that such contamination previously has occurred in connection with one of our facilities or in connection with one of the companies we have purchased. In the event of such an accident or contamination, we could be held liable for any damages that result and any related liability could exceed the limits or fall outside the coverage of our insurance and could exceed our resources. We may not be able to maintain insurance on acceptable terms or at all.
Our business and operations are subject to risks related to climate change.
The long-term effects of global climate change present both physical risks (from the increased frequency of extreme weather conditions or natural disasters) and transition risks (from regulatory requirements or technology changes). Such extreme weather conditions could pose physical risks to our facilities and disrupt operation of our supply chain and may impact operational costs. Concern over global climate change could result in new legal or regulatory requirements designed to mitigate the effects of climate change on the environment. If such laws or regulations are more stringent than current legal or regulatory requirements, we may experience increased compliance burdens and costs to meet the regulatory obligations and such measures may interrupt our operations or the operations of our suppliers, potentially leading to higher costs, and therefore negatively impact our results of operations.
We are subject to requirements relating to information technology which could adversely affect our business.
If we are unable to maintain reliable information technology systems and prevent disruptions, outages, or data breaches, we may suffer regulatory consequences in addition to business consequences. Our worldwide operations means that we are subject to laws and regulations, including data protection and cyber security laws and regulations, in many jurisdictions. The variety of U.S. and international privacy and cybersecurity laws and regulations impacting our operations are described in “Item 1. Business - Government Regulation - Other Factors - Data Privacy and Cybersecurity Laws and Regulations." We have programs to ensure compliance with such laws and regulations. However, there is no guarantee that we will avoid enforcement actions by governmental bodies. Enforcement actions may be costly and interrupt regular operations of our business. In addition, there has been a developing trend of civil lawsuits and class actions relating to breaches of consumer data held by large companies or incidents arising from other cyber-attacks. While Integra has not been named in any such suits, if a substantial breach or loss of data were to occur, we could become a target of such litigation.
If we do not retain our key personnel and attract and retain other highly skilled employees, our business could suffer.
If we fail to recruit, develop and retain the necessary personnel, our business and our ability to obtain new customers, develop new products and provide acceptable levels of customer service could suffer. The success of our business is heavily dependent on the leadership of our key management personnel. Our success also depends on our ability to recruit, develop and retain and motivate highly skilled sales, marketing, manufacturing and scientific personnel. Competition for these persons in our industry is intense, and we may not be able to successfully recruit, train or retain qualified personnel. We are experiencing increasing challenges in building and retaining our workforce in certain markets, where pressure from inflation and competition have exacerbated turnover and retention trends continuing from the COVID-19 pandemic. Labor shortages and competition for qualified personnel could cause disruptions in our business operations.

RISKS RELATED TO TAX AND DEBT
We may have additional tax liabilities.
We are subject to income taxes in the U.S. and many foreign jurisdictions and are commonly audited by various tax authorities. In the ordinary course of our business, there are many transactions and calculations where the ultimate tax determination is uncertain. Significant judgment is required in determining our worldwide provision for income taxes. Although we believe that our tax estimates are reasonable, the final determination of tax audits and any related litigation could be materially different
26

from our historical income tax provisions and accruals. The results of an audit or litigation could have a material, adverse effect on our financial statements in the period or periods for which that determination is made.
Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company's operating results.
We are subject to income taxes, as well as taxes that are not income-based, in both the U.S. and many foreign jurisdictions. Taxes could significantly increase due to changes in tax laws or changes in our interpretation of those laws. For example, the Organization for Economic Co-operation and Development, a global policy forum, is developing a global tax framework that, if implemented, includes a global minimum tax rate of 15%. Taxes could also significantly increase due to changes in accounting guidance. Our future effective tax rate could be unfavorably affected by numerous factors including a change in, or the interpretation of, tax rules and regulations in the jurisdictions in which we operate (including changes in legislation currently being considered), a change in our geographic earnings mix, and/or to the jurisdictions in which we operate, or a change in the measurement of our deferred taxes.
Our leverage and debt service obligations could adversely affect our business.
Our leverage and debt service obligations could adversely affect our business. As of December 31, 2022, our total consolidated external debt was approximately $1.5 billion (See Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations and Note 5, Debt, to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K) for a discussion of our consolidated external debt). We may also incur additional indebtedness in the future. Our substantial indebtedness could have material, adverse consequences, including:
•making it more difficult for us to satisfy our financial obligations;
•increasing our vulnerability to adverse economic, regulatory and industry conditions, and placing us at a disadvantage compared to our competitors that are less leveraged;
•limiting our ability to compete and our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate; and
•limiting our ability to borrow additional funds for working capital, capital expenditures, acquisitions and general corporate or other purposes.
Our debt service obligations will require us to use a portion of our operating cash flow to pay interest and principal on indebtedness instead of for other corporate purposes, including funding future expansion of our business, acquisitions, and ongoing capital expenditures, which could impede our growth. In addition, our ability to comply with, renegotiate or extend the Company’s debt obligations will depend on our operating and financial performance, which in turn is subject to prevailing economic conditions and financial, business and other factors beyond our control. Any disruptions in our operations, the financial markets, or the overall economy, including as a result of COVID-19, may adversely affect the availability and cost of credit to us and/or our ability to comply with our existing obligations.
Changes in the calculation and or complete replacement of LIBOR could have an impact on our business.
The United Kingdom’s Financial Conduct Authority (“FCA”), which regulates LIBOR, announced in July 2017 that it will no longer persuade or require banks to submit rates for LIBOR. On March 5, 2021, the ICE Benchmark Administration, which administers LIBOR, and the FCA announced that all LIBOR settings will either cease to be provided by any administrator, or no longer be representative immediately after December 31, 2021, for all non-U.S. dollar LIBOR settings and one-week and two-month U.S. dollar LIBOR settings, and immediately after June 30, 2023 for the remaining U.S. dollar LIBOR settings. We have multiple debt facilities which utilizes a variable rate equal to Eurodollar LIBOR rate as a component of our interest rate.
Management expects all LIBOR-based contracts to be replaced by the Secured Overnight Financing Rate (“SOFR”), which is calculated based on overnight transactions under repurchase agreements backed by Treasury securities. The Alternative Reference Rates Committee, a group of private-market participants convened by the U.S. Federal Reserve Board and the New York Federal Reserve, has recommended the use of SOFR as a more robust reference rate alternative to LIBOR. The use of SOFR as a substitute for LIBOR is, however, voluntary and may not be suitable for all market participants. There can be no assurance that the replacement rate will be economically equivalent to LIBOR, which could result in higher interest rates for us under our debt facilities. There is no guarantee that a transition from LIBOR to SOFR will not result in financial market disruptions, significant increases in benchmark rates, or our borrowing costs, any of which could have an adverse effect on our business, results of operations and financial condition.

RISKS RELATED TO OUR INTELLECTUAL PROPERTY
Our intellectual property rights may not provide meaningful commercial protection for our products, potentially enabling third parties to use our technology or very similar technology and could reduce our ability to compete in the market.
To compete effectively, we depend, in part, on our ability to maintain the proprietary nature of our technologies and manufacturing processes, which includes the ability to obtain, protect and enforce patents on our technology and to protect our
27

trade secrets. We own or have licensed patents that cover aspects of some of our product lines. Our patents, however, may not provide us with any significant competitive advantage. Others may challenge our patents and, as a result, our patents could be narrowed, invalidated or rendered unenforceable. Competitors may develop products similar to ours that our patents do not cover. In addition, the approval or rejection of patent applications may take several years and our current and future patent applications may not result in the issuance of patents in the U.S. or foreign countries.
Our competitive position depends, in part, upon unpatented trade secrets, which we may be unable to protect.
Our competitive position also depends upon unpatented trade secrets, which are difficult to protect. We cannot assure that others will not independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets, that our trade secrets will not be disclosed or that we can effectively protect our rights to unpatented trade secrets.
In an effort to protect our trade secrets, we require our employees, consultants and advisors to execute confidentiality and invention assignment agreements upon commencement of employment or consulting relationships with us. These agreements provide that, except in specified circumstances, all confidential information developed or made known to the individual during the course of their relationships with us must be kept confidential. We cannot assure, however, that these agreements will provide meaningful protection for our trade secrets or other proprietary information in the event of the unauthorized use or disclosure of confidential information.
Our success will depend partly on our ability to operate without infringing or misappropriating the proprietary rights of others.
We may be sued for infringing the intellectual property rights of others. In addition, we may find it necessary, if threatened, to initiate a lawsuit seeking a declaration from a court that we do not infringe the proprietary rights of others or that their rights are invalid or unenforceable. If we do not prevail in any litigation, in addition to any damages we might have to pay, we would be required to stop the infringing activity (which could include a cessation of selling the products in question) or obtain a license for the proprietary rights involved. Any required license may be unavailable to us on acceptable terms, if at all. In addition, some licenses may be nonexclusive and allow our competitors to access the same technology we license.
If we fail to obtain a required license or are unable to design our products so as not to infringe on the proprietary rights of others, we may be unable to sell some of our products, and this potential inability could have a material, adverse effect on our revenues and profitability.
We may be involved in lawsuits relating to our intellectual property rights and promotional practices, which may be expensive.
To protect or enforce our intellectual property rights, we may have to initiate or defend legal proceedings, such as infringement suits or opposition proceedings, against or by third parties. In addition, we may have to institute proceedings regarding our competitors’ promotional practices or defend proceedings regarding our promotional practices. Legal proceedings are costly, and, even if we prevail, the cost of the legal proceedings could affect our profitability. In addition, litigation is time-consuming and could divert management's attention and resources away from our business. Moreover, in response to our claims against other parties, those parties could assert counterclaims against us.
RISKS RELATED TO GLOBAL OPERATIONS
If any of our facilities or those of our suppliers were damaged and/or our manufacturing or business processes interrupted, we could experience lost revenues and our business could be seriously harmed.
Damage to our manufacturing, distribution, development and/or research facilities because of fire, extreme weather conditions, natural disaster, power loss, communications failure, geopolitical disruption, unauthorized entry or other events, such as a flu or other health epidemic, such as COVID-19, could significantly disrupt our operations, the operations of suppliers and critical infrastructure and delay or prevent product manufacture and shipment during the time required to repair, rebuild or replace the damaged facilities. Certain of our manufacturing facilities are located in Puerto Rico, which in the past has experienced both severe hurricanes and other natural disasters. Climate change may increase both the frequency and severity of extreme weather conditions and natural disasters and, consequently, risks to our operations and growth. Although we maintain property damage and business interruption insurance coverage on these facilities, our insurance might not cover all losses under such circumstances, and we may not be able to renew or obtain such insurance in the future on acceptable terms with adequate coverage or at reasonable costs.
We are exposed to a variety of risks relating to our international sales and operations.
We generate significant revenues outside the U.S. in multiple foreign currencies, and in U.S. dollar-denominated transactions conducted with customers who generate revenue in currencies other than the U.S. dollar. For those foreign customers who purchase our products in U.S. dollars, currency fluctuations between the U.S. dollar and the currencies in which those
28

customers do business may have a negative impact on the demand for our products in foreign countries where the U.S. dollar has increased in value compared to the local currency.
Since we have operations based outside the U.S. and we generate revenues and incur operating expenses in multiple foreign currencies, we experience currency exchange risk with respect to those foreign currency-denominated revenues and expenses. Our most significant currency exchange risk relates to transactions conducted in Australian dollars, British pounds, Canadian dollars, Chinese yuan, Euros, Japanese yen, and Swiss francs.
We cannot predict the consolidated effects of exchange rate fluctuations upon our future operating results because of the number of currencies involved, the variability of currency exposure and the potential volatility of currency exchange rates. Although we address currency risk management through regular operating and financing activities, and, on a limited basis, through the use of derivative financial instruments, those actions may not prove to be fully effective. For a description of our use of derivative financial instruments, see Note 6, Derivative Instruments to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K).
Our international operations subject us to laws regarding sanctioned countries, entities and persons, customs, import-export, laws regarding transactions in foreign countries, the U.S. Foreign Corrupt Practices Act and local anti-bribery and other laws regarding interactions with healthcare professionals, and product registration requirements. Among other things, these laws restrict, and in some cases prevent, U.S. companies from directly or indirectly selling goods, technology or services to people or entities in certain countries. In addition, these laws require that we exercise care in structuring our sales and marketing practices and effecting product registrations in foreign countries.
The Russia-Ukraine conflict and resulting sanctions and export restrictions are creating barriers to doing business in Russia and adversely impacting global supply chains. While we have no manufacturing, distribution or direct material suppliers in the region, we are closely monitoring the potential raw material or supplier impact in both Russia and Ukraine. Materials like palladium and neon, which are both dependent on Russia supply, are part of broader semiconductor shortages in industry. Additional sanctions, export restrictions, and potential countermeasures within Russia may lead to greater uncertainty and geopolitical shifts in Asia that could cause additional adverse impacts on global supply chains and our business, results of operations, financial condition and cash flows.
The United Kingdom’s (“UK”) exit from the European Union on January 31, 2020, commonly referred to as Brexit, has caused, and may continue to cause uncertainty in the global political markets. It is possible that Brexit could, among other things, affect the legal and regulatory environments, including the regulatory landscape concerning medical devices, to which our business is subject, impose greater restrictions on imports and exports between the UK and the EU and other parties, increase currency volatility and create economic and political uncertainty in the region.
As we seek to continue to expand and strengthen our international operations, we may experience difficulty in growing our sales in certain new markets and other international markets in which we are attempting to increase our presence due to, among other things, customer acceptance, undeveloped and/or unfamiliar distribution channels, regulatory restrictions and changes, and business knowledge of these markets.
From time to time, proposals are made to significantly change existing trade agreements and relationships between the U.S. and other countries. In recent years, the U.S. government has implemented substantial changes to U.S. trade policies, including import restrictions, increased import tariffs and changes in U.S. participation in multilateral trade agreements, such as the United States-Mexico-Canada Agreement to replace the former North American Free Trade Agreement. The ongoing global economic competition and trade tensions between the U.S. and China has resulted in the U.S. government assessing supplemental tariffs on certain goods imported from China and China’s assessment of retaliatory tariffs on certain imports of U.S. goods into China. In addition, the United States has assessed or proposed supplemental tariffs and quantitative restrictions on U.S. imports of certain products from other countries as well. Owing to the complex relationships between the U.S. and such other countries, political, diplomatic, military, or other events could result in business disruptions, including increased regulatory enforcement against companies, tariffs, trade embargoes, export restrictions and the termination or modification of existing trade agreements. The imposition of such restrictions could increase the cost of the Company’s products and the components and raw materials that go into making them, require the Company to change its operations and the products it offers and negatively impact consumer confidence and spending, all of which, both individually and in the aggregate, could materially and adversely affect our business, results of operations and financial condition.
GENERAL RISK FACTORS
Cyber-attacks or other disruptions to our information technology systems could adversely affect our business.
We are increasingly dependent on sophisticated information technology for our infrastructure and to support business decisions. Our information systems require an ongoing commitment of significant resources to maintain, protect, and enhance existing systems and develop new systems to keep pace with continuing changes in information processing technology, evolving systems and regulatory standards, the increasing need to protect patient and customer information, and changing customer
29

patterns. An experienced third party maintains the enterprise business system used to support our transaction processing, accounting and financial reporting, and supply chain and manufacturing processes. Any significant breakdown, intrusion, interruption, corruption, or destruction of these systems, as well as any data breaches, could have a material, adverse effect on our business.
Third parties may attempt to breach our systems and may obtain data relating to patients, proprietary or sensitive information. As a result of the COVID-19 pandemic, we may face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. If we, or third parties on whom we rely, fail to maintain or protect our information systems and data integrity effectively, we could lose existing customers, have difficulty attracting new customers, suffer backlash from negative public relations, have regulatory sanctions or penalties imposed, have increases in operating expenses, incur expenses or lose revenues as a result of a data privacy breach, or suffer other adverse consequences.
We have programs, processes (including ongoing improvements) and technologies in place to prevent, detect, contain, respond to and mitigate security related threats and potential incidents. Because the techniques used to obtain unauthorized access or interrupt services change frequently and can be difficult to detect, anticipating, identifying or preventing these threats or mitigating them if and when they occur, may be challenging. We are also dependent on third party vendors to supply and/or support certain aspects of our information technology systems which may contain defects in design or manufacture or other problems that could result in system disruption or unexpectedly compromise the information security of our own systems. In addition, as we grow in part through new acquisitions we may face risks due to implementation, modification, or remediation of controls, procedures, and policies relating to data privacy and cybersecurity at the acquired business. We continue to consolidate and integrate the number of systems we operate, and to upgrade and expand our information system capabilities for stable and secure business operations. Despite our implementation of controls to protect our systems and sensitive, confidential or personal data or information, we may be vulnerable to material security breaches, theft, misplaced, lost or corrupted data, employee errors and/or malfeasance (including misappropriation by departing employees) that could potentially lead to the compromising of sensitive, confidential or personal data or information, improper use of our systems, software solutions or networks, unauthorized access, use, disclosure, modification or destruction of information, defective products, production downtimes and operational disruptions. In addition, a cyber-related attack could result in other negative consequences, including damage to our reputation or competitiveness, remediation or increased protection costs, litigation or regulatory action.
Environmental, social and corporate governance (ESG) issues, including those related to climate change and sustainability, may have an adverse effect on our business, financial condition and results of operations and damage our reputation.
There is an increasing focus from certain investors, customers, consumers, employees and other stakeholders concerning ESG matters. Additionally, public interest and legislative pressure related to public companies’ ESG practices continue to grow. Consistent with these developments, we published our inaugural ESG Report which includes performance highlights in key areas such as employee health and safety, diversity and inclusion, community impact, ethics and compliance, and environmental responsibility. In addition, we formally expanded Board oversight to include ESG strategy and reporting. If, however, our ESG practices fail to meet regulatory requirements or investor, customer, consumer, employee or other stakeholders' evolving expectations and standards for responsible corporate citizenship in areas including environmental stewardship, support for local communities, Board of Director and employee diversity, human capital management, employee health and safety practices, product quality, supply chain management, corporate governance and transparency, our reputation, brand and employee retention may be negatively impacted, and our customers and suppliers may be unwilling to continue to do business with us.
If we do not adapt to or comply with new regulations, or fail to meet evolving investor, industry or stakeholder expectations and concerns regarding ESG issues, investors may reconsider their capital investment in our Company, and customers may choose to stop purchasing our products, which could have a material adverse effect on our reputation, business or financial condition.
ITEM 1B. UNRESOLVED STAFF COMMENTS
As of the filing of this Annual Report on Form 10-K, we had no unresolved comments from the staff of the Securities and Exchange Commission that were received not less than 180 days before the end of our 2022 fiscal year.
ITEM 2.PROPERTIES
As of December 31, 2022, we lease approximately 166,991 square feet of space in Princeton, NJ, where we house our principal headquarters, sales operations, and support functions. This lease expires in 2035.
30

We have key manufacturing and research facilities located in California, Indiana, Maryland, Massachusetts, New Jersey, Ohio, Puerto Rico, Tennessee, Utah, France, Germany, Ireland and Switzerland. Our instrument procurement operations are located in Germany. Our primary distribution centers are located in Kentucky, Nevada, Australia, Belgium, Canada, Italy, Japan, and China. In addition, we lease several smaller facilities to support additional administrative, assembly, and distribution operations. Third parties own and operate the facilities in Nevada, Kentucky, Japan and Belgium. We own facilities in Saint Aubin Le Monial, France, Rietheim-Weilheim, Germany and Ohio and we lease all of our other facilities. We also have repair centers in Ohio, Australia, France, Japan, China and Germany, and field service presence in Canada, Dubai, India, Italy, Netherlands, Singapore, Thailand and United Kingdom.
Our manufacturing facilities are registered with the FDA. Our facilities are subject to FDA inspection to ensure compliance with Quality System regulations. For further information regarding the status of FDA inspections, see the Item 1. Business –Government Regulation and Compliance Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations – FDA Matters in this Annual Report on Form 10-K.

ITEM 3.LEGAL PROCEEDINGS
Information pertaining to legal proceedings can be found in Note 15, Commitment and Contingencies, to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K).
ITEM 4.MINE SAFETY DISCLOSURES
Not applicable.

PART II
ITEM 5.MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Market Information, Holders and Dividends
Our common stock trades on The Nasdaq Global Select Market under the symbol “IART.” The number of stockholders of record as of February 21, 2023 was approximately 779, which includes stockholders whose shares were held in nominee name.
Dividend Policy
We have not paid any cash dividends on our common stock since our formation. Our Senior Credit Facility (as defined below) limits the amount of dividends that we may pay. Any future determinations to pay cash dividends on our common stock will be at the discretion of the Board and will depend upon our financial condition, results of operations, cash flows and other factors deemed relevant by the Board.
Sales of Unregistered Securities
There were no sales of unregistered securities during the years ended December 31, 2022, 2021 or 2020.
Sale of Registered Securities
There were no sales of registered securities during the years ended December 31, 2022, 2021 or 2020.
Issuer Purchases of Equity Securities
On January 12, 2022, the Company entered into a $125.0 million accelerated share repurchase ("2022 ASR") and received 1.48 million shares of the Company common stock at inception of the 2022 ASR, which represented approximately 80% of the expected total shares under the 2022 ASR. On March 24, 2022, the early exercise provision was exercised by 2022 ASR counterparty. Upon settlement on March 24, 2022, the Company received an additional 0.46 million shares determined using the volume-weighted average price of the Company's common stock during the term of the 2022 ASR.
On April 26, 2022, the Board of Directors authorized the Company to repurchase up to $225.0 million of the Company’s common stock. The program allows the Company to repurchase its shares opportunistically from time to time. The repurchase authorization expires in December 2024. This stock repurchase authorization replaces the previous $225 million stock repurchase authorization, of which $100 million remained authorized at the time of its replacement, and which was otherwise set to expire on December 31, 2022. Purchases may be affected through one or more open market transactions, privately negotiated transactions, transactions structured through investment banking institutions, or a combination of the foregoing.
On January 26, 2023, the Company entered into a $150 million accelerated share repurchase ("2023 ASR") and received 2.1 million shares of the Company common stock at inception of the 2023 ASR, which represented approximately 80% of the expected total shares of under the 2023 SAR. The remaining repurchase transactions are expected to be completed in the first half of 2023.
31

For the year ended December 31, 2021, there were no repurchases of the Company’s common stock as part of the share repurchase authorization.
See Note 8, Treasury Stock to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K) for further details.
Securities Authorized for Issuance under Equity Compensation Plan
The information required by this item regarding our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K.
Stock Performance Graph
The graph below compares the five-year total return to stockholders on our common stock with the return of the Standard & Poor’s (S&P) 500 Stock Index and the S&P Healthcare Equipment Index. The Company’s cumulative shareholder return is based on an investment of $100 on December 31, 2017 and is compared to the cumulative total return of the S&P indices mentioned above over the period with a like amount invested.

iart-20221231_g3.jpg

Note: The stock price performance shown on the graph above is not indicative of future price performance. This graph shall not be deemed filed for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing.
ITEM 6.[Reserved]
ITEM 7.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
32

The following discussion and analysis provides information management believes to be relevant to understanding our financial condition and results of operations. For a full understanding of financial condition and results of operations, it should be read together with the selected consolidated financial data and our financial statements with the related notes appearing elsewhere in this report. The discussion focuses on our financial results for the year ended December 31, 2022 and 2021. The comparison of fiscal 2021 to 2020 has been omitted from this Form 10-K, but can be referenced in our Form 10-K for the fiscal year ended December 31, 2021—“Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations” filed with the SEC on February 24, 2022.
We have made statements in this report which constitute forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors, including but not limited to those set forth under Item 1A. Risk Factors. We have made statements in this report which constitute forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements are subject to a number of risks, uncertainties and assumptions about the Company and other matters. Please refer to “Special Note Regarding Forward-Looking Statements” and Item 1A. Risk Factors for a discussion of the factors that could cause actual results to differ materially from those projected in these statements. The following information concerning our business, results of operations and financial condition should also be read in conjunction with the information included under Item 1. Business, Item 1A. Risk Factors and Item 15. Financial Statements and Supplementary Data.
GENERAL
Integra LifeSciences is a global leader in regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians so they can focus on providing the best patient care. Founded in 1989 with the acquisition of an engineered collagen technology platform used to repair and regenerate tissue, Integra LifeSciences Holdings Corporation common stock trades on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “IART.” Integra has developed numerous product lines from this technology for applications ranging from burn and deep tissue wounds to the repair of dura mater in the brain, as well as nerves and tendons. The Company has expanded its base regenerative technology business to include surgical instruments, neurosurgical products and advanced wound care through global acquisitions and product development to meet the evolving needs of its customers and enhance patient care.
Integra manufactures and sells medical technologies and products in two reportable business segments: Codman Specialty Surgical ("CSS") and Tissue Technologies ("TT"). The CSS segment, which represents approximately two-thirds of our total revenue, consists of market-leading technologies and instrumentation used for a wide range of specialties, such as neurosurgery, neurocritical care and otolaryngology. We are the world leader in neurosurgery and one of the top three providers in instruments used in precision, specialty, and general surgical procedures. Our TT segment generates about one-third of our overall revenue and focuses on three main areas: complex wound surgery, surgical reconstruction, and peripheral nerve repair.
We have key manufacturing and research facilities located in California, Indiana, Maryland, Massachusetts, New Jersey, Ohio, Puerto Rico, Tennessee, Utah, France, Germany, Ireland and Switzerland. We source most of our handheld surgical instruments and dural sealant products through specialized third-party vendors.
Integra is committed to delivering high quality products that positively impact the lives of millions of patients and their families. We focus on four key pillars of our strategy: 1) enabling an execution-focused culture, 2) optimizing relevant scale, 3) advancing innovation and agility, and 4) leading in customer experience. We believe that by sharpening our focus on these areas through improved planning and communication, optimization of our infrastructure, and strategically aligned acquisitions, we can build scale, increase competitiveness and achieve our long-term goals.
To this end, the executive leadership team has established the following key priorities aligned to the following areas of focus:
Strategic Acquisitions. An important part of the Company's strategy is pursuing strategic transactions and licensing agreements that increase relevant scale in the clinical areas in which Integra competes. Our growth strategy includes the acquisition of businesses, assets or products lines to increase the breadth of our offerings, the reach of our product portfolios and drive relevant scale to our customers. On December 6, 2022, the Company completed the acquisition of SIA, which develops, markets and sells DuraSorb, a resorbable synthetic matrix for plastic and reconstructive surgery. This acquisition will advance Integra’s global strategy in breast reconstruction, expanding plans to access the U.S. market where SIA is pursuing pre-market approval for use in IBBR. We also continued to advance the development of pioneering neurosurgical technologies with the expansion our product offering of regenerative technologies from our 2021 ACell acquisition. See Note 4, Acquisitions and Divestitures, to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K) for additional details.
33

Portfolio Optimization and New Product Introductions. We are investing in innovative product development to drive a multi-generational pipeline for our key product franchises. Our product development efforts span across our key global franchises focused on potential technological innovations for significant returns on investment. In addition to new product development, we are funding studies to gather clinical evidence to support launches, ensure market access and improve reimbursement for existing products. In addition to acquisitions and organic reinvestment, we continually look to optimize our portfolio towards higher growth and higher margin businesses. As such, we may opportunistically divest businesses or discontinue products where we see limited runway for future value creation in line with our aspirations due in part to changes in the market, business fundamentals or the regulatory environment.
Commercial Channel Investments. Investing in our sales channels is a core part of our strategy to create specialization and greater focus on reaching new and existing customers and addressing their needs. To support our commercial efforts in Tissue Technologies, we utilize a two-tier specialist model to increase our presence in focused segments to help serve the evolving needs of our customers. In addition, we continue to build upon our leadership brands across our product franchises in both CSS and TT to engage customers through enterprise-wide contracts with leading hospitals, integrated delivery networks and global purchasing organizations in the United States. Internationally, we have increased our commercial resources significantly in key emerging markets and are making investments to support our sales organization and maximize our commercial opportunities. Domestically, we have also increased our TT sales force in the United States to support the expanded regenerative tissue product portfolio that includes ACell products. These investments in our international and domestic sales channel position us well for expansion and long-term growth.
Customer Experience. We aspire to be ranked as a best-in-class provider and are committed to strengthening our relationships with all customers. We continue to invest in technologies, systems and processes to enhance the customer experience. In 2022, we outsourced certain transactional back-office finance and customer service activities to enhance customer quality, build scale for future growth, and capture cost efficiencies. We also launched digital tools and programs, resources and virtual product training to drive continued customer familiarity with our growing portfolio of medical technologies globally. .
New Product Introductions and Research and Development Updates
We continue to invest in collecting clinical evidence to support the Company's existing products and new product launches, and to ensure that we obtain market access for broader and more cost-effective solutions.
In 2022, we made progress to several enhancements to our CUSA Clarity Tissue Ablation System. The extended laparoscopic tip was launched in the U.S. to enhance laparoscopic liver procedures. In addition, a single-sided bone tip received 510(k) clearance. Commercial launch is expected in the first quarter of 2023. We continue to update our CUSA Clarity platform by incorporating new ultrasonic handpiece and integrated electrosurgical capabilities.
In each area, we continue to benefit from products launched over the past several years, including our new electrosurgery generator and irrigator system, an innovative customer-centric toolkit for our Certas® Plus Programmable Valve along with additional shunt configurations. In Japan, we are experiencing strong growth as a result of the successful launch of DuraGen in mid-2019, which is the first and only collagen xenograft approved for use as a dural substitute in the country.
In 2022, we continued to advance the two early-stage technology platforms we acquired in 2019. Through the acquisition of Arkiss, we added a platform technology, CerebroFlo EVD, which is a catheter with Endexo technology, a permanent additive designed to reduce the potential for catheter obstruction due to thrombus formation. The CerebroFlo EVD Catheter has demonstrated an average of 99% less thrombus accumulation onto its surface, in vitro, compared to a market leading EVD catheter. In 2019, we also acquired Rebound Therapeutics which specialized in a single-use medical device, known as Aurora Surgiscope, which is the only tubular retractor system designed for cranial surgery with an integrated access channel, camera and lighting. In 2021, we began and continued to conduct a limited clinical launch of the Aurora Surgiscope for use in minimally invasive neurosurgery as well as initiated a registry called MIRROR to collect data on early surgical intervention using this same technology platform for the treatment of ICH. In 2022, we have continued to execute on our growth initiatives. We launched the Aurora Evacuator with Coagulation device in the U.S., designed to be used in conjunction with our Aurora Surgiscope to safely address and evacuate blood in the brain caused by hemorrhagic stroke. 
We are focused on the development of core clinical applications in our electromechanical technologies portfolio. In June 2022, we launched the Neutus® EVD system, our first EVD in China. The Neutus EVD system is manufactured in China by Shanghai Haoju Medical Technology Co., Ltd. under an exclusive distribution arrangement. The device is used in the management of CSF and is highly complementary to our Bactiseal® catheter and advanced intercranial pressure monitoring products. In 2021, we launched our CereLink ICP Monitor System in the U.S. and Europe direct markets and continued the global rollout in the first half of 2022. CereLink provides enhanced accuracy, usability and advanced data presentation that provides clinicians with uncompromised, advanced continuous ICP monitoring that until now, has not been available when treating patients with traumatic brain injuries. Refer below to the information appearing under the FDA Matters heading for additional information on the voluntary recall of the CereLink ICP Monitor System.
34

Within our TT segment, in 2022, we launched NeuraGen 3D Nerve Guide Matrix, a resorbable implant for repair of peripheral nerve discontinuities and engineered to create an optimized environment for nerve regeneration. During 2021, we completed one of the largest diabetic foot ulcers ("DFU"), randomized controlled trials of the PriMatrix Dermal Repair Scaffold for the management of DFU. This multi-center study enrolled more than 225 patients with chronic DFU's over the course of 12-week treatments and 4-week follow-up phases. The results of this study, which was published in the Journal of Wound Care, demonstrated that PriMatrix plus standard of care SOC consisting of sharp debridement, infection elimination, use of dressings and offloading was significantly more likely to achieve complete wound closure compared with SOC alone, with a median number of one application of the product. During 2020, we announced positive clinical and economic data on Integra® Bilayer Wound Matrix ("IBWM") in complex lower extremity reconstruction based on two retrospective studies recently published in Plastic and Reconstructive Surgery, the official journal of the American Society of Plastic Surgeons. As surgeons look for ways to efficiently and effectively repair and close wounds, IBWM helps address the efficiency needed in operating rooms by reducing both the operating time and costs to hospitals and patients.
FDA Matters
On August 18, 2022, the Company, after consultation with the FDA and other regulatory authorities outside of the United States, initiated an immediate voluntary global product removal of all CereLink intracranial pressure monitors as a result of customer reports about monitors whose pressure readings were out of range. The Company believes that the out-of-range readings are principally caused by electrical interference from the external environment and/or interference from a component on the circuit board of the monitor. These out-of-range readings have occurred at a low incidence rate and at a limited number of sites; however, out of an abundance of caution, the Company removed all CereLink monitors from the field.
The Company Is continuing its investigation into the matter in order to remedy the observed issue and plans to resume shipment of the CereLink monitors as soon as any such issues have been resolved. Based on outlook for returning the product to market and feedback from customers, the Company recorded a $1.9 million provision for product returns, as a reduction of net revenue, and a $0.8 million rework accrual in cost of goods sold in 2022.
We manufacture and distribute products derived from human tissue for which FDA has specific regulations governing human cells, tissues and cellular and tissue-based products ("HCT/P"). An HCT/P is a product containing or consisting of human cells or tissue intended for transplantation into a human patient. Refer to Item 1. Business and Item 1A. Risk Factors for further details around these FDA regulations and their potential effect on the Company's portfolio of morselized amniotic material-based products as well as the impact on consolidated revenues.
On March 7, 2019, TEI Biosciences, Inc. ("TEI"), a wholly-owned subsidiary of the Company received a Warning Letter (the “Warning Letter”), dated March 6, 2019, from the FDA. The warning letter related to quality systems issues at TEI's manufacturing facility located in Boston, Massachusetts. The letter resulted from an inspection held at that facility in October and November 2018 and did not identify any new observations that were not already provided in the Form 483 that followed the inspection. The Company submitted its initial response to the FDA Warning Letter on March 28, 2019 and provides regular progress reports to the FDA as to its corrective actions and, since the conclusion of the inspection, has undertaken significant efforts to remediate the observations and continues to do so. On October 28, 2021 the FDA initiated an inspection of the facility and at the conclusion of the inspection issued a FDA Form 483 on November 12, 2021 (the "2021 Form 483"). The Company provided an initial response to the inspection observations and will continue to provide responses to FDA. The Warning Letter and the 2021 FDA Form 483 do not restrict the Company’s ability to manufacture or ship products or require the recall of any products, nor do they restrict our ability to seek FDA 510(k) clearance of products. Additionally, premarket approval applications for Class III devices to which the Quality System regulation violations are reasonably related will not be approved until the violations have been corrected. The TEI Boston facility manufactures extracellular bovine matrix products. We cannot give any assurances that the FDA will be satisfied with our response to the Warning Letter or as to the expected date of the resolution of the matters included in the letter. Until the issues cited in the letter are resolved to the FDA’s satisfaction, the FDA may initiate additional regulatory action without further notice. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively manufacturing, marketing and selling our products and could have a material adverse effect on our business, financial condition and results of operations.
Revenues of products manufactured in the TEI Boston facility for the year ended December 31, 2022 were approximately 5.3% of consolidated revenues.
35

ACQUISITIONS & DIVESTITURES
Acquisitions
Our growth strategy includes the acquisition of businesses, assets or products lines to increase the breadth of our offerings and the reach of our product portfolios and drive relevant scale to our customers. As a result of several acquisitions from 2021 through 2022, our financial results for the year ended December 31, 2022 may not be directly comparable to those of the corresponding prior-year periods. See Note 4, Acquisitions and Divestitures, of the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K) for a further discussion.
Surgical Innovation Associates, Inc.
On December 6, 2022, the Company completed its acquisition of SIA for an acquisition purchase price of $51.5 million. In addition to the purchase price, the acquisition includes two separate contingent considerations payments, which are dependent on 1) achieving certain revenue-based performance milestones in 2023, 2024, and 2025 (up to $50M in additional payments), as well as 2) the approval by the FDA of the PMA application for DuraSorb for certain uses by certain timing targets (up to $40M in additional payments). SIA was a privately-held company whose core technology, DuraSorb is a fully resorbable scaffold of a globally accepted polymer, cleared for use in hernia repair, abdominal wall, and other soft tissue reinforcement. DuraSorb sales will be reported within Integra’s TT segment as part of its Wound Reconstruction and Care franchise. See Note 4, Acquisitions and Divestitures, to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K) for details.
ACell Inc.
On January 20, 2021, the Company acquired ACell for an acquisition purchase price of $306.9 million plus contingent consideration obligations of up to $100 million, that may be payable upon achieving certain revenue-based performance milestones in 2022, 2023 and 2025. ACell was a privately-held company that offered a portfolio of regenerative products for complex wound management, including developing and commercializing products based on MatriStem Urinary Bladder Matrix, a technology platform derived from porcine urinary bladder extracellular matrix. See Note 4, Acquisitions and Divestitures, to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K) for additional details.
Divestiture
On August 31, 2022, the Company completed the sale of its TWC business to Gentell for $28.8 million, which consists of $27.8 million in cash plus $1.0 million in contingent consideration which may be received upon achieving certain revenue-based performance milestones two years after the closing date. The proceeds from the sale of the TWC business of $27.8 million is presented in the consolidated statement of cash flows net of cash transferred of $3.5 million and other transaction fees. The transaction included the sale of the Company's TWC products, such as sponges, gauze and conforming bandages, and certain advanced wound care dressings, such as supportive, calcium alginate, hydrogel, and foam dressings. In connection with the sale, the Company recognized $0.6 million as a gain from the sale of business in the consolidated statement of operations for year ended December 31, 2022. The transaction is subject to final working capital adjustments. See Note 4, Acquisitions and Divestitures, to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Form 10-K) for details.
On January 4, 2021, the Company completed its sale of its Extremity Orthopedics business to Smith & Nephew. The transaction included the sale of the Company's upper and lower Extremity Orthopedics product portfolio, including ankle and shoulder arthroplasty and hand and wrist product lines. The Company received an aggregate purchase price of $240.0 million from Smith & Nephew and concurrently paid $41.5 million to the Consortium of Focused Orthopedists, LLC ("CFO"), effectively terminating the licensing agreement between Integra and CFO relating to the development of shoulder arthroplasty products. The Company recognized a gain of $41.8 million in connection with the sale that is presented in "Gain from the sale of business" in the consolidated statement of operations for the year ended December, 31, 2021. See Note 4, Acquisitions and Divestitures of the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K) for details.

36

OPTIMIZATION AND INTEGRATION ACTIVITIES
As a result of our ongoing acquisition strategy and significant growth in recent years, we have undertaken cost-saving initiatives to consolidate manufacturing operations, distribution facilities and transfer activities, eliminate duplicative positions, realign various sales and marketing activities, and expand and upgrade production capacity for our regenerative technology products. These efforts are expected to continue and while we expect a positive impact from ongoing restructuring, integration, and manufacturing transfer and expansion activities, such results remain uncertain. In support of our continued focus on product margins during 2022, we closed a manufacturing facility located in France and began the transfer of production to the Company’s existing Switzerland facility. The transfer completed in the fourth quarter of 2022. In 2022, we outsourced certain transactional back-office finance and customer service activities to enhance customer quality, build scale for future growth, and capture cost efficiencies. This transition also completed in the fourth quarter of 2022. While the transition was complete in 2022, we are continuing to work with our outsource provider to transform our processes and gain efficiencies.
RESULTS OF OPERATIONS
Executive Summary
Net income for the year ended December 31, 2022 was $180.6 million, or $2.16 per diluted share, compared to $169.1 million, or $1.98 per diluted share for the year ended December 31, 2021.
Income before taxes includes the following special charges: 
 Years Ended December 31,
Dollars in thousands20222021
Acquisition, divestiture and integration-related charges (1)
$(18,849)$(11,712)
Structural optimization charges23,072 20,762 
EU medical device regulation45,147 24,375 
Total49,370 33,425 
(1) See Note 4, Acquisitions and Divestitures of the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K) for details.

The items reported above are reflected in the consolidated statements of operations as follows:
 Years Ended December 31,
Dollars in thousands20222021
Cost of goods sold $11,722 $32,334 
Research and development 21,882 17,487 
Selling, general and administrative20,584 31,013 
Gain from the sale of business(644)(41,798)
Other (income) expense(4,174)(5,611)
Total49,370 33,425 

We typically define special charges as items for which the amounts and/or timing of such expenses may vary significantly from period to period, depending upon our acquisition, divestiture, integration and restructuring activities, and for which the amounts are non-cash in nature, or for which the amounts are not expected to recur at the same magnitude. We believe that given our ongoing strategy of seeking acquisitions, our continuing focus on rationalizing our existing manufacturing and distribution infrastructure and our continuing review of various product lines in relation to our current business strategy, some of the special charges discussed above could recur with similar materiality in the future.
We believe that the separate identification of these special charges provides important supplemental information to investors regarding financial and business trends relating to our financial condition and results of operations. Investors may find this information useful in assessing comparability of our operating performance from period to period, against the business model objectives that management has established, and against other companies in our industry. We provide this information to investors so that they can analyze our operating results in the same way that management does and to use this information in their assessment of our core business and valuation of Integra.
37

Revenues and Gross Margin
Our revenues and gross margin on product revenues were as follows:
 Years Ended December 31,
Dollars in thousands20222021
Segment Net Sales
Codman Specialty Surgical$1,019,564 $1,025,232 
Tissue Technologies538,102 517,216 
Total revenues1,557,666 1,542,448 
Cost of goods sold587,355 597,808 
Gross margin on total revenues $970,311 $944,640 
Gross margin as a percentage of total revenues62.3 %61.2 %
Revenues
For the year ended December 31, 2022, total revenues increased by $15.2 million, or 1.0%, to $1,557.7 million from $1,542.4 million during the prior year. This increase is inclusive of an unfavorable foreign currency impact of $37.9 million, as well as a $10.2 million decrease that impacts both domestic and international revenues, related to the divestiture of the TWC business. Excluding the impacts of these items, domestic revenues increased by $41.6 million, or 3.8%. International revenues increased by $21.7 million or 4.8%.
In the CSS segment, revenues were $1,019.6 million which was a decrease of $5.7 million, or 0.6% as compared to the prior-year period. This increase is inclusive of a $34.1 million unfavorable foreign currency impact on revenue. Excluding the impact of foreign currency, the CSS segment revenues increased $28.4 million as compared to the prior year period. This increase was driven primarily by low single digits growth in both our Neurosurgery and Instruments portfolios as compared to the same period in the prior year. The increase in our Neurosurgery portfolio was driven primarily by growth in advanced energy and CSF management, partially offset by the voluntary recall of the CereLink ICP monitoring system.

In the TT segment, revenues were $538.1 million, which was an increase of $20.9 million, or 4.0% as compared to the prior-year period.. Excluding the impact of foreign currency of $3.8 million and the divestiture impact of TWC of $10.2 million, the TT segment revenues in the third quarter increased by $34.9 million. This increase was driven by mid-single digit increases in our Wound Reconstruction business, led by Integra® Dermal Matrices, SurgiMend and ACell MicroMatrix and low double digit increased in our Private Label business driven by higher customer demand and favorable order timing.
Gross Margin
Gross margin was $970.3 million for the year ended December 31, 2022, an increase of $25.7 million from $944.6 million for the same period last year. Gross margin as a percentage of revenues was 62.3% in 2022 and 61.2% in 2021. The increase in gross margin percentage was due to higher revenues and a reduction of inventory step up amortization in connection with the acquisition of ACell in the prior year. These were partially offset by CereLink recall impacts, unfavorable regional mix, and higher material and labor costs.
Operating Expenses
The following is a summary of operating expenses as a percent of total revenues: 
 Years Ended December 31,
 20222021
Research and development6.5 %6.0 %
Selling, general and administrative39.6 %41.3 %
Intangible asset amortization0.9 %1.1 %
 Total operating expenses47.0 %48.4 %
Total operating expenses, which consist of research and development, selling, general and administrative, and intangible asset amortization expenses, decreased by $16.0 million or 2.1% to $731.4 million in 2022, compared to $747.4 million in the prior year. The decrease in operating expenses is due to lower selling, general and administrative costs and amortization partially offset by higher R&D spending.
38

The Company continues to manage and prioritize its operating costs to increase organic investments that will drive long-term growth including the support of new product development and introductions, clinical studies, geographic expansion and targeted U.S. sales channel expansion.
Research and Development
Research and development expenses for the year ended December 31, 2022 increased by $8.1 million as compared to the prior year. This increase in spending resulted from additional spending on new product development, clinical studies and spending related to the EU Medical Device Regulation compliance activities.
Selling, General and Administrative
Selling, general and administrative expenses for the year ended December 31, 2022 decreased by $21.1 million as compared to the prior year driven primarily by the $18.1 million reduction in fair value of contingent consideration for ACell. The remainder of the decrease is a result of reduced employee related costs and stock-based compensation, partially offset by increased selling costs on commissions and investment in sales force expansion.
Intangible Asset Amortization
Amortization expense (excluding amounts reported in cost of product revenues for technology-based intangible assets) in 2022 was $13.9 million compared to $16.9 million in 2021 primarily due to a reduction associated with the end of the amortization period for a certain customer relationship intangible asset. In addition, there was a decrease in amortization expense as a result of intangible assets sold with the TWC divestiture.
We may discontinue certain products in the future as we continue to assess the profitability of our product lines. As our profitability assessment evolves, we may make further decisions about our trade names and incur additional impairment charges or accelerated amortization. We expect total annual amortization expense to be approximately $82.3 million in 2023, $81.7 million in 2024, $81.7 million in 2025, $81.5 million in 2026, $79.6 million in 2027 and $551.6 million thereafter.

Non-Operating Income and Expenses
The following is a summary of non-operating income and expenses:
 Years Ended December 31,
Dollars in thousands20222021
Interest income$11,917 $6,737 
Interest expense(49,594)(50,395)
Gain from sale of business644 41,798 
Other income, net12,007 19,307 
Total non-operating income and expense$(25,026)$17,447 
Interest Income
Interest income for the year ended December 31, 2022 increased by $5.2 million as compared to the same period last year primarily due to higher interest rates in 2022 compared to 2021.
Interest Expense
Interest expense for the year ended December 31, 2022 decreased by $0.8 million as compared to the same period last year primarily from a lower outstanding borrowing on the Senior Secured Credit Facility partially offset by increased interest rates.
Gain from the sale of businesses
On August 31, 2022, the Company completed its previously announced sale of its TWC business to Gentell and recognized $0.6 million as a gain from the sale of the business for the year ended December 31, 2022. On January 4, 2021, the Company completed its sale of its Extremity Orthopedics business and recognized a gain of $41.8 million in the prior year.
Other Income, Net
Other income, net for the year ended December 31, 2022 decreased by $7.3 million. This was primarily due to due unfavorable impact of foreign exchange, as well as lower income associated with the transition services agreement invoicing from the divestiture of the Extremity Orthopedics business.
39

Income Taxes
Our effective income tax rate was 15.6% and 21.2% of income before income taxes in 2022 and 2021, respectively. See Note 13, Income Taxes, in our consolidated financial statements for a reconciliation of the United States federal statutory rate to our effective tax rate. Our effective tax rate could vary from year to year depending on, among other factors, tax law changes, the geographic and business mix and taxable earnings and losses. We consider these factors and others, including our history of generating taxable earnings, in assessing our ability to realize deferred tax assets.
Our effective tax rate could vary from year to year depending on, among other factors, tax law changes, the geographic and business mix and taxable earnings and losses. We consider these factors and others, including our history of generating taxable earnings, in assessing our ability to realize deferred tax assets. We estimate our worldwide effective income tax rate for 2023 to be approximately 20.7%, estimated based on existing tax laws.
At December 31, 2022, the Company had $9.7 million of valuation allowance against the remaining $195.2 million of gross deferred tax assets recorded at December 31, 2022. Our deferred tax asset valuation allowance decreased by $0.1 million in 2022, remaining substantially unchanged in 2021. This valuation allowance relates to deferred tax assets for which the Company does not believe it has satisfied the more likely than not threshold for realization.
At December 31, 2022, we had net operating loss carryforwards of $79.5 million for federal income tax purposes, $75.5 million for foreign income tax purposes and $37.9 million for state income tax purposes to offset future taxable income. The federal net operating loss carryforwards increased during 2022 due to the acquisition of SIA. Of the total federal net operating loss carryforwards, $60.9 million expire through 2037 and $18.6 million have an indefinite carryforward period. Regarding the foreign net operating loss carryforwards, $16.4 million have an indefinite carryforward period. The state net operating loss carryforwards expire in 2036.
As of December 31, 2022, the Company has not provided deferred income taxes on unrepatriated earnings from foreign subsidiaries as they are deemed to be indefinitely reinvested unless there is a manner under which to remit the earnings with no material tax cost. Such taxes would primarily be attributable to foreign withholding taxes and local income taxes when such earnings are distributed.
GEOGRAPHIC PRODUCT REVENUES AND OPERATIONS
The Company attributes revenues to geographic areas based on the location of the customer. Total revenue by major geographic area consisted of the following:
 Years Ended December 31,
Dollars in thousands20222021
United States$1,126,810 $1,089,526 
Europe170,903 191,327 
Asia Pacific176,477 182,034 
Rest of World83,476 79,561 
Total Revenues$1,557,666 $1,542,448 
The Company generates significant revenues outside the U.S., a portion of which are U.S. dollar-denominated transactions conducted with customers that generate revenue in currencies other than the U.S. dollar. As a result, currency fluctuations between the U.S. dollar and the currencies in which those customers do business could have an impact on the demand for the Company's products in foreign countries. Local economic conditions, regulatory compliance or political considerations, the effectiveness of our sales representatives and distributors, local competition and changes in local medical practice all may combine to affect our sales into markets outside the U.S.
Domestic revenues increased by $37.3 million for the year ended December 31, 2022 compared to the same period last year. These increases are inclusive of $4.4 million related to the divestiture of the TWC business. European sales decreased by $20.4 million for the year ended December 31, 2022 compared to the same period last year. Sales to customers in Asia Pacific decreased by $5.6 million for the year ended December 31, 2022 compared to the same period last year. The Rest of the World for the year ended December 31, 2022 increased by $3.9 million compared to the same period last year. The international revenues were impacted by a $37.9 million unfavorable foreign exchange impact as well as $5.8 million related to the divestiture of the TWC business.
40

LIQUIDITY AND CAPITAL RESOURCES
Working Capital
At December 31, 2022 and December 31, 2021, working capital was $840.6 million and $813.7 million, respectively. Working capital consists of total current assets less total current liabilities as presented in the consolidated balance sheets.
Cash and Marketable Securities
The Company had cash and cash equivalents totaling approximately $456.7 million and $513.4 million at December 31, 2022 and 2021, respectively, which are valued based on Level 1 measurements in the fair value hierarchy. At December 31, 2022, our non-U.S. subsidiaries held approximately $229.8 million of cash and cash equivalents that are available for use outside the U.S. The Company asserts that it has the ability and intends to indefinitely reinvest the undistributed earnings from its foreign operations unless there is no material tax cost to remit the earnings into the U.S.

Cash Flows
 Year Ended December 31,
Dollars in thousands20222021
Net cash provided by operating activities $264,469 $312,427 
Net cash used in investing activities (58,580)(161,443)
Net cash used (provided) by financing activities(251,953)(98,226)
Effect of exchange rate fluctuations on cash(10,723)(9,476)
Net increase (decrease) in cash and cash equivalents$(56,787)$43,282 
Cash Flows Provided by Operating Activities
Operating cash flows for the year ended December 31, 2022 decreased by $48.0 million compared to the same period in 2021. Net income after removing the impact of the gain on sale of businesses and non-cash adjustments increased for the year ended December 31, 2022, by approximately $9.6 million as compared to 2021 primarily due to earnings from higher revenues. The changes in assets and liabilities, net of business acquisitions, decreased cash flows by $39.4 million in 2022 as compared to the increase in cash flows of $18.2 million for the same period in 2021. The change in 2022 is mainly attributable to increases in inventory and accounts receivable. The increase in inventory is due to a build up of safety stock due to supply chain challenges. The increase in accounts receivable is due to increased sales as well as a decrease in days sales outstanding.
Operating cash flows for the year ended December 31, 2021 increased by $108.6 million compared to the same period in 2020. Net income after removing the impact of the gain on sale of business and non-cash adjustments increased for the year ended December 31, 2021, by approximately $49.1 million as compared to the same period in 2020 primarily due to the continuing revenue recovery in the current year as compared to the height of the COVID-19 pandemic in the prior year. The changes in assets and liabilities, net of business acquisitions, increased cash flows from operating activities in the current year by $18.2 million compared to the decrease of $41.3 million for the same period in 2020. The improvement in 2021 working capital is attributable to a decrease in inventory of $5.4 million due to investments in building safety stock made in the prior year where inventory increased by $48.3 million as well as improved sales in 2021.
Cash Flows Used in Investing Activities
During the year ended December 31, 2022, we paid $42.3 million for capital expenditures to support operations improvement initiatives at a number of our manufacturing facilities and other information technology investments, $51.5 million to acquire SIA, as well as the $4.7 million payment related to the final developmental milestone for Rebound Therapeutics Corporation. This was partially offset by the net proceeds from the sale of the TWC business of $24.0 million. The proceeds from the sale of the TWC business of $27.8 million is presented net of cash transferred of $3.5 million and other transaction fees. Additionally, the Company also received $4.9 million proceeds on cross-currency swaps designated as net investment hedge.
During the year ended December 31, 2021, we paid a net cash amount of $303.9 million in relation to the acquisition of ACell and received net proceeds of $190.5 million for the sale of the Extremity Orthopedics business. The Company also paid for $48.0 million capital expenditures to support operations improvement initiatives at a number of our manufacturing facilities and other information technology investments.
41

Cash Flows (Used in) Provided by Financing Activities
Uses of cash from financing activities for the year ended December 31, 2022 primarily related to the purchase of treasury stock of $125.0 million under the 2022 accelerated share repurchase agreement that was completed in the first quarter of 2022. In addition, the Company had $24.6 million in cash taxes paid in net equity settlements as a result of the departure of the former chief executive officer of the Company. The Company also had repayments of $148.6 million under our Senior Credit Facility and Securitization Facility offset by $40.8 million borrowings under our Senior Credit Facility and Securitization Facility. The Company also had $5.5 million proceeds from the exercise of stock options. In this Annual Report on Form 10-K, we refer to the sixth amendment and restatement of our Senior Credit Facility with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent as the "Senior Credit Facility."
Uses of cash from financing activities for the year ended December 31, 2021 were repayments of $125.5 million on the revolving portion of our Senior Credit Facility and Securitization Facility. In addition, the Company had $4.8 million in cash taxes paid in net equity settlements. These uses were offset by $6.8 million proceeds from the exercise of stock options and $25.5 million borrowings under our Senior Credit Facility and Securitization Facility.
Amended and Restated Senior Credit Agreement, Convertible Senior Notes, Securitization and Related Hedging Activities
See Note 5, Debt, to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K) for a discussion of our Amended and Restated Senior Credit Agreement, the 2025 Notes and Securitization Facility and Note 6, Derivative Instruments to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K) for discussion of our hedging activities. We are forecasting that sales and earnings for the next twelve months will be sufficient to remain in compliance with our financial covenants under the terms of the February 2020 Amendment and July 2020 Amendment to the Senior Credit Facility.
Share Repurchase Plan
On January 12, 2022, the Company entered into a $125.0 million accelerated share repurchase ("2022 ASR") and received 1.48 million shares of the Company common stock at inception of the 2022 ASR, which represented approximately 80% of the expected total shares under the 2022 ASR. On March 24, 2022, the early exercise provision was exercised by 2022 ASR counterparty. Upon settlement on March 24, 2022, the Company received an additional 0.46 million shares determined using the volume-weighted average price of the Company's common stock during the term of the 2022 ASR.
On April 26, 2022, the Board of Directors authorized the Company to repurchase up to $225.0 million of the Company’s common stock. The program allows the Company to repurchase its shares opportunistically from time to time. The repurchase authorization expires in December 2024. This stock repurchase authorization replaces the previous $225 million stock repurchase authorization, of which $100 million remained authorized at the time of its replacement, and which was otherwise set to expire on December 31, 2022. Purchases may be affected through one or more open market transactions, privately negotiated transactions, transactions structured through investment banking institutions, or a combination of the foregoing.
On January 26, 2023, the Company entered into a $150 million accelerated share repurchase agreement ("2023 ASR") and received 2.1 million shares of the Company common stock at inception of the 2023 ASR, which represented approximately 80% of the expected total shares of under the 2023 SAR. The remaining repurchase transactions are expected to be completed in the first half of 2023.
For the year ended December 31, 2021, there were no repurchases of the Company’s common stock as part of the shar e repurchase authorization.
See Note 8, Treasury Stock, to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K) for further details.
Dividend Policy
We have not paid any cash dividends on our common stock since our formation. Our Senior Credit Facility limits the amount of dividends that we may pay. Any future determinations to pay cash dividends on our common stock will be at the discretion of the Board and will depend upon our financial condition, results of operations, cash flows and other factors deemed relevant by the Board.
Capital Resources
We believe that our cash and available borrowings under the Senior Credit Facility are sufficient to finance our operations and capital expenditures over the next twelve months. Our future capital requirements will depend on many factors, including the growth of our business, the timing and introduction of new products and investments, strategic plans and acquisitions, among others. Additional sources of liquidity available to us include short term borrowings and the issuance of long term debt and equity securities.
42

Off-Balance Sheet Arrangements
We do not have any off–balance sheet financing arrangements during the year-ended December 31, 2022 that have or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our interests.
Contractual Obligations and Commitments
We will continue to have cash requirements to support seasonal working capital needs and capital expenditures, to pay interest, to service debt, and to fund acquisitions. As part of our ongoing operations, we enter into contractual arrangements that obligate us to make future cash payments.
Our primary obligations include principal and interest payments on revolving portion and Term Loan component of the Senior Credit Facility, Securitization Facility and Convertible Securities. See Note 5, Debt, to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K) for details. The Company also leases some of our manufacturing facilities and office buildings which have future minimum lease payments associated. See Note 11, Leases and Related Party Leases, to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K) for a schedule of our future minimum lease payments. Amounts related to the Company's other obligations, including employment agreements and purchase obligations were not material.
The Company has contingent consideration obligations related to prior and current year acquisitions and future pension contribution obligations. See Note 10, Retirement Benefit Plans, and Note 15, Commitments and Contingencies to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K) for details. The associated obligations are not fixed. The Company also has a liability for uncertain tax benefits including interest and penalties. See Note 12, Income Taxes to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K) for details. The Company cannot make a reliable estimate of the period in which the uncertain tax benefits may be realized.
Employee Termination Benefits
The Company incurred employee termination costs on restructuring activities associated with a closure of a manufacturing facility located in France, outsourcing plans for select transactional back office activities, and executive reorganization in the consolidated statement of operations for the year ended December 31, 2022. In 2021, the Company incurred employee termination costs on restructuring activities associated with the closure of the manufacturing facility in France. Restructuring costs were included in accrued expenses and other current liabilities in the consolidated balance sheet for the year ended December 31, 2022 and 2021. See Note 2, Summary of Significant Accounting Policies, of the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K) for further details.
CRITICAL ACCOUNTING POLICIES AND THE USE OF ESTIMATES
Our discussion and analysis of financial conditions and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances.
As we continue to navigate the COVID-19 pandemic and recent variants of the virus, as well as the adverse impacts to global economic conditions, supply chain and our operations, there may be impact to future estimates including, but not limited to, inventory valuations, fair value measurements, goodwill and long-lived asset impairments, the effectiveness of the Company’s hedging instruments, deferred tax valuation allowances, and allowances for doubtful accounts receivable.
We believe that the following accounting policies, which form the basis for developing these estimates, are those that are most critical to the presentation of our consolidated financial statements and require the more difficult subjective and complex judgments, often because of the need to make estimates about the effect of matters that are inherently uncertain. Because of this uncertainty, actual results could differ from these estimates.
43

Inventories
Inventories, consisting of purchased materials, direct labor and manufacturing overhead, are stated at the lower of cost (determined by the first-in, first-out method) or net realizable value. At each balance sheet date, we evaluate ending inventories for excess quantities, obsolescence or shelf-life expiration. Our evaluation includes an analysis of historical sales levels by product, projections of future demand by product, the risk of technological or competitive obsolescence for our products, general market conditions, a review of the shelf-life expiration dates for our products, and the feasibility of reworking or using excess or obsolete products or components in the production or assembly of other products that are not obsolete or for which we do not have excess quantities in inventory. To the extent that we determine there are excess or obsolete quantities or quantities with a shelf life that is too near its expiration for us to reasonably expect that we can sell those products prior to their expiration, we adjust their carrying value to estimated net realizable value. If future demand or market conditions are lower than our projections, or if we are unable to rework excess or obsolete quantities into other products, we may record further adjustments to the carrying value of inventory through a charge to cost of product revenues in the period the revision is made. As of December 31, 2022, our reserve for inventory obsolesce is 6% of total inventory on our consolidated balance sheets.
The Company capitalizes inventory costs associated with certain products prior to regulatory approval, based on management's judgment of probable economic benefit. The Company could be required to expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or delay of approval by necessary regulatory bodies or a decision by management to discontinue the related development program.
Acquisitions
Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The Company accounts for the acquisition of a business in accordance with ASC Topic 805, Business Combinations ("ASC Topic 805"). Amounts paid to acquire a business are allocated to the assets acquired and liabilities assumed based on the fair values at the date of acquisition. Any excess of the purchase price over the fair value of the net assets acquired in recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred.
Contingent consideration is recorded at fair value as measured on the date of acquisition. The value recorded is based on estimates of future financial projections under various potential scenarios using either a Monte Carlo simulation or the probability-weighted income approach derived from revenue estimates and probability assessment with respect to the likelihood of achieving contingent obligations. Contingent payments related to acquisitions consist of development, regulatory, and commercial milestone payments, in addition to sales-based payments, and are valued using discounted cash flow techniques. Each quarter until such contingent amounts are earned, the fair value of the liability is remeasured at each reporting period and adjusted as a component of operating expenses based on changes to the underlying assumptions. The change in the fair value of sales-based payments is based upon future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payment charges. The estimates used to determine the fair value of the contingent consideration liability are subject to significant judgment and actual results are likely to differ from the amounts originally recorded.
The Company determines the fair value of acquired intangible assets based on detailed valuations that use certain information and assumptions provided by management. The Company allocates any excess purchase price over the fair value of the net tangible and intangible assets acquired to goodwill. Determining the fair value of these intangible assets, acquired as part of a business combination requires the Company to make significant estimates. These estimates include the amount and timing of projected future cash flows, the discount rate used to discount those cash flows to present value, the assessment of the asset’s life cycle, and the consideration of legal, technical, regulatory, economic, and competitive risks. The fair value assigned to other intangible assets is determined by estimating the future cash flows of each project or technology and discounting the net cash flows back to their present values. The discount rate used is determined at the time of measurement in accordance with accepted valuation methodologies.
In our most recent acquisition of SIA, the key areas of judgement relating to the valuation of the acquired definite-lived developed technology intangible assets were the net revenue growth rates, cost of sales, selling and marketing costs, discounts rates, and asset useful life. The key areas of judgement relating to the valuation of the contingent consideration are the inputs to the Monte-Carlo model including revenue-adjusted discount rate, counterpart discount rate, revenue volatility and forecasted revenue, earnings before income taxes and fixed costs. These assumptions were developed with the assistance of a third-party valuation expert.
44

Acquired IPR&D is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&D has an alternative future use. The Company uses the income approach to determine the fair value of developed technology and IPR&D acquired in a business combination. This approach determines fair value by estimating the after-tax cash flows attributable to the respective asset over its useful life and then discounting these after-tax cash flows back to a present value. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each product including net revenues, cost of sales, R&D costs, selling and marketing costs, the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, and competitive trends impacting the asset and each cash flow stream. The Company also uses the income approach, as described above, to determine the estimated fair value of certain other identifiable intangible assets including customer relationships, trade names and business licenses. Customer relationships represent established relationships with customers, which provide a ready channel for the sale of additional products and services. Trade names represent acquired company and product names.
IPR&D acquired in a business combination is capitalized as an indefinite-lived intangible asset. Development costs incurred after the acquisition are expensed as incurred. Upon receipt of regulatory approval, the indefinite-lived intangible asset is then accounted for as a finite-lived intangible asset and amortized on a straight-line basis or accelerated basis, as appropriate, over its estimated useful life. If the research and development project is subsequently abandoned, the indefinite-lived intangible asset is charged to expense. IPR&D acquired outside of a business combination is expensed immediately.
Due to the uncertainty associated with research and development projects, there is risk that actual results will differ materially from the original cash flow projections and that the research and development project will result in a successful commercial product. The risks associated with achieving commercialization include, but are not limited to, delay or failure to obtain regulatory approvals to conduct clinical trials, delay or failure to obtain required market clearances, delays or issues with patent issuance, or validity and litigation.
If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&D with no alternative future use is charged to expense at the acquisition date. Payments that would be recognized as contingent consideration in a business combination are expensed when probable in an asset acquisition. Refer to Note 4, Acquisitions and Divestitures to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K) for details.
Valuation of Goodwill
The excess of the cost over the fair value of net assets of acquired businesses is recorded as goodwill. Goodwill is not subject to amortization but is reviewed for impairment at the reporting unit level annually, or more frequently if impairment indicators arise. The Company's assessment of the recoverability of goodwill is based upon a comparison of the carrying value of goodwill with its estimated fair value. Key assumptions used to estimate the fair value of goodwill include the Company's discounts rate and forecasted operating results. The Company had goodwill on the balance sheet of $1 billion as of December 31, 2022. The Company reviews goodwill for impairment in the third quarter every year in accordance with ASC Topic 350, Intangibles - Goodwill and Other ("ASC Topic 350"), and whenever events or changes in circumstances indicate the carrying value of goodwill may not be recoverable. Refer to Note 7, Goodwill and Other Intangibles, to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K) for more information.
Valuation of Identifiable Intangible Assets
The Company tests intangible assets with indefinite lives for impairment annually in the third quarter in accordance with ASC Topic 350. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a indefinite lived intangible asset below its carrying amount. The Company tests for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of the intangible asset is less than its carrying amount. The Company may elect to bypass this qualitative evaluation and perform a quantitative test. There were no changes to identifiable intangible assets as a result of the Company's assessments.
Product rights and other definite-lived intangible assets are tested periodically for impairment in accordance with ASC Topic 360, Property, Plant and Equipment, ("ASC Topic 360") when events or changes in circumstances indicate that an asset's carrying value may not be recoverable. The impairment test involves comparing the carrying amount of the asset or asset group to the forecasted undiscounted future cash flows. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and impairment exists. An impairment loss is measured as the excess of the asset's carrying value over its fair value, calculated using discounted future cash flows. The computed impairment loss is recognized in the period that the impairment occurs.
45

As of December 31, 2022, the Company has $1.1 billion of identifiable intangible assets, net on the balance sheets.
Income Taxes
Since we conduct operations on a global basis, our effective tax rate has and will depend upon the geographic distribution of our pre-tax earnings among locations with varying tax rates. Changes in the tax rates of the various jurisdictions in which we operate affect our profits. In addition, we maintain a reserve for uncertain tax benefits, changes to which could impact our effective tax rate in the period such changes are made. The effective tax rate can also be impacted by changes in valuation allowances of deferred tax assets, and tax law changes.
Our provision for income taxes may change period-to-period based on specific events, such as the settlement of income tax audits and changes in tax laws, as well as general factors, including the geographic mix of income before taxes, state and local taxes and the effects of the Company's global income tax strategies. We maintain strategic management and operational activities in overseas subsidiaries. See Note 12, Income Taxes, to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K), in our consolidated financial statements for disclosures related to foreign and domestic pretax income, foreign and domestic income tax expense (benefit) and the effect foreign taxes have on our overall effective tax rate.
We recognize a tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position. The amount of the accrual for which an exposure exists is measured by determining the amount that has a greater than 50 percent likelihood of being realized upon ultimate settlement of the position. Components of the reserve are classified as a long-term liability in the consolidated balance sheets. We record interest and penalties accrued in relation to uncertain tax benefits as a component of income tax expense.
We believe that we have identified all reasonably identifiable exposures and that the reserve we have established for identifiable exposures is appropriate under the circumstances; however, it is possible that additional exposures exist and that exposures will be settled at amounts different from the amounts reserved. It is also possible that changes in facts and circumstances could cause us to either materially increase or reduce the carrying amount of our tax reserves.
Our deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and their basis for income tax purposes, and the temporary differences created by the tax effects of capital loss, net operating loss and tax credit carryforwards. We record valuation allowances when it is more likely than not that some portion or all of the deferred tax assets will not be realized. We could recognize no benefit from our deferred tax assets or we could recognize some or all of the future benefit depending on the amount and timing of taxable income we generate in the future.
We intend to indefinitely reinvest substantially all of our foreign earnings in our foreign subsidiaries unless there is a tax–free manner under which to remit the earnings. The current analysis indicates that we have sufficient U.S. liquidity, including borrowing capacity, to fund foreseeable U.S. cash needs without requiring the repatriation of foreign cash. One time or unusual items that may impact our ability or intent to keep the foreign earnings and cash indefinitely reinvested include significant U.S. acquisitions, loans from a foreign subsidiary, and changes in tax laws.
As of December 31, 2022, the Company has not provided deferred income taxes on unrepatriated earnings from foreign subsidiaries as they are deemed to be indefinitely reinvested unless there is a manner under which to remit the earnings with no material tax cost. Such taxes would primarily be attributable to foreign withholding taxes and local income taxes when such earnings are distributed.
Recently Issued and Adopted Accounting Standards
Refer to Note 2, Summary of Significant Accounting Policies, to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K), to the consolidated financial statements for recently adopted accounting pronouncements.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to various market risks, including changes in foreign currency exchange rates and interest rates that could adversely affect our results of operations and financial condition. To manage the volatility relating to these typical business exposures, we may enter into various derivative transactions when appropriate. We do not hold or issue derivative instruments for trading or other speculative purposes.
46

Foreign Currency Exchange and Other Rate Risks
We operate on a global basis and are exposed to the risk that changes in foreign currency exchange rates could adversely affect our financial condition, results of operations and cash flows. We are primarily exposed to foreign currency exchange rate risk with respect to transactions and net assets denominated in Euros, British pounds, Swiss francs, Canadian dollars, Japanese yen, Mexican pesos, Brazilian reais, Australian dollars and Chinese yuan. We manage the foreign currency exposure centrally, on a combined basis, which allows us to net exposures and to take advantage of any natural offsets. To mitigate the impact of currency fluctuations on transactions denominated in nonfunctional currencies, we periodically enter into derivative financial instruments in the form of foreign currency exchange forward contracts with major financial institutions. We temporarily record realized and unrealized gains and losses on these contracts that qualify as cash flow hedges in other comprehensive income, and then recognize them in other income or expense when the hedged item affects net earnings.
From time to time, we enter into foreign currency forward exchange contracts to manage currency exposures for transactions denominated in a currency other than an entity’s functional currency. As a result, the impact of foreign currency gains/losses recognized in earnings are partially offset by gains/losses on the related foreign currency forward exchange contracts in the same reporting period. Refer to Note 6, Derivative Instruments, to the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K) for additional information.
We maintain written policies and procedures governing our risk management activities. With respect to derivatives, changes in hedged items are generally expected to be completely offset by changes in the fair value of hedge instruments. Consequently, foreign currency exchange contracts would not subject us to material risk due to exchange rate movements, because gains and losses on these contracts offset gains and losses on the assets, liabilities or transactions being hedged.
The results of operations discussed herein have not been materially affected by inflation.
Interest Rate Risk
Cash and Cash Equivalents - We are exposed to the risk of interest rate fluctuations on the interest income earned on our cash and cash equivalents. A hypothetical 100 basis points movement in interest rates applicable to our cash and cash equivalents outstanding at December 31, 2022 would increase interest income by approximately $5.1 million on an annual basis. No significant decrease in interest income would be expected as our cash balances are earning interest at rates of approximately one basis points. We are subject to foreign currency exchange risk with respect to cash balances maintained in foreign currencies.
Debt - Our interest rate risk relates primarily to U.S. dollar LIBOR-indexed borrowings. We use interest rate swap derivative instruments to manage our earnings and cash flow exposure to changes in interest rates. These interest rate swaps fix the interest rate on a portion of our expected LIBOR-indexed floating-rate borrowings. The Company held the following interest rate swaps as of December 31, 2022 (dollar amounts in thousands):
Hedged ItemNotional AmountDesignation DateEffective DateTermination DateFixed Interest RateEstimated Fair Value
Assets (Liabilities)
1-month USD LIBOR Loan150,000 December 13, 2017July 1, 2019June 30, 20242.423 %5,012 
1-month USD LIBOR Loan200,000 December 13, 2017January 1, 2018December 31, 20242.313 %8,380 
1-month USD LIBOR Loan75,000 October 10, 2018July 1, 2020June 30, 20253.220 %1,831 
1-month USD LIBOR Loan75,000 October 10, 2018July 1, 2020June 30, 20253.199 %1,905 
1-month USD LIBOR Loan75,000 October 10, 2018July 1, 2020June 30, 20253.209 %1,970 
1-month USD LIBOR Loan100,000 December 18, 2018December 30, 2022December 31, 20272.885 %4,252 
1-month USD LIBOR Loan100,000 December 18, 2018December 30, 2022December 31, 20272.867 %4,153 
1-month USD LIBOR Loan575,000 December 15, 2020July 31, 2025December 31, 20271.415 %23,742 
1-month USD LIBOR Loan125,000 December 15, 2020July 1, 2025December 31, 20271.404 %5,467 
$1,475,000 $56,712 
47

These interest rate swaps were designated as cash flow hedges as of December 31, 2022. The total notional amounts related to the Company’s interest rate swaps were $1.5 billion and with $775.0 million effective as of December 31, 2022. Based on our outstanding borrowings at December 31, 2022, a 100 basis points change in interest rates would have impacted interest expense on the unhedged portion of the debt by $1.1 million on an annualized basis.
ITEM 8.FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Financial statements and the financial statement schedule specified by this Item, together with the report thereon of PricewaterhouseCoopers LLP, are presented following Item 15. Exhibits and Financial Statement Schedule of this Annual Report on Form 10-K.
ITEM 9.CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES
Not applicable.
48

ITEM 9A.CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure. Disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Management has designed our disclosure controls and procedures to provide reasonable assurance of achieving the desired control objectives.
As required by Exchange Act Rule 13a-15(b), we have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2022. Based upon this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of December 31, 2022 to provide such reasonable assurance.
Management’s Report on Internal Control Over Financial Reporting
Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) under the Securities Exchange Act of 1934, as amended. Internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America (“GAAP”). We recognize that because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies and procedures may deteriorate.
To evaluate the effectiveness of our internal control over financial reporting, management used the criteria described in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based upon this evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2022.
The effectiveness of the Company’s internal control over financial reporting as of December 31, 2022 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which appears herein.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that occurred during the quarter ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
ITEM 9B.OTHER INFORMATION
The following disclosure is intended to satisfy any obligation to provide disclosures pursuant to Item 5.03 of Form 8-K.
Effective as of February 21, 2023, based on the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Integra LifeSciences Holdings Corporation (the “Company”), in connection with the new Securities and Exchange Commission rules and changes to the Securities Exchange Act of 1934, as amended (the "Exchange Act"), regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the "DGCL"), and a periodic review of corporate governance matters, the Board approved amendments to the Company’s Second Amended and Restated Bylaws, as amended (the “Third A&R Bylaws”).
The Third A&R Bylaws, among other things:
•Address matters relating to Rule 14a-19 under the Exchange Act (the "Universal Proxy Rules"), including requiring: (a) the stockholder’s nomination notice to include a representation that it intends to solicit proxies from stockholders representing at least 67% of the voting power of shares entitled to vote on the election of directors; (b) the stockholder to comply with the Universal Proxy Rules and provide reasonable evidence thereof prior to the stockholder meeting; and (c) the stockholder to use a proxy card color other than white, which is reserved for the exclusive use of the Board. (Article 2, Sections 2.03, 2.08, and 2.10)
•Enhance the informational and procedural requirements in connection with stockholder proposals and stockholder director nominations, including: (a) requiring additional information about the stockholder making the director
49

nomination or proposal; (b) requiring additional information about the stockholder proposed business and/or director nominee; and (c) providing that the number of nominees a stockholder may nominate for election at the annual meeting of the stockholders may not exceed the number of directors to be elected at such annual meeting. (Article 2, Sections 2.03 and 2.10)
•Modify the provisions relating to adjournment procedures, availability of lists of stockholders entitled to vote at stockholder meetings, and electronic notices, in each case, to reflect amendments to the DGCL. (Article 2, Sections 2.04 and 2.05; Article 4, Section 4.01)
•Provide that any proxies received for disqualified or withdrawn Board nominees will be treated as abstentions. (Article 2, Section 2.08)
•Add a provision for stockholder actions by written consent that requires the Company to engage an independent inspector of election to perform a review of the validity of the applicable consents and revocations. (Article 2, Section 2.09)
•Clarify the powers of the chair of a stockholder meeting, including with respect to the chair’s ability to prescribe rules and regulations for the conduct of the meeting. (Article 2, Section 2.11)
•Add a federal forum provision to designate the federal district courts as the exclusive forum for matters arising under the Securities Act of 1933, as amended, and the Exchange Act. (Article 8, Section 8.02)
•Make various other updates, including ministerial and conforming changes and changes to clarify the Company’s ability to conduct business by means of remote communication.
The foregoing description of the Third A&R Bylaws is qualified in its entirety by the full text of the Third A&R Bylaws filed as Exhibit 3.3 hereto and incorporated herein by reference.

ITEM 9C.DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
Not applicable.
PART III
INCORPORATION BY REFERENCE
The information called for by Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities relating to equity compensation plans, Item 10. Directors, Executive Officers and Corporate Governance, Item 11. Executive Compensation, Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters, Item 13. Certain Relationships and Related Transactions, and Director Independence and Item 14. Principal Accountant Fees and Services is incorporated herein by reference to the Company’s definitive proxy statement for its Annual Meeting of Stockholders scheduled to be held on May 12, 2023, which definitive proxy statement is expected to be filed with the Commission not later than 120 days after the end of the fiscal year to which this report relates.





PART IV
ITEM 15.EXHIBITS AND FINANCIAL STATEMENT SCHEDULE
(a) Documents filed as a part of this report:
1. Financial Statements.
50

All other schedules not listed above have been omitted, because they are not applicable or are not required, or because the required information is included in the consolidated financial statements or notes thereto.
3. Exhibits required to be filed by Item 601 of Regulation S-K.
2.1(a)
2.1(b)
3.1(a)
3.1(b)
3.1(c)
3.1(d)
3.2
3.3
4.1
4.2
4.3
4.4
10.1(a)
10.1(b)
10.2(a)
10.2(b)
10.3(a)
51

10.3(b)
10.3(c)
10.3(d)
10.3(e)
10.3(f)
10.3(g)
10.3(h)
10.3(i)
10.3(j)
10.3(k)
10.3(l)
10.4
10.5
10.6
10.7
10.8
10.9
10.10
10.11(a)
10.11(b)
52

10.12
10.13(a)
10.13(b)
10.13(c)
10.13(d)
10.14
10.15(a)
10.15(b)
Amendment, dated July 14, 2020, to that Sixth Amended and Restated Credit Agreement, among Integra LifeSciences Holdings Corporation, a syndicate of lending banks, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, Citibank N.A., Morgan Stanley MUFG Loan Partners, LLC and Wells Fargo Bank, N.A. as Co-Syndication Agents, and PNC Bank, N.A., Bank of Nova Scotia, Bank of the West, BBVA USA, Capital One, National Association, Citizens Bank, N.A., DNB Capital LLC, Santander Bank, N.A., T.D. Bank, N.A. and Truist Bank, as Co-Documentation Agents (as amended, restated, modified and supplemented from time to time prior to the date hereof, the “Credit Agreement”) (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on July 20, 2020).
10.16
10.17
10.18
10.19
53

10.20
10.21
10.22
10.23
10.24
10.25
10.27
10.28
10.29
10.30
10.31
10.32
10.33
21.1
23.1
31.1
31.2
32.1
32.2
101.INSXBRL Instance Document+#
54

101.SCHXBRL Taxonomy Extension Schema Document+#
101.CALXBRL Taxonomy Extension Calculation Linkbase Document+#
101.DEFXBRL Definition Linkbase Document
101.LABXBRL Taxonomy Extension Labels Linkbase Document+#
101.PREXBRL Taxonomy Extension Presentation Linkbase Document+#
104Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
*Indicates a management contract or compensatory plan or arrangement.
+Indicates this document is filed as an exhibit herewith.
#The financial information of Integra LifeSciences Holdings Corporation Annual Report on Form 10-K for the year ended December 31, 2022 filed on February 22, 2023 formatted in XBRL (Extensible Business Reporting Language): (i) the Consolidated Statements of Operations, (ii) the Consolidated Statement of Comprehensive Income (Loss), (iii) the Consolidated Balance Sheets, (iv) Parenthetical Data to the Consolidated Balance Sheets, (v) the Consolidated Statements of Cash Flows, (vi) the Consolidated Statements of Changes in Stockholders’ Equity, and (vii) Notes to Consolidated Financial Statements, is furnished electronically herewith.
The Company’s Commission File Number for Reports on Form 10-K, Form 10-Q and Form 8-K is 000-26224.

ITEM 16.FORM 10-K SUMMARY

None.
55

SIGNATURES
Pursuant to the requirements of Section 13 of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
                            
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
By:/s/ Jan De Witte
Jan De Witte
President and Chief Executive Officer
(Principal Executive Officer)
By:/s/ Jeffrey A. Mosebrook
Jeffrey A. Mosebrook
Senior Vice President, Finance
(Principal Financial Officer and Principal Accounting Officer)

Date: February 22, 2023
56

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons, on behalf of the registrant in the capacities indicated.
SignatureTitleDate
/s/ Jan De WittePresident and Chief Executive Officer,February 22, 2023
Jan De Witteand Director (Principal Executive Officer)
/s/ Jeffrey A. MosebrookSenior Vice President, FinanceFebruary 22, 2023
Jeffrey A. Mosebrook(Principal Financial Officer and Principal Accounting Officer)
/s/ Stuart M. Essig, Ph.D.Chairman of the BoardFebruary 22, 2023
Stuart M. Essig, Ph.D.
/s/ Keith Bradley, Ph.D.DirectorFebruary 22, 2023
Keith Bradley, Ph.D.
/s/ Shaundra ClayDirectorFebruary 22, 2023
Shaundra Clay
/s/ Barbara B. HillDirectorFebruary 22, 2023
Barbara B. Hill
/s/ Renee LoDirectorFebruary 22, 2023
Renee Lo
/s/ Donald E. Morel, Jr., Ph.D.DirectorFebruary 22, 2023
Donald E. Morel, Jr., Ph.D.
/s/ Raymond G. MurphyDirectorFebruary 22, 2023
Raymond G. Murphy
/s/ Christian S. SchadeDirectorFebruary 22, 2023
Christian S. Schade


57

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of Integra LifeSciences Holdings Corporation

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of Integra LifeSciences Holdings Corporation and its subsidiaries (the “Company”) as of December 31, 2022 and 2021, and the related consolidated statements of operations, of comprehensive income, of changes in stockholders’ equity and of cash flows for each of the three years in the period ended December 31, 2022, including the related notes (collectively referred to as the “consolidated financial statements”). We also have audited the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.

Change in Accounting Principle

As discussed in Note 2 to the consolidated financial statements, the Company changed the manner in which it accounts for convertible instruments in 2021.

Basis for Opinions

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Report on Internal Control Over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and
F-1

that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Critical Audit Matters

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Surgical Innovation Associates, Inc. Acquisition - Valuation of Developed Technology Intangible Asset

As described in Note 4 to the consolidated financial statements, on December 6, 2022, the Company completed its acquisition of Surgical Innovation Associates, Inc. (SIA) for an acquisition purchase price of $51.5 million, and will pay up to an additional $50 million upon the achievement of certain revenue-based performance milestones in 2023, 2024, and 2025 and up to an additional $40.0M upon the approval by the FDA of the Premarketing Approval Application for DuraSorb. The acquisition also resulted in a $75 million developed technology intangible asset being recorded. The estimated fair value of the developed technology acquired was determined by management using the multi-period excess earnings method of the income approach. Management’s significant assumptions used in the estimate of fair value included the estimated net cash flows, including net revenues, cost of sales, research and development costs, selling and marketing costs, working capital, contributory asset charges, discount rate, the asset’s life cycle, and competitive trends impacting the asset and the cash flow stream.

The principal considerations for our determination that performing procedures relating to the valuation of developed technology intangible asset from the acquisition of Surgical Innovation Associates, Inc. is a critical audit matter are (i) the significant judgment by management when developing the fair value estimate of the acquired developed technology intangible asset, (ii) a high degree of auditor judgment , subjectivity, and effort in performing procedures and evaluating management’s significant assumptions related to net revenues, cost of sales, discount rate and the asset’s life cycle; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the acquisition accounting, including controls over management’s valuation of the acquired developed technology intangible asset and controls over the development of significant assumptions related to net revenues, cost of sales, discount rate and the asset’s life cycle. These procedures also included, among others (i) reading the purchase agreement and (ii) testing management’s process for developing the estimated fair value of the developed technology intangible asset. Testing management’s process included evaluating the appropriateness of the multi-period excess earnings method, testing the completeness and accuracy of underlying data used in the method, and evaluating the reasonableness of significant assumptions used by management related to net revenues, cost of sales, discount rate and the asset’s life cycle. Evaluating the reasonableness of management’s assumptions related to net revenues, cost of sales, and the asset’s life cycle involved considering (i) current and past performance of the product associated with the developed technology acquired; (ii) the consistency with external market and industry data; and (iii) whether the assumptions are consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in evaluating (i) the appropriateness of the Company’s multi-period excess earnings method and (ii) the reasonableness of the discount rate and the asset’s life cycle assumptions.

/s/ PricewaterhouseCoopers LLP
Florham Park, New Jersey
February 22, 2023
We have served as the Company’s auditor since 1989.
F-2

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Dollars in thousands, except per share amounts)
 
 Years Ended December 31,
 202220212020
Total revenue, net$1,557,666 $1,542,448 $1,371,868 
Costs and expenses:
Cost of goods sold587,355 597,808 520,834 
Research and development101,193 93,051 77,381 
Selling, general and administrative616,316 637,445 594,526 
Intangible asset amortization13,882 16,914 27,757 
Total costs and expenses1,318,746 1,345,218 1,220,498 
Operating income238,920 197,230 151,370 
Interest income11,917 6,737 9,297 
Interest expense(49,594)(50,395)(71,581)
Gain from sale of businesses644 41,798 — 
Other income, net12,007 19,307 4,434 
Income before income taxes213,894 214,677 93,520 
Provision (benefit) for income taxes33,344 45,602 (40,372)
Net income$180,550 $169,075 $133,892 
Net income per share
       Basic$2.18 $2.00 $1.58 
       Diluted$2.16 $1.98 $1.57 
Weighted average common shares outstanding (See Note 13):
Basic82,997 84,698 84,650 
Diluted83,516 85,485 85,228 
The accompanying notes are an integral part of these consolidated financial statements.
F-3

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Dollars in thousands)

 Years Ended December 31,
 202220212020
Net income$180,550 $169,075 $133,892 
Other comprehensive (loss) income, before tax:
Change in foreign currency translation adjustments(17,807)(17,362)53,363 
Unrealized gain (loss) on derivatives
Unrealized derivative gain (loss) arising during period104,351 68,192 (96,837)
Less: Reclassification adjustments for gain (loss) included in net income18,859 17,024 (24,442)
Unrealized gain (loss) on derivatives85,492 51,168 (72,395)
Defined benefit pension plan - net gain (loss) arising during period7,429 6,998 4,604 
Total other comprehensive gain (loss), before tax75,114 40,804 (14,428)
Income tax (expense) benefit related to items in other comprehensive gain (loss)(19,694)(11,900)16,771 
Total other comprehensive gain (loss), net of tax55,420 28,904 2,343 
Comprehensive income, net of tax$235,970 $197,979 $136,235 
The accompanying notes are an integral part of these consolidated financial statements.


F-4

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONSOLIDATED BALANCE SHEETS
(Dollars in thousands, except per share amounts)
December 31,
20222021
ASSETS
Current Assets:
Cash and cash equivalents$456,661 $513,448 
Trade accounts receivable, net of allowances of $4,304 and $4,735
263,465 231,831 
Inventories, net324,583 317,386 
Prepaid expenses and other current assets116,789 91,051 
Total current assets1,161,498 1,153,716 
Property, plant and equipment, net311,302 311,703 
Right of use asset - operating leases148,284 84,543 
Intangible assets, net1,126,609 1,145,573 
Goodwill1,038,881 1,013,458 
Deferred tax assets, net45,994 56,950 
Other assets57,190 16,440 
Total assets$3,889,758 $3,782,383 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Current portion of borrowings under senior credit facility$38,125 $45,000 
Current portion of lease liability - operating leases14,624 14,775 
Accounts payable, trade102,100 61,837 
Contract liabilities7,253 5,295 
Accrued compensation78,771 92,656 
Accrued expenses and other current liabilities80,033 120,458 
Total current liabilities320,906 340,021 
Long-term borrowings under senior credit facility733,149 824,257 
Long-term borrowings under securitization facility104,700 112,500 
Long-term convertible securities567,341 564,426 
Lease liability - operating leases157,420 90,329 
Deferred tax liabilities63,338 45,788 
Other liabilities138,501 120,258 
Total liabilities2,085,355 2,097,579 
Stockholders’ Equity:
Preferred Stock; no par value; 15,000 authorized shares; none outstanding
— — 
Common stock; $0.01 par value; 240,000 authorized shares; 90,477 and 89,600 issued at December 31, 2022 and 2021, respectively
905 896 
Additional paid-in capital1,276,977 1,264,943 
Treasury stock, at cost; 6,823 and 4,899 shares at December 31, 2022 and 2021, respectively
(362,862)(234,448)
Accumulated other comprehensive income (loss)10,265 (45,155)
        Retained earnings879,118 698,568 
Total stockholders’ equity1,804,403 1,684,804 
Total liabilities and stockholders’ equity$3,889,758 $3,782,383 
The accompanying notes are an integral part of these consolidated financial statements.
F-5

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollars in thousands)
 Years Ended December 31,
 202220212020
OPERATING ACTIVITIES:
Net income$180,550 $169,075 $133,892 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization118,299 119,836 116,031 
Non-cash in-process research and development expense — — 519 
Non-cash impairment charges— 2,754 — 
Deferred income tax (benefit) provision(4,585)(2,755)(64,138)
Share-based compensation27,725 36,210 19,590 
Amortization of debt issuance costs and expenses associated with debt refinancing6,845 7,030 12,076 
Non-cash lease expense2,816 3,834 2,955 
Accretion of bond issuance discount— — 15,415 
Loss (Gain) on disposal of property and equipment and construction in-progress(6,813)2,240 7,855 
Gain from the sale of businesses(644)(41,798)— 
Change in fair value of contingent consideration and others(20,304)(2,162)951 
Changes in assets and liabilities:
Accounts receivable(33,905)7,265 52,105 
Inventories(29,124)5,374 (48,348)
Prepaid expenses and other current assets8,612 (21,143)1,632 
Other non-current assets(2,182)7,875 13,735 
Accounts payable, accrued expenses and other current liabilities17,343 32,874 (57,512)
Contract liabilities4,274 28 (37)
Other non-current liabilities(4,438)(14,110)(2,889)
Net cash provided by operating activities 264,469 312,427 203,832 
INVESTING ACTIVITIES:
Purchases of property and equipment(42,343)(48,022)(38,890)
Proceeds from sale of business23,960 190,468 — 
Acquired in-process research and development and intangibles(4,742)(58)(25,000)
Cash paid for business acquisitions, net of cash acquired(51,509)(303,910)— 
Proceeds from sales of property and equipment11,145 3 3,657 
Net proceeds (payments) on swaps designated as net investment hedges4,909 76 (7,840)
Net cash used in investing activities(58,580)(161,443)(68,073)
FINANCING ACTIVITIES:
Proceeds from borrowings of long-term indebtedness40,750 25,500 171,500 
Payments on debt(148,550)(125,500)(441,000)
Purchase of option hedge on convertible notes— — (104,248)
Proceeds from convertible notes issuance— — 575,000 
Proceeds from sale of stock purchase warrants— — 44,563 
Payment of debt issuance costs— (249)(24,347)
Purchase of treasury stock(125,000)— (100,000)
Proceeds from exercised stock options5,465 6,824 5,232 
Cash taxes paid in net equity settlement(24,618)(4,801)(5,075)
Net cash (used in) provided by financing activities(251,953)(98,226)121,625 
Effect of exchange rate changes on cash and cash equivalents(10,723)(9,476)13,871 
Net increase (decrease) in cash and cash equivalents(56,787)43,282 271,255 
Cash and cash equivalents at beginning of period513,448 470,166 198,911 
Cash and cash equivalents at end of period$456,661 $513,448 $470,166 
The accompanying notes are an integral part of these consolidated financial statements.
F-6

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(Dollars in thousands)
Common StockTreasury StockAdditional Paid-In CapitalAccumulated Other Comprehensive IncomeRetained EarningsTotal Equity
SharesAmountSharesAmount
Balance, January 1, 202088,735 $887 (2,865)$(119,943)$1,213,620 $(76,402)$398,574 $1,416,736 
Net income— — — — — — 133,892 133,892 
Other comprehensive loss, net of tax— — — — — 2,343 — 2,343 
Issuance of common stock through employee stock purchase plan13 — — — 694 — — 694 
Issuance of common stock for vesting of share-based awards, net of shares withheld for taxes503 2 11 526 (1,066)— — (538)
Share-based compensation— 4 — — 19,397 — — 19,401 
Share repurchase and equity component of the convertible note issuance, net— — — — 42,539 — — 42,539 
Accelerated shares repurchased— — (2,060)(115,724)15,724 — — (100,000)
Adoption of Update No. 2016-13— — — — — — (200)(200)
Balance, December 31, 202089,251 893 (4,914)(235,141)1,290,908 (74,059)532,266 1,514,867 
Net income— — — — — — 169,075 169,075 
Other comprehensive loss, net of tax— — — — — 28,904 — 28,904 
Issuance of common stock through employee stock purchase plan18 — — 1,127 — — 1,127 
Issuance of common stock for vesting of share-based awards, net of shares withheld for taxes331 1 15 693 201 — — 895 
Share-based compensation— 2 — — 35,981 — — 35,983 
Adoption of Update No. 2020-06— — — — (63,274)— (2,773)(66,047)
Balance, December 31, 202189,600 $896 (4,899)$(234,448)$1,264,943 $(45,155)$698,568 $1,684,804 
Net income— — — — — — 180,550 180,550 
Other comprehensive income (loss), net of tax— — — — — 55,420 — 55,420 
Issuance of common stock through employee stock purchase plan17 — — — 1,078 — — 1,078 
Issuance of common stock for vesting of share-based awards, net of shares withheld for taxes859 7 14 738 (20,974)— — (20,229)
Share-based compensation— 2 — — 27,778 — — 27,780 
Accelerated shares repurchased— — (1,938)(129,152)4,152 — — (125,000)
Balance, December 31, 202290,476 905 (6,823)(362,862)1,276,977 10,265 879,118 1,804,403 
The accompanying notes are an integral part of these consolidated financial statements.
F-7
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


1. BUSINESS
Integra LifeSciences Holdings Corporation (the “Company”) was incorporated in Delaware in 1989. The Company is a worldwide leader in medical technology. The Company was founded with the acquisition of an engineered collagen technology platform used to repair and regenerate tissue. Since then, Integra has developed numerous product lines from this technology for applications ranging from burn and deep tissue wounds to the repair of dura mater in the brain, as well as nerves and tendons. The Company has expanded its base regenerative technology business to include surgical instruments, neurosurgical products and advanced wound care through global acquisitions and product development to meet the evolving needs of its customers and enhance patient care. The Company sells its products directly through various sales forces and through a variety of other distribution channels.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
BASIS OF PRESENTATION
These financial statements and the accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America and conform to Regulation S-X under the Securities Exchange Act of 1934, as amended.
PRINCIPLES OF CONSOLIDATION
The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. See Note 4, Acquisitions and Divestitures, for details of new subsidiaries included in the consolidation.
USE OF ESTIMATES
The preparation of consolidated financial statements is in conformity with generally accepted accounting principles in the United States ("GAAP") which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates. As the Company continues to navigate the novel coronavirus ("COVID-19") pandemic and recent variants of the virus as well as the adverse impacts to global economic conditions, supply chain and the operations, there may be impact to future estimates including, but not limited to, inventory valuations, fair value measurements, goodwill and long-lived asset impairments, the effectiveness of the Company’s hedging instruments, deferred tax valuation allowances, and allowances for doubtful accounts receivable.
CASH AND CASH EQUIVALENTS
The Company considers all short-term, highly liquid investments purchased with original maturities of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value.
TRADE ACCOUNTS RECEIVABLE AND ALLOWANCES FOR DOUBTFUL ACCOUNTS RECEIVABLE
Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company grants credit to customers in the normal course of business, but generally does not require collateral or any other security to support its receivables.
The Company evaluates the collectability of accounts receivable based on a combination of factors. The Company recognizes a provision for doubtful accounts that reflects the Company’s estimate of expected credit losses for trade accounts receivable. In circumstances where a specific customer is unable to meet its financial obligations to the Company, a provision to the allowances for doubtful accounts is recorded against amounts due to reduce the net recognized receivable to the amount that is reasonably expected to be collected. For all other customers, the Company evaluates measurement of all expected credit losses for trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts.
F - 8
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The Company adopted this guidance on January 1, 2020 using a modified retrospective transition method which requires a cumulative-effect adjustment to the opening balance of retained earnings to be recognized on the date of adoption with no change to financial results reported in prior periods. The cumulative-effect adjustment recorded on January 1, 2020 was not material. The adoption of this ASU did not have a significant impact on the Company's consolidated financial statements and related disclosures. The Company's exposure to credit losses may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the COVID-19 pandemic and recent variants of the virus, and other customer-specific factors. Although the Company has historically not experienced significant credit losses, it is possible that there could be an adverse impact due to customer and governmental responses to the COVID-19 pandemic.
Provisions to the allowances for doubtful accounts are recorded to selling, general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered. Provision for doubtful accounts, net of recoveries, associated with accounts receivable, included in selling, general and administrative expense, was charges of $0.2 million for the year ended December 31, 2022, recoveries of $1.1 million, and charges of $3.6 million for the years ended December 31, 2021 and 2020, respectively.
The below table shows the rollforward of the allowance for doubtful accounts for the years ended December 31, 2022, 2021 and 2020:
Balance at Beginning of PeriodCharged to Costs and ExpensesOtherDeductionsBalance at End of Period
Dollars in thousands
Year Ended:
 December 31, 2022$4,735 238 — (669)$4,304 
December 31, 2021$6,439 (1,059)341 (986)$4,735 
December 31, 2020$4,303 3,635 — (1,499)$6,439 
(1)Deductions primarily relates to allowance for doubtful accounts written off during the year, net of recoveries and other adjustments.


INVENTORIES
Inventories, consisting of purchased materials, direct labor and manufacturing overhead, are stated at the lower of cost, the value determined by the first-in, first-out method, or net realizable value. Inventories consisted of the following:
 December 31,
Dollars in thousands2022 2021
Finished goods172,088 $162,528 
Work in process70,598 65,323 
Raw materials81,897 89,535 
Total inventories, net$324,583 $317,386 
At each balance sheet date, the Company evaluates inventories for excess quantities, obsolescence or shelf life expiration. This evaluation includes analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, a review of the shelf life expiration dates for products, as well as the feasibility of reworking or using excess or obsolete products or components in the production or assembly of other products that are not obsolete or for which there are not excess quantities in inventory. To the extent that management determines there are excess or obsolete inventory or quantities with a shelf life that is too near its expiration for the Company to reasonably expect that it can sell those products prior to their expiration, the Company adjusts the carrying value to estimated net realizable value.
The Company capitalizes inventory costs associated with certain products prior to regulatory approval, based on management's judgment of probable economic benefit. The Company could be required to expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or delay of approval by necessary regulatory bodies or a decision by management to discontinue the related development program. No such amounts were capitalized at December 31, 2022 or 2021.
F-9
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment are stated at historical cost less accumulated depreciation and any impairment charges. The Company provides for depreciation using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the lesser of the lease term or the useful life. The cost of major additions and improvements is capitalized, while maintenance and repair costs that do not improve or extend the lives of the respective assets are charged to operations as incurred. The cost of computer software developed or obtained for internal use is accounted for in accordance with the Accounting Standards Codification 350-40, Internal-Use Software.
Property, plant and equipment balances and corresponding lives were as follows:
 December 31,
Dollars in thousands20222021Useful Lives
Land$966 $1,512 
Buildings and building improvements14,710 19,032 
5-40 years
Leasehold improvements164,292 155,495 
1-20 years
Machinery and production equipment181,780 183,270 
3-20 years
Demonstration equipment3,792 2,791 
4-5 years
Information systems and hardware151,330 148,706 
1-7 years
Furniture, fixtures, and office equipment20,286 20,921 
1-15 years
Construction-in-progress103,875 94,850 
Total641,031 626,577 
Less: Accumulated depreciation(329,729)(314,874)
Property, plant and equipment, net$311,302 $311,703 
Depreciation expense associated with property, plant and equipment was $40.1 million, $39.4 million, and $42.1 million for the years ended December 31, 2022, 2021 and 2020, respectively.
CAPITALIZED INTEREST
The interest cost on capital projects, including facilities build-out and internal use software, is capitalized and included in the cost of the project. Capitalization commences with the first expenditure for the project and continues until the project is substantially complete and ready for its intended use. When no debt is incurred specifically for a project, interest is capitalized on project expenditures using the weighted average cost of the Company's outstanding borrowings. For the years ended December 31, 2022 and 2021, respectively, the Company capitalized $1.4 million and $1.2 million of interest expense into property, plant and equipment.
ACQUISITIONS
Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The Company accounts for the acquisition of a business in accordance with ASC 805, Business Combinations ("ASC Topic 805"). Amounts paid to acquire a business are allocated to the assets acquired and liabilities assumed based on their fair values at the date of acquisition. Any excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred.
Contingent consideration is recorded at fair value as measured on the date of acquisition. The value recorded is based on estimates of future financial projections under various potential scenarios using either a Monte Carlo simulation or the probability-weighted income approach derived from revenue estimates and probability assessment with respect to the likelihood of achieving contingent obligations. Contingent payments related to acquisitions consist of development, regulatory, and commercial milestone payments, in addition to sales-based payments, and are valued using discounted cash flow techniques. Each quarter until such contingent amounts are earned, the fair value of the liability is remeasured at each reporting period and adjusted as a component of operating expenses based on changes to the underlying assumptions. The change in the fair value of sales-based payments is based upon future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payment charges. The estimates used to determine the fair value of the contingent consideration liability are subject to significant judgment and actual results are likely to differ from the amounts originally recorded.
F-10
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The Company determines the fair value of acquired intangible assets based on detailed valuations that use certain information and assumptions provided by management. The Company allocates any excess purchase price over the fair value of the net tangible and intangible assets acquired to goodwill. Determining the fair value of these intangible assets acquired as part of a business combination requires the Company to make significant estimates. These estimates include the amount and timing of projected future cash flows, the discount rate used to discount those cash flows to present value, the assessment of the asset’s life cycle, and the consideration of legal, technical, regulatory, economic, and competitive risks. The fair value assigned to other intangible assets is determined by estimating the future cash flows of each project or technology and discounting the net cash flows back to their present values. The discount rate used is determined at the time of measurement in accordance with accepted valuation methodologies.
Acquired IPR&D is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&D has an alternative future use. The Company uses the income approach to determine the fair value of developed technology and IPR&D acquired in a business combination. This approach determines fair value by estimating the after-tax cash flows attributable to the respective asset over its useful life and then discounting these after-tax cash flows back to a present value. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each product including net revenues, cost of sales, R&D costs, selling and marketing costs, the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, and competitive trends impacting the asset and each cash flow stream. The Company also uses the income approach, as described above, to determine the estimated fair value of certain other identifiable intangible assets including customer relationships, trade names and business licenses. Customer relationships represent established relationships with customers, which provide a ready channel for the sale of additional products and services. Trade names represent acquired company and product names.
IPR&D acquired in a business combination is capitalized as an indefinite-lived intangible asset. Development costs incurred after the acquisition are expensed as incurred. Upon receipt of regulatory approval, the indefinite-lived intangible asset is then accounted for as a finite-lived intangible asset and amortized on a straight-line basis or accelerated basis, as appropriate, over its estimated useful life. If the research and development project is subsequently abandoned, the indefinite-lived intangible asset is charged to expense. IPR&D acquired outside of a business combination is expensed immediately.

Due to the uncertainty associated with research and development projects, there is risk that actual results will differ materially from the original cash flow projections and that the research and development project will result in a successful commercial product. The risks associated with achieving commercialization include, but are not limited to, delay or failure to obtain regulatory approvals to conduct clinical trials, delay or failure to obtain required market clearances, delays or issues with patent
issuance, or validity and litigation.
If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&D with no alternative future use is charged to expense at the acquisition date. Payments that would be recognized as contingent consideration in a business combination are expensed when probable in an asset acquisition. Refer to Note 4, Acquisitions and Divestitures for more information.
GOODWILL AND OTHER INTANGIBLE ASSETS
The excess of the cost over the fair value of net assets of acquired businesses is recorded as goodwill. Goodwill is not subject to amortization but is reviewed for impairment at the reporting unit level annually, or more frequently if impairment indicators arise. The Company's assessment of the recoverability of goodwill is based upon a comparison of the carrying value of goodwill with its estimated fair value. The Company reviews goodwill for impairment in the third quarter every year in accordance with ASC Topic 350, Intangibles - Goodwill and Other ("ASC Topic 350") and whenever events or changes in circumstances indicate the carrying value of goodwill may not be recoverable. Refer to Note 7, Goodwill and Other Intangibles for more information.
The Company has two reportable segments with three underlying reporting units. Refer to Note 16, Segment and Geographic Information for more information on reportable segments.
Other intangible assets include patents, trademarks, purchased technology, and supplier and customer relationships. Identifiable intangible assets are initially recorded at fair market value at the time of acquisition generally using an income or cost approach. The Company capitalizes costs incurred to renew or extend the term of recognized intangible assets and amortizes those costs
over their expected useful lives.
F-11
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The Company tests intangible assets with indefinite lives for impairment annually in the third quarter in accordance with ASC Topic 350. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of an indefinite lived intangible asset below its carrying amount. The Company tests for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of the intangible asset is less than its carrying amount. The Company may elect to bypass this qualitative evaluation and perform a quantitative test.
Product rights and other definite-lived intangible assets are tested periodically for impairment in accordance with ASC 350 Topic when events or changes in circumstances indicate that an asset's carrying value may not be recoverable. The impairment testing involves comparing the carrying amount of the asset or asset group to the forecasted undiscounted future cash flows. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and impairment exists. An impairment loss is measured as the excess of the asset's carrying value over its fair value, calculated using discounted future cash flows. The computed impairment loss is recognized in the period that the impairment occurs.
LONG-LIVED ASSETS
Long-lived assets held and used by the Company, including property, plant and equipment, intangible assets, and leases are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets to be held and used, a recoverability test is performed using projected undiscounted net cash flows applicable to the long-lived assets. If an impairment exists, the amount of such impairment is calculated based on the estimated fair value of the asset. Impairments to long-lived assets to be disposed of are recorded based upon the difference between the carrying value and the fair value of the applicable assets.
INTEGRA FOUNDATION
The Company may periodically make contributions to the Integra Foundation, Inc. The Integra Foundation was incorporated in 2002 exclusively for charitable, educational, and scientific purposes and qualifies under IRC 501(c)(3) as an exempt private foundation. Under its charter, the Integra Foundation engages in activities that promote health, the diagnosis and treatment of disease, and the development of medical science through grants, contributions and other appropriate means. The Integra Foundation is a separate legal entity and is not a subsidiary of the Company; therefore, its results are not included in these consolidated financial statements. The Company contributed $0.0 million, $1.2 million and $0.8 million to the Integra Foundation during the years ended December 31, 2022, 2021 and 2020, respectively. These contributions were recorded in selling, general, and administrative expense.
DERIVATIVES
The Company develops, manufactures, and sells medical devices globally and its earnings and cash flows are exposed to market risk from changes in interest rates and currency exchange rates. The Company addresses these risks through a risk management program that includes the use of derivative financial instruments and operates the program pursuant to documented corporate risk management policies. All derivative financial instruments are recognized in the financial statements at fair value in accordance with the authoritative guidance. Under the guidance, for those instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation, based on the exposure being hedged. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, further, on the type of hedging relationship. The Company's derivative instruments do not subject its earnings or cash flows to material risk, and gains and losses on these derivatives generally offset losses and gains on the item being hedged. The Company has not entered into derivative transactions for speculative purposes. From time to time, the Company may enter into derivatives that are not designated as hedging instruments in order to protect itself from currency volatility due to intercompany balances.
All derivative instruments are recognized at the fair values as either assets or liabilities on the balance sheet. The Company determines the fair value of its derivative instruments using the framework prescribed by the authoritative guidance, by considering the estimated amount the Company would receive to sell or transfer these instruments at the reporting date and by taking into account expected forward interest rates, currency exchange rates, the creditworthiness of the counterparty for assets, and its creditworthiness for liabilities. In certain instances, the Company utilizes a discounted cash flow model to measure fair value. Generally, the Company uses inputs that include quoted prices for similar assets or liabilities in active markets, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The Company has classified all of its derivative assets and liabilities within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of its derivative instruments. The Company classifies derivatives designated as hedges in the same category as the item being hedged for cash flow presentation purposes.
F-12
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The Company entered into foreign currency forward and foreign currency swap contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into other income, net, on the consolidated financial statements. Refer to Note 6, Derivative Instruments for more information.
FOREIGN CURRENCY
All assets and liabilities of foreign subsidiaries which have a functional currency other than the U.S. dollar are translated at the rate of exchange at year-end, while elements of the income statement are translated at the average exchange rates in effect during the year. The net effect of these translation adjustments is shown as a component of accumulated other comprehensive income (loss). These currency translation adjustments are not currently adjusted for income taxes as they relate to permanent investments in non-U.S. subsidiaries. Foreign currency transaction net losses of $3.3 million, net gains of less than $0.1 million, and net losses $1.6 million are reported in other income, net in the statements of operations, for the year ended December 31, 2022, 2021 and 2020, respectively.
INCOME TAXES
Income taxes are accounted for by using the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period when the change is enacted.
The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position. Reserves are established for positions that don't meet this recognition threshold. The reserve is measured as the largest amount of benefit determined on a cumulative probability basis that the Company believes is more likely than not to be realized upon ultimate settlement of the position. These reserves are classified as long-term liabilities in the consolidated balance sheets of the Company, unless the reserves are expected to be paid in cash during the next twelve months, in which case they are classified as current liabilities. The Company also records interest and penalties accrued in relation to uncertain tax benefits as a component of income tax expense.
While the Company believes it has identified all reasonable exposures and the reserve it has established is appropriate under the circumstances, it is possible that additional exposures exist and that exposures may be settled at amounts different than the amounts reserved. It is also possible that changes in facts and circumstances could cause the Company to either materially increase or reduce the carrying amount of its tax reserve.
The Company continues to indefinitely reinvest substantially all of its foreign earnings unless there is a manner under which to remit the earnings without a material tax cost. The current provisional analysis indicates that the Company has sufficient U.S. liquidity, including borrowing capacity, to fund foreseeable U.S. cash needs without requiring the repatriation of foreign cash. One time or unusual items that may impact the ability or intent to keep the foreign earnings and cash indefinitely reinvested include significant U.S. acquisitions, loans from a foreign subsidiary and changes in tax laws.
REVENUE RECOGNITION
Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services.
Total revenue, net, includes product sales, product royalties and other revenues, such as fees received from services.
For products shipped with FOB shipping point terms, the control of the product passes to the customer at the time of shipment. For shipments in which the control of the product is transferred when the customer receives the product, the Company recognizes revenue upon receipt by the customer. Certain products that the Company produces for private label customers have no alternative use and the Company has a right of payment for performance to date. Revenues from those products are recognized over the period that the Company manufactures these products, which is typically one month to three months. The Company uses the input method to measure the manufacturing activities completed to date, which depicts the progress of the Company's performance obligation of transferring control of goods being manufactured for private label customers.
A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and distributors, and also from inventory physically held by field sales representatives. For these types of products sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized.
F-13
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

Revenues from sale of products and services are evidenced by either a contract with the customer or a valid purchase order and an invoice which includes all relevant terms of sale. For product sales, invoices are generally issued upon the transfer of control (or upon the completion of the manufacturing in the case of the private label transactions recognized over time) and are typically payable 30 days after the invoice date. The Company performs a review of each specific customer's creditworthiness and ability to pay prior to acceptance as a customer. Further, the Company performs periodic reviews of its customers' creditworthiness prospectively. Refer to Note 3, Revenue From Contracts With Customers for more information. The Company also maintains a provision for estimated returns and allowances in the same period that the related revenue is recorded. This reserve is based upon an analysis of actual credit memos issued for pricing issues or returned goods over an extended period, as well as assumptions about outstanding accounts receivable and judgment in interpreting the data.
RESEARCH AND DEVELOPMENT
Research and development costs, including salaries, depreciation, consultant and other external fees, and facility costs directly attributable to research and development activities, are expensed in the period in which they are incurred.
EMPLOYEE TERMINATION BENEFITS
The Company does not have a written severance plan, and it does not offer similar termination benefits to affected employees in all restructuring initiatives. Accordingly, in situations where minimum statutory termination benefits must be paid to the affected employees, the Company records employee severance costs associated with these restructuring activities in accordance with the authoritative guidance for non-retirement post-employment benefits. Charges associated with these activities are recorded when the payment of benefits is probable and can be reasonably estimated. In all other situations where the Company pays out termination benefits, including supplemental benefits paid in excess of statutory minimum amounts and benefits offered to affected employees based on management's discretion, the Company records these termination costs in accordance with the authoritative guidance for ASC Topic 712 Compensation - Nonretirement Benefits and ASC Topic 420 One-time Employee Termination Benefits.
The timing of the recognition of charges for employee severance costs other than minimum statutory benefits depends on whether the affected employees are required to render service beyond their legal notification period in order to receive the benefits. If affected employees are required to render service beyond their legal notification period, charges are recognized over the future service period. Otherwise, charges are recognized when management has approved a specific plan and employee communication requirements have been met.
The Company incurred employee termination costs on restructuring activities associated with a closure of a manufacturing facility in France and other reorganization projects in the consolidated statement of operations for the year ended December 31, 2022. In 2021, the Company incurred employee termination costs on restructuring activities associated with the closure of a manufacturing facility in France. The following table summarizes our restructuring related accrual balances included within accrued expenses and other current liabilities in the consolidated balance sheet for the year ended December 31, 2022 and 2021.
Years Ended December 31,
(Dollars in thousands)20222021
Balance, beginning of the year$10,226 $6,372 
Charges:
Cost of Goods Sold$1,494 $3,436 
Research and development72288
Selling, general and administrative$5,582 $466 
Payments and other adjustments$(12,267)$(336)
Balance, end of the year$5,107 $10,226 
Included in the accrual balance as of December 31, 2022 is $2.0 million related to the closure of a manufacturing facility located in France, and other reorganization projects of $3.1M. Included in the accrual balance as of December 31, 2021 is $10.2 million related to the closure of the manufacturing facility located in France.
STOCK-BASED COMPENSATION
Relevant authoritative guidance requires companies to recognize the expense related to the fair value of their stock-based compensation awards. Stock-based compensation expense for stock option awards are based on the grant date fair value using the binomial distribution model. The Company recognizes compensation expense for stock option awards, restricted stock awards, performance stock awards and contract stock awards over the requisite service period of the award. All excess tax benefits and taxes and tax deficiencies from stock-based compensation are included in provision for income taxes in the consolidated statement of operations. Refer to Note 9, Stock-based Compensation for more information.
F-14
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

PENSION BENEFITS
The Company maintains defined benefit pension plans that cover certain employees in France, Japan, Germany and Switzerland. Various factors are considered in determining the pension liability, including the number of employees expected to be paid their salary levels and years of service, the expected return on plan assets, the discount rate used to determine the benefit obligations, the timing of benefit payments and other actuarial assumptions.
Retirement benefit plan assumptions are reassessed on an annual basis or more frequently if changes in circumstances indicate a re-evaluation of assumptions are required. The key benefit plan assumptions are the discount rate and expected rate of return on plan assets. The discount rate is based on average rates on bonds that matched the expected cash outflows of the benefit plans. The expected rate of return is based on historical and expected returns on the various categories of plan assets.
The Company uses the corridor approach in measuring the amount of net periodic benefit pension cost to recognize each period. The corridor approach defers all actuarial gains and losses resulting from variances between actual results and actuarial assumptions. Those unrecognized gains and losses are amortized when the net gains and losses exceed 10% of the greater of the market-related value of plan assets or the projected benefit obligation at the beginning of the year. The amount in excess of the corridor is amortized over the average remaining service period to retirement date of active plan participants.
Deferred Compensation Plan
The Company maintains a deferred compensation plan in which certain employees of the Company may defer the payment and taxation of up to 75% of their base salary and up to 100% of bonus amounts and other eligible cash compensation.
This deferred compensation is invested in funds offered under the Plan and is valued based on Level 1 measurements in the fair value hierarchy. The purpose of the plan is to retain key employees by providing them with an opportunity to defer a portion of their compensation as elected by the participant in accordance with the plan. Any amounts set aside to defray the liabilities assumed by the Company will remain the general assets of the Company until such amounts are distributed to the participants. Assets of the Company's deferred compensation plan are included in Other current assets and recorded at fair value based on their quoted market prices.
CONCENTRATION OF CREDIT RISK
Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, which are held at major financial institutions, investment-grade marketable debt securities and trade receivables.
The Company's products are sold on an uncollateralized basis and on credit terms based upon a credit risk assessment of each customer. A portion of the Company's trade receivables to customers outside the United States includes sales to foreign distributors, who then sell to government owned or supported healthcare systems.
None of the Company's customers accounted for 10% or more of the consolidated net sales during the years ended December 31, 2022, 2021 and 2020.
RECENT ACCOUNTING PRONOUNCEMENTS
In December 2019, the FASB issued ASU 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes, intended to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. This guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. The Company adopted ASU 2019-12 as of January 1, 2021. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures.
F-15
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848), and subsequent amendment to the initial guidance: ASU 2021-01, Reference Rate Reform (Topic 848): Scope (collectively, “Topic 848”). Topic 848 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference London Inter-Bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. The guidance generally can be applied from March 12, 2020 through December 31, 2022. On October 5, 2022, the FASB approved an extension of the sunset date of the reference rate reform from December 31, 2022 to December 31, 2024, past LIBOR’s end date. The Company currently has contracts that are indexed to LIBOR and are continuing to evaluate the scope of impacted contracts and potential risk. The Company expects all LIBOR-based contracts to be replaced by the Secured Overnight Financing Rate (“SOFR”), which is calculated based on overnight transactions under repurchase agreements backed by Treasury securities. The Alternative Reference Rates Committee, a group of private-market participants convened by the U.S. Federal Reserve Board and the New York Federal Reserve, has recommended the use of SOFR as a more robust reference rate alternative to LIBOR. The use of SOFR as a substitute for LIBOR is, however, voluntary and may not be suitable for all market participants. There can be no assurance that the replacement rate will be economically equivalent to LIBOR, which could result in higher interest rates for us under our debt facilities. There is no guarantee that a transition from LIBOR to SOFR will not result in financial market disruptions, significant increases in benchmark rates, or our borrowing costs, any of which could have an adverse effect on our business, results of operations and financial condition.
In August 2020, the FASB issued ASU 2020-06, Debt- Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40):Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. The guidance simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify. The guidance also simplifies the diluted net income per share calculation in certain areas. The ASU will be effective for annual and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years using either the modified retrospective or full retrospective method.
As detailed in Note 5, Debt, on February 4, 2020, the Company issued $575.0 million aggregate principal amount of its 0.5% Convertible Senior Notes due 2025 (the "2025 Notes"). The 2025 Notes are subject to the guidance included in ASU 2020-06. The Company adopted this guidance on January 1, 2021 using the modified retrospective approach which resulted in a cumulative-effect adjustment that increased (decreased) the following consolidated balance sheet accounts:
ADJUSTMENTCONSOLIDATED BALANCE SHEET CLASSIFICATIONAMOUNT
 (in millions)
Deferred tax impact of cumulative-effect adjustmentDeferred tax liabilities$(20.6)
Debt discount reclassificationLong-term convertible securities89.1 
Equity issuance costs reclassificationLong-term convertible securities(2.5)
Debt discount amortization and equity costs reclassification, net of taxRetained Earnings(2.8)
Net impact of cumulative-effect adjustmentAdditional paid-in capital(63.3)
On December 9, 2020, the Company made an irrevocable election under the indenture to require the principal portion of its 2025 Notes to be settled in cash and any excess in shares. Following the irrevocable notice, only the amounts settled in excess of the principal will be considered in diluted earnings per share under the “if-converted” method. Upon adoption of ASU 2020-06, the Company’s 2025 Notes were reflected entirely as a liability since the embedded conversion feature will no longer be separately presented within stockholders’ equity. Additionally, from January 1, 2021, the Company is no longer incurring non-cash interest expense for the amortization of debt discount.
In October 2020, the FASB issued ASU 2020-10, Codification Improvements, which updates various codification topics by clarifying or improving disclosure requirements to align with the regulations of the U.S. Securities and Exchange Commission (the "SEC") . The ASU has been effective for the Company for annual and interim periods beginning after January 1, 2021. The Company adopted this standard on the January 1, 2021. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures.
F-16
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options which provides guidance to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The amendment currently has no impact to the Company as the effect will largely depend on the terms of written call options or financings issued or modified in the future.
There are no other recently issued accounting pronouncements that are expected to have any significant effect on the Company's financial position, results of operations or cash flows.
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest during the years ended December 31, 2022, 2021 and 2020 was $42.2 million (net of $1.4 million that was capitalized into construction in progress), $43.2 million (net of $1.2 million that was capitalized into construction in progress) and $47.3 million (net of $2.3 million that was capitalized into construction in progress), respectively.
Cash paid for income taxes, net of refunds, for the years ended December 31, 2022, 2021 and 2020 was $35.9 million, $49.5 million and $29.8 million, respectively.
NON-CASH INVESTING AND FINANCING ACTIVITIES
Property and equipment purchases included in liabilities at December 31, 2022, 2021 and 2020 were $10.5 million, $4.7 million and $1.6 million, respectively.
During the fourth quarter of 2021, the Company achieved its final developmental milestone which triggered a $5.0 million obligation to be paid to former shareholders of Rebound Therapeutics Corporation ("Rebound"). The Company recorded $5.0 million as an intangible asset in the consolidated balance sheet upon achieving the milestone. The remaining obligation was included in accrued liabilities at December 31, 2021 in the consolidated balance sheets. The milestone was fully paid in 2022.
During the fourth quarter of 2020, the Company achieved another developmental milestone which triggered a $20.0 million obligation to be paid to the former shareholders of Rebound. The Company recorded $20.0 million as an intangible asset in the consolidated balance sheet upon achieving the milestone. The milestone was paid during the fourth quarter of 2020.

3. REVENUES FROM CONTRACTS WITH CUSTOMERS
Summary of Accounting Policies on Revenue Recognition
Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services.
Performance Obligations
The Company's performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers.
Significant Judgments
Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company's strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant.
The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract.
The Company's return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally 90 days.
F-17
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.
Contract Asset and Liability
Revenues recognized from the Company's private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the prepaid expenses and other current assets account in the consolidated balance sheet. Upon invoicing to the customer, the balance is recorded in trade receivable, net in the consolidated balance sheet.
Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.
The following table summarized the changes in the contract asset and liability balances for the year ended December 31, 2022:
Dollars in thousandsTotal
Contract Asset
Contract asset, January 1, 2022$11,412 
Transferred to trade receivable from contract asset included
     in beginning of the year contract asset 		(11,412)
Contract asset, net of transferred to trade receivables on contracts during the period10,122 
Contract asset, December 31, 2022$10,122 
Contract Liability
Contract liability, January 1, 2022$11,946 
Recognition of revenue included in beginning of year contract liability(5,349)
Contract liability, net of revenue recognized on contracts during the period9,596 
Foreign currency translation(66)
Contract liability, December 31, 2022$16,127 
At December 31, 2022, the short-term portion of the contract liability of $7.3 million and the long-term portion of $8.8 million is included in current liabilities and other liabilities, respectively, in the consolidated balance sheet.
As of December 31, 2022, the Company is expected to recognize revenue of approximately $7.3 million in 2023, $4.2 million in 2024, $2.7 million in 2025, $1.1 million in 2026, $0.7 million in 2027, and $0.1 million thereafter.
Shipping and Handling Fees
The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold.
Product Warranties
Certain of the Company's medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to two years from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet.
Taxes Collected from Customers
The Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer.
F-18
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

Disaggregated Revenue
The following table presents revenues disaggregated by the major sources of revenues for years-ended December 31, 2022, 2021 and 2020 (dollar amounts in thousands):
Year Ended December 31, 2022Year Ended December 31, 2021Year Ended December 31, 2020
Neurosurgery$794,017 $802,959 $716,339 
Instruments225,547 222,273 178,492 
Total Codman Specialty Surgical1,019,564 1,025,232 894,831 
Wound Reconstruction and Care(2)(3)
406,689 392,463 293,038 
Extremity Orthopedics(1)
— — 78,316 
Private Label131,413 124,753 105,683 
Total Tissue Technologies538,102 517,216 477,037 
Total revenue$1,557,666 $1,542,448 $1,371,868 
(1) On January 4, 2021, the Company completed its sale of its Extremity Orthopedics business. See Note 4, Acquisitions and Divestitures, for details
(2) See Note 4. Acquisitions and Divestitures, for details around the ACell acquisition.
(3) On August 31, 2022, the Company completed the sale of its non-core traditional wound care ("TWC") business. See Note 4, Acquisitions and Divestitures
See Note 16, Segment and Geographical Information, for details of revenues based on the location of the customer.
4. ACQUISITIONS AND DIVESTITURES
Surgical Innovation Associates, Inc. Acquisition

On December 6, 2022, the Company completed its acquisition of Surgical Innovation Associates, Inc. ("SIA") for an acquisition purchase price of $51.5 million. In addition to the purchase price, the acquisition includes two separate contingent considerations payments, which are dependent on 1) achieving certain revenue-based performance milestones in 2023, 2024, and 2025 (up to $50.0 million in additional payments), as well as 2) the approval by the FDA of the Premarket Approval (“PMA”) Application for DuraSorb for certain uses by certain timing targets (up to $40.0 million in additional payments). SIA's core technology, DuraSorb, is a fully resorbable scaffold of a globally accepted polymer, which is cleared for use in hernia repair, abdominal wall, and other soft tissue reinforcement. DuraSorb sales will be reported within Integra’s Tissue Technologies segment as part of its Wound Reconstruction and Care franchise.

Assets Acquired and Liabilities Assumed at Fair Value

The SIA Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired, and liabilities assumed in a business combination to be recognized at their fair values as of the acquisition date.






















F-19
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date:

Dollars in thousandsValuation as of December 6, 2022Weighted Average Life
Current assets:
Cash$4,438 
Trade accounts receivable, net 1,551 
Inventories, net2,900 
Prepaid expenses and other current assets1,654 
Total current assets$10,543 
Intangible assets75,000 14 years
Goodwill41,854 
Total assets acquired$127,397 
Current liabilities:
Accounts payable and accrued expenses$2,044 
Total current liabilities$2,044 
Deferred Tax Liability11,799 
Contingent consideration57,607 
Total liabilities assumed71,450 
Net assets acquired$55,947 

Developed Technology

The estimated fair value of the developed technology was determined using the multi-period excess earnings method of the income approach, which estimates value based on the present value of future economic benefits. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each product including net revenues, cost of sales, R&D costs, selling and marketing costs, working capital, and contributory asset charges, the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of the asset’s life cycle, and competitive trends impacting the asset and the cash flow stream.

The Company used a discount rate of 18% to arrive at the present value for the acquired intangible assets to reflect the rate of return a market participant would expect to earn and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results.

Goodwill

The Company allocated goodwill related to the SIA Acquisition to the Tissue Technologies segment. Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected revenue and cost synergies of the combined company and assembled workforce. A key factor that contributes to the recognition of goodwill, and a driver for the Company’s acquisition of SIA, is the attractive growth opportunities presented by the surgical matrix business in the breast reconstruction market. Goodwill recognized as a result of this acquisition is non-deductible for income tax purposes.

Contingent Consideration

The Company determines the acquisition date fair value of contingent consideration obligations based on a probability-weighted income approach derived from revenue estimates and a probability assessment with respect to the likelihood of achieving contingent obligations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined using the fair value concepts in ASC 820. The resulting most likely payouts are discounted using an appropriate effective annual interest rate. At each reporting date, the contingent consideration obligation will be revalued to estimated fair value and changes in fair value will be reflected as income or expense in the consolidated statement of operations. Changes in the fair value of the contingent considerations may result from changes in discount periods and rates and changes in the timing and amount of revenue estimates. Changes in assumptions utilized in the contingent consideration fair value estimates could result in an increase in the contingent consideration obligation and a corresponding charge to operating results.

As part of the acquisition, the Company is required to pay to the shareholder of SIA up to $90.0 million for two separate payments, which are dependent on 1) achieving certain revenue-based performance milestones in 2023, 2024, and 2025 (up to $50.0 million in additional payments), as well as 2) the approval by the FDA of the PMA for DuraSorb for certain uses by
F-20
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

certain timing targets (up to $40.0 million in additional payments). The Company used iterations of the Monte Carlo simulation to calculate the fair value of the contingent consideration for the revenue-based milestone that considered the possible outcomes of scenarios related to each specific milestone for the revenue based performance milestone. The Company used probabilities of achieving the conditions to calculate the fair value of the contingent consideration for the PMA approval milestone. The Company estimated the fair value of the contingent consideration for the revenue based milestone to be $32.6 million at the acquisition date and $25.0 million for the PMA approval milestone.

Deferred Tax Liabilities

Deferred tax liabilities result from identifiable intangible assets’ fair value adjustments. These adjustments create excess book basis over tax basis which is tax-effected by the statutory tax rates of applicable jurisdictions.

Sale of non-core traditional wound care business
On August 31, 2022, the Company completed its sale of its non-core traditional wound care ("TWC") business to Gentell, LLC ("Gentell") for $28.8 million, which consists of $27.8 million in cash plus $1.0 million in contingent consideration which may be received upon achieving certain revenue-based performance milestones two years after the closing date. The proceeds from the sale of the TWC business of $27.8 million is presented in the consolidated statement of cash flows net of cash transferred of $3.5 million and other transaction fees. The transaction included the sale of the Company's TWC products, such as sponges, gauze and conforming bandages, and certain advanced wound care dressings, such as supportive, calcium alginate, hydrogel, and foam dressings.
The divestiture did not represent a strategic shift that had a major effect on the Company's operations and financial statements. Goodwill was allocated to the assets and liabilities divested using the relative fair value method of the TWC business to the Company's Tissue Technologies reportable business segment. In connection with the sale, the Company recognized $0.6 million as a gain from the sale of the business in the consolidated statement of operations for the year ended December 31, 2022. The transaction is subject to final working capital adjustments.
In addition to the purchase and sale agreement, the Company also entered into a contract manufacturing agreement with Gentell. Under the terms of the agreement, Gentell received inventory, equipment, and tooling to manufacture certain MediHoney® and TCC-EZ® products on behalf of the Company. On the close date of this transaction, the Company transferred all inventory associated with these products to Gentell and recognized an asset of $11.1 million, as a form of a deposit for the inventory transferred, which based on the expected timing of inventory purchases, was primarily included within prepaid expenses and other current assets in the consolidated balance sheet. This deposit will be utilized by the Company on future orders placed to Gentell for such products. As of December 31, 2022, the Company had a deposit remaining of $8.3 million which is included in prepaid assets and recognized a payable due to Gentell of $2.7 million, which is included in the consolidated balance sheet within accrued expenses and other current liabilities.
Sale of Extremity Orthopedics Business
On January 4, 2021, the Company completed the sale of its Extremity Orthopedics business to Smith & Nephew USD Limited ("Smith & Nephew"). The transaction included the sale of the Company's upper and lower Extremity Orthopedics product portfolio, including ankle and shoulder arthroplasty and hand and wrist product lines. The Company received an aggregate purchase price of $240.0 million from Smith & Nephew and concurrently paid $41.5 million to the Consortium of Focused Orthopedists, LLC ("CFO") effectively terminating the licensing agreement between Integra and CFO relating to the development of shoulder arthroplasty products.

F-21
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

Assets and liabilities divested consisted of the following as of December 31, 2020 (dollar amounts in thousands):
Prepaid expenses and other current assets$713 
Right of use asset - operating leases and Other assets3,186 
Deferred tax assets6,589 
Intangible assets, net13,332 
Property, plant and equipment, net37,893 
Goodwill47,546 
Inventories52,845 
Total assets held for sale$162,104 
Other liabilities$336 
Current portion of lease liability - operating leases539 
Accrued compensation1,767 
Deferred tax liabilities3,440 
Lease liability - operating leases5,669 
Total liabilities held for sale$11,751 
The divestiture did not represent a strategic shift that had a major effect on the Company's operations and financial statements. Goodwill was allocated to the assets and liabilities divested using the relative fair value method of the Extremity Orthopedics business to the Company's Tissue Technologies reporting unit. In connection with the sale, the Company recognized a gain of $41.8 million that is presented in Gain from the sale of business in the consolidated statement of operations for the year ended December 31, 2021. The Company finalized the net working capital to Smith & Nephew as of December 31, 2021.
The Company also entered into a transition services agreement ("TSA") with Smith & Nephew which requires the Company to provide certain services on behalf of Smith & Nephew for the duration of the period subsequent to the sale of the business as defined in the TSA. The Company recognized a payable due to Smith & Nephew of $2.3 million as of December 31, 2022, which is included in the consolidated balance sheet within accrued expenses and other current liabilities. The TSA includes services such as invoicing and cash collections from customers on behalf of Smith & Nephew. As of December 31, 2022, the Company has concluded the majority of the transition services agreement, pending final payment.
ACell, Inc. Acquisition
On January 20, 2021, the Company acquired ACell, Inc. (the "ACell Acquisition") for an acquisition purchase price of $306.9 million plus contingent considerations of up to $100 million, that may be payable upon achieving certain revenue-based performance milestones in 2022, 2023 and 2025. The final working capital adjustments of $1.3 million was finalized and paid as of June 30, 2021. ACell was a privately-held company that offered a portfolio of regenerative products for complex wound management, including developing and commercializing products based on MatriStem Urinary Bladder Matrix, a technology platform derived from porcine urinary bladder extracellular matrix.
Assets Acquired and Liabilities Assumed at Fair Value
The ACell Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination are recognized at their fair values as of the acquisition date.
F-22
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The following table summarizes the final fair values of the assets acquired and liabilities assumed at the acquisition date:
Dollars in thousandsFinal Valuation Weighted Average Life
Current assets:
Cash$2,726 
Trade accounts receivable, net 16,469 
Inventories, net18,299 
Prepaid expenses and other current assets1,498 
Total current assets$38,992 
Property, plant and equipment, net13,769 
Intangible assets245,000 
13-14 years
Goodwill94,147 
Right of use asset - operating leases9,259 
Deferred tax assets7,465 
Other assets148 
Total assets acquired$408,780 
Current liabilities:
Accounts payable$718 
Accrued expenses5,966 
Current portion of lease liability - operating leases1,673 
Total current liabilities$8,357 
Other long-term liability276 
Lease liability - operating leases7,585 
Deferred tax liability61,724 
Contingent consideration23,900 
Total liabilities assumed101,842 
Net assets acquired$306,938 
Intangible Assets
The estimated fair value of the developed technology acquired was determined using the multi-period excess earnings method of the income approach, which estimates value based on the present value of future economic benefits. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each product including net revenues, cost of sales, R&D costs, selling and marketing costs, the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, and competitive trends impacting the asset and each cash flow stream.
The Company used a discount rate of 8.5% to arrive at the present value for the acquired intangible assets to reflect the rate of return a market participant would expect to earn and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results.
Goodwill
The Company allocated goodwill related to the ACell acquisition to the Tissue Technologies segment. Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected synergies of the combined company and assembled workforce. Goodwill recognized as a result of this acquisition is non-deductible for income tax purposes.
F-23
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

Contingent Consideration
As part of the acquisition, the Company is required to make payments to the former shareholders of ACell up to $100 million based on the achievement of certain revenue-based performance milestones in 2022, 2023, and 2025. Based on revenue performance in 2022, no payment will be made for the first performance milestone. The Company used iterations of the Monte Carlo simulation to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specific milestone. The Company estimated the fair value of the contingent consideration to be $23.9 million at the acquisition date. The Company recorded $3.7 million and $21.8 million in other liabilities as of December 31, 2022 and 2021, respectively, in the consolidated balance sheets of the Company. The change in the fair value of the contingent obligation was primarily as a result of changes in the timing and amount of revenue estimates.
The Company determined the acquisition date fair value of contingent consideration obligations using a Monte Carlo simulation, as well as significant unobservable inputs, reflecting the Company’s assessment of the assumptions market participants would use to value these liabilities. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined using the fair value concepts in ASC 820. The resultant most likely payouts are discounted using an appropriate effective annual interest rate. At each reporting date, the contingent consideration obligations is revalued to estimated fair value and changes in fair value will be reflected as income or expense in our consolidated statement of operations. Changes in the fair value of the contingent considerations may result from changes in discount periods and rates and changes in the timing and amount of revenue estimates.
Deferred Tax Liabilities
Deferred tax liabilities result from identifiable intangible assets’ fair value adjustments. These adjustments create excess book basis over tax basis which is tax-effected by the statutory tax rates of applicable jurisdictions.

5. DEBT
Amendment to the Sixth Amended and Restated Senior Credit Agreement
On February 3, 2020, the Company entered into the sixth amendment and restatement (the "February 2020 Amendment") of its Senior Credit Facility (the "Senior Credit Facility") with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. The February 2020 Amendment extended the maturity date to February 3, 2025. The Company continues to have the aggregate principal amount of up to approximately $2.2 billion available to it through the following facilities: (i) a $877.5 million Term Loan facility, and (ii) a $1.3 billion revolving credit facility, which includes a $60 million sublimit for the issuance of standby letters of credit and a $60 million sublimit for swingline loans.
The Company’s maximum consolidated total leverage ratio in the financial covenants (as defined in the Senior Credit Facility) is the following:
Fiscal QuarterMaximum Consolidated Total Leverage Ratio
September 30, 2022 through June 30, 2023
4.50 to 1.00
September 30, 2023 and the last day of each fiscal quarter thereafter
4.00 to 1.00
Borrowings under the Senior Credit Facility bear interest, at the Company’s option, at a rate equal to the following:
i.the Eurodollar Rate (as defined in the amendment and restatement) in effect from time to time plus the applicable rate (ranging from 1.00% to 2.25%), or
ii.the highest of:
1.the weighted average overnight Federal funds rate, as published by the Federal Reserve Bank of New York, plus 0.50%
2.the prime lending rate of Bank of America, N.A. or
3.the one-month Eurodollar Rate plus 1.00%
The applicable rates are based on the Company’s consolidated total leverage ratio (defined as the ratio of (a) consolidated funded indebtedness as of such date less cash that is not subject to any restriction on the use or investment thereof to (b) consolidated EBITDA (as defined by the July 2020 amendment), for the period of four consecutive fiscal quarters ending on such date).
F-24
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The Company will pay an annual commitment fee (ranging from 0.15% to 0.30%), based on the Company's consolidated total leverage ratio, on the amount available for borrowing under the revolving credit facility.
The Senior Credit Facility is collateralized by substantially all of the assets of the Company’s U.S. subsidiaries, excluding intangible assets. The Senior Credit Facility is subject to various financial and negative covenants and at December 31, 2022, the Company was in compliance with all such covenants. In connection with the February 2020 Amendment, the Company capitalized $4.6 million of financing costs in connection with modification of the Senior Credit Facility and wrote off $1.2 million of previously capitalized financing costs during the first quarter of 2020. In connection with the July 2020 amendment, the Company expensed $3.3 million of incremental financing costs in connection with the modification of the Senior Credit Facility during the third quarter of 2020.
There was no balance outstanding at December 31, 2022 under the revolving portion of the Senior Credit Facility and as of December 31, 2021, there was $31.3 million, outstanding under the revolving portion of the Senior Credit Facility at weighted average interest rate of 1.4%. At December 31, 2022 and 2021, there was $771.3 million and $843.8 million, respectively, outstanding, under the Term Loan component of the Senior Credit Facility at weighted average interest rate of 5.6% and 1.4%, respectively. At December 31, 2022 and 2021, there was $38.1 million and $45.0 million, respectively, of the Term Loan component of the Senior Credit Facility was classified as current on the consolidated balance sheets.
The fair value of outstanding borrowings of the Senior Credit Facility's Term Loan components at December 31, 2022 was $800.8 million. This fair values were determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities
Letters of credit outstanding as of December 31, 2022 and 2021 totaled $1.6 million. There were no amounts drawn as of December 31, 2022.
Contractual repayments of the Term Loan component of the Senior Credit Facility are due as follows:
Year-ended December 31, 2022Principal Repayment
Dollars in thousands
2023$38,125 
2024$67,500 
2025$669,375 
$775,000 
Future interest payments on the term loan component of the Senior Credit Facility based on current interest rates are expected to approximate $42.7 million in 2023, $39.1 million in 2024, and $3.6 million in 2025. Interest is calculated on the term loan portion of the Senior Credit Facility based on LIBOR plus the spread paid by the Company. As the revolving credit facility and Securitization Facility can be repaid at any time, no interest has been included in the calculation.
The outstanding balance of the revolving credit component of the Senior Credit Facility is due on February 3, 2025.
Convertible Senior Notes
On February 4, 2020, the Company issued $575.0 million aggregate principal amount of its 0.5% Convertible Senior Notes due 2025 (the "2025 Notes"). The 2025 Notes will mature on August 15, 2025 and bear interest at a rate of 0.5% per annum payable semi-annually in arrears, unless earlier converted, repurchased or redeemed in accordance with the terms of the 2025 Notes. The portion of debt proceeds that was classified as equity at the time of the offering was $104.5 million. The effective interest rate implicit in the liability component was 4.2%. In connection with this offering, the Company capitalized $13.2 million of financing fees.
The 2025 Notes are senior, unsecured obligations of the Company, and are convertible into cash and shares of its common stock based on initial conversion rate, subject to adjustment of 13.5739 shares per $1,000 principal amounts of the 2025 Notes (which represents an initial conversion price of $73.67 per share). The 2025 Notes convert only in the following circumstances: (1) if the closing price of the Company's common stock has been at least 130% of the conversion price during the period; (2) if the average trading price per $1,000 principal amount of the 2025 Notes is less than or equal to 98% of the average conversion value of the 2025 Notes during a period as defined in the indenture; (3) at any time on or after February 20, 2023; or (4) if specified corporate transactions occur. As of December 31, 2022, none of these conditions existed with respect to the 2025 Notes and as a result the 2025 Notes are classified as long term.
F-25
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

On December 9, 2020, the Company entered into the First Supplemental Indenture to the original agreement dated as of February 4, 2020 between the Company and Citibank, N.A., as trustee, governing the Company’s outstanding 2025 Notes. The Company irrevocably elected (1) to eliminate the Company’s option to choose physical settlement on any conversion of the 2025 Notes that occurs on or after the date of the First Supplemental Indenture and (2) with respect to any Combination Settlement for a conversion of the 2025 Notes, the Specified Dollar Amount that will be settled in cash per $1,000 principal amount of the 2025 Notes shall be no lower than $1,000.
Holders of the Notes will have the right to require the Company to repurchase for cash all or a portion of their Notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of a fundamental change (as defined in the indenture relating to the Notes). The Company will also be required to increase the conversion rate for holders who convert their Notes in connection with certain fundamental changes occurring prior to the maturity date or following delivery by the Company of a notice of redemption.
In connection with the issuance of the 2025 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of the 2025 Notes (the “hedge participants”). The cost of the call transactions was $104.2 million for the 2025 Notes. The Company received $44.5 million of proceeds from the warrant transactions for the 2025 Notes. The call transactions involved purchasing call options from the hedge participants, and the warrant transactions involved selling call options to the hedge participants with a higher strike price than the purchased call options. The initial strike price of the call transactions was $73.67, subject to anti-dilution adjustments substantially similar to those in the 2025 Notes. The initial strike price of the warrant transactions was $113.34 for the 2025 Notes, subject to customary anti-dilution adjustments.
At December 31, 2022, the carrying amount of the liability was $575.0 million. The fair value of the 2025 Notes at December 31, 2022 was $560.5 million. Factors that the Company considered when estimating the fair value of the 2025 Notes included recent quoted market prices or dealer quote. The level of the 2025 Notes is considered as Level 1.
As a result of the adoption of ASU 2020-06, for both the years ended December 31, 2022 and 2021, the Company recognized only cash interest related to the contractual interest coupon on the 2025 Notes of $2.9 million.
Securitization Facility
During the fourth quarter of 2018, the Company entered into an accounts receivable securitization facility (the "Securitization Facility") under which accounts receivable of certain domestic subsidiaries are sold on a non-recourse basis to a special purpose entity (“SPE”), which is a bankruptcy-remote, consolidated subsidiary of the Company. Accordingly, the assets of the SPE are not available to satisfy the obligations of the Company or any of its subsidiaries. From time to time, the SPE may finance such accounts receivable with a revolving loan facility secured by a pledge of such accounts receivable. The amount of outstanding borrowings on the Securitization Facility at any one time is limited to $150.0 million. The Securitization Facility Agreement ("Securitization Agreement") governing the Securitization Facility contains certain covenants and termination events. An occurrence of an event of default or a termination event under this Securitization Agreement may give rise to the right of its counterparty to terminate this facility. As of December 31, 2022, the Company was in compliance with the covenants and none of the termination events had occurred.
On May 28, 2021, the Company entered into an amendment (the "May 2021 Amendment") of the Securitization Facility which extended the maturity date from December 21, 2021 to May 28, 2024. The May 2021 Amendment does not increase the Company’s total indebtedness.
At December 31, 2022 and 2021, the Company had $104.7 million and $112.5 million, of outstanding borrowings under its Securitization Facility at a weighted average interest rate of 5.0% and 1.1%, respectively. The fair value of the outstanding borrowing of the Securitization Facility at December 31, 2022 was $104.9 million. These fair values were determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities.
F-26
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

6. DERIVATIVE INSTRUMENTS
Interest Rate Hedging
The Company’s interest rate risk relates to U.S. dollar denominated variable interest rate borrowings. The Company uses interest rate swap derivative instruments to manage earnings and cash flow exposure resulting from changes in interest rates. These interest rate swaps apply a fixed interest rate on a portion of the Company's expected LIBOR-indexed floating-rate borrowings.
The Company held the following interest rate swaps as of December 31, 2022 and 2021 (dollar amounts in thousands):
December 31, 2022December 31, 2021December 31, 2022December 31, 2021
Hedged ItemNotional AmountDesignation DateEffective DateTermination DateFixed Interest RateEstimated Fair Value
Asset (Liability)
1-month USD LIBOR Loan— 300,000 December 13, 2017January 1, 2018December 31, 20222.201 %$— $(5,268)
1-month USD LIBOR Loan150,000 150,000 December 13, 2017July 1, 2019June 30, 20242.423 %5,012 (5,520)
1-month USD LIBOR Loan200,000 200,000 December 13, 2017January 1, 2018December 31, 20242.313 %8,380 (7,421)
1-month USD LIBOR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.220 %1,831 (5,512)
1-month USD LIBOR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.199 %1,905 (5,464)
1-month USD LIBOR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.209 %1,970 (5,494)
1-month USD LIBOR Loan100,000 100,000 December 18, 2018December 30, 2022December 31, 20272.885 %4,252 (6,886)
1-month USD LIBOR Loan100,000 100,000 December 18, 2018December 30, 2022December 31, 20272.867 %4,153 (6,764)
1-month USD LIBOR Loan575,000 575,000 December 15, 2020July 31, 2025December 31, 20271.415 %23,742 3,552 
1-month USD LIBOR Loan125,000 125,000 December 15, 2020July 1, 2025December 31, 20271.404 %5,467 821 
$1,475,000 $1,775,000 $56,712 $(43,956)
The Company has designated these derivative instruments as cash flow hedges. The Company assesses the effectiveness of these derivative instruments and has recorded the changes in the fair value of the derivative instrument designated as a cash flow hedge as unrealized gains or losses in accumulated other comprehensive income (“AOCI”), net of tax, until the hedged item affected earnings, at which point any gain or loss was reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, the Company will reclassify the remaining amount of any gain or loss on the related cash flow hedge recorded in AOCI to interest expense at that time.
Foreign Currency Hedging
From time to time, the Company enters into foreign currency hedge contracts intended to protect the U.S. dollar value of certain forecasted foreign currency denominated transactions. The Company assesses the effectiveness of the contracts that are designated as hedging instruments. The changes in fair value of foreign currency cash flow hedges are recorded in AOCI, net of tax. Those amounts are subsequently reclassified to earnings from AOCI as impacted by the hedged item when the hedged item affects earnings. If the hedged forecasted transaction does not occur, or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. For contracts not designated as hedging instruments, the changes in fair value of the contracts are recognized in other income, net in the consolidated statements of operation, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities.
The success of the Company’s hedging program depends, in part, on forecasts of certain activity denominated in foreign currency. The Company may experience unanticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activities during periods of currency volatility. In addition, changes in currency exchange rates related to any unhedged transactions may affect earnings and cash flows.
Cross-Currency Rate Swaps
On October 2, 2017, the Company entered into cross currency swap agreements to convert a notional amount of $300.0 million equivalent to 291.2 million of Swiss Francs ("CHF") denominated intercompany loans into U.S. dollars. The CHF- denominated intercompany loans were the result of the purchase of intellectual property by a subsidiary in Switzerland as part of an acquisition. On September 26, 2022, the Company amended the CHF-denominated intercompany loan to extend the termination date to September 2023 and as a result, the Company early terminated the cross-currency swap designated as cash flow hedge of an intercompany loan with aggregate notional amount of $50.0 million. Simultaneously, the Company entered into a cross-currency swap agreement to convert a notional amount of CHF 48.5 million equivalent to $49.1 million of this
F-27
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

amended intercompany loan into U.S. dollars. The loss recorded by the Company upon the settlement of the swap was not material for the period. As of December 31, 2022, $49.1 million of the $300.0 million notional amount remain outstanding.
On December 21, 2020, the Company entered into cross-currency swap agreements to convert a notional amount of $471.6 million equivalent to 420.1 million of a CHF-denominated intercompany loan into U.S. dollars. The CHF-denominated intercompany loan was the result of an intra-entity transfer of certain intellectual property rights to a subsidiary in Switzerland completed during the fourth quarter of 2020. The intercompany loan requires quarterly payments of CHF 5.8 million plus accrued interest. As a result, the aggregate notional amount of the related cross-currency swaps will decrease by a corresponding amount.
The objective of these cross-currency swaps is to reduce volatility of earnings and cash flows associated with changes in the foreign currency exchange rate. Under the terms of these contracts, which have been designated as cash flow hedges, the Company will make interest payments in Swiss Francs and receive interest in U.S. dollars. Upon the maturity of these contracts, the Company will pay the principal amount of the loans in Swiss Francs and receive U.S. dollars from the counterparties.
The Company held the following cross-currency rate swaps as of December 31, 2022 and 2021 (dollar amounts in thousands):
December 31, 2022December 31, 2021December 31, 2022December 31, 2021
Effective DateTermination DateFixed RateAggregate Notional AmountFair Value Asset (Liability)
Pay CHFOctober 2, 2017October 2, 20221.95%CHF— 145,598 — (8,283)
Receive U.S.$4.52%$— 150,000 
Pay CHFDecember 21, 2020December 22, 20253.00%CHF374,137 397,137 (4,241)41 
Receive U.S.$3.98%$420,001 445,821 
Pay CHFSeptember 28, 2022September 29, 20231.95%CHF48,532 — (3,528)— 
Receive U.S.$5.32%$49,142 — 
Total$(7,769)$(8,242)
On October 3rd, 2022, in accordance with the termination date, the Company settled cross-currency swaps designated as cash flow hedges of an intercompany loan with aggregate notional amounts of $100 million. Based on the closing exchange rates, the gain upon settlement of these swaps was approximately $1.6 million which was offset by the loss on the settlement of the intercompany loan.
On October 4, 2021 in accordance with the termination date, the Company settled a cross-currency swap designated as a cash flow hedge of an intercompany loan with an aggregate notional amount of $50.0 million. The gain recorded by the Company upon the settlement of the swap was not material for the period.
The cross-currency swaps are carried on the consolidated balance sheet at fair value, and changes in the fair values are recorded as unrealized gains or losses in AOCI.
Net Investment Hedges
The Company manages certain foreign exchange risks through a variety of strategies, including hedging. The Company is exposed to foreign exchange risk from its international operations through foreign currency purchases, net investments in foreign subsidiaries, and foreign currency assets and liabilities created in the normal course of business. On October 1, 2018 ,December 16, 2020 and May 26, 2022, the Company entered into cross-currency swap agreements designated as net investment hedges to partially offset the effects of foreign currency on foreign subsidiaries.
F-28
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The Company held the following cross-currency rate swaps designated as net investment hedges as of December 31, 2022 and 2021 (dollar amounts in thousands):
December 31, 2022December 31, 2021December 31, 2022December 31, 2021
Effective DateTermination DateFixed RateAggregate Notional AmountFair Value
Asset (Liability)
Pay EUROctober 3, 2018September 30, 2023—%EUR51,760 51,760 4,713 2,503 
Receive U.S.$2.57%$60,000 60,000 
Pay EUROctober 3, 2018September 30, 2025—%EUR38,820 38,820 4,307 2,147 
Receive U.S.$2.19%$45,000 45,000 
Pay CHFDecember 16, 2020December 16, 2027—%CHF— 222,300 — (792)
Receive USD1.10%$— 250,000 
Pay CHFMay 26, 2022December 16, 2028—%CHF288,210 — (14,663)— 
Receive U.S.$1.94%$300,000 — 
Total$(5,643)$3,858 
On May 26, 2022, the Company early settled cross-currency swaps designated as net investment hedge with an aggregate notional amount of $250 million equivalent to 222.3 million CHF. The original settlement date was December 16, 2027. As a result of the settlement, the Company recorded a gain of $4.9 million in AOCI. On May 26, 2022, the Company entered into cross-currency swap agreements designated as net investment hedge to replace these swaps with a notional amount of $300 million equivalent to 288 million CHF.
On September 30, 2021, in accordance with the termination date, the Company settled cross-currency swaps designated as net investment hedge with an aggregate notional amount of $52 million equivalent to 44.9 million Euros. As a result of the settlement, the Company recorded a gain of $0.1 million in AOCI.
The cross-currency swaps were carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in AOCI.
Counterparty Credit Risk
The Company manages its concentration of counterparty credit risk on its derivative instruments by limiting acceptable counterparties to a group of major financial institutions with investment grade credit ratings, and by actively monitoring their credit ratings and outstanding positions on an ongoing basis. Therefore, the Company considers the credit risk of the counterparties to be low. Furthermore, none of the Company’s derivative transactions are subject to collateral or other security arrangements, and none contain provisions that depend upon the Company’s credit ratings from any credit rating agency.
Fair Value of Derivative Instruments
The Company has classified all of its derivative instruments within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of the derivative instruments. The fair values of the interest rate swaps and cross-currency swaps were developed using a market approach based on publicly available market yield curves and the terms of the swap. The Company performs ongoing assessments of counterparty credit risk.
F-29
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

Effects of Derivative Instruments on Financial Position and Results of Operations
The following table summarizes the fair value for derivatives designated as hedging instruments in the consolidated balance sheets as of December 31, 2022 and 2021:
 Fair Value as of December 31,
Dollars in thousands20222021
Location on Balance Sheet (1):
Derivatives designated as hedges — Assets:
Prepaid expenses and other current assets
Cash Flow Hedges
Cross-currency swap4,497 4,900 
Interest rate swap(2)
16,682 — 
Net Investment Hedges
Cross-currency swap11,653 5,120 
Other assets
Cash Flow Hedges
Interest rate swap(2)
40,030 4,373 
Net Investment Hedges
Cross-currency swap3,311 2,104 
Total derivatives designated as hedges — Assets$76,173 $16,497 
Derivatives designated as hedges — Liabilities
Accrued expenses and other current liabilities
Cash Flow Hedges
Interest rate swap(2)
$— $18,187 
Cross-currency swap3,528 8,283 
Net Investment Hedges
Cross-currency swap— — 
Other liabilities
Cash Flow Hedges
Interest rate swap(2)
— 30,143 
Cross-currency swap8,738 4,859 
Net Investment Hedges
Cross-currency swap20,608 3,366 
Total derivatives designated as hedges — Liabilities32,874 64,838 
(1)The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.
(2)At December 31, 2022 and 2021, the total notional amounts related to the Company’s interest rate swaps were $1.5 billion and $1.8 billion respectively.
F-30
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The following presents the effect of derivative instruments designated as cash flow hedges and net investment hedges on the accompanying consolidated statement of operations during the years ended December 31, 2022 and 2021:
 
Dollars in thousandsBalance in AOCI
Beginning of
Year		Amount of
Gain (Loss)
Recognized in
AOCI		Amount of Gain (Loss)
Reclassified from
AOCI into
Earnings		Balance in AOCI
End of Year		Location in
Statements of
Operations
Year Ended December 31, 2022
Cash Flow Hedges
Interest rate swap$(43,956)$93,308 $(7,360)$56,712 Interest expense
Cross-currency swap(9,688)8,847 19,430 (20,271)Other income, net
Net Investment Hedges
Cross-currency swap(2,321)2,196 6,789 (6,914)Interest income
$(55,965)$104,351 $18,859 $29,527 
Year Ended December 31, 2021
Cash Flow Hedges
Interest rate swap$(93,769)$27,402 $(22,411)$(43,956)Interest expense
Cross-currency swap(1,073)24,275 32,890 (9,688)Other income, net
Net Investment Hedges
Cross-currency swap(12,291)16,515 6,545 (2,321)Interest income
$(107,133)$68,192 $17,024 $(55,965)

For the years ended December 31, 2022 and 2021, the Company recorded a gain of $11.1 million and gain of $23.8 million, respectively, in other income, net related to change in fair value related to the foreign currency rate translation of the cross-currency swaps, designated as cash flow hedges, to offset the gains or losses recognized on the intercompany loans.
For the years ended December 31, 2022 and 2021, the Company recorded gains of $8.4 million and $9.1 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps designated as cash flow hedges.
The estimated gain that is expected to be reclassified to other income, net from AOCI as of December 31, 2022, for the cross-currency swaps designated as cash flow hedges within the next twelve months is $4.5 million. As of December 31, 2022, the Company does not expect any gains or losses will be reclassified into earnings as a result of the discontinuance of these cash flow hedges because the original forecasted transaction will not occur.
The estimated gain that is expected to be reclassified to interest income from AOCI as of December 31, 2022 for the cross-currency swaps designated as net investment hedges, within the next twelve months is $11.7 million.
Derivative Instruments not designated hedges:
During the fourth quarter of 2020, the Company entered into foreign currency forward contracts, with a notional amount of $4.2 million, to mitigate the foreign exchange risk related to certain intercompany loans denominated in Canadian Dollar ("CAD"). These contracts were settled in third quarter of 2022.
During the second quarter of 2021, the Company entered into a foreign currency swap, with a notional amount of $7.3 million, to mitigate the risk from fluctuations in foreign currency exchange rates associated with an intercompany loan denominated in JPY. In a foreign currency swap transaction, the Company agrees with another party to exchange, at specified intervals, the difference between one currency and another currency at a fixed exchange rate, generally set at inception, calculated by reference to an agreed upon notional amount. The notional amount of each currency is exchanged at the inception and termination of the currency swap by each party. The Company subsequently paid down a portion of this swap, bringing the notional amount down to $6.4 million.
The following table summarizes the gains (losses) of derivative instruments not designated as hedges on the condensed consolidated statements of income, which was included in other income:
F-31
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

Dollars in thousandsDecember 31,
20222021
Foreign currency forward contracts $— $(174)
Foreign currency swaps1,258 629
Total$1,258 $455 
7. GOODWILL AND OTHER INTANGIBLE ASSETS
Goodwill
The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test.
The qualitative evaluation is an assessment of factors including reporting unit specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of a reporting unit is less than its carrying amount, including goodwill. The Company may elect to bypass the qualitative assessment for its three reporting units and perform a quantitative test. The assumptions used in evaluating goodwill for impairment are subject to change and are tracked against historical results by management.
The quantitative test estimates the fair value of the three reporting units using a discounted cash flow model, which incorporates significant estimates and assumptions made by management which, by their nature, are characterized by uncertainty. Inputs used to fair value the Company's reporting units are considered inputs of the fair value hierarchy. For Level 3 measurements, significant increases or decreases in long-term growth rates or discount rates in isolation or in combination could result in a significantly lower or higher fair value measurement. The key assumptions impacting the valuation included the following:
•The reporting unit's financial projections, which are based on management's assessment of regional and macroeconomic variables, industry trends and market opportunities, and the Company's strategic objectives and future growth plans.
•The projected terminal value for the reporting unit, which represents the present value of projected cash flows beyond the last period in the discounted cash flow analysis. The terminal value reflects the Company's assumptions related to long-term growth rates and profitability, which are based on several factors, including local and macroeconomic variables, market opportunities, and future growth plans.
•The discount rate used to measure the present value of the projected future cash flows is set using a weighted-average cost of capital method that considers market and industry data as well as the Company's specific risk factors that are likely to be considered by a market participant. The weighted-average cost of capital is the Company's estimate of the overall after-tax rate of return required by equity and debt holders of a business enterprise.
During the third quarter of 2022, the Company elected to perform a qualitative analysis for its three reporting units. The Company determined, after performing the qualitative analysis, that there was no evidence that it is more likely than not that the fair value was less that the carrying amounts, therefore, it was not necessary to perform a quantitative impairment test.
Changes in the carrying amount of goodwill in 2022 and 2021 were as follows:
Dollars in thousandsCodman Specialty Surgical Tissue TechnologiesTotal
Goodwill at January 1, 2021$671,975 $260,392 $932,367 
ACell Acquisition — 94,147 94,147 
Foreign currency translation(8,547)(4,509)(13,056)
Balance at December 31, 2021$663,428 $350,030 $1,013,458 
Sale of non-core traditional wound care business— (5,019)(5,019)
SIA Acquisition— 41,855 41,855 
Foreign currency translation(7,209)(4,204)(11,413)
Balance at December 31, 2022$656,219 $382,662 $1,038,881 
F-32
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

Other Intangible Assets
The components of the Company's identifiable intangible assets were as follows:
December 31, 2022
Dollars in thousandsWeighted
Average
Life		CostAccumulated AmortizationNet
Completed technology
18 years
$1,204,325 $(370,968)$833,357 
Customer relationships
12 years
193,081 (144,040)49,041 
Trademarks/brand names
28 years
97,265 (34,674)62,591 
Codman trade nameIndefinite166,693 — 166,693 
Supplier relationships
30 years
30,211 (17,170)13,041 
All other
11 years
5,957 (4,071)1,886 
$1,697,532 $(570,923)$1,126,609 
December 31, 2021
Dollars in thousandsWeighted
Average
Life		CostAccumulated AmortizationNet
Completed technology
18 years
$1,132,954 $(307,013)$825,941 
Customer relationships
12 years
211,344 (142,755)68,589 
Trademarks/brand names
28 years
98,367 (31,468)66,899 
Codman trade name
Indefinite
167,758 — 167,758 
Supplier relationships
30 years
30,211 (16,192)14,019 
All other
11 years
6,258 (3,891)2,367 
$1,646,892 $(501,319)$1,145,573 

Intangible Assets with Indefinite Lives
The Company tests intangible assets with indefinite lives for impairment annually in the third quarter in accordance with ASC Topic 350. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a indefinite lived intangible asset below its carrying amount. The Company tests for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of the intangible asset is less than its carrying amount. The Company may elect to bypass this qualitative evaluation and perform a quantitative test.
During the third quarter of 2022, the Company elected to perform a qualitative analysis for its intangible asset with indefinite lives. The Company determined, after performing the qualitative analysis, that there was no evidence that it is more likely than not that the fair value was less that the carrying amounts, therefore, it was not necessary to perform a quantitative impairment test.
Product rights and other definite-lived intangible assets are tested periodically for impairment in accordance with ASC Topic 360 when events or changes in circumstances indicate that an asset's carrying value may not be recoverable. The impairment testing involves comparing the carrying amount of the asset or asset group to the forecasted undiscounted future cash flows. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and impairment exists. An impairment loss is measured as the excess of the asset's carrying value over its fair value, calculated using discounted future cash flows. The computed impairment loss is recognized in the period that the impairment occurs.
Amortization expense (including amounts reported in cost of product revenues) for the years ended December 31, 2022, 2021 and 2020 was $78.3 million, $83.3 million and $74.5 million, respectively.
F-33
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

Annual amortization expense is expected to approximate $82.3 million in 2023, $81.7 million in 2024, $81.7 million in 2025, $81.5 million in 2026, $79.6 million in 2027 and $551.6 million thereafter. Amortization of product technology based intangible assets totaled $64.4 million, $66.5 million and $46.7 million for the years ended December 31, 2022, 2021 and 2020, respectively, and is presented by the Company within cost of goods sold.
8. TREASURY STOCK
As of December 31, 2022 and 2021, there were 6.8 million and 4.9 million shares of treasury stock outstanding with a cost of $362.9 million and $234.4 million, respectively, at a weighted average cost per share of $53.18 and $47.86, respectively.
On January 26, 2023, the Company entered into a $150 million accelerated share repurchase ("2023 ASR") and received 2.1 million shares of the Company common stock at inception of the 2023 ASR, which represented approximately 80% of the expected total shares of under the 2023 SAR. The remaining repurchase transactions are expected to be completed in the first half of 2023.
On April 26 2022, the Board of Directors authorized the Company to repurchase up to $225 million of the Company’s common stock. The program allows the Company to repurchase its shares opportunistically from time to time. The repurchase authorization expires in December 2024. This stock repurchase authorization replaces the previous $225 million stock repurchase authorization, of which $100 million remained authorized at the time of its replacement, and which was otherwise set to expire on December 31, 2022. Purchases may be affected through one or more open market transactions, privately negotiated transactions, transactions structured through investment banking institutions, or a combination of the foregoing.
On January 12, 2022, the Company entered into a $125 million accelerated share repurchase ("2022 ASR") and received 1.48 million shares of Company common stock at inception of the 2022 ASR, which represented approximately 80% of the expected total shares under the 2022 ASR. In March 24, 2022, the early exercise provision was exercised by the 2022 ASR counterparty. Upon settlement on March 24, 2022, the Company received an additional 0.46 million shares determined using the volume-weighted average price of the Company's common stock during the term of the 2022 ASR.
For the year ended December 31, 2021, there were no repurchases of the Company’s common stock as part of the share repurchase authorization.
On August 16, 2022, the Inflation Reduction Act of 2022 (the “Act”) was signed into law. The Act implements a new excise tax of 1% on the net share repurchases made by the company effective for share repurchases performed January 1, 2023, or after.
9. STOCK-BASED COMPENSATION
Stock-based compensation expense - all related to employees and members of the Board of Directors - recognized under the authoritative guidance was as follows:
Years Ended December 31,
Dollars in thousands202220212020
Cost of goods sold549 470 344 
Research and development1,739 1,644 1,471 
Selling, general and administrative$25,437 $34,096 $17,776 
Total stock-based compensation expense27,725 36,210 19,591 
Total estimated tax benefit related to stock-based compensation expense10,574 13,804 6,221 
Net effect on net income$17,151 $22,406 $13,370 
EMPLOYEE STOCK PURCHASE PLAN
The purpose of the Employee Stock Purchase Plan (the “ESPP”) is to provide eligible employees of the Company with the opportunity to acquire shares of common stock at periodic intervals by means of accumulated payroll deductions. The ESPP is a non-compensatory plan. Under the ESPP, a total of 3.0 million shares of common stock are reserved for issuance. These shares will be made available either from the Company’s authorized but unissued shares of common stock or from shares of common stock reacquired by the Company as treasury stock. At December 31, 2022, 2.0 million shares remain available for purchase under the ESPP. During the years ended December 31, 2022, 2021 and 2020, the Company issued 20,780 shares, 16,948 shares and 18,284 shares under the ESPP for $1.1 million, $1.1 million and $1.1 million, respectively.
F-34
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

EQUITY AWARD PLANS
As of December 31, 2022, the Company had stock options, restricted stock awards, performance stock awards, contract stock awards and restricted stock unit awards outstanding under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan (the “2003 Plan”). The 2000 and 2001 Equity Incentive Plans were terminated as of February 19, 2021, and no further awards may be issued under the plans.
In May 2010 and May 2017, the stockholders of the Company approved amendments to the 2003 Plan to increase by 3.5 million and 1.7 million, respectively, the number of shares of common stock that may be issued under the 2003 Plan. The Company has reserved 4.0 million shares under each of the 2000 Plan and the 2001 Plan, and 14.7 million shares under the 2003 Plan. The Plans permit the Company to grant incentive and non-qualified stock options, stock appreciation rights, restricted stock, contract stock, performance stock, or dividend equivalent rights to designated directors, officers, employees and associates of the Company.
Stock options issued under the 2003 Plan became exercisable over specified periods, generally within four years from the date of grant for officers and employees, and within one year from the date of the grant for members of the Board of Directors. The awards generally expire eight years from the grant date for employees and from six to ten for directors and certain executive officers, except in certain instances that result in accelerated vesting due to death, disability, retirement age or change in control provisions within their grant agreements. Restricted stock issued under the 2003 Plan vests ratably over specified periods, generally three years after the date of grant. The vesting of performance stock issued under the 2003 Plan is subject to service and performance conditions.
Stock Options
The Company values stock option grants using the binomial distribution model. Management believes that the binomial distribution model is preferable to the Black-Scholes model because it is a more flexible model that gives consideration to the impact of non-transferability and vesting provisions in valuing employee stock options.
In determining the value of stock options granted, the Company considered that it has never paid cash dividends and does not currently intend to pay cash dividends, and thus has assumed a 0% dividend yield. Expected volatilities are based on the historical volatility of the Company’s stock price. The expected life of stock options is estimated based on historical data on exercise of stock options, post-vesting forfeitures and other factors to estimate the expected term of the stock options granted. The risk-free interest rates are derived from the U.S. Treasury yield curve in effect on the date of grant for instruments with a remaining term similar to the expected life of the options. The Company accounts for forfeitures as they occur.
The following weighted-average assumptions were used in the calculation of fair value:
Years Ended December 31,
202220212020
Dividend yield0%0%0%
Expected volatility30%29%27%
Risk free interest rate2.01%1.30%0.89%
Expected life of option from grant date7 years7 years7 years
Weighted average grant date fair value of options granted
$23.15$22.59$13.03
The following table summarizes the Company’s stock option activity.
SharesWeighted Average Exercise PriceWeighted Average Contractual Term in YearsAggregate Intrinsic Value
Stock Options(In thousands)(In thousands)
Outstanding at January 1, 20221,225 $45.11 4.30$26,970
Granted146 65.11 — — 
Exercised(155)28.32 — — 
Forfeited or Expired(14)50.68 — — 
Outstanding at December 31, 20221,202 $49.63 4.14$10,772 
Exercisable at December 31, 2022871 $45.82 3.30$9,635 
F-35
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The Company recognized $3.5 million, $5.0 million and $3.2 million in expense related to stock options during the years ended December 31, 2022, 2021 and 2020, respectively. The intrinsic value of options exercised for the years ended December 31, 2022, 2021 and 2020 were $4.0 million, $11.1 million and $8.7 million, respectively. Cash received from option exercises and employee stock purchase plan was $5.5 million, $6.8 million and $5.2 million, for the years ended December 31, 2022, 2021 and 2020, respectively. The realized tax benefit from options exercised were $0.6 million, $2.2 million and $1.7 million for the years ended December 31, 2022, 2021 and 2020, respectively.
As of December 31, 2022, there was approximately $3.5 million of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of approximately two years.
Awards of Restricted Stock, Performance Stock and Contract Stock
The following table summarizes the Company’s awards of restricted stock, performance stock and contract stock for the year ended December 31, 2022.
Restricted Stock AwardsPerformance Stock and Contract Stock Awards
SharesWeighted Average Grant Date Fair Value Per ShareSharesWeighted Average Grant Date Fair Value Per Share
(In thousands)(In thousands)
Unvested, January 1, 2022422 $58.78 442 60.62 
Granted334 62.88 245 62.89 
Adjustments for performance achievement related to award target
— — (18)60.76 
Cancellations(34)62.29 (10)59.88 
Released(239)58.27 (252)59.38 
Unvested, December 31, 2022483 $61.63 407 62.88 
The Company recognized $24.3 million, $31.2 million and $16.4 million in expense related to such awards during the years ended December 31, 2022, 2021 and 2020, respectively. The total fair market value of shares vested and released in 2022, 2021 and 2020 was $65.0 million, $15.7 million and $17.3 million, respectively. Vested awards include shares that have been fully earned but had not been delivered as of December 31, 2022.
Performance stock awards have performance features associated with them. Performance stock, restricted stock and contract stock awards generally have requisite service periods of three years. The fair value of these awards is being expensed on a straight-line basis over the vesting period. As of December 31, 2022, there were 129,399 performance stock units ("PSU's") subject to vest and be released based on 2022 performance achievement.
As of December 31, 2022, there was approximately $29.7 million of total unrecognized compensation costs related to unvested restricted stock, performance stock and contract stock awards. These costs are expected to be recognized over a weighted-average period of approximately two years.
At December 31, 2022, there were approximately 3.1 million shares available for grant under the 2003 Plan.
The Company capitalized into inventory, share based compensation costs of $0.6 million, $0.5 million and $0.4 million for the years ended December 31, 2022, 2021 and 2020, respectively. Such share-based compensation was recognized as cost of goods sold when related inventory was sold.
F-36
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

10. RETIREMENT BENEFIT PLANS
DEFINED BENEFIT PLANS
The Company has various defined benefit plans which covers certain employees in France, Japan, Germany and Switzerland.
Net periodic benefit costs for the Company’s defined benefit pension plans for the years ended December 31, 2022 and 2021 included the following (amounts in thousands):
Year ended December 31,
20222021
Service cost$2,419 $2,741 
Interest cost194 100 
Expected return on plan assets(1,381)(893)
Amortization of prior service cost (credit)(326)(281)
Recognized actuarial losses9 186 
Settlements— 51 
Net period benefit cost$915 $1,904 
The following weighted average assumptions were used to develop net periodic pension benefit costs and the actuarial present values of projected pension benefit obligations for the years ended December 31, 2022 and 2021, respectively:
As of December 31,
20222021
Discount rate2.44 %0.37 %
Expected return on plan assets3.61 %3.59 %
Rate of compensation increase1.97 %2.10 %
Interest crediting rate for cash balance plans1.00 %1.00 %
The Company’s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. In 2022 and 2021, the discount rates were prescribed as the current yield on corporate bonds with an average rating of AA or AAA of equivalent currency and term to the liabilities. The expected returns on plan assets represent the average rate of return expected to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid. In developing the expected rates of return, the Company considers returns of historical market data as well as actual returns on the plan assets. Using this reference information, the long-term return expectations for each asset category are developed according to the allocation among those investment categories.
The assessment is determined using projections from external financial sources, long-term historical averages, actual returns by asset class and the various asset class allocations by market.
F-37
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The following sets forth the change in projected benefit obligations and the change in plan assets for the years ended December 31, 2022 and 2021 and a reconciliation of the funded status at December 31, 2022 and 2021, respectively (amounts in thousands):
Year ended December 31,
20222021
Change In Projected Benefit Obligations
Projected benefit obligations, beginning of year$65,184 $72,869 
Interest cost194 100 
Service cost2,419 2,741 
Actuarial (gain) loss(14,822)(5,044)
Plan amendments(390)(586)
Plan settlements(20)(655)
Employee contribution999 917 
Premiums paid(391)(373)
Benefit payment(999)(2,128)
Effect of foreign currency exchange rates(1,810)(2,657)
Projected benefit obligations, end of year$50,364 $65,184 
Year ended December 31,
20222021
Change In Plan Assets
Plan assets at fair value, beginning of year$39,914 $37,825 
Actual return on plan assets(2,863)3,371 
Employer contributions2,356 2,254 
Employee contributions999 917 
Plan settlements— (633)
Benefits paid(998)(2,128)
Premiums paid(391)(373)
Effect of foreign currency exchange rates(964)(1,319)
Plan assets at fair value, end of year$38,053 $39,914 
Year ended December 31,
20222021
Reconciliation Of Funded Status
Fair value of plan assets$38,053 $39,914 
Benefit obligations50,364 65,184 
Unfunded benefit obligations$12,311 $25,270 
The unfunded benefit obligations are included in other liabilities in the consolidated balance sheets at December 31, 2022 and 2021, respectively.
During the periods ended December 31, 2022 and 2021, the Company had a net gain of $7.4 million and $7.0 million, respectively, recognized within accumulated other comprehensive loss that has not been recognized as a component of net periodic benefit cost. The gain recognized during the period ended December 31, 2021, is primarily attributed to a change in the discount rate used to estimate the projected benefit obligation for defined benefit plans which cover certain employees in Switzerland. The combined accumulated benefit obligations for the defined benefit plans was $46.4 million and $60.3 million as of December 31, 2022 and 2021, respectively.
Unrecognized gains and losses are amortized over the average remaining future service for each plan. For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses is determined by using a 10% corridor of the greater of the market value of assets or the accumulated benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service.
Prior service costs/benefits for the pension plans are amortized over the average remaining future service of plan participants at the time of the plan amendment.
F-38
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The net plan assets of the pension plans are invested in common trusts. Common trusts are classified as Level 2 in fair value hierarchy. The fair value of common trusts is valued at net asset value based on the fair values of the underlying investments of the trusts as determined by the sponsor of the trusts. The investment strategy of the Company's defined benefit plans is both to meet the liabilities of the plans as they fall due and to maximize the return on invested assets within appropriate risk profile.
The benefit plans in France and Germany had no assets at December 31, 2022.
As of December 31, 2022, no plan assets are expected to be returned to the Company in the next twelve months.
The following table is the summary of expected future benefit payments (in thousands):
2023$2,211 
2024$2,045 
2025$2,050 
2026$1,929 
2027$1,868 
Next five years$11,068 
As of December 31, 2022, contributions expected to be paid to the plan in 2022 is $2.6 million.
DEFINED CONTRIBUTION PLANS
The Company also has various defined contribution savings plans that cover substantially all employees in the United States, Belgium, Canada, France, Japan, Netherlands, the U.K. and Puerto Rico. The Company matches a certain percentage of each employee’s contributions as per the provisions of the plans. Total contributions by the Company to the plans were $9.8 million, $8.8 million and $6.7 million for the years ended December 31, 2022, 2021 and 2020, respectively.
DEFERRED COMPENSATION PLAN
The Company maintains a Deferred Compensation Plan in which certain employees of the Company may defer the payment and taxation of up to 75% of their base salary and up to 100% of bonus amounts and other eligible cash compensation.
This deferred compensation is invested in funds offered under this plan and is valued based on Level 1 measurements in the fair value hierarchy. Assets of the Company's deferred compensation plan are included in Other current assets and recorded at fair value based on their quoted market prices. The fair value of these assets at December 31, 2022 and 2021 was $4.7 million and $3.8 million. Offsetting liabilities relating to the deferred compensation plan are included in Other liabilities.
11. LEASES AND RELATED PARTY LEASES
The Company leases administrative, manufacturing, research and distribution facilities and vehicles through operating lease agreements. The Company has no finance leases as of December 31, 2022. Many of the Company's leases include both lease (e.g., fixed payments including rent) and non-lease components (e.g., common-area or other maintenance costs). For vehicles, the Company has elected the practical expedient to group lease and non-lease components. 
Most facility leases include one or more options to renew. The exercise of lease renewal options is typically at the Company's sole discretion, therefore, the majority of renewals to extend the lease terms are not included in the ROU assets and lease liabilities as they are not reasonably certain of exercise. The Company regularly evaluates renewal options and when they are reasonably certain of exercise, the renewal period is included in the lease term.
As most of the Company's leases do not provide an implicit rate, the Company uses a collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments.
Total operating lease expense for the year ended December 31, 2022 and 2021, was $22.6 million and $20.3 million, respectively, which includes $0.3 million, in related party operating lease expense.

F-39
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

Supplemental balance sheet information related to operating leases at December 31, 2022 were as follows:
December 31, 2022
December 31, 2021
(In thousands, except lease term and discount rate)
ROU assets$148,284 $84,543 
Current lease liabilities14,624 14,775 
Non-current lease liabilities157,420 90,329 
Total lease liabilities$172,044 $105,104 
Weighted average remaining lease term (in years):
Leased facilities16.9 years10.4 years
Leased vehicles2.0 years2.1 years
Weighted average discount rate:
Leased facilities5.4 %5.1 %
Leased vehicles2.7 %2.6 %
Supplemental cash flow information related to leases was as follows:
December 31, 2022
December 31, 2021
(In thousands)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$17,442 $15,077 
ROU assets obtained in exchange for lease liabilities:
Operating leases72,169 12,610 
Future minimum lease payments under operating leases at December 31, 2022 were as follows:
Related PartiesThird PartiesTotal
(In thousands)
2023296 20,024 20,320 
2024296 20,869 21,165 
2025296 19,198 19,494 
2026296 16,830 17,126 
2027296 15,886 16,182 
Thereafter542 164,622 165,164 
Total minimum lease payments$2,022 $257,429 $259,451 
Less: Imputed interest$87,407 
Total lease liabilities172,044 
Less: Current lease liabilities14,624 
Long-term lease liabilities157,420 
There were no future minimum lease payments under finance leases at December 31, 2022.
F-40
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

Related Party Leases
The Company leases its manufacturing facility in Plainsboro, New Jersey, from a general partnership that is 50% owned by a corporation whose stockholders are trusts, whose beneficiaries include family members of the Company’s principal stockholder and former director. The term of the current lease agreement is through October 31, 2029 at an annual rate of approximately $0.3 million per year. The current lease agreement also provides (i) a 5-year renewal option for the Company to extend the lease from November 1, 2029 through October 31, 2034 at the fair market rental rate of the premises, and (ii) another 5-year renewal option to extend the lease from November 1, 2034 through October 31, 2039 at the fair market rental rate of the premises.
12. INCOME TAXES
Income before income taxes consisted of the following:
Years Ended December 31,
Dollars in thousands202220212020
United States operations$92,642 $91,150 $15,082 
Foreign operations121,252 123,527 78,438 
Total$213,894 $214,677 $93,520 
A reconciliation of the U.S. Federal statutory rate to the Company’s effective tax rate is as follows:
Years Ended December 31,
202220212020
Federal statutory rate21.0 %21.0 %21.0 %
Increase (decrease) in income taxes resulting from:
   State income taxes, net of federal tax benefit0.1 %1.9 %1.2 %
   Foreign operations(3.9)%(4.0)%(7.9)%
 Excess tax benefits from stock compensation(2.4)%(1.2)%(1.0)%
   Intercompany profit in inventory0.3 %(0.2)%1.2 %
   Nondeductible facilitative costs0.2 %0.3 %1.1 %
   Contingent Consideration(2.0)%(0.2)%0.2 %
   Research and development credit(1.4)%(1.2)%(1.6)%
   Return to provision(0.5)%(0.7)%(2.3)%
   Global intangible low-taxed income ("GILTI")2.8 %0.7 %2.5 %
   Nondeductible executive compensation1.8 %0.9 %2.4 %
   Fair market value step up on intra-entity transfer of intellectual property
— %— %(63.3)%
   Gain from sale of business - book to tax differences— %3.9 %2.8 %
   Other(0.4)%— %0.5 %
Effective tax rate15.6 %21.2 %(43.2)%
Our effective tax rate was 15.6% and 21.2% of income before income taxes for the years ended December 31, 2022 and December 31, 2021, respectively. In 2022, the Company’s lower effective tax rate was driven by a $5.1 million income tax benefit related to stock compensation and a $2.4 million income tax benefit related to the filing of amended federal and state returns for prior years. In 2021, the Company's higher effective tax rate was driven in part by an $8.5 million income tax expense for nondeductible goodwill related to the sale of the Extremity Orthopedics business, offset by a $3.1 million income tax benefit related to excess tax benefits from stock compensation. In 2020, the Company’s lower worldwide effective tax rate was primarily driven by an $59.2 million income tax benefit on an intra-entity transfer of certain intellectual property, substantially completed during the fourth quarter in 2020. Excluding this transaction, the effective worldwide tax rate for 2020 was 20.2%.
F-41
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

In December 2020, the Company completed an intra-entity transfer of certain intellectual property rights to one of its subsidiaries in Switzerland. While the transfer did not result in a taxable gain, the Company’s Swiss subsidiary received a step-up in tax basis based on the fair value of the transferred intellectual property rights. The Company determined the fair value using a discounted cash flow model based on expectations of revenue growth rates, royalty rates, discount rates, and useful lives of the intellectual property. The Company recorded a $59.2 million deferred tax benefit in Switzerland related to the amortizable tax basis in the transferred intellectual property.
During 2022, the Company’s foreign operations generated a $0.4 million increase in income tax expense when compared to the same period in 2021, because of geographic and business mix of taxable earnings and losses, among other factors. The 2022 foreign effective tax rate is 15.9%, compared to 15.2% in 2021. The Company’s foreign tax rate is primarily based upon statutory rates.
During 2021, the Company’s foreign operations generated a $63.6 million increase in income tax expense when compared to the same period in 2020, because of the intra-entity transfer of certain intellectual property in 2020, geographic and business mix of taxable earnings and losses, among other factors. The 2021 foreign effective tax rate is 15.2%, compared to (57.1)% in 2020. The Company’s foreign tax rate is primarily based upon statutory rates and is also impacted by the intra-entity transfer of certain intellectual property as described above for 2020.
Changes to income tax laws and regulations, in any of the tax jurisdictions in which the Company operates, could impact the effective tax rate. Various governments, both U.S. and non-U.S., are increasingly focused on tax reform and revenue-raising legislation. On August 16, 2022, the Inflation Reduction Act of 2022 (the “Act”) was signed into law, the company does not expect the law to have a material impact on the company’s effective tax rate. Further, legislation in foreign jurisdictions may be enacted, in response to the base erosion and profit-sharing (BEPS) project begun by the Organization for Economic Cooperation and Development (OECD). The OECD recently finalized major reform of the international tax system with respect to implementing a global minimum tax rate. Such changes in U.S. and Non-U.S. jurisdictions could have an adverse effect on the Company’s effective tax rate.
The provision for income taxes consisted of the following:
Years Ended December 31,
Dollars in thousands202220212020
Current:
   Federal$24,201 $31,938 $6,184 
   State3,835 11,377 5,029 
   Foreign9,893 5,042 12,553 
Total current$37,929 $48,357 $23,766 
Deferred:
   Federal(11,591)(12,830)(5,079)
   State(2,316)(3,688)(1,760)
   Foreign9,322 13,763 (57,299)
Total deferred$(4,585)$(2,755)$(64,138)
Provision for income taxes$33,344 $45,602 $(40,372)
F-42
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

The income tax effects of significant temporary differences that give rise to deferred tax assets and liabilities, shown before jurisdictional netting, are presented below:
December 31,
Dollars in thousands20222021
Assets:
   Doubtful accounts$2,261 $2,029 
   Inventory related items31,950 31,841 
   Tax credits13,084 13,319 
   Accrued vacation2,175 3,042 
   Accrued bonus4,944 7,415 
   Stock compensation10,175 13,955 
   Deferred revenue2,130 1,742 
   Net operating loss carryforwards30,707 26,198 
Capitalization of research and development expenses51,542 36,770 
   Unrealized foreign exchange gain6,228 12,849 
   Charitable contributions carryforward180 206 
   Leases and Other39,788 41,371 
   Total deferred tax assets195,164 190,737 
   Less valuation allowance(9,651)(9,767)
   Deferred tax assets after valuation allowance$185,513 $180,970 
Liabilities:
   Intangible and fixed assets(166,891)(152,150)
   Unrealized foreign exchange loss(12,991)— 
   Leases and Other(22,975)(17,658)
   Total deferred tax liabilities$(202,857)$(169,808)
Total net deferred tax assets (liabilities)$(17,344)$11,162 
The 2017 U.S. Tax Cuts and Jobs Act contained a provision which requires, for tax purposes, the capitalization and amortization of research and development expenses; effective for years beginning after December 31, 2021. The Company’s deferred tax assets increased by $20.2 million within the table above, related to the 2017 Tax Act.
At December 31, 2022, the Company had net operating loss carryforwards of $79.5 million for federal income tax purposes, $75.5 million for foreign income tax purposes and $37.9 million for state income tax purposes to offset future taxable income. The majority of the federal net operating loss carryforwards expire through 2037, while $18.6 million have an indefinite carry forward period. For foreign net operating loss carryforwards, $59.1 million will expire through 2028, while the remaining $16.4 million have an indefinite carry forward period. The state net operating loss carryforwards expire through 2036.
The valuation allowance relates to deferred tax assets for certain items that will be deductible for income tax purposes under very limited circumstances and for which the Company believes it will not satisfy the more likely than not threshold for realization of the associated tax benefit. In the event that the Company determines that it would be able to realize more or less than the recorded amount of net deferred tax assets, an adjustment to the deferred tax asset valuation allowance would be recorded in the period such a determination is made.
The valuation allowance at December 31, 2022 and 2021 primarily remained unchanged from respective prior periods; decreasing by an immaterial amount in both periods.

F-43
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

Balance at Beginning of PeriodCharged to Costs and ExpensesOtherDeductionsBalance at End of Period
Description
Dollars in thousands
Year ended December 31, 2022
Deferred tax assets valuation allowance
15,258 (515)(71)14,672 
Year ended December 31, 2021
Deferred tax assets valuation allowance13,825 1,444 89 (100)15,258 
Year ended December 31, 2020
Deferred tax assets valuation allowance12,069 1,617 — 139 13,825 

As of December 31, 2022, the Company has not provided deferred income taxes on unrepatriated earnings from foreign subsidiaries as they are deemed to be indefinitely reinvested unless there is a manner under which to remit the earnings with no material tax cost. Material taxes would primarily be attributable to foreign withholding taxes and local income taxes when such earnings are distributed. The Company will repatriate foreign earnings when there is no need for reinvestment overseas and no material tax cost to bring the earnings back to the United States. Reinvestment considerations would include future acquisitions, transactions, and capital expenditure plans.
A reconciliation of the beginning and ending amount of uncertain tax benefits is as follows:
Years Ended December 31,
Dollars in thousands202220212020
(In thousands)
Balance, beginning of year$676 $702 $676 
Gross increases:
   Current year tax positions37 — — 
   Prior years' tax positions— — 26 
Other— (26)— 
Balance, end of year$713 $676 $702 
Approximately $0.7 million of the balance at December 31, 2022 relates to uncertain tax positions that, if recognized, would affect the annual effective tax rate. The Company has $0.3 million of uncertain tax positions at December 31, 2022 related to tax positions for which it is reasonably possible that the amounts could be reduced during the twelve months following December 31, 2022.
The Company recognizes interest and penalties relating to uncertain tax positions in income tax expense. The Company recognized a minimal benefit for the years ended December 31, 2022, 2021 and 2020. The Company had minimal interest and penalties accrued for the years ended December 31, 2022 and 2021 and 2020.
The Company files Federal income tax returns, as well as multiple state, local and foreign jurisdiction tax returns. The Company is no longer subject to examinations of its U.S. consolidated Federal income tax returns by the IRS through fiscal year 2015. Additionally, the Company is no longer subject to examinations by the IRS for fiscal year 2017. All significant state and local matters have been concluded through fiscal year 2014. All significant foreign matters have been settled through fiscal 2015.
F-44
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

13. NET INCOME PER SHARE
Basic and diluted net income per share was as follows:
 Years Ended December 31,
 Dollars in thousands, except per share amounts202220212020
Basic net income per share:
Net income$180,550 $169,075 $133,892 
Weighted average common shares outstanding82,997 84,698 84,650 
Basic net income per common share$2.18 $2.00 $1.58 
Diluted net income per share:
Net income$180,550 $169,075 $133,892 
Weighted average common shares outstanding — Basic82,997 84,698 84,650 
Effect of dilutive securities:
Stock options and restricted stock519 787 577 
Weighted average common shares for diluted earnings per share83,516 85,485 85,228 
Diluted net income per common share$2.16 $1.98 $1.57 
Common stock of approximately 0.3 million and 0.1 million shares at December 31, 2022, and 2021 that are issuable through exercise of dilutive securities, respectively, and were not included in the computation of diluted net income per share because their effect would have been anti-dilutive.
Based on the adoption of ASU 2020-06, as the principal amount of the 2025 Notes will be paid in cash and only the conversion spread is settled in shares, the Company will be utilizing the if-converted method and only includes the net number of incremental shares that would be issued upon conversion.
14. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
Changes in accumulated other comprehensive loss by component between December 31, 2022 and 2021 are presented in the table below, net of tax:
Dollars in thousandsGains and Losses on DerivativesDefined Benefit Pension ItemsForeign Currency ItemsTotal
Balance at December 31, 2021
$(42,981)$1,893 $(4,067)$(45,155)
Other comprehensive gain (loss)80,335 7,429 (17,807)69,957 
Less: Amounts reclassified from accumulated other comprehensive income, net
14,537 — — 14,537 
Net current-period other comprehensive gain (loss)65,798 7,429 (17,807)55,420 
Balance at December 31, 2022
$22,817 $9,322 $(21,874)$10,265 
For the year ended December 31, 2022, the Company reclassified a gain of $15.0 million and a loss of $0.4 million from accumulated other comprehensive loss to other income, net and interest income, respectively.
15. COMMITMENTS AND CONTINGENCIES
In consideration for certain technology, manufacturing, distribution, and selling rights and licenses granted to the Company, the Company has agreed to pay royalties on sales of certain products that it sells. The royalty payments that the Company made under these agreements were not significant for any of the periods presented.
The Company is subject to various claims, lawsuits and proceedings in the ordinary course of the Company's business, including claims by current or former employees, distributors and competitors and with respect to its products and product liability claims, lawsuits and proceedings, some of which have been settled by the Company. In the opinion of management, such claims are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material, adverse effect on the Company's financial condition. However, it is possible that the
F-45
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

Company's results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies.
The Company accrues for loss contingencies when it is deemed probable that a loss has been incurred and that loss is estimable. The amounts accrued are based on the full amount of the estimated loss before considering insurance proceeds and do not include an estimate for legal fees expected to be incurred in connection with the loss contingency. The Company consistently accrues legal fees expected to be incurred in connection with loss contingencies as those fees are incurred by outside counsel as a period cost.
Contingent Consideration
The Company determined the fair value of contingent consideration during the twelve-month period ended December 31, 2022 and 2021 to reflect the change in estimate, additions, payments, transfers and the time value of money during the period.
A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the years ended December 31, 2022 and 2021 is as follows (in thousands):
Year ended December 31, 2022Contingent Consideration Liability Related to Acquisition of:
Arkis
 (See Note 4) 		Location in Financial StatementsDerma SciencesACell Inc.
 (See Note 4) 		SIALocation in Financial Statements
Short-termLong-termLong-termShort-termLong-termLong-term
Balance as of January 1, 2022$3,691 $11,408 $230 $— $21,800 $— 
Additions— — — — 57,607 
Transfers from long-term to current portion— — — 4,885 (4,885)— 
Change in fair value of contingent consideration liabilities (846)(1,358)Research and development— (4,885)(13,215)— Selling, general and administrative
Balance as of December 31, 2022$2,845 $10,050 $230 $— $3,700 $57,607 $— 
Year ended December 31, 2021Contingent Consideration Liability Related to Acquisition of:
Arkis
 (See Note 4) 		Location in Financial StatementsDerma SciencesACell Inc.
 (See Note 4)		Location in Financial Statements
Short-termLong-termLong-termLong-term
Balance as of January 1, 2021$3,415 $11,746 $230 $— 
Additions— — — 23,900 
Transfers from long-term to current portion276 (276)— — 
Change in fair value of contingent consideration liabilities — $(62)Research and development— (2,100)Selling, general and administrative
Balance as of December 31, 2021$3,691 $11,408 $230 $21,800 
Derma Sciences
The Company assumed contingent consideration incurred by Derma Sciences, Inc. ("Derma Sciences") related to its acquisitions of BioD and the intellectual property related to Medihoney products. The Company accounted for the contingent liabilities by recording their fair value on the date of the acquisition based on a probability weighted income approach. The Company has already paid $33.3 million related to the aforementioned contingent liabilities. One contingent milestone remains which relates to net sales of Medihoney™ products exceeding certain amounts defined in the agreement between the Company and Derma Sciences. The potential maximum undiscounted payment amounts to $3.0 million. The estimated fair value as of December 31, 2022 and 2021 was $0.2 million.



F-46
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

Arkis BioSciences, Inc.
As part of the acquisition of Arkis BioSciences, Inc. ("Arkis"), the Company is required to pay the former shareholders of Arkis up to $25.5 million based on the timing of certain development milestones of $10 million and commercial sales milestones of $15.5 million, respectively. The Company used a probability weighted income approach to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specified milestone. The Company estimated the fair value of the contingent consideration to be $13.1 million at the acquisition date. The estimated the fair value as of December 31, 2022 was $12.9 million. The Company recorded $2.8 million in accrued expenses and other current liabilities and $10.1 million in other liabilities at December 31, 2022 in the consolidated balance sheets of the Company.

16. SEGMENT AND GEOGRAPHIC INFORMATION
The Company internally manages two global reportable segments and reports the results of its businesses to its chief operating decision maker. The two reportable segments and their activities are described below.
•The Codman Specialty Surgical segment includes (i) the Neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment and (ii) the Instruments business, which sells more than 40,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices.
•The Tissue Technologies segment includes such offerings as skin and wound repair, plastics & surgical reconstruction products, bone grafts, and nerve and tendon repair products.
The Corporate and other category includes (i) various executive, finance, human resource, information systems and legal functions, (ii) brand management, and (iii) share-based compensation costs.
The operating results of the various reportable segments as presented are not comparable to one another because (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions, and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the operating segment results. Net sales and profit by reportable segment for the years ended December 31, 2022, 2021 and 2020 are as follows:
 Years Ended December 31,
Dollars in thousands202220212020
Segment Net Sales
Codman Specialty Surgical$1,019,564 $1,025,232 $894,831 
 Tissue Technologies538,102 517,216 477,037 
Total revenues$1,557,666 $1,542,448 $1,371,868 
Segment Profit
Codman Specialty Surgical$417,873 $439,471 $356,657 
Tissue Technologies233,802 228,199 159,630 
Segment profit651,675 667,670 516,287 
Amortization(13,882)(16,914)(27,757)
Corporate and other(398,873)(453,526)(337,160)
Operating income$238,920 $197,230 $151,370 






F-47
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)




The Company does not allocate any assets to the reportable segments. No asset information is reported to the chief operating decision maker and disclosed in the financial information for each segment. The Company attributes revenue to geographic areas based on the location of the customer. Total revenue, net and long-lived assets (tangible) by major geographic area are summarized below:
Dollars in thousands
United States(1)
EuropeAsia PacificRest of the WorldConsolidated
Total revenue, net:
2022$1,126,810 $170,903 $176,477 $83,476 $1,557,666 
20211,089,526 191,327 182,034 79,561 1,542,448 
2020971,975 172,689 157,174 70,030 1,371,868 
Total long-lived assets:
2022$440,223 $60,857 $12,975 $2,721 $516,776 
2021339,535 55,026 11,289 6,836 412,686 
F-48
 EX-3.3 2 iart-20221231xexx33.htm EX-3.3 Document
Exhibit 3.3

Effective as of February 21, 2023

THIRD AMENDED AND RESTATED BYLAWS
OF
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(the “Corporation”)
ARTICLE 1
OFFICES
Section 1.01    Offices. The Corporation may have offices at such places both within and without the State of Delaware as the Board of Directors may from time to time determine or the business of the Corporation may require.
ARTICLE 2
MEETINGS OF STOCKHOLDERS
Section 2.01    Place of Meeting. Meetings of the stockholders shall be held at such place, within the State of Delaware or elsewhere as may be fixed from time to time by the Board of Directors. If no place is so fixed for a meeting, it shall be held at the Corporation’s then principal executive office. The Board of Directors may, in its sole discretion, determine that a meeting of stockholders shall be held solely by means of remote communication as authorized by Section 211(a)(2) of the General Corporation Law of the State of Delaware (the “DGCL”).
Section 2.02    Annual Meeting. The annual meeting of stockholders shall be held, unless the Board of Directors shall fix some other hour or date therefor, at nine o’clock A.M. on the first Monday of May in each year, if not a legal holiday under the laws of Delaware, and, if a legal holiday, then on the next succeeding secular day not a legal holiday under the laws of Delaware, at which the stockholders shall elect a Board of Directors, and transact such other business as may properly be brought before the meeting.
Section 2.03    Notice of Business to be Brought Before a Meeting.
(a)    At an annual meeting of stockholders, only such business shall be conducted as shall have been properly brought before the meeting. To be properly brought before an annual meeting, business must be (i) brought before the meeting by the Corporation and specified in the notice of meeting given by or at the direction of the Board of Directors, (ii) brought before the meeting by or at the direction of the Board of Directors, or (iii) otherwise properly brought before the meeting by a stockholder who (A) was a stockholder of record (and, with respect to any beneficial owner, if different, on whose behalf such business is proposed, only if such beneficial owner was the beneficial owner of shares of the Corporation) both at the time of giving the notice provided for in this Section 2.03 and at the time of the meeting, (B) is entitled to vote at the meeting, and (C) has complied with this Section 2.03 as to such business. Except for proposals properly made in accordance with Rule 14a-8 under the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (as so amended and inclusive of such rules and regulations, the “Exchange Act”), and included in the notice of meeting given by or at the direction of the Board of Directors, the foregoing clause (iii) shall be the exclusive means for a stockholder to propose business to be brought before an annual meeting of the stockholders. Stockholders shall not be permitted to propose business to be brought before a special meeting of the stockholders, and the only matters that may be brought before a special meeting are the matters specified in the notice of meeting given by or at the direction of the person calling the meeting pursuant to Section 2.04. Stockholders seeking to
1

Exhibit 3.3

Effective as of February 21, 2023

nominate persons for election to the Board must comply with Section 2.10 and this Section 2.03 shall not be applicable to nominations except as expressly provided in Sections 2.03 or 2.10.
(b)    Without qualification, for business to be properly brought before an annual meeting by a stockholder, the stockholder must (i) provide Timely Notice (as defined below) thereof in writing and in proper form to the Secretary of the Corporation and (ii) provide any updates or supplements to such notice at the times and in the forms required by this Section 2.03. To be timely, a stockholder’s notice must be delivered to, or mailed and received at, the principal executive offices of the Corporation not less than ninety (90) days nor more than one hundred twenty (120) days prior to the one-year anniversary of the preceding year’s annual meeting; provided, however, that if the date of the annual meeting is more than thirty (30) days before or more than sixty (60) days after such anniversary date, notice by the stockholder to be timely must be so delivered, or mailed and received, not later than the ninetieth (90th) day prior to such annual meeting or, if later, the tenth (10th) day following the day on which public disclosure of the date of such annual meeting was first made (such notice within such time periods, “Timely Notice”). In no event shall any adjournment of an annual meeting or the announcement thereof commence a new time period for the giving of Timely Notice as described above.
(c)    To be in proper form for purposes of this Section 2.03, a stockholder’s notice to the Secretary shall set forth:
(i)    As to each Proposing Person (as defined below), (A) the name and address of such Proposing Person (including, if applicable, the name and address that appear on the Corporation’s books and records); and (B) the class or series and number of shares of the Corporation that are, directly or indirectly, owned of record or beneficially owned (within the meaning of Rule 13d-3 under the Exchange Act) by such Proposing Persons, except that such Proposing Person shall in all events be deemed to beneficially own any shares of any class or series of the Corporation as to which such Proposing Person has a right to acquire beneficial ownership at any time in the future (whether or not such right is exercisable immediately or only after the passage of time or upon the satisfaction of any conditions or both) pursuant to any agreement, arrangement or understanding (whether or not in writing) (the disclosures to be made pursuant to the foregoing clauses (A) and (B) are referred to as “Stockholder Information”);
(ii)    As to each Proposing Person, (A) any derivative, swap or other transaction or series of transactions engaged in, directly or indirectly, by such Proposing Person, the purpose or effect of which is to give such Proposing Person economic risk similar to ownership of shares of any class or series of the Corporation, including due to the fact that the value of such derivative, swap or other transactions are determined by reference to the price, value or volatility of any shares of any class or series of the Corporation, or which derivative, swap or other transactions provide, directly or indirectly, the opportunity to profit from any increase in the price or value of shares of any class or series of the Corporation (“Synthetic Equity Interests”), which Synthetic Equity Interests shall be disclosed without regard to whether (x) the derivative, swap or other transactions convey any voting rights in such shares to such Proposing Person, (y) the derivative, swap or other transactions are required to be, or are capable of being, settled through delivery of such shares or (z) such Proposing Person may have entered into other transactions that hedge or mitigate the economic effect of such derivative, swap or other transactions, (B) any proxy (other than a revocable proxy or consent given in response to a solicitation made pursuant to, and in accordance with, Section 14(a) of the Exchange Act by way of a solicitation statement filed on Schedule 14A), agreement, arrangement, understanding or relationship pursuant to which such Proposing Person has or shares a right to vote any shares of any class or series of the Corporation, (C) any agreement, arrangement, understanding or relationship, including any repurchase or similar so-called “stock borrowing” agreement or arrangement, engaged in, directly or indirectly, by such Proposing Person, the purpose or effect
2

Exhibit 3.3

Effective as of February 21, 2023

of which is to mitigate loss to, reduce the economic risk (of ownership or otherwise) of shares of any class or series of the Corporation by, manage the risk of share price changes for, or increase or decrease the voting power of, such Proposing Person with respect to the shares of any class or series of the Corporation, or which provides, directly or indirectly, the opportunity to profit from any decrease in the price or value of the shares of any class or series of the Corporation (“Short Interests”), (D) any rights to dividends or other distributions on the shares of any class or series of capital stock of the Corporation, directly or indirectly, owned beneficially by such Proposing Person or any of their affiliates or associates (as such terms are defined in Rule 12b-2 promulgated under the Exchange Act) that are separated or separable from the underlying shares of the Corporation, (E) any performance related fees (other than an asset based fee) that such Proposing Person is entitled to receive based on any increase or decrease in the price or value of shares of any class or series of the Corporation, or any Synthetic Equity Interests or Short Interests, if any, (F)(1) if such Proposing Person is not a natural person, the identity of the natural person or persons associated with such Proposing Person responsible for (i) the formulation of and decision to propose the business to be brought before the meeting and (ii) making voting and investment decisions on behalf of the Proposing Person (irrespective of whether such person or persons have “beneficial ownership” for purposes of Rule 13d-3 of the Exchange Act of any securities owned of record or beneficially by the Proposing Person) (such person or persons, the “Responsible Person”), the manner in which such Responsible Person was selected, any fiduciary duties owed by such Responsible Person to the equity holders or other beneficiaries of such Proposing Person and, the qualifications and background of such Responsible Person or (2) if such Proposing Person is a natural person, the qualifications and background of such natural person, (G) any equity interests or any Synthetic Equity Interests in any principal competitor of the Corporation beneficially owned by such Proposing Person or any of their affiliates or associates, (H) any direct or indirect interest of such Proposing Person or any of their affiliates or associates in any contract with the Corporation, any affiliate of the Corporation or any principal competitor of the Corporation (including, without limitation, in any such case, any employment agreement, collective bargaining agreement or consulting agreement), (I) any pending or threatened litigation in which such Proposing Person or any of their affiliates or associates is a party or material participant involving the Corporation or any of its officers or directors, or any affiliate of the Corporation, (J) any material transaction occurring during the prior twelve months between such Proposing Person or any of their affiliates or associates, on the one hand, and the Corporation, any affiliate of the Corporation or any principal competitor of the Corporation, on the other hand, and (K) any other information relating to such Proposing Person that would be required to be disclosed in a proxy statement or other filing required to be made in connection with solicitations of proxies or consents by such Proposing Person in support of the business proposed to be brought before the meeting pursuant to Section 14(a) of the Exchange Act (the disclosures to be made pursuant to the foregoing clauses (A) through (K) are referred to as “Disclosable Interests”); provided, however, that Disclosable Interests shall not include any such disclosures with respect to the ordinary course business activities of any broker, dealer, commercial bank, trust company or other nominee who is a Proposing Person solely as a result of being the stockholder directed to prepare and submit a notice required by these Bylaws on behalf of a beneficial owner;
(iii)    As to each item of business that the stockholder proposes to bring before the annual meeting, (A) a reasonably brief description of the business desired to be brought before the annual meeting, the reasons for conducting such business at the annual meeting and any material interest in such business of each Proposing Person and (B) the text of the proposal or business (including the text of any resolutions or Bylaw amendment proposed for consideration);
(iv)    A description of all agreements, arrangements or understandings to which any Proposing Person or any of their affiliates or associates is a party (whether the
3

Exhibit 3.3

Effective as of February 21, 2023

counterparty or counterparties are a Proposing Person or any affiliate or associate thereof, on the one hand, or one or more other third parties, on the other hand, (including any nominee(s) proposed pursuant to Section 2.10), (a) pertaining to any nomination(s) made pursuant to Section 2.10 or other business proposed to be brought before the meeting of stockholders or (b) entered into for the purpose of acquiring, holding, disposing or voting of any shares of any class or series of capital stock of the Corporation (which description shall identify the name of each other person who is party to such an agreement, arrangement or understanding), and (ii) identification of the names and addresses of other stockholders (including beneficial owners) known by any of the Proposing Persons to support any nominations made pursuant to Section 2.10 or other business proposal(s) and, to the extent known, the class and number of all shares of the Corporation’s capital stock owned beneficially or of record by such other stockholder(s) or other beneficial owner(s); and
(v)     A statement (i) that the stockholder is a holder of record of capital stock of the Corporation entitled to vote at such meeting, a representation that such stockholder intends to appear in person or by proxy at the meeting to propose such business or propose nominees pursuant to Section 2.10 and an acknowledgement that, if such stockholder (or a qualified representative of such stockholder) does not appear to present such business or proposed nominees, as applicable, at such meeting, the Corporation need not present such business or proposed nominees for a vote at such meeting, notwithstanding that proxies in respect of such vote may have been received by the Corporation, (ii) whether or not the stockholder giving the notice and/or the other Proposing Person(s), if any, (a) will deliver a proxy statement and form of proxy to holders of, in the case of a business proposal, at least the percentage of voting power of all of the shares of capital stock of the Corporation required under applicable law to approve the proposal or, in the case of a nomination or nominations made pursuant to Section 2.10, at least 67 percent of the voting power of all of the shares of capital stock of the Corporation entitled to vote on the election of directors or (b) otherwise solicit proxies or votes from stockholders in support of such proposal or nomination, as applicable, (iii) providing a representation as to whether or not such Proposing Person intends to solicit proxies in support of director nominees other than the Corporation’s director nominees in accordance with Rule 14a-19 promulgated under the Exchange Act, and (iv) that the stockholder will provide any other information relating to such item of business that would be required to be disclosed in a proxy statement or other filing required to be made in connection with solicitations of proxies in support of the business proposed to be brought before the meeting pursuant to Section 14(a) of the Exchange Act.
For purposes of this Section 2.03, the term “Proposing Person” shall mean (i) the stockholder providing the notice of business proposed to be brought before an annual meeting, (ii) the beneficial owner or beneficial owners, if different, on whose behalf the notice of the business proposed to be brought before the annual meeting is made and (iii) any affiliate or associate (each within the meaning of Rule 12b-2 under the Exchange Act for purposes of these Bylaws) of such stockholder or beneficial owner.
(d)    A stockholder providing notice of business proposed to be brought before an annual meeting shall further update and supplement such notice, if necessary, so that the information provided or required to be provided in such notice pursuant to this Section 2.03 shall be true and correct as of the record date for the meeting and as of the date that is ten (10) business days prior to the meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the Secretary at the principal executive offices of the Corporation not later than five (5) business days after the record date for the meeting (in the case of the update and supplement required to be made as of the record date), and not later than eight (8) business days prior to the date for the meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable, on the first practicable date prior to
4

Exhibit 3.3

Effective as of February 21, 2023

the date to which the meeting has been adjourned or postponed), in the case of the update and supplement required to be made as of ten (10) business days prior to the meeting or any adjournment or postponement thereof. For the avoidance of doubt, the obligation to update as set forth in this Section 2.03(d) shall not limit the Corporation’s rights with respect to any deficiencies in any notice provided by a stockholder, extend any applicable deadlines hereunder, or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend or update any proposal or to submit any new proposal, including by changing or adding nominees, matters, business and/or resolutions proposed to be brought before a meeting of the stockholders. Notwithstanding the foregoing, if a Proposing Person no longer plans to solicit proxies in accordance with its representation pursuant to Article II, Section 2.03(c)(v), such Proposing Person shall inform the Corporation of this change by delivering a written notice to the Secretary at the principal executive offices of the Corporation no later than two (2) business days after making the determination not to proceed with a solicitation of proxies. A Proposing Person shall also update its notice so that the information required by Article II, Section 2.03(c) is current through the date of the meeting or any adjournment, postponement, or rescheduling thereof, and such update shall be delivered in writing to the secretary at the principal executive offices of the Corporation no later than two (2) business days after the occurrence of any material change to the information previously disclosed pursuant to Article II, Section 2.03(c).
(e)    Notwithstanding anything in these Bylaws to the contrary, no business shall be conducted at an annual meeting except in accordance with this Section 2.03. The Board of Directors or a designated committee thereof shall have the power to determine whether any business proposed to be brought before the meeting was made in accordance with the provisions of these Bylaws. If neither the Board of Directors nor such designated committee makes a determination as to whether any stockholder proposal was made in accordance with these Bylaws, the presiding officer of the Annual Meeting shall have the power and duty to determine whether the stockholder proposal was made in accordance with the provisions of these Bylaws. If the Board of Directors or a designated committee thereof or the presiding officer of the meeting, as applicable, determines that any stockholder proposal was not made in accordance with the provisions of these Bylaws, such proposal shall be disregarded and shall not be presented for action at the annual meeting.
(f)    This Section 2.03 is expressly intended to apply to any business proposed to be brought before an annual meeting of stockholders other than any proposal made pursuant to Rule 14a-8 under the Exchange Act. In addition to the requirements of this Section 2.03 with respect to any business proposed to be brought before an annual meeting, each Proposing Person shall comply with all applicable requirements of the Exchange Act with respect to any such business. If a stockholder fails to comply with any applicable requirements of the Exchange Act, such stockholder’s proposed business shall be deemed to have not been made in compliance with these Bylaws and shall be disregarded. Nothing in this Section 2.03 shall be deemed to affect the rights of stockholders to request inclusion of proposals in the Corporation’s proxy statement pursuant to Rule 14a-8 under the Exchange Act.
(g)    Notwithstanding the foregoing provisions of this Section 2.03, if the proposing stockholder (or a qualified representative of the stockholder) does not appear at the Annual Meeting to present any business, such business shall be disregarded, notwithstanding that proxies in respect of such vote may have been received by the Corporation. For purposes of this Section 2.03, to be considered a qualified representative of the proposing stockholder, a person must be authorized by a written instrument executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders, and such person must produce such written instrument or electronic transmission, or a reliable reproduction of the written instrument or electronic transmission, to the presiding officer at the meeting of stockholders.
5

Exhibit 3.3

Effective as of February 21, 2023

(h)    Except as otherwise required by law, nothing in this Section 2.03 shall obligate the Corporation or the Board of Directors to include in any proxy statement or other stockholder communication distributed on behalf of the Corporation or the Board of Directors information with respect to any nominee for director or any other matter of business submitted by a stockholder.
(i)    For purposes of these Bylaws, “public disclosure” shall mean disclosure in a press release reported by a national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Sections 13, 14 or 15(d) of the Exchange Act.
Section 2.04    Notice of Meetings. Notice of each meeting of stockholders shall be given which shall state the place, if any (or the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person), date and hour of the meeting and in the case of a special meeting, the purpose or purposes for which the meeting is called. Unless otherwise provided by law, the certificate of incorporation or these bylaws, such notice shall be given to each stockholder entitled to vote at such meeting not less than 10 days nor more than 60 days before the date of the meeting. Notice may be given personally, by mail or by electronic transmission in accordance with Section 232 of the DGCL. If mailed, such notice shall be deemed given when deposited in the United States mail, postage prepaid, directed to each stockholder at such stockholder’s address appearing on the books of the Corporation or given by the stockholder for such purpose. Notice by electronic transmission shall be deemed given as provided in Section 232 of the DGCL. An affidavit of the mailing or other means of giving any notice of any stockholders’ meeting, executed by the secretary, assistant secretary or any transfer agent of the Corporation giving the notice, shall be prima facie evidence of the giving of such notice or report. Notice shall be deemed to have been given to all stockholders of record who share an address if notice is given in accordance with the “householding” rules set forth in Rule 14a-3(e) under the Exchange Act and Section 233 of the DGCL. When a meeting is adjourned to another time or place, if any (including an adjournment taken to address a technical failure to convene or continue a meeting using remote communication), notice need not be given of the adjourned meeting if the time and place, if any (and the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person at such adjourned meeting), thereof are (i) announced at the meeting at which the adjournment is taken, (ii) displayed during the time scheduled for the meeting on the same electronic network used to enable stockholders and proxy holders to participate in the meeting by means of remote communication or (iii) set forth in the notice of the meeting given in accordance with this Section 2.04; provided, however, that if the adjournment is for more than thirty (30) days or a new record date is fixed for the adjourned meeting, in which case a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.
Section 2.05    List of Stockholders. The Corporation shall prepare, no later than the tenth (10th) day before each meeting of stockholders, a complete list of stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of 10 days ending on the day before the meeting date, (a) on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of meeting, or (b) during ordinary business hours at the principal place of business of the Corporation. Except as otherwise provided by law, the stock ledger shall be the only evidence as to the stockholders who are entitled to examine the list of stockholders required by this Section 2.05 or to vote in person or by proxy at any meeting of stockholders.
6

Exhibit 3.3

Effective as of February 21, 2023

Section 2.06    Inspector of Election. Prior to any meeting of stockholders, the board of directors, the chairman of the board, the president or the secretary shall appoint an inspector of election. Such inspectors for election shall have the powers and duties set forth in Section 231 of the DGCL and may include individuals who serve the Corporation in other capacities, including, without limitation, as officers, employees, agents or representatives, to act at such meeting and make a written report thereof. Each inspector of election, before discharging his or her duties, shall take and sign an oath to execute faithfully the duties of inspector with strict impartiality and according to the best of his or her ability. The inspectors of election shall have the duties prescribed by law.
Section 2.07    Special Meetings. Special meetings of the stockholders, for any purpose or purposes, unless otherwise prescribed by statute or by the Certificate of Incorporation, may be called only by the Chairman of the Board, the President or the Board of Directors. Such request shall state the purpose or purposes of the proposed meeting. Business transacted at any special meeting of stockholders shall be limited to the purposes stated in the notice.
Section 2.08    Quorum; Voting.
(a)    The holders of a majority of the stock issued and outstanding and entitled to vote thereat, present in person or by remote communication, or represented by proxy, shall constitute a quorum at all meetings of the stockholders for the transaction of business except as otherwise provided by statute or by the Certificate of Incorporation. If, however, such quorum shall not be present or represented at any meeting of the stockholders, the stockholders entitled to vote thereat, present in person or represented by proxy, shall have power to adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum shall be present or represented. At such adjourned meeting at which a quorum shall be present or represented, any business may be transacted which might have been transacted at the meeting as originally notified. At any meeting of stockholders (at which a quorum is present to organize the meeting), all matters, except as otherwise provided by applicable law, pursuant to any regulation applicable to the Corporation or its securities or by the Certificate of Incorporation or by these Bylaws (including the election of directors), shall be decided by the affirmative vote of a majority in voting power of shares present in person or represented by proxy and entitled to vote thereon. Unless otherwise provided in the Certificate of Incorporation, each stockholder shall at every meeting of stockholders be entitled to one vote in person or by proxy for each share of the capital stock having voting power held by such stockholder, but no shares shall be voted pursuant to a proxy more than three years after the date of the proxy unless the proxy provides for a longer period. The Board of Directors may by resolution establish a method for stockholders to cast their vote by a secure electronic method. In the event the Corporation receives proxies for disqualified or withdrawn nominees for the Board of Directors, such votes for such disqualified or withdrawn nominees in the proxies will be treated as abstentions.
(b)    Any stockholder directly or indirectly soliciting proxies from other stockholders must use a proxy card color other than white, which shall be reserved for the exclusive use by the Board of Directors.
Section 2.09    Action Without a Meeting.
(a)    Unless otherwise restricted by the Certificate of Incorporation, any action required or permitted to be taken at any annual or special meeting of stockholders may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing setting forth the action so taken, (i) shall be signed by the holders of record on the record date (established as provided below) of outstanding stock of the Corporation having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting
7

Exhibit 3.3

Effective as of February 21, 2023

at which all shares entitled to vote thereon were present and voted and (ii) shall be delivered to the Corporation by delivery to its registered office in the State of Delaware, its principal place of business, or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to a Corporation’s registered office shall be by hand or by certified or registered mail, return receipt requested. Every written consent shall bear the date of signature of each stockholder who signs the consent, and no written consent shall be effective to take the corporate action referred to therein unless, within sixty days after the earliest dated consent delivered in the manner required by this Section 2.09 to the Corporation, written consents signed by a sufficient number of stockholders to take action are delivered in the manner required by this Section to the Corporation. Prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing.
(b)    Without qualification, any stockholder of record seeking to have the stockholders authorize or take any action by written consent shall first request in writing that the Board of Directors fix a record date for the purpose of determining the stockholders entitled to take such action, which request shall be in proper form and delivered to, or mailed and received by, the Secretary of the Corporation at the principal executive offices of the Corporation. Within ten (10) days after receipt of a request in proper form and otherwise in compliance with this Section 2.09(b) from any such stockholder, the Board of Directors may adopt a resolution fixing a record date for the purpose of determining the stockholders entitled to take such action, which date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which date shall not be more than ten (10) days after the date upon which the resolution fixing the record date is adopted by the Board of Directors. If no resolution fixing a record date has been adopted by the Board of Directors within such ten (10) day period after the date on which such a request is received, (i) the record date for determining stockholders entitled to consent to such action, when no prior action of the Board of Directors is required by applicable law, shall be the first date on which a valid signed written consent setting forth the action taken or proposed to be taken is delivered to the Corporation in the manner described in this Section 2.09, and (ii) the record date for determining stockholders entitled to consent to such action, when prior action by the Board of Directors is required by applicable law, shall be at the close of business on the date on which the Board of Directors adopts the resolution taking such prior action.
(c)    In the event of the delivery, in the manner provided by this Section 2.09 and applicable law, to the Corporation of written consent or consents to take corporate action and/or any related revocation or revocations, the Corporation shall engage independent inspectors of elections for the purpose of performing promptly a ministerial review of the validity of the consents and revocations. For the purpose of permitting the inspectors to perform such review, no action by written consent and without a meeting shall be effective until such inspectors have completed their review, determined that the requisite number of valid and unrevoked consents delivered to the Corporation in accordance with this Section 2.09 and applicable law have been obtained to authorize or take the action specified in the consents, and certified such determination for entry in the records of the Corporation kept for the purpose of recording the proceedings of meetings of stockholders. Nothing contained in this Section 2.09 shall in any way be construed to suggest or imply that the Board or any stockholder shall not be entitled to contest the validity of any consent or revocation thereof, whether before or after such certification by the independent inspectors, or to take any other action (including, without limitation, the commencement, prosecution or defense of any litigation with respect thereto, and the seeking of injunctive relief in such litigation).
(d)    Notwithstanding anything in these Bylaws to the contrary, no action may be taken by the stockholders by written consent except in accordance with this Section 2.09. If
8

Exhibit 3.3

Effective as of February 21, 2023

the Board of Directors shall determine that any request to fix a record date or to take stockholder action by written consent was not properly made in accordance with this Section 2.09, or the stockholder or stockholders seeking to take such action do not otherwise comply with this Section 2.09, then the Board of Directors shall not be required to fix a record date and any such purported action by written consent shall be null and void to the fullest extent permitted by applicable law. In addition to the requirements of this Section 2.09 with respect to stockholders seeking to take an action by written consent, each soliciting person shall comply with all requirements of applicable law, including all requirements of the Exchange Act, with respect to such action.
Section 2.10    Notice of Nominations for Election to the Board of Directors.
(a)    Nominations of any person for election to the Board of Directors at an annual meeting or at a special meeting (but only if the election of directors is a matter specified in the notice of meeting given by or at the direction of the person calling such special meeting) may be made at such meeting only (i) by or at the direction of the Board of Directors, including by any committee or persons appointed by the Board of Directors, or (ii) by a stockholder who (A) was a stockholder of record (and, with respect to any beneficial owner, if different, on whose behalf such nomination is proposed to be made, only if such beneficial owner was the beneficial owner of shares of the Corporation) both at the time of giving the notice provided for in this Section 2.10 and at the time of the meeting, (B) is entitled to vote at the meeting, and (C) has complied with this Section 2.10 as to such nomination. The foregoing clause (ii) shall be the exclusive means for a stockholder to make any nomination of a person or persons for election to the Board of Directors at an annual meeting or special meeting.
(b)    Without qualification, for a stockholder to make any nomination of a person or persons for election to the Board of Directors at an annual meeting, the stockholder must (i) provide Timely Notice (as defined in Section 2.03) thereof in writing and in proper form to the Secretary of the Corporation and (ii) provide any updates or supplements to such notice at the times and in the forms required by this Section 2.10. Without qualification, if the election of directors is a matter specified in the notice of meeting given by or at the direction of the person calling a special meeting, then for a stockholder to make any nomination of a person or persons for election to the Board of Directors at a special meeting, the stockholder must (i) provide timely notice thereof in writing and in proper form to the Secretary of the Corporation at the principal executive offices of the Corporation, and (ii) provide any updates or supplements to such notice at the times and in the forms required by this Section 2.10. To be timely, a stockholder’s notice for nominations to be made at a special meeting must be delivered to, or mailed and received at, the principal executive offices of the Corporation not earlier than the one hundred twentieth (120th) day prior to such special meeting and not later than the ninetieth (90th) day prior to such special meeting or, if later, the tenth (10th) day following the day on which public disclosure (as defined in Section 2.03) of the date of such special meeting was first made. In no event shall any adjournment of an annual meeting or special meeting or the announcement thereof commence a new time period for the giving of a stockholder’s notice as described above.
(c)    To be in proper form for purposes of this Section 2.10, a stockholder’s notice to the Secretary shall set forth:
(i)    As to each Nominating Person (as defined below), the Stockholder Information (as defined in Section 2.03(c)(i), except that for purposes of this Section 2.10 the term “Nominating Person” shall be substituted for the term “Proposing Person” in all places it appears in Section 2.03(c)(i));
9

Exhibit 3.3

Effective as of February 21, 2023

(ii)    As to each Nominating Person, any Disclosable Interests (as defined in Section 2.03(c)(ii), except that for purposes of this Section 2.10 the term “Nominating Person” shall be substituted for the term “Proposing Person” in all places it appears in Section 2.03(c)(ii) and the disclosure in clause (K) of Section 2.03(c)(ii) shall be made with respect to the election of directors at the meeting);
(iii)    As to each person whom a Nominating Person proposes to nominate for election as a director, (A) all information with respect to such proposed nominee that would be required to be set forth in a stockholder’s notice pursuant to this Section 2.10 if such proposed nominee were a Nominating Person, (B) a questionnaire with respect to the background and qualifications of the nominee completed by the nominee in the form provided by the Corporation (which questionnaire shall be provided by the Secretary upon written request); (C) a representation and agreement in the form provided by the Corporation (which form shall be provided by the Secretary upon written request) that: (a) such proposed nominee is not and will not become party to any agreement, arrangement or understanding with any person or entity as to how such proposed nominee, if elected as a director of the Corporation, will act or vote on any issue or question (a “Voting Commitment”) that has not been disclosed to the Corporation; (b) such proposed nominee is not and will not become a party to any agreement, arrangement, or understanding with any person or entity other than the Corporation with respect to any direct or indirect compensation, reimbursement, or indemnification in connection with service or action as a director that has not been disclosed to the Corporation; (c) such proposed nominee would, if elected as a director, comply with all applicable rules and regulations of the exchanges upon which shares of the Corporation’s capital stock trade, each of the Corporation’s corporate governance, ethics, conflict of interest, confidentiality, stock ownership and trading policies and guidelines applicable generally to the Corporation’s directors and, if elected as a director of the Corporation, such person currently would be in compliance with any such policies and guidelines that have been publicly disclosed; (d) such proposed nominee intends to serve as a director for the full term for which he or she is to stand for election; (e) such proposed nominee, if elected, intends to tender, promptly following such person’s election or re-election, an irrevocable resignation effective upon such person’s failure to receive the required vote for re-election at the next meeting at which such person would face re-election and upon acceptance of such resignation by the Board of Directors; and (f) such proposed nominee will promptly provide to the Corporation such other information as it may reasonably request; (D) all information relating to such proposed nominee that is required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for election of directors in a contested election pursuant to Section 14(a) under the Exchange Act (including such proposed nominee’s written consent to being named in the proxy statement as a nominee and to serving as a director if elected), (E) a description of all arrangements or understandings between or among the stockholder and each nominee and any other person or persons (naming such person or persons) pursuant to which the nominations are to be made by the stockholder or concerning the nominee’s potential service on the Board of Directors, and (F) a description of all direct and indirect compensation and other material monetary agreements, arrangements and understandings during the past three years, and any other material relationships, between or among any Nominating Person, on the one hand, and each proposed nominee, or his or her respective affiliates and associates, on the other hand, including, without limitation, all information that would be required to be disclosed pursuant to Item 404 under Regulation S-K if such Nominating Person were the “registrant” for purposes of such rule and the proposed nominee were a director or executive officer of such registrant (the disclosures to be made pursuant to the foregoing clauses (A) through (F) are referred to as “Nominee Information”); and
(iv)    The Corporation may require any proposed nominee to furnish such other information (A) as may reasonably be required by the Corporation to determine the eligibility of such proposed nominee to serve as an independent director of the Corporation in
10

Exhibit 3.3

Effective as of February 21, 2023

accordance with the Corporation’s Corporate Governance Guidelines or (B) that could be material to a reasonable stockholder’s understanding of the independence or lack of independence of such proposed nominee.
For purposes of this Section 2.10, the term “Nominating Person” shall mean (i) the stockholder providing the notice of the nomination proposed to be made at the meeting, (ii) the beneficial owner or beneficial owners, if different, on whose behalf the notice of the nomination proposed to be made at the meeting is made and (iii) any affiliate or associate of such stockholder or beneficial owner.
(d)    A stockholder providing notice of any nomination proposed to be made at a meeting shall further update and supplement such notice, if necessary, so that the information provided or required to be provided in such notice pursuant to this Section 2.10 shall be true and correct as of the record date for the meeting and as of the date that is ten (10) business days prior to the meeting or any adjournment or postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the Secretary at the principal executive offices of the Corporation not later than five (5) business days after the record date for the meeting (in the case of the update and supplement required to be made as of the record date), and not later than eight (8) business days prior to the date for the meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable, on the first practicable date prior to the date to which the meeting has been adjourned or postponed) (in the case of the update and supplement required to be made as of ten (10) business days prior to the meeting or any adjournment or postponement thereof). For the avoidance of doubt, the obligation to update as set forth in this Section 2.10(d) shall not limit the Corporation’s rights with respect to any deficiencies in any notice provided by a stockholder, extend any applicable deadlines hereunder, or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend or update any nomination or to submit any new nominees, including by changing or adding nominees proposed to be brought before a meeting of the stockholders. Notwithstanding the foregoing, if a Nominating Person no longer plans to solicit proxies in accordance with its representation pursuant to Article II, Section 2.03(c)(v), such Nominating Person shall inform the Corporation of this change by delivering a written notice to the Secretary at the principal executive offices of the Corporation no later than two (2) business days after making the determination not to proceed with a solicitation of proxies. A Nominating Person shall also update its notice so that the information required by Article II, Section 2.10(c) is current through the date of the meeting or any adjournment, postponement, or rescheduling thereof, and such update shall be delivered in writing to the secretary at the principal executive offices of the Corporation no later than two (2) business days after the occurrence of any material change to the information previously disclosed pursuant to Article II, Section 2.10(c).
(e)    Notwithstanding anything in these Bylaws to the contrary, no person shall be eligible for election as a director of the Corporation unless nominated in accordance with this Section 2.10. The Board of Directors or a designated committee thereof shall have the power to determine whether a nomination proposed to be brought before the meeting was made in accordance with the provisions of these Bylaws. If neither the Board of Directors nor such designated committee makes a determination as to whether any stockholder nomination was made in accordance with the provisions of these Bylaws, the presiding officer of the meeting shall have the power and duty to determine whether the stockholder nomination was made in accordance with the provisions of these Bylaws. If the Board of Directors or a designated committee thereof or the presiding officer, as applicable, determines that any stockholder nomination was not made in accordance with the provisions of these Bylaws, such nomination shall be disregarded and shall not be presented for action at the meeting.
11

Exhibit 3.3

Effective as of February 21, 2023

(f)    Notwithstanding the foregoing provisions of this Section 2.10, if the Nominating Person (or a qualified representative of the Nominating Person) does not appear at the meeting to present a nomination, such nomination shall be disregarded, notwithstanding that proxies in respect of such vote may have been received by the Corporation. For purposes of this Section 2.10, to be considered a qualified representative of the Nominating Person, a person must be authorized by a written instrument executed by such Nominating Person or an electronic transmission delivered by such Nominating Person to act for such Nominating Person as proxy at the meeting of stockholders, and such person must produce such written instrument or electronic transmission, or a reliable reproduction of the written instrument or electronic transmission, to the presiding officer at the meeting of stockholders.
(g)    Except as otherwise required by law, including, but not limited to, Rule 14a-19 of the Exchange Act, nothing in this Section 2.10 shall obligate the Corporation or the Board of Directors to include in any proxy statement or other stockholder communication distributed on behalf of the Corporation or the Board of Directors information with respect to any nominee for director submitted by a stockholder.
(h)    Notwithstanding the foregoing provisions of this Bylaw, a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder, including, but not limited to, Rule 14a-19 of the Exchange Act, with respect to the matters set forth in this Bylaw. If a stockholder fails to comply with any applicable requirements of the Exchange Act, including, but not limited to, Rule 14a-19 promulgated thereunder, such stockholder’s proposed nomination shall be deemed to have not been made in compliance with this Bylaw and shall be disregarded.
(i)    Further notwithstanding the foregoing provisions of these Bylaws, unless otherwise required by law, (i) no Nominating Person shall solicit proxies in support of director nominees other than the Corporation’s nominees unless such Nominating Person has complied with Rule 14a-19 promulgated under the Exchange Act in connection with the solicitation of such proxies, including the provision to the Corporation of notices required thereunder with timely notice, and (ii) if any Nominating Person (A) provides notice pursuant to Rule 14a-19(b) promulgated under the Exchange Act, (B) subsequently fails to comply with the requirements of Rule 14a-19(a)(2) or Rule 14a-19(a)(3) promulgated under the Exchange Act, including the provision to the Corporation of notices required thereunder with timely notice, and (C) no other Nominating Person has provided notice pursuant to, and in compliance with, Rule 14a-19 under the Exchange Act that it intends to solicit proxies in support of the election of such proposed nominee in accordance with Rule 14a-19(b) under the Exchange Act, then such proposed nominee shall be disqualified from nomination, the Corporation shall disregard the nomination of such proposed nominee and no vote on the election of such proposed nominee shall occur. Upon request by the Corporation, if any Nominating Person provides notice pursuant to Rule 14a-19(b) promulgated under the Exchange Act, such Nominating Person shall deliver to the Corporation, no later than five (5) business days prior to the applicable meeting date, reasonable evidence that it has met the requirements of Rule 14a-19(a)(3) promulgated under the Exchange Act.
(j)    The number of nominees a stockholder may nominate for election at the annual meeting of stockholders (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate for election at the annual meeting of stockholders on behalf of such beneficial owner) shall not exceed the number of directors to be elected at such annual meeting of stockholders.
Section 2.11    Chairman and Secretary at Meetings. At any meeting of stockholders, the Chairman of the Board of Directors, or in his or her absence, the President, or if neither such person is available, then a person designated by the Board of Directors, shall preside at and act as
12

Exhibit 3.3

Effective as of February 21, 2023

chairman of the meeting. The Secretary, or in his or her absence a person designated by the chairman of the meeting, shall act as secretary of the meeting and keep a record of the proceedings thereof. The Board of Directors may adopt by resolution such rules, regulations, and procedures for the conduct of the meeting of stockholders as it shall deem appropriate.
Except to the extent inconsistent with such rules, regulations, and procedures as adopted by the Board of Directors, the chairman of the meeting shall have the right and authority to convene and to adjourn the meeting, to prescribe such rules, regulations and procedures, and to do all such acts as, in the judgment of such chairman of the meeting, are appropriate for the proper conduct of the meeting. Such rules, regulations, or procedures, whether adopted by the Board of Directors or the chairman of the meeting, may include, without limitation, the following: (a) the establishment of an agenda for the meeting; (b) rules and procedures for maintaining order at the meeting and the safety of those present at the meeting; (c) limitations on attendance at or participation in the meeting to stockholders of record of the Corporation, their duly authorized and constituted proxies, or such other persons as the chair of the meeting shall determine; (d) restrictions on entry to the meeting after the time fixed for the commencement thereof; (e) the determination of the circumstances in which any person may make a statement or ask questions and limitations on the time allotted to questions or comments; (f) the determination of when the polls shall open and close for any given matter to be voted on at the meeting; (g) the exclusion or removal of any stockholders or any other individual who refuses to comply with meeting rules, regulations, or procedures; (h) restrictions on the use of audio and video recording devices, cell phones, and other electronic devices; (i) rules, regulations, and procedures for compliance with any federal, state, or local laws or regulations (including those concerning safety, health, or security); (j) procedures (if any) requiring attendees to provide the Corporation advance notice of their intent to attend the meeting; and (k) rules, regulations, or procedures regarding the participation by means of remote communication of stockholders and proxy holders not physically present at a meeting, whether such meeting is to be held at a designated place or solely by means of remote communication.
The chairman of the meeting, in addition to making any other determinations provided for elsewhere in these bylaws or that may be appropriate to the conduct of the meeting, shall, if the facts warrant, determine and declare to the meeting that business or a nomination was not properly brought before the meeting, and if such chairman should so determine, such chairman shall so declare to the meeting and shall not be required to transact or consider any such business or nomination. Unless and to the extent determined by the Board of Directors or the chairman of the meeting, meetings of stockholders shall not be required to be held in accordance with the rules of parliamentary procedure. The chairman of the meeting shall fix and announce at the meeting the date and time of the opening and closing of the polls for each matter upon which the stockholders will vote at the meeting.
ARTICLE 3
DIRECTORS
Section 3.01    Number and Term of Office. The number of directors of the Corporation shall be not less than three nor more than thirteen, as designated from time to time by resolution of the Board of Directors. The directors shall be elected at the annual meeting of the stockholders, except as provided in Section 3.02 hereof. Except as provided in Section 3.02 hereof, each director shall be elected by the vote of the majority of the votes cast with respect to the director, provided that if the number of nominees exceeds the number of directors to be elected, the directors shall be elected by the vote of a plurality of the votes cast. For purposes of this Section 3.01, a majority of the votes cast means that the number of shares voted “for” a director must exceed the number of votes cast “against” that director. If a director is not elected, the director shall offer to tender his or her resignation to the Board of Directors. The Nominating
13

Exhibit 3.3

Effective as of February 21, 2023

and Corporate Governance Committee will make a recommendation to the Board of Directors on whether to accept or reject the resignation, or whether other action should be taken. The Board of Directors will act on the Committee’s recommendation and publicly disclose its decision and the rationale behind it within 90 days from the date of the certification of the election results.
The director who tenders his or her resignation will not participate in the Board of Directors’ decision. Directors shall hold office until the next annual meeting of stockholders and until their successors shall be duly elected and qualified or until their earlier death, resignation or removal. Directors need not be stockholders. If, for any cause, the Board of Directors shall not have been elected at an annual meeting of stockholders, they may be elected as soon thereafter as convenient at a special meeting of the stockholders called for that purpose in the manner provided in these Bylaws.
Section 3.02    Vacancies. Vacancies and newly created directorships resulting from any increase in the authorized number of directors may only be filled by a majority of the directors then in office, though less than a quorum, or by a sole remaining director, and the directors so chosen shall hold office until the next annual election and until their successors are duly elected and shall qualify, unless sooner displaced. If there are no directors in office, then an election of directors may be held in the manner provided by statute.
Section 3.03    Resignations. Any director may resign at any time by giving written notice (or notice by electronic transmission) to the Board of Directors, the Chairman of the Board, the President, or the Secretary. Such resignation shall take effect at the time of receipt thereof or at any later time specified therein; and, unless otherwise specified therein, the acceptance of such resignation shall not be necessary to make it effective. A resignation which is conditioned upon the director failing to receive a specified vote for re-election as a director may provide that it is irrevocable.
Section 3.04    Direction of Management. The business of the Corporation shall be managed under the direction of its Board of Directors, which may exercise all such powers of the Corporation and do all such lawful acts and things as are not by statute or by the Certificate of Incorporation or by these Bylaws directed or required to be exercised or done by the stockholders.
Section 3.05    Place of Meetings. The Board of Directors of the Corporation may hold meetings, both regular and special, either within or without the State of Delaware.
Section 3.06    Annual Meeting. Immediately after each annual election of directors or at such other time as the Board of Directors may determine, the Board of Directors shall meet for the purpose of organization, election of officers, and the transaction of other business, at the place where such election of directors was held or, if notice of such meeting is given, at the place specified in such notice. Notice of such meeting need not be given. In the absence of a quorum at said meeting, the same may be held at any other time and place which shall be specified in a notice given as hereinafter provided for special meetings of the Board of Directors, or as shall be specified in a written waiver signed by the directors, if any, not attending and participating in the meeting.
Section 3.07    Regular Meetings. Regular meetings of the Board of Directors may be held without notice at such time and place as shall from time to time be determined by the Board of Directors.
Section 3.08    Special Meetings. Special meetings of the Board of Directors may be called by the Chairman of the Board or the President on 2 days’ notice to each director either
14

Exhibit 3.3

Effective as of February 21, 2023

personally (including by telephone or by means of electronic transmission), or in the manner specified in Section 4.01. Special meetings shall be called by the Chairman of the Board, or the President or the Secretary in like manner and on like notice of the written request (or request by electronic transmission) of two directors.
Section 3.09    Quorum; Voting. At all meetings of the Board of Directors, a majority of the directors shall constitute a quorum for the transaction of business; and at all meetings of any committee of the Board of Directors, a majority of the members of such committee shall constitute a quorum for the transaction of business. The act of a majority of the directors present at any meeting of the Board of Directors or any committee thereof at which there is a quorum present shall be the act of the Board of Directors or such committee, as the case may be, except as may be otherwise specifically provided by statute or by the Certificate of Incorporation. If a quorum shall not be present at any meeting of the Board of Directors or committee thereof, the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum shall be present.
Section 3.10    Action Without a Meeting. Any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting, if all members of the Board of Directors or committee, as the case may be, consent thereto in writing or by electronic transmission, and the writing or writings (or electronic transmission or transmissions) are filed with the minutes of proceedings of the Board of Directors or committee, as applicable.
Section 3.11    Telephonic Meeting Permitted. Members of the Board of Directors or any committee thereof may participate in and act at any meeting of such board or committee through the use of a conference telephone or other communications equipment by means of which all persons participating can hear each other, and participation in the meeting pursuant to this Section 3.11 shall constitute presence in person at the meeting except when the person attends for the express purpose of objecting at the beginning of the meeting to the transaction of any business because the meeting is not lawfully called or convened.
Section 3.12    Committees of Directors. The Corporation elects to be governed by Section 141(c)(2) of the DGCL. The Board of Directors may, by resolution passed by a majority of the whole Board of Directors, designate one or more committees, each committee to consist of one or more of the directors of the Corporation. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. Any such committee, to the extent provided in the resolution, shall have and may exercise all of the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation, except as expressly limited by Section 141(c)(2) of the DGCL. Such committee or committees shall have such name or names as may be determined from time to time by resolution adopted by the Board of Directors. Each committee shall keep regular minutes of its meetings and report the same to the Board of Directors when requested.
Section 3.13    Compensation of Directors. Each director shall be entitled to receive such compensation, if any, as may from time to time be fixed by the Board of Directors. Members of special or standing committees may be allowed like compensation for attending committee meetings. Directors may also be reimbursed by the Corporation for all reasonable expenses incurred in traveling to and from the place of each meeting of the Board of Directors or of any such committee or otherwise incurred in the performance of their duties as directors. No payment referred to herein shall preclude any director from serving the Corporation in any other capacity and receiving compensation therefor.
15

Exhibit 3.3

Effective as of February 21, 2023

Section 3.14    Presiding Director. The Board of Directors may appoint a presiding director of the Board of Directors to hold such position for a term not to exceed one year. Such term shall end on the earlier of the date of the next annual meeting of stockholders or until such presiding director’s earlier death, resignation or removal from such position. The Board of Directors shall determine the qualifications and duties of any such presiding director, including, but not limited to, presiding over meetings of the Board of Directors if the Chairman of the Board is absent.
ARTICLE 4
NOTICES
Section 4.01    Notices. Subject to Section 2.04 of the Bylaws with respect to notice of meetings of stockholders, whenever, under the provisions of law or of the Certificate of Incorporation or of these Bylaws, notice is required to be given to any director or stockholder, such requirement shall not be construed to necessitate personal notice. Whenever written notice is required by law to be given to any director or stockholder, such notice may be given by mail, addressed to such director or stockholder, at such person’s address as it appears on the records of the Corporation, with postage thereon prepaid, and such notice shall be deemed given when deposited in the United States mail. Notice to directors may also be given by electronic transmission. Without limiting the manner by which notice otherwise may be given to stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section 232 of the DGCL.
Section 4.02    Waiver of Notice. Whenever, under the provisions of law or of the Certificate of Incorporation or of these Bylaws, notice is required to be given, a waiver thereof in writing or electronic transmission, by the person or persons entitled to said notice, whether before or after the time of the event for which notice is to be given, shall be deemed equivalent thereto. In the case of a stockholder, such waiver of notice may be signed by such stockholder’s attorney or proxy duly appointed in writing or otherwise permitted by law. Neither the business nor the purpose of any meeting need be specified in any waiver.
ARTICLE 5
OFFICERS
Section 5.01    Number. The officers of the Corporation shall be a Chairman of the Board, a Chief Executive Officer, a President, a Chief Financial Officer, a Secretary and a Treasurer, and may also include one or more Vice Presidents (who may be further classified by such descriptions as “executive”, “senior”, “assistant”, or otherwise), one or more Assistant Secretaries and Assistant Treasurers, and such other officers as may be elected by the Board of Directors. Any number of offices may be held by the same person.
Section 5.02    Election and Term of Office. The officers of the Corporation shall be elected by the Board of Directors. Officers shall hold office at the pleasure of the Board of Directors.
Section 5.03    Removal. Any officer may be removed at any time by the Board of Directors with or without cause. Any vacancy occurring in any office of the Corporation may be filled by the Board of Directors.
Section 5.04    Chairman of the Board. The Chairman of the Board shall preside at all meetings of the Board of Directors and shall perform such other duties, if any, as from time to time may be assigned to him by the Board of Directors.
16

Exhibit 3.3

Effective as of February 21, 2023

Section 5.05    Chief Executive Officer. The Chief Executive Officer shall have overall responsibility for the management of the business and operations of the Corporation and shall see that all orders and resolutions of the Board of Directors are carried into effect. In the absence of the Chairman of the Board and any Presiding Director, he or she shall preside over meetings of the Board of Directors. In general, he or she shall perform such duties as from time to time may be assigned to him or her by the Board of Directors.
Section 5.06    Chief Financial Officer. The Chief Financial Officer shall have general responsibility for the financial affairs of the Corporation and shall perform such other duties, if any, as from time to time may be assigned to him by the Board of Directors.
Section 5.07    President. In the absence of the Chief Executive Officer, the President shall have overall responsibility for the management of the business and operations of the Corporation and shall see that all orders and resolutions of the Board of Directors are carried into effect. In the absence of the Chairman of the Board, any Presiding Director and the Chief Executive Officer, he or she shall preside over meetings of the Board of Directors. In general, he or she shall perform such duties as from time to time may be assigned to him or her by the Board of Directors.
Section 5.08    Executive Vice Presidents or Senior Vice Presidents. The Executive Vice Presidents or Senior Vice Presidents shall perform such managerial duties and have such authority as may be specified in these Bylaws or by the Board of Directors, the Chairman of the Board, the Chief Executive Officer or the President. In the absence or disability of the President, the Executive Vice Presidents or Senior Vice Presidents, in order of seniority established by the Board of Directors or the Chairman of the Board, shall perform the duties and exercise the powers of the President.
Section 5.09    Vice Presidents. The Vice Presidents shall perform such duties and have such authority as may be specified in these Bylaws or by the Board of Directors, the Chairman of the Board, the Chief Executive Officer or the President.
Section 5.10    Secretary. The Secretary shall attend all meetings of the Board of Directors and all meetings of the stockholders and record all the proceedings of the meetings of the stockholders and of the Board of Directors in a book to be kept for that purpose and shall perform like duties for the standing committees when required. He or she shall give, or cause to be given, notice of all meetings of the stockholders and special meetings of the Board of Directors, and shall perform such other duties as may be prescribed by the Board of Directors, the Chairman of the Board, the Chief Executive Officer or the President. He shall have custody of the corporate seal of the Corporation and he or she, or an Assistant Secretary, shall have authority to affix the same to any instrument, and when so affixed it may be attested by his or her signature or by the signature of such Assistant Secretary. The Board of Directors may give general authority to any other officer to affix the seal of the Corporation and to attest the affixing by his or her signature.
Section 5.11    Assistant Secretaries. The Assistant Secretary or Secretaries shall, in the absence or disability of the Secretary, perform the duties and exercise the authority of the Secretary, and shall perform such other duties and have such other authority as the Board of Directors, the Chairman of the Board, the Chief Executive Officer or the President may from time to time prescribe.
Section 5.12    Treasurer. The Treasurer shall have the custody of the corporate funds and securities and shall keep full and accurate accounts of receipts and disbursements in books belonging to the Corporation and shall deposit all monies and other valuable effects in the name
17

Exhibit 3.3

Effective as of February 21, 2023

and to the credit of the Corporation in such depositories as may be designated by the Board of Directors. He or she shall disburse the funds of the Corporation as may be ordered by the Board of Directors, the Chairman of the Board, or the President, or the Chief Executive Officer, taking proper vouchers for such disbursements, and shall render to the Board of Directors when the Board of Directors so requires, an account of all his transactions as Treasurer and of the financial condition of the Corporation.
Section 5.13    Assistant Treasurers. The Assistant Treasurer or Treasurers shall, in the absence or disability of the Treasurer, perform the duties and exercise the authority of the Treasurer and shall perform such other duties and have such other authority as the Board of Directors may from time to time prescribe.
ARTICLE 6
INDEMNIFICATION OF DIRECTORS AND OFFICERS
Section 6.01    Indemnification. Any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such person is or was a director or officer of the Corporation, or is or was serving while a director or officer of the Corporation at the request of the Corporation as a director, officer, employee, agent, fiduciary or other representative of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, shall be indemnified by the Corporation against expenses (including attorneys’ fees), judgments, fines, excise taxes and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding to the full extent permissible under applicable law.
Section 6.02    Advances. To the fullest extent permitted by applicable law as it exists now or is hereafter amended, expenses (including attorneys’ fees) incurred by a present or former director or officer in defending any civil, criminal, administrative or investigative action, suit or proceeding for which indemnification is or may be available pursuant to this Article 6 shall be paid by the Corporation in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of the director or officer to repay such amount if it shall ultimately be determined that he or she is not entitled to be indemnified by the Corporation as authorized in this Article 6. Such expenses (including attorneys’ fees) incurred by other employees and agents may be so paid upon such terms and conditions, if any, as the Corporation deems appropriate. The Board of Directors may authorize the Corporation’s counsel to represent a director, officer, employee or agent in any action, suit or proceeding, whether or not the Corporation is a party to such action, suit or proceeding.
Section 6.03    Procedure. Any indemnification of a director or officer of the Corporation under Section 6.01, or advance of costs, charges and expenses of a director or officer under Section 6.02, shall be made promptly, and in any event within sixty (60) days, upon the written request of the director or officer. The right to indemnification or advances as granted by this Article 6 shall be enforceable, to the fullest extent permitted by law, by the director or officer in any court of competent jurisdiction if the Corporation denies such request, in whole or in part. Such person’s costs and expenses incurred in connection with successfully establishing his or her right to indemnification, in whole or in part, in any such action shall also be indemnified by the Corporation, to the fullest extent permitted by law. It shall be a defense to any such action (other than an action brought to enforce a claim for the advance of costs, charges and expenses under Section 6.02 where the required undertaking, if any, has been received by the Corporation) that the claimant has not met the standard of conduct set forth under Delaware law, but the burden of proving such defense shall be on the Corporation. Neither the failure of the Corporation (including its board of directors or a committee thereof, its independent legal counsel, and its
18

Exhibit 3.3

Effective as of February 21, 2023

stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because he or she has met the applicable standard of conduct under Delaware law, nor the fact that there has been an actual determination by the Corporation (including its board of directors or a committee thereof, its independent legal counsel, and its stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that the claimant has not met the applicable standard of conduct.
Section 6.04    Other Rights. The indemnification and advancement of expenses provided by this Article 6 shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any insurance or other agreement, vote of shareholders or disinterested directors or otherwise, both as to actions in their official capacity and as to actions in another capacity while holding an office, and shall continue as to a person who has ceased to be a director or officer and shall inure to the benefit of the heirs, executors and administrators of such person.
Section 6.05    Insurance. The Corporation shall have power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee, agent, fiduciary or other representative of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, against any liability asserted against him or her and incurred by him or her in any such capacity, or arising out of his status as such, whether or not the Corporation would have the power to indemnify him or her against such liability under the provisions of these Bylaws.
Section 6.06    Modification. The duties of the Corporation to indemnify and to advance expenses to a director or officer provided in this Article 6 shall constitute a contract between the Corporation, on the one hand, and, on the other hand, each individual who serves or has served as a director or officer of the Corporation, in consideration of such person’s past or current and any future performance of services for the Corporation, and pursuant to this Article 6, the Corporation intends to be legally bound to each such current or former director or officer of the Corporation, the rights conferred under this Article 6 are present contractual rights, and such rights are fully vested, and shall be deemed to have vested fully, immediately upon such director or officer commencing service as a director or officer of the Corporation. Neither amendment nor repeal nor modification of any provision of this Article 6 nor the adoption of any provision of the Corporation’s certificate of incorporation, as amended or restated from time to time, inconsistent with this Article 6 shall eliminate or reduce the effect of this Article 6 in respect of any act or omission occurring, or any cause of action or claim that accrues or arises or any state of facts existing, at the time of or before such amendment, repeal, modification or adoption of an inconsistent provision (even in the case of a proceeding based on such a state of facts that is commenced after such time). The rights provided by, or granted pursuant to, this Article 6 shall continue notwithstanding that the person has ceased to be a director or officer of the Corporation and shall inure to the benefit of the estate, heirs, executors, administrators, legatees and distributees of such person.
ARTICLE 7
CERTIFICATES OF STOCK
Section 7.01    Stock Certificates. Every holder of stock in the Corporation shall be entitled to have a certificate in the form prescribed by the Board of Directors signed on behalf of the Corporation by the Chairman of the Board or the President or a Vice President and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary of the Corporation, representing the number of shares owned by him in the Corporation; provided, that
19

Exhibit 3.3

Effective as of February 21, 2023

the board of directors may provide by resolution or resolutions that some or all classes or series of its stock shall be uncertificated shares. Any or all signatures on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if such person were such officer, transfer agent, or registrar at the date of issue.
Section 7.02    Lost Certificates. The Board of Directors may direct a new certificate or certificates to be issued in place of any certificate or certificates theretofore issued by the Corporation alleged to have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen or destroyed. When authorizing such issue of a new certificate or certificates, the Board of Directors may, in its discretion and as a condition precedent to the issuance thereof, require the owner of such lost, stolen or destroyed certificate or certificates, or his legal representative, to advertise the same in such manner as it shall require and/or to give the Corporation a bond in such sum as it may direct or indemnity against any claim that may be made against the Corporation with respect to the certificate alleged to have been lost, stolen or destroyed.
Section 7.03    Transfers of Stock. Upon surrender to the Corporation or the transfer agent of the Corporation of a certificate for shares duly endorsed or accompanied by proper evidence of succession, assignment or authority to transfer, it shall be the duty of the Corporation to issue a new certificate to the person entitled thereto, cancel the old certificate and record the transaction upon its books.
Section 7.04    Fixing Record Date. The Board of Directors of the Corporation may fix a record date for the purpose of determining the stockholders entitled to notice of, or to vote at, any meeting of stockholders or any adjournment thereof, or to consent to corporate action in writing without a meeting, or to receive payment of any dividend or other distribution or allotment of any rights, or to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action. Such record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors and such record date shall not be (i) in the case of such a meeting of stockholders, more than 60 nor less than 10 days before the date of the meeting of stockholders, or (ii) except for record dates to be fixed in accordance with the provisions of Section 2.09, in other cases, more than 60 days prior to the payment or allotment or change, conversion or exchange or other action. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting unless the Board of Directors fixes a new record date for the adjourned meeting. Notwithstanding anything in this Section 7.04 to the contrary, a record date for determining stockholders entitled to take action by written consent shall be fixed in accordance with Section 2.09(b) of these Bylaws.
Section 7.05    Registered Stockholders. The Corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of stock to receive dividends and to vote as such owner, and shall be entitled to hold liable for calls and assessments a person registered on its books as the owner of stock, and shall not be bound to recognize any equitable or other claim to, or interest in, such stock on the part of any other person, whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware.
ARTICLE 8
MISCELLANEOUS
Section 8.01    Amendments. These Bylaws may be altered, amended or repealed, and new Bylaws may be adopted, by the stockholders or by the Board of Directors at any regular
20

Exhibit 3.3

Effective as of February 21, 2023

meeting of the stockholders or of the Board of Directors or at any special meeting of the stockholders or of the Board of Directors if notice of such alteration, amendment, repeal or adoption of new Bylaws be contained in the notice of such special meeting.
Section 8.02    Exclusive Jurisdiction of Delaware Courts or the United States Federal District Courts. Unless the Corporation consents in writing to the selection of an alternative forum, the sole and exclusive forum for (a) any derivative action or proceeding brought on behalf of the Corporation, (b) any action asserting a claim of breach of a fiduciary duty owed by any director or officer or other employee of the Corporation to the Corporation or the Corporation’s stockholders, (c) any action asserting a claim against the Corporation or any director or officer or other employee of the Corporation arising pursuant to any provision of the DGCL or the Certificate of Incorporation or these Bylaws (in each case, as they may be amended from time to time) or (d) any action asserting a claim against the Corporation or any director or officer or other employee of the Corporation governed by the internal affairs doctrine shall be a state court located within the State of Delaware (or, if no state court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware); provided, however, that this sentence will not apply to any causes of action arising under the Securities Act of 1933, as amended, or the Exchange Act, or to any claim for which the federal courts have exclusive jurisdiction. Unless the Corporation consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Exchange Act, or the respective rules and regulations promulgated thereunder. To the fullest extent permitted by law, any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this
Section 8.03    Severability. If any provision or provisions of these Bylaws shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of these Bylaws (including, without limitation, each portion of any paragraph containing any such provision held to be invalid, illegal or unenforceable, that is not itself held to be invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby; and (b) to the fullest extent possible, the provisions of these Bylaws (including, without limitation, each such portion of any paragraph containing any such provision held to be invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.
21

 EX-4.4 3 iart-20221231xexx44.htm EX-4.4 Document
Exhibit 4.4

Description of the Company’s Common Stock Registered
Under Section 12 of the Exchange Act

The following is a description of the common stock of Integra LifeSciences Holdings Corporation (the “Company”). The description does not purport to be complete and is subject to and qualified in its entirety by reference to the Company’s amended and restated certificate of incorporation, or the certificate of incorporation, and its third amended and restated by-laws, or the bylaws) each of which are filed as exhibits to this Annual Report on Form 10-K, and to the provisions of the Delaware General Corporation Law (“DGCL”).
General Matters
Authorized Shares
The Company’s authorized capital stock consists of 255,000,000 shares of stock, of which 240,000,000 shares are designated as common stock, par value $0.01 per share, and 15,000,000 shares are designated as preferred stock, no par value. As of December 31, 2022, we had 90,476,671 shares of common stock outstanding, 6,822,864 shares were designated as treasury stock, and no shares of preferred stock outstanding.

Dividends

Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of common stock are entitled to receive dividends out of assets legally available therefor at such times and in such amounts as the board of directors may from time to time determine. However, our senior credit facility limits the amount of dividends that we may pay. Any future determinations to pay cash dividends on our common stock will be at the discretion of our board of directors and will depend upon our financial condition, results of operations, cash flows and other factors that our board of directors deems relevant.

Voting Rights

Each stockholder is entitled to one vote in person or by proxy for each share of the capital stock having voting power held by such stockholder. Stockholders do not have cumulative voting rights. The Company’s board of directors is not classified and each director is elected annually. The voting standard for the election of directors is a majority of votes cast in uncontested elections. In contested elections where the number of nominees exceeds the number of directors to be elected, the vote standard is a plurality of the votes cast. Holders of a majority of the outstanding shares of common stock entitled to vote in any election of directors may elect all of the directors standing for election.

Preemptive or Similar Rights

Our common stock is not entitled to preemptive rights and is not subject to conversion or redemption.

Right to Receive Liquidation Distributions

Upon the occurrence of a liquidation, dissolution or winding-up, the holders of shares of common stock would be entitled to share ratably in the distribution of all of our assets remaining available for distribution after satisfaction of all its liabilities and the payment of the liquidation preference of any outstanding preferred stock.

Stock Exchange

Our common stock is traded on the Nasdaq Global Select Market under the symbol “IART”.






Preferred Stock


Exhibit 4.4
The Company’s Board of Directors has the authority to issue up to 15,000,000 shares of Preferred Stock from time to time in one or more series and with such rights and preferences as determined by the Board with respect to each series. The issuance of preferred stock could have the effect of decreasing the market price of our common stock and could adversely affect the voting and other rights of holders of common stock.

Statutory Business Combination Provision

As a Delaware corporation, we are subject to Section 203 of the General Corporation Law of the State of Delaware, or DGCL. In general, Section 203 of the DGCL prevents an “interested stockholder,” which is defined generally as a person owning 15% or more of a Delaware corporation’s outstanding voting stock or any affiliate or associate of that person, from engaging in a broad range of “business combinations” with the corporation for three years following the date that person became an interested stockholder unless:

•before that person became an interested stockholder, the board of directors of the corporation approved the transaction in which that person became an interested stockholder or approved the business combination;

•on completion of the transaction that resulted in that person’s becoming an interested stockholder, that person owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, other than stock held by (1) directors who are also officers of the corporation or (2) any employee stock plan that does not provide employees with the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

•following the transaction in which that person became an interested stockholder, both the board of directors of the corporation and the holders of at least two-thirds of the outstanding voting stock of the corporation not owned by that person approve the business combination.

Under Section 203 of the DGCL, the restrictions described above also do not apply to specific business combinations proposed by an interested stockholder following the announcement or notification of designated extraordinary transactions involving the corporation and a person who had not been an interested stockholder during the previous three years or who became an interested stockholder with the approval of a majority of the corporation’s directors, if a majority of the directors who were directors prior to any person’s becoming an interested stockholder during the previous three years, or were recommended for election or elected to succeed those directors by a majority of those directors, approve or do not oppose that extraordinary transaction.

Anti-Takeover Effects of our Certificate of Incorporation and our Bylaws

Some of the provisions of our certificate of incorporation and bylaws discussed below may have the effect, either alone or in combination with the provisions of our certificate of incorporation discussed above and Section 203 of the DGCL, of making more difficult or discouraging a tender offer, proxy contest, merger or other takeover attempt that our board of directors opposes but that a stockholder might consider to be in its best interest.

Special Meetings of Stockholders. Our bylaws provide that a special meeting of our stockholders may only be called by (i) the chairman of our board of directors, (ii) the president or (iii) our board of directors.

Stockholder Action by Written Consent. Our stockholders may act by written consent without a meeting, subject to the requirements in our bylaws for setting a record date for the written consent. Any stockholder seeking to have the stockholders authorize or take corporate action must request that our Board of Directors fix a record date. Such notice must include the same information required for a stockholder proposal and be submitted to our Board of Directors as described in our bylaws.

Vacancies on the Board of Directors. Our certificate of incorporation provides that the number of directors will be fixed exclusively by, and may be increased or decreased exclusively by, our board of directors from time to time, but will not be less than three nor more than thirteen. Our bylaws provide that vacancies on the board of directors arising through death, resignation, retirement or removal shall be filled only by a majority of the directors then in office whether or not the remaining directors constitute a quorum. These provisions will prevent our stockholders from removing incumbent directors without cause and filling the resulting vacancies with their own nominees.

Our certificate of incorporation provides that the number of directors will be fixed exclusively by, and may be increased or decreased exclusively by, our board of directors from time to time, but will not be less than three nor more than thirteen. Our certificate of incorporation provides that directors may be removed only by the Delaware Chancery Court under Section 225(c) of the DGCL or for cause (as such term is defined in our certificate of incorporation) as determined by a vote of at least 80% of the voting power of our outstanding voting stock. A vacancy on our board of directors may be filled by a vote of a majority of

Exhibit 4.4
the directors in office, and a director appointed to fill a vacancy serves for the remainder of the term of the class of directors in which the vacancy occurred.

Advance Notice Requirements for Stockholder Proposals and Director Nominations. Our bylaws contain provisions requiring that advance notice be delivered to us of any business to be brought by a stockholder before an annual meeting of stockholders and providing for certain procedures to be followed by stockholders in nominating persons for election to our board of directors. Generally, the advance notice provisions provide that the stockholder must give written notice to our Secretary not less than 90 days nor more than 120 days prior to the anniversary date of the immediately preceding annual meeting, except that in the event that the annual meeting is called for a date that is more than 30 days before or more than 60 days after such anniversary date, notice by the stockholder to be timely must be so delivered not later than the 90th day prior to the date of such annual meeting (or, if later, then the 10th day following the day on which public disclosure of the date of such annual meeting was first made). The notice must set forth specific information regarding that stockholder and that business or director nominee, as described in our bylaws.

Amendment of Certain Provisions of the Certificate of Incorporation and Bylaws. Under the DGCL, the stockholders of a corporation have the right to adopt, amend or repeal the bylaws and, with the approval of the board of directors, the certificate of incorporation of a corporation. In addition, if the certificate of incorporation so provides, the bylaws may be adopted, amended or repealed by the board of directors. Our Certificate provides that the bylaws may be amended or repealed by our board of directors. Our certificate of incorporation and bylaws also confer on our board of directors the power to adopt, amend or repeal our amended and restated bylaws with the affirmative vote of a majority of the directors then in office.

Forum Selection. Our bylaws provide, unless we consent in writing to the selection of an alternative forum, that the sole and exclusive forum for (a) any derivative action or proceeding brought on our behalf, (b) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (c) any action asserting a claim against us or any of our directors, officers or other employees arising pursuant to any provision of the DGCL, our certificate of incorporation or our bylaws (in each case, as they may be amended from time to time) or (d) any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine, will be a state court located within the State of Delaware (or, if no state court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware). Any person that purchases or otherwise acquires an interest in our stock will be deemed to have notice of and agree to comply with the foregoing provisions.

Our bylaws provide that a state court of the State of Delaware (or, if no state court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for: (i) any derivative action or proceeding brought on behalf of Integra; (ii) any action asserting a claim of breach of a fiduciary duty owed by any director or officer of Integra to Integra or the stockholders; (iii)  any action asserting a claim against Integra arising pursuant to any provision of the DGCL, our certificate of incorporation or our bylaws (as each may be amended, from time to time); or (iv) any other action asserting a claim against Integra or any director or officer of Integra that is governed by or subject to the internal affairs doctrine for choice of law purposes. However, the forum selection provision does not apply to any claims, actions or proceedings arising under the Securities Act of 1933, as amended, which we refer to as the “Securities Act,” or the Exchange Act. Unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Exchange Act, or the respective rules and regulations promulgated thereunder. Any person or entity purchasing or otherwise acquiring any interest in shares of our stock will be deemed to have notice of and consented to the exclusive forum provisions in our bylaws.

Preferred Stock. As discussed above under “General Matters—Preferred Stock,” our certificate of incorporation authorizes our board of directors, without the approval of our stockholders, to provide for the issuance of all or any shares of our preferred stock in one or more series and to determine the designation, powers, preferences and relative, participating, optional or other special rights, and the qualifications, limitations or restrictions applicable to any of those rights, including dividend rights, voting rights, conversion or exchange rights, terms of redemption and liquidation preferences, of each series. The issuance of shares of our preferred stock, or the issuance of rights to purchase shares of preferred stock, could be used to discourage an unsolicited acquisition proposal. In addition, under some circumstances, the issuance of preferred stock could adversely affect the voting power of our common stockholders.




 EX-10.3(H) 4 iart-20221231xexx103h.htm EX-10.3(H) Document
Exhibit 10.3(h)

RESTRICTED STOCK AGREEMENT
THIS RESTRICTED STOCK AGREEMENT (the “Award Agreement”), dated as of [ ] (the “Award Date”), is made by and between Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”), and [ ], a non-employee director of the Company, hereinafter referred to as the “Participant”:
WHEREAS, the Company maintains the Integra LifeSciences Holdings Corporation 2003 Equity Incentive Plan, as amended (the “Plan”), and wishes to carry out the Plan, the terms of which are hereby incorporated by reference and made part of this Award Agreement; and
NOW, THEREFORE, in consideration of the various covenants herein contained, and intending to be legally bound hereby, the parties hereto agree as follows:
ARTICLE I.
DEFINITIONS
Capitalized terms not otherwise defined below shall have the meaning set forth in the Plan. The masculine pronoun shall include the feminine and neuter, and the singular the plural, where the context so indicates.
Section 1.1    Restricted Stock. “Restricted Stock” shall mean [ ] shares of Common Stock of the Company issued under this Award Agreement and subject to the Restrictions imposed hereunder.
Section 1.2    Restrictions. “Restrictions” shall mean the forfeiture and transferability restrictions imposed upon Restricted Stock under the Plan and this Award Agreement.
Section 1.3    Rule 16b-3. “Rule 16b-3” shall mean that certain Rule 16b-3 under the Exchange Act, as such Rule may be amended from time to time.
Section 1.4    Secretary. “Secretary” shall mean the Secretary of the Company.
Section 1.5    Termination of Service. “Termination of Service” shall mean the time when the Participant ceases to provide services to the Company and its Related Corporations and Affiliates as an employee or Associate for any reason with or without cause, including, but not by way of limitation, a termination by resignation, discharge, death, or Disability, but excluding a termination where the Participant is simultaneously reemployed by, or remains employed by, or continues to provide services to, the Company and/or one or more of its Related Corporations and Affiliates or a successor entity thereto.
Section 1.6    Vested Shares. “Vested Shares” shall mean the shares of Restricted Stock which are no longer subject to the Restrictions by reason of Section 3.2.
Section 1.7    Vesting Date. “Vesting Date” shall mean each of the twelve-month anniversary date of the Award Date.
| ||
Exhibit 10.3(h)
ARTICLE II.
ISSUANCE OF RESTRICTED STOCK
Section 2.1    Issuance of Restricted Stock. On the date hereof the Company issues to the Participant the Restricted Stock subject to the Restrictions and other conditions set forth in this Award Agreement. The Company shall cause the Restricted Stock to be issued in the name of the Participant or held in book entry form, but if a stock certificate is issued it shall be delivered to and held in custody by the Company until the Restrictions lapse or such Restricted Stock is forfeited. As a further condition to the Company’s obligations under this Award Agreement, the Participant’s spouse, if any, shall execute and deliver to the Company the Consent of Spouse attached hereto as Exhibit A.
Section 2.2    Restrictions. Until vested pursuant to Section 3.2, the Restricted Stock shall be subject to forfeiture as provided in Section 3.1 and may not be sold, assigned, transferred, pledged, or otherwise encumbered or disposed of.
Section 2.3    Voting and Dividend Rights. The Participant, shall have all the rights of a stockholder with respect to his Restricted Stock, including the right to vote the Restricted Stock, except that the Participant shall have the right to receive all dividends or other distributions paid or made with respect to only those outstanding vested shares of Common Stock.
ARTICLE III.
RESTRICTIONS
Section 3.1    Forfeiture. Upon the Participant’s Termination of Service other than by (i) death or Disability or (ii) a Qualifying Termination upon a Change in Control as further described in Section 3.2, the Participant’s rights in Restricted Stock that has not yet vested pursuant to Section 3.2 shall lapse, and such Restricted Stock shall be surrendered to the Company without consideration (and, in the event of certificates representing such Restricted Stock are held by the Company, such Restricted Stock shall be so transferred without any further action by the Participant).
Section 3.2    Termination of Restrictions. The Restrictions shall terminate and lapse, and such shares shall vest in the Participant and become Vested Shares on the Vesting Date as provided in Section 3.3, provided that the Participant has continued to serve as an employee or an Associate from the Award Date to and including such Vesting Date. Notwithstanding the foregoing, (i) in the event that a Change in Control occurs and the Participant incurs a Qualifying Termination on or within twelve (12) months following the date of such Change in Control or (ii) in the event of the Participant’s death or Disability, all Restrictions shall lapse and all Restricted Stock shall become Vested Shares upon such Qualifying Termination, death or Disability.
Section 3.3    Lapse of Restrictions. All of the shares of Restricted Stock shall become Vested Shares on the Vesting Date. On the Vesting Date, the Company shall issue new certificates evidencing such Vested Shares and deliver such certificates to the Participant or his legal representative, or record such Vested Shares in book entry form, free from the legend provided for in Section 4.2 and any of the other Restrictions; provided, however, such certificates shall bear any other legends and such book entry accounts shall be subject to any other restrictions as the Company may determine are required to comply with Section 4.6. Such Vested Shares shall cease to be considered Restricted Stock subject to the terms and conditions of this Award Agreement. Notwithstanding the foregoing, no such new certificate shall be delivered to the
| ||
Exhibit 10.3(h)
Participant or his legal representative unless and until the Participant or his legal representative shall have paid to the Company in cash or by check the full amount of all federal, state and local withholding or other employment taxes applicable to the taxable income of the Participant resulting from the lapse of the Restrictions
Section 3.4    Clawback. Notwithstanding anything contained in the Plan or the Award Agreement to the contrary, the Restricted Stock shall be subject to the provisions of any clawback, repayment or recapture policy implemented by the Company, including any such policy adopted to comply with applicable law (including without limitation the Dodd-Frank Wall Street Reform and Consumer Protection Act) or securities exchange listing standards and any rules or regulations promulgated thereunder, to the extent set forth in such policy and/or in any notice or agreement relating to the Restricted Stock under the Plan.
ARTICLE IV.
MISCELLANEOUS
Section 4.1    No Additional Rights. Nothing in this Award Agreement or in the Plan shall confer upon any person any right to a position as an Associate or continued employment by the Company or any of its Related Corporations or Affiliates or affect in any way the right of any of the foregoing to terminate the services of an individual at any time.
Section 4.2    Legend. Any certificates representing shares of Restricted Stock issued pursuant to this Award Agreement may include, until all Restrictions lapse and new certificates are issued pursuant to Section 3.3, bear the following legend:
    THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN VESTING REQUIREMENTS AND MAY BE SUBJECT TO FORFEITURE UNDER THE TERMS OF THAT CERTAIN RESTRICTED STOCK AGREEMENT BY AND BETWEEN INTEGRA LIFESCIENCES HOLDINGS CORPORATION AND THE HOLDER OF THE SECURITIES. PRIOR TO VESTING OF OWNERSHIP IN THE SECURITIES, THEY MAY NOT BE, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, OR OTHERWISE ENCUMBERED OR DISPOSED OF UNDER ANY CIRCUMSTANCES. COPIES OF THE ABOVE REFERENCED AGREEMENT ARE ON FILE AT THE OFFICES OF THE CORPORATION AT 1100 CAMPUS DRIVE, PRINCETON, NEW JERSEY 08540.
Section 4.3    Tax Withholding. On the Vesting Date, the Company shall notify the Participant of the amount of tax which must be withheld by the Company under all applicable federal, state and local tax laws. Subject to any applicable legal conditions or restrictions, the Company shall withhold from the shares of Restricted Stock a number of whole shares of common stock having a fair market value, determined as of the Vesting Date, not in excess of the minimum tax required to be withheld by law.
Section 4.4    Notices. Any notice to be given under the terms of this Award Agreement to the Company shall be addressed to the Company in care of its Secretary, and any notice to be given to the Participant shall be addressed to him at the address given beneath his signature hereto. By a notice given pursuant to this Section 4.4, either party may hereafter designate a different address for notices to be given to it or him. Any notice which is required to be given to the Participant shall, if the Participant is then deceased, be given to the Participant’s personal representative if such representative has previously informed the Company of his status and address by written notice under this Section 4.4. Any notice shall have been deemed duly given when enclosed in a
| ||
Exhibit 10.3(h)
properly sealed envelope or wrapper addressed as aforesaid, deposited (with postage prepaid) in a post office or branch post office regularly maintained by the United States Postal Service.
Section 4.5    Titles. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Award Agreement.
Section 4.6    Conformity to Securities Laws. This Award Agreement is intended to conform to the extent necessary with all provisions of the Securities Act and the Exchange Act and any and all regulations and rules promulgated by the Securities and Exchange Commission thereunder, including without limitation Rule 16b-3. Notwithstanding anything herein to the contrary, this Award Agreement shall be administered, and the Restricted Stock shall be issued, only in such a manner as to conform to such laws, rules and regulations. To the extent permitted by applicable law, this Award Agreement and the Restricted Stock issued hereunder shall be deemed amended to the extent necessary to conform to such laws, rules and regulations.
Section 4.7    Amendment. This Award Agreement may be amended only by a writing executed by the parties hereto which specifically states that it is amending this Award Agreement.
Section 4.8    Governing Law. The laws of the State of Delaware shall govern the interpretation, validity, administration, enforcement and performance of the terms of this Award Agreement regardless of the law that might be applied under principles of conflicts of laws.

*****

IN WITNESS HEREOF, this Award Agreement has been executed and delivered by the parties hereto.

                                INTEGRA LIFESCIENCES
THE PARTICIPANT                        HOLDINGS CORPORATION

        
                                By                    
[ ]                Name:
                                Title:

                        



| ||
Exhibit 10.3(h)


| ||
 EX-10.3(I) 5 iart-20221231xexx103i.htm EX-10.3(I) Document
Exhibit 10.3(i)
RESTRICTED STOCK AGREEMENT
THIS RESTRICTED STOCK AGREEMENT (the “Award Agreement”), dated as of [ ] (the “Award Date”), is made by and between Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”), and [ ], an employee of the Company (or one or more of its Related Corporations or Affiliates), hereinafter referred to as the “Participant”:
WHEREAS, the Company maintains the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the “Plan”), and wishes to carry out the Plan, the terms of which are hereby incorporated by reference and made part of this Award Agreement; and
NOW, THEREFORE, in consideration of the various covenants herein contained, and intending to be legally bound hereby, the parties hereto agree as follows:
ARTICLE I.
DEFINITIONS
Capitalized terms not otherwise defined below shall have the meaning set forth in the Plan. The masculine pronoun shall include the feminine and neuter, and the singular the plural, where the context so indicates.
Section 1.1    Restricted Stock. “Restricted Stock” shall mean
[ ] shares of Common Stock of the Company issued under this Award Agreement and subject to the Restrictions imposed hereunder.
Section 1.2    Restrictions. “Restrictions” shall mean the forfeiture and transferability restrictions imposed upon Restricted Stock under the Plan and this Award Agreement.
Section 1.3    Rule 16b-3. “Rule 16b-3” shall mean that certain Rule 16b-3 under the Exchange Act, as such Rule may be amended from time to time.
Section 1.4    Secretary. “Secretary” shall mean the Secretary of the Company.
Section 1.5    Termination of Service. “Termination of Service” shall mean the time when the Participant ceases to provide services to the Company and its Related Corporations and Affiliates as an employee or Associate for any reason with or without cause, including, but not by way of limitation, a termination by resignation, discharge, death, or Disability, but excluding a termination where the Participant is simultaneously reemployed by, or remains employed by, or continues to provide services to, the Company and/or one or more of its Related Corporations and Affiliates or a successor entity thereto.
Section 1.6    Vested Shares. “Vested Shares” shall mean the shares of Restricted Stock which are no longer subject to the Restrictions by reason of Section 3.2.
Section 1.7    Vesting Date. “Vesting Date” shall mean each of the first, second and third anniversaries of the Award Date.

Exhibit 10.3(i)
ARTICLE II.
ISSUANCE OF RESTRICTED STOCK
Section 2.1    Issuance of Restricted Stock. On the date hereof the Company issues to the Participant the Restricted Stock subject to the Restrictions and other conditions set forth in this Award Agreement. The Company shall cause the Restricted Stock to be issued in the name of the Participant or held in book entry form, but if a stock certificate is issued it shall be delivered to and held in custody by the Company until the Restrictions lapse or such Restricted Stock is forfeited. As a further condition to the Company’s obligations under this Award Agreement, the Participant’s spouse, if any, shall execute and deliver to the Company the Consent of Spouse attached hereto as Exhibit A.
Section 2.2    Restrictions. Until vested pursuant to Section 3.2, the Restricted Stock shall be subject to forfeiture as provided in Section 3.1 and may not be sold, assigned, transferred, pledged, or otherwise encumbered or disposed of.
Section 2.3    Voting and Dividend Rights. The Participant shall have all the rights of a stockholder with respect to his Restricted Stock, including the right to vote the Restricted Stock, except that the Participant shall have the right to receive all dividends or other distributions paid or made with respect to only those outstanding vested shares of Common Stock.
ARTICLE III.
RESTRICTIONS
Section 3.1    Forfeiture. Upon the Participant’s Termination of Service other than by reason of death or Disability, the Participant’s rights in Restricted Stock that has not yet vested pursuant to Section 3.2 shall lapse, and such Restricted Stock shall be surrendered to the Company without consideration (and, in the event of certificates representing such Restricted Stock are held by the Company, such Restricted Stock shall be so transferred without any further action by the Participant).
Section 3.2    Termination of Restrictions. The Restrictions shall terminate and lapse, and such shares shall vest in the Participant and become Vested Shares on each Vesting Date as provided in Section 3.3, provided that the Participant has continued to serve as an employee or an Associate from the Award Date to and including such Vesting Date. Notwithstanding the foregoing, (i) in the event that a Change in Control occurs and the Participant incurs a Qualifying Termination on or within twelve (12) months following the date of such Change in Control or (ii) in the event of the Participant’s death or Disability, all Restrictions shall lapse and all Restricted Stock shall become Vested Shares upon such Qualifying Termination, death or Disability.
Section 3.3    Lapse of Restrictions. Thirty-three percent (33%) of the shares of Restricted Stock shall become Vested Shares on each of the first two Vesting Dates, and thirty-four percent (34%) of the shares of Restricted Stock shall become Vested Shares on the third Vesting Date. On each Vesting Date, the Company shall issue new certificates evidencing the Vested Shares or record such Vested Shares in book entry form, free from the legend provided for in Section 4.2 and any of the other Restrictions; provided, however, such

Exhibit 10.3(i)
certificates shall bear any other legends and such book entry accounts shall be subject to any other restrictions as the Company may determine are required to comply with Section 4.6. Such Vested Shares shall cease to be considered Restricted Stock subject to the terms and conditions of this Award Agreement. Notwithstanding the foregoing, no such new certificate shall be delivered to the Participant or his legal representative unless and until the Participant or his legal representative shall have satisfied the full amount of all federal, state and local withholding or other employment taxes applicable to the taxable income of the Participant resulting from the lapse of the Restrictions in accordance with Section 4.3.
Section 3.4    Clawback. Notwithstanding anything contained in the Plan or the Award Agreement to the contrary, the Restricted Stock shall be subject to the provisions of any clawback, repayment or recapture policy implemented by the Company, including any such policy adopted to comply with applicable law (including without limitation the Dodd-Frank Wall Street Reform and Consumer Protection Act) or securities exchange listing standards and any rules or regulations promulgated thereunder, to the extent set forth in such policy and/or in any notice or agreement relating to the Restricted Stock under the Plan.

ARTICLE IV.
MISCELLANEOUS
Section 4.1    No Additional Rights. Nothing in this Award Agreement or in the Plan shall confer upon any person any right to a position as an Associate or continued employment by the Company or any of its Related Corporations or Affiliates or affect in any way the right of any of the foregoing to terminate the services of an individual at any time.
Section 4.2    Legend. Any certificates representing shares of Restricted Stock issued pursuant to this Award Agreement shall, until all Restrictions lapse and new certificates are issued pursuant to Section 3.3, bear the following legend:
    THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN VESTING REQUIREMENTS AND MAY BE SUBJECT TO FORFEITURE UNDER THE TERMS OF THAT CERTAIN RESTRICTED STOCK AGREEMENT BY AND BETWEEN INTEGRA LIFESCIENCES HOLDINGS CORPORATION AND THE HOLDER OF THE SECURITIES. PRIOR TO VESTING OF OWNERSHIP IN THE SECURITIES, THEY MAY NOT BE, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, OR OTHERWISE ENCUMBERED OR DISPOSED OF UNDER ANY CIRCUMSTANCES. COPIES OF THE ABOVE REFERENCED AGREEMENT ARE ON FILE AT THE OFFICES OF THE CORPORATION AT 1100 CAMPUS ROAD, PRINCETON, NEW JERSEY 08540.
Section 4.3    Tax Withholding. On each Vesting Date, the Company shall notify the Participant of the amount of tax which must be withheld by the Company under all applicable federal, state and local tax laws. Subject to any applicable legal conditions or restrictions, the Company shall withhold from the shares of Restricted Stock a number of whole shares of common stock

Exhibit 10.3(i)
having a fair market value, determined as of each Vesting Date, not in excess of the minimum of tax required to be withheld by law.
Section 4.4    Notices. Any notice to be given under the terms of this Award Agreement to the Company shall be addressed to the Company in care of its Secretary, and any notice to be given to the Participant shall be addressed to him at the address given beneath his signature hereto. By a notice given pursuant to this Section 4.4, either party may hereafter designate a different address for notices to be given to it or him. Any notice which is required to be given to the Participant shall, if the Participant is then deceased, be given to the Participant’s personal representative if such representative has previously informed the Company of his status and address by written notice under this Section 4.4. Any notice shall have been deemed duly given when enclosed in a properly sealed envelope or wrapper addressed as aforesaid, deposited (with postage prepaid) in a post office or branch post office regularly maintained by the United States Postal Service.
Section 4.5    Titles. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Award Agreement.
Section 4.6    Conformity to Securities Laws. This Award Agreement is intended to conform to the extent necessary with all provisions of the Securities Act and the Exchange Act and any and all regulations and rules promulgated by the Securities and Exchange Commission thereunder, including without limitation Rule 16b-3. Notwithstanding anything herein to the contrary, this Award Agreement shall be administered, and the Restricted Stock shall be issued, only in such a manner as to conform to such laws, rules and regulations. To the extent permitted by applicable law, this Award Agreement and the Restricted Stock issued hereunder shall be deemed amended to the extent necessary to conform to such laws, rules and regulations.
Section 4.7    Amendment. This Award Agreement may be amended only by a writing executed by the parties hereto which specifically states that it is amending this Award Agreement.
Section 4.8    Governing Law. The laws of the State of Delaware shall govern the interpretation, validity, administration, enforcement and performance of the terms of this Award Agreement regardless of the law that might be applied under principles of conflicts of laws.
Section 4.9 Electronic Delivery and Acceptance. Participant hereby consents to receive the Notice of Grant of Award and Award Agreement and any other documents related to this award or future awards by electronic delivery and to accept this or future awards through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. Participant acknowledges that he/she has read, understand and agrees to the terms of the Notice of Grant of Award, Award Agreement and Plan. By clicking the “ACCEPT” button on E*TRADE’s on-line grant agreement response page, it will act as Participant’s electronic signature to these documents and will result in a contract between Integra LifeSciences Holdings Corporation and the Participant with respect to the award. In the event of any conflict or inconsistency between the terms and conditions of this Award Agreement or any other contracts or documents related to this award, on the one hand, and any terms or

Exhibit 10.3(i)
conditions set forth in the Plan, the terms and conditions set forth in the Plan shall prevail.
*****
IN WITNESS HEREOF, this Award Agreement has been executed and delivered by the parties hereto.
                                INTEGRA LIFESCIENCES
THE PARTICIPANT                        HOLDINGS CORPORATION

        
                                By                
[ ]                        Name:
                                Title:

                        


 EX-10.3(J) 6 iart-20221231xexx103j.htm EX-10.3(J) Document
Exhibit 10.3(j)

PERFORMANCE STOCK AGREEMENT
    THIS PERFORMANCE STOCK AGREEMENT (the “Award Agreement”), dated as of [          ] (the “Award Date”), is made by and between Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”), and [          ], an employee of the Company (or one or more of its Related Corporations or Affiliates), hereinafter referred to as the “Participant.”
    WHEREAS, the Company has determined to grant to the Participant an award of Performance Stock (as defined below), on the terms set forth herein, under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the “Plan”), the terms of which are hereby incorporated by reference and made part of this Award Agreement.
    NOW, THEREFORE, in consideration of the various covenants herein contained, and intending to be legally bound hereby, the parties hereto agree as follows:
ARTICLE I.
DEFINITIONS
    Capitalized terms not otherwise defined below shall have the meaning set forth in the Plan. The masculine pronoun shall include the feminine and neuter, and the singular the plural, where the context so indicates.

Section 1.1    Annual Organic Revenue. “Annual Organic Revenue” shall mean the Company’s gross revenue with respect to an applicable fiscal year excluding the effects of currency exchange rates, acquired revenues, product discontinuances and divestitures.
Section 1.2    Catch-Up Performance Goal. “Catch-Up Performance Goal” shall mean the specific goal determined by the Committee, as specified in Exhibit A.
Section 1.3    Catch-Up Shares. “Catch-Up Shares” shall have the meaning as specified in Exhibit A.
Section 1.4    Change in Control. “Change in Control” shall have the meaning set forth in the Plan.
Section 1.5    Chief Human Resources Officer. “Chief Human Resources Officer” shall mean the Chief Human Resources Officer of the Company.
Section 1.6    Good Reason. “Good Reason” shall have the meaning set forth in the Plan.
Section 1.7    Performance Goals. “Performance Goals” shall mean the specific goal or goals determined by the Committee, as specified in Exhibit A, including (if applicable) the Catch-Up Performance Goal.
Section 1.8    Performance Period. “Performance Period” shall mean the period or periods of time that the Performance Goals must be met, as specified in Exhibit A.
Section 1.9    Performance-Vest. “Performance-Vest” shall mean that, with respect to a share of Performance Stock, the applicable Performance Goal has been achieved.

Section 1.10    Performance Vesting Percentage. “Performance Vesting Percentage” shall mean the percentage determined in accordance with Exhibit A attached hereto, which is a function of whether and to what extent the Performance Goals are achieved during the Performance Period.
Section 1.11    Qualifying Termination. “Qualifying Termination” shall mean a Termination of Service by the Company without Cause or by the Participant for Good Reason.
Section 1.12    Rule 16b-3. “Rule 16b-3” shall mean that certain Rule 16b-3 under the Exchange Act, as such Rule may be amended from time to time.
Section 1.13    Termination of Service. “Termination of Service” shall mean the time when the Participant ceases to provide services to the Company and its Related Corporations and Affiliates as an employee or Associate for any reason with or without Cause, including, but not by way of limitation, a termination by resignation, discharge, death, or Disability. A Termination of Service shall not include a termination where the Participant is simultaneously reemployed by, or remains employed by, or continues to provide services to, the Company and/or one or more of its Related Corporations and Affiliates or a successor entity thereto.
Section 1.14    Vest or Vested. “Vest” or “Vested” shall mean that, with respect to a share of Performance Stock, both (i) such share of Performance Stock has Performance-Vested and (ii) the continued service condition has been satisfied.
ARTICLE II.
AWARD OF PERFORMANCE STOCK
Section 2.1    Award of Shares of Performance Stock. Effective as of the Award Date, the Company grants to the Participant an award of [          ] target shares of Performance Stock (the “Target Performance Shares”). Each share of Performance Stock represents the Participant’s right to receive one Share under this Award Agreement if the Performance Goals are met during the Performance Period and the vesting conditions set forth herein are satisfied.
Section 2.2    Forfeiture. Shares of Performance Stock shall be subject to forfeiture as provided in Section 3.2 below.
Section 2.3    Dividend Equivalents. The Participant shall be entitled to receive, with respect to each outstanding Vested but unissued share of Performance Stock, dividend equivalent amounts equal to the regular quarterly cash dividend paid or made with respect to the Shares underlying such Vested but unissued shares of Performance Stock (to the extent regular quarterly cash dividends are paid). Such dividend equivalent amounts shall be aggregated and paid to the Participant within thirty (30) days following the date on which the Shares underlying the Vested shares of Performance Stock are issued to the Participant, but in no event later than December 31 of the year in which the Shares underlying the Vested shares of Performance Stock are issued to the Participant. Notwithstanding the foregoing, if a “Change in Control” occurs prior to the date on which such dividend equivalent amounts are paid, such dividend equivalent amounts shall be paid to the Participant on the date of the Change in Control; provided, however, that such payment shall only occur if the Change in Control meets the requirements of Section 409A(a)(2)(A)(v) of the Internal Revenue Code of 1986, as amended (the “Code”) and its corresponding regulations. For the avoidance of doubt, such dividend equivalent amounts shall only be paid to the extent that the shares of Performance Stock are Vested as of the applicable dividend payment date, and the Participant shall not be entitled to receive any dividend equivalent amounts with respect to shares of Performance Stock that have not Vested as of such dividend payment date. The dividend equivalents and any amounts that may become payable in respect thereof shall be treated separately from the shares of Performance Stock and the rights
2

arising in connection therewith for purposes of the designation of time and form of payments required by Code Section 409A.
Section 2.4    Voting Rights. The Participant shall not have any voting rights in respect of the shares of Performance Stock and any Shares underlying the shares of Performance Stock unless and until such Shares shall have been issued by the Company and the Participant becomes the holder of record of such Shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company).
ARTICLE III.
RESTRICTIONS
Section 3.1    Vesting.
(a)    Subject to paragraph (b) below and Sections 3.2 and 3.5 below, shares of Performance Stock shall Vest in cumulative installments as follows:
(i)    With respect to fiscal year [          ], a number of shares of Performance Stock equal to the product of (x) thirty-three percent (33%) of the Target Performance Shares, multiplied by (y) the applicable Performance Vesting Percentage determined in accordance with Exhibit A attached hereto, shall Vest on the first anniversary of the Award Date;
(ii)    With respect to fiscal year [          ], a number of shares of Performance Stock equal to the product of (x) thirty-three percent (33%) of the Target Performance Shares, multiplied by (y) the applicable Performance Vesting Percentage determined in accordance with Exhibit A attached hereto, shall Vest on the second anniversary of the Award Date; and
(iii)    With respect to fiscal year [          ], a number of shares of Performance Stock equal to the product of (x) thirty-four percent (34%) of the Target Performance Shares, multiplied by (y) the applicable Performance Vesting Percentage determined in accordance with Exhibit A attached hereto, shall Vest on the third anniversary of the Award Date.
(b)    Subject to Sections 3.2 and 3.5 below, in the event that the Company achieves the Catch-Up Performance Goal with respect to the Performance Period, then any Catch-Up Shares shall Vest on the third anniversary of the Award Date.

Section 3.2    Effect of Termination of Service; Forfeiture.
(a)    In the event the Participant incurs, prior to or on the last day of the Performance Period, a Termination of Service by reason of the Participant’s Disability or death, any shares of Performance Stock which have not Vested in accordance with Section 3.1 above on or prior to such Termination of Service shall remain outstanding and eligible to Vest in accordance with Section 3.1 above and Section 3.5 below based on the Company’s achievement of the Performance Goals during the Performance Period.

(b)    Immediately upon the Participant’s Termination of Service that is not either (i) a Qualifying Termination within twelve (12) months following the date of a Change in Control (and prior to or on the last day of the Performance Period) or (ii) a Termination of Service by reason of the Participant’s Disability or death, the Participant shall automatically and without further action forfeit all shares of Performance Stock (and all dividend equivalent rights with respect to such shares of Performance Stock) which have not Vested in accordance with Section
3

3.1 above or Section 3.5 below on or prior to such Termination of Service, and the Participant shall have no further right to or interest in or with respect to such shares of Performance Stock (or such dividend equivalents).

(c)    Any shares of Performance Stock that do not Performance-Vest in connection with a Change in Control pursuant to Sections 3.5(a) and 3.5(b) below (and all dividend equivalent rights with respect to such shares of Performance Stock) shall thereupon automatically be forfeited as of such Change in Control, and the Participant shall have no further right to or interest in or with respect to such shares of Performance Stock (or such dividend equivalents).

(d)    Any shares of Performance Stock that fail to vest as of the third anniversary of the Award Date (and all dividend equivalent rights with respect to such Performance Stock) shall automatically and without further action be cancelled and forfeited, and the Participant shall have no further right to or interest in or with respect to such unvested shares of Performance Stock (or such dividend equivalents).

Section 3.3    Issuance of Shares.
(a)    Subject to a determination of the Committee as to whether and to what extent the applicable Performance Goals have been met, Shares represented by shares of Performance Stock which Vest pursuant to Section 3.1 above or Section 3.5 below shall be issued to the Participant or his or her legal representative on or within five (5) business days following the date on which such shares of Performance Stock Vest pursuant to Section 3.1 above or Section 3.5 below (but in no event later than December 31 of the applicable year in which such shares of Performance Stock Vest).

(b)    All Shares issued hereunder shall be issued in certificated form or shall be recorded with the Company’s transfer agent. All such Shares shall be issued free from any restrictions; provided, however, that such Shares shall be subject to any restrictions and conditions as may be required pursuant to Section 4.6 below and those that the Company imposes on its employees in general with respect to selling its Shares. Notwithstanding the foregoing, the Company shall not be required to issue or record such Shares in the name of the Participant or his or her legal representative unless the Participant or his or her legal representative shall have satisfied the full amount of all federal, state and local withholding or other employment taxes applicable to the taxable income of the Participant resulting from the vesting of the shares of Performance Stock and issuance of the Shares as provided in this Award Agreement (including, without limitation, in the manner set forth in Section 4.3 below).

Section 3.4    Clawback. Notwithstanding anything contained in the Plan or the Award Agreement to the contrary, the shares of Performance Stock, and any related payments, shall be subject to the provisions of any clawback, repayment or recapture policy implemented by the Company, including any such policy adopted to comply with applicable law (including without limitation the Dodd-Frank Wall Street Reform and Consumer Protection Act) or securities exchange listing standards and any rules or regulations promulgated thereunder, to the extent set forth in such policy and/or in any notice or agreement relating to the shares of Performance Stock under the Plan.
Section 3.5    Change in Control. In the event that a Change in Control occurs during the Performance Period:
(a)    A number of shares of Performance Stock shall Performance-Vest equal to a number determined at the greater of (i) the achievement of the “Target Level” Performance Vesting Percentage with respect to the fiscal year in which the Change in Control occurs, as
4

specified in Exhibit A attached hereto and (ii) the Company’s actual achievement of the Performance Goal for such year through the Change in Control. Subject to Sections 3.5(d) and (e) below, such Performance-Vested shares of Performance Stock shall remain outstanding and eligible to Vest on the anniversary of the Award Date immediately following the Change in Control, subject to the Participant’s continuous service.
(b)    In addition, and subject to Sections 3.5(d) and (e) below, a number of shares of Performance Stock shall Performance-Vest equal to the number of shares of Performance Stock that could vest with respect to each fiscal year of the Performance Period following the fiscal year in which the Change in Control occurs (if any) based on the achievement of the “Target Level” Performance Vesting Percentage with respect to each such year, as specified in Exhibit A, and shall remain outstanding and eligible to Vest on the date(s) outlined in Section 3.1(a)(ii) and/or (iii) (excluding any Catch-Up Shares which are forfeited in the event of a Change in Control), subject to the Participant’s continued service.
(c)    In addition, if the Change in Control occurs following the completion of a fiscal year in the Performance Period but prior to the date on which shares of Performance Stock with respect to such year become Vested pursuant to Section 3.1(a) above, then such shares of Performance Stock shall Vest as of immediately prior to the Change in Control in a number determined in accordance with Section 3.1(a) above.
(d)    If the Participant incurred a Termination of Service by reason of the Participant’s Disability or death, in either case, prior to the Change in Control date, then any shares of Performance Stock that Performance-Vest in accordance with Sections 3.5(a) and (b) above shall Vest as of immediately prior to the Change in Control.
(e)     Notwithstanding Sections 3.5(a) and 3.5(b) above, if the Participant incurs (1) a Qualifying Termination on or within twelve (12) months following the date of a Change in Control and prior to or on the last day of the Performance Period, or (2) a Termination of Service by reason of the Participant’s Disability or death on or following a Change in Control and prior to or on the last day of the Performance Period, then in either case any Performance-Vested shares of Performance Stock that are then-outstanding and have not yet Vested shall Vest in full upon such Termination of Service.
ARTICLE IV.
MISCELLANEOUS
Section 4.1    No Additional Rights. Nothing in this Award Agreement or in the Plan shall confer upon any person any right to a position as an Associate or continued employment by the Company or any of its Related Corporations or Affiliates or affect in any way the right of any of the foregoing to terminate the services of an individual at any time.
Section 4.2    Anti-Assignment. The Participant shall have no right to sell, assign, transfer, pledge, or otherwise encumber or dispose of the Participant’s award of shares of Performance Stock.
Section 4.3    Tax Withholding. In satisfaction of all applicable requirements with respect to amounts required by federal, state or local tax law to be withheld with respect to the vesting, distribution or payment of the shares of Performance Stock, the Company shall withhold Shares otherwise issuable upon such distribution or payment of the shares of Performance Stock having a Fair Market Value equal to the sums required to be withheld. Subject to the following sentence, the number of Shares which shall be so withheld in order to satisfy the Participant’s federal, state and local withholding tax liabilities with respect to the vesting of the shares of Performance Stock or issuance of Shares in payment of the shares of Performance Stock shall be
5

limited to the number of Shares which have a Fair Market Value on the date of issuance equal to the aggregate amount of such liabilities based on the minimum statutory withholding rates for federal, state and local tax purposes that are applicable to, and required in connection with, all or a portion of such supplemental taxable income. In the event that the number of Shares having a Fair Market Value equal to the sums required to be withheld is not a whole number of Shares, the number of Shares so withheld shall be rounded up to the nearest whole share.
Section 4.4    Notices. Any notice to be given under the terms of this Award Agreement to the Company shall be addressed to the Company in care of its Chief Human Resources Officer, and any notice to be given to the Participant shall be addressed to the Participant at his or her address of record maintained by the Human Resources Department. By a notice given pursuant to this Section 4.4, either party may hereafter designate a different address for notices to be given to it or him. Any notice which is required to be given to the Participant shall, if the Participant is then deceased, be given to the Participant’s personal representative if such representative has previously informed the Company of his or her status and address by written notice under this Section 4.4. Any notice shall have been deemed duly given when enclosed in a properly sealed envelope or wrapper addressed as aforesaid, deposited (with postage prepaid) in a post office or branch post office regularly maintained by the United States Postal Service.
Section 4.5    Titles. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Award Agreement.
Section 4.6    Conformity to Securities Laws. This Award Agreement is intended to conform to the extent necessary with all provisions of the Securities Act and the Exchange Act and any and all regulations and rules promulgated by the Securities and Exchange Commission thereunder, including, without limitation, Rule 16b-3. Notwithstanding anything herein to the contrary, this Award Agreement shall be administered, and the shares of Performance Stock shall be issued, only in such a manner as to conform to such laws, rules and regulations. To the extent permitted by applicable law, this Award Agreement and the shares of Performance Stock issued hereunder shall be deemed amended to the extent necessary to conform to such laws, rules and regulations.
Section 4.7    Amendment. This Award Agreement may be amended only by a writing executed by the parties hereto which specifically states that it is amending this Award Agreement.
Section 4.8    Governing Law. The laws of the State of Delaware shall govern the interpretation, validity, administration, enforcement and performance of the terms of this Award Agreement regardless of the law that might be applied under principles of conflicts of laws.
Section 4.9    Section 409A. This Award Agreement shall be interpreted in accordance with the requirements of Section 409A of the Code. Notwithstanding any provision in this Award Agreement to the contrary, if a payment is deemed to be deferred compensation subject to the requirements of Section 409A of the Code, such payment may only be made under this Award Agreement upon an event and in a manner permitted by Section 409A of the Code. If a payment is not made by the designated payment date under this Award Agreement, the payment shall be made by December 31 of the calendar year in which the designated date occurs. In no event may the Participant, directly or indirectly, designate the calendar year of payment. A termination of service shall not be deemed to have occurred for purposes of any provision of this Award Agreement providing for the payment of any amounts or benefits upon or following a termination of service that are considered “nonqualified deferred compensation” under Section 409A of the Code unless such termination is also a “separation from service” within the meaning of Section 409A of the Code and, for purposes of any such provision of this award Agreement, references to a “termination,” “Termination of Service” or like terms shall mean “separation
6

from service.” Notwithstanding anything to the contrary in this Award Agreement, no amounts payable to the Participant under this Award Agreement shall be paid to the Participant prior to the expiration of the 6-month period following the Participant’s “separation from service” if the Company determines that paying such amounts at the time or times indicated in this Award Agreement would be a prohibited distribution under Section 409A(a)(2)(b)(i) of the Code. If the payment of any such amounts is delayed as a result of the previous sentence, then on the first day following the end of such 6-month period, the Company shall pay the Participant a lump-sum amount equal to the cumulative amount that would have otherwise been payable to the Participant during such 6-month period.
Section 4.10    Electronic Delivery and Acceptance. Participant hereby consents to receive the Notice of Grant of Award and Award Agreement and any other documents related to this award or future awards by electronic delivery and to accept this or future awards through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. Participant acknowledges that he/she has read, understand and agrees to the terms of the Notice of Grant of Award, Award Agreement and Plan. By clicking the “ACCEPT” button on E*TRADE’s on-line grant agreement response page, it will act as Participant’s electronic signature to these documents and will result in a contract between Integra LifeSciences Holdings Corporation and the Participant with respect to the award. In the event of any conflict or inconsistency between the terms and conditions of this Award Agreement or any other contracts or documents related to this award, on the one hand, and any terms or conditions set forth in the Plan, the terms and conditions set forth in the Plan shall prevail.

[Signature page follows]

7

    IN WITNESS WHEREOF, the parties hereto have executed this Performance Stock Agreement as of the date first above written.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION


THE PARTICIPANT    
Electronic signature to be provided
and recorded via online grant
acceptance process on www.etrade.com



                    
INTEGRA LIFESCIENCES
HOLDINGS CORPORATION

                       

By                    
Name:
Title:


    





EXHIBIT A
PERFORMANCE GOALS AND PERFORMANCE PERIOD
Capitalized terms shall have the meaning set forth in Performance Stock Agreement.
The “Performance Period” shall be the three-year period beginning [          ] and ending [          ].
The “Catch-Up Performance Goal” shall mean that the Company achieves, as of the end of the Performance Period (but not due to a Change in Control), an average 3-year Annual Organic Revenue growth rate of at least [          ]%.
With respect to each fiscal year in the Performance Period, the “Performance Goal” is that the Company achieves a Threshold Level or higher level of growth in Annual Organic Revenue over the immediately preceding fiscal year, as set forth in the table below. A number of shares of Performance Stock will Performance-Vest in accordance with Section 3.1 of the Performance Stock Agreement based on the percentage growth in Annual Organic Revenue over the immediately preceding fiscal year:
  Growth in Annual Organic Revenue over the Prior Fiscal Year (%)Performance Vesting Percentage
  [          ][          ]
“Threshold Level” [          ][          ]
“Target Level” [          ][          ]
“Maximum Level” [          ][          ]
In the event that the growth in Annual Organic Revenue over the immediately preceding fiscal year falls between the “Threshold Level” and the “Target Level,” then the Performance Vesting Percentage shall be determined by extrapolating between the “Threshold Level,” anchor points of [          ] Annual Organic Revenue growth (with a [          ] Performance Vesting Percentage) and [          ] Annual Organic Revenue growth (with an [          ] Performance Vesting Percentage), and the “Target Level.” In the event that the growth in Annual Organic Revenue over the immediately preceding fiscal year falls between the “Target Level” and the “Maximum Level,” then the Performance Vesting Percentage shall be determined by means of linear interpolation between the “Target Level,” anchor points of [          ] Annual Organic Revenue growth (with a [          ] Performance Vesting Percentage) and the “Maximum Level.”
Notwithstanding the forgoing, in the event that (i) a Change in Control does not occur during the Performance Period, (ii) the Performance Goal with respect to a given fiscal year in the Performance Period is not achieved at the applicable Target Level or higher, and (iii) the Catch-Up Performance Goal is achieved, then a number of shares of Performance Stock equal to the difference between (x) the number of shares of Performance Stock which would have Vested in the event that the Performance Goal had been achieved at the Target Level with respect to such
A-<#>

fiscal year and (y) the number of shares of Performance Stock which actually became Vested based on the applicable Performance Vesting Percentage for such fiscal year, shall become Vested in accordance with Section 3.1(b) of the Performance Stock Agreement (such number of shares, the “Catch-Up Shares”).
A-1

 EX-10.3(K) 7 iart-20221231xexx103k.htm EX-10.3(K) Document
Exhibit 10.3(k)
    

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
    2003 EQUITY INCENTIVE PLAN
    NON-QUALIFIED STOCK OPTION AGREEMENT

    NON-QUALIFIED STOCK OPTION AGREEMENT (together with the attached Notice of Grant of Stock Options and Option Agreement (“Notice of Grant”), the “Option Agreement”) made as of the date (the “Grant Date”) set forth in Notice of Grant, between Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”), and the named Key Employee of the Company, a Related Corporation, or an affiliate (the “Employee”).

    WHEREAS, the Company desires to afford the Employee an opportunity to purchase shares of common stock of the Company, par value $.01 per share (“Common Stock”), as hereinafter provided, in accordance with the provisions of the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the “Plan”). Requests for hardcopies of the “Plan” should be directed to Mythili Seshan at the New Jersey Corporate Office.

    NOW, THEREFORE, in consideration of the mutual covenants hereinafter set forth and for other good and valuable consideration the legal sufficiency of which is hereby acknowledged, the parties hereto, intending to be legally bound hereby, agree as follows:

    Capitalized terms not otherwise defined below shall have the meaning set forth in the Plan. The masculine pronoun shall include the feminine and neuter, and the singular the plural, where the context so indicates.

Grant of Option. Effective [          ], the Company hereby grants to the Employee a non-qualified stock option (the “Option”) to purchase all or any part of an aggregate of the number of shares of Common Stock as set forth in the attached Notice of Grant, subject to adjustment in accordance with Section 8 of the Plan.
Purchase Price. The purchase price per share of the shares of Common Stock covered by the Option shall be that set forth in the attached Notice of Grant, subject to adjustment in accordance with Section 8 of the Plan. It is the determination of the Company’s Compensation Committee (the “Committee”) that on the Grant Date the per share Option exercise price was not less than the greater of one hundred percent (100%) of the fair market value of the Common Stock, or the par value thereof.
Term. Unless earlier terminated pursuant to any provision of this Option Agreement, this Option shall expire on [          ] (the “Expiration Date”). Notwithstanding anything herein to the contrary, this Option shall not be exercisable after the Expiration Date.
Exercise of Option. Twenty Five percent (25%) of the shares of Stock Options shall become vested each of the first and second, third and fourth anniversaries of the grant date. Any portion of the Option that becomes exercisable in accordance with the foregoing shall remain exercisable, subject to the provisions contained in this Option Agreement, until the expiration of the term of this Option as set forth above or until other termination of the Option as set forth in this Option Agreement.

Exhibit 10.3(k)
        Notwithstanding anything contained herein, no portion of the Option which has not become vested and exercisable as of the Employee’s termination of employment or in connection with Employee’s termination of employment shall thereafter become vested or exercisable.

Method of Exercising Option. Subject to the terms and conditions of this Option Agreement, the Option may be exercised in whole or in part by written notice to the Company, at its principal office, which currently is located at 1100 Campus Road, Princeton, New Jersey 08540. Such notice shall state the election to exercise the Option, and the number of shares with respect to which it is being exercised; shall be signed by the person or persons so exercising the Option; shall, unless the Company otherwise notifies the Employee, be accompanied by the investment certificate referred to below; and shall be accompanied by payment of the full Option price of such shares.
        The Option price shall be paid to the Company: (i) in cash; (ii) in cash equivalent; (iii) in Common Stock of the Company, in accordance with Section 7.1(f)(ii) of the Plan (as in effect on the date of this Option Agreement); (iv) by delivering a properly executed notice of exercise of the Option, in accordance with Section 7.1(f)(iii) of the Plan (as in effect on the date of this Option Agreement); (v) in Common Stock of the Company issuable pursuant to the exercise of the Option or otherwise withheld in net settlement of the Option, in accordance with Section 7.1(f)(iv) of the Plan (as in effect on the date of this Option Agreement); or (vi) by any combination of (i)-(v).
        Upon receipt of such notice and payment, the Company, as promptly as practicable, shall deliver or cause to be delivered a certificate or certificates representing the shares with respect to which the Option is so exercised. Such certificate(s) shall be registered in the name of the person or persons so exercising the Option (or, if the Option is exercised by the Employee and if the Employee so requests in the notice exercising the Option, shall be registered in the name of the Employee and the Employee’s spouse, jointly, with right of survivorship) and shall be delivered as provided above to or upon the written order of the person or persons exercising the Option. In the event the Option is exercised by any person or persons after the legal disability or death of the Employee, such notice shall be accompanied by appropriate proof of the right of such person or persons to exercise the Option. All shares that are purchased upon the exercise of the Option as provided herein shall be fully paid and not assessable by the Company.
Shares to be Purchased for Investment. Unless the Company has theretofore notified the Employee that a registration statement covering the shares to be acquired upon the exercise of the Option has become effective under the Securities Act of 1933 and the Company has not thereafter notified the Employee that such registration statement is no longer effective, it shall be a condition to any exercise of this Option that the shares acquired upon such exercise be acquired for investment and not with a view to distribution, and the person effecting such exercise shall submit to the Company a certificate of such investment intent, together with such other evidence supporting the same as the Company may request. The Company shall be entitled to delay the transferability of the shares issued upon any such exercise to the extent necessary to avoid a risk of violation of the Securities Act of 1933 (or of any rules or regulations promulgated thereunder) or of any state laws or regulations. Such restrictions may, at the option of the Company, be noted or set forth in full on the share certificates.
Non-Transferability of Option. This Option is not assignable or transferable, in whole or in part, by the Employee other than by will or by the laws of descent and distribution, and during the lifetime of the Employee the Option shall be exercisable only by the Employee or by his or her guardian or legal representative.

Exhibit 10.3(k)
Termination of Employment. If the Employee’s employment with the Company and all Related Corporations is terminated prior to the Expiration Date for any reason other than by (i) death or disability or (ii) a Qualifying Termination upon a Change in Control as further described below, this Option may be exercised, to the extent of the number of shares with respect to which the Employee could have exercised it on the date of such termination of employment, or to any greater extent permitted by the Committee, by the Employee at any time prior to the earlier of (i) the Expiration Date or (ii) six (6) months after such termination of employment.
Death. Notwithstanding anything contained in this Option Agreement to the contrary, if the Employee dies during his employment with the Company and Related Corporations and prior to the Expiration Date, the Option shall become fully vested and exercisable and such Option upon such death can be exercised by the Employee’s estate, personal representative or beneficiary who acquired the right to exercise such Option by bequest or inheritance or by reason of the Employee’s death, at any time prior to the earlier of (i) the Expiration Date or (ii) one year after the date of the Employee’s death.
Disability. Notwithstanding anything contained in this Option Agreement to the contrary, if the Employee incurs a disability, as defined in the Plan, during his employment with the Company and Related Corporations and, prior to the Expiration Date, the Employee’s employment is terminated as a consequence of such disability, this Option shall become fully vested and exercisable and such Option upon such termination due to such Disability can be exercised by the Employee, or in the event of the Employee’s legal disability, by the Employee’s legal representative, at any time prior to the earlier of (i) the Expiration Date or (ii) one year after the date of such termination of employment due to such Disability.
Double Trigger Change in Control. Notwithstanding anything contained in this Option Agreement to the contrary, if during the Employee’s employment with the Company and Related Corporations and prior to the Expiration Date, a Change in Control occurs and the Employee incurs a Qualifying Termination on or within twelve (12) months following the date of such Change in Control, this Option shall become fully vested and exercisable and such Option upon such Qualifying Termination can be exercised by the Employee at any time prior to the Expiration Date.
Clawback Notwithstanding anything contained in the Plan or the Option Agreement to the contrary, the Option shall be subject to the provisions of any clawback, repayment or recapture policy implemented by the Company, including any such policy adopted to comply with applicable law (including without limitation the Dodd-Frank Wall Street Reform and Consumer Protection Act) or securities exchange listing standards and any rules or regulations promulgated thereunder, to the extent set forth in such policy and/or in any notice or agreement relating to the Option under the Plan.
Withholding of Taxes. The obligation of the Company to deliver shares of Common Stock upon the exercise of the Option shall be subject to applicable federal, state and local tax withholding requirements. If the exercise of any Option is subject to the withholding requirements of applicable federal, state or local tax laws, the Committee, in its discretion, may permit the Employee, subject to the provisions of the Plan and such additional withholding rules (the “Withholding Rules”) as shall be adopted by the Committee, to satisfy the withholding tax, in whole or in part, by electing to have the Company withhold (or by returning to the Company) shares of Common Stock, which shares shall be valued, for this purpose, at their fair market value on the date of exercise of the Option (or, if later, the date on which the Employee recognizes ordinary income

Exhibit 10.3(k)
with respect to such exercise). An election to use shares of Common Stock to satisfy tax withholding requirements must be made in compliance with and subject to the Withholding Rules. The Committee may not withhold shares in excess of the number necessary to satisfy the minimum tax withholding requirements.
Construction. This Option Agreement is made under and subject to the provisions of the Plan as in effect on the Grant Date, and all of the provisions of the Plan as in effect on the Grant Date are hereby incorporated herein as provisions of this Option Agreement.
Governing Law. This Non-Qualified Stock Option Agreement shall be governed by applicable federal law and otherwise by the laws of the State of Delaware.

    IN WITNESS WHEREOF, this Option Agreement has been executed and delivered by the parties hereto.

THE PARTICIPANT    
Electronic signature to be provided
and recorded via online grant
acceptance process on www.etrade.com



                
INTEGRA LIFESCIENCES
HOLDINGS CORPORATION

    
By                    
Name:
Title:


EX-10.3(L) 8 iart-20221231xexx103l.htm EX-10.3(L) Document
Exhibit 10.3(l)

RESTRICTED STOCK UNIT AWARD AGREEMENT FOR PARTICIPANTS OUTSIDE THE UNITED STATES
THIS RESTRICTED STOCK UNIT AWARD AGREEMENT including any exhibit, appendix or addendum hereto (the “Award Agreement”), dated as of [          ] (the “Award Date”), is made by and between Integra LifeSciences Holdings Corporation, a Delaware corporation (the “Company”), and [          ] hereinafter referred to as the “Participant,” a Key Employee or Associate (as defined in the Plan).
WHEREAS, the Company has established and maintains the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended from time to time (the “Plan”);
WHEREAS the Company has determined that it would be to the advantage and best interest of the Company and its shareholders to grant an award of Restricted Stock Units (“RSUs”) provided for herein to the Participant as an incentive for increased efforts during the Participant’s employment with or services for the Company or its Related Corporations or Affiliates;
WHEREAS, Restricted Stock Units can be granted, and the shares of common stock of the Company (the “Shares”) subject to the RSUs can be issued, under Section 7.8 of the Plan; and
NOW, THEREFORE, in consideration of the various covenants herein contained, and intending to be legally bound hereby, the parties hereto agree as follows:
ARTICLE I.
DEFINITIONS
Capitalized terms not otherwise defined below shall have the meaning set forth in the Plan. The masculine pronoun shall include the feminine and neuter, and the singular the plural, where the context so indicates.
Section 1.1    “Award Date” shall have the meaning set forth in the recitals.
Section 1.2    “Cause” shall mean, with respect to any Participant, “Cause” as defined in such Participant’s employment agreement or severance agreement with the Company if such an agreement exists and contains a definition of Cause or, if no such agreement exists or such agreement does not contain a definition of Cause, then Cause shall mean (i) the Participant’s neglect of duties or responsibilities that he or she is required to perform for the Company or any willful failure by the Participant to obey a lawful direction of the Board or the Company; (ii) the Participant’s engaging in any act of dishonesty, fraud, embezzlement, misrepresentation or other act of moral turpitude; (iii) the Participant’s knowing violation of any federal or state law or regulation applicable to the Company’s business; (iv) the Participant’s material breach of any confidentiality, non-compete agreement or invention assignment agreement or any other material agreement between the Participant and the Company; (v) the Participant’s conviction of, or plea of nolo contendere to, any felony or crime of moral turpitude which conviction or plea is materially and demonstrably injurious to the Company or any of its subsidiaries; (vi) failure by the Participant to comply with the Company’s material written policies or rules; or (vii) the Participant’s act or omission in the course of his or her employment which constitutes gross negligence or willful misconduct.

Exhibit 10.3(l)
Section 1.3    “Plan” shall have the meaning set forth in the recitals.
Section 1.4    “Restricted Stock Units” or “RSUs” shall mean a conditional right to receive Shares pursuant to the terms of the Plan and this Award Agreement upon vesting and settlement, subject to the Participant’s continued employment through each vesting date set forth in the Notice of Grant of Award, unless otherwise set forth in this Award Agreement.
Section 1.5    “Rule 16b-3” shall mean that certain Rule 16b-3 under the U.S. Exchange Act, as such Rule may be amended from time to time.
Section 1.6    “Secretary” shall mean the Secretary of the Company.
Section 1.7    “Service Recipient” shall mean the Company, Related Corporation or Affiliate with which the Participant has an employment or service relationship.
Section 1.8    “Termination Date” shall mean the date the Participant is no longer actively providing services to the Company, a Related Corporation or Affiliate (regardless of the reason for such termination and whether or not later found to be invalid or in breach of applicable laws in the jurisdiction where the Participant is employed or rendering services or the terms of the Participant’s employment or service agreement, if any) and, unless otherwise expressly provided for in this Award Agreement or determined by the Company, will not be extended by any notice period (e.g., the Participant’s period of employment or service will not include any contractual notice period or any period of “garden leave” or similar period mandated under applicable laws in the jurisdiction where the Participant is rendering services or the terms of the Participant’s employment or service agreement, if any). The Committee shall have the exclusive discretion to determine when the Participant’s service is terminated for purposes of this Award of RSUs (including when the Participant is no longer considered to be providing service while on a leave of absence).
ARTICLE II.
GRANT OF RESTRICTED STOCK UNITS AND ISSUANCE OF SHARES
Section 2.1    Grant of RSUs. The Company hereby grants [          ] RSUs to the Participant as of the Award Date, in accordance with and subject to the terms, conditions and restrictions of this Award Agreement and the Plan. RSUs shall be credited to an account maintained for the Participant on the books of the Company, as of the Award Date.
Section 2.2    Vesting of RSUs. Subject to the terms and conditions of this Award Agreement and the Plan, 33% of the RSUs awarded hereunder shall vest on each of the first and second anniversary of the Award Date and 34% will vest on the third anniversary of the Award Date (each a “Vesting Date”) provided the Participant remains a Key Employee or Associate from the Award Date until the Vesting Date.
Section 2.3    Termination of Service (other than by (i) Death or Disability or (ii) a Qualifying Termination on or Following a Change in Control). Upon the Participant’s termination of service prior to the Vesting Date, other than by (i) death or Disability or (ii) a Qualifying Termination on or within twelve months following the date of a Change in Control and, except as otherwise determined by the Compensation Committee of the Company (the “Committee”), any RSUs granted to the Participant under this Award Agreement which have not yet vested on the Termination Date shall terminate without payment and shall be of no further force or effect from and after the Termination Date.
Section 2.4    Death or Disability. If a Participant dies or suffers a Disability prior to the Vesting Date, all RSUs held by the Participant immediately prior to death or Disability,

Exhibit 10.3(l)
which have not yet vested at the time of death or Disability, shall become fully vested and all forfeiture restrictions thereon shall lapse upon such death or Disability.
Section 2.5    Change in Control. In the event that a Change in Control occurs and the Participant incurs a Qualifying Termination on or within twelve (12) months following the date of such Change in Control, the RSUs shall become fully vested and all forfeiture restrictions shall lapse upon such Qualifying Termination.
Section 2.6    Acceleration of Vesting. Notwithstanding the provisions of Sections 2.2, 2.3, 2.4, and 2.5, the Committee may, in its sole discretion, at any time prior to or following the events contemplated in such Sections, permit the vesting of any or all RSUs held by the Participant and the issuance of Shares in respect of such RSUs in the manner and on the terms authorized by the Committee, provided that the Committee will not, in any case, authorize the vesting of an RSU or the issuance of a Share pursuant to this Section beyond the Vesting Date. If so accelerated, such RSUs will be considered as having vested as of the date specified by the Committee. If the Participant is a U.S. taxpayer, the payment of Shares upon vesting pursuant to this Section 2.6 shall in all cases be paid at a time or in a manner that is exempt from, or complies with, Section 409A. The prior sentence may be superseded in a future agreement or amendment to this Award Agreement only by direct and specific reference to such sentence. Notwithstanding anything in the Plan or this Award Agreement or any other agreement (whether entered into before, on or after the Award Date), if the vesting of the balance, or some lesser portion of the balance, of the RSUs is accelerated in connection with the Participant’s termination of service (provided that such termination is a “separation from service” within the meaning of Section 409A, as determined by the Company), other than due to the Participant’s death, and if (x) the Participant is a U.S. taxpayer and a “specified employee” within the meaning of Section 409A at the time of such termination of service and (y) the payment of such accelerated RSUs will result in the imposition of additional tax under Section 409A if paid to the Participant on or within the six (6) month period following the Participant’s termination of service, then the payment of such accelerated RSUs will not be made until the date six (6) months and one (1) day following the date of Participant’s termination of service, unless the Participant dies following his or her termination of service, in which case, the RSUs will be paid in Shares to the Participant’s estate as soon as practicable following his or her death.
Section 2.7    Settlement. On or as soon as administratively practicable (and any event within 30 days) following each Vesting Date, the Company shall cause to be issued to the Participant Shares with respect to the RSUs that become vested on such Vesting Date.
Section 2.8    Fractions. No fractional Share will be issued pursuant to an award granted hereunder. The number of Shares issuable to the Participant upon payment of any award granted under this Award Agreement will be rounded down to the nearest whole number of Share. No payment or other adjustment will be made with respect to the fractional Share so disregarded.
Section 2.9    Section 409A. It is the intent of this Award Agreement that it and all payments and benefits to U.S. taxpayers hereunder be exempt from, or comply with, the requirements of Section 409A so that none of the RSUs provided under this Award Agreement or Shares issuable thereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to be so exempt or so comply. Each payment payable under this Award Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). However, in no event will the Company reimburse the Participant, or be otherwise responsible for, any taxes or costs that may be imposed on the Participant as a result of Section 409A.

Exhibit 10.3(l)
Section 2.10    Adjustments to Restricted Stock Units. In the event of any subdivision, consolidation, stock dividend, capital reorganization, reclassification, exchange, or other change with respect to the Shares, or a consolidation, amalgamation, merger, spin-off, sale, lease or exchange of all or substantially all of the property of the Company or other distribution of the Company's assets to stockholders (other than the payment of ordinary cash dividends), the account of the Participant and the RSUs held by the Participant shall be adjusted in such manner, if any, as the Committee may in its discretion deem appropriate to preserve, proportionally, the interests of the Participant under the Plan.
Section 2.11    Forfeiture/Clawback. Notwithstanding anything contained in the Plan or the Award Agreement to the contrary, the RSUs shall be subject to the provisions of any clawback, repayment or recapture policy implemented by the Company, including any such policy adopted to comply with applicable law (including without limitation the Dodd-Frank Wall Street Reform and Consumer Protection Act) or securities exchange listing standards and any rules or regulations promulgated thereunder, to the extent set forth in such policy and/or in any notice or agreement relating to the RSUs under the Plan.
ARTICLE III.
ADDITIONAL TERMS AND CONDITIONS
Section 3.1    Status of Plan. The terms of the Plan are incorporated by reference into, and made part of, this Award Agreement. In the event of a conflict between the Plan and this Award Agreement, the terms of the Plan shall govern.
Section 3.2    Committee’s Authority. The Committee shall have the power to interpret the Plan and this Award Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret or revoke any such rules (including, but not limited to, the determination of whether or not any RSUs have vested). All actions taken and all interpretations and determinations made by the Committee in good faith shall be final and binding upon the Participant, the Company and all other interested persons. The Committee shall not be personally liable for any action, determination or interpretation made in good faith with respect to the Plan or this Award Agreement. The Committee shall, in its absolute discretion, determine when such conditions have been fulfilled.
Section 3.3    Nature of Grant. By accepting the grant of the RSUs, the Participant acknowledges, understands and agrees that:
(i)    the Plan is established voluntarily by the Company, is discretionary in nature and may be modified, amended, suspended or terminated by the Company at any time to the extent permitted in the Plan;
(ii)    the grant of the RSUs is exceptional voluntary and occasional and does not create any contractual or other right to receive future grants of RSUs or benefits in lieu of RSUs, even if RSUs have been awarded in the past;
(iii)    all decisions with respect to future grants of RSUs, if any, will be at the sole discretion of the Company;
(iv)    the Participant is voluntarily participating in the Plan;
(v)    the grant of the RSUs and any Shares subject to the RSUs, and the income from and value of same, are not intended to replace any pension rights or compensation;

Exhibit 10.3(l)
(vi)    unless otherwise agreed with the Company in writing, the RSUs and the Shares subject to the RSUs, and the income from and value of same, are not granted as consideration for, or in connection with, any service the Participant may provide as a director of a Related Corporation or an Affiliate;
(vii)    the award of the RSUs and the Shares subject to the RSUs, and the income from and value of same are not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, end of service payments, bonuses, holiday pay, long-service awards, pension or retirement or welfare benefits or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Company or any Related Corporation or Affiliate;
(viii)    the future value of the Shares underlying the RSUs is unknown, indeterminable and cannot be predicted with certainty;
(ix)    no claim or entitlement to compensation or damages shall arise from forfeiture of the RSUs resulting from the Participant’s termination of employment, or other service relationship (for any reason whatsoever and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where the Participant is employed or the terms of the Participant’s employment agreement, if any);
(x)    neither the Company, the Service Recipient nor any other Related Corporation or Affiliate shall be liable for any exchange rate fluctuation between the Participant’s local currency and the U.S. Dollar that may affect the value of the RSUs or of any amounts due to the Participant pursuant to the vesting and settlement of the RSUs or the subsequent sale of any Shares acquired upon settlement; and
(xi)    the Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding the Participant’s participation in the Plan or sale of the Shares acquired upon vesting and settlement of the RSUs. The Participant should consult with his or her own personal tax, legal and financial advisors regarding his or her participation in the Plan before taking any action related to the Plan.
Section 3.4    Responsibility for Taxes. The Participant acknowledges that, regardless of any action taken by the Company or, if different, the Service Recipient, the ultimate liability for all income tax, social insurance, payroll tax, fringe benefits tax, payment on account, and other tax-related items related to the Participant’s participation in the Plan and legally applicable to the Participant or deemed applicable to the Participant (“Tax-Related Items”) is and remains Participant’s responsibility and may exceed the amount, if any, actually withheld by the Company or the Service Recipient. The Participant further acknowledges that the Company and/or the Service Recipient (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the RSUs or the underlying Shares, including, but not limited to, the grant, vesting or settlement of the RSUs, the subsequent sale of Shares acquired pursuant to such settlement and the receipt of any dividends or other distributions paid on the Shares, and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the RSUs to reduce or eliminate the Participant’s liability for Tax-Related Items or achieve any particular tax result. Further, if the Participant is subject to Tax-Related Items in more than one jurisdiction, the Participant acknowledges that the Company and/or the Service Recipient (or former service recipient, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
(i)    Tax Withholding. Prior to any relevant taxable or tax withholding event, as applicable, the Participant agrees to make arrangements satisfactory to the Company and the

Exhibit 10.3(l)
Service Recipient to satisfy any applicable withholding obligations the Company or the Service Recipient may have for Tax-Related Items. In this regard, the Participant authorizes the Company and the Service Recipient, as applicable, and their respective agents, at their discretion, to satisfy any applicable withholding obligation for Tax-Related Items by one or a combination of the following:
(a)    withholding from wages or other cash compensation payable to the Participant by the Company or any Service Recipient;
(b)    requiring the Participant to tender a cash payment or make a payment in a form acceptable to the Company or the Service Recipient;
(c)    withholding from proceeds of the sale of Shares to be issued upon vesting of the RSUs either through a voluntary sale or through a mandatory sale arranged by the Company (on the Participant’s behalf pursuant to this authorization without further consent);
(d)    withholding in Shares to be issued upon vesting of the RSUs (in which case the Participant will be deemed to have been issued the full number of Shares subject to the vested portion of the RSUs, notwithstanding that a number of the Shares are held back solely for the purpose of paying the Tax-Related Items); and
(e)    any other method acceptable to the Company and to the extent required under the Plan and applicable laws, approved by the Committee.
The Company and/or the Service Recipient may withhold or account for Tax-Related Items by considering statutory withholding rates or other applicable withholding rates, including minimum or maximum rates applicable in the Participant’s jurisdiction(s). In the event of over-withholding or if the maximum applicable rate for the Participant’s jurisdiction is used in connection with the withholding methods described in (c) or (d) above, the Participant may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent amount in Shares), or if not refunded, the Participant may be able to seek a refund from the applicable tax authorities. In the event of under-withholding, the Participant may be required to pay additional Tax-Related Items directly to the applicable tax authorities or to the Company and/or the Service Recipient. If any applicable withholding obligation for Tax-Related Items is satisfied by withholding in Shares, for tax purposes, the Participant will be deemed to have been issued the full number of Shares subject to the vested RSUs, notwithstanding that a number of the Shares is held back solely for the purpose of paying the Tax-Related Items. The Participant agrees to pay to the Company or the Service Recipient any amount of Tax-Related Items that the Company or the Service Recipient may be required to withhold or account for as a result of the Participant’s participation in the Plan that cannot be satisfied by the means previously described. The Company may refuse to deliver the Shares or the proceeds of the sale of Shares, if the Participant fails to comply with the Participant’s obligations for Tax-Related Items.
(ii)    Tax Consequences. The Participant has reviewed with his or her own tax advisors the applicable tax consequences of this investment and the transactions contemplated by this Award Agreement. With respect to such matters, the Participant relies solely on such advisors and not on any statements or representations of the Company or any of its agents, written or oral.
Section 3.5    Restricted Stock Units Non-Transferable. Except to the limited extent provided in Section 2, this Award and the rights and privileges conferred hereby will not be transferred, assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and will not be subject to sale under execution, attachment or similar process. Upon any attempt to transfer, assign, pledge, hypothecate or otherwise dispose of this Award, or any

Exhibit 10.3(l)
right or privilege conferred hereby, or upon any attempted sale under any execution, attachment or similar process, this Award and the rights and privileges conferred hereby immediately will become null and void.
Section 3.6    Unfunded and Unsecured Plan. The Participant acknowledges that the Plan is unfunded and the Company’s obligations under the Plan and this Award Agreement are unsecured and that, to the extent the Participant or his or her estate holds any rights by virtue of a grant of RSUs, such rights shall be no greater than the rights of an unsecured creditor of the Company.
Section 3.7    No Stockholder Rights. Under no circumstances shall RSUs be considered Shares or other securities of the Company, nor shall they entitle the Participant to exercise voting rights, to receive dividends or other distributions or credit therefor, or to exercise or receive any other rights attaching to the ownership of Shares or other securities of the Company, nor shall the Participant be considered the owner of Shares by virtue of the award of RSUs.
Section 3.8    No Guarantee of Continued Employment. THE PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE VESTING OF THE RESTRICTED STOCK UNITS PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS AN EMPLOYEE OR SERVICE PROVIDER AT THE WILL OF THE COMPANY (OR, IF DIFFERENT, THE SERVICE RECIPIENT) AND NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS AWARD OF RESTRICTED STOCK UNITS OR, AS APPLICABLE, ACQUIRING SHARES HEREUNDER. THE PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH IN THE NOTICE OF GRANT OF AWARD DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS AN EMPLOYEE OR SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH THE PARTICIPANT’S RIGHT OR THE RIGHT OF THE COMPANY (OR SUBSIDIARY EMPLOYING THE PARTICIPANT) TO TERMINATE THE PARTICIPANT’S EMPLOYMENT OR SERVICE RELATIONSHIP AT ANY TIME, WITH OR WITHOUT CAUSE.
Section 3.9    Notices. Any notice to be given under the terms of this Award Agreement to the Company shall be addressed to the Company in care of its Secretary, and any notice to be given to the Participant shall be addressed to him at the address given beneath his signature hereto. By a notice given pursuant to this Section 3.9, either party may hereafter designate a different address for notices to be given to it or him. Any notice which is required to be given to the Participant shall, if the Participant is then deceased, be given to the Participant’s personal representative if such representative has previously informed the Company of his status and address by written notice under this Section 3.9. Any notice shall have been deemed duly given when enclosed in a properly sealed envelope or wrapper addressed as aforesaid, deposited (with postage prepaid) in a post office or branch post office regularly maintained by the U.S. Postal Service or comparable foreign postal service.
Section 3.10    Compliance with Laws. Notwithstanding any other provision of the Plan or this Award Agreement, unless there is an available exemption from any registration, qualification or other legal requirement applicable to the Shares, the Company shall not be required to permit the issuance and/or deliver any Shares prior to the completion of any registration or qualification of the Shares under any U.S. or non-U.S. local, state or federal securities or exchange control law or under rulings or regulations of the U.S. Securities and Exchange Commission (“SEC”) or of any other governmental regulatory body, or prior to

Exhibit 10.3(l)
obtaining any approval or other clearance from any U.S. or non-U.S. local, state or federal governmental agency, which registration, qualification or approval the Company shall, in its absolute discretion, deem necessary or advisable. The Participant understands that the Company is under no obligation to register or qualify the Shares with the SEC or any state or non-U.S. securities commission or to seek approval or clearance from any governmental authority for the issuance or sale of the Shares subject to the RSUs. Further, the Participant agrees that the Company shall have unilateral authority to amend this Award Agreement without the Participant’s consent to the extent necessary to comply with securities or other laws applicable to issuance of the Shares subject to the RSUs.
Section 3.11    Modifications to the Award Agreement. Modifications to this Award Agreement or the Plan can be made only in an express written contract executed by a duly authorized officer of the Company. Notwithstanding anything to the contrary in the Plan or this Award Agreement, the Company reserves the right to revise this Award Agreement as it deems necessary or advisable, in its sole discretion and without the consent of the Participant, to comply with Section 409A of the Code or to otherwise avoid imposition of any additional tax or income recognition under Section 409A of the Code prior to the actual issuance of Shares pursuant to this award of RSUs.
Section 3.12    Amendment, Suspension or Termination of the Plan. By accepting this Award Agreement or RSUs, the Participant expressly warrants that he or she has received an award of RSUs under the Plan, and has received, read and understood a description of the Plan. The Participant understands that the Plan is discretionary in nature and may be amended, suspended or terminated by the Company at any time.
Section 3.13    Governing Law and Venue. The laws of the State of Delaware shall govern the interpretation, validity, administration, enforcement and performance of the terms of this Award Agreement regardless of the law that might be applied under principles of conflicts of laws. For purposes of litigating any dispute that arises under this grant or this Award Agreement, the parties hereby submit to and consent to the jurisdiction of the State of New Jersey and agree that such litigation shall be conducted in the state and/or federal courts located in New Jersey, where this grant is made and/or to be performed.
Section 3.14    Assignment. Rights and obligations of the Company under this Award Agreement may be assigned by the Company to a successor in the business of the Company, any company resulting from any amalgamation, reorganization, combination, merger or arrangement of the Company, or any company acquiring all or substantially all of the assets or business of the Company.
Section 3.15    Consent to the Collection, Processing, Use and Transfer of the Participant’s Personal Data.
(a) General. The Company is located at 1100 Campus Road, Princeton New Jersey, 08540, United States of America and grants awards under the Plan to employees of the Company and Related Corporations or Affiliates in its sole discretion. In conjunction with the Company’s grant of the RSUs under the Plan to the Participant and its ongoing administration of such awards, the Company is providing the following information about its data collection, processing and transfer practices (“Personal Data Activities”). In accepting the grant of the RSUs, the Participant expressly and explicitly consents to the Personal Data Activities as described herein.

(b) Data Collection, Processing and Usage. The Company collects, processes and uses the Participant’s personal data, including the Participant’s name, home address, email address, and telephone number, date of birth, social insurance number or other identification

Exhibit 10.3(l)
number, salary, citizenship, job title, any Shares or directorships held in the Company, and details of all RSUs or any other equity compensation awards granted, canceled, exercised, vested, or outstanding in the Participant’s favor, which the Company receives from the Participant or the Service Recipient. In granting the RSUs under the Plan, the Company will collect the Participant’s personal data for purposes of allocating Shares and implementing, administering and managing the Plan. The Company’s legal basis for the collection, processing and usage of the Participant’s personal data is the Participant’s consent.

(c) Stock Plan Administration Service Provider. The Company transfers the Participant’s personal data to E*TRADE Securities LLC and its affiliated companies (“E*TRADE”), American Stock Transfer & Trust Company, LLC and its affiliated companies (“AST”), independent service providers based in the United States, which assist the Company with the implementation, administration and management of the Plan (together, the “Stock Plan Administrator”). In the future, the Company may select a different Stock Plan Administrator and share the Participant’s personal data with another company that serves in a similar manner. The Stock Plan Administrator will open an account for the Participant to receive and trade Shares acquired under the Plan. The Participant will be asked to agree on separate terms and data processing practices with the Stock Plan Administrator, which is a condition to the Participant’s ability to participate in the Plan.

(d) International Data Transfers. The Company and the Stock Plan Administrator are based in the United States. The Participant should note that the Participant’s country of residence may have enacted data privacy laws that are different from the United States. The Company’s legal basis for the transfer of the Participant’s personal data to the United States is the Participant’s consent.

(e) Voluntariness and Consequences of Consent Denial or Withdrawal. The Participant’s participation in the Plan and his or her grant of consent is purely voluntary. The Participant may deny or withdraw his or her consent at any time. If the Participant does not consent, or if the Participant later withdraws his or her consent, the Participant may be unable to participate in the Plan. This would not affect the Participant’s existing employment or salary; instead, the Participant merely may forfeit the opportunities associated with the Plan.    

(f) Data Subjects Rights. The Participant may have a number of rights under the data privacy laws in the Participant’s country of residence. For example, the Participant’s rights may include the right to (i) request access or copies of personal data the Company processes, (ii) request rectification of incorrect data, (iii) request deletion of data, (iv) place restrictions on processing, (v) lodge complaints with competent authorities in the Participant’s country of residence, and/or (vi) request a list with the names and addresses of any potential recipients of the Participant’s personal data. To receive clarification regarding the Participant’s rights or to exercise his or her rights, the Participant should contact his or her local human resources department.

Section 3.16    Electronic Delivery and Acceptance. The Participant hereby consents to receive the Notice of Grant of Award and Award Agreement and any other documents related to this award or future awards by electronic delivery and to accept this or future awards through an on-line or electronic system established and maintained by the Company or another third-party designated by the Company. The Participant acknowledges that he/she has read, understands and agrees to the terms of the Notice of Grant of Award and Award Agreement. Further, if the Participant does not decline the Award by written notice to the Company no later than 60 days following the date of grant or such other date that may be communicated by the Company, the Company will automatically accept the Award, subject to all terms and conditions set forth in the Notice

Exhibit 10.3(l)
of Grant of Award and Award Agreement and the Plan, on the Participant’s behalf. If the Participant properly declines the Award, the Award will be cancelled and the Participant will not be entitled to any benefits from the Award nor any compensation or benefits in lieu of the cancelled Award.
Section 3.17    Waivers. No waiver by either party of any breach of, or of compliance with, any condition or provision of this Award Agreement by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time.
Section 3.18    Exhibit. Notwithstanding any provisions in this Award Agreement, this Award of RSUs shall be subject to any special terms and conditions for the Participant’s country set forth in Exhibit A attached hereto. Moreover, if the Participant relocates to one of the countries included in Exhibit A, the special terms and conditions for such country will apply to the Participant, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons. Exhibit A constitutes part of this Award Agreement.
Section 3.19    Entire Agreement. The Notice of Grant of Award, this Award Agreement and the Plan constitute the entire contract between the parties hereto with regard to the subject matter hereof. They supersede any other agreements, representations or understandings (whether oral or written and whether express or implied) which relate to the subject matter hereof. The Participant expressly warrants that he or she is not accepting this Award Agreement in reliance on any promises, representations, or inducements other than those contained herein.
Section 3.20    Severability. The provisions of this Award Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.
Section 3.21    Language. If the Participant has received this Award Agreement, or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.
Section 3.22    Foreign Asset/Account Reporting Requirements, Exchange Controls and Tax Requirements. The Participant acknowledges that his or her country may have certain foreign asset and/or account reporting requirements and exchange controls which may affect his or her ability to acquire or hold Shares under the Plan or cash received from participating in the Plan (including from any dividends or sale proceeds arising from the sale of Shares) in a brokerage or bank account outside his or her country. The Participant understands that he or she may be required to report such accounts, assets or transactions to the tax or other authorities in his or her country. The Participant also may be required to repatriate sale proceeds or other funds received as a result of the Participant’s participation in the Plan to his or her country through a designated bank or broker and/or within a certain time after receipt. In addition, the Participant may be subject to tax payment and/or reporting obligations in connection with any income realized under the Plan and/or from the sale of Shares. The Participant acknowledges that it is his or her responsibility to be compliant with all such requirements, and that the Participant should consult his or her personal legal and tax advisors, as applicable, to ensure the Participant’s compliance.
Section 3.23    Insider Trading and Market-abuse Laws. The Participant acknowledges that, depending on the Participant’s or his or her broker’s country of residence or where the Shares are listed, the Participant may be subject to insider-trading restrictions and/or

Exhibit 10.3(l)
market-abuse laws, which may affect the Participant’s ability to accept, acquire, sell or otherwise dispose of Shares, rights to Shares (e.g., the RSUs), or rights linked to the value of Shares (e.g., phantom awards, futures) during such times as the Participant is considered to have “inside information” regarding the Company (as defined by law or regulations in the Participant’s country). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders the Participant placed before the Participant possessed inside information. Furthermore, the Participant could be prohibited from (i) disclosing the inside information to any third party (other than on a “need to know” basis) and (ii) “tipping” third parties, including fellow employees, or causing them otherwise to buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under the Company’s insider-trading policy. The Participant understands that it is the Participant’s responsibility to comply with any applicable restrictions as well as any Company insider trading policy, and the Participant should consult his or her personal legal advisor on this matter.
Section 3.24    Imposition of Other Requirements. The Company reserves the right to impose other requirements on the Participant’s participation in the Plan, on this award of RSUs and on any Shares received from the RSUs, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.




[SIGNATURE PAGE FOLLOWS]

Exhibit 10.3(l)

IN WITNESS HEREOF, this Award Agreement has been executed and delivered by the parties hereto.


THE PARTICIPANT    
Electronic signature to be provided
and recorded via online grant
acceptance process on www.etrade.com


                    
INTEGRA LIFESCIENCES
HOLDINGS CORPORATION




By                
Name:
Title:




Exhibit 10.3(l)
EXHIBIT A

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
FIFTH AMENDED AND RESTATED
2003 EQUITY INCENTIVE PLAN

RESTRICTED STOCK UNIT AWARD AGREEMENT
NON-U.S. AND COUNTRY-SPECIFIC PROVISIONS

Terms and Conditions
This Exhibit A includes special terms and conditions applicable to the Participant if the Participant resides and/or works outside the U.S. and, as applicable, in one of the countries listed below. These terms and conditions supplement or replace (as indicated) the terms and conditions set forth in the Restricted Stock Unit Award Agreement to which it is attached. Capitalized terms used and not defined in this Exhibit A will have the meanings set forth in the Restricted Stock Unit Award Agreement or the Plan, as applicable.

Notifications

This Exhibit A also includes information regarding tax, securities law, exchange controls and certain other issues of which the Participant should be aware with respect to his or her participation in the Plan. The information is based on the exchange control, securities and other laws in effect in the respective countries as of January 2022. Such laws are often complex and change frequently. In addition, other laws and regulations generally applicable to the acquisition, holding or disposal of securities and financial instruments as well as cross-border fund transfers may apply to the Participant. As a result, the Participant should not rely on the information noted herein as the only source of information relating to the consequences of the Participant’s participation in the Plan because the information may be out of date at the time the RSUs vest or the Participant receives or sells the Shares.

In addition, the information in this Exhibit A is general in nature and may not apply to the Participant’s particular situation. The Company is not in a position to assure the Participant of any particular result. Accordingly, the Participant should seek appropriate professional advice as to how the relevant laws in the Participant’s country apply to the Participant’s situation.

* * * * *

If the Participant is a citizen or resident of a country other than the one in which the Participant is currently residing and/or working, transfers employment and/or residency after the date of grant, or is considered a resident of another country for local law purposes, the terms and conditions and information contained herein may not be applicable to the Participant. The Company shall, in its sole discretion, determine to what extent the terms and conditions herein shall apply to the Participant in such a case.

Exhibit 10.3(l)

EUROPEAN UNION/EUROPEAN ECONOMIC AREA

Terms and Conditions

If the Participant resides and/or is employed in the European Union/European Economic Area, the following provision replaces Section 3.15 of the Award Agreement:

(a) General. The Company is located at 1100 Campus Road, Princeton, New Jersey 08540, United States of America and grants awards under the Plan to employees of the Company and its Related Corporations or Affiliates in its sole discretion. In conjunction with the Company’s grant of the RSUs under the Plan to the Participant and its ongoing administration of such awards, the Company is providing the following information about its data collection, processing and transfer practices (“Personal Data Activities”). The Participant should carefully review this information about the Company’s Personal Data Activities.

(b) Data Collection, Processing and Usage. The Company collects, processes and uses the Participant’s personal data, including the Participant’s name, home address, email address, and telephone number, date of birth, social insurance number or other identification number, salary, citizenship, job title, any Shares or directorships held in the Company, and details of all RSUs or any other equity compensation awards granted, canceled, exercised, vested, or outstanding in the Participant’s favor, which the Company receives from the Participant or the Service Recipient. In granting the RSUs under the Plan, the Company will collect the Participant’s personal data for purposes of allocating Shares and implementing, administering and managing the Plan. The Company’s legal basis for the collection, processing and usage of the Participant’s personal data is the Company legitimate interest of managing the Plan and generally administering employee equity awards granted under the Plan, and to satisfy its contractual obligations under the terms of the Award Agreement and this Exhibit A. The Participant’s refusal to provide personal data may affect the Participant’s ability to participate in the Plan.

(c) Stock Plan Administration Service Provider. The Company transfers the Participant’s personal data to E*TRADE Securities LLC and its affiliated companies (“E*TRADE”), American Stock Transfer & Trust Company, LLC and its affiliated companies (“AST”), independent service providers based in the United States, which assists the Company with the implementation, administration and management of the Plan (together, the “Stock Plan Administrator”). In the future, the Company may select a different Stock Plan Administrator and share the Participant’s personal data with another company that serves in a similar manner. The Stock Plan Administrator will open an account for the Participant to receive and trade Shares acquired under the Plan. The Participant will be asked to agree on separate terms and data processing practices with the Stock Plan Administrator, which is a condition to the Participant’s ability to participate in the Plan.

(d) International Data Transfers. The Company and the Stock Plan Administrator are based in the United States. The Participant should note that the Participant’s country of residence has enacted data privacy laws that are different from the United States. The Participant understands and acknowledges that the United States has enacted data privacy laws that are less protective or otherwise different from those applicable in the Participant’s country of residence. For example, an appropriate level of protection can be achieved by implementing safeguards such as the Standard Contractual Clauses adopted by the EU Commission. The legal basis for the transfer of the Participant’s personal data from the Participant’s country of residence to the Company in the United States and onward transfer of the Participant’s personal data by the Company to the Stock Plan Administrator will be based on the applicable

Exhibit 10.3(l)
data protection laws.1 The Participant may request a copy of such appropriate safeguards at privacy@integralife.com.

(e) Data Retention. The Company will use the Participant’s personal data only as long as necessary to implement, administer and manage the Participant’s participation in the Plan or as required to comply with legal or regulatory obligations, including, without limitation, under tax and securities laws. When the Company no longer needs the Participant’s personal data for any of the above purposes, which will generally be seven (7) years after he or she participates in the Plan, the Company will cease to use the Participant’s personal data and remove it from its systems. If the Company keeps the Participant’s personal data longer, it would be to satisfy legal or regulatory obligations and the Company’s legal basis would be relevant laws or regulations.

(f) Data Subject Rights. The Participant understands that he or she may have a number of rights under data privacy laws in the Participant’s country of residence. Subject to the conditions under applicable law and depending on where the Participant is based, such rights may include the right to (i) request access to, or copies of, the Participant’s personal data processed by the Company, (ii) rectification of incorrect personal data of the Participant, (iii) deletion of the Participant’s personal data, (iv) restrictions on the processing of the Participant’s personal data, (v) object to the processing of the Participant’s personal data for legitimate interests, (vi) portability of the Participant’s personal data, (vii) lodge complaints with competent authorities in the Participant’s country of residence, and/or to (viii) receive a list with the names and addresses of any potential recipients of the Participant’s personal data. To receive clarification regarding these rights or to exercise these rights, the Participant can contact privacy@integralife.com.

(g) Necessary Disclosure of Personal Data. The Participant understands that providing the Company with the Participant’s personal data is necessary for the performance of the Award Agreement and that the Participant’s refusal to provide the Participant’s personal data would make it impossible for the Company to perform its contractual obligations and may affect the Participant’s ability to participate in the Plan.

AUSTRALIA

Terms and Conditions

Nature of Plan and the RSUs. The Plan is a plan to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the “Act”) applies (subject to the conditions in that Act).

In addition, the offer of the RSUs is intended to comply with the provisions of the Corporations Act 2001, Australian Securities and Investments Commission (“ASIC”) Regulatory Guide 49 and ASIC Class Order 14/1000. Additional details are set forth in the Offer Document for the Offer of RSUs to Australian Resident Employees.

Notifications

Exchange Control Information. Exchange control reporting is required for cash transactions exceeding A$10,000 and international fund transfers of any amount. The Australian bank
1 NTD: Integra’s data privacy team/counsel should confirm this is consistent with the company’s approach to data privacy compliance.

Exhibit 10.3(l)
assisting with the transaction will file the report for the Participant. If there is no Australian bank involved in the transfer, the Participant will be responsible for filing the report.

BELGIUM

Notifications

Foreign Asset/Account Reporting Information. The Participant will be required to report any securities (e.g., the Shares acquired under the Plan) or bank accounts (including brokerage accounts) held outside of Belgium on the Participant’s annual tax return. The Participant will also be required to complete a separate report providing the National Bank of Belgium with details regarding any such account (including the account number, the name of the bank in which such account is held and the country in which such account is located). This report, as well as additional information on how to complete it, can be found on the website of the National Bank of Belgium, www.nbb.be, under Kredietcentrales / Centrales des crédits caption.

Stock Exchange Tax Information. A stock exchange tax applies to transactions executed by a Belgian resident through a non-Belgian financial intermediary, such as a U.S. broker. The stock exchange tax will apply when Shares acquired pursuant to the RSUs are sold. The Participant should consult with a personal tax or financial advisor for additional details on the Participant’s obligations with respect to the stock exchange tax.

Annual Securities Account Tax Information. A new “annual securities accounts tax” has been implemented, which imposes a 0.15% annual tax on the value of qualifying securities held in a Belgian or foreign securities account. The tax will not apply unless the total value of securities the Participant holds in such an account exceeds an average of €1 million on four reference dates within the relevant reporting period (i.e., December 31, March 31, June 30 and September 30). Different payment obligations may apply, depending on whether the securities account is held with a Belgian or foreign financial institution. The Participant should consult with her or her personal tax advisor for more information regarding the annual securities accounts tax payment obligations.

CANADA

Terms and Conditions

RSUs and Dividend Equivalents Payable Only in Shares. In no event will the Participant receive a cash payment in connection with the vesting and settlement of the RSUs or any dividend equivalents thereon.

Termination Date. This provision replaces Section 1.8 of the Award Agreement:

IMPORTANT: For purposes of the RSUs, in the event of the termination of the Participant’s employment or service relationship (whether or not later found to be invalid or unlawful for any reason, including for breaching either applicable employment laws or the Participant’s employment agreement, if any), unless otherwise required by applicable legislation and unless otherwise provided in this Section, the Participant’s employment or service relationship will be considered terminated effective as of the date that is the earliest of (i) the date the Participant’s employment relationship with the Company or any Affiliate is terminated, (ii) the date the Participant receives notice of termination from the Participant’s employer, or (iii) the date the Participant is no longer actively providing services to the Company or any Affiliate, regardless of any period during which notice, pay in lieu of notice or related payments or damages are provided or required to be provided under local law. The Participant will not earn or be entitled to any pro-rated vesting for

Exhibit 10.3(l)
that portion of time before the date on which the Participant’s right to vest terminates, nor will the Participant be entitled to any compensation for lost vesting. The Committee shall have the exclusive discretion to determine when the Participant is no longer providing services for purposes of the Participant’s RSUs (including whether the Participant may still be considered to be providing services while on a leave of absence). Notwithstanding
the foregoing, if applicable employment standards legislation explicitly requires continued entitlement to vesting during a statutory notice period, the Participant’s right to vest in the RSUs under the Plan, if any, will terminate effective as of the last day of the Participant’s minimum statutory notice period, but the Participant will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of the Participant’s statutory notice period, nor will the Participant be entitled to any compensation for lost vesting;

The following provisions will also apply if the Participant is a resident of Quebec:

Language Consent. The parties acknowledge that it is their express wish that the Award Agreement, including this Exhibit A, as well as all documents, notices, and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.

Consentement Relatif à la Langue Utilisée. Les parties reconnaissent avoir expressément souhaité que la convention ainsi que cette Exhibit A, ainsi que tous les documents, avis et procédures judiciares, éxécutés, donnés ou intentés en vertu de, ou liés directement ou indirectement à la présente convention, soient rédigés en langue anglaise.
Data Privacy. This provision supplements Section 3.15 of the Award Agreement:

The Participant hereby authorizes the Company and the Company’s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan. The Participant further authorizes the Company and any Affiliate, as well as E*TRADE, AST or such other third party service provider as may be selected by the Company to assist with the Plan, to disclose and discuss the Plan with their advisors. The Participant further authorizes the Company, any Related Corporation and any Affiliate to record such information and to keep such information in the Participant’s employee file.
Notifications

Securities Law Information. The Participant is permitted to sell the Shares acquired under the Plan through the Company’s designated broker, provided the resale of such Shares takes place outside of Canada through the facilities of a stock exchange on which the Shares are listed. The Shares are currently listed on the NASDAQ Stock Market.

Foreign Asset/Account Reporting Information. Foreign specified property held by a Canadian resident must be reporting annually on a Form T1135 (Foreign Income Verification Statement) if the total cost of the foreign specified property exceeds C$100,000 at any time during the year. Thus, unvested RSUs must be reported - generally at a nil cost- if the C$100,000 cost threshold is exceeded because of other foreign specified property held by the Participant. When the Shares are acquired, their cost generally is the adjusted cost base (“ACB”) of the Shares. The ACB would ordinarily equal the fair market value of the Shares at the time of acquisition, but if the Participant owns other Shares, this ACB may need to be averaged with the ACB of the other Shares. The Participant should consult with his or her personal legal advisor regarding what

Exhibit 10.3(l)
reporting obligations, if any, will apply to the Participant with respect to the Shares acquired under the Plan.

CHINA

Terms and Conditions

The following terms and conditions apply only if the Participant is subject to exchange control restrictions or regulations in China, as determined by the Company in its sole discretion.

Compliance with Law. The following provision supplements Section 3(b) of the Plan:

The Participant acknowledges that the Participant’s participation in the Plan is subject to the Company obtaining approval from the State Administration of Foreign Exchange (“SAFE”). Without limitation to the foregoing, the Participant understands and agrees that the issuance and delivery of Shares pursuant to the RSUs will be delayed until the Company obtains such approval or the Committee has otherwise determined that the issuance of the Shares can be made in compliance with applicable laws.

Sale of Shares. To facilitate compliance with any applicable laws and regulations in China, the Participant agrees that the Company (or a brokerage firm instructed by the Company, if applicable) is entitled to (i) sell all the Shares issued to the Participant at settlement (on the Participant’s behalf and at the Participant’s direction pursuant to this authorization), either at the time of settlement or when the Participant ceases employment with the Service Recipient, or at such other time determined by the Company, or (ii) require that any Shares acquired under the Plan be held with a designated brokerage firm until such Shares are sold.
The Participant also agrees to sign any agreements, forms and/or consents that may be reasonably requested by the Company (or the Company’s designated brokerage firm) to effectuate the sale of the Shares and acknowledges that neither the Company nor the designated brokerage firm is under any obligation to arrange for such sale of the Shares at any particular price (it being understood that the sale will occur at the then-current market price) and that brokerage fees or commissions may be incurred in any such sale. In any event, when the Shares acquired under the Plan are sold, the proceeds of the sale of the Shares, less any Tax-Related Items and brokerage fees or commissions, will be remitted to the Participant in accordance with applicable exchange control laws and regulations.
Termination of Employment. The Participant acknowledges and agrees that any Shares acquired under the Plan and held in the Participant’s brokerage account must be sold within sixty (60) days following termination of the Participant’s Employment, or within such other period as determined by the Company or required by SAFE (the “Mandatory Sale Date”). This includes any Shares that vest upon the Participant’s termination of Employment. The Participant understands that any Shares held by the Participant that have not been sold by the Mandatory Sale Date will automatically be sold by the Company’s designated broker at the Company’s direction (on the Participant’s behalf pursuant to this authorization without further consent), as described above.

Exchange Control Restrictions. By entering into this Award Agreement, the Participant acknowledges and agrees that pursuant to local exchange control requirements, any Shares acquired upon vesting of the RSUs must be held in an account with the Company’s designated broker and may not be transferred from such account. The Participant further understands that he or she is permitted to sell Shares acquired under the Plan only through the Company’s designated broker. The Participant further understands and agrees that, due to exchange control laws in China, the Participant must immediately repatriate the proceeds from the sale of Shares

Exhibit 10.3(l)
and any cash dividends paid on such Shares to China. The Participant understands that such repatriation of the proceeds will need to be effected through a special exchange control account established by the Company or a Related Corporation or Affiliate, and the Participant hereby consents and agrees that the proceeds from the sale of Shares or the receipt of any cash dividends may be transferred to such special account prior to being delivered to the Participant. The Company may deliver the proceeds to the Participant in U.S. dollars or local currency at the Company’s discretion. If the proceeds are paid in U.S. dollars, the Participant understands that he or she will be required to set up a U.S. dollar bank account in China so that the proceeds may be deposited into this account. The Participant agrees to bear any currency fluctuation risk between the time the Shares are sold or dividends are paid and the time the proceeds are distributed to the Participant. The Company is under no obligation to secure any particular exchange conversion rate.

FRANCE

Terms and Conditions
Restricted Stock Units Not French-qualified. The RSUs granted under this Award Agreement are not intended to qualify for special tax and social security treatment pursuant to Sections L. 225-197-1 to L. 225-197-5 and Sections L. 22-10-59 and L. 22-10-60 of the French Commercial Code, as amended.
Language Consent. By accepting the Award Agreement, the Participant confirms having read and understood the Plan and the Award Agreement, which were provided in the English language. The Participant accepts the terms of those documents accordingly.
Consentement Relatif à la Langue Utilisée. En acceptant cette Attribution, le Participant confirme avoir lu et comprendre le Plan et ce Contrat qui ont été transmis en langue anglaise. Le Participant accepte les dispositions de ces documents en connaissance de cause.
Notifications

Foreign Asset/Account Reporting Information. French residents holding cash or securities (including Shares acquired under the Plan) outside of France or maintaining foreign bank or brokerage account (including accounts opened or closed during the tax year) must declare such assets and accounts to the French tax authorities when filing an annual tax return. Failure to comply could trigger significant penalties.

GERMANY

Notifications

Exchange Control Information. The Participant must report any cross-border payments in excess of €12,500 to the German Federal Bank (Bundesbank). The report must be filed electronically and the form of report (Allgemeine Meldeportal Statistik) can be accessed via the Bundesbank’s website (www.bundesbank.de). The Participant is responsible for complying with applicable reporting obligations and should consult his or her personal legal advisor on this matter.

Foreign Asset/Account Reporting Information. If the Participant’s acquisition of Shares under the Plan leads to a “qualified participation” at any point during the calendar year, the Participant must report the acquisition when he or she files a tax return for the relevant year. A “qualified participation” is attained if (i) the value of the Shares acquired exceeds €150,000, or (ii) in the

Exhibit 10.3(l)
unlikely event the Participant holds Shares exceeding 10% of the Company’s total common stock.

IRELAND

There are no country-specific provisions.

ITALY

Terms and Conditions

Plan Document Acknowledgment. By accepting the Award Agreement, the Participant further acknowledges that the Participant has received a copy of the Plan, has reviewed the Plan and the Award Agreement in their entirety and fully understands and accepts all provisions of the Plan and the Award Agreement. The Participant further acknowledges that the Participant has read and specifically and expressly approves, without limitation, the following sections of the Award Agreement: “Vesting of RSUs”; “Responsibility for Taxes”; “Electronic Delivery and Participation”; “Insider Trading Restrictions; Market Abuse Laws”; “Imposition of Other Requirements”; “Nature of Grant”; and “Foreign Asset/Account, Exchange Control and Tax Reporting” (including the “Foreign Asset/Account Reporting Information” and “Foreign Asset Tax Information” below).

Notifications

Foreign Asset/Account Reporting Information. If the Participant holds investments abroad or foreign financial assets (e.g., cash, Shares) that may generate income taxable in Italy, the Participant is required to report them on his or her annual tax return (UNICO Form, RW Schedule) or on a special form if no tax return is due. The same reporting duties apply if the Participant is the beneficial owner of the investments, even if the Participant does not directly hold investments abroad or foreign assets.

Foreign Asset Tax Information. The value of the financial assets held outside of Italy by Italian residents is subject to a foreign asset tax. Such tax is currently levied at an annual rate of 2 per thousand (0.2%). The taxable amount will be the fair market value of the financial assets (e.g., Shares) assessed at the end of the calendar year. No tax payment duties arise if the value of the foreign assets held abroad does not exceed a certain threshold.

JAPAN

Notifications

Exchange Control Information. If Participant acquires Shares valued at more than ¥100,000,000 in a single transaction, the Participant must file a Securities Acquisition Report with the Ministry of Finance through the Bank of Japan within 20 days of the acquisition of the Shares.

Foreign Asset/Account Reporting Information. The Participant will be required to report details of any assets (such as Shares) held outside of Japan as of December 31st to the extent such assets have a total net fair market value exceeding ¥50,000,000. Such report will be due by March 15th each year. The Participant should consult with his or her personal tax advisor as to whether the reporting obligation extends to any outstanding RSUs held by the Participant and to ensure compliance with applicable reporting obligations.

MEXICO


Exhibit 10.3(l)
Terms and Conditions

Acceptance of the Award Agreement: By accepting the RSUs, the Participant acknowledges that he or she has received a copy of the Plan and the Award Agreement, including this Exhibit, which the Participant has reviewed. The Participant acknowledges further that he or she accepts all the provisions of the Plan and the Award Agreement, including this Exhibit. The Participant also acknowledges that he or she has read and specifically and expressly approves the terms and conditions set forth in Section 3.3 of the Award Agreement, which clearly provide as follows:

(1)    the Participant’s participation in the Plan does not constitute an acquired right;
(2)    The Plan and the Participant’s participation in it are offered by the Company on a wholly discretionary basis; and
(3)    the Participant’s participation in the Plan is voluntary.
Labor Law Policy and Acknowledgement: In accepting the RSUs, Participant expressly recognizes that Integra LifeSciences Holdings Corporation at 1100 Campus Road, Princeton, New Jersey 08540, USA, is solely responsible for the administration of the Plan and that the Participant’s participation in the Plan and acquisition of the Shares do not constitute an employment relationship between the Participant and the Company since the Participant is participating in the Plan on a wholly commercial basis and the Participant’s sole employer is a Mexican subsidiary of the Company (“Integra-Mexico”). Based on the foregoing, the Participant expressly recognizes that the Plan and the benefits that the Participant may derive from his or her participation in the Plan do not establish any rights between the Participant and Integra-Mexico, and do not form part of the employment conditions and/or benefits provided by Integra-Mexico and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of the Participant’s employment.
The Participant further understands that his or her participation in the Plan is a result of a unilateral and discretionary decision of the Company; therefore, the Company reserves the absolute right to amend and/or discontinue the Participant’s participation at any time without any liability to the Participant.
Finally, the Participant hereby declares that he or she does not reserve any action or right to bring any claim against the Company for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and the Participant therefore grants a full and broad release to the Company, its subsidiaries, branches, representation offices, its shareholders, officers, agents or legal representatives with respect to any claim that may arise.
Spanish Translation
Reconocimiento del Acuerdo
Aceptando este Premio (Award), el Participante reconoce que ha recibido una copia del Plan, el Anuncio de la Subvención y el Acuerdo, con inclusión de este Apéndice, que el Participante ha revisado. El Participante reconoce, además, que acepta todas las disposiciones del Plan, el Anuncio de la Subvención, y en el Acuerdo, incluyendo este Apéndice. El Participante también reconoce que ha leído y que concretamente aprueba de forma expresa los términos y condiciones establecidos en la Sección 3.3 del Acuerdo, que claramente dispone lo siguiente:
(1)    La participación del Participante en el Plan no constituye un derecho adquirido;

Exhibit 10.3(l)
(2)    El Plan y la participación del Participante en el Plan se ofrecen por la Compañía en su discrecionalidad total; y
(3)    Que la participación del Participante en el Plan es voluntaria.
Política de la Ley Laboral y Reconocimiento

Aceptando este Premio (Award), el Participante reconoce expresamente que Integra LifeSciences Holdings Corporation con oficinas registradas ubicadas en 1100 Campus Road, Princeton, New Jersey 08540, en los Estados Unidos de América, es el único responsable de la administración del Plan y que participación del Participante en el mismo y la adquisición de acciones no constituye de ninguna manera una relación laboral entre el Participante y la Compañía, debido a que la participación de esa persona en el Plan deriva únicamente de una relación comercial y el único Patrón del participante es una afiliada Mexicana de la Compañía (“Integra-México”). Derivado de lo anterior, el Participante reconoce expresamente que el Plan y los beneficios que pudieran derivar para el Participante por su participación en el mismo, no establecen ningún derecho entre el Participante e Integra-México, y no forman parte de las condiciones laborales y/o prestaciones otorgadas por Integra-México, y cualquier modificación al Plan o la terminación del mismo de ninguna manera podrá ser interpretada como una modificación o desmejora de los términos y condiciones de trabajo del Participante.
Asimismo, el Participante reconoce que su participación en el Plan es resultado de la decisión unilateral y discrecional de la Compañía, por lo tanto, la Compañía se reserva el derecho absoluto para modificar y/o discontinuar la participación del Participante en cualquier momento, sin ninguna responsabilidad hacia el Participante.
Finalmente el Participante manifiesta que no se reserva ninguna acción o derecho que ejercitar en contra de la Compañía, por cualquier compensación o daños o perjuicios en relación con cualquier disposición del Plan o de los beneficios derivados del mismo, y en consecuencia exime amplia y completamente a la Compañía, sus afiliadas, sucursales, oficinas de representación, sus accionistas, administradores, agentes y representantes legales con respecto a cualquier reclamo que pudiera surgir.

Notifications
Securities Law Information. The RSUs and Shares offered under the Plan have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico. In addition, the Plan, the Award Agreement, and any other document relating to the RSUs and Shares may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present employees of Integra-Mexico made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.

SINGAPORE

Notifications

Securities Law Information. The grant of the RSUs is being made pursuant to the “Qualifying Person” exemption” under section 273(1)(f) of the Securities and Futures Act (Chapter 289, 2006 Ed.) (“SFA”). The Plan has not been lodged or registered as a prospectus with the Monetary Authority of Singapore. The Participant should note that the RSUs are subject to section 257 of

Exhibit 10.3(l)
the SFA and the Participant should not make any subsequent sale of the Shares in Singapore or any offer of such subsequent sale of the Shares subject to the RSUs in Singapore, unless such sale or offer is made (i) six months or more after the date of grant or (ii) pursuant to the exemptions under Part XIII Division 1 Subdivision (4) (other than section 280) of the SFA, or any other applicable provisions of the SFA. The Company’s Common Stock is traded on the NASDAQ Stock Market, which is located outside of Singapore, under the ticker symbol “IART” and the Shares acquired under the Plan may be sold through this exchange.

Director Reporting Information. If the Participant is a director (including an alternate, substitute or shadow director) of a Singapore Affiliate, he or she is subject to certain notification requirements under the Singapore Companies Act, regardless of whether he or she is a Singapore resident or employed in Singapore. Among these requirements is the obligation to notify the Singapore Affiliate in writing when the Participant receives or disposes of an interest in the Company, Related Corporation, or an Affiliate (e.g., Options, RSUs, Shares). These notifications must be made within two (2) business days of acquiring or disposing of any interest in the Company, Related Corporation, or any Affiliate or within two (2) business days of becoming a director if such an interest exists at that time.

SWITZERLAND

Notifications

Securities Law Information. Neither this Award Agreement nor any other materials relating to the offer of RSUs (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (“FinSA”), (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than an employee of Integra LifeSciences Holdings Corporation or one of its Subsidiaries or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority (“FINMA”).

UNITED KINGDOM

Terms and Conditions

Responsibility for Taxes. This provision supplements Section 3.4 of the Award Agreement:

Without limitation to Section 3.4 of the Award Agreement, the Participant hereby agrees that the Participant is liable for all Tax-Related Items and hereby covenants to pay all such Tax-Related Items, as and when requested by the Company or if different, the Service Recipient or by Her Majesty’s Revenue & Customs (“HRMC”) (or any other tax authority or any other relevant authority).  The Participant also hereby agrees to indemnify and keep indemnified the Company and, if different, the Service Recipient against any Tax-Related Items that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on the Participant’s behalf.

Notwithstanding the foregoing, if the Participant is a director or executive officer of the Company (within the meaning of Section 13(k) of the Exchange Act), the terms of the immediately foregoing provision will not apply. In the event that the Participant is a director or executive officer of the Company and the income tax not collected from or paid by the Participant within ninety (90) days of the end of the U.K. tax year in which an event giving rise to the indemnification described above occurs, the amount of any uncollected income tax may constitute a benefit to the Participant on which additional income tax and National Insurance contributions (“NICs”) may be payable.  The Participant will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment

Exhibit 10.3(l)
regime and for paying to the Company and/or the Service Recipient (as appropriate) the amount of any NICs due on this additional benefit, which the Company and/or the Service Recipient may recover from the Participant by any of the means referred to in Section 3.4 of the Award Agreement.



EX-21.1 9 iart-20221231xexx211.htm EX-21.1 Document

EXHIBIT 21.1
Subsidiaries of Integra LifeSciences Holdings Corporation

Name of SubsidiaryState or Country of Incorporation or Organization
ACell, Inc.Delaware
Arkis Biosciences Inc.Delaware
Ascension Orthopedics LimitedUnited Kingdom
BIMECO, Inc.Florida
BioD, LLCDelaware
BioDlogics, LLCDelaware
BioRecovery, LLCDelaware
CardioDyne, Inc.Massachusetts
Cathtec IncorporatedMassachusetts
Caveangle LimitedUnited Kingdom
Confluent Surgical, Inc.Delaware
Derma First Aid Products, Inc.Pennsylvania
Derma Sciences Europe LimitedUnited Kingdom
Derma Sciences, Inc.Delaware
EndoSolutions, Inc.Delaware
Fiber Imaging Technologies, Inc.Massachusetts
GMS, Gesellschaft für medizinische Sondentechnik mbHGermany
ILS Financing (Ireland) LimitedIreland
ILS Financing CorporationDelaware
ILS Services Switzerland Ltd.Switzerland
ILS Surgical Investments, LLCDelaware
INS Sweden ABSweden
Integra Burlington MA, Inc. (formerly known as Integra Radionics, Inc.)Delaware
Integra Canada ULC (formerly known as Canada Microsurgical ULC)Canada
Integra CI, Inc.Cayman Islands
Integra Euro Holdings, Inc.Delaware
Integra France Holdings SASFrance
Integra German Holdings GmbHGermany
Integra GmbHGermany
Integra Japan K.K.Japan
Integra LifeSciences (Canada) Holdings, Inc.Delaware
Integra LifeSciences (Ireland) LimitedIreland


Integra LifeSciences (Shanghai) Co., Ltd.China
Integra LifeSciences Austria GmbHAustria
Integra LifeSciences Brazil Ltda.Brazil
Integra LifeSciences CorporationDelaware
Integra LifeSciences Enterprises, LLLPDelaware
Integra LifeSciences Financing (Cyprus) LimitedCyprus
Integra LifeSciences Italy S.r.l.Italy
Integra LifeSciences Korea Ltd.Korea
Integra LifeSciences Middle East FZ-LLCDubai
Integra LifeSciences Production CorporationDelaware
Integra LifeSciences Sales LLC (f/k/a Integra Healthcare Products LLC)Delaware
Integra LifeSciences Services (France) SASFrance
Integra LifeSciences Shared Services (Ireland) LimitedIreland
Integra LifeSciences Singapore Pte. Ltd.Singapore
Integra LifeSciences Spain, S.L.Spain
Integra LifeSciences Switzerland SárlSwitzerland
Integra LifeSciences Taiwan Company LimitedTaiwan
Integra LS (Benelux) NVBelgium
Integra LS Mexico, S. DE R. L. DE C.V.Mexico
Integra Luxtec, Inc.Massachusetts
Integra ME GmbHGermany
Integra MicroFrance SASFrance
Integra NeuroSciences (International), Inc.Delaware
Integra NeuroSciences Holdings (UK) LimitedUnited Kingdom
Integra NeuroSciences Holdings B.V.Netherlands
Integra NeuroSciences Implants (France) SASFrance
Integra NeuroSciences LimitedUnited Kingdom
Integra Neurosciences Pty Ltd. (AUS)Australia
Integra Neurosciences Pty Ltd. (NZ)New Zealand
Integra Receivables LLCDelaware
Integra Sales, Inc.Delaware
Integra Selector LLCDelaware
Integra Switzerland Holdings SarlSwitzerland
Integra York PA, Inc. (formerly known as Miltex, Inc.)Delaware
IsoTis NVNetherlands
IsoTis T.E. Facility B.V.Netherlands
J. Jamner Surgical Instruments, Inc.Delaware


Jarit GmbHGermany
LXU Healthcare, Inc. - Medical Specialty ProductsDelaware
MedEfficiency, Inc.Delaware
Minnesota Scientific, Inc.Minnesota
Newdeal SASFrance
Newdeal, Inc.Texas
Precise Dental Holding Corp.New Jersey
Precise Dental Internacional, S.A. de C.V.Mexico
Precise Dental Products, Ltd.California
Precision Dental International, Inc.California
Rebound Therapeutics CorporationDelaware
Spembly Cryosurgery LimitedUnited Kingdom
Spembly Medical LimitedUnited Kingdom
Surgical Innovation Associates, Inc.Delaware
Tarsus Medical Inc.Delaware
TEI Biosciences (UK) LimitedUnited Kingdom
TEI Biosciences Inc.Delaware
TEI Medical Inc.Delaware
TGX Medical Systems, LLCDelaware


 EX-23.1 10 iart-20221231xexx231.htm EX-23.1 Document
EXHIBIT 23.1
                                        
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-231709, 333-221210, 333-216212, 333-170210, 333-155263, 333-127488, 333-109042, 333-261744 and 333-266353) of Integra LifeSciences Holdings Corporation of our report dated February 22, 2023 relating to the financial statements, financial statement schedule and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Florham Park, New Jersey
February 22, 2023





EX-31.1 11 iart-20221231xexx311.htm EX-31.1 Document

Exhibit 31.1
Certification of Principal Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Jan De Witte, certify that:
1.I have reviewed this annual report on Form 10-K of Integra LifeSciences Holdings Corporation;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
Date:February 22, 2023/s/ Jan De Witte
Jan De Witte
President and Chief Executive Officer


 EX-31.2 12 iart-20221231xexx312.htm EX-31.2 Document

Exhibit 31.2
Certification of Principal Financial Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Jeffrey A. Mosebrook, certify that:
1.I have reviewed this annual report on Form 10-K of Integra LifeSciences Holdings Corporation;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date:February 22, 2023/s/ Jeffrey A. Mosebrook
Jeffrey A. Mosebrook
Senior Vice President, Finance


 EX-32.1 13 iart-20221231xexx321.htm EX-32.1 Document

Exhibit 32.1
Certification of Principal Executive Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
I, Jan De Witte, President and Chief Executive Officer of Integra LifeSciences Holdings Corporation (the “Company”), hereby certify that, to my knowledge:
1.The Annual Report on Form 10-K of the Company for the year ended December 31, 2022 (the “Report”) fully complies with the requirement of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:February 22, 2023/s/ Jan De Witte
Jan De Witte
President and Chief Executive Officer


 EX-32.2 14 iart-20221231xexx322.htm EX-32.2 Document

Exhibit 32.2
Certification of Principal Financial Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
I, Jeffrey A. Mosebrook, Senior Vice President, Finance of Integra LifeSciences Holdings Corporation (the “Company”), hereby certify that, to my knowledge:
1.The Annual Report on Form 10-K of the Company for the year ended December 31, 2022 (the “Report”) fully complies with the requirement of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:February 22, 2023/s/ Jeffrey A. Mosebrook
Jeffrey A. Mosebrook
Senior Vice President, Finance


 EX-101.SCH 15 iart-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - BUSINESS link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - ACQUISITIONS AND DIVESTITURES link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - DERIVATIVE INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - TREASURY STOCK link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - RETIREMENT BENEFIT PLANS link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - LEASES AND RELATED PARTY LEASES link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - NET INCOME PER SHARE link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - ACQUISITIONS AND DIVESTITURES (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - DERIVATIVE INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - RETIREMENT BENEFIT PLANS (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - LEASES AND RELATED PARTY LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - NET INCOME PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Roll forward of Valuation for Doubtful Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Inventories, Net) (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property, Plant and Equipment Balances and Corresponding Lives) (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Restructuring Charges (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Adoption of 2020-06 (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Narrative, Revenue Remaining Performance Obligation) (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Narrative, Revenue Remaining Performance Obligation) (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Schedule of Changes in Contract Assets and Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Schedule of Revenues Disaggregated by Major Source) (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - ACQUISITIONS AND DIVESTITURES - Business Acquisition, Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - ACQUISITIONS AND DIVESTITURES - Fair Value Acquisition SIA (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - ACQUISITIONS AND DIVESTITURES - Divestitures, Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - ACQUISITIONS AND DIVESTITURES - Assets and Liabilities Divested (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - ACQUISITIONS AND DIVESTITURES - Fair Value Acquisition ACell (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - DEBT (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - DEBT (Maximum Total Leverage Ratio Table) (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - DEBT (Schedule of Debt Maturity) (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - DERIVATIVE INSTRUMENTS (Schedule of Interest Rate Swap Derivatives) (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - DERIVATIVE INSTRUMENTS (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - DERIVATIVE INSTRUMENTS (Schedule of Cross-Currency Swap Derivatives) (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - DERIVATIVE INSTRUMENTS (Schedule of Net Investment Hedges Derivatives) (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - DERIVATIVE INSTRUMENTS (Fair Value of Derivative Instruments By Balance Sheet Location) (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - DERIVATIVE INSTRUMENTS (Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations) (Details) link:presentationLink link:calculationLink link:definitionLink 0000064 - Disclosure - DERIVATIVE INSTRUMENTS- (Schedule of Gains and (Loss) of Derivative Instruments) (Details) link:presentationLink link:calculationLink link:definitionLink 0000065 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000066 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Schedule of Changes in Carrying Amount of Goodwill) (Details) link:presentationLink link:calculationLink link:definitionLink 0000067 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Components of Company's Identifiable Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 0000068 - Disclosure - TREASURY STOCK - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000069 - Disclosure - STOCK-BASED COMPENSATION (Summary of Employee Stock-Based Compensation Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 0000070 - Disclosure - STOCK-BASED COMPENSATION (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000071 - Disclosure - STOCK-BASED COMPENSATION (Summary of Weighted-Average Assumptions) (Details) link:presentationLink link:calculationLink link:definitionLink 0000072 - Disclosure - STOCK-BASED COMPENSATION (Summary of Stock Option Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 0000073 - Disclosure - STOCK-BASED COMPENSATION (Summary of Vested and Unvested Restricted Stock, Performance Stock, and Contract Stock) (Details) link:presentationLink link:calculationLink link:definitionLink 0000074 - Disclosure - RETIREMENT BENEFIT PLANS (Schedule of Net Periodic Benefit Costs) (Details) link:presentationLink link:calculationLink link:definitionLink 0000075 - Disclosure - RETIREMENT BENEFIT PLANS (Schedule of Assumptions Used Periodic Benefit Cost and Actuarial Present Value) (Details) link:presentationLink link:calculationLink link:definitionLink 0000076 - Disclosure - RETIREMENT BENEFIT PLANS (Schedule of Change in Benefit Obligations and Plan Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 0000077 - Disclosure - RETIREMENT BENEFIT PLANS (Scheduled of Funded Status) (Details) link:presentationLink link:calculationLink link:definitionLink 0000078 - Disclosure - RETIREMENT BENEFIT PLANS (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000079 - Disclosure - RETIREMENT BENEFIT PLANS (Schedule of Expected Benefit Payments and Minimum Contribution on Unfunded Plans) (Details) link:presentationLink link:calculationLink link:definitionLink 0000080 - Disclosure - LEASES AND RELATED PARTY LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000081 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000082 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000083 - Disclosure - LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases Current Period (Details) link:presentationLink link:calculationLink link:definitionLink 0000083 - Disclosure - LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases Current Period (Details) link:presentationLink link:calculationLink link:definitionLink 0000084 - Disclosure - INCOME TAXES (Schedule of Income Before Income Taxes) (Details) link:presentationLink link:calculationLink link:definitionLink 0000085 - Disclosure - INCOME TAXES (Schedule of Effective Tax Rate Reconciliation) (Details) link:presentationLink link:calculationLink link:definitionLink 0000086 - Disclosure - INCOME TAXES (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000087 - Disclosure - INCOME TAXES (Schedule of Provision for Income Taxes) (Details) link:presentationLink link:calculationLink link:definitionLink 0000088 - Disclosure - INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 0000089 - Disclosure - INCOME TAXES (Tax Valuation Allowance) (Details) link:presentationLink link:calculationLink link:definitionLink 0000090 - Disclosure - INCOME TAXES (Schedule of Uncertain Tax Benefits Reconciliation) (Details) link:presentationLink link:calculationLink link:definitionLink 0000091 - Disclosure - NET INCOME PER SHARE (Basic and Diluted Net Income Per Share) (Details) link:presentationLink link:calculationLink link:definitionLink 0000092 - Disclosure - NET INCOME PER SHARE (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000093 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Schedule of Accumulated Other Comprehensive Income (Loss)) (Details) link:presentationLink link:calculationLink link:definitionLink 0000094 - Disclosure - AACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000095 - Disclosure - COMMITMENTS AND CONTINGENCIES (Fair Value Contingent Consideration) (Details) link:presentationLink link:calculationLink link:definitionLink 0000096 - Disclosure - COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000097 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000098 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 0000099 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Net Sales and Profit by Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 0000100 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Total Revenue by Major Geographic Area) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 16 iart-20221231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 17 iart-20221231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 18 iart-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Business Acquisition [Axis] Business Acquisition [Axis] Foreign Current Foreign Tax Expense (Benefit) Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Provision (recoveries) for doubtful accounts Accounts Receivable, Credit Loss Expense (Reversal) Other non-current liabilities Increase (Decrease) in Other Noncurrent Liabilities Deferred tax assets, net Deferred Income Tax Assets, Net Payments and other adjustments Restructuring Reserve, Accrual Adjustment Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Debt Instrument [Axis] Debt Instrument [Axis] Schedule of Components of Indefinite-Lived Intangible Assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Accrued expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses Total Property, Plant and Equipment, Gross Fair value Debt Instrument, Fair Value Disclosure Additional paid-in capital Additional Paid in Capital Five Year Option Lease From November 1, 2034 Through October 31, 2039 Five Year Lease Period Two [Member] Five Year Lease Period Two Accrued bonus Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Bonuses Interest rates available to the company at its option Debt Instrument, Basis Spread on Variable Rate Tissue Technologies Tissue Technologies [Member] Tissue Technologies [Member] Depreciation expense Depreciation Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Total net deferred tax assets (liabilities) Deferred Tax Assets, Net Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Debt, interest rate Convertible notes, interest rate Debt Instrument, Interest Rate, Stated Percentage Schedule of Geographic Revenue, by Area Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Effect of Derivative Instruments Designated as Cash Flow Hedges on Statements of Operations Derivative Instruments, Gain (Loss) [Table Text Block] Additional paid-in capital Additional Paid in Capital, Common Stock Plan assets expected to be returned next twelve months Defined Benefit Plan, Plan Assets, Expected to be Returned to Employer, Amount Reconciliation Of Funded Status Defined Benefit Plan, Funded (Unfunded) Status of Plan [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] State Current State and Local Tax Expense (Benefit) Income taxes paid Income Taxes Paid Transfers from long-term to current portion Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers From Long-Term to Current Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers From Long-Term to Current Employee Employee [Member] Employee [Member] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Securitization facility, outstanding borrowings, maximum limit Transferor's Interests In Transferred Financial Assets, Maximum Investment Limit Transferor's Interests In Transferred Financial Assets, Maximum Investment Limit Segment Profit Segment Reporting Information, Profit (Loss) [Abstract] Shares excluded from computation as their effect would be antidilutive (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Plan settlements Defined Benefit Plan, Plan Assets, Payment for Settlement Interest paid, capitalized into construction in progress Interest Paid, Capitalized, Investing Activities Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Cross Currency Interest Rate Swap, Contract Two Cross Currency Interest Rate Swap, Contract Two [Member] Cross Currency Interest Rate Swap, Contract Two Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Interest expense Interest Expense [Member] Secured Debt Secured Debt [Member] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Information systems and hardware Information Systems and Hardware [Member] Information Systems and Hardware [Member] Current year tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Increase (decrease) in income taxes resulting from: Effective Income Tax Rate Reconciliation, Percent [Abstract] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Related Party [Domain] Related Party [Domain] Standby Letters of Credit Standby Letters of Credit [Member] Hedging Designation [Domain] Hedging Designation [Domain] Plan assets at fair value, beginning of year Plan assets at fair value, end of year Fair value of plan assets Benefit plans, assets Defined Benefit Plan, Plan Assets, Amount DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag Weighted Average Exercise Price, Forfeited or Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Lease Contractual Term [Domain] Lease Contractual Term [Domain] Plan Name [Domain] Plan Name [Domain] Share repurchase and equity component of the convertible note issuance, net Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Line of credit facility outstanding Long-Term Line of Credit Entity Address, State or Province Entity Address, State or Province Employee Stock Purchase Plan Employee Stock [Member] Weighted Average Contractual Term in Years, Outstanding at end of year Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Interest payments, year one Interest Payments, Year One Interest Payments, Year One Award Type [Axis] Award Type [Axis] Actuarial (gain) loss Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) 2027 Defined Benefit Plan, Expected Future Benefit Payment, Year Five 2003 Plan Two Thousand Three Plan [Member] Two thousand three Plan [Member] Current portion of lease liability - operating leases Current lease liabilities Less: Current lease liabilities Operating Lease, Liability, Current Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Proceeds from sale of business Proceeds from Divestiture of Businesses Costs and expenses: Costs and Expenses [Abstract] Derivative, notional amount, terminated Derivative, Notional Amount, Terminated Derivative, Notional Amount, Terminated Other Unrecognized Tax Benefits, Reductions Resulting From Other Unrecognized Tax Benefits, Reductions Resulting From Other Trade accounts receivable, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Property, plant and equipment, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Effective foreign income tax rate Effective Foreign Income Tax Rate Reconciliation, Continuing Operations Effective Foreign Income Tax Rate Reconciliation, Continuing Operations Effective Income Tax rate reconciliation, prior year income taxes, amount Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount Total liabilities Liabilities Third Parties Third Parties [Member] Third Parties [Member] Weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Schedule of Expected Benefit Payments Schedule of Expected Benefit Payments [Table Text Block] Position [Axis] Position [Axis] Derma Sciences Derma Sciences [Member] Derma Sciences [Member] Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Revenue Recognition Revenue Recognition and Shipping and Handling Fees Revenue from Contract with Customer [Policy Text Block] Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Document Type Document Type Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Useful Lives Property, Plant and Equipment, Useful Life Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Unvested at beginning of year (in dollars per share) Unvested at end of year (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Asset Acquisition [Axis] Asset Acquisition [Axis] Deferred income tax (benefit) provision Total deferred Deferred Income Tax Expense (Benefit) Loss (Gain) on disposal of property and equipment and construction in-progress Gain (Loss) On Disposition Of Property Plant Equipment And Construction In-Progress Gain (Loss) On Disposition Of Property Plant Equipment And Construction In-Progress Cross Currency Interest Rate Swap, Contract Three Cross Currency Interest Rate Swap, Contract Three [Member] Cross Currency Interest Rate Swap, Contract Three Goodwill Disposal Group, Including Discontinued Operation, Goodwill Unrealized derivative gain (loss) arising during period Gain (loss) recorded in AOCL, change in fair value Amount of Gain (Loss) Recognized in AOCI Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Interest Rate Swap Designated December 13, 2017 Tranche 3 Interest Rate Swap Designated December 13, 2017 Tranche 3 [Member] Interest Rate Swap Designated December 13, 2017 Tranche 3 [Member] Schedule of Changes in Contract Assets and Contract Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Current portion of borrowings under senior credit facility Term loan component of senior credit facility, classified as current Secured Debt, Current Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table] Derivative Instruments, Gain (Loss) [Table] Initial strike price (in dollars per share) Option Indexed to Issuer's Equity, Strike Price Debt Disclosure [Abstract] Debt Disclosure [Abstract] Trade Accounts Receivable And Allowances For Doubtful Accounts Receivable Accounts Receivable [Policy Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Employer contributions Defined Benefit Plan, Plan Assets, Contributions by Employer Leases and Other Deferred Tax Assets, Leases And Other Deferred Tax Assets, Leases And Other Accrued expenses and other current liabilities Accrued Liabilities, Current Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Gain from sale of businesses Gain from the sale of businesses Gain (Loss) on Disposition of Business Stockholders’ Equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Foreign operations Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent 2000 Plan Two Thousand Plan [Member] Two Thousand Plan [Member] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Product warranty period (up to) Revenue, Product Warranty Period Revenue, Product Warranty Period Other Noncurrent Liabilities Other Noncurrent Liabilities [Member] Interest cost Interest cost Defined Benefit Plan, Interest Cost Summary Of Weighted-Average Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Income Tax [Table] Income Tax [Table] Income Tax [Table] Directors and Certain Executive Officers Directors and Certain Executive Officers [Member] Directors and Certain Executive Officers [Member] Schedule of Provision for Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Summary of Fair Value in Balance Sheet for Derivatives Designated as Hedging Instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Weighted-average period for cost recognition, in years Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted Average Contractual Term in Years, Exercisable at end of year Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Schedule of Components of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Payments to acquire business Payments to Acquire Businesses, Gross Derivative Contract [Domain] Derivative, Name [Domain] Derivative Contract [Domain] Entity Registrant Name Entity Registrant Name Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] 2026 Defined Benefit Plan, Expected Future Benefit Payment, Year Four Deferred tax assets Disposal Group, Including Discontinued Operation, Deferred Tax Assets Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Current portion of lease liability - operating leases Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Current Portion of Lease Liability, Operating Leases Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Current Portion of Lease Liability, Operating Leases Benefit payment Defined Benefit Plan, Benefit Obligation, Benefits Paid RETIREMENT BENEFIT PLANS Retirement Benefits [Text Block] Income Tax [Line Items] Income Tax [Line Items] Income Tax [Line Items] Leases [Abstract] Leases [Abstract] DefinedBenefitPlanNetPeriodicBenefitCostCreditSettlementGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag DefinedBenefitPlanNetPeriodicBenefitCostCreditSettlementGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag DefinedBenefitPlanNetPeriodicBenefitCostCreditSettlementGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Accrued compensation Disposal Group, Including Discontinued Operation, Accrued Liabilities Principles Of Consolidation Consolidation, Policy [Policy Text Block] Extremity Orthopedics Extremity Orthopedics [Member] Extremity Orthopedics [Member] TREASURY STOCK Treasury Stock [Text Block] Minimum Minimum [Member] Initial conversion rate Debt Instrument, Convertible, Conversion Ratio Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Proceeds from borrowings of long-term indebtedness Proceeds from Issuance of Secured Debt Excess tax benefits from stock compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount Premiums paid Defined Benefit Plan, Benefit Obligation, Premiums Paid Defined Benefit Plan, Benefit Obligation, Premiums Paid SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Trading Symbol Trading Symbol Entity File Number Entity File Number Other liabilities Other Liabilities [Member] Research and development credit Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Treasury stock, average cost per share (in dollars per share) Treasury Stock Acquired, Average Cost Per Share Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Expected annual amortization expense, 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Four Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Foreign Deferred Foreign Income Tax Expense (Benefit) Title of Individual [Axis] Title of Individual [Axis] Derivatives Derivatives, Policy [Policy Text Block] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Effective tax rate Effective tax rate Effective Income Tax Rate Reconciliation, Percent Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Contributions expected to be paid to plan Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year Use Of Estimates Use of Estimates, Policy [Policy Text Block] Raw materials Inventory, Raw Materials, Gross Net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Balance, Beginning of Period Balance, End of Period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Plan settlements Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement Accounts payable, accrued expenses and other current liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities INCOME TAXES Income Tax Disclosure [Text Block] Weighted average interest rate on debt Debt, Weighted Average Interest Rate Long-term borrowings under senior credit facility Secured Long-Term Debt, Noncurrent Credit Facility [Domain] Credit Facility [Domain] Interest payments, year three Interest Payments, Year Three Interest Payments, Year Three Basic (in dollars per share) Basic net income per common share (in dollars per share) Earnings Per Share, Basic Neurosurgery Neurosurgery [Member] Neurosurgery [Member] Unrealized gain (loss) on derivatives Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax [Abstract] Requisite service periods of performance stock, restricted stock and contract stock awards, in years Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Fair value of shares vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Total liabilities held for sale Disposal Group, Including Discontinued Operation, Liabilities Accounting Standards Update and Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Corporate and other Corporate, Non-Segment [Member] Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Global intangible low-taxed income ("GILTI") Effective Income Tax Rate Reconciliation, GILTI, Percent Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Lease Contractual Term [Axis] Lease Contractual Term [Axis] Defined benefit pension plan - net gain (loss) arising during period Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Entity Interactive Data Current Entity Interactive Data Current DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag Effective worldwide tax rate Effective Worldwide Income Tax Rate Reconciliation, Percent Effective Worldwide Income Tax Rate Reconciliation, Percent Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Lease liability - operating leases Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Lease Liability, Operating Leases Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Lease Liability, Operating Leases Other income, net Other Nonoperating Income (Expense) [Member] Reorganization Projects Reorganization Projects [Member] Reorganization Projects Total other comprehensive gain (loss), net of tax Other comprehensive loss, net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Issuance of common stock for vesting of share-based awards, net of shares withheld for taxes Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Other comprehensive gain (loss) OCI, before Reclassifications, Net of Tax, Attributable to Parent Purchase of treasury stock Payments for Repurchase of Common Stock Class of Stock [Axis] Class of Stock [Axis] Income Taxes Income Tax, Policy [Policy Text Block] Wound Reconstruction and Care Regenerative Skin And Wound [Member] Regenerative Skin And Wound [Member] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income Not Disclosed Flag DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag Gain (loss) recognized in other income Gain (Loss) on Derivative Instruments, Net, Pretax Current Assets: Assets, Current [Abstract] Penalties and interest expense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Consortium of Focused Orthopedists, LLC Consortium of Focused Orthopedists, LLC [Member] Consortium of Focused Orthopedists, LLC [Member] Accelerated share repurchase program, receipt (payment) Accelerated Share Repurchases, Settlement (Payment) or Receipt Cross-Currency Interest Rate Swap One Cross Currency Interest Rate Contract One [Member] Cross Currency Interest Rate Contract One [Member] Asset Acquisition [Domain] Asset Acquisition [Domain] Retained earnings Retained Earnings (Accumulated Deficit) Settlements Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Proceeds from convertible notes issuance Proceeds from Convertible Debt Doubtful accounts Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss Related Parties Related Parties [Member] Related Parties [Member] Weighted Average Exercise Price, Exercisable at end of year (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Accelerated share repurchases, percentage of expected total repurchased Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased, Percent Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased, Percent Document Fiscal Year Focus Document Fiscal Year Focus Foreign Plan Foreign Plan [Member] OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Sale of business, disposition price Disposal Group, Including Discontinued Operation, Consideration Business combination, contingent consideration, liability, current Business Combination, Contingent Consideration, Liability, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Acquired in-process research and development and intangibles Payments To Acquire In Process Research And Development And Intangible Assets Payments To Acquire In Process Research And Development And Intangible Assets Total current Current Income Tax Expense (Benefit) Liabilities: Deferred Tax Liabilities, Gross [Abstract] Operating lease expense Operating Lease, Expense Milestone Payment Two Milestone Payment Two [Member] Milestone Payment Two [Member] Excess tax benefits from stock compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent Summary Of Restricted Stock, Performance Stock, and Contract Stock Activity Share-Based Payment Arrangement, Activity [Table Text Block] Inventories Increase (Decrease) in Inventories Estimated Fair Value Fair Value Asset (Liability) Derivative, Fair Value, Net Stock compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Position [Domain] Position [Domain] Goodwill Beginning of period End of period Goodwill Accrued Expenses and Other Current Liabilities Other Current Liabilities [Member] Treasury stock, at cost; shares (in shares) Balance, Beginning of Period, Treasury Stock (in shares) Balance, End of Period, Treasury Stock (in shares) Treasury Stock, Shares Property, Plant and Equipment by Type [Axis] Long-Lived Tangible Asset [Axis] Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Provision (benefit) for income taxes Provision for income taxes Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Less valuation allowance Deferred Tax Assets, Valuation Allowance Deferred tax liabilities Deferred tax liabilities Deferred Income Tax Liabilities, Net Hedging Relationship [Axis] Hedging Relationship [Axis] Entity Public Float Entity Public Float Balance Sheet Location [Domain] Balance Sheet Location [Domain] Cost of goods sold Cost of Goods and Services Sold Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Total derivatives designated as hedges — Liabilities Derivative Liability, Subject to Master Netting Arrangement, before Offset Concentration risk, threshold percentage Concentration Risk, Threshold Percentage Concentration Risk, Threshold Percentage 2023 Defined Benefit Plan, Expected Future Benefit Payment, Year One Unrealized foreign exchange gain Deferred Tax Assets, Unrealized Currency Losses Long-term convertible securities Convertible Debt, Noncurrent Restricted Stock, Performance Stock and Contract Stock Restricted Stock, Performance Stock, And Contract Stock [Member] Restricted stock, performance stock and contract stock member Charitable contributions carryforward Deferred Tax Assets, Charitable Contribution Carryforwards Common stock; $0.01 par value; 240,000 authorized shares; 90,477 and 89,600 issued at December 31, 2022 and 2021, respectively Common Stock, Value, Issued Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Swingline Loan Swingline Loan [Member] Swingline Loan [Member] Assets: Deferred Tax Assets, Gross [Abstract] Other SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account Initial conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Foreign operations Income (Loss) from Continuing Operations before Income Taxes, Foreign Cross-Currency Interest Rate Swap Three Cross Currency Interest Rate Contract Three [Member] Cross Currency Interest Rate Contract Three [Member] Text Block [Abstract] Contract liability, net of revenue recognized on contracts during the period Contract With Customer, Liability, Net Of Revenue Recognized And Foreign Currency Translation Contract With Customer, Liability, Net Of Revenue Recognized And Foreign Currency Translation Current Liabilities: Liabilities, Current [Abstract] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Proceeds from exercised stock options Proceeds from Stock Options Exercised Additions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Accelerated share repurchases, shares received at inception Accelerated Share Repurchases. Shares Received at Inception Accelerated Share Repurchases. Shares Received at Inception Interest Rate Swap Designated October 10, 2018 Tranche 1 Interest Rate Swap Designated October 10, 2018 Tranche 1 [Member] Interest Rate Swap Designated October 10, 2018 Tranche 1 [Member] Contract liabilities Short-term portion of contract liability Contract with Customer, Liability, Current Summary of Valuation Allowance Summary of Valuation Allowance [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Income Statement Location [Domain] Income Statement Location [Domain] Current portion of lease liability - operating leases Disposal Group, Including Discontinued Operation, Lease Liability, Current Disposal Group, Including Discontinued Operation, Lease Liability, Current Amendment Flag Amendment Flag Weighted Average Life Finite-Lived Intangible Asset, Useful Life Switzerland Swiss Federal Tax Administration (FTA) [Member] Goodwill acquisition Goodwill, Acquired During Period ACQUISITIONS AND DIVESTITURES Mergers, Acquisitions and Dispositions Disclosures [Text Block] Total liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Construction-in-progress Construction in Progress [Member] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Deferred tax asset, increase Deferred Tax Asset, Increase Due To 2017 Tax Act Deferred Tax Asset, Increase Due To 2017 Tax Act Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Other assets Other Assets, Noncurrent Goodwill And Other Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Exercisable at end of year (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Cross-Currency Interest Rate Swap Four Cross Currency Interest Rate Contract Four [Member] Cross Currency Interest Rate Contract Four [Member] Expected annual amortization expense, thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Counterparty Name [Axis] Counterparty Name [Axis] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Fair market value step up on intra-entity transfer of intellectual property Effective Income Tax Rate Reconciliation, Transfer Intra-Entity Intellectual Property, Rate Differential On FMV Step-Up, Percent Effective Income Tax Rate Reconciliation, Transfer Intra-Entity Intellectual Property, Rate Differential On FMV Step-Up, Percent Codman Specialty Surgical Codman Specialty Surgical [Member] Codman Specialty Surgical [Member] Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Total assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Operating cash flows from operating leases Operating Lease, Payments ROU assets obtained in exchange for lease liabilities: Right Of Use Asset Obtained In Exchange For Lease Liability [Abstract] Right Of Use Asset Obtained In Exchange For Lease Liability [Abstract] Employee Stock Option Share-Based Payment Arrangement, Option [Member] Treasury stock, at cost; 6,823 and 4,899 shares at December 31, 2022 and 2021, respectively Treasury Stock, Value Accelerated share repurchases, percentage of expected total repurchased Accelerated Share Repurchases, Percentage Of Expected Total Repurchased Accelerated Share Repurchases, Percentage Of Expected Total Repurchased Trade accounts receivable, allowances Accounts Receivable, Allowance for Credit Loss, Current Common stock, authorized shares (in shares) Common Stock, Shares Authorized Intercompany profit in inventory Effective Income Tax Rate Reconciliation, Deduction, Intercompany Inventory, Percent Effective Income Tax Rate Reconciliation, Deduction, Intercompany Inventory, Percent Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Maximum Maximum [Member] Short Short [Member] Combination settlement for debt conversion, minimum settled in cash per principal amount Debt Instrument, Combination Settlement For Debt Conversion, Minimum Settled In Cash Per Principal Amount Debt Instrument, Combination Settlement For Debt Conversion, Minimum Settled In Cash Per Principal Amount Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Derivatives Not Designated as Hedging Instruments Derivatives Not Designated as Hedging Instruments [Table Text Block] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Work in process Inventory, Work in Process, Gross Contract liabilities Increase (Decrease) in Contract with Customer, Liability Designated as Hedging Instrument Designated as Hedging Instrument [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Number of products offered (more than) Segment Reporting Information, Number Of Products Offered Number of products sold by a segment ACell ACell [Member] ACell Accumulated Other Comprehensive Income (Loss) [Roll Forward] Accumulated Other Comprehensive Income (Loss) [Roll Forward] Accumulated Other Comprehensive Income (Loss) [Roll Forward] Schedule of Net Periodic Benefit Costs Schedule of Net Benefit Costs [Table Text Block] Foreign currency transaction gain (loss) Foreign Currency Transaction Gain (Loss), Realized Interest income Interest Income [Member] Total estimated tax benefit related to stock-based compensation expense Share-Based Payment Arrangement, Expense, Tax Benefit Long Long [Member] Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Gain (loss) recognized within accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax Trademarks/brand names Trademarks Brand Names [Member] Trademarks Brand Names. Schedule of Uncertain Tax Benefits Reconciliation Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Class of Treasury Stock [Table] Class of Treasury Stock [Table] DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfPriorServiceCostCreditStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfPriorServiceCostCreditStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfPriorServiceCostCreditStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag Completed technology Completed Technology [Member] Completed technology. Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] BioD Earnout Payments and Medihoney Earnout Payments BioD Earnout Payments and Medihoney Earnout Payments [Member] BioD Earnout Payments and Medihoney Earnout Payments [Member] Schedule of Weighted Average Assumptions Used Defined Benefit Plan, Assumptions [Table Text Block] Cumulative Effect, Period of Adoption, Adjustment, Debt Discount Amortization and Equity Costs Reclassification Cumulative Effect, Period of Adoption, Adjustment, Debt Discount Amortization and Equity Costs Reclassification [Member] Cumulative Effect, Period of Adoption, Adjustment, Debt Discount Amortization and Equity Costs Reclassification SEGMENT AND GEOGRAPHIC INFORMATION Segment Reporting Disclosure [Text Block] Selling, general and administrative Selling, General and Administrative Expenses [Member] Effective income tax reconciliation, tax benefit, excess stock-based compensation deductions Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount Total net deferred tax assets (liabilities) Deferred Tax Liabilities, Net 1-month USD LIBOR Loan One Month USD LIBOR [Member] One Month USD LIBOR [Member] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Cross Currency Interest Rate Swap, Contract One Cross Currency Interest Rate Swap, Contract One [Member] Cross Currency Interest Rate Swap, Contract One Weighted average common shares outstanding (See Note 13): Weighted Average Number of Shares Outstanding, Diluted [Abstract] Inventories, net Total inventories, net Inventory, Net Codman Codman [Member] Codman [Member] Income Tax Authority [Axis] Income Tax Authority [Axis] Basic (in shares) Weighted average common shares outstanding - Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Net proceeds (payments) on swaps designated as net investment hedges Payments for (Proceeds from) Derivative Instrument, Investing Activities Debt proceeds, classified as equity at time of offering Debt Instrument, Convertible, Carrying Amount of Equity Component Interest Rate Swap Designated October 10, 2018 Tranche 3 Interest Rate Swap Designated October 10, 2018 Tranche 3 [Member] Interest Rate Swap Designated October 10, 2018 Tranche 3 [Member] Change In Plan Assets Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Notional Amount Notional amount Aggregate Notional Amount Derivative, Notional Amount Preferred Stock; no par value; 15,000 authorized shares; none outstanding Preferred Stock, Value, Issued Concentration risk, number of customers over benchmark Concentration Risk, Number of Customers Over Benchmark Concentration Risk, Number of Customers Over Benchmark Integra Foundation Foundation [Policy Text Block] Foundation [Policy Text Block]. Restricted Stock Awards Restricted Stock [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Supplemental Cash Flow Information Cash Flow, Lessee [Table Text Block] Cash Flow, Lessee [Table Text Block] Business Acquisition, number of payments Business Acquisition, Number Of Contingent Liabilities Business Acquisition, Number Of Contingent Liabilities Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Income tax benefit, transfer intra-entity intellectual property, amount Effective Income Tax Rate Reconciliation, Income Tax Benefit, Transfer Intra-Entity Intellectual Property, Amount Effective Income Tax Rate Reconciliation, Income Tax Benefit, Transfer Intra-Entity Intellectual Property, Amount STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Unrealized gain (loss) on derivatives Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax, Parent Summary Of Employee Stock-Based Compensation Expense Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Effect of foreign currency exchange rates Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Working capital adjustment Business Combination, Working Capital Adjustment Business Combination, Working Capital Adjustment Sale of non-core traditional wound care business Goodwill, Written off Related to Sale of Business Unit Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Eurodollar Rate Eurodollar [Member] Related Party [Axis] Related Party [Axis] Goodwill [Roll Forward] Goodwill [Roll Forward] Foreign currency translation Contract With Customer, Liability, Increase From Foreign Currency Translation Contract With Customer, Liability, Increase From Foreign Currency Translation Land Land [Member] Stock options and restricted stock (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Diluted net income per share: Earnings Per Share, Diluted [Abstract] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Disposal Group Name [Domain] Disposal Group Name [Domain] Derivative Instruments, Gain (Loss) [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Level 2 Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Total assets held for sale Disposal Group, Including Discontinued Operation, Assets Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Nondeductible executive compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Percent Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Percent Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Employee contribution Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant Period for revenue based performance milestone Disposal Group, Including Discontinued Operation, Consideration, Contingent Consideration, Period Disposal Group, Including Discontinued Operation, Consideration, Contingent Consideration, Period Net Definite And Indefinite Lived Intangible Assets Net Excluding Goodwill Definite And Indefinite Lived Intangible Assets Net Excluding Goodwill. Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Debt Covenant Period [Domain] Debt Covenant Period [Domain] [Domain] for Debt Covenant Period [Axis] Maximum selling price of the company's common stock of the conversion price Debt Instrument, Maximum Selling Price Of Common Stock Of The Conversion Price During Period Debt Instrument, Maximum Selling Price Of Common Stock Of The Conversion Price During Period Customer Concentration Risk Customer Concentration Risk [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Operating loss carryforwards, subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Performance obligations expected to be satisfied Revenue, Remaining Performance Obligation, Amount Expiration period, in years Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Schedule of Derivative Instruments Schedule of Derivative Instruments [Table Text Block] Income Tax Authority [Domain] Income Tax Authority [Domain] Europe Europe [Member] Other comprehensive income (loss), net investment hedge, gain (loss), reclassification, before tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Credit Facility [Axis] Credit Facility [Axis] Equity [Abstract] Capitalized Interest Interest Capitalization, Policy [Policy Text Block] Released (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Entity Tax Identification Number Entity Tax Identification Number Common stock reserved for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Employee Termination Benefits Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block] Fixed Interest Rate Fixed Rate Derivative, Fixed Interest Rate Surgical Innovation Association Inc Surgical Innovation Associates Inc [Member] Surgical Innovation Associates Inc Research and development Research and Development Expense (Excluding Acquired in Process Cost) Segment Net Sales Segment Reporting Information, Operating Income (Loss) [Abstract] Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Private Label Private Label [Member] Private Label [Member] All other All Other [Member] All Other [Member] Restructuring and Related Costs Restructuring and Related Costs [Table Text Block] Entity Central Index Key Entity Central Index Key Payments on debt Repayments of Secured Debt Interest income Interest income Investment Income, Interest Contingent Consideration Effective Income Tax Rate Reconciliation, Contingent Consideration, Percent Effective Income Tax Rate Reconciliation, Contingent Consideration, Percent Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Schedule of Share-Based Compensation, Arrangements by Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Return to provision Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent Concentration Of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] City Area Code City Area Code ASSETS Assets [Abstract] Pension Benefits Pension and Other Postretirement Plans, Policy [Policy Text Block] 2023 Long-Term Debt, Maturity, Year One Share-based compensation Share-Based Payment Arrangement, Noncash Expense Weighted average grant date fair value of options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Variable Rate [Axis] Variable Rate [Axis] Other liabilities Other Liabilities, Noncurrent Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Expected annual amortization expense, 2023 Finite-Lived Intangible Asset, Expected Amortization, Year One Projected benefit obligations, beginning of year Projected benefit obligations, end of year Benefit obligations Defined Benefit Plan, Benefit Obligation Basic And Diluted Net Income Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability BUSINESS Business Description and Basis of Presentation [Text Block] Rebound Rebound Therapeutics Corporation [Member] Rebound Therapeutics Corporation [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Total minimum lease payments Lessee, Operating Lease, Liability, to be Paid Rate of compensation increase Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase Entity Address, Postal Zip Code Entity Address, Postal Zip Code 2001 Plan Two Thousand One Plan [Member] Two Thousand One Plan [Member] Contract Liability Change In Contract With Customer, Liability [Roll Forward] Change In Contract With Customer, Liability [Roll Forward] Reconciliation of Uncertain Tax Benefits [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] 2024 Long-Term Debt, Maturity, Year Two Supplemental Balance Sheet Information Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Lease liability - operating leases Disposal Group, Including Discontinued Operation, Lease Liability, Noncurrent Disposal Group, Including Discontinued Operation, Lease Liability, Noncurrent Debt Covenant Period [Axis] Debt Covenant Period [Axis] Debt Covenant Period [Axis] Acquisitions Business Combinations Policy [Policy Text Block] Plan amendments Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment Valuation Allowance [Line Items] Valuation Allowance [Line Items] Number of renewal options (or more) Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity FDA Approval Of Premarket Approval FDA Approval Of Premarket Approval [Member] FDA Approval Of Premarket Approval Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Prepaid expenses and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Deductions SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Restructuring costs Balance, beginning of the year Balance, end of the year Restructuring Reserve Inventory, capitalized expenses Inventory, Capitalized Expenses Inventory, Capitalized Expenses Deferred compensation plan, fair value of assets Deferred Compensation Plan Assets Depreciation and amortization Other Depreciation and Amortization Statistical Measurement [Domain] Statistical Measurement [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Cash interest Interest Expense, Debt, Excluding Amortization Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Total long-lived assets Long-Lived Assets Period for extended lease Lessee, Operating Lease, Option to Extend Option Indexed to Issuer's Equity [Axis] Option Indexed to Issuer's Equity [Axis] Net period benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Federal Domestic Tax Authority [Member] Transferred to trade receivable from contract asset included in beginning of the year contract asset Contract with Customer, Asset, Reclassified to Receivable Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Net income Net income Net Income (Loss) Attributable to Parent Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Schedule of Contractual Repayments of Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Amortization of prior service cost (credit) Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Subsequent Event Type [Axis] Subsequent Event Type [Axis] Overnight Federal Funds Rate Fed Funds Effective Rate Overnight Index Swap Rate [Member] Redemption price, percentage Debt Instrument, Redemption Price, Percentage LEASES AND RELATED PARTY LEASES Lessee, Operating Leases [Text Block] Treasury stock Treasury Stock, Common, Value Instruments Instruments [Member] Instruments [Member] Plan Name [Axis] Plan Name [Axis] Net effect on net income Share-Based Payment Arrangement, Expense, after Tax Contract asset, Beginning of period Contract asset, End of Period Contract with Customer, Asset, after Allowance for Credit Loss Effect of dilutive securities: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Rest of the World Rest Of World [Member] Revenues from rest of the world. Derivative Instrument [Axis] Derivative, by Nature [Axis] Derivative Instrument [Axis] Intangible and fixed assets Deferred Tax Liabilities, Goodwill and Intangible Assets Goodwill [Line Items] Goodwill [Line Items] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Deferred income tax benefit, transfer intra-entity intellectual property, amount Effective Income Tax Rate Reconciliation, Deferred Income Tax Benefit, Transfer Intra-Entity Intellectual Property, Amount Effective Income Tax Rate Reconciliation, Deferred Income Tax Benefit, Transfer Intra-Entity Intellectual Property, Amount Option to extend lease, years Option To Extend Lease, Years Option to extend lease, years. Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Nondeductible facilitative costs Effective Income Tax Rate Reconciliation, Nondeductible Expense, Legal and Professional, Percent Effective Income Tax Rate Reconciliation, Nondeductible Expense, Legal and Professional, Percent Tax expense related to sale of business Effective Income Tax Rate Reconciliation, Disposition of Business, Amount Interest Rate Swap Designated December 13, 2017 Tranche 1 Interest Rate Swap Designated December 13, 2017 Tranche 1 [Member] Interest Rate Swap Designated December 13, 2017 Tranche 1 [Member] Gain (loss) estimated to be reclassified to earnings during next twelve months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Forfeited or Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Document Annual Report Document Annual Report Liability Class [Axis] Liability Class [Axis] Cross-Currency Interest Rate Swap Two Cross Currency Interest Rate Contract Two [Member] Cross Currency Interest Rate Contract Two [Member] Cash paid for business acquisitions, net of cash acquired Payments For (Proceeds From) Business Acquisitions Payments For (Proceeds From) Business Acquisitions Interest Rate Swap Designated October 10, 2018 Tranche 2 Interest Rate Swap Designated October 10, 2018 Tranche 2 [Member] Interest Rate Swap Designated October 10, 2018 Tranche 2 [Member] Geographical [Axis] Geographical [Axis] Less: Reclassification adjustments for gain (loss) included in net income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Arkis Arkis BioSciences Inc. [Member] Arkis BioSciences Inc. [Member] Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Schedule of Property, Plant and Equipment Balances and Corresponding Lives Property, Plant and Equipment [Table Text Block] Revenue Based Performance Milestones Revenue Based Performance Milestones [Member] Revenue Based Performance Milestones Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Interest payments, year two Interest Payments, Year Two Interest Payments, Year Two Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] 2025 Defined Benefit Plan, Expected Future Benefit Payment, Year Three Restructuring Type [Axis] Restructuring Type [Axis] Premiums paid Defined Benefit Plan, Plan Assets, Premiums Paid Defined Benefit Plan, Plan Assets, Premiums Paid Total current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets Segments [Axis] Segments [Axis] DEBT Debt Disclosure [Text Block] Cash divested from deconsolidation Cash Divested from Deconsolidation Product and Service [Domain] Product and Service [Domain] Shell Company Entity Shell Company 2023 Lessee, Operating Lease, Liability, to be Paid, Year One 2025 Long-Term Debt, Maturity, Year Three Leased vehicles Vehicles [Member] Affiliated Entity Affiliated Entity [Member] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Consolidation Items [Domain] Consolidation Items [Domain] Subsequent Event Subsequent Event [Member] Option Indexed to Issuer's Equity, Type [Domain] Option Indexed to Issuer's Equity, Type [Domain] Sales Revenue, Net Revenue Benchmark [Member] Document Period End Date Document Period End Date Increase in authorized shares (in shares) Increase In Authorized Shares The increase in the number of authorized shares under the Plan. Schedule of Changes in Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Total assets Assets Net income per share Earnings Per Share [Abstract] Performance Shares Units Performance Shares [Member] Interest rate swap Interest Rate Swap [Member] Balance, Beginning of Period (in shares) Balance, End of Period (in shares) Shares, Issued Secured long-term debt, securitization program Secured Long-Term Debt, Securitization Program Secured Long-Term Debt, Securitization Program Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Increase in unrecognized tax benefits is reasonably possible Increase in Unrecognized Tax Benefits is Reasonably Possible 2027 Lessee, Operating Lease, Liability, to be Paid, Year Five Weighted Average Exercise Price, Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Stock repurchase program, authorized amount (up to) Stock Repurchase Program, Authorized Amount Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Less: Amounts reclassified from accumulated other comprehensive income, net Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Product Warranties Extended Product Warranty, Policy [Policy Text Block] Accrued compensation Employee-related Liabilities, Current Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Segments [Domain] Segments [Domain] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Intangible assets, net Disposal Group, Including Discontinued Operation, Intangible Assets NET INCOME PER SHARE Earnings Per Share [Text Block] Interest paid Interest Paid, Including Capitalized Interest, Operating and Investing Activities Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Cash And Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Award Type [Domain] Award Type [Domain] Finished goods Inventory, Finished Goods, Gross Change in foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent Net Investment Hedging Net Investment Hedges Net Investment Hedging [Member] Inventories, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Foreign currency translation Goodwill, Foreign Currency Translation Gain (Loss) Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Foreign Currency Items Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Customer Relationships Customer relationships Customer Relationships [Member] Entity Address, City or Town Entity Address, City or Town Gains and Losses on Derivatives Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Effect of foreign currency exchange rates Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Number of days from shipment to issue a credit on returned goods Return Policy, Issue Of Credit, Number Of Days From Shipment Return Policy, Issue of Credit, Number of Days from Shipment GERMANY GERMANY Next five years Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Inventory purchase, prepaid expenses and other current assets Discontinued Operation, Continuing Involvement, Prepaid Assets , Current Discontinued Operation, Continuing Involvement, Prepaid Expenses, Current Assets Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Auditor Name Auditor Name Operating loss carryforwards Operating Loss Carryforwards Right of use asset-operating leases and Other assets Disposal Group, Including Discontinued Operation, Right of Use Asset Operating Leases and Other Assets Disposal Group, Including Discontinued Operation, Right of Use Asset Operating Leases and Other Assets Treasury stock outstanding (in shares) Treasury Stock, Common, Shares Milestone Payment One Milestone Payment One [Member] Milestone Payment One [Member] Accounts payable, trade Accounts Payable, Trade, Current Long-term portion of contract liability Contract with Customer, Liability, Noncurrent Number of liabilities Business Combination, Contingent Consideration, Number Of Liabilities Business Combination, Contingent Consideration, Number Of Liabilities Prior years' tax positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Disposal Group Classification [Axis] Disposal Group Classification [Axis] Long-term borrowings under securitization facility Secured Long-Term Debt, Securitization Program, Noncurrent Secured Long-Term Debt, Securitization Program, Noncurrent Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Accretion of bond issuance discount Accretion Expense Vested or expected to vest at end of year (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Capitalization of research and development expenses Deferred Tax Assets, Tax Deferred Expense, Reserves And Accruals, Capitalized Research And Development Deferred Tax Assets, Tax Deferred Expense, Reserves And Accruals, Capitalized Research And Development State Deferred State and Local Income Tax Expense (Benefit) Intangible asset amortization Amortization Amortization of Intangible Assets Warrant strike price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Schedule of Changes in Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Defer payment and taxation, base salary, percentage (up to) Defined Benefit Plan, Defer Payment And Taxation, Base Salary, Percentage Defined Benefit Plan, Defer Payment And Taxation, Base Salary, Percentage 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Other assets Other Assets [Member] Defined Benefit Pension Items Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Inventories Inventory, Policy [Policy Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Treasury Stock Treasury Stock [Member] Total stockholders’ equity Balance, Beginning of Period Balance, End of Period Stockholders' Equity Attributable to Parent DERIVATIVE INSTRUMENTS Derivative Instruments and Hedging Activities Disclosure [Text Block] Director Director [Member] Cancellations (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Accelerated share repurchases, additional shares received Accelerated Share Repurchases, Additional Shares Received Accelerated Share Repurchases, Additional Shares Received Tax credits Deferred Tax Assets, Tax Credit Carryforwards Supplier relationships Supplier Relation Ships [Member] Supplier Relation Ships [Member] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Expected annual amortization expense, 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Three Schedule of Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Retained Earnings Retained Earnings [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Common Stock Common Stock [Member] Valuation Allowance [Table] Valuation Allowance [Table] Discontinued operation, continuing involvement, prepaid asset Discontinued Operation, Continuing Involvement, Prepaid Asset Discontinued Operation, Continuing Involvement, Prepaid Asset Number of reportable segments Number of Reportable Segments Shares available for purchase (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to) Contingent consideration, liability Business Combination, Contingent Consideration, Liability Statement [Table] Statement [Table] Schedule of Major Classes of Assets and Liabilities Held For Sale Disposal Groups, Including Discontinued Operations [Table Text Block] Released (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Furniture, fixtures, and office equipment Furniture and Fixtures [Member] Lease liability - operating leases Non-current lease liabilities Long-term lease liabilities Operating Lease, Liability, Noncurrent Total contributions made Defined Contribution Plan, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Accelerated share repurchases, shares received at inception Treasury Stock, Shares, Acquired Payment for contingent consideration Payment for Contingent Consideration Liability, Financing Activities Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Leasehold improvements Leasehold Improvements [Member] FRANCE FRANCE Disposal Group Name [Axis] Disposal Group Name [Axis] Trade accounts receivable, net of allowances of $4,304 and $4,735 Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Gain from sale of business - book to tax differences Effective Income Tax Rate Reconciliation, Assets Held-For-Sale, Outside Basis Difference, Percent Effective Income Tax Rate Reconciliation, Assets Held-For-Sale, Outside Basis Difference, Percent Statement [Line Items] Statement [Line Items] Unvested at beginning of year (in shares) Unvested at end of year (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Schedule of Benefit Obligations and Plan Assets Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block] Variable Rate [Domain] Variable Rate [Domain] Selling, general and administrative Selling, General and Administrative Expense Change in fair value of contingent consideration and others Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Contract Asset Change In Contract With Customer, Asset [Roll Forward] Change In Contract With Customer, Asset [Roll Forward] Right of use asset - operating leases ROU assets Operating Lease, Right-of-Use Asset Accelerated shares repurchased Stock Repurchased During Period, Value Accumulated Other Comprehensive Income Total AOCI Attributable to Parent [Member] ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Comprehensive Income (Loss) Note [Text Block] Auditor Firm ID Auditor Firm ID Demonstration equipment Demonstration Equipment [Member] Demonstration Equipment Type of Restructuring [Domain] Type of Restructuring [Domain] Document Transition Report Document Transition Report Foreign Tax Authority Foreign Tax Authority [Member] 2024 Defined Benefit Plan, Expected Future Benefit Payment, Year Two Total other comprehensive gain (loss), before tax Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent Local Phone Number Local Phone Number Summary Of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Operating income Operating income Operating Income (Loss) Inventory related items Deferred Tax Assets, Inventory Contract asset, net of transferred to trade receivables on contracts during the period Contract With Customer, Asset, Net Of Reclassified To Receivable Contract With Customer, Asset, Net Of Reclassified To Receivable Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets State and Local Jurisdiction State and Local Jurisdiction [Member] Annual rate of lease agreement Annual Rate Of Lease Agreement Annual rate of lease agreement. Accelerated shares repurchased (in shares) Stock Repurchased During Period, Shares Effective income tax rate reconciliation, foreign income tax rate differential, increase (decrease), amount Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Property, Plant And Equipment Property, Plant and Equipment, Policy [Policy Text Block] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) Additional Paid-In Capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Basic net income per share: Earnings Per Share, Basic [Abstract] Intrinsic value, options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Derivative [Line Items] Derivative [Line Items] Diluted (in shares) Weighted average common shares for diluted earnings per share (in shares) Weighted Average Number of Shares Outstanding, Diluted ESPP proceeds received Employee Stock Purchase Plan Proceeds Proceeds received from employees in connection with the employee stock purchase plan. Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Sale of extremity orthopedics business, payment for terminating license agreement Disposal Group, Including Discontinued Operation, Payment Related To Contract Termination Disposal Group, Including Discontinued Operation, Payment Related To Contract Termination Expected life of option from grant date Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Schedule of Impact on Statement of Operations Accounting Standards Update and Change in Accounting Principle [Table Text Block] Buildings and building improvements Building and Building Improvements [Member] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Capitalized incremental financing costs Debt Issuance Costs, Gross Total current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities One-Month Eurodollar Rate One Month Eurodollar Rate [Member] One Month Eurodollar Rate [Member] Interest Rate Swap Designated December 13, 2017 Tranche 2 Interest Rate Swap Designated December 13, 2017 Tranche 2 [Member] Interest Rate Swap Designated December 13, 2017 Tranche 2 [Member] Gross increases: Unrecognized Tax Benefits, Increases During Period [Abstract] Unrecognized Tax Benefits, Increases During Period [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Asia Pacific Asia Pacific [Member] Operating Segments Operating Segments [Member] Convertible Debt Convertible Debt [Member] Deferred tax assets Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Aggregate Intrinsic Value, Exercisable at end of year Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Preferred stock, authorized shares (in shares) Preferred Stock, Shares Authorized Asset Acquisition, Development Milestone Payment To Be Paid Asset Acquisition, Development Milestone Payment To Be Paid Asset Acquisition, Development Milestone Payment Non-cash impairment charges Impairment of Intangible Assets, Finite-Lived 2025 Notes Two Thousand Twenty Five Senior Convertible Notes [Member] Two Thousand Twenty Five Senior Convertible Notes [Member] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Foreign Currency Forward Contract Foreign Exchange Forward [Member] Common stock, issued (in shares) Common Stock, Shares, Issued Interest expense capitalized into property, plant, and equipment Interest Costs Capitalized Adjustment Property and equipment purchases included in liabilities Capital Expenditures Incurred but Not yet Paid Cash Flow Hedging Cash Flow Hedges Cash Flow Hedging [Member] Term Loan Facility Term Loan Facility [Member] Term Loan Facility [Member] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Convertible notes, aggregate principal amount Debt Instrument, Face Amount Issuance of common stock through employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Comprehensive income, net of tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent Cash received from option exercises and employee stock purchase plan Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Schedule of Net Sales and Profit, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Entity Current Reporting Status Entity Current Reporting Status Operating loss carryforwards, not subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration Convertible debt Convertible Debt Schedule of Funded Status Schedule of Net Funded Status [Table Text Block] Cross-Currency Interest Rate Swap Cross-currency swap Cross Currency Interest Rate Contract [Member] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Prepaid expenses and other current assets Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current Federal statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Charged to Costs and Expenses SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Issuance of common stock through employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Schedule of Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Derivative [Table] Derivative [Table] Outstanding at beginning of year (in shares) Outstanding at end of year (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number State income taxes, net of federal tax benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Non-cash lease expense Noncash Lease Expense Noncash Lease Expense Cost Cost Of Definite And Indefinite Lived Intangible Assets Gross Excluding Goodwill Cost Of Definite And Indefinite Lived Intangible Assets Gross Excluding Goodwill. Contingent consideration Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability Basis Of Presentation Basis of Accounting, Policy [Policy Text Block] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Change in fair value of contingent consideration liabilities Change in fair value of contingent consideration liabilities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Title of Individual [Domain] Title of Individual [Domain] Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to) Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Cancellations (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Principal Repayment Long-Term Debt Other income, net Other Nonoperating Income (Expense) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Business combination, contingent consideration, liability, noncurrent Business Combination, Contingent Consideration, Liability, Noncurrent Security facility, weighted average interest rate Debt, Weighted Average Interest Rate, From Securitization Debt, Weighted Average Interest Rate, From Securitization Derivative instruments not designated as hedging instruments, gain (loss), net Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Manufacturing period for products shipped with no alternative use and right of payment for performance Revenue From Contract With Customer, Products Shipped With No Alternative Use And Right Of Payment For Performance, Manufacturing Period Revenue From Contract With Customer, Products Shipped With No Alternative Use And Right Of Payment For Performance, Manufacturing Period Line of credit facility, fair value of amount outstanding Line of Credit Facility, Fair Value of Amount Outstanding Expected return on plan assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets Total current assets Assets, Current Recognition of revenue included in beginning of year contract liability Contract with Customer, Liability, Revenue Recognized Smaller Reporting Company Entity Small Business Transitional supply agreement, payable Disposal Group, Including Discontinued Operation, Transitional Supply Agreement, Payable Disposal Group, Including Discontinued Operation, Transitional Supply Agreement, Payable Number of reporting units Number of Reporting Units Shares issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Defer payment and taxation, bonus and other eligible cash compensation, percentage (up to) Defined Benefit Plan, Defer Payment And Taxation, Bonus And Other Compensation, Percentage Defined Benefit Plan, Defer Payment And Taxation, Bonus And Other Compensation, Percentage Sale of business, contingent consideration Disposal Group, Including Discontinued Operation, Consideration, Contingent Consideration Disposal Group, Including Discontinued Operation, Consideration, Contingent Consideration Performance obligations expected to be satisfied, expected timing Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Deferred tax liabilities Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Total unrecognized compensation costs related to unvested awards Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Tax benefit realized from stock options exercised Share-Based Payment Arrangement, Exercise of Option, Tax Benefit Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Accrued vacation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Vacation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Vacation Aggregate Intrinsic Value, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Maximum average conversion value of notes Debt Instrument, Maximum Average Conversion Value Of Notes Debt Instrument, Maximum Average Conversion Value Of Notes Cumulative Effect, Period of Adoption, Adjustment, Debt Discount Reclassification Cumulative Effect, Period of Adoption, Adjustment, Debt Discount Reclassification [Member] Cumulative Effect, Period of Adoption, Adjustment, Debt Discount Reclassification Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Total costs and expenses Costs and Expenses Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Debt Instrument [Line Items] Debt Instrument [Line Items] Business Combination and Asset Acquisition [Abstract] Issuance of common stock for vesting of share-based awards, net of shares withheld for taxes (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Payment of debt issuance costs Payments of Debt Issuance Costs Total lease liabilities Operating Lease, Liability Balance at Beginning of Period Balance at End of Period SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Future minimum lease payments, finance leases Finance Lease, Liability, to be Paid Expected annual amortization expense, 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Two Weighted Average Exercise Price, Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Benefits paid Defined Benefit Plan, Plan Assets, Benefits Paid Inventories Disposal Group, Including Discontinued Operation, Inventory ACell, Inc. ACell, Inc. [Member] ACell, Inc. Charges: Restructuring Charges Other non-current assets Increase (Decrease) in Other Operating Assets Hedging Relationship [Domain] Hedging Relationship [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Auditor Location Auditor Location Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Previously capitalized financing costs, written-off Write off of Deferred Debt Issuance Cost Entity Filer Category Entity Filer Category Federal Current Federal Tax Expense (Benefit) United States (Includes long-lived assets in Puerto Rico) UNITED STATES Adjustments for performance achievement related to award target (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Adjustments for Performance Achievement, Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Adjustments for Performance Achievement, Shares Total stock-based compensation expense Share-based compensation expense recognized Share-Based Payment Arrangement, Expense Security Exchange Name Security Exchange Name Weighted Average Exercise Price, Outstanding at beginning of year (in dollars per share) Weighted Average Exercise Price, Outstanding at end of year (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted Average Life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Purchase of option hedge on convertible notes Cost of call transactions Payments For Option Index To Issuers Equity Payments For Options Indexed to Issuer's Equity Amount of Gain (Loss) Reclassified from AOCI into Earnings Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Percent of manufacturing facility owned by corporation whose shareholders are trusts whose beneficiaries include family members of company's former director Percent Of Manufacturing Facility Owned By Corporation Whose Shareholders Are Trusts, Whose Beneficiaries Include Family Members Of Company's Former Director Percent Of Manufacturing Facility Owned By Corporation Whose Shareholders Are Trusts, Whose Beneficiaries Include Family Members Of Company's Former Director Letters of credit outstanding Letters of Credit Outstanding, Amount Penalties and interest accrued Income Tax Examination, Penalties and Interest Accrued Other long-term liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Total revenue, net Total revenue Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Service cost Service cost Defined Benefit Plan, Service Cost SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] Securitization facility, fair value of amount outstanding Securitization Facility, Fair Value Of Amount Outstanding Securitization Facility, Fair Value Of Amount Outstanding Cover [Abstract] Cover [Abstract] Interest crediting rate for cash balance plans Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate Entity Voluntary Filers Entity Voluntary Filers Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Audit Information [Abstract] Audit Information REVENUES FROM CONTRACTS WITH CUSTOMERS Revenue from Contract with Customer [Text Block] Segment Reporting [Abstract] Segment Reporting [Abstract] Deferred revenue Deferred Tax Assets, Deferred Income Change In Projected Benefit Obligations Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Call Option Call Option [Member] Risk free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Recognized actuarial losses Defined Benefit Plan, Amortization of Gain (Loss) Cash taxes paid in net equity settlement Payment, Tax Withholding, Share-Based Payment Arrangement Total liabilities and stockholders’ equity Liabilities and Equity Property, plant and equipment, net Disposal Group, Including Discontinued Operation, Property, Plant and Equipment Incremental financing cost expense Amortization of Debt Issuance Costs Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Traditional Wound Care Traditional Wound Care [Member] Traditional Wound Care Remaining amount under share repurchase Stock Repurchase Program, Remaining Authorized Repurchase Amount Total deferred tax assets Deferred Tax Assets, Gross Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Schedule of Income (Loss) Before Income Taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Less: Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount September 30, 2023 and the last day of each fiscal quarter thereafter Debt Covenant Period 4 [Member] Debt Covenant Period 4 [Member] Diluted (in dollars per share) Diluted net income per common share (in dollars per share) Earnings Per Share, Diluted Proceeds from sales of property and equipment Proceeds from Sale of Property, Plant, and Equipment Accumulated benefit obligation Defined Benefit Plan, Accumulated Benefit Obligation Contingent Consideration Liability Contingent Consideration Liability [Member] Contingent Consideration Liability [Member] Award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Consolidation Items [Axis] Consolidation Items [Axis] Debt Instrument, Covenant, Maximum Leverage Ratio Debt Instrument, Covenant, Maximum Leverage Ratio Debt Instrument, Covenant, Maximum Leverage Ratio Amortization of product technology Cost, Amortization 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Taxes Collected from Customers Revenue, Transaction Price Measurement, Tax Exclusion [Policy Text Block] Balance, beginning of year Balance, end of year Unrecognized Tax Benefits Deferred tax assets after valuation allowance Deferred Tax Assets, Net of Valuation Allowance United States operations Income (Loss) from Continuing Operations before Income Taxes, Domestic Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Line of credit, commitment fee percentage Line of Credit Facility, Commitment Fee Percentage Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Discount rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Accounts Receivable, Allowance for Credit Loss Accounts Receivable, Allowance for Credit Loss [Table Text Block] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Amortization expense Amortization Intercompany loan, quarterly payment Intercompany Loan, Quarterly Payment Intercompany Loan, Quarterly Payment Derivative fair value Total derivatives designated as hedges — Assets Derivative Asset, Subject to Master Netting Arrangement, before Offset Schedule of Operating Lease Maturities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Income tax (expense) benefit related to items in other comprehensive gain (loss) Other Comprehensive Income (Loss), Tax Capitalized share-based compensation cost Share-Based Payment Arrangement, Amount Capitalized Contract liability, Beginning of Period Contract liability, End of Period Contract with Customer, Liability Product and Service [Axis] Product and Service [Axis] Class of Stock [Domain] Class of Stock [Domain] Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Interest expense Interest Expense Codman trade name Trade Names [Member] Disposal group, payable recognized Disposal Group, Including Discontinued Operation, Accounts Payable Five Year Option Lease From November 1, 2029 Through October 31, 2034 Five Year Option Lease Period One [Member] Five Year Option Lease Period One Leases and Other Deferred Tax Liabilities, Leases And Other Deferred Tax Liabilities, Leases And Other Schedule of Long-term Debt Maximum Leverage Ratios Schedule of Long-Term Debt Instruments [Table Text Block] Machinery and production equipment Machinery and Equipment [Member] Leased facilities Building [Member] Proceeds from sale of stock purchase warrants Proceeds from warrant transactions Proceeds from Issuance of Warrants Interest Rate Swap Designated December 15, 2020 Tranche 2 Interest Rate Swap Designated December 15, 2020 Tranche 2 [Member] Interest Rate Swap Designated December 15, 2020 Tranche 2 Unfunded benefit obligations Defined Benefit Plan, Funded (Unfunded) Status of Plan Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Contributions to Integra Foundation Charitable contributions Charitable contributions Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Total deferred tax liabilities Deferred Tax Liabilities, Gross Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Other comprehensive (loss) income, before tax: Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent [Abstract] Interest Rate Swap Designated December 18, 2018 Tranche 1 Interest Rate Swap Designated December 18, 2018 Tranche 1 [Member] Interest Rate Swap Designated December 18, 2018 Tranche 1 [Member] Employee contributions Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Currency Swap Currency Swap [Member] September 30, 2022 through June 30, 2023 Debt Covenant Period 3 [Member] Debt Covenant Period 3 [Member] Unrealized foreign exchange loss Deferred Tax Liabilities, Unrealized Foreign Exchange Loss Deferred Tax Liabilities, Unrealized Foreign Exchange Loss Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Other liabilities Disposal Group, Including Discontinued Operation, Other Liabilities Expected annual amortization expense, 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Five Accrued expenses and other current liabilities Accrued Expenses And Other Current Liabilities [Member] Accrued expenses and other current liabilities. Discount rate Business Combination, Intangible Asset Acquired, Discount Rate Business Combination, Intangible Asset Acquired, Discount Rate Research And Development Research and Development Expense, Policy [Policy Text Block] Weighted Average Grant Date Fair Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] SEC Schedule, 12-09, Allowance, Credit Loss SEC Schedule, 12-09, Allowance, Credit Loss [Member] Interest Rate Swap Designated December 15, 2020 Tranche 1 Interest Rate Swap Designated December 15, 2020 Tranche 1 [Member] Interest Rate Swap Designated December 15, 2020 Tranche 1 Interest Rate Swap Designated December 18, 2018 Tranche 2 Interest Rate Swap Designated December 18, 2018 Tranche 2 [Member] Interest Rate Swap Designated December 18, 2018 Tranche 2 [Member] Non-cash in-process research and development expense Noncash Or Part Noncash, In Process Research And Development Noncash Or Part Noncash, In Process Research And Development Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Right of use asset - operating leases Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Asset, Operating Leases Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Asset, Operating Leases Performance Stock and Contract Stock Awards Performance Stock and Contract Stock [Member] Performance Stock and Contract Stock [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, No Par Value Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Lessee [Abstract] Cash Flow, Lessee [Abstract] Adjustments for performance achievement related to award target (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Adjustments for Performance Achievement, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Adjustments for Performance Achievement, Weighted Average Grant Date Fair Value Disposal Group Classification [Domain] Disposal Group Classification [Domain] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Research and development Research and Development Expense [Member] Cost of goods sold Cost of Sales [Member] Amortization of debt issuance costs and expenses associated with debt refinancing Amortization Of Debt Issuance Costs And Debt Refinanced Fees Amortization Of Debt Issuance Costs And Debt Refinanced Fees Senior Credit Facility Senior Credit Facility [Member] Senior Credit Facility. Closure of Facility Closure of Facility [Member] Closure of Facility Accounting Standards Update [Extensible List] Accounting Standards Update [Extensible Enumeration] Accounting Standards Update 2016-13 [Member] Accounting Standard Update 2020-06 [Member] Accounting Standard Update 2020-06 EX-101.PRE 19 iart-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 20 iart-20221231_g1.jpg begin 644 iart-20221231_g1.jpg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end GRAPHIC 21 iart-20221231_g2.jpg begin 644 iart-20221231_g2.jpg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end GRAPHIC 22 iart-20221231_g3.jpg begin 644 iart-20221231_g3.jpg M_]C_X 02D9)1@ ! 0$!2@%* #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" /A!G4# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]%O#?ANWU M^REN;F6<2^:5^1ASP#DY!YYK7_X5_I__ #VNO^^E_P#B:/A__P @:;_KX;_T M%:Z:@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_ M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P") MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_ M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z? M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_ M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P") MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_ M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z? M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_ M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P") MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_ M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z? M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_ M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P") MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_ M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z? M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_ M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P") MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_ M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z? M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_ M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P") MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_ M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z? M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_ M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P") MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_ M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z? M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_ M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P") MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_ M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z? M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_ M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P") MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_ M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z? M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_ M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P") MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_ M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z? M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_ M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P") MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_ M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z? M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_ M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P") MH_X5_I__ #VNO^^E_P#B:Z:B@#RW68#H>K7%K:S2K&NWG=@G*@\XQZT5-XP_ MY&.[_P" ?^@+10!TWP__ .0--_U\-_Z"M=-7,_#_ /Y TW_7PW_H*UTU !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M 'F?C#_D8[O_ (!_Z M%'C#_ )&.[_X!_P"@+10!TWP__P"0--_U\-_Z"M=- M7,_#_P#Y TW_ %\-_P"@K734 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 >9^,/\ D8[O_@'_ * M%'C#_D8[O_@' M_H"T4 =-\/\ _D#3?]?#?^@K735S/P__ .0--_U\-_Z"M=-0 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !117+?%'QY:_##X>Z[XHO 'BTVV:58R<>;(<+&F>V MYRJY]Z ,CXK?'7P;\&;.*7Q-JJP7,PW06%NOFW,H]0@Z#@_,V!QC->$2?\%' M?!HO J>%]=:U_P">C&$/_P!\[R/3^*O*OV:?@_<_M2>/=>\>^/YY=1TNWN L MD.]E%U.1N$0(.5CC4K\H(X* <9K[?A^$?@>WTT:>G@W018@8^SG3(2AXQR"O M)QW- '/?"3]H[P-\:6>#P_J;)J:)YCZ9?1^3U>*Z/\ LF^"_"GQ9T?QWX;2;0;BQ,QETVW.;:8R1/'D \QXWDX!V\8P M.M>6_M_?&B]\+Z-IO@31[EK:ZUB(W.H21,5?[-N*I&".SLKY]DQT8T =O\1O MVY/AQX#OIK"RFNO%-[$2K_V2JM K>AE9@I^J;A7&Z;_P4<\'S72)?>%]:M+< M\&6%HI2/^ EEX_&NL_9O_9)\-?#GPMI^I^(](MM8\6W,2S3O?1"5+,D9$4:- ME05Z%NI.<''%>P>)/A-X,\7Z9)I^K^%]*O+9UV8:U1648P-K@!E('0J010 S MX:_%GPK\7-';4?"^K1:C%'@30X*30,AP>AP<$UU]?FOXPT?4?V*_V MCK&\TBXFG\/S[;B-&.3<63L5E@?L64AL'U"-QTK]([6ZBOK6&Y@<2P3(LD;K MT92,@_E0!\R_\/"/APFO2V,FGZZ+-9?*74%MXFC(!QOVB3=MZG@$X[=J^E]/ MOK?5+&VO;29;BTN(UFAFC.5=& *L#Z$$&OR7^%'PW_X6+X1^(1@B\S4=%TM- M5ML#D^7(/,7\8R_'F.#STS[7X@URT\,Z#J6L7[F. MQT^VDN[AU&2L<:%V./H#7P'\ ?#]GX3_ &Y+S1=/C\JQT^?4+6!?1$A=1GWP M*^T_CG_R1/X@_P#8O:A_Z324 >"R?\%&O ZR,$\-^(&0$[6*P D>N/,XKI/" M_P"WO\+O$5]':W3ZOH&\X$^IVB^5GW,3O@>Y 'KBO+O^">WA#0?$WAGQC)K& MB:=JKQ7=NL;7UI',4!1L@%@<5[%^T+^S#X)\9_#W6[O3M!L-$U^QLY+FTO-/ M@6#+1J6".$ #*V-N2"1G(Z4 >[6-];:I9P7=G/'=6DZ"2*>%PZ2*1D,I'!!' M>J/BKQ-8^#/#.J:[J?L\)#M^;F(>X#4 =7\(?VRO!_QA\:P^&+'3M5TR_N$=[9KY(@DNQ2Q7 M*N2&V@GIC@\^OOE?F3\3OAIJ'[+?B7X5>*;2.1;E[."\NE8G_C]C8-/$?12L MB+[_ #5^E.BZO:^(-'L=4L91-97L$=S!(.C1NH93^((H C\1:]:>%_#^IZS? MLR6.G6LMY<,@R1'&A=B!W. :^77_ ."C?@<.P3PUX@9<\$K "1]/,KWOXY_\ MD3^(/_8O:A_Z325\L?\ !/;PAH/B;PSXQDUC1-.U5XKNW6-KZTCF* HV0"P. M* /3_#?[?7PMUZ^6VNCK.@JV +C4K-3'D]LQ/(1]2 *^A]-U.TUG3[>^L+J& M]LKA!)#<6[AXY%/1E8<$5X1^T=^SCX%\1_"_Q'J-IX?T[1-9TRPFOK>^TZW2 MW8M%&7VOM #*0NWYLXSD8KSK_@G%XLU#4O"WBWP]<2/+8:7<6]Q:AN1'YPDW MJ#V&8@V/4L>] 'T)\;OC1I'P)\(P>(-9L[R^@N+Q+*.&Q52YD9'?)W, !MC; M\<5O?#OQQ9?$KP3I/B;3H9[>RU*'SHXKD 2*,D$-@D=0>AKY\_X*+?\ )$]$ M_P"QA@_])KFO3/V3_P#DW?P/_P!>3?\ HUZ -OXM?'+PA\%=-BNO$VH-%/K$#WKP5?\ @H]X/^W!#X6UP6>>90T)DQZ[-V/_ !ZO M)/$EK;_%?]NY]&\9R-)I*:F]DEO(Y"&**)FAB'HLC!<@=?,;N:^\Y/AWX5FT MO^S)/#6D/IVW8+5K&(Q;<8QMVXZ#% &3\*?C)X7^-&A2ZIX9O7N(X7$=Q;SQ MF.:!R,A74^H[@D'!YXKMF8*I9B ,DGM7%?#CX.>%?A+-K+^%M/.FQZK*DT\ M E9XU900-@8G:/F/&<<\8KYX_;^^-%[X7T;3? FCW+6UUK$1N=0DB8J_V;<5 M2,$=G97S[)CHQH [?XC?MR?#CP'?36%E-=>*;V(E7_LE5:!6]#*S!3]4W"N- MTW_@HYX/FND2^\+ZU:6YX,L+12D?\!++Q^-=9^S?^R3X:^'/A;3]3\1Z1;:Q MXMN8EFG>^B$J69(R(HT;*@KT+=26SKLPU MJBLHQ@;7 #*0.A4@B@!GPU^+/A7XN:.VH^%]6BU&*/ FAP4F@8YP)$/*]#@] M#@X)KKZ_-?QAH^H_L5_M'6-YI%Q-/X?GVW$:,^TG') KZ45@RAE(((R".]?D#\.?AA<_$;PYXTNK .^H:!IZZFD M*\^;&K@2KCU"$L/]S'>OO+]B/XS?\+(^&*:%J$X?7?#H2U?O2G M?";XG:;\8/ UCXHTFWNK2SNFD00WBJ)%9'*-G:Q&,@XYZ>E>5_MW?\F[ZK_U M^VO_ *-%3_L-?\FXZ#_U\7?_ */>@#WVBBDH P?&WCSP_P##G0Y=8\2:K;Z3 MI\9QYL[/,E)7GU=>RU]S^# M?@OX(\ Z5%I^B^&=.MHD7!E>W62:3C&7D8%F/)ZGO0!XYX(_;\^'7B>^BL]5 M@U+PS+(VT3WD:R6XSTRZ$D?4J /6OI&RO;?4K."[M)X[JUG19(IX7#I(A&0R ML."".HZ M8/BW_!/SXK:A'J>L?#?5I9#'!&][IZ2YS"RL%FB'L=P8#L0_K0!]0_&?XR:+ M\#O!Z^(=7WAC1KV[FM"TEQ<: M?%)(Y\QQDL5R: .9\+_M_P#@OQ1XETK1H] URVDU"ZBM$FD6$JC2.%!;$F<9 M(SCG'K7U#7-VGPU\(:?=0W-KX5T2VN87$D$89HUFADL;!'CD4,K*;J8$$'J"* /4/\ AXYX)_Z%G7_R@_\ CE>E? O] MJKPY\>?$&H:/I.EZIIUW9VOVLF]6/8R;U0X*L>5)&0<=>_./:*_/?\ :$T*[_9C_::TCQ_HMN1I M&IW#7XB084L?ENX/;<'+#T\P8^[7W3-XZT:#P,WB]KQ?[!%A_:7VKL8-F\,/ M:?&3]JKPQ\&_%UAX9O-.U36M8NHTE\C3$1M@=BJ*=S#+,0<*.V/4 M5Z%\1/B%IOPP\"ZEXKUJ.X&GV$:/+% JM*2[JBJ!D#)9U'7'O7Q;^RSX;O\ M]H3]H37/B?X@BWV6FW'VJ.-N5^T'BWB'J(D4'V*)GK7T7^VI_P FR^,O^W/_ M -+8* /.O^'CG@G_ *%G7_R@_P#CE'_#QSP3_P!"SK_Y0?\ QRI_V&? OAOQ M#\#5N]5\/:5J=U_:=PGGWEE%*^T!,#0K, '5)$# , 2,@'G!-:<\T=M#)-*ZQQ1J7= MV. J@9))]*2VMH;.WBM[>)(((D$<<4:A510,!0!P !VKQ3]LCXB?\*]^!>LB M&7R]0UG&E6^#@_O ?,/X1A^>Q(H P?!?[=7@3QMXZL/#5MI^L6AU"Y%I;7US M'$(F=CA-P#E@&. ..XR!V^CJ_+'QW\$;SX=_ WX<_$*#S8-0U*>22Z<$YBWG MS+1E],HC-GU85^D7PH\=0_$KX<>'O$T)7_B8VB2RJO1)1\LJ?\!<,/PH ZRO ME+4/^"BG@.UO9X;?0=>NX8W*K.J0J) /X@#)G!]Z^K:_.[_@GWX;TCQ+X]\3 MPZOI5EJL4>F*Z1WUNDRJWFJ,@,#@XH ]VT/_ (*#_#+5+J*"\M=>T=6'SW%U M9QO$A_[9R,Y_!:^AO#'BK2/&FB6VL:%J-OJFF7"[HKFW?'[K3I_#&EZ;*/"AE:33);!KXQJ=R+-'+''N'IE9"#Z[5]* /OFBBB@"*ZNH;&UFN M;F:.WMX4,DDTK!410,EF)X [FOF_P ;?M\_#CPO?RV>FQZEXFEC)4SV$2K; MY'H[L"1GN%([@GOYG^W1\6M6\0^,--^$WAR1SYK0&_BA8AKBXE(\F _[(!1L M="77^[7NOP7_ &4?!7PK\/6B7FD6.O\ B$HK76IWT"S?O.I$2N"$4'@8 )'4 MF@#C/"?_ 4&^'FN7D=MJUEJWA[>TVVU'3 M;N&^L+E!+#_2-1(C,5!&UVP?;]:]AKX&_X)N_\CMX MQ_[!T/\ Z-K[YH XGXP?%?2_@OX)G\3:O;75Y:Q2QPB&S53(S.<#[S 8_&K' MPI^)6G?%WP)IWBK2[>YM+*],@6&["B12DC(V=I(ZJ<<],5Y%^WM_R;Y=_P#8 M1M?_ $(UJ_L1?\FU^%_^NEY_Z52T :'QR_:G\+? ?6=/TG5[+4=1U"\@^U"* MP2,B.+E=-\&_CAX9^.>@W.I^''N4^RRB*YM+V,1SPL1E2P M5F&",X()'![@U\>?MX0I#HI462-])LU9&&0P-Y< @BK'P)N'_9Q_:\U MKP-=.T>C:O*;&$N>"&_>6CGU."$^LAH ^^Z**\P_:4^)H^$_P=U[6HI?*U&2 M/[%88.&^T2 JK#W4;G^B&@#SKQG^WM\/O"/BB[T9++6-8^QS-!/>6,47D[E. M&V%I 6PP1W,+,N"4=0RDCL<$5^3_B[X M:GPG\#?!?B6ZBVW_ (CO[N52P^86T:QK&/Q8R-[AEK]0_A3_ ,DN\'?]@:S_ M /1"4 <1JG[3OAS2OCE%\+I-.U-]8>2*$WBI']G#R1"51]_=C:RY..N>.]>P MU\#>,?\ E(Y;_P#81L?_ $@BK[YH JZIJ$6DZ;=WTX8P6L+SR;!D[54L<>^! M7E_P(_:1T#X_2:VFBZ=J6GOI7E&7[>L8#K)OVE=CMS\AR#[=:[[QU_R)/B'_ M +!UQ_Z*:OC;_@FK_P ?WQ!_ZYV/\[B@#ZD^-WQHTCX$^$8/$&LV=Y?07%XE ME'#8JIF?LG_\F[^!_P#KR;_T:] 'K5%%% 'D M_P =OVD/#?P"CTI=9M;[4+O4O,,-M8*A953;N9MS# RP ZYY]*WO@W\8-$^- MW@\>(=#2X@@6=K::WNU42Q2* 2#M)&,,I!ST(Z=*^0/%FEQ?M3?MG7>AS.\O MAO0XI+65HF^[% "'(_WKA\9]"*L?L+^)+OX<_&#Q;\--7?RY;AI%1">/M5LS M!@O^\F\Y](Q0!]+?'C]I'0/@ =%36=.U#49=4\XQ+8JF%$>S<6+,/[XQC/?I MW\F_X>.>"?\ H6=?_*#_ ..5]/ZYX5T7Q,(1K&CV&K"'=Y7VZU2;R\XSMW X MS@9QZ"O'_P!I3X<^$]*^!/C2[LO"^C6=W#8,T<]OI\*.AW+R&"Y!^E ' ?\ M#QSP3_T+.O\ Y0?_ !RNU^#_ .V5X6^,GCBV\+Z=HVK6%[<1221RW2Q>7\BE MB#MY MKZITGP'X:\/W@N]+\.Z3IMVH*B>TL8HI #U&Y5!P: /./BY^U#X;^#GCO1O" MNJZ;JEY>ZE#'<":S2,QQH\K1KG6.)X[%5+C>P4,=S 9('U(KXT_;J_Y.6\%_\ 8*LO_2RXK[;^)7@N#XB> M =?\-7.T1ZE9R6ZNPR$<]M+ M;W042Q2+C*MM)'(*L.>C#Z5W-?!__!/GQE<>&?'?BKP#J8:WEN$-S'#(?N7$ M#;)4QZE3D_\ 7*OO"@#COBU\4M)^#G@B\\3ZRD\UK;LD:P6P4RRN[ *JAB!Z MD\] :B^#_P 4['XR>![;Q/IMA>:=9W$LD21WRJ';8VTL-K$$9!'U!KY8_P"" MAGC"?6-:\'_#[3MT]Q(WV^6!.2\CDQ0+]?\ 6_\ ?0KZX^&O@N#X=^ = \-6 M^TIIMG' SKT=P/G?_@3%F_&@#YWU#_@HIX#M;V>&WT'7KN&-RJSJD*B0#^( MR9P?>H/^'CG@G_H6=?\ R@_^.5Y%_P $^_#>D>)?'OB>'5]*LM5BCTQ72.^M MTF56\U1D!@<'%?<__"J?!/\ T)V@?^"N#_XF@#%^!_QLT?X[>%;K7-&L[RQA MMKMK.2&^50^\(CY&UB",./QS7HE4-&T'3/#MH;72=.M-+MBYD,-G L*%B "V MU0!G@<^U7Z ,[Q%KUIX7\/ZGK-^S)8Z=:RWEPR#)$<:%V('_CG_R1/X@_]B]J'_I-)7RQ_P $]O"&@^)O#/C& M36-$T[57BN[=8VOK2.8H"C9 + XH ]/\-_M]?"W7KY;:Z.LZ"K8 N-2LU,>3 MVS$\A'U( KZ'TW4[36=/M[ZPNH;VRN$$D-Q;N'CD4]&5AP17A'[1W[./@7Q' M\+_$>HVGA_3M$UG3+":^M[[3K=+=BT49?:^T ,I"[?FSC.1BO.O^"<7BS4-2 M\+>+?#UQ(\MAI=Q;W%J&Y$?G"3>H/89B#8]2Q[T ?1/QG^,FB_ [P>OB'7(; MJYMY+E+2&"S16DDE968#YB !A&).>U>#_P##QSP3_P!"SK_Y0?\ QRKW_!1; M_DB>B?\ 8PP?^DUS75_LO_#OPIJ_P#\&WE]X8T:]NYK0M)<7&GQ22.?,<9+% M97JOQT_:4\/_ %30SJVGZCJ3ZN) M7A6Q5,*L>S)8NPZ^8N ,]^G?M%^%?@I6#+X/T$$'((TR#C_QVM37/"NB^)A" M-8T>PU80[O*^W6J3>7G&=NX'&<#./04 ?,'_ \<\$_]"SK_ .4'_P M.>"?^A9U_P#*#_XY7?\ [2GPY\)Z5\"?&EW9>%]&L[N&P9HY[?3X4=#N7D,% MR#]*\N_8!\%^'O$GPIUVXU?0=,U6X36GC66]LXYG5?(A.T%E) R2<>YH ]'^ M#_[97A;XR>.+;POIVC:M87MQ%))'+=+%Y?R*6(.UR1P#VK>^*W[3OASX1?$# M1/".J:=J=W?:I%%,LUHD9BC625HESN<$GB:3X#\->'[P7>E^'=) MTV[4%1/:6,44@!ZCBM(ML@:1BSJBJH) R691R1UKXE_8K_ .3J/&7_ %YZA_Z5 MQ5](_MJ?\FR^,O\ MS_]+8* /.T_X*-^!RZA_#7B!4SR56 D#Z>978^"_P!N M;X6^,-02SFO+_P .2R.$C;6K=8XV)]7C=U4>[$"N4_89\"^&_$/P-6[U7P]I M6IW7]IW">?>644K[0$P-S*3BHOVS?V>_!EO\)]4\7:-HMEH.LZ2T4A?3X5@C MN$>549710%)^?(;&: /K".1)HUDC971@&5E.00>A!KS'XZ?M">'?@%IV MF7&N6][>SZD\B6UM8HI9@FW>Q+, -Z^^2*X']@OQ9J'B?X%"WOY'F&CZC+I M]O(_/[D)'(JY[[?,('H !7E__!2W_FG/_<2_]M: /ICX+_'KPM\=M)O+SPZ] MU#+9.J7-E?1JD\6[.UB%9@5.#@@GH>E>C5^:G@O4+S]D?X\:!?3O(WAC7+"W MFE=LD/9SJI8^[12 ^Y"?[5?I/!/'=0QS0NLL4BATD0Y5E(R"#W&* /(8_P!J M#PS)\<#\,%T_5#K'FF#[9Y9^,/^1CN_\ M@'_H"T4>,/\ D8[O_@'_ * M% '3?#__ ) TW_7PW_H*UTUV@D _B4+))@_C&I_"OI6OG_ /;E\,S>(OV?-5F@1I'TNZ@ORJC)*AC& MQ_!9"Q]@: )?V'=,AL/V;_#L\0P][/=W$ONPN)(__08UKWNOF7]@'QI;:[\% M6T(2K]MT.]EC>'(W"*5C*CX]"S2#_@)KZ:H *_.[]IC_ (J3]MC1]+N&S"M[ MI-D-_0(YC8_AF0_G7Z(U^=W[:UK/X%_::T;Q08GD@FBL]0C(Z,T#[60'U_=J M?^!"@#]$:*J:1JMKKNDV6I64HGLKR!+B"5>CQNH96_$$5;H ^(O^"E5BG_%O M[P8$G^G0MZD?N"/RY_.OJ7X&WH:?;R-)#%R1+<,@2/']XB-3CT<>M?;O@?P__ ,(GX)\/ MZ'G/]F:?;V62ZGD_NHBEF/Y"OB[]C#0[SXM?&CQC\6=9ASY4LBVN[D+/ M-G*J?^FU#_ -)I*^/OA+_RD&U__L(:I_Z+DK[! M^.?_ "1/X@_]B]J'_I-)0!\@_L(_%KP?\-_#OBR#Q-K]IHTMU=0/"ERQ!=0C M D8'8D5Z7^T7^V3X,L_A_JVB^$=477]T62V1O)MD<;6=G( +;22RV%S#%#]FN#$ K*Q.<#GD"OK3P?^R5\*_! M-]'>V7A6&ZO(R&2;499+K:1T(1V*@YYSC- 'FO[ ?PEU+P3X'U;Q-J]M)9W' MB!HOLL$HPPMHPQ60CMO+G&>RJ>AKS?QA(?VB/VY+#1P?M&@^'9EAD'5/+MB9 M)L_[TV8\^A6OL/XO>.XOAG\,_$?B:0J&T^T=X5;HTQ^6)?Q=E'XU^=W[.L_Q M=\,W&J>+_ ?A/^WVU'=:3:A/1YY=]_X=G-FP)^8P-EX M3],%D'_7.O.+[XJ_M0ZE9W%I<_#JSFMKB-HI8VTYL,K#!!_?=P:\X_8T\1ZE M\(?VA)O"6OV\NEOK$9T^XM;@;3'< >9"2/4\J/\ KK0!]R_'/_DB?Q!_[%[4 M/_2:2O@3]EO]I[2_V?\ 2->L]0T2[U5M2GBE1K:54"!58$'=]:^^_CG_ ,D3 M^(/_ &+VH?\ I-)7S-_P3ET^UOO"_C0W%M#<%;RW \V,-CY']10!R?Q!_:^\ M4?M#6O\ PKWP1X;CT>37,VDDES?H9IT/6-2P1$##(.2Q() Q7TW^S#\!4^ W M@62RNIX[S7M1D6XU">+.P$#"1)GJJY;G')8GT \<_;@_9[TJ+PC_ ,)_X8TZ M+2]3TR1/[02Q01+-"2%$NU1S@G/W17L/[)_P 7)/B]\(-/O;Z?SM;T MYCI^H,3\SN@&V0_[R%23_>W>E 'GO_!1;_DB>B?]C#!_Z37->F?LG_\ )N_@ M?_KR;_T:]>9_\%%O^2)Z)_V,,'_I--_M;?L MG:QXT\1-X]\"CS-;VHU[IR/Y %!7(SM!'/!X?X:_MT>*_A[? M+X=^)^B7.H?92(I;KRO(U"''_/2-L+(C(_7@\[3E3W!H UO 7Q"\/\ Q-\.P:WX;U*+4K"7@LAP M\;8Y1U/*L,]#Z@]"*^$?VF/^*D_;8T?2[ALPK>Z39#?T".8V/X9D/YU/^Q)J M6H^ _P!HK7?!8NVN;"9+JUG$?^J>6W8[90.W"N!_OU!^VM:S^!?VFM&\4&)Y M()HK/4(R.C- ^UD!]?W:G_@0H _1&BJFD:K:Z[I-EJ5E*)[*\@2X@E7H\;J& M5OQ!%6Z /B+_ (*56*?\6_O!@2?Z="WJ1^X(_+G\Z^I?@;=R7WP7\!SRDM*^ MA6)9CU)\A,G\>M?'W_!0WQ)'XD^(GA'PGI_^EZAI]O(TD,7)$MPR!(\?WB(U M./1QZU]N^!_#_P#PB?@GP_H><_V9I]O99SG/EQJG_LM 'PU_P3C4/\0?%JL MRG2E!!&0?WJUG^*+6Y_8U_:F@U6SCD7PCJ;&41QK\KV4K?O81ZM$P! SGY8\ M_>K1_P""OE*Q^+;>,OV-_$/@[4)]^I^'+NT>W\QOFDLVG4*!Z^6Q MV^RL@KZM_8:_Y-QT'_KXN_\ T>] 'OM3 M);6EM&TTTTAPL:*"68GL 37Y]?LB6DGQ*_:PUSQE%$XM+>34-5+MT4W#.B* M?8_!S]N?0OAG\,] \+W7AC4 M+V?38#$]Q#/&JN=[-D \]Z]._P""BW_)$]$_[&&#_P!)KFNV_9;\(Z%?_L_^ M"[BZT73[F>2S8O+-:QLS'S'Y)(R: .2^&O[=GA[XC>.='\-1>&=3L9M3G%O' MB>)XXC-''%)N@NU7[WEYY##KL.> 3DX./HBOSE\4:?:^$_V_+.W\/PI M% ?$-B6BA7"H9DB,^ />20T ?HU1110!Y/\ M.?"-?C%\)=4TJ"(/K%H/MVF MMCGST!^3_@:ED^K ]J^!_P#A?FKW_P"SM;?">..XEOVU01A@"2UID.L&.N[S MC^0 K]4*_._PUH&G#_@H.]B+.(6::WVK]OV?:=0D7^.Y< OSW"\(#Z(*Y?]M3_DV7QE_P!N?_I;!7M] M>(?MJ?\ )LOC+_MS_P#2V"@#Y1_9Y_:)\>_#'X>C1?#OP^G\2Z=]KEF^W1P7 M#C>VW*Y12.,#\Z]E\&_M;?$[7?%NBZ;J'PEO+6QO+R&VGN%M[E3$CN%+Y9,? M*#GGCCJ.M=/^P%_R0%?^PK<_R2OI&@ KX4_; U&X^,?[17@[X8:?*WD6CQQ7 M!CYV2SE6D8COLA"-[9:OMW7=:M?#FB:AJU])Y5E8V\ES/)_=C12S'\@:_,;X M6ZY\3O$OQ7USXE^#/#/_ D&KFYF>5I83+%;-/NX'S+R$RH]!0!]^?'/X7V_ MCSX(Z[X4LK95>.Q!TZ)!]V6$!H5'IDH%^A->"?\ !.KXB?;_ SX@\%7,F9M M/E&H6BL>?*D^60#V5PI^LM5?^%Q?M3_]$^M?_!>W_P >KQ'X4^(_$'P/_:=T MO4?%FEMXN1@=35?]A/XP3^/_AO< M>'=4N3/JWAUEB1Y&R\EJP/E$D]2I#)[ )ZT ?35%%% 'YX>$5'BK_@H7.+TF M7RM>OBN[_IWAE,?Y>4OY5^A]?G-XNO%^#'[=S:MJ#>182:NMVUP_"B&ZCP[Y M]%\UP?\ =-?HPK!E!!R#R"* %HHHH ^!O^";O_([>,?^P=#_ .C:^^:_/O\ MX)]WH\/_ !F\4Z!=D17,NG2(%?AC)#,H*@>N&8X_V37Z"4 ?.G[>W_)OEW_V M$;7_ -"-:O[$7_)M?A?_ *Z7G_I5+7/?\% M4AL?@3':NP\V\U6WCC7/)VJ[ MDX] %_45U7[%]A-I_P"S;X16=2CRBYF"D?PMCPC_P4 T[5+LB*UFU'3'\R3A5C:"* M%FSZ AN?:OT$H P_'7_(D^(?^P=O,_^"BW M_)$]$_[&&#_TFN:],_9/_P"3=_ __7DW_HUZ /6JXKXT>/D^&'PM\2>)2RK- M8VC&W#=&G;Y(A^+LOX9KM:^,?^"B7CR1K+POX#L6:2XO9?[1N8H_O%03'"N. M^YC(<>J"@#0_X)X>!)+7PKXC\;7H9[K5KG[)!))RQCC^9VSWW.V#[QUY]^UQ MI]S\$_VFO#GQ#TV,K#?M%?E5X#S0E4GC_P"!1[,_]=#6AX#\5?M)_#?PCIGA MO1OAW!'INGQ^7$);$LYRQ8LQ\T9)))/'>N1^/U_\=/B9X/1_&_@5+'2M'D:] M-[;69C:$;2K9/F-\N"">/X1Z4 ?HGI>IVVM:79ZA9RB>SNX4N(95Z.CJ&4CZ M@BO-OVI/^3?/'/\ V#F_]"6N*_88^(G_ FOP2MM+GEWW_AZ8V#AC\QA/SPM M]-I*#_KG7:_M2?\ )OGCG_L'-_Z$M 'DO_!.;_DD/B#_ +#LG_I/!7U;7RE_ MP3F_Y)#X@_[#LG_I/!7U;0!^?_[=7_)RW@O_ +!5E_Z67%?H!7Y__MU?\G+> M"_\ L%67_I9<5^@% 'YY_'^VD_9[_:_TOQE:HT>FW]Q%JQV#JKDQW:?4_O#_ M -M!7Z$0S1W$*31.LD4BAU=3D,I&00?2OF3]O_X>?\)/\)+;Q';Q;[SP]="1 MV R?L\I"2#\&\H^P4UA^%_C_ /9_V&KG6C<_\3O3[5O#JD-\XGXCB8>XB='_ M . F@#S_ .$T?_#0O[:VK>*7'VC1=&G>]A;JICAQ%:X]"6V28]FK[[KY<_X) M^_#W_A&OA/>>))X]MWX@NBR,1S]GA)1/SL]0T2[U5M2GBE1K:54"!58$'=]:^^_CG_P D3^(/_8O:A_Z325\S?\$Y M=/M;[POXT-Q;0W!6\MP/-C#8^1_44 &X]'DUS- MI)).\U[49%N-0GBSL! M PD29ZJN6YQR6)] /'/VX/V>]*B\(_\ "?\ AC3HM+U/3)$_M!+%!$LT)(42 M[5Q\Z-MY'."<_=%>P_LG_%R3XO?"#3[V^G\[6].8Z?J#$_,[H!MD/^\A4D_W MMWI0!Y[_ ,%%O^2)Z)_V,,'_ *37->2_"']J+XD>"?AOH.AZ/\,;C6M-LH#' M!?I;7+"9=S'.54@\DCCTKUK_ (*+?\D3T3_L88/_ $FN:],_9/\ ^3=_ _\ MUY-_Z->@#SOX/_M._$/QY\1-)T'7?AC=:+IEX9%EU#R+A!!MC9@Q+IMP2H') M'7\#]/444 >6?M2?\F^>.?\ L'-_Z$M>2_\ !.;_ ))#X@_[#LG_ *3P5ZU^ MU)_R;YXY_P"P19H)D62.1#E64C((/H0:?)(D,;R2,L<: LS,< =230!\ _L5_\ M)U'C+_KSU#_TKBKZ1_;4_P"39?&7_;G_ .EL%?-G["&[7/VB/%^L0H?LC:== M2;NP,EU$5'U(#?E7TG^VI_R;+XR_[<__ $M@H ^6OV>U7/'/QY\:_MDW4'P^\):':Z'I\[+<7,=Q?*TDRH M=$KY&$X.1TKRW]M3 MX+P_"S6-%^)?@F#^PR;M4NTL0(T@N1\\4R ?=W88''&0.[&@#ZQ^!OPEL_@K M\.=/\,VLWVN:,M/=W>W;Y\[?>;&>!P% ]%'>OE__ (*6_P#-.?\ N)?^VM?4 M_P %?B1#\6?ACH/B>+8LUY !=1)TCN%.V5<=AN!QGL0>]?+'_!2W_FG/_<2_ M]M: /0/V@_@S_P +6_9G\.WMA!YOB#0=*M[VT"+EY8_(3S8A]5 8 =611WI? MV$_C-_PGGP[?PKJ,_F:UX=58XRYYELSQ&??9]P^@">M>]?#?_DG?A?\ [!5K M_P"B5KX5^)NDW/[(7[46G^*-+A>/PMJDK7"PQ_=:W<@7-N!ZH3N4=OW?I0!< ML_\ E(LW_85D_P#2,U^@-?GSH]W!J'_!0FWO+69+FTNK_P"T0S1G*O&]CN5@ M?0@BOT&H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \S\8?\ (QW?_ /_ M $!:*/&'_(QW?_ /_0%HH Z;X?\ _(&F_P"OAO\ T%:Z:N9^'_\ R!IO^OAO M_05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JZII=KK>EW>G7\"W5C=PO M;SP2?=DC92K*?8@D5:HH _//Q1\$_BA^R=\0)_$_P_CNM:\/MN"RV\)G_66]_O5]T44 M?)/P8U+XY?&+XJZ+XL\403>%?!>G&63^S=KVL=QNC9% B8[Y#E@=S_*,$KSQ M7J?[3OP @^/7@F.UMY8[3Q#IK--IUU*#M)(^>)\=%?"\]BH/J#['10!^>?@? MX_?%;]E.S7POXP\)W&I:):MLMDOBT7EC)^6&Y561DST&&QT&.E=1JG_!0;Q- MXMA.E^"_A^4UF9<1NUP]\X)&"5A2-22">"21ZCM7W)3(XDA79&BQKDG:HP.3 MD_K0!\U?8WQ<\ P_$_ MX:^(?#$P7.H6K)"S=$F'S1-^#JI_"NOHH _+K]E_X-ZKXV^.&CZ?K&GW4.FZ M'*UY>I/FEV@CT+5^HM%% 'PA\*=)OHOV_M?N'L[A(/MVIOYK1 M,%VF-\'.,8.1^8KZ[^-EO+=?!GQ[!!&\TTF@7Z)'&I9F8V\@ '4D]J[2B@# MX^_X)RZ?=6/A7QF;BVFMP][;[3+&5SB-LXS]1^=?8-%% 'R%_P %#/%&HOX; M\->#]-M;FX_M&X:]N?(B9LK'A8TX'.6^9)?R=F'T KO:* "O@[]N[P'J?A?XJ>&OB%H5O,9;I8Q)-!&6\N[ MMV!C-% 'F?CK6G\<_LV>(]5MK29)=6\*75PEIL/F!I+1B$ MVXR3DXKPK_@G+I]U8^%?&9N+::W#WMOM,L97.(VSC/U'YU]@T4 9WB+0K/Q1 MH.HZ/J$?FV.H6\EK.GJCJ58?D:^&/V.I->^#G[0FO^ -4M+G[+J'FVKR>2PC M\Z#<\N]:^^** /F#_@H787.H?!72%M;>:Y:/7X'<0H6*K]GN!DX MZ#) S[BO2?V5[>6T_9\\$Q3Q/#*MD'W\3^'?M4KVU]<(P7RRY*[+E 5 P1\K@L.!QTJ#6/V_/%?C;3I-* M\$^ 9+;6KA?*2X6X>_>-FR 4C6)QK[GIJ1K'D*H4$DG:,:AXT\91F'Q#?Q&"WLW<2201LP9Y)""1O8@<9R!G/+$#TC]IWX M 0?'KP3':V\L=IXATUFFTZZE!VDD?/$^.BOA>>Q4'U!]CHH _//P/\?OBM^R MG9KX7\8>$[C4M$M6V6R7Q:+RQD_+#)O%L)TO MP7\/RFLS+B-VN'OG!(P2L*1J203P22/4=J^Y*9'$D*[(T6-<\B>8#A-O\*=00,A=H!^RJ** / M@K_@G;H]_IOQ"\6F[LKBU"Z:L9\Z)DPWG#Y3D=>#Q[&OO6BB@#\V/VPO@+JG MP[^(FH:WH.G7+^%M>/GDVD9,<$Q8-)"P7H-X#J#@<@#[M?6?[%.FW>E?L[>' MHKVVFM)7EN95CF0HQ5IW*M@]B.1ZCFO=** "BBB@#XF_:7_9@\5Z#\0F^)GP MOCGDNVG^VW-E8_\ 'Q!<=6EB7_EHKG)* $Y)X(.!1T?_ (*&^(?#=N-.\7^ MQ/JT*[9)([EK)B0/XHGC;!)ZX('H.U?<],DB28 .BN%(8;AG!'(/UH _/WQE M\;OBW^UI9GPUX0\(S:3X=NF"W+6S,ZR 'E9KI@J!ZW?,L^I7R# =P,*B9YV)D@9ZDL>,X'K%% 'S!_P %"["YU#X* MZ0MK;S7+1Z_ [B%"Q5?L]P,G'09(&?<5Z3^RO;RVG[/G@F*>)X95LCE)%*L, MR.1P?8UZM10 4444 %?(GQ!_:D^*'P4^('B&V\1^!O[9\*"\D;3;U$>W'V?/ MR?OU5T;"XR"NX$G)KZ[HH ^(M5_X*(:IKUNUAX2\ .VL3 K"\]TUR%/J(DC! M?_OH?C6W^RO^S7XGC\>7'Q/^)4M2.\]G:7+@S&:0'=-*H^[@$A4/(ST&T M5]?QPQP[RB*F]MS;1CX-C-_M@:3>ZY^SGXPL]/M)KVZ9;5UAMT+N52ZA=B M.3A5)^@->R44 ?G7\"?VC?&/P/\ @\-0?#:^U=!=27/VB031'Y\<;1$>F/6 MO1/^&[O&W_1([K_O[/\ _&:^T** /E;]JKXK:IJ7[+VCSP:1=Z=J7BY8$GLP MC,]M&5\V12<#KM"\@9#GBNX_8V^'4GP\^!FDK=6[6^I:L[ZG M1^[5..Q)KW&B@ KXX_X*'_#&?6-&\.^,M/M9+B>R=M.O/)0LWE/EXF..RL'' MUD%?8]% 'GG[/WC2Z^('P<\+ZS?1RQ:A):B&Z$RE6:6(F-WY_O%-W_ J^3?^ M"=NCW^F_$+Q:;NRN+4+IJQGSHF3#>']3NS8(8XF9&M+E@82"!SL?RP3_L-7Z#T4 %%% M% 'SW^UI^S*?CCH]KJVB-%;^+-,C,<(E.U+R');R6;^$@DE6/&6(/!R/GOP? M^U1\5?V>;"'PSXV\)S:E:60$-N=3$EO,J#@*L^&610. <'C')&!7Z$44 ?#% MQ^V-\6?B]&=+^'?@-K">X^3[9"KWCQ DC/F,JQI_O.,<=J^IO@-X7\3^#_A? MI.F^,=2?5?$8,LUU/).T[ R2,X0N?O%0P'ID8&1@UZ#10!\.?M$?LY^-? 'Q M2G^*?PTCDN@;@ZA+;V:!KBUG.?,(CQ^\C;)) !/S,",/4&MT+XY)C:)BO/.-WM[U]S4QHD:17**77(5B.1GK@T ?GVWAC MXI?MK>/-+O\ 7M*E\.>#+-_E=HVBAAB)!?RBPS+*P &[&,@?=%??6B:+9>'= M'L=*TZW6UL+*%+>"%.B1J J@?@*NT4 ?!7[<&CW]]^TAX*EM[&XN(CIMF@DB MB9E+"\G)&0.H!''N*^]:** /S._;(^$^H^#?C=J5UI-C=2:=XC47T8M8V8&1 MVQ-&<#D^8-V/]M:^[O@!\-U^%'PD\/>'F0+>Q0":]([W$GSR<]\$[1[**]#H MH ^-_P#@H[I]U?:%X&-M;37 2YNPQBC+;P\1>&!$WB33HC;O:R,(_M<. M2RJK'@.K%L9(!#'D8&?(?"?[<'CGX3V,/ASQ[X-EU._LQY*SW,K6-R57 &\& M-@Y&/O#&>"],DB29"DB+(AYVL,C@Y% 'Y\^-_C5\5/VO+./PMX4\(R: M7H%Q(INC S2(^&R/.N6555 0#@ $D=^E?8GP%^#]G\$OAS8>'H&CGO3_ *1J M%U&#B>X8#BT4 ?,_\ P4 T'4M>^"VEIIMA<7\D&NP32I;1 M-(R)Y$Z[B .FYU&?<5XE\,OVKOB#\,_ >C^%[7X<27L&FQ&)+B:&X5G&XMD@ M+CO7Z"T4 ?('P_\ VRO'OBKQSX?T6_\ ALUG9:C?PVDURB7 ,*R.%,F67&%S MN.>P[=:X3PSI.H?'S]MZYUB\L;D:'HUZTZM-"P18;7Y(1R,?/(%8C_::OOJB M@ JGK&DVVO:1?:9>Q^=9WL#VT\9_BC=2K#\035RB@#X!_9#CUKX-?M):YX'U M"UNOLE]Y]@\ODL$,D.Z2&;.,8*A\?]=!7U?^TY;37GP"\;PP1//*VG-MCC4L MQY!X KT^B@#Y9_X)XV-S8_"'7AO(-?4U%% 'P5^ MW#H]_>_M(>"IK>RN)XFTVSC$D<3,I87DY*Y ZX8<>XK[UHHH RO%?ANT\8>& M=5T*_7=9ZE:R6DO'(5U*DCW&J* ,?P?X9M/!?A72-!L5Q::;:16D?&"0BAKX#U'5I[J#[')!-%-#Y95P2?PO<6MY]F6&9F82K ML5MP+(I_BQT].:]4HHH XOXV6\MU\&?'L$$;S32:!?HD<:EF9C;R =23VK MYR_X)RZ?=6/A7QF;BVFMP][;[3+&5SB-LXS]1^=?8-% &=XBT*S\4:#J.CZA M'YMCJ%O):SIZHZE6'Y&OAC]CJ37O@Y^T)K_@#5+2Y^RZAYMJ\GDL(_.@W/'* M#TVLF_'KO6OOBB@#YG_X* :#J6O?!;2TTVPN+^2#78)I4MHFD9$\B==Q '3< MZC/N*\=^%O[67C/X8_#_ $7PO%\+[S4(]-A,(N7:9#)EBV=OE''7UK[ZHH ^ M,%_;N\;;AGX1W9'?$T__ ,9K[)L[@W=G!.T3P-)&KF*0?,F1G:?<5-10!YA^ MTY;37GP"\;PP1//*VG-MCC4LQY!X KRC_@GC8W-C\(=>%S;RVY?7)&42H5W# MR(1D9Z\@U]344 %>'_M6_L^R?'CP7:IIDL-OXCTJ1I;)I^$E5@!)$S8^7.U2 M#ZJ,\$D>X44 ?GSX&_:B^(_[,^GQ^#?&_A"74;73_P!S:"[D-M+&@S\BS!76 M5!QM(SQQG&,6?&?[5WQ'_:(TFY\)^ _!=QI\%^#;W4MH[74K1L,%#)L5(E() MR3V/4=_OMT61&1U#HPP589!'I2JH50J@ 8 ':@#Q7]E?X CX%^!9(]0\F7Q M-J;";4)H3N5 ,^7"K=PH)R>[,W48I?VRK2>^_9L\8PVT,EQ,1:,(XD+,0+R$ MDX'H 3]!7M5% 'SI^P79W%E\!8TN()(';4[E@LJ%21\@SSVR#^5>L_&'X?P_ M%'X9^(?#$H7??VK+ S=$G7YHF_!U4_3-=E10!\4_\$^/$VL:'JGBKP%JUA=V ML:?\3&$30LHBD5EBF0DC@G,?'^RWK2_\%(M-O+Z/X>/;6D]PD9U!7:*-F"D_ M9L D#C.#^1K[5HH Y_X>Q/#X!\,QR(T^#:_&GX M67VFVT2-KME_IFF.V ?.4',>3T#KE>N,E2>E>MT4 ?E_^RKX6\0VO[3'A6/4 M-*U&&>QEE%P+B!U,"I;NHW9'R@?*HS[#TK]0*** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** /,_&'_(QW?\ P#_T!:*/&'_(QW?_ #_ - 6B@#IOA__ M ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \S\8?\C'=_\ /\ MT!:*/&'_ ",=W_P#_P! 6B@#IOA__P @:;_KX;_T%:Z:N9^'_P#R!IO^OAO_ M $%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@#S/QA_P C'=_\ _\ 0%HH\8?\C'=_\ _] 6B@#IOA_P#\@:;_ M *^&_P#05KIJYGX?_P#(&F_Z^&_]!6NFH **** "BBN,\-_%?1/%7C_Q+X/L M5NCJOA\1F\=X@(?G ("MGD\\Y Z&@#LZ*** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** /,_&'_(QW?\ P#_T!:*/&'_(QW?_ #_ - 6 MB@#IOA__ ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** /F[XV_' M/QI-\6++X5?#&WLT\1R0K/>:I?@,ELI7?@ @CA,,20WW@ ,UQ>F? ?\ : ^& M?B#6O&'A_P 5:!X@UO5F274[.6()]M9=VU1NC55Z_P +1]?:K_[07PV\=^ ? MC=:?&3P#IIU\^2L6HZ;&A>0[8_*/R#YF5D"_=R5*YQBNK^&_[<7@3QE>PZ7K ML=UX,UEF\MHM2 -N)/[OG#[OU=4% 'N3:AJT?@\WW]G+)KJV'G?V>K@*UQY> M?*#9Z;_ESFOG6'X9_M%^/+,B0N3M)QS MLZ=J ,?]FOXW>-YOBGX@^%?Q&EAU#6]-1Y(-1B55+[""5.T ,K(ZLIV@X!SU MX[S]J'XZW/P5\(6(T:U2^\4:U.;338) 6"D ;I"HY;&Y %[EQVXKRO\ 9!T= M/B+\3/%?Q:U?6=+N==U!3''H]A/ODLHWV\R \C"HJ+USAN'?[?'Q13_A(3']I.A"W01! ML9\H-MV9[8V[<]\O:3 MJEMKFE66I64HFL[R%+B"0='C=0RG\015NO*/V5;YM0_9Y\#RN22MCY/S>B.R M#]%KU>@ HHHH ***RKKQ1IEG6]E?VMW<65D1MDC.H6@#C/%6C:=X)_;R\(VW@B.*PEOK=&U>RL@%B!82F4,HX&8E1 MRN.N&ZG-:O[64G_""_M&_"/QU>8CTA)$L[BX/2-4GW.3_P G8C_ '3Z5[#\ M%/V9O#7P7O;K5H;B[U[Q+=AEGUC46W2;6.6"C^') R3ECZXXKK?BM\*/#_QD M\)3>'_$,#R6S,)89X2%FMY0"!(A(.#@D<@@@D$4 =7)?6T=BUX]Q$MFL?G&X M+@1A,9W;NF,5G_>%7 MX_V'=6DL1HEY\7_$=QX2&%&BJC*FP8PO,Q3 QQ^[P/2OHCX>_#W0_A=X4L_# MWAZT^R:=; D;CN>1SRSNW\3$]_H!@ "@#Y@_8>N8_!'CSXG_ _U!TMM3MK\ M2P0DX,JQM(CE<]0!Y9^C9KT']N;Q?:^'/@#JVGR2JM[K4T-G;1DC*H_%FDZW?>#/%BJ VIZ;SYA"[0S*&4[@O&Y6&1P MX0J07>6VG1>?'_T44 %%%% !5232;*:1GD ML[>1VY+-$I)_'%6Z* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_ M8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q= M/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7 M]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[% MT_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_ M8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q= M/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7 M]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[% MT_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_ M8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q= M/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7 M]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[% MT_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_ M8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q= M/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7 M]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[% MT_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_ M8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q= M/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7 M]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[% MT_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_ M8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q= M/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7 M]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[% MT_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_ M8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q= M/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7 M]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[% MT_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_ M8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q= M/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7 M]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[% MT_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_ M8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q= M/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7 M]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[% MT_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_ M8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q= M/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7 M]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[% MT_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_ M8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q= M/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7 M]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[% MT_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_ M8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q= M/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7 M]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[% MT_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_ M8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q= M/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7 M]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[% MT_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_ M8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q= M/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7 M]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[% MT_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_ M8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q= M/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7 M]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[% MT_\ Y\+7_ORO^%7:* &1Q)#&J1HL:+P%48 _"GT44 %%%% !1110!YGXP_Y& M.[_X!_Z M%'C#_D8[O\ X!_Z M% '3?#_P#Y TW_ %\-_P"@K735S/P__P"0 M--_U\-_Z"M=-0 4444 0W=G!J%N]O=01W,$@P\4R!E8>A!X-/AACMH8X88UB MBC4(D: !54# Z"GT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% 'F?C#_D8[O_ (!_Z M%'C#_ )&.[_X!_P"@+10!TWP__P"0 M--_U\-_Z"M=-7,_#_P#Y TW_ %\-_P"@K734 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 >9^,/\ D8[O_@'_ * M M%'C#_D8[O_@'_H"T4 =-\/\ _D#3?]?#?^@K735S/P__ .0--_U\-_Z"M=-0 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110!YGXP_Y&.[_X!_Z M%'C#_D8[O\ X!_Z M% '3?#_P#Y TW_ %\-_P"@ MK735S/P__P"0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110!YGXP_Y&.[_ . ?^@+11XP_Y&.[_P" M?^@+10!TWP__ .0--_U\-_Z"M=-7,_#_ /Y TW_7PW_H*UTU !1110 5Y_X/ M^,%EXQ^)WC#P9;:?<13^&Q#YUX[*8Y3(N<*!R,<]?2O'OC5\5?'7B_XXVGPA M^'NHP>'KA+=;G4=8D0-(@*>9M7@X 0IT&XE@,@ DY-O^R7\4O .I:GXC\'_% MQKOQ'?.LMV-0L3$EXRYQYC%Y0QY.,KW[4 ?6]%8LTFN1^#7DCBMY?$BV!98L MXA:Z\OA.O"/QLUGX/^/M4;Q!-;Q--9:E,Y>7A!(/G/S,KQ MMN^8DJ1BMG]O;QMK_@OX9Z%+X?UF^T2>XU98Y9]/N&@D9!#(=N]2#C(!QGG MH ^FJ*^4K']D_P")%[8V]Q_PT+XJ3SHUDVXN3C(!QG[97T#\+O!^J> _!-AH MFL>)+OQ;J%N9#)JU\&$LNYV8 [G<_*"%Y8]/P !UE%?(7B;QKXZ_:4^-FN>! M/!?B2?PAX/\ #I:+4=5L21/-(K%&P5*L& M]*URP8M9:E:Q7<);@['4,,^AP>:U* "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBOS<^*GQ@\)/_!M? M!_1IO%/BNT;5M\ZO)JE^@G9!*P4L7;<>.Y]*] D^,W@".-G/C?PZ0HR=NJP, M?R#9->C&K"45*^Y\=7P->C6G1Y6^5M72?0[*BN#_ .%\?#O_ *'31?\ P,3_ M !J6W^.'P]N7*IXVT$$#/[S4(D'YLPJO:0_F1E]3Q/\ S[E]S.WHKE;7XK>" M;V39;^,= G?^[%JD#']&K>L=8L-2_P"/.^MKK_KA*K_R-4I)[,QE1J4_CBU\ MBY1115&04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% 'F?C#_ )&.[_X!_P"@+11XP_Y&.[_X!_Z M% ' M3?#_ /Y TW_7PW_H*UTU"_VYM+CU:+0?B1 MX;U#P+K60CR31.8 2<;F5@)(P3[,!W:OH+2?B%X9US7=0T6QURQN-8T^4PW- M@LP$T;CL4/)'N..M>,?MQ/X0_P"%*ZBFOM:#7/D.CJVW[3YV]<^7WV[=V[MC MWQ0!]"6]Q%>6\4\$B302J'CDC8,KJ1D$$=0146I:E:Z/I]S?WUQ':65M&TTT M\S!4C11EF)[ 5Y5^RS'?:+^SEX/.NO]GDBLGE9KCY/+MS([1%B>@$13GTKQ MSQ9XHUO]LSQM/X-\)W$VF?"[2YE.KZV@PU\P.0B9Z@D?*OMO;^%: '_LVV=S M\:/VBO&7QB:W>WT"+=I^EF0;6D8(D8./:)L_MBV ML5Y^S?XR65=P2*"1?9EN(B#7C'[%6J0_#?XI?$?X:ZI+':7HO=]E'(VTS>4S MJP7/7*%&&.P)KT']NKQY9>'?@I>>'_/0ZOK\T-O;VJG,AC619'?;Z?(%SZN* M .S_ &4+I[O]G?P.[@@BR,?/HLCJ/T KUJN*^"OA"?P%\)O"F@7?%W8Z?$DZ M@?=E(W./P8D?A7:T %%%% !6;<>(]-M9GAENE21#AE*GC]*TJI3:+87$C22V MD+R,D_\_B_]\M_A1_PE>D_\_B_]\M_A4W_"/Z;_ ,^,'_? MH_X1_3?^?&#_ +X% $/_ E>D_\ /XO_ 'RW^%'_ E>D_\ /XO_ 'RW^%3? M\(_IO_/C!_WP*/\ A']-_P"?&#_O@4 0_P#"5Z3_ ,_B_P#?+?X4?\)7I/\ MS^+_ -\M_A4W_"/Z;_SXP?\ ? H_X1_3?^?&#_O@4 0_\)7I/_/XO_?+?X4? M\)7I/_/XO_?+?X5-_P (_IO_ #XP?]\"C_A']-_Y\8/^^!0!#_PE>D_\_B_] M\M_A1_PE>D_\_B_]\M_A4W_"/Z;_ ,^,'_? H_X1_3?^?&#_ +X% $/_ E> MD_\ /XO_ 'RW^%'_ E>D_\ /XO_ 'RW^%3?\(_IO_/C!_WP*/\ A']-_P"? M&#_O@4 0_P#"5Z3_ ,_B_P#?+?X4?\)7I/\ S^+_ -\M_A4W_"/Z;_SXP?\ M? H_X1_3?^?&#_O@4 0_\)7I/_/XO_?+?X4?\)7I/_/XO_?+?X5-_P (_IO_ M #XP?]\"C_A']-_Y\8/^^!0!#_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_A4W_" M/Z;_ ,^,'_? H_X1_3?^?&#_ +X% $/_ E>D_\ /XO_ 'RW^%'_ E>D_\ M/XO_ 'RW^%3?\(_IO_/C!_WP*/\ A']-_P"?&#_O@4 0_P#"5Z3_ ,_B_P#? M+?X4?\)7I/\ S^+_ -\M_A4W_"/Z;_SXP?\ ? H_X1_3?^?&#_O@4 0_\)7I M/_/XO_?+?X4?\)7I/_/XO_?+?X5-_P (_IO_ #XP?]\"C_A']-_Y\8/^^!0! M#_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_A4W_"/Z;_ ,^,'_? H_X1_3?^?&#_ M +X% $/_ E>D_\ /XO_ 'RW^%'_ E>D_\ /XO_ 'RW^%3?\(_IO_/C!_WP M*/\ A']-_P"?&#_O@4 0_P#"5Z3_ ,_B_P#?+?X4?\)7I/\ S^+_ -\M_A4W M_"/Z;_SXP?\ ? H_X1_3?^?&#_O@4 0_\)7I/_/XO_?+?X4?\)7I/_/XO_?+ M?X5-_P (_IO_ #XP?]\"C_A']-_Y\8/^^!0!#_PE>D_\_B_]\M_A1_PE>D_\ M_B_]\M_A4W_"/Z;_ ,^,'_? H_X1_3?^?&#_ +X% $/_ E>D_\ /XO_ 'RW M^%'_ E>D_\ /XO_ 'RW^%3?\(_IO_/C!_WP*/\ A']-_P"?&#_O@4 0_P#" M5Z3_ ,_B_P#?+?X4?\)7I/\ S^+_ -\M_A4W_"/Z;_SXP?\ ? H_X1_3?^?& M#_O@4 0_\)7I/_/XO_?+?X4?\)7I/_/XO_?+?X5-_P (_IO_ #XP?]\"C_A' M]-_Y\8/^^!0!#_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_A4W_"/Z;_ ,^,'_? MH_X1_3?^?&#_ +X% $/_ E>D_\ /XO_ 'RW^%'_ E>D_\ /XO_ 'RW^%3? M\(_IO_/C!_WP*/\ A']-_P"?&#_O@4 0_P#"5Z3_ ,_B_P#?+?X4?\)7I/\ MS^+_ -\M_A4W_"/Z;_SXP?\ ? H_X1_3?^?&#_O@4 0_\)7I/_/XO_?+?X4? M\)7I/_/XO_?+?X5-_P (_IO_ #XP?]\"C_A']-_Y\8/^^!0!#_PE>D_\_B_] M\M_A1_PE>D_\_B_]\M_A4W_"/Z;_ ,^,'_? H_X1_3?^?&#_ +X% $/_ E> MD_\ /XO_ 'RW^%'_ E>D_\ /XO_ 'RW^%3?\(_IO_/C!_WP*/\ A']-_P"? M&#_O@4 0_P#"5Z3_ ,_B_P#?+?X4?\)7I/\ S^+_ -\M_A4W_"/Z;_SXP?\ M? H_X1_3?^?&#_O@4 0_\)7I/_/XO_?+?X4?\)7I/_/XO_?+?X5-_P (_IO_ M #XP?]\"C_A']-_Y\8/^^!0!#_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_A4W_" M/Z;_ ,^,'_? H_X1_3?^?&#_ +X% $/_ E>D_\ /XO_ 'RW^%'_ E>D_\ M/XO_ 'RW^%3?\(_IO_/C!_WP*/\ A']-_P"?&#_O@4 0_P#"5Z3_ ,_B_P#? M+?X4?\)7I/\ S^+_ -\M_A4W_"/Z;_SXP?\ ? H_X1_3?^?&#_O@4 0_\)7I M/_/XO_?+?X4?\)7I/_/XO_?+?X5-_P (_IO_ #XP?]\"C_A']-_Y\8/^^!0! M#_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_A4W_"/Z;_ ,^,'_? H_X1_3?^?&#_ M +X% $/_ E>D_\ /XO_ 'RW^%'_ E>D_\ /XO_ 'RW^%3?\(_IO_/C!_WP M*/\ A']-_P"?&#_O@4 0_P#"5Z3_ ,_B_P#?+?X4?\)7I/\ S^+_ -\M_A4W M_"/Z;_SXP?\ ? H_X1_3?^?&#_O@4 0_\)7I/_/XO_?+?X4?\)7I/_/XO_?+ M?X5-_P (_IO_ #XP?]\"C_A']-_Y\8/^^!0!#_PE>D_\_B_]\M_A1_PE>D_\ M_B_]\M_A4W_"/Z;_ ,^,'_? H_X1_3?^?&#_ +X% $/_ E>D_\ /XO_ 'RW M^%'_ E>D_\ /XO_ 'RW^%3?\(_IO_/C!_WP*/\ A']-_P"?&#_O@4 0_P#" M5Z3_ ,_B_P#?+?X4?\)7I/\ S^+_ -\M_A4W_"/Z;_SXP?\ ? H_X1_3?^?& M#_O@4 0_\)7I/_/XO_?+?X4?\)7I/_/XO_?+?X5-_P (_IO_ #XP?]\"C_A' M]-_Y\8/^^!0!#_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_A4W_"/Z;_ ,^,'_? MH_X1_3?^?&#_ +X% $/_ E>D_\ /XO_ 'RW^%'_ E>D_\ /XO_ 'RW^%3? M\(_IO_/C!_WP*/\ A']-_P"?&#_O@4 0_P#"5Z3_ ,_B_P#?+?X4?\)7I/\ MS^+_ -\M_A4W_"/Z;_SXP?\ ? H_X1_3?^?&#_O@4 0_\)7I/_/XO_?+?X4? M\)7I/_/XO_?+?X5-_P (_IO_ #XP?]\"C_A']-_Y\8/^^!0!#_PE>D_\_B_] M\M_A1_PE>D_\_B_]\M_A4W_"/Z;_ ,^,'_? H_X1_3?^?&#_ +X% $/_ E> MD_\ /XO_ 'RW^%'_ E>D_\ /XO_ 'RW^%3?\(_IO_/C!_WP*/\ A']-_P"? M&#_O@4 0_P#"5Z3_ ,_B_P#?+?X4?\)7I/\ S^+_ -\M_A4W_"/Z;_SXP?\ M? H_X1_3?^?&#_O@4 0_\)7I/_/XO_?+?X4?\)7I/_/XO_?+?X5-_P (_IO_ M #XP?]\"C_A']-_Y\8/^^!0!#_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_A4W_" M/Z;_ ,^,'_? H_X1_3?^?&#_ +X% $/_ E>D_\ /XO_ 'RW^%'_ E>D_\ M/XO_ 'RW^%3?\(_IO_/C!_WP*/\ A']-_P"?&#_O@4 0_P#"5Z3_ ,_B_P#? M+?X4?\)7I/\ S^+_ -\M_A4W_"/Z;_SXP?\ ? H_X1_3?^?&#_O@4 0_\)7I M/_/XO_?+?X4?\)7I/_/XO_?+?X5-_P (_IO_ #XP?]\"C_A']-_Y\8/^^!0! M#_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_A4W_"/Z;_ ,^,'_? H_X1_3?^?&#_ M +X% $/_ E>D_\ /XO_ 'RW^%'_ E>D_\ /XO_ 'RW^%3?\(_IO_/C!_WP M*/\ A']-_P"?&#_O@4 0_P#"5Z3_ ,_B_P#?+?X4?\)7I/\ S^+_ -\M_A4W M_"/Z;_SXP?\ ? H_X1_3?^?&#_O@4 0_\)7I/_/XO_?+?X4?\)7I/_/XO_?+ M?X5-_P (_IO_ #XP?]\"C_A']-_Y\8/^^!0!#_PE>D_\_B_]\M_A1_PE>D_\ M_B_]\M_A4W_"/Z;_ ,^,'_? H_X1_3?^?&#_ +X% $/_ E>D_\ /XO_ 'RW M^%'_ E>D_\ /XO_ 'RW^%3?\(_IO_/C!_WP*/\ A']-_P"?&#_O@4 0_P#" M5Z3_ ,_B_P#?+?X4?\)7I/\ S^+_ -\M_A4W_"/Z;_SXP?\ ? H_X1_3?^?& M#_O@4 0_\)7I/_/XO_?+?X4?\)7I/_/XO_?+?X5-_P (_IO_ #XP?]\"C_A' M]-_Y\8/^^!0!#_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_A4W_"/Z;_ ,^,'_? MH_X1_3?^?&#_ +X% $/_ E>D_\ /XO_ 'RW^%'_ E>D_\ /XO_ 'RW^%3? M\(_IO_/C!_WP*/\ A']-_P"?&#_O@4 0_P#"5Z3_ ,_B_P#?+?X4?\)7I/\ MS^+_ -\M_A4W_"/Z;_SXP?\ ? H_X1_3?^?&#_O@4 0_\)7I/_/XO_?+?X4? M\)7I/_/XO_?+?X5-_P (_IO_ #XP?]\"C_A']-_Y\8/^^!0!#_PE>D_\_B_] M\M_A1_PE>D_\_B_]\M_A4W_"/Z;_ ,^,'_? H_X1_3?^?&#_ +X% $/_ E> MD_\ /XO_ 'RW^%'_ E>D_\ /XO_ 'RW^%3?\(_IO_/C!_WP*/\ A']-_P"? M&#_O@4 0_P#"5Z3_ ,_B_P#?+?X4?\)7I/\ S^+_ -\M_A4W_"/Z;_SXP?\ M? H_X1_3?^?&#_O@4 0_\)7I/_/XO_?+?X4?\)7I/_/XO_?+?X5-_P (_IO_ M #XP?]\"C_A']-_Y\8/^^!0!#_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_A4W_" M/Z;_ ,^,'_? H_X1_3?^?&#_ +X% $/_ E>D_\ /XO_ 'RW^%'_ E>D_\ M/XO_ 'RW^%3?\(_IO_/C!_WP*/\ A']-_P"?&#_O@4 0_P#"5Z3_ ,_B_P#? M+?X4?\)7I/\ S^+_ -\M_A4W_"/Z;_SXP?\ ? H_X1_3?^?&#_O@4 0_\)7I M/_/XO_?+?X4?\)7I/_/XO_?+?X5YY\0OC/\ #+X:F2'4[NUNK].#I^GQB>?/ MH0.$/^\17SIXW_;.FOO,@\*^%;'2XN@NM0 GE^H0853]=UY@\ MEQV-LZ=.T>[T7_!^5S[,?Q=H\:,[WT:JHR68$ #\JXCQ+^TM\-_"JN+KQ/;W M$ZC_ %%BK3N3Z?(" ?J17YY^*/'WB'QI,TFLZK<7@)SY60D0^D:@*/P%8"J6 M8 #)/ KS9YB_L1^\^RPW!\%KBJM_*/^;_R/LKQ1^WMIT#M'X=\,7%V.@GU* M=81]=B!L_P#?0KY%\1ZU+XD\0ZIJ\\:13ZA=2W=JM(Y8@9[9-=?X3^ ? MQ \:;&TSPM?>2W(N+M/LT1'J&DV@_AFN,UO2+CP_K5_I=V%%W8W$EM,$.0'1 MBK8/<9!K@K5*U1)U-CZK+L'E^"E*&$MS==;OYZZ%*BBBN4]T**^X_P!E?X2^ M#?$WP?TK5M6\-:=J>HRSS[[B[@$C-ME8*.>,8 KVB/X.> X6W1^"] C;^\NF MP@_^@UZE/ 2J14N;<^(Q7%5#"UIT/9-N+:Z=#\M**_5'_A5/@O\ Z%+1?_ " M+_XFFR?"3P1,A23PAH;H>JMI\1'_ *#6G]FR_F./_7&C_P ^7]Z/RPHK]0KG MX&_#RZ3:_@K0U'_3.PCC/YJ!6'>?LM_"V^SYGA*W7_KC<3Q?^@N*EY=4Z21M M'C#"/XZ6F^-/$&BL&T_7=2L&!R#;7DD9[?W2/0?E77Z5^T;\2] M&V_9_&.HR;>GVIEN/3KY@;/3O7USJG[%/PVU!2((=4TT^MK>[L?]_%>N/U3] M@71IL_V;XMOK3T^U6J3_ /H+)4?5,3#X7]S-O[?R;$_QH_\ @4;_ )7/*]#_ M &V/B-I>!>-I>L+QG[5:;&_ Q,@S^%>A:'^WTORIK/A!AZS6-YG_ ,<9?_9J MYC7/V$/%UGN;2]=TG45'\,WF0.?H-K#\S7GVN?LL_$[0MQ?PQ->1CI)8S1SY M^BJV[\Q1S8REO?\ ,?L>'<;\/(GZ\OX:'U=X?_;0^&VLA!=W6H:([<$7UHS M'ZQ%^/?^5>@Z/\:O OB#']G^*=-NG/\ RS68!_\ OD\_I7YEZUX9UCPW+Y>K M:3?:7)G&R]MGA.?3# 5FU4M7EHB](EE+1_BARI_*O M4_#/[7GBS1]B:GINC:]$/O-/:B&4_1HR%'_?)KKAF%-_$K'@8CA'&4]:,U+\ M'_E^)]Y?\)7I/_/XO_?+?X4?\)7I/_/XO_?+?X5\U^%?VS/ FH[(]>\+7.C2 MG@R6ZID_\_B_]\M_A1_PE>D_\_B_]\M_ MA4W_ C^F_\ /C!_WP*/^$?TW_GQ@_[X% $/_"5Z3_S^+_WRW^%'_"5Z3_S^ M+_WRW^%3?\(_IO\ SXP?]\"C_A']-_Y\8/\ O@4 0_\ "5Z3_P _B_\ ?+?X M4?\ "5Z3_P _B_\ ?+?X5-_PC^F_\^,'_? H_P"$?TW_ )\8/^^!0!#_ ,)7 MI/\ S^+_ -\M_A1_PE>D_P#/XO\ WRW^%3?\(_IO_/C!_P!\"C_A']-_Y\8/ M^^!0!#_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_A4W_ C^F_\ /C!_WP*/^$?T MW_GQ@_[X% $/_"5Z3_S^+_WRW^%'_"5Z3_S^+_WRW^%3?\(_IO\ SXP?]\"C M_A']-_Y\8/\ O@4 7+>XCNH4FB;?&XRK>M24R&%+>-8XD"1J,!5& *?0 444 M4 %%%% 'F?C#_D8[O_@'_H"T4>,/^1CN_P#@'_H"T4 =-\/_ /D#3?\ 7PW_ M *"M=-7,_#__ ) TW_7PW_H*UTU !1110!\R?M8?LZ^!]4\&^*_'?]EW$'B: M&V,PELI6 GEX52\?(/49P 3W-4_V>_V/OA_'X)\*^*-;TFXU?6;RQAO9+?4I M-T"/(H;'E $ 'H^[WKZGHH QO%WA6S\:>$]6\/7S2Q6&I6DEG,ULP1U1U*G M:2" <'N"/:OG+_AW3\-_^@WXJ_\ NV_^1Z^IJ* /G'P;^PCX!\$>+-(\06. MK^));W2[J.\ACGNX/+9T8, P6%25R.0",BN_^,O[._A/XX_89M>%]:ZA8J4M MK[3[CRY8U)R1@AE/(!Y7/H:]/HH ^:=/_8-\$F]MY]G^&=(M-+TJSAT_3K5!'!;6Z!4C4=@*OT4 >._&3]E MGP7\:=3BU;45N])UV-57^TM,D6.20+]T.&4AL=C@'H,X %9/P[_8W\%>!?%$ M/B*\NM4\5ZQ;L'MIM:G$BPL/NL%"C+ ]"V<<$ $9KWBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBJNI:G9Z/8S7M_=0V5G"NZ2XN)!&B#U+'@4#2;=D6J@O;ZWTVUENKN MXBM;:)=TDTSA$0>I8\ 5\T_%']MS1-!\ZQ\&VG]O7JY7[=+M.M^[CY[_=_G8^R/B5^VCX1\)^;:^'HW\4Z@O'F0MY=JI]Y",M_P ! M!!_O"OESXA?M*^/?B-YL-WJ[:9IS\&PTO,$9'HQ!W,/9F(]J\_\ #_AK5?%F MI1Z?HVG7.IWK](;6(NV/4XZ#W/%?2/PZ_89UG5EBNO&&IIHL#8)L;+$UQCT+ M_<0_3?7FNIB<4[1V_ ^RC@\GR**G5:YN[UE\ET^2^9\NJI9@ ,D\ "O5O O[ M,/Q"\>+%-!HK:58R8(N]5/D+@]PI&\CW"D5]S^ /@7X)^&H1]%T.!;U?^7^Y M'G7!/J';[OT7 ]J[VNJGERWJ/[CQ,9Q?)WC@Z=O.7^2_S/E_P/\ L*^']-\N M?Q3K%SK4PY-K9C[/!]"W+L/<%:]X\*?"_P )>!T0:%X=T_3G48$T< ,Q^LAR MQ_$UU%%>G3H4Z?PQ/B\5F>,QK_?U&UVV7W+0*\D\0?LK_#?Q-KE]JU[HLIO+ MV9KB=H[R5%:1CEFP&P,DD\>M>MT5I*$9Z25SDH8FOAFY4)N+?9V/%/\ ACOX M7?\ 0%N?_ ^;_P"*H_X8[^%W_0%N?_ ^;_XJO:Z*S^KTOY%]QV?VMC_^?\O_ M )F)X-\&Z1X!\.VNAZ':_8]-MMWEQ[V4 M_@XV_P#C]?=U%<<\'1GTMZ'OX?B/,J&GM.9>:O\ CO\ B?EEXJ^$?C/P3O;6 MO#6HV,2?>N# 7A_[^+E?UKD:_7NN+\5?!CP-XUWG6/"^G74K_>N$A\J8_P#; M1-K?K7%/+?Y)?>?2X?C'IB:7SB_T?^9^+O!6T:)XCU'3XUZ01W#&+ M\8SE3^(KV'PK^W%XXT?8FL6FG:_$/O.\9MYC_P "3Y1_WQ7K?BK]A7PEJ>^3 M0]7U'1)6Z1R[;F$?0':WYL:\=\5?L2^/=$WR:5)I_B"$=%MYO)E_%9,+^3&N M?V.*H?#?Y?Y'J_VAD69_QE%-_P RL_O_ .">U^%/VY/!6K[$UJPU'0)3]Y]@ MN81_P)/F_P#'*]D\*_%+PCXW5?[#\1:?J,C=((YU$WXQG##\17YF^*/A]XF\ M%R%==T'4-*&<"2YMV5&^CXVG\#6 &*D$'!'0U<?#5' M'Y\R_P _Q/UZHK\P?"GQX\?>"]BZ7XIOUA3I;W,GVB(#T"2;@/PQ7LGA7]O# MQ%8A(_$'A^QU5!P9;.1K:0^YSO4GZ 5VPS"E+XM#YO$<)XZEK2:FON?XZ?B? M;5%>">%_VTOAYKVQ-0DO] F/!^V6Y>//LT>[CW(%>N^&_'OAOQC&&T/7=/U7 MC)2UN4=Q]5!R/Q%=L*U.I\,KGS.(P&*PO\:FX_+3[]C>HHHK8X HHHH **** M "BBB@ HHHH **** /,_&'_(QW?_ #_ - 6BCQA_P C'=_\ _\ 0%HH Z;X M?_\ (&F_Z^&_]!6NFKF?A_\ \@:;_KX;_P!!6NFH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "HKFZAL[>2>XE2""-2SR2,%50.I)/05XG\ M6OVM/"7PY\ZQTV0>)=;7*_9[.0>3$W_327D?@N3V.*^-/B=\<_%_Q8N&_MK4 MF2PW;H]-MGRY^8CU8DUP5L93I:+5GU>6\.XO'6G-*?B=??:?$.K3 M7BJVZ.U4[((O]R,<#Z]3W)K&\-^%]7\7ZI'IVBZ=<:G?2?=AMHRYQZGT'N>! M7U5\*OV'>(;_ ,>7O/#?V1I\GZ22C^2?]]5Y7-B,8[+;\#[J-'*>'8K,>%'NQ KZH^&/[#,4:Q7OC MG4C(_#?V7IKX4>SRXR?<*![,:^H_#/A/1O!FEIIVAZ9;:79)TBMHPH)]6/5C M[G)K6KT*. A#6>K_ /D8OA7P7H7@?318:!I5K MI5J.J6\84N?5FZL?D45$H1FK25 MS>CB*V'ES49N+\G8^4O%G[!>EW&^3PWXENK)NHM]2B693[;TVD#\#7CGBG]C M_P")/AO>\&F6^N0+_P M--N QQ_N/M8_@#7Z(45Q3P-&6RL?2X?B?,:&DI*: M\U^JLS\E]<\,ZQX9N/(U?2KW2YLX\N\MWB/Y,!6='(\,BNC,CJ*\T\4?LR_#;Q9O:?PS;6,[?\ +;32;8@^ MNU"%/X@UQ3RZ2^"1]+A^,*4M,12:]'?\'8^&/"_[07Q#\'[%T_Q5?O"O @O' M%S&!Z!9 V!],5ZWX;_;Q\36*HFM^']-U55X+VKO;.?KG>,_0"NM\4?L$Z=-O MD\.^*+FU/58-2@64'VWIMQ_WR:\H\1_L9_$G0RYM+.QUR)>=UA=*#C_=DV'/ ML,UER8NCM?\ ,[_K'#^9?'RI^:Y7]^GYGO?AW]N3P/J>U-5L-4T:4_>8Q+/$ M/Q4[C_WS7CG[3'[05YKWC73Y/ OC+48M#73T+?V;<36H,QDDW;E^4YV[.HXK MQ7Q%\.O%/A$M_;/A[4]-1?\ EI<6KJA^C8P?P-<[653%5I1Y)G;@\AR^C66) MH:KM=-?U\SK_ /A<7C[_ *'CQ)_X-KC_ .+H_P"%Q>/O^AX\2?\ @VN/_BZY M"BN3VD^Y[_U6A_S[7W(^SOV(_'GB/Q9>^++;7-2+^T+EYS&Q,@. MTN20#@<=.*^K:^-?V _^0QXS_P"N%K_Z%)7V57TN#;=!-_UJ?C'$<(T\SJ1@ MK+3_ -)04445VGS04444 >9^,/\ D8[O_@'_ * M%'C#_D8[O_@'_H"T4 =- M\/\ _D#3?]?#?^@K735S/P__ .0--_U\-_Z"M=-0 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !17.>-_B%X>^'.DG4/$.J0:=!SL5SF24CLB#YF/T%?'GQ M<_;2USQ1YVG>#HI/#VF'*F^<@WDH]01Q%^&3_M"N:MB*='XGKV/:R_*,7F3_ M ',;1[O;_@_(^G_BI\??"/PEA9-5OOM6J[=O0L,X0>[$>V:^+?BU^ MU%XO^*)FLXYSH.A/E?[/LG(,B^DLG!?Z<+[5Y#/<2W<\DTTCS32,6>21BS,Q MZDD]37N/PC_9)\5?$3R;_5E;PUH;8;SKF,_:)E_Z9QG!P?[S8'.1FO%GB*V* M?)!:?UN?I&'RG+S/S#3+9@URX_VVY5![#)_P!TU]0?#3X, M>%/A/9^5H.FJMTR[9=0N,27,OU?' _V5P/:NXKLHX",=:NI\YF7%=6M>G@ER MKN]_EV_/T,#P;X#\/_#[2UT_P]I5OIEMQN\I?GD([NY^9C[DFM^BBO62459' MP??$3X#^#/BEJMOJ7B'3' MNKZ"'[.LT5Q)$3&&+!2%(!P6;\ZY,51=:GRQW/?R3,*>6XOVU5/ELUI_2/S% MHK]$/^&._A=_T!;G_P #YO\ XJC_ (8[^%W_ $!;G_P/F_\ BJ\C^SZO='Z# M_K=@/Y9?OTKM:]G#TW1I*$MS\XSC&4\?C9XBDFHNV^^B2"B MBBND\8**** /,_&'_(QW?_ /_0%HH\8?\C'=_P# /_0%HH Z;X?_ /(&F_Z^ M&_\ 05KIJYGX?_\ (&F_Z^&_]!6NFH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **9-, MEO$\LKK'&BEF=S@*!R23V%?/?Q8_;*\->#?.L/#*KXGU9M8UFP\/Z=/?ZG>06%E"NZ2X MN) B(/6^K8'^R17S)\0_BMXG M^*6H_:_$.J272JQ:*U7Y((?]Q!P..,]3W)JGX)^'OB'XC:L-.\/:7/J5QQO: M,8CB!_B=S\JCZFO%JXZ=1\M)6_,_2,#PSAL)'V^/DI-=-HKU[_@O(H^)/%&K M>,-6EU/6M0N-3OI?O37#ECCT'H!V X%=C\*_@+XM^+=PK:38_9],#8DU2\RE MNOJ <9<^R@^^*^G_ (1_L6Z)X:\G4?&4J>(-2&&%C'D6D1]^AD_' _V37TE; M6T-G;QP6\2001J$2*-0JJHX ' %51P$I/FK,RS#BFE07LW7HO1=?R]3 MR'X1_LN^$?A;Y-Y)#_;VO)@_VA>H,1MZQ1\A/KRWO7L=%%>S"G&FN6"LC\XQ M&*K8NHZE>3D_,****T.4**** "BBB@ HHHH **** "BBB@ HHKYS_:@^/\?P M]T^\M+>\>TAM4_TR:#_6R.WW88SZG/)'KU !KEQ&(6'BG9MMI)+=M[)&[WGBS0]-N/(N]9T^UFSCRYKI$;\B:T+>YBNX5E@E2:)N5DC8,I^A%?C; MK'[4'BB[U"22P@LK&US\D+1F1L?[3$\GZ 5[W^S-^U=?7&L+9R 6E^/WDUFC M'[/>(/O;022K@?4]\XR*K$4M6?B+2[?4+&99K:90RD'D9&<'T([BK];QDI)-;,]4****8!1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110!YGXP_Y&.[_X!_Z M%'C#_D8[O\ X!_Z M% '3?#_P#Y M TW_ %\-_P"@K735S/P__P"0--_U\-_Z"M=-0 4444 %%%>9>!/C&_C;XM>. MO!R:2MO;>&?(7^T!<;C,T@R04VC;@ANYZ4 >FT444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !12$XY/ KQOXG?M6>"/AS MYMK#=?\ "0ZNF1]CTU@RHWH\OW5]"!N(]*SG4C35YNQU8?"U\7/V="#D_+^M M#V6O%/BI^UAX-^'/G6=I/_PD>LIQ]DL'!C1O227E1]!N([@5\D?%3]ICQG\4 MO.M9KS^Q]%?C^S=/)167TD?[S_0_+["O++.SN-0NHK:U@DN;F5ML<,*%W-W.7/NQ/MBN$T70]1\2:E#I^E6-QJ-],<1V]M&7=OP%?0WPI_ M8KU_Q,8;_P 7S-X=TUL,+./#7D@]"/NQ_CD^JU]?> ?ACX9^&>F_8O#NE0V* ML,23XW33>[N?F/TS@=@*QIX2K7?/5=OS/1Q>?X#*X>PP45)KHOA7J^OROZGS M#\)?V(9[CR=1\>W/V:+AAH]E("Y]I)1P/HF?]X5]9^&_"^D>#])BTS1-.M], ML8_NPVZ!1GU/J3W)Y-:E%>S2H4Z*]Q'YQCLTQ68RO7EIV6R^7],****Z#R0H MHHH **** "BBB@ HHK$\6^-_#_@/2VU'Q'K5AH=B/^6]_<+$K'T7>+KQB=WY'ZG^,/B%X8^'MD+OQ-X@TW0K!>,_^"BG MPB\,;TTZ[U/Q1.O 73;,HF?=YBG'N,U^5^IZK>ZU?2WFHWEQ?WDIS)<74K22 M.?4LQ)-7?#G@_7O&%W]ET'1=0UJYZ>3I]K)._P"2 U[5/):,%>K)O\$>7/-* MLG:G&WXGV7XR_P""H_B"ZWQ^%?!>G::O03:M,-CRZ!!X=MGZ3ZU=K%CZQI MOD'XK7M/A_\ X)8ZA)M;7/B!;6_]Z+3]-:7/'9WD7'/^S6O_ EX;3W?_2O\ MR/\ ;ZVNOY?Y'R'X@^-GQ!\5,QU?QMX@U!6_Y9S:E,8QQCA-VT?@*]%^,DDU M]\%/ EQ"[2VNR'SF)W$R>3C+'UR'_$U]A^'_ /@F7\,M- ;4]7\0ZQ)W4W$4 M,9_!8]W_ (]6_P#$3]CW0+/P'_8?A.PFDTE4=9M.GN7EOS><8ZCSX?$X>#E[*5VDMTTT[>:O=&L,#B.67/U7<_*2NR^#L5Q-\3O#HM< M^8+H,VW^X 2__CNZO2M>_9)U>QU26&SU6%(%;'EW\;QS(/0@ Y/Y?2O?_P!F MO]D2?3KP7I\R8R82XU2:/RT2/()2%3G)/KSVZ5KF/$^7XC!SHX.7M*DTTHI/ MJK:W6B74XJ.#JNHDUL?)?Q\N4C^+FKR6KE)(_)W/&<$.(DZ$=^E8>D?%KQSX M?"C2_&?B#30HP!::I/$ ,8Q\KCM7ZN:Y^Q1\&?$4L\U[X.5[J9B[W*:A=)(6 M/5B1+R?KQ[5PNL?\$V?A'J6XVLOB#223D"TOT8#KQ^]C?C_"N_+\PPN&PE+" MU$WR14;V[*W<[*F7XCGK^%_P#@II\2-*V)K.C:#KL0^\XBDMIF_P"!*Q7_ ,( M#ZG/EL!] 3]:]Z\$_M:?"3Q]Y::9XXTV&X?@6^I.;*3/]T"4+N/^[FORO\:? MLU?%'X>J\FN^!]7MH(_OW,$/VF%?K)$64?G7FA!4D$8-3+*<)67-1E;T=U_7 MS'',<12=JBOZJQ^^D%Q'=0I+#(LL3CH(ZU)7X9>!_BOXR^&MR)O" M_B;4]#.=S1VERRQ/_O1YVM_P(&OICX=_\%,/'WA_RH/%>D:;XKMEX:>,?8KD M^Y9 8_PV#ZUY=;):\-:;4OP?]?,[Z>:4I?&K?B?IK17S9\-?V_OA1X_:*WO] M1G\(:@V!Y6M($A)]IE)0#W9^,/^1CN_\ @'_H"T4>,/\ MD8[O_@'_ * M% '3?#__ ) TW_7PW_H*UTU,?BE^T3;_!_PQXEF\':9;VRW&H:A9DBXD)B$I 8%6QM9 %# M '))R.!))^P_J/AN6;5O!GQ1\0:5XCDP\MU,+%%62UF<(+C:"H*L?ER5.PJWRLO<,XSJ/Q!^).N:SX@D(DWV; 00/Z)Y@ M)('; 3Z"OJ32M4M-$4#]3Z
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htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Feb. 21, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2022    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 000-26224    
Entity Registrant Name INTEGRA LIFESCIENCES HOLDINGS CORP    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 51-0317849    
Entity Address, Address Line One 1100 Campus Road    
Entity Address, Postal Zip Code 08540    
Entity Address, City or Town Princeton    
Entity Address, State or Province NJ    
City Area Code 609    
Local Phone Number 275-0500    
Title of 12(b) Security Common Stock, Par Value $.01 Per Share    
Trading Symbol IART    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Smaller Reporting Company false    
Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Shell Company false    
Entity Public Float     $ 3,916.0
Entity Common Stock, Shares Outstanding (in shares)   81,636,066  
Documents Incorporated by Reference Certain portions of the registrant’s definitive proxy statement relating to its scheduled May 12, 2023 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission, are incorporated by reference in Part III of this Annual Report on Form 10-K.    
Amendment Flag false    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Entity Central Index Key 0000917520    
XML 24 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Audit Information
 12 Months Ended
Dec. 31, 2022
Audit Information [Abstract]  
Auditor Name PricewaterhouseCoopers LLP
Auditor Location Florham Park, New Jersey
Auditor Firm ID 238000
XML 25 R3.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]      
Total revenue, net $ 1,557,666 $ 1,542,448 $ 1,371,868
Costs and expenses:      
Cost of goods sold 587,355 597,808 520,834
Research and development 101,193 93,051 77,381
Selling, general and administrative 616,316 637,445 594,526
Intangible asset amortization 13,882 16,914 27,757
Total costs and expenses 1,318,746 1,345,218 1,220,498
Operating income 238,920 197,230 151,370
Interest income 11,917 6,737 9,297
Interest expense (49,594) (50,395) (71,581)
Gain from sale of businesses 644 41,798 0
Other income, net 12,007 19,307 4,434
Income before income taxes 213,894 214,677 93,520
Provision (benefit) for income taxes 33,344 45,602 (40,372)
Net income $ 180,550 $ 169,075 $ 133,892
Net income per share      
Basic (in dollars per share) $ 2.18 $ 2.00 $ 1.58
Diluted (in dollars per share) $ 2.16 $ 1.98 $ 1.57
Weighted average common shares outstanding (See Note 13):      
Basic (in shares) 82,997 84,698 84,650
Diluted (in shares) 83,516 85,485 85,228
XML 26 R4.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Statement of Comprehensive Income [Abstract]      
Net income $ 180,550 $ 169,075 $ 133,892
Other comprehensive (loss) income, before tax:      
Change in foreign currency translation adjustments (17,807) (17,362) 53,363
Unrealized gain (loss) on derivatives      
Unrealized derivative gain (loss) arising during period 104,351 68,192 (96,837)
Less: Reclassification adjustments for gain (loss) included in net income 18,859 17,024 (24,442)
Unrealized gain (loss) on derivatives 85,492 51,168 (72,395)
Defined benefit pension plan - net gain (loss) arising during period 7,429 6,998 4,604
Total other comprehensive gain (loss), before tax 75,114 40,804 (14,428)
Income tax (expense) benefit related to items in other comprehensive gain (loss) (19,694) (11,900) 16,771
Total other comprehensive gain (loss), net of tax 55,420 28,904 2,343
Comprehensive income, net of tax $ 235,970 $ 197,979 $ 136,235
XML 27 R5.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current Assets:    
Cash and cash equivalents $ 456,661 $ 513,448
Trade accounts receivable, net of allowances of $4,304 and $4,735 263,465 231,831
Inventories, net 324,583 317,386
Prepaid expenses and other current assets 116,789 91,051
Total current assets 1,161,498 1,153,716
Property, plant and equipment, net 311,302 311,703
Right of use asset - operating leases 148,284 84,543
Intangible assets, net 1,126,609 1,145,573
Goodwill 1,038,881 1,013,458
Deferred tax assets, net 45,994 56,950
Other assets 57,190 16,440
Total assets 3,889,758 3,782,383
Current Liabilities:    
Current portion of borrowings under senior credit facility 38,125 45,000
Current portion of lease liability - operating leases 14,624 14,775
Accounts payable, trade 102,100 61,837
Contract liabilities 7,253 5,295
Accrued compensation 78,771 92,656
Accrued expenses and other current liabilities 80,033 120,458
Total current liabilities 320,906 340,021
Long-term borrowings under senior credit facility 733,149 824,257
Long-term borrowings under securitization facility 104,700 112,500
Long-term convertible securities 567,341 564,426
Lease liability - operating leases 157,420 90,329
Deferred tax liabilities 63,338 45,788
Other liabilities 138,501 120,258
Total liabilities 2,085,355 2,097,579
Stockholders’ Equity:    
Preferred Stock; no par value; 15,000 authorized shares; none outstanding 0 0
Common stock; $0.01 par value; 240,000 authorized shares; 90,477 and 89,600 issued at December 31, 2022 and 2021, respectively 905 896
Additional paid-in capital 1,276,977 1,264,943
Treasury stock, at cost; 6,823 and 4,899 shares at December 31, 2022 and 2021, respectively (362,862) (234,448)
Accumulated other comprehensive income (loss) 10,265 (45,155)
Retained earnings 879,118 698,568
Total stockholders’ equity 1,804,403 1,684,804
Total liabilities and stockholders’ equity $ 3,889,758 $ 3,782,383
XML 28 R6.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Trade accounts receivable, allowances $ 4,304 $ 4,735
Preferred stock, par value (in dollars per share) $ 0 $ 0
Preferred stock, authorized shares (in shares) 15,000,000 15,000,000
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized shares (in shares) 240,000,000 240,000,000
Common stock, issued (in shares) 90,477,000 89,600,000
Treasury stock, at cost; shares (in shares) 6,823,000 4,899,000
XML 29 R7.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
OPERATING ACTIVITIES:      
Net income $ 180,550 $ 169,075 $ 133,892
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 118,299 119,836 116,031
Non-cash in-process research and development expense 0 0 519
Non-cash impairment charges 0 2,754 0
Deferred income tax (benefit) provision (4,585) (2,755) (64,138)
Share-based compensation 27,725 36,210 19,590
Amortization of debt issuance costs and expenses associated with debt refinancing 6,845 7,030 12,076
Non-cash lease expense 2,816 3,834 2,955
Accretion of bond issuance discount 0 0 15,415
Loss (Gain) on disposal of property and equipment and construction in-progress (6,813) 2,240 7,855
Gain from the sale of businesses (644) (41,798) 0
Change in fair value of contingent consideration and others (20,304) (2,162) 951
Changes in assets and liabilities:      
Accounts receivable (33,905) 7,265 52,105
Inventories (29,124) 5,374 (48,348)
Prepaid expenses and other current assets 8,612 (21,143) 1,632
Other non-current assets (2,182) 7,875 13,735
Accounts payable, accrued expenses and other current liabilities 17,343 32,874 (57,512)
Contract liabilities 4,274 28 (37)
Other non-current liabilities (4,438) (14,110) (2,889)
Net cash provided by operating activities 264,469 312,427 203,832
INVESTING ACTIVITIES:      
Purchases of property and equipment (42,343) (48,022) (38,890)
Proceeds from sale of business 23,960 190,468 0
Acquired in-process research and development and intangibles (4,742) (58) (25,000)
Cash paid for business acquisitions, net of cash acquired (51,509) (303,910) 0
Proceeds from sales of property and equipment 11,145 3 3,657
Net proceeds (payments) on swaps designated as net investment hedges 4,909 76 (7,840)
Net cash used in investing activities (58,580) (161,443) (68,073)
FINANCING ACTIVITIES:      
Proceeds from borrowings of long-term indebtedness 40,750 25,500 171,500
Payments on debt (148,550) (125,500) (441,000)
Purchase of option hedge on convertible notes 0 0 (104,248)
Proceeds from convertible notes issuance 0 0 575,000
Proceeds from sale of stock purchase warrants 0 0 44,563
Payment of debt issuance costs 0 (249) (24,347)
Purchase of treasury stock (125,000) 0 (100,000)
Proceeds from exercised stock options 5,465 6,824 5,232
Cash taxes paid in net equity settlement (24,618) (4,801) (5,075)
Net cash (used in) provided by financing activities (251,953) (98,226) 121,625
Effect of exchange rate changes on cash and cash equivalents (10,723) (9,476) 13,871
Net increase (decrease) in cash and cash equivalents (56,787) 43,282 271,255
Cash and cash equivalents at beginning of period 513,448 470,166 198,911
Cash and cash equivalents at end of period $ 456,661 $ 513,448 $ 470,166
XML 30 R8.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Treasury Stock
Additional Paid-In Capital
Additional Paid-In Capital
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Income
Retained Earnings
Retained Earnings
Cumulative Effect, Period of Adoption, Adjustment
Balance, Beginning of Period (in shares) at Dec. 31, 2019     88,735,000            
Balance, Beginning of Period at Dec. 31, 2019 $ 1,416,736 $ (200) $ 887 $ (119,943) $ 1,213,620   $ (76,402) $ 398,574 $ (200)
Balance, Beginning of Period, Treasury Stock (in shares) at Dec. 31, 2019       (2,865,000)          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income 133,892             133,892  
Other comprehensive loss, net of tax 2,343           2,343    
Issuance of common stock through employee stock purchase plan (in shares)     13,000            
Issuance of common stock through employee stock purchase plan 694       694        
Issuance of common stock for vesting of share-based awards, net of shares withheld for taxes (in shares)     503,000 11,000          
Issuance of common stock for vesting of share-based awards, net of shares withheld for taxes (538)   $ 2 $ 526 (1,066)        
Share-based compensation 19,401   $ 4   19,397        
Share repurchase and equity component of the convertible note issuance, net 42,539       42,539        
Accelerated shares repurchased (in shares)       (2,060,000)          
Accelerated shares repurchased (100,000)     $ (115,724) 15,724        
Balance, End of Period (in shares) at Dec. 31, 2020     89,251,000            
Balance, End of Period at Dec. 31, 2020 $ 1,514,867 $ (66,047) $ 893 $ (235,141) 1,290,908 $ (63,274) (74,059) 532,266 $ (2,773)
Balance, End of Period, Treasury Stock (in shares) at Dec. 31, 2020       (4,914,000)          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Accounting Standards Update [Extensible List] Accounting Standard Update 2020-06 [Member]                
Net income $ 169,075             169,075  
Other comprehensive loss, net of tax 28,904           28,904    
Issuance of common stock through employee stock purchase plan (in shares)     18,000            
Issuance of common stock through employee stock purchase plan 1,127       1,127        
Issuance of common stock for vesting of share-based awards, net of shares withheld for taxes (in shares)     331,000 15,000          
Issuance of common stock for vesting of share-based awards, net of shares withheld for taxes 895   $ 1 $ 693 201        
Share-based compensation 35,983   $ 2   35,981        
Balance, End of Period (in shares) at Dec. 31, 2021     89,600,000            
Balance, End of Period at Dec. 31, 2021 $ 1,684,804   $ 896 $ (234,448) 1,264,943   (45,155) 698,568  
Balance, End of Period, Treasury Stock (in shares) at Dec. 31, 2021 (4,899,000)     (4,899,000)          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net income $ 180,550             180,550  
Other comprehensive loss, net of tax 55,420           55,420    
Issuance of common stock through employee stock purchase plan (in shares)     17,000            
Issuance of common stock through employee stock purchase plan 1,078       1,078        
Issuance of common stock for vesting of share-based awards, net of shares withheld for taxes (in shares)     859,000 14,000          
Issuance of common stock for vesting of share-based awards, net of shares withheld for taxes (20,229)   $ 7 $ 738 (20,974)        
Share-based compensation 27,780   $ 2   27,778        
Accelerated shares repurchased (in shares)       (1,938,000)          
Accelerated shares repurchased (125,000)     $ (129,152) 4,152        
Balance, End of Period (in shares) at Dec. 31, 2022     90,476,000            
Balance, End of Period at Dec. 31, 2022 $ 1,804,403   $ 905 $ (362,862) $ 1,276,977   $ 10,265 $ 879,118  
Balance, End of Period, Treasury Stock (in shares) at Dec. 31, 2022 (6,823,000)     (6,823,000)          
XML 31 R9.htm IDEA: XBRL DOCUMENT v3.22.4
BUSINESS
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BUSINESS BUSINESSIntegra LifeSciences Holdings Corporation (the “Company”) was incorporated in Delaware in 1989. The Company is a worldwide leader in medical technology. The Company was founded with the acquisition of an engineered collagen technology platform used to repair and regenerate tissue. Since then, Integra has developed numerous product lines from this technology for applications ranging from burn and deep tissue wounds to the repair of dura mater in the brain, as well as nerves and tendons. The Company has expanded its base regenerative technology business to include surgical instruments, neurosurgical products and advanced wound care through global acquisitions and product development to meet the evolving needs of its customers and enhance patient care. The Company sells its products directly through various sales forces and through a variety of other distribution channels.
XML 32 R10.htm IDEA: XBRL DOCUMENT v3.22.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
BASIS OF PRESENTATION
These financial statements and the accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America and conform to Regulation S-X under the Securities Exchange Act of 1934, as amended.
PRINCIPLES OF CONSOLIDATION
The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. See Note 4, Acquisitions and Divestitures, for details of new subsidiaries included in the consolidation.
USE OF ESTIMATES
The preparation of consolidated financial statements is in conformity with generally accepted accounting principles in the United States ("GAAP") which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates. As the Company continues to navigate the novel coronavirus ("COVID-19") pandemic and recent variants of the virus as well as the adverse impacts to global economic conditions, supply chain and the operations, there may be impact to future estimates including, but not limited to, inventory valuations, fair value measurements, goodwill and long-lived asset impairments, the effectiveness of the Company’s hedging instruments, deferred tax valuation allowances, and allowances for doubtful accounts receivable.
CASH AND CASH EQUIVALENTS
The Company considers all short-term, highly liquid investments purchased with original maturities of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value.
TRADE ACCOUNTS RECEIVABLE AND ALLOWANCES FOR DOUBTFUL ACCOUNTS RECEIVABLE
Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company grants credit to customers in the normal course of business, but generally does not require collateral or any other security to support its receivables.
The Company evaluates the collectability of accounts receivable based on a combination of factors. The Company recognizes a provision for doubtful accounts that reflects the Company’s estimate of expected credit losses for trade accounts receivable. In circumstances where a specific customer is unable to meet its financial obligations to the Company, a provision to the allowances for doubtful accounts is recorded against amounts due to reduce the net recognized receivable to the amount that is reasonably expected to be collected. For all other customers, the Company evaluates measurement of all expected credit losses for trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The Company adopted this guidance on January 1, 2020 using a modified retrospective transition method which requires a cumulative-effect adjustment to the opening balance of retained earnings to be recognized on the date of adoption with no change to financial results reported in prior periods. The cumulative-effect adjustment recorded on January 1, 2020 was not material. The adoption of this ASU did not have a significant impact on the Company's consolidated financial statements and related disclosures. The Company's exposure to credit losses may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the COVID-19 pandemic and recent variants of the virus, and other customer-specific factors. Although the Company has historically not experienced significant credit losses, it is possible that there could be an adverse impact due to customer and governmental responses to the COVID-19 pandemic.
Provisions to the allowances for doubtful accounts are recorded to selling, general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered. Provision for doubtful accounts, net of recoveries, associated with accounts receivable, included in selling, general and administrative expense, was charges of $0.2 million for the year ended December 31, 2022, recoveries of $1.1 million, and charges of $3.6 million for the years ended December 31, 2021 and 2020, respectively.
The below table shows the rollforward of the allowance for doubtful accounts for the years ended December 31, 2022, 2021 and 2020:
Balance at Beginning of PeriodCharged to Costs and ExpensesOtherDeductionsBalance at End of Period
Dollars in thousands
Year Ended:
 December 31, 2022$4,735 238 — (669)$4,304 
December 31, 2021$6,439 (1,059)341 (986)$4,735 
December 31, 2020$4,303 3,635 — (1,499)$6,439 
(1)Deductions primarily relates to allowance for doubtful accounts written off during the year, net of recoveries and other adjustments.


INVENTORIES
Inventories, consisting of purchased materials, direct labor and manufacturing overhead, are stated at the lower of cost, the value determined by the first-in, first-out method, or net realizable value. Inventories consisted of the following:
 December 31,
Dollars in thousands2022 2021
Finished goods172,088 $162,528 
Work in process70,598 65,323 
Raw materials81,897 89,535 
Total inventories, net$324,583 $317,386 
At each balance sheet date, the Company evaluates inventories for excess quantities, obsolescence or shelf life expiration. This evaluation includes analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, a review of the shelf life expiration dates for products, as well as the feasibility of reworking or using excess or obsolete products or components in the production or assembly of other products that are not obsolete or for which there are not excess quantities in inventory. To the extent that management determines there are excess or obsolete inventory or quantities with a shelf life that is too near its expiration for the Company to reasonably expect that it can sell those products prior to their expiration, the Company adjusts the carrying value to estimated net realizable value.
The Company capitalizes inventory costs associated with certain products prior to regulatory approval, based on management's judgment of probable economic benefit. The Company could be required to expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or delay of approval by necessary regulatory bodies or a decision by management to discontinue the related development program. No such amounts were capitalized at December 31, 2022 or 2021.
PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment are stated at historical cost less accumulated depreciation and any impairment charges. The Company provides for depreciation using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the lesser of the lease term or the useful life. The cost of major additions and improvements is capitalized, while maintenance and repair costs that do not improve or extend the lives of the respective assets are charged to operations as incurred. The cost of computer software developed or obtained for internal use is accounted for in accordance with the Accounting Standards Codification 350-40, Internal-Use Software.
Property, plant and equipment balances and corresponding lives were as follows:
 December 31,
Dollars in thousands20222021Useful Lives
Land$966 $1,512 
Buildings and building improvements14,710 19,032 
5-40 years
Leasehold improvements164,292 155,495 
1-20 years
Machinery and production equipment181,780 183,270 
3-20 years
Demonstration equipment3,792 2,791 
4-5 years
Information systems and hardware151,330 148,706 
1-7 years
Furniture, fixtures, and office equipment20,286 20,921 
1-15 years
Construction-in-progress103,875 94,850 
Total641,031 626,577 
Less: Accumulated depreciation(329,729)(314,874)
Property, plant and equipment, net$311,302 $311,703 
Depreciation expense associated with property, plant and equipment was $40.1 million, $39.4 million, and $42.1 million for the years ended December 31, 2022, 2021 and 2020, respectively.
CAPITALIZED INTEREST
The interest cost on capital projects, including facilities build-out and internal use software, is capitalized and included in the cost of the project. Capitalization commences with the first expenditure for the project and continues until the project is substantially complete and ready for its intended use. When no debt is incurred specifically for a project, interest is capitalized on project expenditures using the weighted average cost of the Company's outstanding borrowings. For the years ended December 31, 2022 and 2021, respectively, the Company capitalized $1.4 million and $1.2 million of interest expense into property, plant and equipment.
ACQUISITIONS
Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The Company accounts for the acquisition of a business in accordance with ASC 805, Business Combinations ("ASC Topic 805"). Amounts paid to acquire a business are allocated to the assets acquired and liabilities assumed based on their fair values at the date of acquisition. Any excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred.
Contingent consideration is recorded at fair value as measured on the date of acquisition. The value recorded is based on estimates of future financial projections under various potential scenarios using either a Monte Carlo simulation or the probability-weighted income approach derived from revenue estimates and probability assessment with respect to the likelihood of achieving contingent obligations. Contingent payments related to acquisitions consist of development, regulatory, and commercial milestone payments, in addition to sales-based payments, and are valued using discounted cash flow techniques. Each quarter until such contingent amounts are earned, the fair value of the liability is remeasured at each reporting period and adjusted as a component of operating expenses based on changes to the underlying assumptions. The change in the fair value of sales-based payments is based upon future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payment charges. The estimates used to determine the fair value of the contingent consideration liability are subject to significant judgment and actual results are likely to differ from the amounts originally recorded.
The Company determines the fair value of acquired intangible assets based on detailed valuations that use certain information and assumptions provided by management. The Company allocates any excess purchase price over the fair value of the net tangible and intangible assets acquired to goodwill. Determining the fair value of these intangible assets acquired as part of a business combination requires the Company to make significant estimates. These estimates include the amount and timing of projected future cash flows, the discount rate used to discount those cash flows to present value, the assessment of the asset’s life cycle, and the consideration of legal, technical, regulatory, economic, and competitive risks. The fair value assigned to other intangible assets is determined by estimating the future cash flows of each project or technology and discounting the net cash flows back to their present values. The discount rate used is determined at the time of measurement in accordance with accepted valuation methodologies.
Acquired IPR&D is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&D has an alternative future use. The Company uses the income approach to determine the fair value of developed technology and IPR&D acquired in a business combination. This approach determines fair value by estimating the after-tax cash flows attributable to the respective asset over its useful life and then discounting these after-tax cash flows back to a present value. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each product including net revenues, cost of sales, R&D costs, selling and marketing costs, the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, and competitive trends impacting the asset and each cash flow stream. The Company also uses the income approach, as described above, to determine the estimated fair value of certain other identifiable intangible assets including customer relationships, trade names and business licenses. Customer relationships represent established relationships with customers, which provide a ready channel for the sale of additional products and services. Trade names represent acquired company and product names.
IPR&D acquired in a business combination is capitalized as an indefinite-lived intangible asset. Development costs incurred after the acquisition are expensed as incurred. Upon receipt of regulatory approval, the indefinite-lived intangible asset is then accounted for as a finite-lived intangible asset and amortized on a straight-line basis or accelerated basis, as appropriate, over its estimated useful life. If the research and development project is subsequently abandoned, the indefinite-lived intangible asset is charged to expense. IPR&D acquired outside of a business combination is expensed immediately.

Due to the uncertainty associated with research and development projects, there is risk that actual results will differ materially from the original cash flow projections and that the research and development project will result in a successful commercial product. The risks associated with achieving commercialization include, but are not limited to, delay or failure to obtain regulatory approvals to conduct clinical trials, delay or failure to obtain required market clearances, delays or issues with patent
issuance, or validity and litigation.
If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&D with no alternative future use is charged to expense at the acquisition date. Payments that would be recognized as contingent consideration in a business combination are expensed when probable in an asset acquisition. Refer to Note 4, Acquisitions and Divestitures for more information.
GOODWILL AND OTHER INTANGIBLE ASSETS
The excess of the cost over the fair value of net assets of acquired businesses is recorded as goodwill. Goodwill is not subject to amortization but is reviewed for impairment at the reporting unit level annually, or more frequently if impairment indicators arise. The Company's assessment of the recoverability of goodwill is based upon a comparison of the carrying value of goodwill with its estimated fair value. The Company reviews goodwill for impairment in the third quarter every year in accordance with ASC Topic 350, Intangibles - Goodwill and Other ("ASC Topic 350") and whenever events or changes in circumstances indicate the carrying value of goodwill may not be recoverable. Refer to Note 7, Goodwill and Other Intangibles for more information.
The Company has two reportable segments with three underlying reporting units. Refer to Note 16, Segment and Geographic Information for more information on reportable segments.
Other intangible assets include patents, trademarks, purchased technology, and supplier and customer relationships. Identifiable intangible assets are initially recorded at fair market value at the time of acquisition generally using an income or cost approach. The Company capitalizes costs incurred to renew or extend the term of recognized intangible assets and amortizes those costs
over their expected useful lives.
The Company tests intangible assets with indefinite lives for impairment annually in the third quarter in accordance with ASC Topic 350. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of an indefinite lived intangible asset below its carrying amount. The Company tests for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of the intangible asset is less than its carrying amount. The Company may elect to bypass this qualitative evaluation and perform a quantitative test.
Product rights and other definite-lived intangible assets are tested periodically for impairment in accordance with ASC 350 Topic when events or changes in circumstances indicate that an asset's carrying value may not be recoverable. The impairment testing involves comparing the carrying amount of the asset or asset group to the forecasted undiscounted future cash flows. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and impairment exists. An impairment loss is measured as the excess of the asset's carrying value over its fair value, calculated using discounted future cash flows. The computed impairment loss is recognized in the period that the impairment occurs.
LONG-LIVED ASSETS
Long-lived assets held and used by the Company, including property, plant and equipment, intangible assets, and leases are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets to be held and used, a recoverability test is performed using projected undiscounted net cash flows applicable to the long-lived assets. If an impairment exists, the amount of such impairment is calculated based on the estimated fair value of the asset. Impairments to long-lived assets to be disposed of are recorded based upon the difference between the carrying value and the fair value of the applicable assets.
INTEGRA FOUNDATION
The Company may periodically make contributions to the Integra Foundation, Inc. The Integra Foundation was incorporated in 2002 exclusively for charitable, educational, and scientific purposes and qualifies under IRC 501(c)(3) as an exempt private foundation. Under its charter, the Integra Foundation engages in activities that promote health, the diagnosis and treatment of disease, and the development of medical science through grants, contributions and other appropriate means. The Integra Foundation is a separate legal entity and is not a subsidiary of the Company; therefore, its results are not included in these consolidated financial statements. The Company contributed $0.0 million, $1.2 million and $0.8 million to the Integra Foundation during the years ended December 31, 2022, 2021 and 2020, respectively. These contributions were recorded in selling, general, and administrative expense.
DERIVATIVES
The Company develops, manufactures, and sells medical devices globally and its earnings and cash flows are exposed to market risk from changes in interest rates and currency exchange rates. The Company addresses these risks through a risk management program that includes the use of derivative financial instruments and operates the program pursuant to documented corporate risk management policies. All derivative financial instruments are recognized in the financial statements at fair value in accordance with the authoritative guidance. Under the guidance, for those instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation, based on the exposure being hedged. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, further, on the type of hedging relationship. The Company's derivative instruments do not subject its earnings or cash flows to material risk, and gains and losses on these derivatives generally offset losses and gains on the item being hedged. The Company has not entered into derivative transactions for speculative purposes. From time to time, the Company may enter into derivatives that are not designated as hedging instruments in order to protect itself from currency volatility due to intercompany balances.
All derivative instruments are recognized at the fair values as either assets or liabilities on the balance sheet. The Company determines the fair value of its derivative instruments using the framework prescribed by the authoritative guidance, by considering the estimated amount the Company would receive to sell or transfer these instruments at the reporting date and by taking into account expected forward interest rates, currency exchange rates, the creditworthiness of the counterparty for assets, and its creditworthiness for liabilities. In certain instances, the Company utilizes a discounted cash flow model to measure fair value. Generally, the Company uses inputs that include quoted prices for similar assets or liabilities in active markets, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The Company has classified all of its derivative assets and liabilities within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of its derivative instruments. The Company classifies derivatives designated as hedges in the same category as the item being hedged for cash flow presentation purposes.
The Company entered into foreign currency forward and foreign currency swap contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into other income, net, on the consolidated financial statements. Refer to Note 6, Derivative Instruments for more information.
FOREIGN CURRENCY
All assets and liabilities of foreign subsidiaries which have a functional currency other than the U.S. dollar are translated at the rate of exchange at year-end, while elements of the income statement are translated at the average exchange rates in effect during the year. The net effect of these translation adjustments is shown as a component of accumulated other comprehensive income (loss). These currency translation adjustments are not currently adjusted for income taxes as they relate to permanent investments in non-U.S. subsidiaries. Foreign currency transaction net losses of $3.3 million, net gains of less than $0.1 million, and net losses $1.6 million are reported in other income, net in the statements of operations, for the year ended December 31, 2022, 2021 and 2020, respectively.
INCOME TAXES
Income taxes are accounted for by using the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period when the change is enacted.
The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position. Reserves are established for positions that don't meet this recognition threshold. The reserve is measured as the largest amount of benefit determined on a cumulative probability basis that the Company believes is more likely than not to be realized upon ultimate settlement of the position. These reserves are classified as long-term liabilities in the consolidated balance sheets of the Company, unless the reserves are expected to be paid in cash during the next twelve months, in which case they are classified as current liabilities. The Company also records interest and penalties accrued in relation to uncertain tax benefits as a component of income tax expense.
While the Company believes it has identified all reasonable exposures and the reserve it has established is appropriate under the circumstances, it is possible that additional exposures exist and that exposures may be settled at amounts different than the amounts reserved. It is also possible that changes in facts and circumstances could cause the Company to either materially increase or reduce the carrying amount of its tax reserve.
The Company continues to indefinitely reinvest substantially all of its foreign earnings unless there is a manner under which to remit the earnings without a material tax cost. The current provisional analysis indicates that the Company has sufficient U.S. liquidity, including borrowing capacity, to fund foreseeable U.S. cash needs without requiring the repatriation of foreign cash. One time or unusual items that may impact the ability or intent to keep the foreign earnings and cash indefinitely reinvested include significant U.S. acquisitions, loans from a foreign subsidiary and changes in tax laws.
REVENUE RECOGNITION
Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services.
Total revenue, net, includes product sales, product royalties and other revenues, such as fees received from services.
For products shipped with FOB shipping point terms, the control of the product passes to the customer at the time of shipment. For shipments in which the control of the product is transferred when the customer receives the product, the Company recognizes revenue upon receipt by the customer. Certain products that the Company produces for private label customers have no alternative use and the Company has a right of payment for performance to date. Revenues from those products are recognized over the period that the Company manufactures these products, which is typically one month to three months. The Company uses the input method to measure the manufacturing activities completed to date, which depicts the progress of the Company's performance obligation of transferring control of goods being manufactured for private label customers.
A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and distributors, and also from inventory physically held by field sales representatives. For these types of products sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized.
Revenues from sale of products and services are evidenced by either a contract with the customer or a valid purchase order and an invoice which includes all relevant terms of sale. For product sales, invoices are generally issued upon the transfer of control (or upon the completion of the manufacturing in the case of the private label transactions recognized over time) and are typically payable 30 days after the invoice date. The Company performs a review of each specific customer's creditworthiness and ability to pay prior to acceptance as a customer. Further, the Company performs periodic reviews of its customers' creditworthiness prospectively. Refer to Note 3, Revenue From Contracts With Customers for more information. The Company also maintains a provision for estimated returns and allowances in the same period that the related revenue is recorded. This reserve is based upon an analysis of actual credit memos issued for pricing issues or returned goods over an extended period, as well as assumptions about outstanding accounts receivable and judgment in interpreting the data.
RESEARCH AND DEVELOPMENT
Research and development costs, including salaries, depreciation, consultant and other external fees, and facility costs directly attributable to research and development activities, are expensed in the period in which they are incurred.
EMPLOYEE TERMINATION BENEFITS
The Company does not have a written severance plan, and it does not offer similar termination benefits to affected employees in all restructuring initiatives. Accordingly, in situations where minimum statutory termination benefits must be paid to the affected employees, the Company records employee severance costs associated with these restructuring activities in accordance with the authoritative guidance for non-retirement post-employment benefits. Charges associated with these activities are recorded when the payment of benefits is probable and can be reasonably estimated. In all other situations where the Company pays out termination benefits, including supplemental benefits paid in excess of statutory minimum amounts and benefits offered to affected employees based on management's discretion, the Company records these termination costs in accordance with the authoritative guidance for ASC Topic 712 Compensation - Nonretirement Benefits and ASC Topic 420 One-time Employee Termination Benefits.
The timing of the recognition of charges for employee severance costs other than minimum statutory benefits depends on whether the affected employees are required to render service beyond their legal notification period in order to receive the benefits. If affected employees are required to render service beyond their legal notification period, charges are recognized over the future service period. Otherwise, charges are recognized when management has approved a specific plan and employee communication requirements have been met.
The Company incurred employee termination costs on restructuring activities associated with a closure of a manufacturing facility in France and other reorganization projects in the consolidated statement of operations for the year ended December 31, 2022. In 2021, the Company incurred employee termination costs on restructuring activities associated with the closure of a manufacturing facility in France. The following table summarizes our restructuring related accrual balances included within accrued expenses and other current liabilities in the consolidated balance sheet for the year ended December 31, 2022 and 2021.
Years Ended December 31,
(Dollars in thousands)20222021
Balance, beginning of the year$10,226 $6,372 
Charges:
Cost of Goods Sold$1,494 $3,436 
Research and development72288
Selling, general and administrative$5,582 $466 
Payments and other adjustments$(12,267)$(336)
Balance, end of the year$5,107 $10,226 
Included in the accrual balance as of December 31, 2022 is $2.0 million related to the closure of a manufacturing facility located in France, and other reorganization projects of $3.1M. Included in the accrual balance as of December 31, 2021 is $10.2 million related to the closure of the manufacturing facility located in France.
STOCK-BASED COMPENSATION
Relevant authoritative guidance requires companies to recognize the expense related to the fair value of their stock-based compensation awards. Stock-based compensation expense for stock option awards are based on the grant date fair value using the binomial distribution model. The Company recognizes compensation expense for stock option awards, restricted stock awards, performance stock awards and contract stock awards over the requisite service period of the award. All excess tax benefits and taxes and tax deficiencies from stock-based compensation are included in provision for income taxes in the consolidated statement of operations. Refer to Note 9, Stock-based Compensation for more information.
PENSION BENEFITS
The Company maintains defined benefit pension plans that cover certain employees in France, Japan, Germany and Switzerland. Various factors are considered in determining the pension liability, including the number of employees expected to be paid their salary levels and years of service, the expected return on plan assets, the discount rate used to determine the benefit obligations, the timing of benefit payments and other actuarial assumptions.
Retirement benefit plan assumptions are reassessed on an annual basis or more frequently if changes in circumstances indicate a re-evaluation of assumptions are required. The key benefit plan assumptions are the discount rate and expected rate of return on plan assets. The discount rate is based on average rates on bonds that matched the expected cash outflows of the benefit plans. The expected rate of return is based on historical and expected returns on the various categories of plan assets.
The Company uses the corridor approach in measuring the amount of net periodic benefit pension cost to recognize each period. The corridor approach defers all actuarial gains and losses resulting from variances between actual results and actuarial assumptions. Those unrecognized gains and losses are amortized when the net gains and losses exceed 10% of the greater of the market-related value of plan assets or the projected benefit obligation at the beginning of the year. The amount in excess of the corridor is amortized over the average remaining service period to retirement date of active plan participants.
Deferred Compensation Plan
The Company maintains a deferred compensation plan in which certain employees of the Company may defer the payment and taxation of up to 75% of their base salary and up to 100% of bonus amounts and other eligible cash compensation.
This deferred compensation is invested in funds offered under the Plan and is valued based on Level 1 measurements in the fair value hierarchy. The purpose of the plan is to retain key employees by providing them with an opportunity to defer a portion of their compensation as elected by the participant in accordance with the plan. Any amounts set aside to defray the liabilities assumed by the Company will remain the general assets of the Company until such amounts are distributed to the participants. Assets of the Company's deferred compensation plan are included in Other current assets and recorded at fair value based on their quoted market prices.
CONCENTRATION OF CREDIT RISK
Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, which are held at major financial institutions, investment-grade marketable debt securities and trade receivables.
The Company's products are sold on an uncollateralized basis and on credit terms based upon a credit risk assessment of each customer. A portion of the Company's trade receivables to customers outside the United States includes sales to foreign distributors, who then sell to government owned or supported healthcare systems.
None of the Company's customers accounted for 10% or more of the consolidated net sales during the years ended December 31, 2022, 2021 and 2020.
RECENT ACCOUNTING PRONOUNCEMENTS
In December 2019, the FASB issued ASU 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes, intended to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. This guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. The Company adopted ASU 2019-12 as of January 1, 2021. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures.
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848), and subsequent amendment to the initial guidance: ASU 2021-01, Reference Rate Reform (Topic 848): Scope (collectively, “Topic 848”). Topic 848 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference London Inter-Bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. The guidance generally can be applied from March 12, 2020 through December 31, 2022. On October 5, 2022, the FASB approved an extension of the sunset date of the reference rate reform from December 31, 2022 to December 31, 2024, past LIBOR’s end date. The Company currently has contracts that are indexed to LIBOR and are continuing to evaluate the scope of impacted contracts and potential risk. The Company expects all LIBOR-based contracts to be replaced by the Secured Overnight Financing Rate (“SOFR”), which is calculated based on overnight transactions under repurchase agreements backed by Treasury securities. The Alternative Reference Rates Committee, a group of private-market participants convened by the U.S. Federal Reserve Board and the New York Federal Reserve, has recommended the use of SOFR as a more robust reference rate alternative to LIBOR. The use of SOFR as a substitute for LIBOR is, however, voluntary and may not be suitable for all market participants. There can be no assurance that the replacement rate will be economically equivalent to LIBOR, which could result in higher interest rates for us under our debt facilities. There is no guarantee that a transition from LIBOR to SOFR will not result in financial market disruptions, significant increases in benchmark rates, or our borrowing costs, any of which could have an adverse effect on our business, results of operations and financial condition.
In August 2020, the FASB issued ASU 2020-06, Debt- Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40):Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. The guidance simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify. The guidance also simplifies the diluted net income per share calculation in certain areas. The ASU will be effective for annual and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years using either the modified retrospective or full retrospective method.
As detailed in Note 5, Debt, on February 4, 2020, the Company issued $575.0 million aggregate principal amount of its 0.5% Convertible Senior Notes due 2025 (the "2025 Notes"). The 2025 Notes are subject to the guidance included in ASU 2020-06. The Company adopted this guidance on January 1, 2021 using the modified retrospective approach which resulted in a cumulative-effect adjustment that increased (decreased) the following consolidated balance sheet accounts:
ADJUSTMENTCONSOLIDATED BALANCE SHEET CLASSIFICATIONAMOUNT
 (in millions)
Deferred tax impact of cumulative-effect adjustmentDeferred tax liabilities$(20.6)
Debt discount reclassificationLong-term convertible securities89.1 
Equity issuance costs reclassificationLong-term convertible securities(2.5)
Debt discount amortization and equity costs reclassification, net of taxRetained Earnings(2.8)
Net impact of cumulative-effect adjustmentAdditional paid-in capital(63.3)
On December 9, 2020, the Company made an irrevocable election under the indenture to require the principal portion of its 2025 Notes to be settled in cash and any excess in shares. Following the irrevocable notice, only the amounts settled in excess of the principal will be considered in diluted earnings per share under the “if-converted” method. Upon adoption of ASU 2020-06, the Company’s 2025 Notes were reflected entirely as a liability since the embedded conversion feature will no longer be separately presented within stockholders’ equity. Additionally, from January 1, 2021, the Company is no longer incurring non-cash interest expense for the amortization of debt discount.
In October 2020, the FASB issued ASU 2020-10, Codification Improvements, which updates various codification topics by clarifying or improving disclosure requirements to align with the regulations of the U.S. Securities and Exchange Commission (the "SEC") . The ASU has been effective for the Company for annual and interim periods beginning after January 1, 2021. The Company adopted this standard on the January 1, 2021. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures.
In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options which provides guidance to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The amendment currently has no impact to the Company as the effect will largely depend on the terms of written call options or financings issued or modified in the future.
There are no other recently issued accounting pronouncements that are expected to have any significant effect on the Company's financial position, results of operations or cash flows.
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest during the years ended December 31, 2022, 2021 and 2020 was $42.2 million (net of $1.4 million that was capitalized into construction in progress), $43.2 million (net of $1.2 million that was capitalized into construction in progress) and $47.3 million (net of $2.3 million that was capitalized into construction in progress), respectively.
Cash paid for income taxes, net of refunds, for the years ended December 31, 2022, 2021 and 2020 was $35.9 million, $49.5 million and $29.8 million, respectively.
NON-CASH INVESTING AND FINANCING ACTIVITIES
Property and equipment purchases included in liabilities at December 31, 2022, 2021 and 2020 were $10.5 million, $4.7 million and $1.6 million, respectively.
During the fourth quarter of 2021, the Company achieved its final developmental milestone which triggered a $5.0 million obligation to be paid to former shareholders of Rebound Therapeutics Corporation ("Rebound"). The Company recorded $5.0 million as an intangible asset in the consolidated balance sheet upon achieving the milestone. The remaining obligation was included in accrued liabilities at December 31, 2021 in the consolidated balance sheets. The milestone was fully paid in 2022.
During the fourth quarter of 2020, the Company achieved another developmental milestone which triggered a $20.0 million obligation to be paid to the former shareholders of Rebound. The Company recorded $20.0 million as an intangible asset in the consolidated balance sheet upon achieving the milestone. The milestone was paid during the fourth quarter of 2020.
XML 33 R11.htm IDEA: XBRL DOCUMENT v3.22.4
REVENUES FROM CONTRACTS WITH CUSTOMERS
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
REVENUES FROM CONTRACTS WITH CUSTOMERS REVENUES FROM CONTRACTS WITH CUSTOMERS
Summary of Accounting Policies on Revenue Recognition
Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services.
Performance Obligations
The Company's performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers.
Significant Judgments
Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company's strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant.
The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract.
The Company's return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally 90 days.
The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.
Contract Asset and Liability
Revenues recognized from the Company's private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the prepaid expenses and other current assets account in the consolidated balance sheet. Upon invoicing to the customer, the balance is recorded in trade receivable, net in the consolidated balance sheet.
Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.
The following table summarized the changes in the contract asset and liability balances for the year ended December 31, 2022:
Dollars in thousandsTotal
Contract Asset
Contract asset, January 1, 2022$11,412 
Transferred to trade receivable from contract asset included
     in beginning of the year contract asset 		(11,412)
Contract asset, net of transferred to trade receivables on contracts during the period10,122 
Contract asset, December 31, 2022$10,122 
Contract Liability
Contract liability, January 1, 2022$11,946 
Recognition of revenue included in beginning of year contract liability(5,349)
Contract liability, net of revenue recognized on contracts during the period9,596 
Foreign currency translation(66)
Contract liability, December 31, 2022$16,127 
At December 31, 2022, the short-term portion of the contract liability of $7.3 million and the long-term portion of $8.8 million is included in current liabilities and other liabilities, respectively, in the consolidated balance sheet.
As of December 31, 2022, the Company is expected to recognize revenue of approximately $7.3 million in 2023, $4.2 million in 2024, $2.7 million in 2025, $1.1 million in 2026, $0.7 million in 2027, and $0.1 million thereafter.
Shipping and Handling Fees
The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold.
Product Warranties
Certain of the Company's medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to two years from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet.
Taxes Collected from Customers
The Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer.
Disaggregated Revenue
The following table presents revenues disaggregated by the major sources of revenues for years-ended December 31, 2022, 2021 and 2020 (dollar amounts in thousands):
Year Ended December 31, 2022Year Ended December 31, 2021Year Ended December 31, 2020
Neurosurgery$794,017 $802,959 $716,339 
Instruments225,547 222,273 178,492 
Total Codman Specialty Surgical1,019,564 1,025,232 894,831 
Wound Reconstruction and Care(2)(3)
406,689 392,463 293,038 
Extremity Orthopedics(1)
— — 78,316 
Private Label131,413 124,753 105,683 
Total Tissue Technologies538,102 517,216 477,037 
Total revenue$1,557,666 $1,542,448 $1,371,868 
(1) On January 4, 2021, the Company completed its sale of its Extremity Orthopedics business. See Note 4, Acquisitions and Divestitures, for details
(2) See Note 4. Acquisitions and Divestitures, for details around the ACell acquisition.
(3) On August 31, 2022, the Company completed the sale of its non-core traditional wound care ("TWC") business. See Note 4, Acquisitions and Divestitures
See Note 16, Segment and Geographical Information, for details of revenues based on the location of the customer.
XML 34 R12.htm IDEA: XBRL DOCUMENT v3.22.4
ACQUISITIONS AND DIVESTITURES
 12 Months Ended
Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]  
ACQUISITIONS AND DIVESTITURES ACQUISITIONS AND DIVESTITURES
Surgical Innovation Associates, Inc. Acquisition

On December 6, 2022, the Company completed its acquisition of Surgical Innovation Associates, Inc. ("SIA") for an acquisition purchase price of $51.5 million. In addition to the purchase price, the acquisition includes two separate contingent considerations payments, which are dependent on 1) achieving certain revenue-based performance milestones in 2023, 2024, and 2025 (up to $50.0 million in additional payments), as well as 2) the approval by the FDA of the Premarket Approval (“PMA”) Application for DuraSorb for certain uses by certain timing targets (up to $40.0 million in additional payments). SIA's core technology, DuraSorb, is a fully resorbable scaffold of a globally accepted polymer, which is cleared for use in hernia repair, abdominal wall, and other soft tissue reinforcement. DuraSorb sales will be reported within Integra’s Tissue Technologies segment as part of its Wound Reconstruction and Care franchise.

Assets Acquired and Liabilities Assumed at Fair Value

The SIA Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired, and liabilities assumed in a business combination to be recognized at their fair values as of the acquisition date.
The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date:

Dollars in thousandsValuation as of December 6, 2022Weighted Average Life
Current assets:
Cash$4,438 
Trade accounts receivable, net 1,551 
Inventories, net2,900 
Prepaid expenses and other current assets1,654 
Total current assets$10,543 
Intangible assets75,000 14 years
Goodwill41,854 
Total assets acquired$127,397 
Current liabilities:
Accounts payable and accrued expenses$2,044 
Total current liabilities$2,044 
Deferred Tax Liability11,799 
Contingent consideration57,607 
Total liabilities assumed71,450 
Net assets acquired$55,947 

Developed Technology

The estimated fair value of the developed technology was determined using the multi-period excess earnings method of the income approach, which estimates value based on the present value of future economic benefits. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each product including net revenues, cost of sales, R&D costs, selling and marketing costs, working capital, and contributory asset charges, the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of the asset’s life cycle, and competitive trends impacting the asset and the cash flow stream.

The Company used a discount rate of 18% to arrive at the present value for the acquired intangible assets to reflect the rate of return a market participant would expect to earn and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results.

Goodwill

The Company allocated goodwill related to the SIA Acquisition to the Tissue Technologies segment. Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected revenue and cost synergies of the combined company and assembled workforce. A key factor that contributes to the recognition of goodwill, and a driver for the Company’s acquisition of SIA, is the attractive growth opportunities presented by the surgical matrix business in the breast reconstruction market. Goodwill recognized as a result of this acquisition is non-deductible for income tax purposes.

Contingent Consideration

The Company determines the acquisition date fair value of contingent consideration obligations based on a probability-weighted income approach derived from revenue estimates and a probability assessment with respect to the likelihood of achieving contingent obligations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined using the fair value concepts in ASC 820. The resulting most likely payouts are discounted using an appropriate effective annual interest rate. At each reporting date, the contingent consideration obligation will be revalued to estimated fair value and changes in fair value will be reflected as income or expense in the consolidated statement of operations. Changes in the fair value of the contingent considerations may result from changes in discount periods and rates and changes in the timing and amount of revenue estimates. Changes in assumptions utilized in the contingent consideration fair value estimates could result in an increase in the contingent consideration obligation and a corresponding charge to operating results.

As part of the acquisition, the Company is required to pay to the shareholder of SIA up to $90.0 million for two separate payments, which are dependent on 1) achieving certain revenue-based performance milestones in 2023, 2024, and 2025 (up to $50.0 million in additional payments), as well as 2) the approval by the FDA of the PMA for DuraSorb for certain uses by
certain timing targets (up to $40.0 million in additional payments). The Company used iterations of the Monte Carlo simulation to calculate the fair value of the contingent consideration for the revenue-based milestone that considered the possible outcomes of scenarios related to each specific milestone for the revenue based performance milestone. The Company used probabilities of achieving the conditions to calculate the fair value of the contingent consideration for the PMA approval milestone. The Company estimated the fair value of the contingent consideration for the revenue based milestone to be $32.6 million at the acquisition date and $25.0 million for the PMA approval milestone.

Deferred Tax Liabilities

Deferred tax liabilities result from identifiable intangible assets’ fair value adjustments. These adjustments create excess book basis over tax basis which is tax-effected by the statutory tax rates of applicable jurisdictions.

Sale of non-core traditional wound care business
On August 31, 2022, the Company completed its sale of its non-core traditional wound care ("TWC") business to Gentell, LLC ("Gentell") for $28.8 million, which consists of $27.8 million in cash plus $1.0 million in contingent consideration which may be received upon achieving certain revenue-based performance milestones two years after the closing date. The proceeds from the sale of the TWC business of $27.8 million is presented in the consolidated statement of cash flows net of cash transferred of $3.5 million and other transaction fees. The transaction included the sale of the Company's TWC products, such as sponges, gauze and conforming bandages, and certain advanced wound care dressings, such as supportive, calcium alginate, hydrogel, and foam dressings.
The divestiture did not represent a strategic shift that had a major effect on the Company's operations and financial statements. Goodwill was allocated to the assets and liabilities divested using the relative fair value method of the TWC business to the Company's Tissue Technologies reportable business segment. In connection with the sale, the Company recognized $0.6 million as a gain from the sale of the business in the consolidated statement of operations for the year ended December 31, 2022. The transaction is subject to final working capital adjustments.
In addition to the purchase and sale agreement, the Company also entered into a contract manufacturing agreement with Gentell. Under the terms of the agreement, Gentell received inventory, equipment, and tooling to manufacture certain MediHoney® and TCC-EZ® products on behalf of the Company. On the close date of this transaction, the Company transferred all inventory associated with these products to Gentell and recognized an asset of $11.1 million, as a form of a deposit for the inventory transferred, which based on the expected timing of inventory purchases, was primarily included within prepaid expenses and other current assets in the consolidated balance sheet. This deposit will be utilized by the Company on future orders placed to Gentell for such products. As of December 31, 2022, the Company had a deposit remaining of $8.3 million which is included in prepaid assets and recognized a payable due to Gentell of $2.7 million, which is included in the consolidated balance sheet within accrued expenses and other current liabilities.
Sale of Extremity Orthopedics Business
On January 4, 2021, the Company completed the sale of its Extremity Orthopedics business to Smith & Nephew USD Limited ("Smith & Nephew"). The transaction included the sale of the Company's upper and lower Extremity Orthopedics product portfolio, including ankle and shoulder arthroplasty and hand and wrist product lines. The Company received an aggregate purchase price of $240.0 million from Smith & Nephew and concurrently paid $41.5 million to the Consortium of Focused Orthopedists, LLC ("CFO") effectively terminating the licensing agreement between Integra and CFO relating to the development of shoulder arthroplasty products.
Assets and liabilities divested consisted of the following as of December 31, 2020 (dollar amounts in thousands):
Prepaid expenses and other current assets$713 
Right of use asset - operating leases and Other assets3,186 
Deferred tax assets6,589 
Intangible assets, net13,332 
Property, plant and equipment, net37,893 
Goodwill47,546 
Inventories52,845 
Total assets held for sale$162,104 
Other liabilities$336 
Current portion of lease liability - operating leases539 
Accrued compensation1,767 
Deferred tax liabilities3,440 
Lease liability - operating leases5,669 
Total liabilities held for sale$11,751 
The divestiture did not represent a strategic shift that had a major effect on the Company's operations and financial statements. Goodwill was allocated to the assets and liabilities divested using the relative fair value method of the Extremity Orthopedics business to the Company's Tissue Technologies reporting unit. In connection with the sale, the Company recognized a gain of $41.8 million that is presented in Gain from the sale of business in the consolidated statement of operations for the year ended December 31, 2021. The Company finalized the net working capital to Smith & Nephew as of December 31, 2021.
The Company also entered into a transition services agreement ("TSA") with Smith & Nephew which requires the Company to provide certain services on behalf of Smith & Nephew for the duration of the period subsequent to the sale of the business as defined in the TSA. The Company recognized a payable due to Smith & Nephew of $2.3 million as of December 31, 2022, which is included in the consolidated balance sheet within accrued expenses and other current liabilities. The TSA includes services such as invoicing and cash collections from customers on behalf of Smith & Nephew. As of December 31, 2022, the Company has concluded the majority of the transition services agreement, pending final payment.
ACell, Inc. Acquisition
On January 20, 2021, the Company acquired ACell, Inc. (the "ACell Acquisition") for an acquisition purchase price of $306.9 million plus contingent considerations of up to $100 million, that may be payable upon achieving certain revenue-based performance milestones in 2022, 2023 and 2025. The final working capital adjustments of $1.3 million was finalized and paid as of June 30, 2021. ACell was a privately-held company that offered a portfolio of regenerative products for complex wound management, including developing and commercializing products based on MatriStem Urinary Bladder Matrix, a technology platform derived from porcine urinary bladder extracellular matrix.
Assets Acquired and Liabilities Assumed at Fair Value
The ACell Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination are recognized at their fair values as of the acquisition date.
The following table summarizes the final fair values of the assets acquired and liabilities assumed at the acquisition date:
Dollars in thousandsFinal Valuation Weighted Average Life
Current assets:
Cash$2,726 
Trade accounts receivable, net 16,469 
Inventories, net18,299 
Prepaid expenses and other current assets1,498 
Total current assets$38,992 
Property, plant and equipment, net13,769 
Intangible assets245,000 
13-14 years
Goodwill94,147 
Right of use asset - operating leases9,259 
Deferred tax assets7,465 
Other assets148 
Total assets acquired$408,780 
Current liabilities:
Accounts payable$718 
Accrued expenses5,966 
Current portion of lease liability - operating leases1,673 
Total current liabilities$8,357 
Other long-term liability276 
Lease liability - operating leases7,585 
Deferred tax liability61,724 
Contingent consideration23,900 
Total liabilities assumed101,842 
Net assets acquired$306,938 
Intangible Assets
The estimated fair value of the developed technology acquired was determined using the multi-period excess earnings method of the income approach, which estimates value based on the present value of future economic benefits. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each product including net revenues, cost of sales, R&D costs, selling and marketing costs, the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, and competitive trends impacting the asset and each cash flow stream.
The Company used a discount rate of 8.5% to arrive at the present value for the acquired intangible assets to reflect the rate of return a market participant would expect to earn and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results.
Goodwill
The Company allocated goodwill related to the ACell acquisition to the Tissue Technologies segment. Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected synergies of the combined company and assembled workforce. Goodwill recognized as a result of this acquisition is non-deductible for income tax purposes.
Contingent Consideration
As part of the acquisition, the Company is required to make payments to the former shareholders of ACell up to $100 million based on the achievement of certain revenue-based performance milestones in 2022, 2023, and 2025. Based on revenue performance in 2022, no payment will be made for the first performance milestone. The Company used iterations of the Monte Carlo simulation to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specific milestone. The Company estimated the fair value of the contingent consideration to be $23.9 million at the acquisition date. The Company recorded $3.7 million and $21.8 million in other liabilities as of December 31, 2022 and 2021, respectively, in the consolidated balance sheets of the Company. The change in the fair value of the contingent obligation was primarily as a result of changes in the timing and amount of revenue estimates.
The Company determined the acquisition date fair value of contingent consideration obligations using a Monte Carlo simulation, as well as significant unobservable inputs, reflecting the Company’s assessment of the assumptions market participants would use to value these liabilities. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined using the fair value concepts in ASC 820. The resultant most likely payouts are discounted using an appropriate effective annual interest rate. At each reporting date, the contingent consideration obligations is revalued to estimated fair value and changes in fair value will be reflected as income or expense in our consolidated statement of operations. Changes in the fair value of the contingent considerations may result from changes in discount periods and rates and changes in the timing and amount of revenue estimates.
Deferred Tax Liabilities
Deferred tax liabilities result from identifiable intangible assets’ fair value adjustments. These adjustments create excess book basis over tax basis which is tax-effected by the statutory tax rates of applicable jurisdictions.
XML 35 R13.htm IDEA: XBRL DOCUMENT v3.22.4
DEBT
 12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
DEBT DEBT
Amendment to the Sixth Amended and Restated Senior Credit Agreement
On February 3, 2020, the Company entered into the sixth amendment and restatement (the "February 2020 Amendment") of its Senior Credit Facility (the "Senior Credit Facility") with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. The February 2020 Amendment extended the maturity date to February 3, 2025. The Company continues to have the aggregate principal amount of up to approximately $2.2 billion available to it through the following facilities: (i) a $877.5 million Term Loan facility, and (ii) a $1.3 billion revolving credit facility, which includes a $60 million sublimit for the issuance of standby letters of credit and a $60 million sublimit for swingline loans.
The Company’s maximum consolidated total leverage ratio in the financial covenants (as defined in the Senior Credit Facility) is the following:
Fiscal QuarterMaximum Consolidated Total Leverage Ratio
September 30, 2022 through June 30, 2023
4.50 to 1.00
September 30, 2023 and the last day of each fiscal quarter thereafter
4.00 to 1.00
Borrowings under the Senior Credit Facility bear interest, at the Company’s option, at a rate equal to the following:
i.the Eurodollar Rate (as defined in the amendment and restatement) in effect from time to time plus the applicable rate (ranging from 1.00% to 2.25%), or
ii.the highest of:
1.the weighted average overnight Federal funds rate, as published by the Federal Reserve Bank of New York, plus 0.50%
2.the prime lending rate of Bank of America, N.A. or
3.the one-month Eurodollar Rate plus 1.00%
The applicable rates are based on the Company’s consolidated total leverage ratio (defined as the ratio of (a) consolidated funded indebtedness as of such date less cash that is not subject to any restriction on the use or investment thereof to (b) consolidated EBITDA (as defined by the July 2020 amendment), for the period of four consecutive fiscal quarters ending on such date).
The Company will pay an annual commitment fee (ranging from 0.15% to 0.30%), based on the Company's consolidated total leverage ratio, on the amount available for borrowing under the revolving credit facility.
The Senior Credit Facility is collateralized by substantially all of the assets of the Company’s U.S. subsidiaries, excluding intangible assets. The Senior Credit Facility is subject to various financial and negative covenants and at December 31, 2022, the Company was in compliance with all such covenants. In connection with the February 2020 Amendment, the Company capitalized $4.6 million of financing costs in connection with modification of the Senior Credit Facility and wrote off $1.2 million of previously capitalized financing costs during the first quarter of 2020. In connection with the July 2020 amendment, the Company expensed $3.3 million of incremental financing costs in connection with the modification of the Senior Credit Facility during the third quarter of 2020.
There was no balance outstanding at December 31, 2022 under the revolving portion of the Senior Credit Facility and as of December 31, 2021, there was $31.3 million, outstanding under the revolving portion of the Senior Credit Facility at weighted average interest rate of 1.4%. At December 31, 2022 and 2021, there was $771.3 million and $843.8 million, respectively, outstanding, under the Term Loan component of the Senior Credit Facility at weighted average interest rate of 5.6% and 1.4%, respectively. At December 31, 2022 and 2021, there was $38.1 million and $45.0 million, respectively, of the Term Loan component of the Senior Credit Facility was classified as current on the consolidated balance sheets.
The fair value of outstanding borrowings of the Senior Credit Facility's Term Loan components at December 31, 2022 was $800.8 million. This fair values were determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities
Letters of credit outstanding as of December 31, 2022 and 2021 totaled $1.6 million. There were no amounts drawn as of December 31, 2022.
Contractual repayments of the Term Loan component of the Senior Credit Facility are due as follows:
Year-ended December 31, 2022Principal Repayment
Dollars in thousands
2023$38,125 
2024$67,500 
2025$669,375 
$775,000 
Future interest payments on the term loan component of the Senior Credit Facility based on current interest rates are expected to approximate $42.7 million in 2023, $39.1 million in 2024, and $3.6 million in 2025. Interest is calculated on the term loan portion of the Senior Credit Facility based on LIBOR plus the spread paid by the Company. As the revolving credit facility and Securitization Facility can be repaid at any time, no interest has been included in the calculation.
The outstanding balance of the revolving credit component of the Senior Credit Facility is due on February 3, 2025.
Convertible Senior Notes
On February 4, 2020, the Company issued $575.0 million aggregate principal amount of its 0.5% Convertible Senior Notes due 2025 (the "2025 Notes"). The 2025 Notes will mature on August 15, 2025 and bear interest at a rate of 0.5% per annum payable semi-annually in arrears, unless earlier converted, repurchased or redeemed in accordance with the terms of the 2025 Notes. The portion of debt proceeds that was classified as equity at the time of the offering was $104.5 million. The effective interest rate implicit in the liability component was 4.2%. In connection with this offering, the Company capitalized $13.2 million of financing fees.
The 2025 Notes are senior, unsecured obligations of the Company, and are convertible into cash and shares of its common stock based on initial conversion rate, subject to adjustment of 13.5739 shares per $1,000 principal amounts of the 2025 Notes (which represents an initial conversion price of $73.67 per share). The 2025 Notes convert only in the following circumstances: (1) if the closing price of the Company's common stock has been at least 130% of the conversion price during the period; (2) if the average trading price per $1,000 principal amount of the 2025 Notes is less than or equal to 98% of the average conversion value of the 2025 Notes during a period as defined in the indenture; (3) at any time on or after February 20, 2023; or (4) if specified corporate transactions occur. As of December 31, 2022, none of these conditions existed with respect to the 2025 Notes and as a result the 2025 Notes are classified as long term.
On December 9, 2020, the Company entered into the First Supplemental Indenture to the original agreement dated as of February 4, 2020 between the Company and Citibank, N.A., as trustee, governing the Company’s outstanding 2025 Notes. The Company irrevocably elected (1) to eliminate the Company’s option to choose physical settlement on any conversion of the 2025 Notes that occurs on or after the date of the First Supplemental Indenture and (2) with respect to any Combination Settlement for a conversion of the 2025 Notes, the Specified Dollar Amount that will be settled in cash per $1,000 principal amount of the 2025 Notes shall be no lower than $1,000.
Holders of the Notes will have the right to require the Company to repurchase for cash all or a portion of their Notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of a fundamental change (as defined in the indenture relating to the Notes). The Company will also be required to increase the conversion rate for holders who convert their Notes in connection with certain fundamental changes occurring prior to the maturity date or following delivery by the Company of a notice of redemption.
In connection with the issuance of the 2025 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of the 2025 Notes (the “hedge participants”). The cost of the call transactions was $104.2 million for the 2025 Notes. The Company received $44.5 million of proceeds from the warrant transactions for the 2025 Notes. The call transactions involved purchasing call options from the hedge participants, and the warrant transactions involved selling call options to the hedge participants with a higher strike price than the purchased call options. The initial strike price of the call transactions was $73.67, subject to anti-dilution adjustments substantially similar to those in the 2025 Notes. The initial strike price of the warrant transactions was $113.34 for the 2025 Notes, subject to customary anti-dilution adjustments.
At December 31, 2022, the carrying amount of the liability was $575.0 million. The fair value of the 2025 Notes at December 31, 2022 was $560.5 million. Factors that the Company considered when estimating the fair value of the 2025 Notes included recent quoted market prices or dealer quote. The level of the 2025 Notes is considered as Level 1.
As a result of the adoption of ASU 2020-06, for both the years ended December 31, 2022 and 2021, the Company recognized only cash interest related to the contractual interest coupon on the 2025 Notes of $2.9 million.
Securitization Facility
During the fourth quarter of 2018, the Company entered into an accounts receivable securitization facility (the "Securitization Facility") under which accounts receivable of certain domestic subsidiaries are sold on a non-recourse basis to a special purpose entity (“SPE”), which is a bankruptcy-remote, consolidated subsidiary of the Company. Accordingly, the assets of the SPE are not available to satisfy the obligations of the Company or any of its subsidiaries. From time to time, the SPE may finance such accounts receivable with a revolving loan facility secured by a pledge of such accounts receivable. The amount of outstanding borrowings on the Securitization Facility at any one time is limited to $150.0 million. The Securitization Facility Agreement ("Securitization Agreement") governing the Securitization Facility contains certain covenants and termination events. An occurrence of an event of default or a termination event under this Securitization Agreement may give rise to the right of its counterparty to terminate this facility. As of December 31, 2022, the Company was in compliance with the covenants and none of the termination events had occurred.
On May 28, 2021, the Company entered into an amendment (the "May 2021 Amendment") of the Securitization Facility which extended the maturity date from December 21, 2021 to May 28, 2024. The May 2021 Amendment does not increase the Company’s total indebtedness.
At December 31, 2022 and 2021, the Company had $104.7 million and $112.5 million, of outstanding borrowings under its Securitization Facility at a weighted average interest rate of 5.0% and 1.1%, respectively. The fair value of the outstanding borrowing of the Securitization Facility at December 31, 2022 was $104.9 million. These fair values were determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities.
XML 36 R14.htm IDEA: XBRL DOCUMENT v3.22.4
DERIVATIVE INSTRUMENTS
 12 Months Ended
Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVE INSTRUMENTS DERIVATIVE INSTRUMENTS
Interest Rate Hedging
The Company’s interest rate risk relates to U.S. dollar denominated variable interest rate borrowings. The Company uses interest rate swap derivative instruments to manage earnings and cash flow exposure resulting from changes in interest rates. These interest rate swaps apply a fixed interest rate on a portion of the Company's expected LIBOR-indexed floating-rate borrowings.
The Company held the following interest rate swaps as of December 31, 2022 and 2021 (dollar amounts in thousands):
December 31, 2022December 31, 2021December 31, 2022December 31, 2021
Hedged ItemNotional AmountDesignation DateEffective DateTermination DateFixed Interest RateEstimated Fair Value
Asset (Liability)
1-month USD LIBOR Loan— 300,000 December 13, 2017January 1, 2018December 31, 20222.201 %$— $(5,268)
1-month USD LIBOR Loan150,000 150,000 December 13, 2017July 1, 2019June 30, 20242.423 %5,012 (5,520)
1-month USD LIBOR Loan200,000 200,000 December 13, 2017January 1, 2018December 31, 20242.313 %8,380 (7,421)
1-month USD LIBOR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.220 %1,831 (5,512)
1-month USD LIBOR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.199 %1,905 (5,464)
1-month USD LIBOR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.209 %1,970 (5,494)
1-month USD LIBOR Loan100,000 100,000 December 18, 2018December 30, 2022December 31, 20272.885 %4,252 (6,886)
1-month USD LIBOR Loan100,000 100,000 December 18, 2018December 30, 2022December 31, 20272.867 %4,153 (6,764)
1-month USD LIBOR Loan575,000 575,000 December 15, 2020July 31, 2025December 31, 20271.415 %23,742 3,552 
1-month USD LIBOR Loan125,000 125,000 December 15, 2020July 1, 2025December 31, 20271.404 %5,467 821 
$1,475,000 $1,775,000 $56,712 $(43,956)
The Company has designated these derivative instruments as cash flow hedges. The Company assesses the effectiveness of these derivative instruments and has recorded the changes in the fair value of the derivative instrument designated as a cash flow hedge as unrealized gains or losses in accumulated other comprehensive income (“AOCI”), net of tax, until the hedged item affected earnings, at which point any gain or loss was reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, the Company will reclassify the remaining amount of any gain or loss on the related cash flow hedge recorded in AOCI to interest expense at that time.
Foreign Currency Hedging
From time to time, the Company enters into foreign currency hedge contracts intended to protect the U.S. dollar value of certain forecasted foreign currency denominated transactions. The Company assesses the effectiveness of the contracts that are designated as hedging instruments. The changes in fair value of foreign currency cash flow hedges are recorded in AOCI, net of tax. Those amounts are subsequently reclassified to earnings from AOCI as impacted by the hedged item when the hedged item affects earnings. If the hedged forecasted transaction does not occur, or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. For contracts not designated as hedging instruments, the changes in fair value of the contracts are recognized in other income, net in the consolidated statements of operation, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities.
The success of the Company’s hedging program depends, in part, on forecasts of certain activity denominated in foreign currency. The Company may experience unanticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activities during periods of currency volatility. In addition, changes in currency exchange rates related to any unhedged transactions may affect earnings and cash flows.
Cross-Currency Rate Swaps
On October 2, 2017, the Company entered into cross currency swap agreements to convert a notional amount of $300.0 million equivalent to 291.2 million of Swiss Francs ("CHF") denominated intercompany loans into U.S. dollars. The CHF- denominated intercompany loans were the result of the purchase of intellectual property by a subsidiary in Switzerland as part of an acquisition. On September 26, 2022, the Company amended the CHF-denominated intercompany loan to extend the termination date to September 2023 and as a result, the Company early terminated the cross-currency swap designated as cash flow hedge of an intercompany loan with aggregate notional amount of $50.0 million. Simultaneously, the Company entered into a cross-currency swap agreement to convert a notional amount of CHF 48.5 million equivalent to $49.1 million of this
amended intercompany loan into U.S. dollars. The loss recorded by the Company upon the settlement of the swap was not material for the period. As of December 31, 2022, $49.1 million of the $300.0 million notional amount remain outstanding.
On December 21, 2020, the Company entered into cross-currency swap agreements to convert a notional amount of $471.6 million equivalent to 420.1 million of a CHF-denominated intercompany loan into U.S. dollars. The CHF-denominated intercompany loan was the result of an intra-entity transfer of certain intellectual property rights to a subsidiary in Switzerland completed during the fourth quarter of 2020. The intercompany loan requires quarterly payments of CHF 5.8 million plus accrued interest. As a result, the aggregate notional amount of the related cross-currency swaps will decrease by a corresponding amount.
The objective of these cross-currency swaps is to reduce volatility of earnings and cash flows associated with changes in the foreign currency exchange rate. Under the terms of these contracts, which have been designated as cash flow hedges, the Company will make interest payments in Swiss Francs and receive interest in U.S. dollars. Upon the maturity of these contracts, the Company will pay the principal amount of the loans in Swiss Francs and receive U.S. dollars from the counterparties.
The Company held the following cross-currency rate swaps as of December 31, 2022 and 2021 (dollar amounts in thousands):
December 31, 2022December 31, 2021December 31, 2022December 31, 2021
Effective DateTermination DateFixed RateAggregate Notional AmountFair Value Asset (Liability)
Pay CHFOctober 2, 2017October 2, 20221.95%CHF— 145,598 — (8,283)
Receive U.S.$4.52%$— 150,000 
Pay CHFDecember 21, 2020December 22, 20253.00%CHF374,137 397,137 (4,241)41 
Receive U.S.$3.98%$420,001 445,821 
Pay CHFSeptember 28, 2022September 29, 20231.95%CHF48,532 — (3,528)— 
Receive U.S.$5.32%$49,142 — 
Total$(7,769)$(8,242)
On October 3rd, 2022, in accordance with the termination date, the Company settled cross-currency swaps designated as cash flow hedges of an intercompany loan with aggregate notional amounts of $100 million. Based on the closing exchange rates, the gain upon settlement of these swaps was approximately $1.6 million which was offset by the loss on the settlement of the intercompany loan.
On October 4, 2021 in accordance with the termination date, the Company settled a cross-currency swap designated as a cash flow hedge of an intercompany loan with an aggregate notional amount of $50.0 million. The gain recorded by the Company upon the settlement of the swap was not material for the period.
The cross-currency swaps are carried on the consolidated balance sheet at fair value, and changes in the fair values are recorded as unrealized gains or losses in AOCI.
Net Investment Hedges
The Company manages certain foreign exchange risks through a variety of strategies, including hedging. The Company is exposed to foreign exchange risk from its international operations through foreign currency purchases, net investments in foreign subsidiaries, and foreign currency assets and liabilities created in the normal course of business. On October 1, 2018 ,December 16, 2020 and May 26, 2022, the Company entered into cross-currency swap agreements designated as net investment hedges to partially offset the effects of foreign currency on foreign subsidiaries.
The Company held the following cross-currency rate swaps designated as net investment hedges as of December 31, 2022 and 2021 (dollar amounts in thousands):
December 31, 2022December 31, 2021December 31, 2022December 31, 2021
Effective DateTermination DateFixed RateAggregate Notional AmountFair Value
Asset (Liability)
Pay EUROctober 3, 2018September 30, 2023—%EUR51,760 51,760 4,713 2,503 
Receive U.S.$2.57%$60,000 60,000 
Pay EUROctober 3, 2018September 30, 2025—%EUR38,820 38,820 4,307 2,147 
Receive U.S.$2.19%$45,000 45,000 
Pay CHFDecember 16, 2020December 16, 2027—%CHF— 222,300 — (792)
Receive USD1.10%$— 250,000 
Pay CHFMay 26, 2022December 16, 2028—%CHF288,210 — (14,663)— 
Receive U.S.$1.94%$300,000 — 
Total$(5,643)$3,858 
On May 26, 2022, the Company early settled cross-currency swaps designated as net investment hedge with an aggregate notional amount of $250 million equivalent to 222.3 million CHF. The original settlement date was December 16, 2027. As a result of the settlement, the Company recorded a gain of $4.9 million in AOCI. On May 26, 2022, the Company entered into cross-currency swap agreements designated as net investment hedge to replace these swaps with a notional amount of $300 million equivalent to 288 million CHF.
On September 30, 2021, in accordance with the termination date, the Company settled cross-currency swaps designated as net investment hedge with an aggregate notional amount of $52 million equivalent to 44.9 million Euros. As a result of the settlement, the Company recorded a gain of $0.1 million in AOCI.
The cross-currency swaps were carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in AOCI.
Counterparty Credit Risk
The Company manages its concentration of counterparty credit risk on its derivative instruments by limiting acceptable counterparties to a group of major financial institutions with investment grade credit ratings, and by actively monitoring their credit ratings and outstanding positions on an ongoing basis. Therefore, the Company considers the credit risk of the counterparties to be low. Furthermore, none of the Company’s derivative transactions are subject to collateral or other security arrangements, and none contain provisions that depend upon the Company’s credit ratings from any credit rating agency.
Fair Value of Derivative Instruments
The Company has classified all of its derivative instruments within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of the derivative instruments. The fair values of the interest rate swaps and cross-currency swaps were developed using a market approach based on publicly available market yield curves and the terms of the swap. The Company performs ongoing assessments of counterparty credit risk.
Effects of Derivative Instruments on Financial Position and Results of Operations
The following table summarizes the fair value for derivatives designated as hedging instruments in the consolidated balance sheets as of December 31, 2022 and 2021:
 Fair Value as of December 31,
Dollars in thousands20222021
Location on Balance Sheet (1):
Derivatives designated as hedges — Assets:
Prepaid expenses and other current assets
Cash Flow Hedges
Cross-currency swap4,497 4,900 
Interest rate swap(2)
16,682 — 
Net Investment Hedges
Cross-currency swap11,653 5,120 
Other assets
Cash Flow Hedges
Interest rate swap(2)
40,030 4,373 
Net Investment Hedges
Cross-currency swap3,311 2,104 
Total derivatives designated as hedges — Assets$76,173 $16,497 
Derivatives designated as hedges — Liabilities
Accrued expenses and other current liabilities
Cash Flow Hedges
Interest rate swap(2)
$— $18,187 
Cross-currency swap3,528 8,283 
Net Investment Hedges
Cross-currency swap— — 
Other liabilities
Cash Flow Hedges
Interest rate swap(2)
— 30,143 
Cross-currency swap8,738 4,859 
Net Investment Hedges
Cross-currency swap20,608 3,366 
Total derivatives designated as hedges — Liabilities32,874 64,838 
(1)The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.
(2)At December 31, 2022 and 2021, the total notional amounts related to the Company’s interest rate swaps were $1.5 billion and $1.8 billion respectively.
The following presents the effect of derivative instruments designated as cash flow hedges and net investment hedges on the accompanying consolidated statement of operations during the years ended December 31, 2022 and 2021:
 
Dollars in thousandsBalance in AOCI
Beginning of
Year		Amount of
Gain (Loss)
Recognized in
AOCI		Amount of Gain (Loss)
Reclassified from
AOCI into
Earnings		Balance in AOCI
End of Year		Location in
Statements of
Operations
Year Ended December 31, 2022
Cash Flow Hedges
Interest rate swap$(43,956)$93,308 $(7,360)$56,712 Interest expense
Cross-currency swap(9,688)8,847 19,430 (20,271)Other income, net
Net Investment Hedges
Cross-currency swap(2,321)2,196 6,789 (6,914)Interest income
$(55,965)$104,351 $18,859 $29,527 
Year Ended December 31, 2021
Cash Flow Hedges
Interest rate swap$(93,769)$27,402 $(22,411)$(43,956)Interest expense
Cross-currency swap(1,073)24,275 32,890 (9,688)Other income, net
Net Investment Hedges
Cross-currency swap(12,291)16,515 6,545 (2,321)Interest income
$(107,133)$68,192 $17,024 $(55,965)

For the years ended December 31, 2022 and 2021, the Company recorded a gain of $11.1 million and gain of $23.8 million, respectively, in other income, net related to change in fair value related to the foreign currency rate translation of the cross-currency swaps, designated as cash flow hedges, to offset the gains or losses recognized on the intercompany loans.
For the years ended December 31, 2022 and 2021, the Company recorded gains of $8.4 million and $9.1 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps designated as cash flow hedges.
The estimated gain that is expected to be reclassified to other income, net from AOCI as of December 31, 2022, for the cross-currency swaps designated as cash flow hedges within the next twelve months is $4.5 million. As of December 31, 2022, the Company does not expect any gains or losses will be reclassified into earnings as a result of the discontinuance of these cash flow hedges because the original forecasted transaction will not occur.
The estimated gain that is expected to be reclassified to interest income from AOCI as of December 31, 2022 for the cross-currency swaps designated as net investment hedges, within the next twelve months is $11.7 million.
Derivative Instruments not designated hedges:
During the fourth quarter of 2020, the Company entered into foreign currency forward contracts, with a notional amount of $4.2 million, to mitigate the foreign exchange risk related to certain intercompany loans denominated in Canadian Dollar ("CAD"). These contracts were settled in third quarter of 2022.
During the second quarter of 2021, the Company entered into a foreign currency swap, with a notional amount of $7.3 million, to mitigate the risk from fluctuations in foreign currency exchange rates associated with an intercompany loan denominated in JPY. In a foreign currency swap transaction, the Company agrees with another party to exchange, at specified intervals, the difference between one currency and another currency at a fixed exchange rate, generally set at inception, calculated by reference to an agreed upon notional amount. The notional amount of each currency is exchanged at the inception and termination of the currency swap by each party. The Company subsequently paid down a portion of this swap, bringing the notional amount down to $6.4 million.
The following table summarizes the gains (losses) of derivative instruments not designated as hedges on the condensed consolidated statements of income, which was included in other income:
Dollars in thousandsDecember 31,
20222021
Foreign currency forward contracts $— $(174)
Foreign currency swaps1,258 629
Total$1,258 $455 
XML 37 R15.htm IDEA: XBRL DOCUMENT v3.22.4
GOODWILL AND OTHER INTANGIBLE ASSETS
 12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS
Goodwill
The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test.
The qualitative evaluation is an assessment of factors including reporting unit specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of a reporting unit is less than its carrying amount, including goodwill. The Company may elect to bypass the qualitative assessment for its three reporting units and perform a quantitative test. The assumptions used in evaluating goodwill for impairment are subject to change and are tracked against historical results by management.
The quantitative test estimates the fair value of the three reporting units using a discounted cash flow model, which incorporates significant estimates and assumptions made by management which, by their nature, are characterized by uncertainty. Inputs used to fair value the Company's reporting units are considered inputs of the fair value hierarchy. For Level 3 measurements, significant increases or decreases in long-term growth rates or discount rates in isolation or in combination could result in a significantly lower or higher fair value measurement. The key assumptions impacting the valuation included the following:
•The reporting unit's financial projections, which are based on management's assessment of regional and macroeconomic variables, industry trends and market opportunities, and the Company's strategic objectives and future growth plans.
•The projected terminal value for the reporting unit, which represents the present value of projected cash flows beyond the last period in the discounted cash flow analysis. The terminal value reflects the Company's assumptions related to long-term growth rates and profitability, which are based on several factors, including local and macroeconomic variables, market opportunities, and future growth plans.
•The discount rate used to measure the present value of the projected future cash flows is set using a weighted-average cost of capital method that considers market and industry data as well as the Company's specific risk factors that are likely to be considered by a market participant. The weighted-average cost of capital is the Company's estimate of the overall after-tax rate of return required by equity and debt holders of a business enterprise.
During the third quarter of 2022, the Company elected to perform a qualitative analysis for its three reporting units. The Company determined, after performing the qualitative analysis, that there was no evidence that it is more likely than not that the fair value was less that the carrying amounts, therefore, it was not necessary to perform a quantitative impairment test.
Changes in the carrying amount of goodwill in 2022 and 2021 were as follows:
Dollars in thousandsCodman Specialty Surgical Tissue TechnologiesTotal
Goodwill at January 1, 2021$671,975 $260,392 $932,367 
ACell Acquisition — 94,147 94,147 
Foreign currency translation(8,547)(4,509)(13,056)
Balance at December 31, 2021$663,428 $350,030 $1,013,458 
Sale of non-core traditional wound care business— (5,019)(5,019)
SIA Acquisition— 41,855 41,855 
Foreign currency translation(7,209)(4,204)(11,413)
Balance at December 31, 2022$656,219 $382,662 $1,038,881 
Other Intangible Assets
The components of the Company's identifiable intangible assets were as follows:
December 31, 2022
Dollars in thousandsWeighted
Average
Life		CostAccumulated AmortizationNet
Completed technology
18 years
$1,204,325 $(370,968)$833,357 
Customer relationships
12 years
193,081 (144,040)49,041 
Trademarks/brand names
28 years
97,265 (34,674)62,591 
Codman trade nameIndefinite166,693 — 166,693 
Supplier relationships
30 years
30,211 (17,170)13,041 
All other
11 years
5,957 (4,071)1,886 
$1,697,532 $(570,923)$1,126,609 
December 31, 2021
Dollars in thousandsWeighted
Average
Life		CostAccumulated AmortizationNet
Completed technology
18 years
$1,132,954 $(307,013)$825,941 
Customer relationships
12 years
211,344 (142,755)68,589 
Trademarks/brand names
28 years
98,367 (31,468)66,899 
Codman trade name
Indefinite
167,758 — 167,758 
Supplier relationships
30 years
30,211 (16,192)14,019 
All other
11 years
6,258 (3,891)2,367 
$1,646,892 $(501,319)$1,145,573 

Intangible Assets with Indefinite Lives
The Company tests intangible assets with indefinite lives for impairment annually in the third quarter in accordance with ASC Topic 350. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a indefinite lived intangible asset below its carrying amount. The Company tests for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of the intangible asset is less than its carrying amount. The Company may elect to bypass this qualitative evaluation and perform a quantitative test.
During the third quarter of 2022, the Company elected to perform a qualitative analysis for its intangible asset with indefinite lives. The Company determined, after performing the qualitative analysis, that there was no evidence that it is more likely than not that the fair value was less that the carrying amounts, therefore, it was not necessary to perform a quantitative impairment test.
Product rights and other definite-lived intangible assets are tested periodically for impairment in accordance with ASC Topic 360 when events or changes in circumstances indicate that an asset's carrying value may not be recoverable. The impairment testing involves comparing the carrying amount of the asset or asset group to the forecasted undiscounted future cash flows. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and impairment exists. An impairment loss is measured as the excess of the asset's carrying value over its fair value, calculated using discounted future cash flows. The computed impairment loss is recognized in the period that the impairment occurs.
Amortization expense (including amounts reported in cost of product revenues) for the years ended December 31, 2022, 2021 and 2020 was $78.3 million, $83.3 million and $74.5 million, respectively.
Annual amortization expense is expected to approximate $82.3 million in 2023, $81.7 million in 2024, $81.7 million in 2025, $81.5 million in 2026, $79.6 million in 2027 and $551.6 million thereafter. Amortization of product technology based intangible assets totaled $64.4 million, $66.5 million and $46.7 million for the years ended December 31, 2022, 2021 and 2020, respectively, and is presented by the Company within cost of goods sold.
XML 38 R16.htm IDEA: XBRL DOCUMENT v3.22.4
TREASURY STOCK
 12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
TREASURY STOCK TREASURY STOCK
As of December 31, 2022 and 2021, there were 6.8 million and 4.9 million shares of treasury stock outstanding with a cost of $362.9 million and $234.4 million, respectively, at a weighted average cost per share of $53.18 and $47.86, respectively.
On January 26, 2023, the Company entered into a $150 million accelerated share repurchase ("2023 ASR") and received 2.1 million shares of the Company common stock at inception of the 2023 ASR, which represented approximately 80% of the expected total shares of under the 2023 SAR. The remaining repurchase transactions are expected to be completed in the first half of 2023.
On April 26 2022, the Board of Directors authorized the Company to repurchase up to $225 million of the Company’s common stock. The program allows the Company to repurchase its shares opportunistically from time to time. The repurchase authorization expires in December 2024. This stock repurchase authorization replaces the previous $225 million stock repurchase authorization, of which $100 million remained authorized at the time of its replacement, and which was otherwise set to expire on December 31, 2022. Purchases may be affected through one or more open market transactions, privately negotiated transactions, transactions structured through investment banking institutions, or a combination of the foregoing.
On January 12, 2022, the Company entered into a $125 million accelerated share repurchase ("2022 ASR") and received 1.48 million shares of Company common stock at inception of the 2022 ASR, which represented approximately 80% of the expected total shares under the 2022 ASR. In March 24, 2022, the early exercise provision was exercised by the 2022 ASR counterparty. Upon settlement on March 24, 2022, the Company received an additional 0.46 million shares determined using the volume-weighted average price of the Company's common stock during the term of the 2022 ASR.
For the year ended December 31, 2021, there were no repurchases of the Company’s common stock as part of the share repurchase authorization.
On August 16, 2022, the Inflation Reduction Act of 2022 (the “Act”) was signed into law. The Act implements a new excise tax of 1% on the net share repurchases made by the company effective for share repurchases performed January 1, 2023, or after.
XML 39 R17.htm IDEA: XBRL DOCUMENT v3.22.4
STOCK-BASED COMPENSATION
 12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
Stock-based compensation expense - all related to employees and members of the Board of Directors - recognized under the authoritative guidance was as follows:
Years Ended December 31,
Dollars in thousands202220212020
Cost of goods sold549 470 344 
Research and development1,739 1,644 1,471 
Selling, general and administrative$25,437 $34,096 $17,776 
Total stock-based compensation expense27,725 36,210 19,591 
Total estimated tax benefit related to stock-based compensation expense10,574 13,804 6,221 
Net effect on net income$17,151 $22,406 $13,370 
EMPLOYEE STOCK PURCHASE PLAN
The purpose of the Employee Stock Purchase Plan (the “ESPP”) is to provide eligible employees of the Company with the opportunity to acquire shares of common stock at periodic intervals by means of accumulated payroll deductions. The ESPP is a non-compensatory plan. Under the ESPP, a total of 3.0 million shares of common stock are reserved for issuance. These shares will be made available either from the Company’s authorized but unissued shares of common stock or from shares of common stock reacquired by the Company as treasury stock. At December 31, 2022, 2.0 million shares remain available for purchase under the ESPP. During the years ended December 31, 2022, 2021 and 2020, the Company issued 20,780 shares, 16,948 shares and 18,284 shares under the ESPP for $1.1 million, $1.1 million and $1.1 million, respectively.
EQUITY AWARD PLANS
As of December 31, 2022, the Company had stock options, restricted stock awards, performance stock awards, contract stock awards and restricted stock unit awards outstanding under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan (the “2003 Plan”). The 2000 and 2001 Equity Incentive Plans were terminated as of February 19, 2021, and no further awards may be issued under the plans.
In May 2010 and May 2017, the stockholders of the Company approved amendments to the 2003 Plan to increase by 3.5 million and 1.7 million, respectively, the number of shares of common stock that may be issued under the 2003 Plan. The Company has reserved 4.0 million shares under each of the 2000 Plan and the 2001 Plan, and 14.7 million shares under the 2003 Plan. The Plans permit the Company to grant incentive and non-qualified stock options, stock appreciation rights, restricted stock, contract stock, performance stock, or dividend equivalent rights to designated directors, officers, employees and associates of the Company.
Stock options issued under the 2003 Plan became exercisable over specified periods, generally within four years from the date of grant for officers and employees, and within one year from the date of the grant for members of the Board of Directors. The awards generally expire eight years from the grant date for employees and from six to ten for directors and certain executive officers, except in certain instances that result in accelerated vesting due to death, disability, retirement age or change in control provisions within their grant agreements. Restricted stock issued under the 2003 Plan vests ratably over specified periods, generally three years after the date of grant. The vesting of performance stock issued under the 2003 Plan is subject to service and performance conditions.
Stock Options
The Company values stock option grants using the binomial distribution model. Management believes that the binomial distribution model is preferable to the Black-Scholes model because it is a more flexible model that gives consideration to the impact of non-transferability and vesting provisions in valuing employee stock options.
In determining the value of stock options granted, the Company considered that it has never paid cash dividends and does not currently intend to pay cash dividends, and thus has assumed a 0% dividend yield. Expected volatilities are based on the historical volatility of the Company’s stock price. The expected life of stock options is estimated based on historical data on exercise of stock options, post-vesting forfeitures and other factors to estimate the expected term of the stock options granted. The risk-free interest rates are derived from the U.S. Treasury yield curve in effect on the date of grant for instruments with a remaining term similar to the expected life of the options. The Company accounts for forfeitures as they occur.
The following weighted-average assumptions were used in the calculation of fair value:
Years Ended December 31,
202220212020
Dividend yield0%0%0%
Expected volatility30%29%27%
Risk free interest rate2.01%1.30%0.89%
Expected life of option from grant date7 years7 years7 years
Weighted average grant date fair value of options granted
$23.15$22.59$13.03
The following table summarizes the Company’s stock option activity.
SharesWeighted Average Exercise PriceWeighted Average Contractual Term in YearsAggregate Intrinsic Value
Stock Options(In thousands)(In thousands)
Outstanding at January 1, 20221,225 $45.11 4.30$26,970
Granted146 65.11 — — 
Exercised(155)28.32 — — 
Forfeited or Expired(14)50.68 — — 
Outstanding at December 31, 20221,202 $49.63 4.14$10,772 
Exercisable at December 31, 2022871 $45.82 3.30$9,635 
The Company recognized $3.5 million, $5.0 million and $3.2 million in expense related to stock options during the years ended December 31, 2022, 2021 and 2020, respectively. The intrinsic value of options exercised for the years ended December 31, 2022, 2021 and 2020 were $4.0 million, $11.1 million and $8.7 million, respectively. Cash received from option exercises and employee stock purchase plan was $5.5 million, $6.8 million and $5.2 million, for the years ended December 31, 2022, 2021 and 2020, respectively. The realized tax benefit from options exercised were $0.6 million, $2.2 million and $1.7 million for the years ended December 31, 2022, 2021 and 2020, respectively.
As of December 31, 2022, there was approximately $3.5 million of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of approximately two years.
Awards of Restricted Stock, Performance Stock and Contract Stock
The following table summarizes the Company’s awards of restricted stock, performance stock and contract stock for the year ended December 31, 2022.
Restricted Stock AwardsPerformance Stock and Contract Stock Awards
SharesWeighted Average Grant Date Fair Value Per ShareSharesWeighted Average Grant Date Fair Value Per Share
(In thousands)(In thousands)
Unvested, January 1, 2022422 $58.78 442 60.62 
Granted334 62.88 245 62.89 
Adjustments for performance achievement related to award target
— — (18)60.76 
Cancellations(34)62.29 (10)59.88 
Released(239)58.27 (252)59.38 
Unvested, December 31, 2022483 $61.63 407 62.88 
The Company recognized $24.3 million, $31.2 million and $16.4 million in expense related to such awards during the years ended December 31, 2022, 2021 and 2020, respectively. The total fair market value of shares vested and released in 2022, 2021 and 2020 was $65.0 million, $15.7 million and $17.3 million, respectively. Vested awards include shares that have been fully earned but had not been delivered as of December 31, 2022.
Performance stock awards have performance features associated with them. Performance stock, restricted stock and contract stock awards generally have requisite service periods of three years. The fair value of these awards is being expensed on a straight-line basis over the vesting period. As of December 31, 2022, there were 129,399 performance stock units ("PSU's") subject to vest and be released based on 2022 performance achievement.
As of December 31, 2022, there was approximately $29.7 million of total unrecognized compensation costs related to unvested restricted stock, performance stock and contract stock awards. These costs are expected to be recognized over a weighted-average period of approximately two years.
At December 31, 2022, there were approximately 3.1 million shares available for grant under the 2003 Plan.
The Company capitalized into inventory, share based compensation costs of $0.6 million, $0.5 million and $0.4 million for the years ended December 31, 2022, 2021 and 2020, respectively. Such share-based compensation was recognized as cost of goods sold when related inventory was sold.
XML 40 R18.htm IDEA: XBRL DOCUMENT v3.22.4
RETIREMENT BENEFIT PLANS
 12 Months Ended
Dec. 31, 2022
Retirement Benefits [Abstract]  
RETIREMENT BENEFIT PLANS RETIREMENT BENEFIT PLANS
DEFINED BENEFIT PLANS
The Company has various defined benefit plans which covers certain employees in France, Japan, Germany and Switzerland.
Net periodic benefit costs for the Company’s defined benefit pension plans for the years ended December 31, 2022 and 2021 included the following (amounts in thousands):
Year ended December 31,
20222021
Service cost$2,419 $2,741 
Interest cost194 100 
Expected return on plan assets(1,381)(893)
Amortization of prior service cost (credit)(326)(281)
Recognized actuarial losses9 186 
Settlements— 51 
Net period benefit cost$915 $1,904 
The following weighted average assumptions were used to develop net periodic pension benefit costs and the actuarial present values of projected pension benefit obligations for the years ended December 31, 2022 and 2021, respectively:
As of December 31,
20222021
Discount rate2.44 %0.37 %
Expected return on plan assets3.61 %3.59 %
Rate of compensation increase1.97 %2.10 %
Interest crediting rate for cash balance plans1.00 %1.00 %
The Company’s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. In 2022 and 2021, the discount rates were prescribed as the current yield on corporate bonds with an average rating of AA or AAA of equivalent currency and term to the liabilities. The expected returns on plan assets represent the average rate of return expected to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid. In developing the expected rates of return, the Company considers returns of historical market data as well as actual returns on the plan assets. Using this reference information, the long-term return expectations for each asset category are developed according to the allocation among those investment categories.
The assessment is determined using projections from external financial sources, long-term historical averages, actual returns by asset class and the various asset class allocations by market.
The following sets forth the change in projected benefit obligations and the change in plan assets for the years ended December 31, 2022 and 2021 and a reconciliation of the funded status at December 31, 2022 and 2021, respectively (amounts in thousands):
Year ended December 31,
20222021
Change In Projected Benefit Obligations
Projected benefit obligations, beginning of year$65,184 $72,869 
Interest cost194 100 
Service cost2,419 2,741 
Actuarial (gain) loss(14,822)(5,044)
Plan amendments(390)(586)
Plan settlements(20)(655)
Employee contribution999 917 
Premiums paid(391)(373)
Benefit payment(999)(2,128)
Effect of foreign currency exchange rates(1,810)(2,657)
Projected benefit obligations, end of year$50,364 $65,184 
Year ended December 31,
20222021
Change In Plan Assets
Plan assets at fair value, beginning of year$39,914 $37,825 
Actual return on plan assets(2,863)3,371 
Employer contributions2,356 2,254 
Employee contributions999 917 
Plan settlements— (633)
Benefits paid(998)(2,128)
Premiums paid(391)(373)
Effect of foreign currency exchange rates(964)(1,319)
Plan assets at fair value, end of year$38,053 $39,914 
Year ended December 31,
20222021
Reconciliation Of Funded Status
Fair value of plan assets$38,053 $39,914 
Benefit obligations50,364 65,184 
Unfunded benefit obligations$12,311 $25,270 
The unfunded benefit obligations are included in other liabilities in the consolidated balance sheets at December 31, 2022 and 2021, respectively.
During the periods ended December 31, 2022 and 2021, the Company had a net gain of $7.4 million and $7.0 million, respectively, recognized within accumulated other comprehensive loss that has not been recognized as a component of net periodic benefit cost. The gain recognized during the period ended December 31, 2021, is primarily attributed to a change in the discount rate used to estimate the projected benefit obligation for defined benefit plans which cover certain employees in Switzerland. The combined accumulated benefit obligations for the defined benefit plans was $46.4 million and $60.3 million as of December 31, 2022 and 2021, respectively.
Unrecognized gains and losses are amortized over the average remaining future service for each plan. For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses is determined by using a 10% corridor of the greater of the market value of assets or the accumulated benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service.
Prior service costs/benefits for the pension plans are amortized over the average remaining future service of plan participants at the time of the plan amendment.
The net plan assets of the pension plans are invested in common trusts. Common trusts are classified as Level 2 in fair value hierarchy. The fair value of common trusts is valued at net asset value based on the fair values of the underlying investments of the trusts as determined by the sponsor of the trusts. The investment strategy of the Company's defined benefit plans is both to meet the liabilities of the plans as they fall due and to maximize the return on invested assets within appropriate risk profile.
The benefit plans in France and Germany had no assets at December 31, 2022.
As of December 31, 2022, no plan assets are expected to be returned to the Company in the next twelve months.
The following table is the summary of expected future benefit payments (in thousands):
2023$2,211 
2024$2,045 
2025$2,050 
2026$1,929 
2027$1,868 
Next five years$11,068 
As of December 31, 2022, contributions expected to be paid to the plan in 2022 is $2.6 million.
DEFINED CONTRIBUTION PLANS
The Company also has various defined contribution savings plans that cover substantially all employees in the United States, Belgium, Canada, France, Japan, Netherlands, the U.K. and Puerto Rico. The Company matches a certain percentage of each employee’s contributions as per the provisions of the plans. Total contributions by the Company to the plans were $9.8 million, $8.8 million and $6.7 million for the years ended December 31, 2022, 2021 and 2020, respectively.
DEFERRED COMPENSATION PLAN
The Company maintains a Deferred Compensation Plan in which certain employees of the Company may defer the payment and taxation of up to 75% of their base salary and up to 100% of bonus amounts and other eligible cash compensation.
This deferred compensation is invested in funds offered under this plan and is valued based on Level 1 measurements in the fair value hierarchy. Assets of the Company's deferred compensation plan are included in Other current assets and recorded at fair value based on their quoted market prices. The fair value of these assets at December 31, 2022 and 2021 was $4.7 million and $3.8 million. Offsetting liabilities relating to the deferred compensation plan are included in Other liabilities.
XML 41 R19.htm IDEA: XBRL DOCUMENT v3.22.4
LEASES AND RELATED PARTY LEASES
 12 Months Ended
Dec. 31, 2022
Leases [Abstract]  
LEASES AND RELATED PARTY LEASES LEASES AND RELATED PARTY LEASES
The Company leases administrative, manufacturing, research and distribution facilities and vehicles through operating lease agreements. The Company has no finance leases as of December 31, 2022. Many of the Company's leases include both lease (e.g., fixed payments including rent) and non-lease components (e.g., common-area or other maintenance costs). For vehicles, the Company has elected the practical expedient to group lease and non-lease components. 
Most facility leases include one or more options to renew. The exercise of lease renewal options is typically at the Company's sole discretion, therefore, the majority of renewals to extend the lease terms are not included in the ROU assets and lease liabilities as they are not reasonably certain of exercise. The Company regularly evaluates renewal options and when they are reasonably certain of exercise, the renewal period is included in the lease term.
As most of the Company's leases do not provide an implicit rate, the Company uses a collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments.
Total operating lease expense for the year ended December 31, 2022 and 2021, was $22.6 million and $20.3 million, respectively, which includes $0.3 million, in related party operating lease expense.
Supplemental balance sheet information related to operating leases at December 31, 2022 were as follows:
December 31, 2022
December 31, 2021
(In thousands, except lease term and discount rate)
ROU assets$148,284 $84,543 
Current lease liabilities14,624 14,775 
Non-current lease liabilities157,420 90,329 
Total lease liabilities$172,044 $105,104 
Weighted average remaining lease term (in years):
Leased facilities16.9 years10.4 years
Leased vehicles2.0 years2.1 years
Weighted average discount rate:
Leased facilities5.4 %5.1 %
Leased vehicles2.7 %2.6 %
Supplemental cash flow information related to leases was as follows:
December 31, 2022
December 31, 2021
(In thousands)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$17,442 $15,077 
ROU assets obtained in exchange for lease liabilities:
Operating leases72,169 12,610 
Future minimum lease payments under operating leases at December 31, 2022 were as follows:
Related PartiesThird PartiesTotal
(In thousands)
2023296 20,024 20,320 
2024296 20,869 21,165 
2025296 19,198 19,494 
2026296 16,830 17,126 
2027296 15,886 16,182 
Thereafter542 164,622 165,164 
Total minimum lease payments$2,022 $257,429 $259,451 
Less: Imputed interest$87,407 
Total lease liabilities172,044 
Less: Current lease liabilities14,624 
Long-term lease liabilities157,420 
There were no future minimum lease payments under finance leases at December 31, 2022.
Related Party Leases
The Company leases its manufacturing facility in Plainsboro, New Jersey, from a general partnership that is 50% owned by a corporation whose stockholders are trusts, whose beneficiaries include family members of the Company’s principal stockholder and former director. The term of the current lease agreement is through October 31, 2029 at an annual rate of approximately $0.3 million per year. The current lease agreement also provides (i) a 5-year renewal option for the Company to extend the lease from November 1, 2029 through October 31, 2034 at the fair market rental rate of the premises, and (ii) another 5-year renewal option to extend the lease from November 1, 2034 through October 31, 2039 at the fair market rental rate of the premises.
XML 42 R20.htm IDEA: XBRL DOCUMENT v3.22.4
INCOME TAXES
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
Income before income taxes consisted of the following:
Years Ended December 31,
Dollars in thousands202220212020
United States operations$92,642 $91,150 $15,082 
Foreign operations121,252 123,527 78,438 
Total$213,894 $214,677 $93,520 
A reconciliation of the U.S. Federal statutory rate to the Company’s effective tax rate is as follows:
Years Ended December 31,
202220212020
Federal statutory rate21.0 %21.0 %21.0 %
Increase (decrease) in income taxes resulting from:
   State income taxes, net of federal tax benefit0.1 %1.9 %1.2 %
   Foreign operations(3.9)%(4.0)%(7.9)%
 Excess tax benefits from stock compensation(2.4)%(1.2)%(1.0)%
   Intercompany profit in inventory0.3 %(0.2)%1.2 %
   Nondeductible facilitative costs0.2 %0.3 %1.1 %
   Contingent Consideration(2.0)%(0.2)%0.2 %
   Research and development credit(1.4)%(1.2)%(1.6)%
   Return to provision(0.5)%(0.7)%(2.3)%
   Global intangible low-taxed income ("GILTI")2.8 %0.7 %2.5 %
   Nondeductible executive compensation1.8 %0.9 %2.4 %
   Fair market value step up on intra-entity transfer of intellectual property
— %— %(63.3)%
   Gain from sale of business - book to tax differences— %3.9 %2.8 %
   Other(0.4)%— %0.5 %
Effective tax rate15.6 %21.2 %(43.2)%
Our effective tax rate was 15.6% and 21.2% of income before income taxes for the years ended December 31, 2022 and December 31, 2021, respectively. In 2022, the Company’s lower effective tax rate was driven by a $5.1 million income tax benefit related to stock compensation and a $2.4 million income tax benefit related to the filing of amended federal and state returns for prior years. In 2021, the Company's higher effective tax rate was driven in part by an $8.5 million income tax expense for nondeductible goodwill related to the sale of the Extremity Orthopedics business, offset by a $3.1 million income tax benefit related to excess tax benefits from stock compensation. In 2020, the Company’s lower worldwide effective tax rate was primarily driven by an $59.2 million income tax benefit on an intra-entity transfer of certain intellectual property, substantially completed during the fourth quarter in 2020. Excluding this transaction, the effective worldwide tax rate for 2020 was 20.2%.
In December 2020, the Company completed an intra-entity transfer of certain intellectual property rights to one of its subsidiaries in Switzerland. While the transfer did not result in a taxable gain, the Company’s Swiss subsidiary received a step-up in tax basis based on the fair value of the transferred intellectual property rights. The Company determined the fair value using a discounted cash flow model based on expectations of revenue growth rates, royalty rates, discount rates, and useful lives of the intellectual property. The Company recorded a $59.2 million deferred tax benefit in Switzerland related to the amortizable tax basis in the transferred intellectual property.
During 2022, the Company’s foreign operations generated a $0.4 million increase in income tax expense when compared to the same period in 2021, because of geographic and business mix of taxable earnings and losses, among other factors. The 2022 foreign effective tax rate is 15.9%, compared to 15.2% in 2021. The Company’s foreign tax rate is primarily based upon statutory rates.
During 2021, the Company’s foreign operations generated a $63.6 million increase in income tax expense when compared to the same period in 2020, because of the intra-entity transfer of certain intellectual property in 2020, geographic and business mix of taxable earnings and losses, among other factors. The 2021 foreign effective tax rate is 15.2%, compared to (57.1)% in 2020. The Company’s foreign tax rate is primarily based upon statutory rates and is also impacted by the intra-entity transfer of certain intellectual property as described above for 2020.
Changes to income tax laws and regulations, in any of the tax jurisdictions in which the Company operates, could impact the effective tax rate. Various governments, both U.S. and non-U.S., are increasingly focused on tax reform and revenue-raising legislation. On August 16, 2022, the Inflation Reduction Act of 2022 (the “Act”) was signed into law, the company does not expect the law to have a material impact on the company’s effective tax rate. Further, legislation in foreign jurisdictions may be enacted, in response to the base erosion and profit-sharing (BEPS) project begun by the Organization for Economic Cooperation and Development (OECD). The OECD recently finalized major reform of the international tax system with respect to implementing a global minimum tax rate. Such changes in U.S. and Non-U.S. jurisdictions could have an adverse effect on the Company’s effective tax rate.
The provision for income taxes consisted of the following:
Years Ended December 31,
Dollars in thousands202220212020
Current:
   Federal$24,201 $31,938 $6,184 
   State3,835 11,377 5,029 
   Foreign9,893 5,042 12,553 
Total current$37,929 $48,357 $23,766 
Deferred:
   Federal(11,591)(12,830)(5,079)
   State(2,316)(3,688)(1,760)
   Foreign9,322 13,763 (57,299)
Total deferred$(4,585)$(2,755)$(64,138)
Provision for income taxes$33,344 $45,602 $(40,372)
The income tax effects of significant temporary differences that give rise to deferred tax assets and liabilities, shown before jurisdictional netting, are presented below:
December 31,
Dollars in thousands20222021
Assets:
   Doubtful accounts$2,261 $2,029 
   Inventory related items31,950 31,841 
   Tax credits13,084 13,319 
   Accrued vacation2,175 3,042 
   Accrued bonus4,944 7,415 
   Stock compensation10,175 13,955 
   Deferred revenue2,130 1,742 
   Net operating loss carryforwards30,707 26,198 
Capitalization of research and development expenses51,542 36,770 
   Unrealized foreign exchange gain6,228 12,849 
   Charitable contributions carryforward180 206 
   Leases and Other39,788 41,371 
   Total deferred tax assets195,164 190,737 
   Less valuation allowance(9,651)(9,767)
   Deferred tax assets after valuation allowance$185,513 $180,970 
Liabilities:
   Intangible and fixed assets(166,891)(152,150)
   Unrealized foreign exchange loss(12,991)— 
   Leases and Other(22,975)(17,658)
   Total deferred tax liabilities$(202,857)$(169,808)
Total net deferred tax assets (liabilities)$(17,344)$11,162 
The 2017 U.S. Tax Cuts and Jobs Act contained a provision which requires, for tax purposes, the capitalization and amortization of research and development expenses; effective for years beginning after December 31, 2021. The Company’s deferred tax assets increased by $20.2 million within the table above, related to the 2017 Tax Act.
At December 31, 2022, the Company had net operating loss carryforwards of $79.5 million for federal income tax purposes, $75.5 million for foreign income tax purposes and $37.9 million for state income tax purposes to offset future taxable income. The majority of the federal net operating loss carryforwards expire through 2037, while $18.6 million have an indefinite carry forward period. For foreign net operating loss carryforwards, $59.1 million will expire through 2028, while the remaining $16.4 million have an indefinite carry forward period. The state net operating loss carryforwards expire through 2036.
The valuation allowance relates to deferred tax assets for certain items that will be deductible for income tax purposes under very limited circumstances and for which the Company believes it will not satisfy the more likely than not threshold for realization of the associated tax benefit. In the event that the Company determines that it would be able to realize more or less than the recorded amount of net deferred tax assets, an adjustment to the deferred tax asset valuation allowance would be recorded in the period such a determination is made.
The valuation allowance at December 31, 2022 and 2021 primarily remained unchanged from respective prior periods; decreasing by an immaterial amount in both periods.
Balance at Beginning of PeriodCharged to Costs and ExpensesOtherDeductionsBalance at End of Period
Description
Dollars in thousands
Year ended December 31, 2022
Deferred tax assets valuation allowance
15,258 (515)(71)14,672 
Year ended December 31, 2021
Deferred tax assets valuation allowance13,825 1,444 89 (100)15,258 
Year ended December 31, 2020
Deferred tax assets valuation allowance12,069 1,617 — 139 13,825 

As of December 31, 2022, the Company has not provided deferred income taxes on unrepatriated earnings from foreign subsidiaries as they are deemed to be indefinitely reinvested unless there is a manner under which to remit the earnings with no material tax cost. Material taxes would primarily be attributable to foreign withholding taxes and local income taxes when such earnings are distributed. The Company will repatriate foreign earnings when there is no need for reinvestment overseas and no material tax cost to bring the earnings back to the United States. Reinvestment considerations would include future acquisitions, transactions, and capital expenditure plans.
A reconciliation of the beginning and ending amount of uncertain tax benefits is as follows:
Years Ended December 31,
Dollars in thousands202220212020
(In thousands)
Balance, beginning of year$676 $702 $676 
Gross increases:
   Current year tax positions37 — — 
   Prior years' tax positions— — 26 
Other— (26)— 
Balance, end of year$713 $676 $702 
Approximately $0.7 million of the balance at December 31, 2022 relates to uncertain tax positions that, if recognized, would affect the annual effective tax rate. The Company has $0.3 million of uncertain tax positions at December 31, 2022 related to tax positions for which it is reasonably possible that the amounts could be reduced during the twelve months following December 31, 2022.
The Company recognizes interest and penalties relating to uncertain tax positions in income tax expense. The Company recognized a minimal benefit for the years ended December 31, 2022, 2021 and 2020. The Company had minimal interest and penalties accrued for the years ended December 31, 2022 and 2021 and 2020.
The Company files Federal income tax returns, as well as multiple state, local and foreign jurisdiction tax returns. The Company is no longer subject to examinations of its U.S. consolidated Federal income tax returns by the IRS through fiscal year 2015. Additionally, the Company is no longer subject to examinations by the IRS for fiscal year 2017. All significant state and local matters have been concluded through fiscal year 2014. All significant foreign matters have been settled through fiscal 2015.
XML 43 R21.htm IDEA: XBRL DOCUMENT v3.22.4
NET INCOME PER SHARE
 12 Months Ended
Dec. 31, 2022
Earnings Per Share [Abstract]  
NET INCOME PER SHARE NET INCOME PER SHARE
Basic and diluted net income per share was as follows:
 Years Ended December 31,
 Dollars in thousands, except per share amounts202220212020
Basic net income per share:
Net income$180,550 $169,075 $133,892 
Weighted average common shares outstanding82,997 84,698 84,650 
Basic net income per common share$2.18 $2.00 $1.58 
Diluted net income per share:
Net income$180,550 $169,075 $133,892 
Weighted average common shares outstanding — Basic82,997 84,698 84,650 
Effect of dilutive securities:
Stock options and restricted stock519 787 577 
Weighted average common shares for diluted earnings per share83,516 85,485 85,228 
Diluted net income per common share$2.16 $1.98 $1.57 
Common stock of approximately 0.3 million and 0.1 million shares at December 31, 2022, and 2021 that are issuable through exercise of dilutive securities, respectively, and were not included in the computation of diluted net income per share because their effect would have been anti-dilutive.
Based on the adoption of ASU 2020-06, as the principal amount of the 2025 Notes will be paid in cash and only the conversion spread is settled in shares, the Company will be utilizing the if-converted method and only includes the net number of incremental shares that would be issued upon conversion.
XML 44 R22.htm IDEA: XBRL DOCUMENT v3.22.4
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
 12 Months Ended
Dec. 31, 2022
Stockholders' Equity Note [Abstract]  
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
Changes in accumulated other comprehensive loss by component between December 31, 2022 and 2021 are presented in the table below, net of tax:
Dollars in thousandsGains and Losses on DerivativesDefined Benefit Pension ItemsForeign Currency ItemsTotal
Balance at December 31, 2021
$(42,981)$1,893 $(4,067)$(45,155)
Other comprehensive gain (loss)80,335 7,429 (17,807)69,957 
Less: Amounts reclassified from accumulated other comprehensive income, net
14,537 — — 14,537 
Net current-period other comprehensive gain (loss)65,798 7,429 (17,807)55,420 
Balance at December 31, 2022
$22,817 $9,322 $(21,874)$10,265 
For the year ended December 31, 2022, the Company reclassified a gain of $15.0 million and a loss of $0.4 million from accumulated other comprehensive loss to other income, net and interest income, respectively.
XML 45 R23.htm IDEA: XBRL DOCUMENT v3.22.4
COMMITMENTS AND CONTINGENCIES
 12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
In consideration for certain technology, manufacturing, distribution, and selling rights and licenses granted to the Company, the Company has agreed to pay royalties on sales of certain products that it sells. The royalty payments that the Company made under these agreements were not significant for any of the periods presented.
The Company is subject to various claims, lawsuits and proceedings in the ordinary course of the Company's business, including claims by current or former employees, distributors and competitors and with respect to its products and product liability claims, lawsuits and proceedings, some of which have been settled by the Company. In the opinion of management, such claims are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material, adverse effect on the Company's financial condition. However, it is possible that the
Company's results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies.
The Company accrues for loss contingencies when it is deemed probable that a loss has been incurred and that loss is estimable. The amounts accrued are based on the full amount of the estimated loss before considering insurance proceeds and do not include an estimate for legal fees expected to be incurred in connection with the loss contingency. The Company consistently accrues legal fees expected to be incurred in connection with loss contingencies as those fees are incurred by outside counsel as a period cost.
Contingent Consideration
The Company determined the fair value of contingent consideration during the twelve-month period ended December 31, 2022 and 2021 to reflect the change in estimate, additions, payments, transfers and the time value of money during the period.
A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the years ended December 31, 2022 and 2021 is as follows (in thousands):
Year ended December 31, 2022Contingent Consideration Liability Related to Acquisition of:
Arkis
 (See Note 4) 		Location in Financial StatementsDerma SciencesACell Inc.
 (See Note 4) 		SIALocation in Financial Statements
Short-termLong-termLong-termShort-termLong-termLong-term
Balance as of January 1, 2022$3,691 $11,408 $230 $— $21,800 $— 
Additions— — — — 57,607 
Transfers from long-term to current portion— — — 4,885 (4,885)— 
Change in fair value of contingent consideration liabilities (846)(1,358)Research and development— (4,885)(13,215)— Selling, general and administrative
Balance as of December 31, 2022$2,845 $10,050 $230 $— $3,700 $57,607 $— 
Year ended December 31, 2021Contingent Consideration Liability Related to Acquisition of:
Arkis
 (See Note 4) 		Location in Financial StatementsDerma SciencesACell Inc.
 (See Note 4)		Location in Financial Statements
Short-termLong-termLong-termLong-term
Balance as of January 1, 2021$3,415 $11,746 $230 $— 
Additions— — — 23,900 
Transfers from long-term to current portion276 (276)— — 
Change in fair value of contingent consideration liabilities — $(62)Research and development— (2,100)Selling, general and administrative
Balance as of December 31, 2021$3,691 $11,408 $230 $21,800 
Derma Sciences
The Company assumed contingent consideration incurred by Derma Sciences, Inc. ("Derma Sciences") related to its acquisitions of BioD and the intellectual property related to Medihoney products. The Company accounted for the contingent liabilities by recording their fair value on the date of the acquisition based on a probability weighted income approach. The Company has already paid $33.3 million related to the aforementioned contingent liabilities. One contingent milestone remains which relates to net sales of Medihoney™ products exceeding certain amounts defined in the agreement between the Company and Derma Sciences. The potential maximum undiscounted payment amounts to $3.0 million. The estimated fair value as of December 31, 2022 and 2021 was $0.2 million.
Arkis BioSciences, Inc.
As part of the acquisition of Arkis BioSciences, Inc. ("Arkis"), the Company is required to pay the former shareholders of Arkis up to $25.5 million based on the timing of certain development milestones of $10 million and commercial sales milestones of $15.5 million, respectively. The Company used a probability weighted income approach to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specified milestone. The Company estimated the fair value of the contingent consideration to be $13.1 million at the acquisition date. The estimated the fair value as of December 31, 2022 was $12.9 million. The Company recorded $2.8 million in accrued expenses and other current liabilities and $10.1 million in other liabilities at December 31, 2022 in the consolidated balance sheets of the Company.
XML 46 R24.htm IDEA: XBRL DOCUMENT v3.22.4
SEGMENT AND GEOGRAPHIC INFORMATION
 12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
SEGMENT AND GEOGRAPHIC INFORMATION SEGMENT AND GEOGRAPHIC INFORMATION
The Company internally manages two global reportable segments and reports the results of its businesses to its chief operating decision maker. The two reportable segments and their activities are described below.
•The Codman Specialty Surgical segment includes (i) the Neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment and (ii) the Instruments business, which sells more than 40,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices.
•The Tissue Technologies segment includes such offerings as skin and wound repair, plastics & surgical reconstruction products, bone grafts, and nerve and tendon repair products.
The Corporate and other category includes (i) various executive, finance, human resource, information systems and legal functions, (ii) brand management, and (iii) share-based compensation costs.
The operating results of the various reportable segments as presented are not comparable to one another because (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions, and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the operating segment results. Net sales and profit by reportable segment for the years ended December 31, 2022, 2021 and 2020 are as follows:
 Years Ended December 31,
Dollars in thousands202220212020
Segment Net Sales
Codman Specialty Surgical$1,019,564 $1,025,232 $894,831 
 Tissue Technologies538,102 517,216 477,037 
Total revenues$1,557,666 $1,542,448 $1,371,868 
Segment Profit
Codman Specialty Surgical$417,873 $439,471 $356,657 
Tissue Technologies233,802 228,199 159,630 
Segment profit651,675 667,670 516,287 
Amortization(13,882)(16,914)(27,757)
Corporate and other(398,873)(453,526)(337,160)
Operating income$238,920 $197,230 $151,370 
The Company does not allocate any assets to the reportable segments. No asset information is reported to the chief operating decision maker and disclosed in the financial information for each segment. The Company attributes revenue to geographic areas based on the location of the customer. Total revenue, net and long-lived assets (tangible) by major geographic area are summarized below:
Dollars in thousands
United States(1)
EuropeAsia PacificRest of the WorldConsolidated
Total revenue, net:
2022$1,126,810 $170,903 $176,477 $83,476 $1,557,666 
20211,089,526 191,327 182,034 79,561 1,542,448 
2020971,975 172,689 157,174 70,030 1,371,868 
Total long-lived assets:
2022$440,223 $60,857 $12,975 $2,721 $516,776 
2021339,535 55,026 11,289 6,836 412,686 
XML 47 R25.htm IDEA: XBRL DOCUMENT v3.22.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Basis Of Presentation BASIS OF PRESENTATION These financial statements and the accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America and conform to Regulation S-X under the Securities Exchange Act of 1934, as amended.
Principles Of Consolidation
PRINCIPLES OF CONSOLIDATION
The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. See Note 4, Acquisitions and Divestitures, for details of new subsidiaries included in the consolidation.
Use Of Estimates USE OF ESTIMATES The preparation of consolidated financial statements is in conformity with generally accepted accounting principles in the United States ("GAAP") which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates.
Cash And Cash Equivalents
CASH AND CASH EQUIVALENTS
The Company considers all short-term, highly liquid investments purchased with original maturities of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value.
Trade Accounts Receivable And Allowances For Doubtful Accounts Receivable
TRADE ACCOUNTS RECEIVABLE AND ALLOWANCES FOR DOUBTFUL ACCOUNTS RECEIVABLE
Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company grants credit to customers in the normal course of business, but generally does not require collateral or any other security to support its receivables.
The Company evaluates the collectability of accounts receivable based on a combination of factors. The Company recognizes a provision for doubtful accounts that reflects the Company’s estimate of expected credit losses for trade accounts receivable. In circumstances where a specific customer is unable to meet its financial obligations to the Company, a provision to the allowances for doubtful accounts is recorded against amounts due to reduce the net recognized receivable to the amount that is reasonably expected to be collected. For all other customers, the Company evaluates measurement of all expected credit losses for trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The Company adopted this guidance on January 1, 2020 using a modified retrospective transition method which requires a cumulative-effect adjustment to the opening balance of retained earnings to be recognized on the date of adoption with no change to financial results reported in prior periods. The cumulative-effect adjustment recorded on January 1, 2020 was not material. The adoption of this ASU did not have a significant impact on the Company's consolidated financial statements and related disclosures. The Company's exposure to credit losses may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the COVID-19 pandemic and recent variants of the virus, and other customer-specific factors. Although the Company has historically not experienced significant credit losses, it is possible that there could be an adverse impact due to customer and governmental responses to the COVID-19 pandemic.Provisions to the allowances for doubtful accounts are recorded to selling, general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered.
Inventories
INVENTORIES
Inventories, consisting of purchased materials, direct labor and manufacturing overhead, are stated at the lower of cost, the value determined by the first-in, first-out method, or net realizable value. Inventories consisted of the following:
 December 31,
Dollars in thousands2022 2021
Finished goods172,088 $162,528 
Work in process70,598 65,323 
Raw materials81,897 89,535 
Total inventories, net$324,583 $317,386 
At each balance sheet date, the Company evaluates inventories for excess quantities, obsolescence or shelf life expiration. This evaluation includes analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, a review of the shelf life expiration dates for products, as well as the feasibility of reworking or using excess or obsolete products or components in the production or assembly of other products that are not obsolete or for which there are not excess quantities in inventory. To the extent that management determines there are excess or obsolete inventory or quantities with a shelf life that is too near its expiration for the Company to reasonably expect that it can sell those products prior to their expiration, the Company adjusts the carrying value to estimated net realizable value.
The Company capitalizes inventory costs associated with certain products prior to regulatory approval, based on management's judgment of probable economic benefit. The Company could be required to expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or delay of approval by necessary regulatory bodies or a decision by management to discontinue the related development program.
Property, Plant And Equipment
PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment are stated at historical cost less accumulated depreciation and any impairment charges. The Company provides for depreciation using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the lesser of the lease term or the useful life. The cost of major additions and improvements is capitalized, while maintenance and repair costs that do not improve or extend the lives of the respective assets are charged to operations as incurred. The cost of computer software developed or obtained for internal use is accounted for in accordance with the Accounting Standards Codification 350-40, Internal-Use Software.
Capitalized Interest CAPITALIZED INTERESTThe interest cost on capital projects, including facilities build-out and internal use software, is capitalized and included in the cost of the project. Capitalization commences with the first expenditure for the project and continues until the project is substantially complete and ready for its intended use. When no debt is incurred specifically for a project, interest is capitalized on project expenditures using the weighted average cost of the Company's outstanding borrowings.
Acquisitions
ACQUISITIONS
Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The Company accounts for the acquisition of a business in accordance with ASC 805, Business Combinations ("ASC Topic 805"). Amounts paid to acquire a business are allocated to the assets acquired and liabilities assumed based on their fair values at the date of acquisition. Any excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred.
Contingent consideration is recorded at fair value as measured on the date of acquisition. The value recorded is based on estimates of future financial projections under various potential scenarios using either a Monte Carlo simulation or the probability-weighted income approach derived from revenue estimates and probability assessment with respect to the likelihood of achieving contingent obligations. Contingent payments related to acquisitions consist of development, regulatory, and commercial milestone payments, in addition to sales-based payments, and are valued using discounted cash flow techniques. Each quarter until such contingent amounts are earned, the fair value of the liability is remeasured at each reporting period and adjusted as a component of operating expenses based on changes to the underlying assumptions. The change in the fair value of sales-based payments is based upon future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payment charges. The estimates used to determine the fair value of the contingent consideration liability are subject to significant judgment and actual results are likely to differ from the amounts originally recorded.
The Company determines the fair value of acquired intangible assets based on detailed valuations that use certain information and assumptions provided by management. The Company allocates any excess purchase price over the fair value of the net tangible and intangible assets acquired to goodwill. Determining the fair value of these intangible assets acquired as part of a business combination requires the Company to make significant estimates. These estimates include the amount and timing of projected future cash flows, the discount rate used to discount those cash flows to present value, the assessment of the asset’s life cycle, and the consideration of legal, technical, regulatory, economic, and competitive risks. The fair value assigned to other intangible assets is determined by estimating the future cash flows of each project or technology and discounting the net cash flows back to their present values. The discount rate used is determined at the time of measurement in accordance with accepted valuation methodologies.
Acquired IPR&D is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&D has an alternative future use. The Company uses the income approach to determine the fair value of developed technology and IPR&D acquired in a business combination. This approach determines fair value by estimating the after-tax cash flows attributable to the respective asset over its useful life and then discounting these after-tax cash flows back to a present value. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each product including net revenues, cost of sales, R&D costs, selling and marketing costs, the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, and competitive trends impacting the asset and each cash flow stream. The Company also uses the income approach, as described above, to determine the estimated fair value of certain other identifiable intangible assets including customer relationships, trade names and business licenses. Customer relationships represent established relationships with customers, which provide a ready channel for the sale of additional products and services. Trade names represent acquired company and product names.
IPR&D acquired in a business combination is capitalized as an indefinite-lived intangible asset. Development costs incurred after the acquisition are expensed as incurred. Upon receipt of regulatory approval, the indefinite-lived intangible asset is then accounted for as a finite-lived intangible asset and amortized on a straight-line basis or accelerated basis, as appropriate, over its estimated useful life. If the research and development project is subsequently abandoned, the indefinite-lived intangible asset is charged to expense. IPR&D acquired outside of a business combination is expensed immediately.

Due to the uncertainty associated with research and development projects, there is risk that actual results will differ materially from the original cash flow projections and that the research and development project will result in a successful commercial product. The risks associated with achieving commercialization include, but are not limited to, delay or failure to obtain regulatory approvals to conduct clinical trials, delay or failure to obtain required market clearances, delays or issues with patent
issuance, or validity and litigation.
If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&D with no alternative future use is charged to expense at the acquisition date. Payments that would be recognized as contingent consideration in a business combination are expensed when probable in an asset acquisition.
Goodwill And Other Intangible Assets
GOODWILL AND OTHER INTANGIBLE ASSETS
The excess of the cost over the fair value of net assets of acquired businesses is recorded as goodwill. Goodwill is not subject to amortization but is reviewed for impairment at the reporting unit level annually, or more frequently if impairment indicators arise. The Company's assessment of the recoverability of goodwill is based upon a comparison of the carrying value of goodwill with its estimated fair value. The Company reviews goodwill for impairment in the third quarter every year in accordance with ASC Topic 350, Intangibles - Goodwill and Other ("ASC Topic 350") and whenever events or changes in circumstances indicate the carrying value of goodwill may not be recoverable. Refer to Note 7, Goodwill and Other Intangibles for more information.
The Company has two reportable segments with three underlying reporting units. Refer to Note 16, Segment and Geographic Information for more information on reportable segments.
Other intangible assets include patents, trademarks, purchased technology, and supplier and customer relationships. Identifiable intangible assets are initially recorded at fair market value at the time of acquisition generally using an income or cost approach. The Company capitalizes costs incurred to renew or extend the term of recognized intangible assets and amortizes those costs
over their expected useful lives.
The Company tests intangible assets with indefinite lives for impairment annually in the third quarter in accordance with ASC Topic 350. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of an indefinite lived intangible asset below its carrying amount. The Company tests for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of the intangible asset is less than its carrying amount. The Company may elect to bypass this qualitative evaluation and perform a quantitative test.
Product rights and other definite-lived intangible assets are tested periodically for impairment in accordance with ASC 350 Topic when events or changes in circumstances indicate that an asset's carrying value may not be recoverable. The impairment testing involves comparing the carrying amount of the asset or asset group to the forecasted undiscounted future cash flows. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and impairment exists. An impairment loss is measured as the excess of the asset's carrying value over its fair value, calculated using discounted future cash flows. The computed impairment loss is recognized in the period that the impairment occurs.
Long-Lived Assets LONG-LIVED ASSETS Long-lived assets held and used by the Company, including property, plant and equipment, intangible assets, and leases are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets to be held and used, a recoverability test is performed using projected undiscounted net cash flows applicable to the long-lived assets. If an impairment exists, the amount of such impairment is calculated based on the estimated fair value of the asset. Impairments to long-lived assets to be disposed of are recorded based upon the difference between the carrying value and the fair value of the applicable assets.
Integra Foundation INTEGRA FOUNDATION The Company may periodically make contributions to the Integra Foundation, Inc. The Integra Foundation was incorporated in 2002 exclusively for charitable, educational, and scientific purposes and qualifies under IRC 501(c)(3) as an exempt private foundation. Under its charter, the Integra Foundation engages in activities that promote health, the diagnosis and treatment of disease, and the development of medical science through grants, contributions and other appropriate means. The Integra Foundation is a separate legal entity and is not a subsidiary of the Company; therefore, its results are not included in these consolidated financial statements.
Derivatives
DERIVATIVES
The Company develops, manufactures, and sells medical devices globally and its earnings and cash flows are exposed to market risk from changes in interest rates and currency exchange rates. The Company addresses these risks through a risk management program that includes the use of derivative financial instruments and operates the program pursuant to documented corporate risk management policies. All derivative financial instruments are recognized in the financial statements at fair value in accordance with the authoritative guidance. Under the guidance, for those instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation, based on the exposure being hedged. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, further, on the type of hedging relationship. The Company's derivative instruments do not subject its earnings or cash flows to material risk, and gains and losses on these derivatives generally offset losses and gains on the item being hedged. The Company has not entered into derivative transactions for speculative purposes. From time to time, the Company may enter into derivatives that are not designated as hedging instruments in order to protect itself from currency volatility due to intercompany balances.
All derivative instruments are recognized at the fair values as either assets or liabilities on the balance sheet. The Company determines the fair value of its derivative instruments using the framework prescribed by the authoritative guidance, by considering the estimated amount the Company would receive to sell or transfer these instruments at the reporting date and by taking into account expected forward interest rates, currency exchange rates, the creditworthiness of the counterparty for assets, and its creditworthiness for liabilities. In certain instances, the Company utilizes a discounted cash flow model to measure fair value. Generally, the Company uses inputs that include quoted prices for similar assets or liabilities in active markets, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The Company has classified all of its derivative assets and liabilities within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of its derivative instruments. The Company classifies derivatives designated as hedges in the same category as the item being hedged for cash flow presentation purposes.
The Company entered into foreign currency forward and foreign currency swap contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into other income, net, on the consolidated financial statements.
Foreign Currency FOREIGN CURRENCY All assets and liabilities of foreign subsidiaries which have a functional currency other than the U.S. dollar are translated at the rate of exchange at year-end, while elements of the income statement are translated at the average exchange rates in effect during the year. The net effect of these translation adjustments is shown as a component of accumulated other comprehensive income (loss). These currency translation adjustments are not currently adjusted for income taxes as they relate to permanent investments in non-U.S. subsidiaries.
Income Taxes
INCOME TAXES
Income taxes are accounted for by using the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period when the change is enacted.
The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position. Reserves are established for positions that don't meet this recognition threshold. The reserve is measured as the largest amount of benefit determined on a cumulative probability basis that the Company believes is more likely than not to be realized upon ultimate settlement of the position. These reserves are classified as long-term liabilities in the consolidated balance sheets of the Company, unless the reserves are expected to be paid in cash during the next twelve months, in which case they are classified as current liabilities. The Company also records interest and penalties accrued in relation to uncertain tax benefits as a component of income tax expense.
While the Company believes it has identified all reasonable exposures and the reserve it has established is appropriate under the circumstances, it is possible that additional exposures exist and that exposures may be settled at amounts different than the amounts reserved. It is also possible that changes in facts and circumstances could cause the Company to either materially increase or reduce the carrying amount of its tax reserve.
The Company continues to indefinitely reinvest substantially all of its foreign earnings unless there is a manner under which to remit the earnings without a material tax cost. The current provisional analysis indicates that the Company has sufficient U.S. liquidity, including borrowing capacity, to fund foreseeable U.S. cash needs without requiring the repatriation of foreign cash. One time or unusual items that may impact the ability or intent to keep the foreign earnings and cash indefinitely reinvested include significant U.S. acquisitions, loans from a foreign subsidiary and changes in tax laws.
Revenue Recognition
REVENUE RECOGNITION
Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services.
Total revenue, net, includes product sales, product royalties and other revenues, such as fees received from services.
For products shipped with FOB shipping point terms, the control of the product passes to the customer at the time of shipment. For shipments in which the control of the product is transferred when the customer receives the product, the Company recognizes revenue upon receipt by the customer. Certain products that the Company produces for private label customers have no alternative use and the Company has a right of payment for performance to date. Revenues from those products are recognized over the period that the Company manufactures these products, which is typically one month to three months. The Company uses the input method to measure the manufacturing activities completed to date, which depicts the progress of the Company's performance obligation of transferring control of goods being manufactured for private label customers.
A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and distributors, and also from inventory physically held by field sales representatives. For these types of products sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized.
Revenues from sale of products and services are evidenced by either a contract with the customer or a valid purchase order and an invoice which includes all relevant terms of sale. For product sales, invoices are generally issued upon the transfer of control (or upon the completion of the manufacturing in the case of the private label transactions recognized over time) and are typically payable 30 days after the invoice date. The Company performs a review of each specific customer's creditworthiness and ability to pay prior to acceptance as a customer. Further, the Company performs periodic reviews of its customers' creditworthiness prospectively. Refer to Note 3, Revenue From Contracts With Customers for more information. The Company also maintains a provision for estimated returns and allowances in the same period that the related revenue is recorded. This reserve is based upon an analysis of actual credit memos issued for pricing issues or returned goods over an extended period, as well as assumptions about outstanding accounts receivable and judgment in interpreting the data.
Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services.
Performance Obligations
The Company's performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers.
Significant Judgments
Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company's strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant.
The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract.
The Company's return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally 90 days.
The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.
Contract Asset and Liability
Revenues recognized from the Company's private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the prepaid expenses and other current assets account in the consolidated balance sheet. Upon invoicing to the customer, the balance is recorded in trade receivable, net in the consolidated balance sheet.
Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.
Shipping and Handling FeesThe Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold.
Research And Development RESEARCH AND DEVELOPMENT Research and development costs, including salaries, depreciation, consultant and other external fees, and facility costs directly attributable to research and development activities, are expensed in the period in which they are incurred.
Employee Termination Benefits
EMPLOYEE TERMINATION BENEFITS
The Company does not have a written severance plan, and it does not offer similar termination benefits to affected employees in all restructuring initiatives. Accordingly, in situations where minimum statutory termination benefits must be paid to the affected employees, the Company records employee severance costs associated with these restructuring activities in accordance with the authoritative guidance for non-retirement post-employment benefits. Charges associated with these activities are recorded when the payment of benefits is probable and can be reasonably estimated. In all other situations where the Company pays out termination benefits, including supplemental benefits paid in excess of statutory minimum amounts and benefits offered to affected employees based on management's discretion, the Company records these termination costs in accordance with the authoritative guidance for ASC Topic 712 Compensation - Nonretirement Benefits and ASC Topic 420 One-time Employee Termination Benefits.
The timing of the recognition of charges for employee severance costs other than minimum statutory benefits depends on whether the affected employees are required to render service beyond their legal notification period in order to receive the benefits. If affected employees are required to render service beyond their legal notification period, charges are recognized over the future service period. Otherwise, charges are recognized when management has approved a specific plan and employee communication requirements have been met.
Stock-Based Compensation STOCK-BASED COMPENSATION Relevant authoritative guidance requires companies to recognize the expense related to the fair value of their stock-based compensation awards. Stock-based compensation expense for stock option awards are based on the grant date fair value using the binomial distribution model. The Company recognizes compensation expense for stock option awards, restricted stock awards, performance stock awards and contract stock awards over the requisite service period of the award. All excess tax benefits and taxes and tax deficiencies from stock-based compensation are included in provision for income taxes in the consolidated statement of operations.
Pension Benefits
PENSION BENEFITS
The Company maintains defined benefit pension plans that cover certain employees in France, Japan, Germany and Switzerland. Various factors are considered in determining the pension liability, including the number of employees expected to be paid their salary levels and years of service, the expected return on plan assets, the discount rate used to determine the benefit obligations, the timing of benefit payments and other actuarial assumptions.
Retirement benefit plan assumptions are reassessed on an annual basis or more frequently if changes in circumstances indicate a re-evaluation of assumptions are required. The key benefit plan assumptions are the discount rate and expected rate of return on plan assets. The discount rate is based on average rates on bonds that matched the expected cash outflows of the benefit plans. The expected rate of return is based on historical and expected returns on the various categories of plan assets.
The Company uses the corridor approach in measuring the amount of net periodic benefit pension cost to recognize each period. The corridor approach defers all actuarial gains and losses resulting from variances between actual results and actuarial assumptions. Those unrecognized gains and losses are amortized when the net gains and losses exceed 10% of the greater of the market-related value of plan assets or the projected benefit obligation at the beginning of the year. The amount in excess of the corridor is amortized over the average remaining service period to retirement date of active plan participants.
Deferred Compensation Plan
The Company maintains a deferred compensation plan in which certain employees of the Company may defer the payment and taxation of up to 75% of their base salary and up to 100% of bonus amounts and other eligible cash compensation.
This deferred compensation is invested in funds offered under the Plan and is valued based on Level 1 measurements in the fair value hierarchy. The purpose of the plan is to retain key employees by providing them with an opportunity to defer a portion of their compensation as elected by the participant in accordance with the plan. Any amounts set aside to defray the liabilities assumed by the Company will remain the general assets of the Company until such amounts are distributed to the participants. Assets of the Company's deferred compensation plan are included in Other current assets and recorded at fair value based on their quoted market prices.
Concentration Of Credit Risk
CONCENTRATION OF CREDIT RISK
Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, which are held at major financial institutions, investment-grade marketable debt securities and trade receivables.
The Company's products are sold on an uncollateralized basis and on credit terms based upon a credit risk assessment of each customer. A portion of the Company's trade receivables to customers outside the United States includes sales to foreign distributors, who then sell to government owned or supported healthcare systems.
Recent Accounting Pronouncements
RECENT ACCOUNTING PRONOUNCEMENTS
In December 2019, the FASB issued ASU 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes, intended to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. This guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. The Company adopted ASU 2019-12 as of January 1, 2021. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures.
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848), and subsequent amendment to the initial guidance: ASU 2021-01, Reference Rate Reform (Topic 848): Scope (collectively, “Topic 848”). Topic 848 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference London Inter-Bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. The guidance generally can be applied from March 12, 2020 through December 31, 2022. On October 5, 2022, the FASB approved an extension of the sunset date of the reference rate reform from December 31, 2022 to December 31, 2024, past LIBOR’s end date. The Company currently has contracts that are indexed to LIBOR and are continuing to evaluate the scope of impacted contracts and potential risk. The Company expects all LIBOR-based contracts to be replaced by the Secured Overnight Financing Rate (“SOFR”), which is calculated based on overnight transactions under repurchase agreements backed by Treasury securities. The Alternative Reference Rates Committee, a group of private-market participants convened by the U.S. Federal Reserve Board and the New York Federal Reserve, has recommended the use of SOFR as a more robust reference rate alternative to LIBOR. The use of SOFR as a substitute for LIBOR is, however, voluntary and may not be suitable for all market participants. There can be no assurance that the replacement rate will be economically equivalent to LIBOR, which could result in higher interest rates for us under our debt facilities. There is no guarantee that a transition from LIBOR to SOFR will not result in financial market disruptions, significant increases in benchmark rates, or our borrowing costs, any of which could have an adverse effect on our business, results of operations and financial condition.
In August 2020, the FASB issued ASU 2020-06, Debt- Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40):Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. The guidance simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify. The guidance also simplifies the diluted net income per share calculation in certain areas. The ASU will be effective for annual and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years using either the modified retrospective or full retrospective method.
As detailed in Note 5, Debt, on February 4, 2020, the Company issued $575.0 million aggregate principal amount of its 0.5% Convertible Senior Notes due 2025 (the "2025 Notes"). The 2025 Notes are subject to the guidance included in ASU 2020-06. The Company adopted this guidance on January 1, 2021 using the modified retrospective approach which resulted in a cumulative-effect adjustment that increased (decreased) the following consolidated balance sheet accounts:
ADJUSTMENTCONSOLIDATED BALANCE SHEET CLASSIFICATIONAMOUNT
 (in millions)
Deferred tax impact of cumulative-effect adjustmentDeferred tax liabilities$(20.6)
Debt discount reclassificationLong-term convertible securities89.1 
Equity issuance costs reclassificationLong-term convertible securities(2.5)
Debt discount amortization and equity costs reclassification, net of taxRetained Earnings(2.8)
Net impact of cumulative-effect adjustmentAdditional paid-in capital(63.3)
On December 9, 2020, the Company made an irrevocable election under the indenture to require the principal portion of its 2025 Notes to be settled in cash and any excess in shares. Following the irrevocable notice, only the amounts settled in excess of the principal will be considered in diluted earnings per share under the “if-converted” method. Upon adoption of ASU 2020-06, the Company’s 2025 Notes were reflected entirely as a liability since the embedded conversion feature will no longer be separately presented within stockholders’ equity. Additionally, from January 1, 2021, the Company is no longer incurring non-cash interest expense for the amortization of debt discount.
In October 2020, the FASB issued ASU 2020-10, Codification Improvements, which updates various codification topics by clarifying or improving disclosure requirements to align with the regulations of the U.S. Securities and Exchange Commission (the "SEC") . The ASU has been effective for the Company for annual and interim periods beginning after January 1, 2021. The Company adopted this standard on the January 1, 2021. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures.
In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options which provides guidance to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The amendment currently has no impact to the Company as the effect will largely depend on the terms of written call options or financings issued or modified in the future.
There are no other recently issued accounting pronouncements that are expected to have any significant effect on the Company's financial position, results of operations or cash flows.
Revenue Recognition and Shipping and Handling Fees
REVENUE RECOGNITION
Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services.
Total revenue, net, includes product sales, product royalties and other revenues, such as fees received from services.
For products shipped with FOB shipping point terms, the control of the product passes to the customer at the time of shipment. For shipments in which the control of the product is transferred when the customer receives the product, the Company recognizes revenue upon receipt by the customer. Certain products that the Company produces for private label customers have no alternative use and the Company has a right of payment for performance to date. Revenues from those products are recognized over the period that the Company manufactures these products, which is typically one month to three months. The Company uses the input method to measure the manufacturing activities completed to date, which depicts the progress of the Company's performance obligation of transferring control of goods being manufactured for private label customers.
A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and distributors, and also from inventory physically held by field sales representatives. For these types of products sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized.
Revenues from sale of products and services are evidenced by either a contract with the customer or a valid purchase order and an invoice which includes all relevant terms of sale. For product sales, invoices are generally issued upon the transfer of control (or upon the completion of the manufacturing in the case of the private label transactions recognized over time) and are typically payable 30 days after the invoice date. The Company performs a review of each specific customer's creditworthiness and ability to pay prior to acceptance as a customer. Further, the Company performs periodic reviews of its customers' creditworthiness prospectively. Refer to Note 3, Revenue From Contracts With Customers for more information. The Company also maintains a provision for estimated returns and allowances in the same period that the related revenue is recorded. This reserve is based upon an analysis of actual credit memos issued for pricing issues or returned goods over an extended period, as well as assumptions about outstanding accounts receivable and judgment in interpreting the data.
Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services.
Performance Obligations
The Company's performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers.
Significant Judgments
Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company's strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant.
The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract.
The Company's return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally 90 days.
The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.
Contract Asset and Liability
Revenues recognized from the Company's private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the prepaid expenses and other current assets account in the consolidated balance sheet. Upon invoicing to the customer, the balance is recorded in trade receivable, net in the consolidated balance sheet.
Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.
Shipping and Handling FeesThe Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold.
Product Warranties
Product Warranties
Certain of the Company's medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to two years from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet.
Taxes Collected from Customers Taxes Collected from CustomersThe Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer.
XML 48 R26.htm IDEA: XBRL DOCUMENT v3.22.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Schedule of Inventories Inventories consisted of the following:
 December 31,
Dollars in thousands2022 2021
Finished goods172,088 $162,528 
Work in process70,598 65,323 
Raw materials81,897 89,535 
Total inventories, net$324,583 $317,386 
Schedule of Property, Plant and Equipment Balances and Corresponding Lives
Property, plant and equipment balances and corresponding lives were as follows:
 December 31,
Dollars in thousands20222021Useful Lives
Land$966 $1,512 
Buildings and building improvements14,710 19,032 
5-40 years
Leasehold improvements164,292 155,495 
1-20 years
Machinery and production equipment181,780 183,270 
3-20 years
Demonstration equipment3,792 2,791 
4-5 years
Information systems and hardware151,330 148,706 
1-7 years
Furniture, fixtures, and office equipment20,286 20,921 
1-15 years
Construction-in-progress103,875 94,850 
Total641,031 626,577 
Less: Accumulated depreciation(329,729)(314,874)
Property, plant and equipment, net$311,302 $311,703 
Schedule of Impact on Statement of Operations The Company adopted this guidance on January 1, 2021 using the modified retrospective approach which resulted in a cumulative-effect adjustment that increased (decreased) the following consolidated balance sheet accounts:
ADJUSTMENTCONSOLIDATED BALANCE SHEET CLASSIFICATIONAMOUNT
 (in millions)
Deferred tax impact of cumulative-effect adjustmentDeferred tax liabilities$(20.6)
Debt discount reclassificationLong-term convertible securities89.1 
Equity issuance costs reclassificationLong-term convertible securities(2.5)
Debt discount amortization and equity costs reclassification, net of taxRetained Earnings(2.8)
Net impact of cumulative-effect adjustmentAdditional paid-in capital(63.3)
Summary of Valuation Allowance The valuation allowance at December 31, 2022 and 2021 primarily remained unchanged from respective prior periods; decreasing by an immaterial amount in both periods.
Balance at Beginning of PeriodCharged to Costs and ExpensesOtherDeductionsBalance at End of Period
Description
Dollars in thousands
Year ended December 31, 2022
Deferred tax assets valuation allowance
15,258 (515)(71)14,672 
Year ended December 31, 2021
Deferred tax assets valuation allowance13,825 1,444 89 (100)15,258 
Year ended December 31, 2020
Deferred tax assets valuation allowance12,069 1,617 — 139 13,825 
Restructuring and Related Costs The following table summarizes our restructuring related accrual balances included within accrued expenses and other current liabilities in the consolidated balance sheet for the year ended December 31, 2022 and 2021.
Years Ended December 31,
(Dollars in thousands)20222021
Balance, beginning of the year$10,226 $6,372 
Charges:
Cost of Goods Sold$1,494 $3,436 
Research and development72288
Selling, general and administrative$5,582 $466 
Payments and other adjustments$(12,267)$(336)
Balance, end of the year$5,107 $10,226 
Accounts Receivable, Allowance for Credit Loss
The below table shows the rollforward of the allowance for doubtful accounts for the years ended December 31, 2022, 2021 and 2020:
Balance at Beginning of PeriodCharged to Costs and ExpensesOtherDeductionsBalance at End of Period
Dollars in thousands
Year Ended:
 December 31, 2022$4,735 238 — (669)$4,304 
December 31, 2021$6,439 (1,059)341 (986)$4,735 
December 31, 2020$4,303 3,635 — (1,499)$6,439 
(1)Deductions primarily relates to allowance for doubtful accounts written off during the year, net of recoveries and other adjustments.
XML 49 R27.htm IDEA: XBRL DOCUMENT v3.22.4
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of Changes in Contract Assets and Contract Liabilities
The following table summarized the changes in the contract asset and liability balances for the year ended December 31, 2022:
Dollars in thousandsTotal
Contract Asset
Contract asset, January 1, 2022$11,412 
Transferred to trade receivable from contract asset included
     in beginning of the year contract asset 		(11,412)
Contract asset, net of transferred to trade receivables on contracts during the period10,122 
Contract asset, December 31, 2022$10,122 
Contract Liability
Contract liability, January 1, 2022$11,946 
Recognition of revenue included in beginning of year contract liability(5,349)
Contract liability, net of revenue recognized on contracts during the period9,596 
Foreign currency translation(66)
Contract liability, December 31, 2022$16,127 
Schedule of Disaggregation of Revenue
The following table presents revenues disaggregated by the major sources of revenues for years-ended December 31, 2022, 2021 and 2020 (dollar amounts in thousands):
Year Ended December 31, 2022Year Ended December 31, 2021Year Ended December 31, 2020
Neurosurgery$794,017 $802,959 $716,339 
Instruments225,547 222,273 178,492 
Total Codman Specialty Surgical1,019,564 1,025,232 894,831 
Wound Reconstruction and Care(2)(3)
406,689 392,463 293,038 
Extremity Orthopedics(1)
— — 78,316 
Private Label131,413 124,753 105,683 
Total Tissue Technologies538,102 517,216 477,037 
Total revenue$1,557,666 $1,542,448 $1,371,868 
(1) On January 4, 2021, the Company completed its sale of its Extremity Orthopedics business. See Note 4, Acquisitions and Divestitures, for details
(2) See Note 4. Acquisitions and Divestitures, for details around the ACell acquisition.
(3) On August 31, 2022, the Company completed the sale of its non-core traditional wound care ("TWC") business. See Note 4, Acquisitions and Divestitures
XML 50 R28.htm IDEA: XBRL DOCUMENT v3.22.4
ACQUISITIONS AND DIVESTITURES (Tables)
 12 Months Ended
Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]  
Schedule of Major Classes of Assets and Liabilities Held For Sale
Assets and liabilities divested consisted of the following as of December 31, 2020 (dollar amounts in thousands):
Prepaid expenses and other current assets$713 
Right of use asset - operating leases and Other assets3,186 
Deferred tax assets6,589 
Intangible assets, net13,332 
Property, plant and equipment, net37,893 
Goodwill47,546 
Inventories52,845 
Total assets held for sale$162,104 
Other liabilities$336 
Current portion of lease liability - operating leases539 
Accrued compensation1,767 
Deferred tax liabilities3,440 
Lease liability - operating leases5,669 
Total liabilities held for sale$11,751 
Schedule of Assets Acquired and Liabilities Assumed
The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date:

Dollars in thousandsValuation as of December 6, 2022Weighted Average Life
Current assets:
Cash$4,438 
Trade accounts receivable, net 1,551 
Inventories, net2,900 
Prepaid expenses and other current assets1,654 
Total current assets$10,543 
Intangible assets75,000 14 years
Goodwill41,854 
Total assets acquired$127,397 
Current liabilities:
Accounts payable and accrued expenses$2,044 
Total current liabilities$2,044 
Deferred Tax Liability11,799 
Contingent consideration57,607 
Total liabilities assumed71,450 
Net assets acquired$55,947 
The following table summarizes the final fair values of the assets acquired and liabilities assumed at the acquisition date:
Dollars in thousandsFinal Valuation Weighted Average Life
Current assets:
Cash$2,726 
Trade accounts receivable, net 16,469 
Inventories, net18,299 
Prepaid expenses and other current assets1,498 
Total current assets$38,992 
Property, plant and equipment, net13,769 
Intangible assets245,000 
13-14 years
Goodwill94,147 
Right of use asset - operating leases9,259 
Deferred tax assets7,465 
Other assets148 
Total assets acquired$408,780 
Current liabilities:
Accounts payable$718 
Accrued expenses5,966 
Current portion of lease liability - operating leases1,673 
Total current liabilities$8,357 
Other long-term liability276 
Lease liability - operating leases7,585 
Deferred tax liability61,724 
Contingent consideration23,900 
Total liabilities assumed101,842 
Net assets acquired$306,938 
XML 51 R29.htm IDEA: XBRL DOCUMENT v3.22.4
DEBT (Tables)
 12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Maximum Leverage Ratios
The Company’s maximum consolidated total leverage ratio in the financial covenants (as defined in the Senior Credit Facility) is the following:
Fiscal QuarterMaximum Consolidated Total Leverage Ratio
September 30, 2022 through June 30, 2023
4.50 to 1.00
September 30, 2023 and the last day of each fiscal quarter thereafter
4.00 to 1.00
Schedule of Contractual Repayments of Debt
Contractual repayments of the Term Loan component of the Senior Credit Facility are due as follows:
Year-ended December 31, 2022Principal Repayment
Dollars in thousands
2023$38,125 
2024$67,500 
2025$669,375 
$775,000 
XML 52 R30.htm IDEA: XBRL DOCUMENT v3.22.4
DERIVATIVE INSTRUMENTS (Tables)
 12 Months Ended
Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Derivative Instruments
The Company held the following interest rate swaps as of December 31, 2022 and 2021 (dollar amounts in thousands):
December 31, 2022December 31, 2021December 31, 2022December 31, 2021
Hedged ItemNotional AmountDesignation DateEffective DateTermination DateFixed Interest RateEstimated Fair Value
Asset (Liability)
1-month USD LIBOR Loan— 300,000 December 13, 2017January 1, 2018December 31, 20222.201 %$— $(5,268)
1-month USD LIBOR Loan150,000 150,000 December 13, 2017July 1, 2019June 30, 20242.423 %5,012 (5,520)
1-month USD LIBOR Loan200,000 200,000 December 13, 2017January 1, 2018December 31, 20242.313 %8,380 (7,421)
1-month USD LIBOR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.220 %1,831 (5,512)
1-month USD LIBOR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.199 %1,905 (5,464)
1-month USD LIBOR Loan75,000 75,000 October 10, 2018July 1, 2020June 30, 20253.209 %1,970 (5,494)
1-month USD LIBOR Loan100,000 100,000 December 18, 2018December 30, 2022December 31, 20272.885 %4,252 (6,886)
1-month USD LIBOR Loan100,000 100,000 December 18, 2018December 30, 2022December 31, 20272.867 %4,153 (6,764)
1-month USD LIBOR Loan575,000 575,000 December 15, 2020July 31, 2025December 31, 20271.415 %23,742 3,552 
1-month USD LIBOR Loan125,000 125,000 December 15, 2020July 1, 2025December 31, 20271.404 %5,467 821 
$1,475,000 $1,775,000 $56,712 $(43,956)
The Company held the following cross-currency rate swaps as of December 31, 2022 and 2021 (dollar amounts in thousands):
December 31, 2022December 31, 2021December 31, 2022December 31, 2021
Effective DateTermination DateFixed RateAggregate Notional AmountFair Value Asset (Liability)
Pay CHFOctober 2, 2017October 2, 20221.95%CHF— 145,598 — (8,283)
Receive U.S.$4.52%$— 150,000 
Pay CHFDecember 21, 2020December 22, 20253.00%CHF374,137 397,137 (4,241)41 
Receive U.S.$3.98%$420,001 445,821 
Pay CHFSeptember 28, 2022September 29, 20231.95%CHF48,532 — (3,528)— 
Receive U.S.$5.32%$49,142 — 
Total$(7,769)$(8,242)
The Company held the following cross-currency rate swaps designated as net investment hedges as of December 31, 2022 and 2021 (dollar amounts in thousands):
December 31, 2022December 31, 2021December 31, 2022December 31, 2021
Effective DateTermination DateFixed RateAggregate Notional AmountFair Value
Asset (Liability)
Pay EUROctober 3, 2018September 30, 2023—%EUR51,760 51,760 4,713 2,503 
Receive U.S.$2.57%$60,000 60,000 
Pay EUROctober 3, 2018September 30, 2025—%EUR38,820 38,820 4,307 2,147 
Receive U.S.$2.19%$45,000 45,000 
Pay CHFDecember 16, 2020December 16, 2027—%CHF— 222,300 — (792)
Receive USD1.10%$— 250,000 
Pay CHFMay 26, 2022December 16, 2028—%CHF288,210 — (14,663)— 
Receive U.S.$1.94%$300,000 — 
Total$(5,643)$3,858 
Summary of Fair Value in Balance Sheet for Derivatives Designated as Hedging Instruments
The following table summarizes the fair value for derivatives designated as hedging instruments in the consolidated balance sheets as of December 31, 2022 and 2021:
 Fair Value as of December 31,
Dollars in thousands20222021
Location on Balance Sheet (1):
Derivatives designated as hedges — Assets:
Prepaid expenses and other current assets
Cash Flow Hedges
Cross-currency swap4,497 4,900 
Interest rate swap(2)
16,682 — 
Net Investment Hedges
Cross-currency swap11,653 5,120 
Other assets
Cash Flow Hedges
Interest rate swap(2)
40,030 4,373 
Net Investment Hedges
Cross-currency swap3,311 2,104 
Total derivatives designated as hedges — Assets$76,173 $16,497 
Derivatives designated as hedges — Liabilities
Accrued expenses and other current liabilities
Cash Flow Hedges
Interest rate swap(2)
$— $18,187 
Cross-currency swap3,528 8,283 
Net Investment Hedges
Cross-currency swap— — 
Other liabilities
Cash Flow Hedges
Interest rate swap(2)
— 30,143 
Cross-currency swap8,738 4,859 
Net Investment Hedges
Cross-currency swap20,608 3,366 
Total derivatives designated as hedges — Liabilities32,874 64,838 
(1)The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.
(2)At December 31, 2022 and 2021, the total notional amounts related to the Company’s interest rate swaps were $1.5 billion and $1.8 billion respectively.
Effect of Derivative Instruments Designated as Cash Flow Hedges on Statements of Operations
The following presents the effect of derivative instruments designated as cash flow hedges and net investment hedges on the accompanying consolidated statement of operations during the years ended December 31, 2022 and 2021:
 
Dollars in thousandsBalance in AOCI
Beginning of
Year		Amount of
Gain (Loss)
Recognized in
AOCI		Amount of Gain (Loss)
Reclassified from
AOCI into
Earnings		Balance in AOCI
End of Year		Location in
Statements of
Operations
Year Ended December 31, 2022
Cash Flow Hedges
Interest rate swap$(43,956)$93,308 $(7,360)$56,712 Interest expense
Cross-currency swap(9,688)8,847 19,430 (20,271)Other income, net
Net Investment Hedges
Cross-currency swap(2,321)2,196 6,789 (6,914)Interest income
$(55,965)$104,351 $18,859 $29,527 
Year Ended December 31, 2021
Cash Flow Hedges
Interest rate swap$(93,769)$27,402 $(22,411)$(43,956)Interest expense
Cross-currency swap(1,073)24,275 32,890 (9,688)Other income, net
Net Investment Hedges
Cross-currency swap(12,291)16,515 6,545 (2,321)Interest income
$(107,133)$68,192 $17,024 $(55,965)
Derivatives Not Designated as Hedging Instruments The following table summarizes the gains (losses) of derivative instruments not designated as hedges on the condensed consolidated statements of income, which was included in other income:
Dollars in thousandsDecember 31,
20222021
Foreign currency forward contracts $— $(174)
Foreign currency swaps1,258 629
Total$1,258 $455 
XML 53 R31.htm IDEA: XBRL DOCUMENT v3.22.4
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)
 12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Changes in Carrying Amount of Goodwill
Changes in the carrying amount of goodwill in 2022 and 2021 were as follows:
Dollars in thousandsCodman Specialty Surgical Tissue TechnologiesTotal
Goodwill at January 1, 2021$671,975 $260,392 $932,367 
ACell Acquisition — 94,147 94,147 
Foreign currency translation(8,547)(4,509)(13,056)
Balance at December 31, 2021$663,428 $350,030 $1,013,458 
Sale of non-core traditional wound care business— (5,019)(5,019)
SIA Acquisition— 41,855 41,855 
Foreign currency translation(7,209)(4,204)(11,413)
Balance at December 31, 2022$656,219 $382,662 $1,038,881 
Schedule of Components of Indefinite-Lived Intangible Assets
The components of the Company's identifiable intangible assets were as follows:
December 31, 2022
Dollars in thousandsWeighted
Average
Life		CostAccumulated AmortizationNet
Completed technology
18 years
$1,204,325 $(370,968)$833,357 
Customer relationships
12 years
193,081 (144,040)49,041 
Trademarks/brand names
28 years
97,265 (34,674)62,591 
Codman trade nameIndefinite166,693 — 166,693 
Supplier relationships
30 years
30,211 (17,170)13,041 
All other
11 years
5,957 (4,071)1,886 
$1,697,532 $(570,923)$1,126,609 
December 31, 2021
Dollars in thousandsWeighted
Average
Life		CostAccumulated AmortizationNet
Completed technology
18 years
$1,132,954 $(307,013)$825,941 
Customer relationships
12 years
211,344 (142,755)68,589 
Trademarks/brand names
28 years
98,367 (31,468)66,899 
Codman trade name
Indefinite
167,758 — 167,758 
Supplier relationships
30 years
30,211 (16,192)14,019 
All other
11 years
6,258 (3,891)2,367 
$1,646,892 $(501,319)$1,145,573 
Schedule of Components of Finite-Lived Intangible Assets
The components of the Company's identifiable intangible assets were as follows:
December 31, 2022
Dollars in thousandsWeighted
Average
Life		CostAccumulated AmortizationNet
Completed technology
18 years
$1,204,325 $(370,968)$833,357 
Customer relationships
12 years
193,081 (144,040)49,041 
Trademarks/brand names
28 years
97,265 (34,674)62,591 
Codman trade nameIndefinite166,693 — 166,693 
Supplier relationships
30 years
30,211 (17,170)13,041 
All other
11 years
5,957 (4,071)1,886 
$1,697,532 $(570,923)$1,126,609 
December 31, 2021
Dollars in thousandsWeighted
Average
Life		CostAccumulated AmortizationNet
Completed technology
18 years
$1,132,954 $(307,013)$825,941 
Customer relationships
12 years
211,344 (142,755)68,589 
Trademarks/brand names
28 years
98,367 (31,468)66,899 
Codman trade name
Indefinite
167,758 — 167,758 
Supplier relationships
30 years
30,211 (16,192)14,019 
All other
11 years
6,258 (3,891)2,367 
$1,646,892 $(501,319)$1,145,573 
XML 54 R32.htm IDEA: XBRL DOCUMENT v3.22.4
STOCK-BASED COMPENSATION (Tables)
 12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Summary Of Employee Stock-Based Compensation Expense
Stock-based compensation expense - all related to employees and members of the Board of Directors - recognized under the authoritative guidance was as follows:
Years Ended December 31,
Dollars in thousands202220212020
Cost of goods sold549 470 344 
Research and development1,739 1,644 1,471 
Selling, general and administrative$25,437 $34,096 $17,776 
Total stock-based compensation expense27,725 36,210 19,591 
Total estimated tax benefit related to stock-based compensation expense10,574 13,804 6,221 
Net effect on net income$17,151 $22,406 $13,370 
Summary Of Weighted-Average Assumptions
The following weighted-average assumptions were used in the calculation of fair value:
Years Ended December 31,
202220212020
Dividend yield0%0%0%
Expected volatility30%29%27%
Risk free interest rate2.01%1.30%0.89%
Expected life of option from grant date7 years7 years7 years
Weighted average grant date fair value of options granted
$23.15$22.59$13.03
Summary Of Stock Option Activity
The following table summarizes the Company’s stock option activity.
SharesWeighted Average Exercise PriceWeighted Average Contractual Term in YearsAggregate Intrinsic Value
Stock Options(In thousands)(In thousands)
Outstanding at January 1, 20221,225 $45.11 4.30$26,970
Granted146 65.11 — — 
Exercised(155)28.32 — — 
Forfeited or Expired(14)50.68 — — 
Outstanding at December 31, 20221,202 $49.63 4.14$10,772 
Exercisable at December 31, 2022871 $45.82 3.30$9,635 
Summary Of Restricted Stock, Performance Stock, and Contract Stock Activity
The following table summarizes the Company’s awards of restricted stock, performance stock and contract stock for the year ended December 31, 2022.
Restricted Stock AwardsPerformance Stock and Contract Stock Awards
SharesWeighted Average Grant Date Fair Value Per ShareSharesWeighted Average Grant Date Fair Value Per Share
(In thousands)(In thousands)
Unvested, January 1, 2022422 $58.78 442 60.62 
Granted334 62.88 245 62.89 
Adjustments for performance achievement related to award target
— — (18)60.76 
Cancellations(34)62.29 (10)59.88 
Released(239)58.27 (252)59.38 
Unvested, December 31, 2022483 $61.63 407 62.88 
XML 55 R33.htm IDEA: XBRL DOCUMENT v3.22.4
RETIREMENT BENEFIT PLANS (Tables)
 12 Months Ended
Dec. 31, 2022
Retirement Benefits [Abstract]  
Schedule of Net Periodic Benefit Costs
Net periodic benefit costs for the Company’s defined benefit pension plans for the years ended December 31, 2022 and 2021 included the following (amounts in thousands):
Year ended December 31,
20222021
Service cost$2,419 $2,741 
Interest cost194 100 
Expected return on plan assets(1,381)(893)
Amortization of prior service cost (credit)(326)(281)
Recognized actuarial losses9 186 
Settlements— 51 
Net period benefit cost$915 $1,904 
Schedule of Weighted Average Assumptions Used
The following weighted average assumptions were used to develop net periodic pension benefit costs and the actuarial present values of projected pension benefit obligations for the years ended December 31, 2022 and 2021, respectively:
As of December 31,
20222021
Discount rate2.44 %0.37 %
Expected return on plan assets3.61 %3.59 %
Rate of compensation increase1.97 %2.10 %
Interest crediting rate for cash balance plans1.00 %1.00 %
Schedule of Benefit Obligations and Plan Assets
The following sets forth the change in projected benefit obligations and the change in plan assets for the years ended December 31, 2022 and 2021 and a reconciliation of the funded status at December 31, 2022 and 2021, respectively (amounts in thousands):
Year ended December 31,
20222021
Change In Projected Benefit Obligations
Projected benefit obligations, beginning of year$65,184 $72,869 
Interest cost194 100 
Service cost2,419 2,741 
Actuarial (gain) loss(14,822)(5,044)
Plan amendments(390)(586)
Plan settlements(20)(655)
Employee contribution999 917 
Premiums paid(391)(373)
Benefit payment(999)(2,128)
Effect of foreign currency exchange rates(1,810)(2,657)
Projected benefit obligations, end of year$50,364 $65,184 
Year ended December 31,
20222021
Change In Plan Assets
Plan assets at fair value, beginning of year$39,914 $37,825 
Actual return on plan assets(2,863)3,371 
Employer contributions2,356 2,254 
Employee contributions999 917 
Plan settlements— (633)
Benefits paid(998)(2,128)
Premiums paid(391)(373)
Effect of foreign currency exchange rates(964)(1,319)
Plan assets at fair value, end of year$38,053 $39,914 
Schedule of Funded Status
Year ended December 31,
20222021
Reconciliation Of Funded Status
Fair value of plan assets$38,053 $39,914 
Benefit obligations50,364 65,184 
Unfunded benefit obligations$12,311 $25,270 
Schedule of Expected Benefit Payments
The following table is the summary of expected future benefit payments (in thousands):
2023$2,211 
2024$2,045 
2025$2,050 
2026$1,929 
2027$1,868 
Next five years$11,068 
XML 56 R34.htm IDEA: XBRL DOCUMENT v3.22.4
LEASES AND RELATED PARTY LEASES (Tables)
 12 Months Ended
Dec. 31, 2022
Leases [Abstract]  
Supplemental Balance Sheet Information
Supplemental balance sheet information related to operating leases at December 31, 2022 were as follows:
December 31, 2022
December 31, 2021
(In thousands, except lease term and discount rate)
ROU assets$148,284 $84,543 
Current lease liabilities14,624 14,775 
Non-current lease liabilities157,420 90,329 
Total lease liabilities$172,044 $105,104 
Weighted average remaining lease term (in years):
Leased facilities16.9 years10.4 years
Leased vehicles2.0 years2.1 years
Weighted average discount rate:
Leased facilities5.4 %5.1 %
Leased vehicles2.7 %2.6 %
Supplemental Cash Flow Information
Supplemental cash flow information related to leases was as follows:
December 31, 2022
December 31, 2021
(In thousands)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$17,442 $15,077 
ROU assets obtained in exchange for lease liabilities:
Operating leases72,169 12,610 
Schedule of Operating Lease Maturities
Future minimum lease payments under operating leases at December 31, 2022 were as follows:
Related PartiesThird PartiesTotal
(In thousands)
2023296 20,024 20,320 
2024296 20,869 21,165 
2025296 19,198 19,494 
2026296 16,830 17,126 
2027296 15,886 16,182 
Thereafter542 164,622 165,164 
Total minimum lease payments$2,022 $257,429 $259,451 
Less: Imputed interest$87,407 
Total lease liabilities172,044 
Less: Current lease liabilities14,624 
Long-term lease liabilities157,420 
XML 57 R35.htm IDEA: XBRL DOCUMENT v3.22.4
INCOME TAXES (Tables)
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Schedule of Income (Loss) Before Income Taxes Income before income taxes consisted of the following:
Years Ended December 31,
Dollars in thousands202220212020
United States operations$92,642 $91,150 $15,082 
Foreign operations121,252 123,527 78,438 
Total$213,894 $214,677 $93,520 
Schedule of Effective Income Tax Rate Reconciliation
A reconciliation of the U.S. Federal statutory rate to the Company’s effective tax rate is as follows:
Years Ended December 31,
202220212020
Federal statutory rate21.0 %21.0 %21.0 %
Increase (decrease) in income taxes resulting from:
   State income taxes, net of federal tax benefit0.1 %1.9 %1.2 %
   Foreign operations(3.9)%(4.0)%(7.9)%
 Excess tax benefits from stock compensation(2.4)%(1.2)%(1.0)%
   Intercompany profit in inventory0.3 %(0.2)%1.2 %
   Nondeductible facilitative costs0.2 %0.3 %1.1 %
   Contingent Consideration(2.0)%(0.2)%0.2 %
   Research and development credit(1.4)%(1.2)%(1.6)%
   Return to provision(0.5)%(0.7)%(2.3)%
   Global intangible low-taxed income ("GILTI")2.8 %0.7 %2.5 %
   Nondeductible executive compensation1.8 %0.9 %2.4 %
   Fair market value step up on intra-entity transfer of intellectual property
— %— %(63.3)%
   Gain from sale of business - book to tax differences— %3.9 %2.8 %
   Other(0.4)%— %0.5 %
Effective tax rate15.6 %21.2 %(43.2)%
Schedule of Provision for Income Taxes
The provision for income taxes consisted of the following:
Years Ended December 31,
Dollars in thousands202220212020
Current:
   Federal$24,201 $31,938 $6,184 
   State3,835 11,377 5,029 
   Foreign9,893 5,042 12,553 
Total current$37,929 $48,357 $23,766 
Deferred:
   Federal(11,591)(12,830)(5,079)
   State(2,316)(3,688)(1,760)
   Foreign9,322 13,763 (57,299)
Total deferred$(4,585)$(2,755)$(64,138)
Provision for income taxes$33,344 $45,602 $(40,372)
Schedule of Deferred Tax Assets and Liabilities
The income tax effects of significant temporary differences that give rise to deferred tax assets and liabilities, shown before jurisdictional netting, are presented below:
December 31,
Dollars in thousands20222021
Assets:
   Doubtful accounts$2,261 $2,029 
   Inventory related items31,950 31,841 
   Tax credits13,084 13,319 
   Accrued vacation2,175 3,042 
   Accrued bonus4,944 7,415 
   Stock compensation10,175 13,955 
   Deferred revenue2,130 1,742 
   Net operating loss carryforwards30,707 26,198 
Capitalization of research and development expenses51,542 36,770 
   Unrealized foreign exchange gain6,228 12,849 
   Charitable contributions carryforward180 206 
   Leases and Other39,788 41,371 
   Total deferred tax assets195,164 190,737 
   Less valuation allowance(9,651)(9,767)
   Deferred tax assets after valuation allowance$185,513 $180,970 
Liabilities:
   Intangible and fixed assets(166,891)(152,150)
   Unrealized foreign exchange loss(12,991)— 
   Leases and Other(22,975)(17,658)
   Total deferred tax liabilities$(202,857)$(169,808)
Total net deferred tax assets (liabilities)$(17,344)$11,162 
Schedule of Uncertain Tax Benefits Reconciliation
A reconciliation of the beginning and ending amount of uncertain tax benefits is as follows:
Years Ended December 31,
Dollars in thousands202220212020
(In thousands)
Balance, beginning of year$676 $702 $676 
Gross increases:
   Current year tax positions37 — — 
   Prior years' tax positions— — 26 
Other— (26)— 
Balance, end of year$713 $676 $702 
Summary of Valuation Allowance The valuation allowance at December 31, 2022 and 2021 primarily remained unchanged from respective prior periods; decreasing by an immaterial amount in both periods.
Balance at Beginning of PeriodCharged to Costs and ExpensesOtherDeductionsBalance at End of Period
Description
Dollars in thousands
Year ended December 31, 2022
Deferred tax assets valuation allowance
15,258 (515)(71)14,672 
Year ended December 31, 2021
Deferred tax assets valuation allowance13,825 1,444 89 (100)15,258 
Year ended December 31, 2020
Deferred tax assets valuation allowance12,069 1,617 — 139 13,825 
XML 58 R36.htm IDEA: XBRL DOCUMENT v3.22.4
NET INCOME PER SHARE (Tables)
 12 Months Ended
Dec. 31, 2022
Earnings Per Share [Abstract]  
Basic And Diluted Net Income Per Share
Basic and diluted net income per share was as follows:
 Years Ended December 31,
 Dollars in thousands, except per share amounts202220212020
Basic net income per share:
Net income$180,550 $169,075 $133,892 
Weighted average common shares outstanding82,997 84,698 84,650 
Basic net income per common share$2.18 $2.00 $1.58 
Diluted net income per share:
Net income$180,550 $169,075 $133,892 
Weighted average common shares outstanding — Basic82,997 84,698 84,650 
Effect of dilutive securities:
Stock options and restricted stock519 787 577 
Weighted average common shares for diluted earnings per share83,516 85,485 85,228 
Diluted net income per common share$2.16 $1.98 $1.57 
XML 59 R37.htm IDEA: XBRL DOCUMENT v3.22.4
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)
 12 Months Ended
Dec. 31, 2022
Stockholders' Equity Note [Abstract]  
Schedule of Changes in Accumulated Other Comprehensive Loss
Changes in accumulated other comprehensive loss by component between December 31, 2022 and 2021 are presented in the table below, net of tax:
Dollars in thousandsGains and Losses on DerivativesDefined Benefit Pension ItemsForeign Currency ItemsTotal
Balance at December 31, 2021
$(42,981)$1,893 $(4,067)$(45,155)
Other comprehensive gain (loss)80,335 7,429 (17,807)69,957 
Less: Amounts reclassified from accumulated other comprehensive income, net
14,537 — — 14,537 
Net current-period other comprehensive gain (loss)65,798 7,429 (17,807)55,420 
Balance at December 31, 2022
$22,817 $9,322 $(21,874)$10,265 
XML 60 R38.htm IDEA: XBRL DOCUMENT v3.22.4
COMMITMENTS AND CONTINGENCIES (Tables)
 12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Contingent Consideration
A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the years ended December 31, 2022 and 2021 is as follows (in thousands):
Year ended December 31, 2022Contingent Consideration Liability Related to Acquisition of:
Arkis
 (See Note 4) 		Location in Financial StatementsDerma SciencesACell Inc.
 (See Note 4) 		SIALocation in Financial Statements
Short-termLong-termLong-termShort-termLong-termLong-term
Balance as of January 1, 2022$3,691 $11,408 $230 $— $21,800 $— 
Additions— — — — 57,607 
Transfers from long-term to current portion— — — 4,885 (4,885)— 
Change in fair value of contingent consideration liabilities (846)(1,358)Research and development— (4,885)(13,215)— Selling, general and administrative
Balance as of December 31, 2022$2,845 $10,050 $230 $— $3,700 $57,607 $— 
Year ended December 31, 2021Contingent Consideration Liability Related to Acquisition of:
Arkis
 (See Note 4) 		Location in Financial StatementsDerma SciencesACell Inc.
 (See Note 4)		Location in Financial Statements
Short-termLong-termLong-termLong-term
Balance as of January 1, 2021$3,415 $11,746 $230 $— 
Additions— — — 23,900 
Transfers from long-term to current portion276 (276)— — 
Change in fair value of contingent consideration liabilities — $(62)Research and development— (2,100)Selling, general and administrative
Balance as of December 31, 2021$3,691 $11,408 $230 $21,800 
XML 61 R39.htm IDEA: XBRL DOCUMENT v3.22.4
SEGMENT AND GEOGRAPHIC INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
Schedule of Net Sales and Profit, by Segment Net sales and profit by reportable segment for the years ended December 31, 2022, 2021 and 2020 are as follows:
 Years Ended December 31,
Dollars in thousands202220212020
Segment Net Sales
Codman Specialty Surgical$1,019,564 $1,025,232 $894,831 
 Tissue Technologies538,102 517,216 477,037 
Total revenues$1,557,666 $1,542,448 $1,371,868 
Segment Profit
Codman Specialty Surgical$417,873 $439,471 $356,657 
Tissue Technologies233,802 228,199 159,630 
Segment profit651,675 667,670 516,287 
Amortization(13,882)(16,914)(27,757)
Corporate and other(398,873)(453,526)(337,160)
Operating income$238,920 $197,230 $151,370 
Schedule of Geographic Revenue, by Area Total revenue, net and long-lived assets (tangible) by major geographic area are summarized below:
Dollars in thousands
United States(1)
EuropeAsia PacificRest of the WorldConsolidated
Total revenue, net:
2022$1,126,810 $170,903 $176,477 $83,476 $1,557,666 
20211,089,526 191,327 182,034 79,561 1,542,448 
2020971,975 172,689 157,174 70,030 1,371,868 
Total long-lived assets:
2022$440,223 $60,857 $12,975 $2,721 $516,776 
2021339,535 55,026 11,289 6,836 412,686 
XML 62 R40.htm IDEA: XBRL DOCUMENT v3.22.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)
 1 Months Ended 12 Months Ended
May 31, 2019
Dec. 31, 2022
USD ($)
reporting_unit
Segment
Customer
Dec. 31, 2021
USD ($)
Customer
Dec. 31, 2020
USD ($)
Customer
Feb. 04, 2020
USD ($)
Summary Of Significant Accounting Policies [Line Items]          
Provision (recoveries) for doubtful accounts   $ (200,000) $ 1,100,000 $ (3,600,000)  
Inventory, capitalized expenses   0 0    
Depreciation expense   40,100,000 39,400,000 42,100,000  
Interest expense capitalized into property, plant, and equipment   $ 1,400,000 1,200,000    
Number of reportable segments | Segment   2      
Number of reporting units | reporting_unit   3      
Contributions to Integra Foundation   $ 0.0 1,200,000 800,000  
Foreign currency transaction gain (loss)   (3,300,000) 100,000 (1,600,000)  
Restructuring costs   $ 5,107,000 10,226,000 6,372,000  
Defer payment and taxation, base salary, percentage (up to) 75.00% 75.00%      
Defer payment and taxation, bonus and other eligible cash compensation, percentage (up to) 100.00% 100.00%      
Interest paid   $ 42,200,000 43,200,000 47,300,000  
Interest paid, capitalized into construction in progress   1,400,000 1,200,000 2,300,000  
Income taxes paid   35,900,000 49,500,000 29,800,000  
Property and equipment purchases included in liabilities   10,500,000 4,700,000 1,600,000  
Closure of Facility          
Summary Of Significant Accounting Policies [Line Items]          
Restructuring costs   2,000,000 10,200,000    
Reorganization Projects          
Summary Of Significant Accounting Policies [Line Items]          
Restructuring costs   $ 3,100,000      
2025 Notes          
Summary Of Significant Accounting Policies [Line Items]          
Convertible debt         $ 575,000,000
Convertible Debt | 2025 Notes          
Summary Of Significant Accounting Policies [Line Items]          
Debt, interest rate         0.50%
Rebound          
Summary Of Significant Accounting Policies [Line Items]          
Asset Acquisition, Development Milestone Payment To Be Paid     $ 5,000,000 $ 20,000,000  
Sales Revenue, Net | Customer Concentration Risk          
Summary Of Significant Accounting Policies [Line Items]          
Concentration risk, threshold percentage   10.00% 10.00% 10.00%  
Concentration risk, number of customers over benchmark | Customer   0 0 0  
Minimum          
Summary Of Significant Accounting Policies [Line Items]          
Manufacturing period for products shipped with no alternative use and right of payment for performance   1 month      
Maximum          
Summary Of Significant Accounting Policies [Line Items]          
Manufacturing period for products shipped with no alternative use and right of payment for performance   3 months      
XML 63 R41.htm IDEA: XBRL DOCUMENT v3.22.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Roll forward of Valuation for Doubtful Accounts (Details) - SEC Schedule, 12-09, Allowance, Credit Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]      
Balance at Beginning of Period $ 4,735 $ 6,439 $ 4,303
Charged to Costs and Expenses 238 (1,059) 3,635
Other 0 341 0
Deductions (669) 986 (1,499)
Balance at End of Period $ 4,304 $ 4,735 $ 6,439
XML 64 R42.htm IDEA: XBRL DOCUMENT v3.22.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Inventories, Net) (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]    
Finished goods $ 172,088 $ 162,528
Work in process 70,598 65,323
Raw materials 81,897 89,535
Total inventories, net $ 324,583 $ 317,386
XML 65 R43.htm IDEA: XBRL DOCUMENT v3.22.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property, Plant and Equipment Balances and Corresponding Lives) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]    
Total $ 641,031 $ 626,577
Less: Accumulated depreciation (329,729) (314,874)
Property, plant and equipment, net 311,302 311,703
Land    
Property, Plant and Equipment [Line Items]    
Total 966 1,512
Buildings and building improvements    
Property, Plant and Equipment [Line Items]    
Total $ 14,710 19,032
Buildings and building improvements | Minimum    
Property, Plant and Equipment [Line Items]    
Useful Lives 5 years  
Buildings and building improvements | Maximum    
Property, Plant and Equipment [Line Items]    
Useful Lives 40 years  
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Total $ 164,292 155,495
Leasehold improvements | Minimum    
Property, Plant and Equipment [Line Items]    
Useful Lives 1 year  
Leasehold improvements | Maximum    
Property, Plant and Equipment [Line Items]    
Useful Lives 20 years  
Machinery and production equipment    
Property, Plant and Equipment [Line Items]    
Total $ 181,780 183,270
Machinery and production equipment | Minimum    
Property, Plant and Equipment [Line Items]    
Useful Lives 3 years  
Machinery and production equipment | Maximum    
Property, Plant and Equipment [Line Items]    
Useful Lives 20 years  
Demonstration equipment    
Property, Plant and Equipment [Line Items]    
Total $ 3,792 2,791
Demonstration equipment | Minimum    
Property, Plant and Equipment [Line Items]    
Useful Lives 4 years  
Demonstration equipment | Maximum    
Property, Plant and Equipment [Line Items]    
Useful Lives 5 years  
Information systems and hardware    
Property, Plant and Equipment [Line Items]    
Total $ 151,330 148,706
Information systems and hardware | Minimum    
Property, Plant and Equipment [Line Items]    
Useful Lives 1 year  
Information systems and hardware | Maximum    
Property, Plant and Equipment [Line Items]    
Useful Lives 7 years  
Furniture, fixtures, and office equipment    
Property, Plant and Equipment [Line Items]    
Total $ 20,286 20,921
Furniture, fixtures, and office equipment | Minimum    
Property, Plant and Equipment [Line Items]    
Useful Lives 1 year  
Furniture, fixtures, and office equipment | Maximum    
Property, Plant and Equipment [Line Items]    
Useful Lives 15 years  
Construction-in-progress    
Property, Plant and Equipment [Line Items]    
Total $ 103,875 $ 94,850
XML 66 R44.htm IDEA: XBRL DOCUMENT v3.22.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Restructuring Charges (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Restructuring Reserve [Roll Forward]    
Balance, beginning of the year $ 10,226 $ 6,372
Payments and other adjustments (12,267) (336)
Balance, end of the year 5,107 10,226
Cost of goods sold    
Restructuring Reserve [Roll Forward]    
Charges: 1,494 3,436
Research and development    
Restructuring Reserve [Roll Forward]    
Charges: 72 288
Selling, general and administrative    
Restructuring Reserve [Roll Forward]    
Charges: $ 5,582 $ 466
XML 67 R45.htm IDEA: XBRL DOCUMENT v3.22.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Adoption of 2020-06 (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Deferred tax liabilities $ 63,338 $ 45,788  
Long-term convertible securities 567,341 564,426  
Retained earnings $ 879,118 $ 698,568  
Cumulative Effect, Period of Adoption, Adjustment      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Deferred tax liabilities     $ (20,600)
Retained earnings     (2,800)
Additional paid-in capital     (63,300)
Cumulative Effect, Period of Adoption, Adjustment, Debt Discount Reclassification      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Long-term convertible securities     89,100
Cumulative Effect, Period of Adoption, Adjustment, Debt Discount Amortization and Equity Costs Reclassification      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Long-term convertible securities     $ (2,500)
XML 68 R46.htm IDEA: XBRL DOCUMENT v3.22.4
REVENUES FROM CONTRACTS WITH CUSTOMERS (Narrative) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]    
Number of days from shipment to issue a credit on returned goods 90 days  
Short-term portion of contract liability $ 7,253 $ 5,295
Long-term portion of contract liability $ 8,800  
Product warranty period (up to) 2 years  
XML 69 R47.htm IDEA: XBRL DOCUMENT v3.22.4
REVENUES FROM CONTRACTS WITH CUSTOMERS (Narrative, Revenue Remaining Performance Obligation) (Details)
$ in Millions
Dec. 31, 2022
USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01  
Revenue from Contract with Customer [Abstract]  
Performance obligations expected to be satisfied $ 7.3
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Performance obligations expected to be satisfied, expected timing 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01  
Revenue from Contract with Customer [Abstract]  
Performance obligations expected to be satisfied $ 4.2
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Performance obligations expected to be satisfied, expected timing 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01  
Revenue from Contract with Customer [Abstract]  
Performance obligations expected to be satisfied $ 2.7
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Performance obligations expected to be satisfied, expected timing 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01  
Revenue from Contract with Customer [Abstract]  
Performance obligations expected to be satisfied $ 1.1
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Performance obligations expected to be satisfied, expected timing 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01  
Revenue from Contract with Customer [Abstract]  
Performance obligations expected to be satisfied $ 0.7
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Performance obligations expected to be satisfied, expected timing 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-01-01  
Revenue from Contract with Customer [Abstract]  
Performance obligations expected to be satisfied $ 0.1
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Performance obligations expected to be satisfied, expected timing 1 year
XML 70 R48.htm IDEA: XBRL DOCUMENT v3.22.4
REVENUES FROM CONTRACTS WITH CUSTOMERS (Schedule of Changes in Contract Assets and Liabilities) (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
USD ($)
Contract Asset  
Contract asset, Beginning of period $ 11,412
Transferred to trade receivable from contract asset included in beginning of the year contract asset (11,412)
Contract asset, net of transferred to trade receivables on contracts during the period 10,122
Contract asset, End of Period 10,122
Contract Liability  
Contract liability, Beginning of Period 11,946
Recognition of revenue included in beginning of year contract liability (5,349)
Contract liability, net of revenue recognized on contracts during the period 9,596
Foreign currency translation (66)
Contract liability, End of Period $ 16,127
XML 71 R49.htm IDEA: XBRL DOCUMENT v3.22.4
REVENUES FROM CONTRACTS WITH CUSTOMERS (Schedule of Revenues Disaggregated by Major Source) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Disaggregation of Revenue [Line Items]      
Total revenue $ 1,557,666 $ 1,542,448 $ 1,371,868
Codman Specialty Surgical      
Disaggregation of Revenue [Line Items]      
Total revenue 1,019,564 1,025,232 894,831
Codman Specialty Surgical | Neurosurgery      
Disaggregation of Revenue [Line Items]      
Total revenue 794,017 802,959 716,339
Codman Specialty Surgical | Instruments      
Disaggregation of Revenue [Line Items]      
Total revenue 225,547 222,273 178,492
Tissue Technologies      
Disaggregation of Revenue [Line Items]      
Total revenue 538,102 517,216 477,037
Tissue Technologies | Wound Reconstruction and Care      
Disaggregation of Revenue [Line Items]      
Total revenue 406,689 392,463 293,038
Tissue Technologies | Extremity Orthopedics      
Disaggregation of Revenue [Line Items]      
Total revenue 0 0 78,316
Tissue Technologies | Private Label      
Disaggregation of Revenue [Line Items]      
Total revenue $ 131,413 $ 124,753 $ 105,683
XML 72 R50.htm IDEA: XBRL DOCUMENT v3.22.4
ACQUISITIONS AND DIVESTITURES - Business Acquisition, Narrative (Details) - Surgical Innovation Association Inc
$ in Thousands
Dec. 06, 2022
USD ($)
contingentLiability
Business Acquisition [Line Items]  
Payments to acquire business $ 51,500
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to) $ 90,000
Discount rate 18.00%
Business Acquisition, number of payments | contingentLiability 2
Revenue Based Performance Milestones  
Business Acquisition [Line Items]  
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to) $ 50,000
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to) 32,600
FDA Approval Of Premarket Approval  
Business Acquisition [Line Items]  
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to) 40,000
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to) $ 25,000
XML 73 R51.htm IDEA: XBRL DOCUMENT v3.22.4
ACQUISITIONS AND DIVESTITURES - Fair Value Acquisition SIA (Details) - USD ($)
$ in Thousands
Dec. 06, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Business Acquisition [Line Items]        
Goodwill   $ 1,038,881 $ 1,013,458 $ 932,367
Surgical Innovation Association Inc        
Business Acquisition [Line Items]        
Cash $ 4,438      
Trade accounts receivable, net 1,551      
Inventories, net 2,900      
Prepaid expenses and other current assets 1,654      
Total current assets 10,543      
Intangible assets 75,000      
Goodwill 41,854      
Total assets acquired 127,397      
Accounts payable 2,044      
Total current liabilities 2,044      
Deferred tax liability 11,799      
Contingent consideration 57,607      
Total liabilities assumed 71,450      
Net assets acquired $ 55,947      
Weighted Average Life 14 years      
XML 74 R52.htm IDEA: XBRL DOCUMENT v3.22.4
ACQUISITIONS AND DIVESTITURES - Divestitures, Narrative (Details) - USD ($)
 12 Months Ended
Aug. 31, 2022
Jan. 20, 2021
Jan. 04, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Jun. 30, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Proceeds from sale of business       $ 23,960,000 $ 190,468,000 $ 0  
Gain from sale of businesses       644,000 41,798,000 $ 0  
ACell, Inc.              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Payments to acquire business   $ 306,900,000          
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to)   $ 100,000,000          
Working capital adjustment             $ 1,300,000
Discount rate   8.50%          
Contingent consideration   $ 23,900,000          
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to)       3,700,000 21,800,000    
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Traditional Wound Care              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Sale of business, disposition price $ 28,800,000            
Proceeds from sale of business 27,800,000            
Sale of business, contingent consideration $ 1,000,000            
Period for revenue based performance milestone 2 years            
Cash divested from deconsolidation $ 3,500,000            
Gain from sale of businesses       600,000      
Discontinued operation, continuing involvement, prepaid asset $ 11,100,000            
Inventory purchase, prepaid expenses and other current assets       8,300,000      
Disposal group, payable recognized       2,700,000      
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Extremity Orthopedics              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Sale of business, disposition price     $ 240,000,000        
Gain from sale of businesses         $ 41,800,000    
Transitional supply agreement, payable       $ 2,300,000      
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Extremity Orthopedics | Consortium of Focused Orthopedists, LLC              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Sale of extremity orthopedics business, payment for terminating license agreement     $ 41,500,000        
XML 75 R53.htm IDEA: XBRL DOCUMENT v3.22.4
ACQUISITIONS AND DIVESTITURES - Assets and Liabilities Divested (Details) - Disposal Group, Disposed of by Sale, Not Discontinued Operations - Extremity Orthopedics
$ in Thousands
Dec. 31, 2020
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Prepaid expenses and other current assets $ 713
Right of use asset-operating leases and Other assets 3,186
Deferred tax assets 6,589
Intangible assets, net 13,332
Property, plant and equipment, net 37,893
Goodwill 47,546
Inventories 52,845
Total assets held for sale 162,104
Other liabilities 336
Current portion of lease liability - operating leases 539
Accrued compensation 1,767
Deferred tax liabilities 3,440
Lease liability - operating leases 5,669
Total liabilities held for sale $ 11,751
XML 76 R54.htm IDEA: XBRL DOCUMENT v3.22.4
ACQUISITIONS AND DIVESTITURES - Fair Value Acquisition ACell (Details) - USD ($)
$ in Thousands
Jan. 20, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Business Acquisition [Line Items]        
Goodwill   $ 1,038,881 $ 1,013,458 $ 932,367
ACell, Inc.        
Business Acquisition [Line Items]        
Cash $ 2,726      
Trade accounts receivable, net 16,469      
Inventories, net 18,299      
Prepaid expenses and other current assets 1,498      
Total current assets 38,992      
Property, plant and equipment, net 13,769      
Intangible assets 245,000      
Goodwill 94,147      
Right of use asset - operating leases 9,259      
Deferred tax assets 7,465      
Other assets 148      
Total assets acquired 408,780      
Accounts payable 718      
Accrued expenses 5,966      
Current portion of lease liability - operating leases 1,673      
Total current liabilities 8,357      
Other long-term liability 276      
Lease liability - operating leases 7,585      
Deferred tax liability 61,724      
Contingent consideration 23,900      
Total liabilities assumed 101,842      
Net assets acquired $ 306,938      
ACell, Inc. | Minimum        
Business Acquisition [Line Items]        
Weighted Average Life 13 years      
ACell, Inc. | Maximum        
Business Acquisition [Line Items]        
Weighted Average Life 14 years      
XML 77 R55.htm IDEA: XBRL DOCUMENT v3.22.4
DEBT (Narrative) (Details)
 3 Months Ended 12 Months Ended
Feb. 04, 2020
USD ($)
$ / shares
Sep. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 09, 2020
USD ($)
Feb. 03, 2020
USD ($)
Debt Instrument [Line Items]                
Term loan component of senior credit facility, classified as current       $ 38,125,000 $ 45,000,000      
Interest payments, year one       42,700,000        
Interest payments, year two       39,100,000        
Interest payments, year three       3,600,000        
Cost of call transactions       0 0 $ 104,248,000    
Proceeds from warrant transactions       0 0 $ 44,563,000    
Long-term convertible securities       567,341,000 564,426,000      
Securitization facility, outstanding borrowings, maximum limit       150,000,000        
Secured long-term debt, securitization program       $ 104,700,000 $ 112,500,000      
Security facility, weighted average interest rate       5.00% 1.10%      
Level 2                
Debt Instrument [Line Items]                
Securitization facility, fair value of amount outstanding       $ 104,900,000        
Revolving Credit Facility                
Debt Instrument [Line Items]                
Maximum borrowing capacity               $ 1,300,000,000
Line of credit facility outstanding       $ 0 $ 31,300,000      
Weighted average interest rate on debt         1.40%      
Standby Letters of Credit                
Debt Instrument [Line Items]                
Maximum borrowing capacity               60,000,000
Swingline Loan                
Debt Instrument [Line Items]                
Maximum borrowing capacity               60,000,000
Senior Credit Facility                
Debt Instrument [Line Items]                
Maximum borrowing capacity               2,200,000,000
Capitalized incremental financing costs               4,600,000
Previously capitalized financing costs, written-off     $ 1,200,000          
Incremental financing cost expense   $ 3,300,000            
Senior Credit Facility | Minimum                
Debt Instrument [Line Items]                
Line of credit, commitment fee percentage       0.15%        
Senior Credit Facility | Maximum                
Debt Instrument [Line Items]                
Line of credit, commitment fee percentage       0.30%        
Senior Credit Facility | Eurodollar Rate | Minimum                
Debt Instrument [Line Items]                
Interest rates available to the company at its option       1.00%        
Senior Credit Facility | Eurodollar Rate | Maximum                
Debt Instrument [Line Items]                
Interest rates available to the company at its option       2.25%        
Senior Credit Facility | Overnight Federal Funds Rate                
Debt Instrument [Line Items]                
Interest rates available to the company at its option       0.50%        
Senior Credit Facility | One-Month Eurodollar Rate                
Debt Instrument [Line Items]                
Interest rates available to the company at its option       1.00%        
Senior Credit Facility | Standby Letters of Credit                
Debt Instrument [Line Items]                
Line of credit facility outstanding       $ 0        
Letters of credit outstanding       1,600,000 $ 1,600,000      
Term Loan Facility | Secured Debt                
Debt Instrument [Line Items]                
Maximum borrowing capacity               $ 877,500,000
Line of credit facility outstanding       $ 771,300,000 $ 843,800,000      
Weighted average interest rate on debt       5.60% 1.40%      
Term loan component of senior credit facility, classified as current       $ 38,100,000 $ 45,000,000      
Term Loan Facility | Secured Debt | Level 2                
Debt Instrument [Line Items]                
Line of credit facility, fair value of amount outstanding       800,800,000        
2025 Notes | Convertible Debt                
Debt Instrument [Line Items]                
Capitalized incremental financing costs $ 13,200,000              
Convertible notes, aggregate principal amount $ 575,000,000              
Convertible notes, interest rate 0.50%              
Debt proceeds, classified as equity at time of offering $ 104,500,000              
Effective interest rate 4.20%              
Initial conversion rate 0.0135739              
Initial conversion price (in dollars per share) | $ / shares $ 73.67              
Maximum selling price of the company's common stock of the conversion price 130.00%              
Maximum average conversion value of notes 98.00%              
Combination settlement for debt conversion, minimum settled in cash per principal amount             $ 1,000  
Redemption price, percentage 100.00%              
Warrant strike price (in dollars per share) | $ / shares $ 113.34              
Long-term convertible securities       575,000,000        
Fair value       560,500,000        
Cash interest       $ 2,900,000 $ 2,900,000      
2025 Notes | Convertible Debt | Call Option                
Debt Instrument [Line Items]                
Cost of call transactions $ 104,200,000              
Proceeds from warrant transactions $ 44,500,000              
Initial strike price (in dollars per share) | $ / shares $ 73.67              
XML 78 R56.htm IDEA: XBRL DOCUMENT v3.22.4
DEBT (Maximum Total Leverage Ratio Table) (Details) - Senior Credit Facility
Jul. 14, 2020
September 30, 2022 through June 30, 2023  
Debt Instrument [Line Items]  
Debt Instrument, Covenant, Maximum Leverage Ratio 4,500
September 30, 2023 and the last day of each fiscal quarter thereafter  
Debt Instrument [Line Items]  
Debt Instrument, Covenant, Maximum Leverage Ratio 4,000.00
XML 79 R57.htm IDEA: XBRL DOCUMENT v3.22.4
DEBT (Schedule of Debt Maturity) (Details)
$ in Thousands
Dec. 31, 2022
USD ($)
Debt Disclosure [Abstract]  
2023 $ 38,125
2024 67,500
2025 669,375
Principal Repayment $ 775,000
XML 80 R58.htm IDEA: XBRL DOCUMENT v3.22.4
DERIVATIVE INSTRUMENTS (Schedule of Interest Rate Swap Derivatives) (Details) - Cash Flow Hedging - Designated as Hedging Instrument - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Derivative [Line Items]    
Notional Amount $ 1,475,000,000 $ 1,775,000,000
Estimated Fair Value 56,712,000 (43,956,000)
1-month USD LIBOR Loan | Interest Rate Swap Designated December 13, 2017 Tranche 1    
Derivative [Line Items]    
Notional Amount $ 0 300,000,000
Fixed Interest Rate 2.201%  
Estimated Fair Value $ 0 (5,268,000)
1-month USD LIBOR Loan | Interest Rate Swap Designated December 13, 2017 Tranche 2    
Derivative [Line Items]    
Notional Amount $ 150,000,000 150,000,000
Fixed Interest Rate 2.423%  
Estimated Fair Value $ 5,012,000 (5,520,000)
1-month USD LIBOR Loan | Interest Rate Swap Designated December 13, 2017 Tranche 3    
Derivative [Line Items]    
Notional Amount $ 200,000,000 200,000,000
Fixed Interest Rate 2.313%  
Estimated Fair Value $ 8,380,000 (7,421,000)
1-month USD LIBOR Loan | Interest Rate Swap Designated October 10, 2018 Tranche 1    
Derivative [Line Items]    
Notional Amount $ 75,000,000 75,000,000
Fixed Interest Rate 3.22%  
Estimated Fair Value $ 1,831,000 (5,512,000)
1-month USD LIBOR Loan | Interest Rate Swap Designated October 10, 2018 Tranche 2    
Derivative [Line Items]    
Notional Amount $ 75,000,000 75,000,000
Fixed Interest Rate 3.199%  
Estimated Fair Value $ 1,905,000 (5,464,000)
1-month USD LIBOR Loan | Interest Rate Swap Designated October 10, 2018 Tranche 3    
Derivative [Line Items]    
Notional Amount $ 75,000,000 75,000,000
Fixed Interest Rate 3.209%  
Estimated Fair Value $ 1,970,000 (5,494,000)
1-month USD LIBOR Loan | Interest Rate Swap Designated December 18, 2018 Tranche 1    
Derivative [Line Items]    
Notional Amount $ 100,000,000 100,000,000
Fixed Interest Rate 2.885%  
Estimated Fair Value $ 4,252,000 (6,886,000)
1-month USD LIBOR Loan | Interest Rate Swap Designated December 18, 2018 Tranche 2    
Derivative [Line Items]    
Notional Amount $ 100,000,000 100,000,000
Fixed Interest Rate 2.867%  
Estimated Fair Value $ 4,153,000 (6,764,000)
1-month USD LIBOR Loan | Interest Rate Swap Designated December 15, 2020 Tranche 1    
Derivative [Line Items]    
Notional Amount $ 575,000,000 575,000,000
Fixed Interest Rate 1.415%  
Estimated Fair Value $ 23,742,000 3,552,000
1-month USD LIBOR Loan | Interest Rate Swap Designated December 15, 2020 Tranche 2    
Derivative [Line Items]    
Notional Amount $ 125,000,000 125,000,000
Fixed Interest Rate 1.404%  
Estimated Fair Value $ 5,467,000 $ 821,000
XML 81 R59.htm IDEA: XBRL DOCUMENT v3.22.4
DERIVATIVE INSTRUMENTS (Narrative) (Details)
SFr in Thousands, € in Millions
 12 Months Ended
Oct. 03, 2022
USD ($)
May 26, 2022
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2022
CHF (SFr)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Sep. 26, 2022
USD ($)
Sep. 26, 2022
CHF (SFr)
May 26, 2022
CHF (SFr)
Oct. 04, 2021
USD ($)
Sep. 30, 2021
EUR (€)
Jun. 30, 2021
USD ($)
Dec. 21, 2020
USD ($)
Dec. 21, 2020
CHF (SFr)
Oct. 02, 2017
USD ($)
Oct. 02, 2017
CHF (SFr)
Derivative [Line Items]                                  
Gain (loss) recorded in AOCL, change in fair value       $ 104,351,000   $ 68,192,000 $ (96,837,000)                    
Designated as Hedging Instrument                                  
Derivative [Line Items]                                  
Gain (loss) recorded in AOCL, change in fair value       104,351,000   68,192,000                      
Derivative fair value       76,173,000   16,497,000                      
Cash Flow Hedging | Designated as Hedging Instrument                                  
Derivative [Line Items]                                  
Notional amount       1,475,000,000   1,775,000,000                      
Foreign Currency Forward Contract | Not Designated as Hedging Instrument                                  
Derivative [Line Items]                                  
Notional amount             $ 4,200,000                    
Currency Swap | Not Designated as Hedging Instrument                                  
Derivative [Line Items]                                  
Notional amount     $ 6,400,000                   $ 7,300,000        
Cross-Currency Interest Rate Swap                                  
Derivative [Line Items]                                  
Notional amount                           $ 471,600,000 SFr 420,100    
Intercompany loan, quarterly payment | SFr         SFr 5,800                        
Other comprehensive income (loss), net investment hedge, gain (loss), reclassification, before tax $ 1,600,000 $ 4,900,000                              
Gain (loss) recognized in other income       8,400,000   9,100,000                      
Gain (loss) estimated to be reclassified to earnings during next twelve months       4,500,000                          
Cross-Currency Interest Rate Swap | Designated as Hedging Instrument                                  
Derivative [Line Items]                                  
Notional amount   300,000,000               SFr 288,000              
Cross-Currency Interest Rate Swap | Cash Flow Hedging | Designated as Hedging Instrument                                  
Derivative [Line Items]                                  
Notional amount                     $ 50,000,000            
Gain (loss) recognized in other income       11,100,000   $ 23,800,000                      
Cross-Currency Interest Rate Swap | Net Investment Hedging                                  
Derivative [Line Items]                                  
Notional amount     52,000,000                 € 44.9          
Gain (loss) recorded in AOCL, change in fair value     $ 100,000                            
Cross-Currency Interest Rate Swap | Net Investment Hedging | Designated as Hedging Instrument                                  
Derivative [Line Items]                                  
Derivative, notional amount, terminated   $ 250,000,000               SFr 222,300              
Gain (loss) estimated to be reclassified to earnings during next twelve months       11,700,000                          
Cross-Currency Interest Rate Swap | Short                                  
Derivative [Line Items]                                  
Notional amount                               $ 300,000,000  
Cross-Currency Interest Rate Swap | Short | Codman                                  
Derivative [Line Items]                                  
Notional amount       $ 49,100,000         SFr 48,500                
Derivative, notional amount, terminated $ 100,000,000             $ 50,000,000                  
Cross-Currency Interest Rate Swap | Long                                  
Derivative [Line Items]                                  
Notional amount | SFr                                 SFr 291,200
XML 82 R60.htm IDEA: XBRL DOCUMENT v3.22.4
DERIVATIVE INSTRUMENTS (Schedule of Cross-Currency Swap Derivatives) (Details)
SFr in Thousands
Dec. 31, 2022
USD ($)
Dec. 31, 2022
CHF (SFr)
May 26, 2022
USD ($)
May 26, 2022
CHF (SFr)
Dec. 31, 2021
USD ($)
Dec. 31, 2021
CHF (SFr)
Oct. 04, 2021
USD ($)
Dec. 21, 2020
USD ($)
Dec. 21, 2020
CHF (SFr)
Oct. 02, 2017
USD ($)
Oct. 02, 2017
CHF (SFr)
Cross-Currency Interest Rate Swap                      
Derivative [Line Items]                      
Aggregate Notional Amount               $ 471,600,000 SFr 420,100    
Cross-Currency Interest Rate Swap | Long                      
Derivative [Line Items]                      
Aggregate Notional Amount | SFr                     SFr 291,200
Cross-Currency Interest Rate Swap | Short                      
Derivative [Line Items]                      
Aggregate Notional Amount                   $ 300,000,000  
Designated as Hedging Instrument | Cross-Currency Interest Rate Swap                      
Derivative [Line Items]                      
Aggregate Notional Amount     $ 300,000,000 SFr 288,000              
Cash Flow Hedging | Designated as Hedging Instrument                      
Derivative [Line Items]                      
Aggregate Notional Amount $ 1,475,000,000       $ 1,775,000,000            
Fair Value Asset (Liability) 56,712,000       (43,956,000)            
Cash Flow Hedging | Designated as Hedging Instrument | Cross Currency Interest Rate Swap, Contract One                      
Derivative [Line Items]                      
Fair Value Asset (Liability) $ (3,528,000)       0            
Cash Flow Hedging | Designated as Hedging Instrument | Cross Currency Interest Rate Swap, Contract One | Long                      
Derivative [Line Items]                      
Fixed Rate 1.95% 1.95%                  
Aggregate Notional Amount | SFr   SFr 48,532       SFr 0          
Cash Flow Hedging | Designated as Hedging Instrument | Cross Currency Interest Rate Swap, Contract One | Short                      
Derivative [Line Items]                      
Fixed Rate 5.32% 5.32%                  
Aggregate Notional Amount $ 49,142,000       0            
Cash Flow Hedging | Designated as Hedging Instrument | Cross Currency Interest Rate Swap, Contract Two                      
Derivative [Line Items]                      
Fair Value Asset (Liability) $ 0       (8,283,000)            
Cash Flow Hedging | Designated as Hedging Instrument | Cross Currency Interest Rate Swap, Contract Two | Long                      
Derivative [Line Items]                      
Fixed Rate 1.95% 1.95%                  
Aggregate Notional Amount | SFr   SFr 0       145,598          
Cash Flow Hedging | Designated as Hedging Instrument | Cross Currency Interest Rate Swap, Contract Two | Short                      
Derivative [Line Items]                      
Fixed Rate 4.52% 4.52%                  
Aggregate Notional Amount $ 0       150,000,000            
Cash Flow Hedging | Designated as Hedging Instrument | Cross Currency Interest Rate Swap, Contract Three                      
Derivative [Line Items]                      
Fair Value Asset (Liability) $ (4,241,000)       41,000            
Cash Flow Hedging | Designated as Hedging Instrument | Cross Currency Interest Rate Swap, Contract Three | Long                      
Derivative [Line Items]                      
Fixed Rate 3.00% 3.00%                  
Aggregate Notional Amount | SFr   SFr 374,137       SFr 397,137          
Cash Flow Hedging | Designated as Hedging Instrument | Cross Currency Interest Rate Swap, Contract Three | Short                      
Derivative [Line Items]                      
Fixed Rate 3.98% 3.98%                  
Aggregate Notional Amount $ 420,001,000       445,821,000            
Cash Flow Hedging | Designated as Hedging Instrument | Cross-Currency Interest Rate Swap                      
Derivative [Line Items]                      
Aggregate Notional Amount             $ 50,000,000        
Fair Value Asset (Liability) $ (7,769,000)       $ (8,242,000)            
XML 83 R61.htm IDEA: XBRL DOCUMENT v3.22.4
DERIVATIVE INSTRUMENTS (Schedule of Net Investment Hedges Derivatives) (Details)
€ in Thousands, SFr in Thousands
Dec. 31, 2022
USD ($)
Dec. 31, 2022
CHF (SFr)
Dec. 31, 2022
EUR (€)
May 26, 2022
USD ($)
May 26, 2022
CHF (SFr)
Dec. 31, 2021
USD ($)
Dec. 31, 2021
CHF (SFr)
Dec. 31, 2021
EUR (€)
Sep. 30, 2021
USD ($)
Sep. 30, 2021
EUR (€)
Dec. 21, 2020
USD ($)
Dec. 21, 2020
CHF (SFr)
Oct. 02, 2017
USD ($)
Oct. 02, 2017
CHF (SFr)
Cross-Currency Interest Rate Swap                            
Derivative [Line Items]                            
Aggregate Notional Amount                     $ 471,600,000 SFr 420,100    
Cross-Currency Interest Rate Swap | Long                            
Derivative [Line Items]                            
Aggregate Notional Amount | SFr                           SFr 291,200
Cross-Currency Interest Rate Swap | Short                            
Derivative [Line Items]                            
Aggregate Notional Amount                         $ 300,000,000  
Designated as Hedging Instrument | Cross-Currency Interest Rate Swap                            
Derivative [Line Items]                            
Aggregate Notional Amount       $ 300,000,000 SFr 288,000                  
Net Investment Hedging | Cross-Currency Interest Rate Swap                            
Derivative [Line Items]                            
Aggregate Notional Amount                 $ 52,000,000 € 44,900        
Net Investment Hedging | Designated as Hedging Instrument | Cross-Currency Interest Rate Swap One                            
Derivative [Line Items]                            
Fair Value Asset (Liability) $ 4,713,000         $ 2,503,000                
Net Investment Hedging | Designated as Hedging Instrument | Cross-Currency Interest Rate Swap One | Long                            
Derivative [Line Items]                            
Fixed Interest Rate 0.00% 0.00% 0.00%                      
Aggregate Notional Amount | €     € 51,760         € 51,760            
Net Investment Hedging | Designated as Hedging Instrument | Cross-Currency Interest Rate Swap One | Short                            
Derivative [Line Items]                            
Fixed Interest Rate 2.57% 2.57% 2.57%                      
Aggregate Notional Amount $ 60,000,000         60,000,000                
Net Investment Hedging | Designated as Hedging Instrument | Cross-Currency Interest Rate Swap Two                            
Derivative [Line Items]                            
Fair Value Asset (Liability) $ 4,307,000         2,147,000                
Net Investment Hedging | Designated as Hedging Instrument | Cross-Currency Interest Rate Swap Two | Long                            
Derivative [Line Items]                            
Fixed Interest Rate 0.00% 0.00% 0.00%                      
Aggregate Notional Amount | €     € 38,820         € 38,820            
Net Investment Hedging | Designated as Hedging Instrument | Cross-Currency Interest Rate Swap Two | Short                            
Derivative [Line Items]                            
Fixed Interest Rate 2.19% 2.19% 2.19%                      
Aggregate Notional Amount $ 45,000,000         45,000,000                
Net Investment Hedging | Designated as Hedging Instrument | Cross-Currency Interest Rate Swap Three                            
Derivative [Line Items]                            
Fair Value Asset (Liability) $ 0         (792,000)                
Net Investment Hedging | Designated as Hedging Instrument | Cross-Currency Interest Rate Swap Three | Long                            
Derivative [Line Items]                            
Fixed Interest Rate 0.00% 0.00% 0.00%                      
Aggregate Notional Amount | SFr   SFr 0         SFr 222,300              
Net Investment Hedging | Designated as Hedging Instrument | Cross-Currency Interest Rate Swap Three | Short                            
Derivative [Line Items]                            
Fixed Interest Rate 1.10% 1.10% 1.10%                      
Aggregate Notional Amount $ 0         250,000,000                
Net Investment Hedging | Designated as Hedging Instrument | Cross-Currency Interest Rate Swap Four                            
Derivative [Line Items]                            
Fair Value Asset (Liability) $ (14,663,000)         0                
Net Investment Hedging | Designated as Hedging Instrument | Cross-Currency Interest Rate Swap Four | Long                            
Derivative [Line Items]                            
Fixed Interest Rate 0.00% 0.00% 0.00%                      
Aggregate Notional Amount | SFr   SFr 288,210         SFr 0              
Net Investment Hedging | Designated as Hedging Instrument | Cross-Currency Interest Rate Swap Four | Short                            
Derivative [Line Items]                            
Fixed Interest Rate 1.94% 1.94% 1.94%                      
Aggregate Notional Amount $ 300,000,000         0                
Net Investment Hedging | Designated as Hedging Instrument | Cross-Currency Interest Rate Swap                            
Derivative [Line Items]                            
Fair Value Asset (Liability) $ (5,643,000)         $ 3,858,000                
XML 84 R62.htm IDEA: XBRL DOCUMENT v3.22.4
DERIVATIVE INSTRUMENTS (Fair Value of Derivative Instruments By Balance Sheet Location) (Details)
SFr in Thousands, € in Millions
Dec. 31, 2022
USD ($)
May 26, 2022
USD ($)
May 26, 2022
CHF (SFr)
Dec. 31, 2021
USD ($)
Oct. 04, 2021
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2021
EUR (€)
Dec. 21, 2020
USD ($)
Dec. 21, 2020
CHF (SFr)
Cross-currency swap                  
Derivatives, Fair Value [Line Items]                  
Aggregate Notional Amount               $ 471,600,000 SFr 420,100
Cross-currency swap | Net Investment Hedges                  
Derivatives, Fair Value [Line Items]                  
Aggregate Notional Amount           $ 52,000,000 € 44.9    
Designated as Hedging Instrument                  
Derivatives, Fair Value [Line Items]                  
Total derivatives designated as hedges — Assets $ 76,173,000     $ 16,497,000          
Total derivatives designated as hedges — Liabilities 32,874,000     64,838,000          
Designated as Hedging Instrument | Cash Flow Hedges                  
Derivatives, Fair Value [Line Items]                  
Aggregate Notional Amount 1,475,000,000     1,775,000,000          
Designated as Hedging Instrument | Interest rate swap | Cash Flow Hedges                  
Derivatives, Fair Value [Line Items]                  
Aggregate Notional Amount 1,500,000,000     1,800,000,000          
Designated as Hedging Instrument | Interest rate swap | Cash Flow Hedges | Prepaid expenses and other current assets                  
Derivatives, Fair Value [Line Items]                  
Total derivatives designated as hedges — Assets 16,682,000     0          
Designated as Hedging Instrument | Interest rate swap | Cash Flow Hedges | Other assets                  
Derivatives, Fair Value [Line Items]                  
Total derivatives designated as hedges — Assets 40,030,000     4,373,000          
Designated as Hedging Instrument | Interest rate swap | Cash Flow Hedges | Accrued expenses and other current liabilities                  
Derivatives, Fair Value [Line Items]                  
Total derivatives designated as hedges — Liabilities 0     18,187,000          
Designated as Hedging Instrument | Interest rate swap | Cash Flow Hedges | Other liabilities                  
Derivatives, Fair Value [Line Items]                  
Total derivatives designated as hedges — Liabilities 0     30,143,000          
Designated as Hedging Instrument | Cross-currency swap                  
Derivatives, Fair Value [Line Items]                  
Aggregate Notional Amount   $ 300,000,000 SFr 288,000            
Designated as Hedging Instrument | Cross-currency swap | Cash Flow Hedges                  
Derivatives, Fair Value [Line Items]                  
Aggregate Notional Amount         $ 50,000,000        
Designated as Hedging Instrument | Cross-currency swap | Cash Flow Hedges | Prepaid expenses and other current assets                  
Derivatives, Fair Value [Line Items]                  
Total derivatives designated as hedges — Assets 4,497,000     4,900,000          
Designated as Hedging Instrument | Cross-currency swap | Cash Flow Hedges | Accrued expenses and other current liabilities                  
Derivatives, Fair Value [Line Items]                  
Total derivatives designated as hedges — Liabilities 3,528,000     8,283,000          
Designated as Hedging Instrument | Cross-currency swap | Cash Flow Hedges | Other liabilities                  
Derivatives, Fair Value [Line Items]                  
Total derivatives designated as hedges — Liabilities 8,738,000     4,859,000          
Designated as Hedging Instrument | Cross-currency swap | Net Investment Hedges | Prepaid expenses and other current assets                  
Derivatives, Fair Value [Line Items]                  
Total derivatives designated as hedges — Assets 11,653,000     5,120,000          
Designated as Hedging Instrument | Cross-currency swap | Net Investment Hedges | Other assets                  
Derivatives, Fair Value [Line Items]                  
Total derivatives designated as hedges — Assets 3,311,000     2,104,000          
Designated as Hedging Instrument | Cross-currency swap | Net Investment Hedges | Accrued expenses and other current liabilities                  
Derivatives, Fair Value [Line Items]                  
Total derivatives designated as hedges — Liabilities 0     0          
Designated as Hedging Instrument | Cross-currency swap | Net Investment Hedges | Other liabilities                  
Derivatives, Fair Value [Line Items]                  
Total derivatives designated as hedges — Liabilities $ 20,608,000     $ 3,366,000          
XML 85 R63.htm IDEA: XBRL DOCUMENT v3.22.4
DERIVATIVE INSTRUMENTS (Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Sep. 30, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Derivative Instruments, Gain (Loss) [Roll Forward]        
Balance, Beginning of Period   $ 1,684,804 $ 1,514,867 $ 1,416,736
Amount of Gain (Loss) Recognized in AOCI   104,351 68,192 (96,837)
Balance, End of Period   1,804,403 1,684,804 1,514,867
Accumulated Other Comprehensive Income        
Derivative Instruments, Gain (Loss) [Roll Forward]        
Balance, Beginning of Period   (45,155) (74,059) (76,402)
Balance, End of Period   10,265 (45,155) (74,059)
Cross-currency swap | Net Investment Hedges        
Derivative Instruments, Gain (Loss) [Roll Forward]        
Amount of Gain (Loss) Recognized in AOCI $ 100      
Designated as Hedging Instrument        
Derivative Instruments, Gain (Loss) [Roll Forward]        
Amount of Gain (Loss) Recognized in AOCI   104,351 68,192  
Amount of Gain (Loss) Reclassified from AOCI into Earnings   18,859 17,024  
Designated as Hedging Instrument | Accumulated Other Comprehensive Income        
Derivative Instruments, Gain (Loss) [Roll Forward]        
Balance, Beginning of Period   (55,965) (107,133)  
Balance, End of Period   29,527 (55,965) (107,133)
Designated as Hedging Instrument | Interest rate swap | Interest expense | Cash Flow Hedges        
Derivative Instruments, Gain (Loss) [Roll Forward]        
Balance, Beginning of Period   (43,956) (93,769)  
Amount of Gain (Loss) Recognized in AOCI   93,308 27,402  
Amount of Gain (Loss) Reclassified from AOCI into Earnings   (7,360) (22,411)  
Balance, End of Period   56,712 (43,956) (93,769)
Designated as Hedging Instrument | Cross-currency swap | Other income, net | Cash Flow Hedges        
Derivative Instruments, Gain (Loss) [Roll Forward]        
Balance, Beginning of Period   (9,688) (1,073)  
Amount of Gain (Loss) Recognized in AOCI   8,847 24,275  
Amount of Gain (Loss) Reclassified from AOCI into Earnings   19,430 32,890  
Balance, End of Period   (20,271) (9,688) (1,073)
Designated as Hedging Instrument | Cross-currency swap | Interest income | Net Investment Hedges        
Derivative Instruments, Gain (Loss) [Roll Forward]        
Balance, Beginning of Period   (2,321) (12,291)  
Amount of Gain (Loss) Recognized in AOCI   2,196 16,515  
Amount of Gain (Loss) Reclassified from AOCI into Earnings   6,789 6,545  
Balance, End of Period   $ (6,914) $ (2,321) $ (12,291)
XML 86 R64.htm IDEA: XBRL DOCUMENT v3.22.4
DERIVATIVE INSTRUMENTS- (Schedule of Gains and (Loss) of Derivative Instruments) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Derivative Instruments, Gain (Loss) [Line Items]    
Derivative instruments not designated as hedging instruments, gain (loss), net $ 1,258 $ 455
Foreign Currency Forward Contract    
Derivative Instruments, Gain (Loss) [Line Items]    
Derivative instruments not designated as hedging instruments, gain (loss), net 0 (174)
Currency Swap    
Derivative Instruments, Gain (Loss) [Line Items]    
Derivative instruments not designated as hedging instruments, gain (loss), net $ 1,258 $ 629
XML 87 R65.htm IDEA: XBRL DOCUMENT v3.22.4
GOODWILL AND OTHER INTANGIBLE ASSETS (Narrative) (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2022
USD ($)
reporting_unit
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Goodwill [Line Items]      
Number of reporting units | reporting_unit 3    
Amortization expense $ 78.3 $ 83.3 $ 74.5
Expected annual amortization expense, 2023 82.3    
Expected annual amortization expense, 2024 81.7    
Expected annual amortization expense, 2025 81.7    
Expected annual amortization expense, 2026 81.5    
Expected annual amortization expense, 2027 79.6    
Expected annual amortization expense, thereafter 551.6    
Amortization of product technology $ 64.4 $ 66.5 $ 46.7
XML 88 R66.htm IDEA: XBRL DOCUMENT v3.22.4
GOODWILL AND OTHER INTANGIBLE ASSETS (Schedule of Changes in Carrying Amount of Goodwill) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Goodwill [Roll Forward]    
Beginning of period $ 1,013,458 $ 932,367
Sale of non-core traditional wound care business (5,019)  
Foreign currency translation (11,413) (13,056)
End of period 1,038,881 1,013,458
ACell, Inc.    
Goodwill [Roll Forward]    
Goodwill acquisition   94,147
Surgical Innovation Association Inc    
Goodwill [Roll Forward]    
Goodwill acquisition 41,855  
Codman Specialty Surgical    
Goodwill [Roll Forward]    
Beginning of period 663,428 671,975
Sale of non-core traditional wound care business 0  
Foreign currency translation (7,209) (8,547)
End of period 656,219 663,428
Codman Specialty Surgical | ACell, Inc.    
Goodwill [Roll Forward]    
Goodwill acquisition   0
Codman Specialty Surgical | Surgical Innovation Association Inc    
Goodwill [Roll Forward]    
Goodwill acquisition 0  
Tissue Technologies    
Goodwill [Roll Forward]    
Beginning of period 350,030 260,392
Sale of non-core traditional wound care business (5,019)  
Foreign currency translation (4,204) (4,509)
End of period 382,662 350,030
Tissue Technologies | ACell, Inc.    
Goodwill [Roll Forward]    
Goodwill acquisition   $ 94,147
Tissue Technologies | Surgical Innovation Association Inc    
Goodwill [Roll Forward]    
Goodwill acquisition $ 41,855  
XML 89 R67.htm IDEA: XBRL DOCUMENT v3.22.4
GOODWILL AND OTHER INTANGIBLE ASSETS (Components of Company's Identifiable Intangible Assets) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Acquired Finite-Lived Intangible Assets [Line Items]    
Cost $ 1,697,532 $ 1,646,892
Accumulated Amortization (570,923) (501,319)
Net 1,126,609 1,145,573
Codman trade name    
Acquired Finite-Lived Intangible Assets [Line Items]    
Cost 166,693 167,758
Net $ 166,693 $ 167,758
Completed technology    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life 18 years 18 years
Cost $ 1,204,325 $ 1,132,954
Accumulated Amortization (370,968) (307,013)
Net $ 833,357 $ 825,941
Customer relationships    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life 12 years 12 years
Cost $ 193,081 $ 211,344
Accumulated Amortization (144,040) (142,755)
Net $ 49,041 $ 68,589
Trademarks/brand names    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life 28 years 28 years
Cost $ 97,265 $ 98,367
Accumulated Amortization (34,674) (31,468)
Net $ 62,591 $ 66,899
Supplier relationships    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life 30 years 30 years
Cost $ 30,211 $ 30,211
Accumulated Amortization (17,170) (16,192)
Net $ 13,041 $ 14,019
All other    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life 11 years 11 years
Cost $ 5,957 $ 6,258
Accumulated Amortization (4,071) (3,891)
Net $ 1,886 $ 2,367
XML 90 R68.htm IDEA: XBRL DOCUMENT v3.22.4
TREASURY STOCK - Narrative (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 12 Months Ended
Jan. 26, 2023
Jan. 12, 2022
Dec. 31, 2022
Dec. 31, 2021
Apr. 26, 2022
Mar. 24, 2022
Equity, Class of Treasury Stock [Line Items]            
Treasury stock outstanding (in shares)     6,800 4,900    
Treasury stock     $ 362.9 $ 234.4    
Treasury stock, average cost per share (in dollars per share)     $ 53.18 $ 47.86    
Stock repurchase program, authorized amount (up to)         $ 225.0  
Accelerated share repurchase program, receipt (payment)   $ 125.0        
Accelerated share repurchases, shares received at inception   1,480        
Accelerated share repurchases, percentage of expected total repurchased   80.00%        
Remaining amount under share repurchase         $ 100.0  
Accelerated share repurchases, additional shares received           460
Subsequent Event            
Equity, Class of Treasury Stock [Line Items]            
Stock repurchase program, authorized amount (up to) $ 150.0          
Accelerated share repurchases, shares received at inception 2,100          
Accelerated share repurchases, percentage of expected total repurchased 80.00%          
XML 91 R69.htm IDEA: XBRL DOCUMENT v3.22.4
STOCK-BASED COMPENSATION (Summary of Employee Stock-Based Compensation Expense) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
Total stock-based compensation expense $ 27,725 $ 36,210 $ 19,591
Total estimated tax benefit related to stock-based compensation expense 10,574 13,804 6,221
Net effect on net income 17,151 22,406 13,370
Cost of goods sold      
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
Total stock-based compensation expense 549 470 344
Research and development      
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
Total stock-based compensation expense 1,739 1,644 1,471
Selling, general and administrative      
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
Total stock-based compensation expense $ 25,437 $ 34,096 $ 17,776
XML 92 R70.htm IDEA: XBRL DOCUMENT v3.22.4
STOCK-BASED COMPENSATION (Narrative) (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
May 31, 2017
May 31, 2010
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Shares available for purchase (in shares)     3,100,000    
Dividend yield     0.00% 0.00% 0.00%
Share-based compensation expense recognized     $ 27,725 $ 36,210 $ 19,591
Intrinsic value, options exercised     4,000 11,100 8,700
Cash received from option exercises and employee stock purchase plan     5,500 6,800 5,200
Tax benefit realized from stock options exercised     600 2,200 1,700
Capitalized share-based compensation cost     $ 600 $ 500 $ 400
2003 Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Common stock reserved for issuance (in shares)     14,700,000    
Increase in authorized shares (in shares) 1,700,000 3,500,000      
2000 Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Common stock reserved for issuance (in shares)     4,000,000    
2001 Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Common stock reserved for issuance (in shares)     4,000,000    
Employee Stock Purchase Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Common stock reserved for issuance (in shares)     3,000,000    
Shares available for purchase (in shares)     2,000,000    
Shares issued (in shares)     20,780 16,948 18,284
ESPP proceeds received     $ 1,100 $ 1,100 $ 1,100
Employee Stock Option          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Award vesting period     4 years    
Share-based compensation expense recognized     $ 3,500 5,000 3,200
Total unrecognized compensation costs related to unvested awards     $ 3,500    
Weighted-average period for cost recognition, in years     2 years    
Employee Stock Option | Director          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Award vesting period     1 year    
Employee Stock Option | Employee          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Expiration period, in years     8 years    
Employee Stock Option | Directors and Certain Executive Officers | Minimum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Expiration period, in years     6 years    
Employee Stock Option | Directors and Certain Executive Officers | Maximum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Expiration period, in years     10 years    
Restricted Stock Units (RSUs)          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Award vesting period     3 years    
Restricted Stock, Performance Stock and Contract Stock          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share-based compensation expense recognized     $ 24,300 31,200 16,400
Total unrecognized compensation costs related to unvested awards     $ 29,700    
Weighted-average period for cost recognition, in years     2 years    
Fair value of shares vested     $ 65,000 $ 15,700 $ 17,300
Requisite service periods of performance stock, restricted stock and contract stock awards, in years     3 years    
Performance Shares Units          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vested or expected to vest at end of year (in shares)     129,399    
XML 93 R71.htm IDEA: XBRL DOCUMENT v3.22.4
STOCK-BASED COMPENSATION (Summary of Weighted-Average Assumptions) (Details) - $ / shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Share-Based Payment Arrangement [Abstract]      
Dividend yield 0.00% 0.00% 0.00%
Expected volatility 30.00% 29.00% 27.00%
Risk free interest rate 2.01% 1.30% 0.89%
Expected life of option from grant date 7 years 7 years 7 years
Weighted average grant date fair value of options granted (in dollars per share) $ 23.15 $ 22.59 $ 13.03
XML 94 R72.htm IDEA: XBRL DOCUMENT v3.22.4
STOCK-BASED COMPENSATION (Summary of Stock Option Activity) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]    
Outstanding at beginning of year (in shares) 1,225  
Granted (in shares) 146  
Exercised (in shares) (155)  
Forfeited or Expired (in shares) (14)  
Outstanding at end of year (in shares) 1,202 1,225
Exercisable at end of year (in shares) 871  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]    
Weighted Average Exercise Price, Outstanding at beginning of year (in dollars per share) $ 45.11  
Weighted Average Exercise Price, Granted (in dollars per share) 65.11  
Weighted Average Exercise Price, Exercised (in dollars per share) 28.32  
Weighted Average Exercise Price, Forfeited or Expired (in dollars per share) 50.68  
Weighted Average Exercise Price, Outstanding at end of year (in dollars per share) 49.63 $ 45.11
Weighted Average Exercise Price, Exercisable at end of year (in dollars per share) $ 45.82  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures    
Weighted Average Contractual Term in Years, Outstanding at end of year 4 years 1 month 20 days 4 years 3 months 18 days
Weighted Average Contractual Term in Years, Exercisable at end of year 3 years 3 months 18 days  
Aggregate Intrinsic Value, Outstanding $ 10,772 $ 26,970
Aggregate Intrinsic Value, Exercisable at end of year $ 9,635  
XML 95 R73.htm IDEA: XBRL DOCUMENT v3.22.4
STOCK-BASED COMPENSATION (Summary of Vested and Unvested Restricted Stock, Performance Stock, and Contract Stock) (Details)
shares in Thousands
 12 Months Ended
Dec. 31, 2022
$ / shares
shares
Restricted Stock Awards  
Shares  
Unvested at beginning of year (in shares) | shares 422
Granted (in shares) | shares 334
Adjustments for performance achievement related to award target (in shares) | shares 0
Cancellations (in shares) | shares (34)
Released (in shares) | shares (239)
Unvested at end of year (in shares) | shares 483
Weighted Average Grant Date Fair Value Per Share  
Unvested at beginning of year (in dollars per share) | $ / shares $ 58.78
Granted (in dollars per share) | $ / shares 62.88
Adjustments for performance achievement related to award target (in dollars per share) | $ / shares 0
Cancellations (in dollars per share) | $ / shares 62.29
Released (in dollars per share) | $ / shares 58.27
Unvested at end of year (in dollars per share) | $ / shares $ 61.63
Performance Stock and Contract Stock Awards  
Shares  
Unvested at beginning of year (in shares) | shares 442
Granted (in shares) | shares 245
Adjustments for performance achievement related to award target (in shares) | shares (18)
Cancellations (in shares) | shares (10)
Released (in shares) | shares (252)
Unvested at end of year (in shares) | shares 407
Weighted Average Grant Date Fair Value Per Share  
Unvested at beginning of year (in dollars per share) | $ / shares $ 60.62
Granted (in dollars per share) | $ / shares 62.89
Adjustments for performance achievement related to award target (in dollars per share) | $ / shares 60.76
Cancellations (in dollars per share) | $ / shares 59.88
Released (in dollars per share) | $ / shares 59.38
Unvested at end of year (in dollars per share) | $ / shares $ 62.88
XML 96 R74.htm IDEA: XBRL DOCUMENT v3.22.4
RETIREMENT BENEFIT PLANS (Schedule of Net Periodic Benefit Costs) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Retirement Benefits [Abstract]    
Service cost $ 2,419 $ 2,741
Interest cost 194 100
Expected return on plan assets (1,381) (893)
Amortization of prior service cost (credit) (326) (281)
Recognized actuarial losses 9 186
Settlements 0 51
Net period benefit cost $ 915 $ 1,904
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income Not Disclosed Flag Net periodic benefit costs  
DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfPriorServiceCostCreditStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag Net periodic benefit costs  
DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag Net periodic benefit costs  
DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag Net periodic benefit costs  
DefinedBenefitPlanNetPeriodicBenefitCostCreditSettlementGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag Net periodic benefit costs  
XML 97 R75.htm IDEA: XBRL DOCUMENT v3.22.4
RETIREMENT BENEFIT PLANS (Schedule of Assumptions Used Periodic Benefit Cost and Actuarial Present Value) (Details)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Retirement Benefits [Abstract]    
Discount rate 2.44% 0.37%
Expected return on plan assets 3.61% 3.59%
Rate of compensation increase 1.97% 2.10%
Interest crediting rate for cash balance plans 1.00% 1.00%
XML 98 R76.htm IDEA: XBRL DOCUMENT v3.22.4
RETIREMENT BENEFIT PLANS (Schedule of Change in Benefit Obligations and Plan Assets) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Change In Projected Benefit Obligations    
Projected benefit obligations, beginning of year $ 65,184 $ 72,869
Interest cost 194 100
Service cost 2,419 2,741
Actuarial (gain) loss (14,822) (5,044)
Plan amendments (390) (586)
Plan settlements (20) (655)
Employee contribution 999 917
Premiums paid (391) (373)
Benefit payment (999) (2,128)
Effect of foreign currency exchange rates (1,810) (2,657)
Projected benefit obligations, end of year 50,364 65,184
Change In Plan Assets    
Plan assets at fair value, beginning of year 39,914 37,825
Actual return on plan assets (2,863) 3,371
Employer contributions 2,356 2,254
Employee contributions 999 917
Plan settlements 0 (633)
Benefits paid (998) (2,128)
Premiums paid (391) (373)
Effect of foreign currency exchange rates (964) (1,319)
Plan assets at fair value, end of year $ 38,053 $ 39,914
XML 99 R77.htm IDEA: XBRL DOCUMENT v3.22.4
RETIREMENT BENEFIT PLANS (Scheduled of Funded Status) (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Reconciliation Of Funded Status      
Fair value of plan assets $ 38,053 $ 39,914 $ 37,825
Benefit obligations 50,364 65,184 $ 72,869
Unfunded benefit obligations $ 12,311 $ 25,270  
XML 100 R78.htm IDEA: XBRL DOCUMENT v3.22.4
RETIREMENT BENEFIT PLANS (Narrative) (Details) - USD ($)
 1 Months Ended 12 Months Ended
May 31, 2019
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]        
Gain (loss) recognized within accumulated other comprehensive loss   $ 7,400,000 $ 7,000,000  
Accumulated benefit obligation   46,400,000 60,300,000  
Benefit plans, assets   38,053,000 39,914,000 $ 37,825,000
Plan assets expected to be returned next twelve months   0    
Contributions expected to be paid to plan   2,600,000    
Total contributions made   $ 9,800,000 $ 8,800,000 6,700,000
Defer payment and taxation, base salary, percentage (up to) 75.00% 75.00%    
Defer payment and taxation, bonus and other eligible cash compensation, percentage (up to) 100.00% 100.00%    
Deferred compensation plan, fair value of assets   $ 4,700,000   $ 3,800,000
FRANCE        
Defined Benefit Plan Disclosure [Line Items]        
Benefit plans, assets   0    
GERMANY        
Defined Benefit Plan Disclosure [Line Items]        
Benefit plans, assets   $ 0    
XML 101 R79.htm IDEA: XBRL DOCUMENT v3.22.4
RETIREMENT BENEFIT PLANS (Schedule of Expected Benefit Payments and Minimum Contribution on Unfunded Plans) (Details)
$ in Thousands
Dec. 31, 2022
USD ($)
Retirement Benefits [Abstract]  
2023 $ 2,211
2024 2,045
2025 2,050
2026 1,929
2027 1,868
Next five years $ 11,068
XML 102 R80.htm IDEA: XBRL DOCUMENT v3.22.4
LEASES AND RELATED PARTY LEASES - Narrative (Details)
 12 Months Ended
Dec. 31, 2022
USD ($)
renewal_option
Dec. 31, 2021
USD ($)
Operating Leased Assets [Line Items]    
Number of renewal options (or more) | renewal_option 1  
Operating lease expense $ 22,600,000 $ 20,300,000
Future minimum lease payments, finance leases 0  
Affiliated Entity    
Operating Leased Assets [Line Items]    
Operating lease expense $ 300,000 $ 300,000
Percent of manufacturing facility owned by corporation whose shareholders are trusts whose beneficiaries include family members of company's former director 50.00%  
Annual rate of lease agreement $ 300,000  
Affiliated Entity | Five Year Option Lease From November 1, 2029 Through October 31, 2034    
Operating Leased Assets [Line Items]    
Option to extend lease, years 5 years  
Period for extended lease November 1, 2029 through October 31, 2034  
Affiliated Entity | Five Year Option Lease From November 1, 2034 Through October 31, 2039    
Operating Leased Assets [Line Items]    
Option to extend lease, years 5 years  
Period for extended lease November 1, 2034 through October 31, 2039  
XML 103 R81.htm IDEA: XBRL DOCUMENT v3.22.4
LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Lessee, Lease, Description [Line Items]    
ROU assets $ 148,284 $ 84,543
Current lease liabilities 14,624 14,775
Non-current lease liabilities 157,420 90,329
Total lease liabilities $ 172,044 $ 105,104
Leased facilities    
Lessee, Lease, Description [Line Items]    
Weighted average remaining lease term (in years) 16 years 10 months 24 days 10 years 4 months 24 days
Weighted average discount rate 5.40% 5.10%
Leased vehicles    
Lessee, Lease, Description [Line Items]    
Weighted average remaining lease term (in years) 2 years 2 years 1 month 6 days
Weighted average discount rate 2.70% 2.60%
XML 104 R82.htm IDEA: XBRL DOCUMENT v3.22.4
LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:    
Operating cash flows from operating leases $ 17,442 $ 15,077
ROU assets obtained in exchange for lease liabilities:    
Operating leases $ 72,169 $ 12,610
XML 105 R83.htm IDEA: XBRL DOCUMENT v3.22.4
LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases Current Period (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Operating Leased Assets [Line Items]    
2023 $ 20,320  
2024 21,165  
2025 19,494  
2026 17,126  
2027 16,182  
Thereafter 165,164  
Total minimum lease payments 259,451  
Less: Imputed interest 87,407  
Total lease liabilities 172,044 $ 105,104
Less: Current lease liabilities 14,624 14,775
Long-term lease liabilities 157,420 $ 90,329
Related Parties    
Operating Leased Assets [Line Items]    
2023 296  
2024 296  
2025 296  
2026 296  
2027 296  
Thereafter 542  
Total minimum lease payments 2,022  
Third Parties    
Operating Leased Assets [Line Items]    
2023 20,024  
2024 20,869  
2025 19,198  
2026 16,830  
2027 15,886  
Thereafter 164,622  
Total minimum lease payments $ 257,429  
XML 106 R84.htm IDEA: XBRL DOCUMENT v3.22.4
INCOME TAXES (Schedule of Income Before Income Taxes) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]      
United States operations $ 92,642 $ 91,150 $ 15,082
Foreign operations 121,252 123,527 78,438
Income before income taxes $ 213,894 $ 214,677 $ 93,520
XML 107 R85.htm IDEA: XBRL DOCUMENT v3.22.4
INCOME TAXES (Schedule of Effective Tax Rate Reconciliation) (Details)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]      
Federal statutory rate 21.00% 21.00% 21.00%
Increase (decrease) in income taxes resulting from:      
State income taxes, net of federal tax benefit 0.10% 1.90% 1.20%
Foreign operations (3.90%) (4.00%) (7.90%)
Excess tax benefits from stock compensation (2.40%) (1.20%) (1.00%)
Intercompany profit in inventory 0.30% (0.20%) 1.20%
Nondeductible facilitative costs 0.20% 0.30% 1.10%
Contingent Consideration (2.00%) (0.20%) 0.20%
Research and development credit (1.40%) (1.20%) (1.60%)
Return to provision (0.50%) (0.70%) (2.30%)
Global intangible low-taxed income ("GILTI") 2.80% 0.70% 2.50%
Nondeductible executive compensation 1.80% 0.90% 2.40%
Fair market value step up on intra-entity transfer of intellectual property 0.00% 0.00% (63.30%)
Gain from sale of business - book to tax differences 0.00% 3.90% 2.80%
Other (0.40%) 0.00% 0.50%
Effective tax rate 15.60% 21.20% (43.20%)
XML 108 R86.htm IDEA: XBRL DOCUMENT v3.22.4
INCOME TAXES (Narrative) (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Dec. 31, 2020
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Tax [Line Items]        
Effective tax rate   15.60% 21.20% (43.20%)
Effective income tax reconciliation, tax benefit, excess stock-based compensation deductions   $ 5,100    
Effective Income Tax rate reconciliation, prior year income taxes, amount   2,400    
Excess tax benefits from stock compensation     $ 3,100  
Income tax benefit, transfer intra-entity intellectual property, amount       $ 59,200
Effective worldwide tax rate       20.20%
Effective income tax rate reconciliation, foreign income tax rate differential, increase (decrease), amount   $ 400 $ 63,600  
Effective foreign income tax rate   15.90% 15.20% (57.10%)
Deferred tax asset, increase   $ 20,200    
Unrecognized tax benefits that would impact effective tax rate   700    
Increase in unrecognized tax benefits is reasonably possible   300    
Penalties and interest expense   0 $ 0 $ 0
Penalties and interest accrued $ 0 0 0 $ 0
Extremity Orthopedics        
Income Tax [Line Items]        
Tax expense related to sale of business     $ 8,500  
Foreign Tax Authority        
Income Tax [Line Items]        
Operating loss carryforwards   75,500    
Operating loss carryforwards, not subject to expiration   16,400    
Operating loss carryforwards, subject to expiration   59,100    
Foreign Tax Authority | Switzerland        
Income Tax [Line Items]        
Deferred income tax benefit, transfer intra-entity intellectual property, amount $ 59,200      
Federal        
Income Tax [Line Items]        
Operating loss carryforwards   79,500    
Operating loss carryforwards, not subject to expiration   18,600    
State and Local Jurisdiction        
Income Tax [Line Items]        
Operating loss carryforwards   $ 37,900    
XML 109 R87.htm IDEA: XBRL DOCUMENT v3.22.4
INCOME TAXES (Schedule of Provision for Income Taxes) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Current:      
Federal $ 24,201 $ 31,938 $ 6,184
State 3,835 11,377 5,029
Foreign 9,893 5,042 12,553
Total current 37,929 48,357 23,766
Deferred:      
Federal (11,591) (12,830) (5,079)
State (2,316) (3,688) (1,760)
Foreign 9,322 13,763 (57,299)
Total deferred (4,585) (2,755) (64,138)
Provision for income taxes $ 33,344 $ 45,602 $ (40,372)
XML 110 R88.htm IDEA: XBRL DOCUMENT v3.22.4
INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Assets:    
Doubtful accounts $ 2,261 $ 2,029
Inventory related items 31,950 31,841
Tax credits 13,084 13,319
Accrued vacation 2,175 3,042
Accrued bonus 4,944 7,415
Stock compensation 10,175 13,955
Deferred revenue 2,130 1,742
Net operating loss carryforwards 30,707 26,198
Capitalization of research and development expenses 51,542 36,770
Unrealized foreign exchange gain 6,228 12,849
Charitable contributions carryforward 180 206
Leases and Other 39,788 41,371
Total deferred tax assets 195,164 190,737
Less valuation allowance (9,651) (9,767)
Deferred tax assets after valuation allowance 185,513 180,970
Liabilities:    
Intangible and fixed assets (166,891) (152,150)
Unrealized foreign exchange loss (12,991) 0
Leases and Other (22,975) (17,658)
Total deferred tax liabilities (202,857) (169,808)
Total net deferred tax assets (liabilities) $ 17,344  
Total net deferred tax assets (liabilities)   $ 11,162
XML 111 R89.htm IDEA: XBRL DOCUMENT v3.22.4
INCOME TAXES (Tax Valuation Allowance) (Details) - SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Valuation Allowance [Line Items]        
Balance at Beginning of Period $ 15,258 $ 13,825 $ 12,069  
Charged to Costs and Expenses   (515) 1,444 $ 1,617
Other     89 0
Deductions   (71) (100) 139
Balance at End of Period $ 14,672 $ 15,258 $ 13,825 $ 12,069
XML 112 R90.htm IDEA: XBRL DOCUMENT v3.22.4
INCOME TAXES (Schedule of Uncertain Tax Benefits Reconciliation) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Reconciliation of Uncertain Tax Benefits [Roll Forward]      
Balance, beginning of year $ 676 $ 702 $ 676
Gross increases:      
Current year tax positions 37 0 0
Prior years' tax positions 0 0 26
Other 0 (26) 0
Balance, end of year $ 713 $ 676 $ 702
XML 113 R91.htm IDEA: XBRL DOCUMENT v3.22.4
NET INCOME PER SHARE (Basic and Diluted Net Income Per Share) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Basic net income per share:      
Net income $ 180,550 $ 169,075 $ 133,892
Weighted average common shares outstanding - Basic (in shares) 82,997 84,698 84,650
Basic net income per common share (in dollars per share) $ 2.18 $ 2.00 $ 1.58
Diluted net income per share:      
Net income $ 180,550 $ 169,075 $ 133,892
Weighted average common shares outstanding - Basic (in shares) 82,997 84,698 84,650
Effect of dilutive securities:      
Stock options and restricted stock (in shares) 519 787 577
Weighted average common shares for diluted earnings per share (in shares) 83,516 85,485 85,228
Diluted net income per common share (in dollars per share) $ 2.16 $ 1.98 $ 1.57
XML 114 R92.htm IDEA: XBRL DOCUMENT v3.22.4
NET INCOME PER SHARE (Narrative) (Details) - shares
shares in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Earnings Per Share [Abstract]    
Shares excluded from computation as their effect would be antidilutive (in shares) 0.3 0.1
XML 115 R93.htm IDEA: XBRL DOCUMENT v3.22.4
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Schedule of Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Balance, Beginning of Period $ 1,684,804 $ 1,514,867 $ 1,416,736
Other comprehensive gain (loss) 69,957    
Less: Amounts reclassified from accumulated other comprehensive income, net 14,537    
Total other comprehensive gain (loss), net of tax 55,420 28,904 2,343
Balance, End of Period 1,804,403 1,684,804 1,514,867
Total      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Balance, Beginning of Period (45,155) (74,059) (76,402)
Total other comprehensive gain (loss), net of tax 55,420 28,904 2,343
Balance, End of Period 10,265 (45,155) $ (74,059)
Gains and Losses on Derivatives      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Balance, Beginning of Period (42,981)    
Other comprehensive gain (loss) 80,335    
Less: Amounts reclassified from accumulated other comprehensive income, net 14,537    
Total other comprehensive gain (loss), net of tax 65,798    
Balance, End of Period 22,817 (42,981)  
Defined Benefit Pension Items      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Balance, Beginning of Period 1,893    
Other comprehensive gain (loss) 7,429    
Less: Amounts reclassified from accumulated other comprehensive income, net 0    
Total other comprehensive gain (loss), net of tax 7,429    
Balance, End of Period 9,322 1,893  
Foreign Currency Items      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Balance, Beginning of Period (4,067)    
Other comprehensive gain (loss) (17,807)    
Less: Amounts reclassified from accumulated other comprehensive income, net 0    
Total other comprehensive gain (loss), net of tax (17,807)    
Balance, End of Period $ (21,874) $ (4,067)  
XML 116 R94.htm IDEA: XBRL DOCUMENT v3.22.4
AACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Narrative) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Other income, net $ 12,007 $ 19,307 $ 4,434
Interest income (11,917) $ (6,737) $ (9,297)
Gains and Losses on Derivatives | Reclassification out of Accumulated Other Comprehensive Income      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Other income, net 15,000    
Interest income $ (400)    
XML 117 R95.htm IDEA: XBRL DOCUMENT v3.22.4
COMMITMENTS AND CONTINGENCIES (Fair Value Contingent Consideration) (Details) - Contingent Consideration Liability - Level 3 - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Arkis | Other Noncurrent Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, Beginning of Period $ 11,408 $ 11,746
Transfers from long-term to current portion 0 (276)
Change in fair value of contingent consideration liabilities (1,358) (62)
Balance, End of Period 10,050 11,408
Additions 0 0
Arkis | Accrued Expenses and Other Current Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, Beginning of Period 3,691 3,415
Transfers from long-term to current portion 0 276
Change in fair value of contingent consideration liabilities (846) 0
Balance, End of Period 2,845 3,691
Additions 0 0
Derma Sciences | Other Noncurrent Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, Beginning of Period 230 230
Transfers from long-term to current portion 0 0
Change in fair value of contingent consideration liabilities 0 0
Balance, End of Period 230 230
Additions 0 0
ACell | Other Noncurrent Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, Beginning of Period 21,800 0
Transfers from long-term to current portion (4,885) 0
Change in fair value of contingent consideration liabilities (13,215) (2,100)
Balance, End of Period 3,700 21,800
Additions 0 23,900
ACell | Accrued Expenses and Other Current Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, Beginning of Period 0  
Transfers from long-term to current portion 4,885  
Change in fair value of contingent consideration liabilities (4,885)  
Balance, End of Period 0 0
Additions  
Surgical Innovation Association Inc | Other Noncurrent Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, Beginning of Period 0  
Transfers from long-term to current portion 0  
Change in fair value of contingent consideration liabilities 0  
Balance, End of Period 57,607 $ 0
Additions $ 57,607  
XML 118 R96.htm IDEA: XBRL DOCUMENT v3.22.4
COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details) - Contingent Consideration Liability - Level 3 - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Arkis | Accrued Expenses and Other Current Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, Beginning of Period $ 3,691 $ 3,415
Additions 0 0
Transfers from long-term to current portion 0 276
Change in fair value of contingent consideration liabilities 846 0
Balance, End of Period 2,845 3,691
Arkis | Other Noncurrent Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, Beginning of Period 11,408 11,746
Additions 0 0
Transfers from long-term to current portion 0 (276)
Change in fair value of contingent consideration liabilities 1,358 62
Balance, End of Period 10,050 11,408
Derma Sciences | Other Noncurrent Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, Beginning of Period 230 230
Additions 0 0
Transfers from long-term to current portion 0 0
Change in fair value of contingent consideration liabilities 0 0
Balance, End of Period 230 230
ACell | Accrued Expenses and Other Current Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, Beginning of Period 0  
Additions  
Transfers from long-term to current portion 4,885  
Change in fair value of contingent consideration liabilities 4,885  
Balance, End of Period 0 0
ACell | Other Noncurrent Liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, Beginning of Period 21,800 0
Additions 0 23,900
Transfers from long-term to current portion (4,885) 0
Change in fair value of contingent consideration liabilities 13,215 2,100
Balance, End of Period $ 3,700 $ 21,800
XML 119 R97.htm IDEA: XBRL DOCUMENT v3.22.4
COMMITMENTS AND CONTINGENCIES - Narrative (Details)
 12 Months Ended
Dec. 31, 2022
USD ($)
liability
Dec. 31, 2021
USD ($)
Jul. 29, 2019
USD ($)
Derma Sciences      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Number of liabilities | liability 1    
Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to) $ 3,000,000    
Derma Sciences | BioD Earnout Payments and Medihoney Earnout Payments      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Payment for contingent consideration 33,300,000    
Derma Sciences | Level 3      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Contingent consideration, liability 200,000 $ 200,000  
Arkis      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Contingent consideration, liability 12,900,000   $ 25,500,000
Business combination, contingent consideration, liability, current 2,800,000    
Business combination, contingent consideration, liability, noncurrent $ 10,100,000    
Contingent consideration     13,100,000
Arkis | Milestone Payment One      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Contingent consideration, liability     10,000,000
Arkis | Milestone Payment Two      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Contingent consideration, liability     $ 15,500,000
XML 120 R98.htm IDEA: XBRL DOCUMENT v3.22.4
SEGMENT AND GEOGRAPHIC INFORMATION (Narrative) (Details)
 12 Months Ended
Dec. 31, 2022
product
Segment
Segment Reporting Information [Line Items]  
Number of reportable segments | Segment 2
Codman Specialty Surgical  
Segment Reporting Information [Line Items]  
Number of products offered (more than) | product 40,000
XML 121 R99.htm IDEA: XBRL DOCUMENT v3.22.4
SEGMENT AND GEOGRAPHIC INFORMATION (Net Sales and Profit by Reportable Segment) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Segment Net Sales      
Total revenues $ 1,557,666 $ 1,542,448 $ 1,371,868
Segment Profit      
Amortization (13,882) (16,914) (27,757)
Operating income 238,920 197,230 151,370
Codman Specialty Surgical      
Segment Net Sales      
Total revenues 1,019,564 1,025,232 894,831
Tissue Technologies      
Segment Net Sales      
Total revenues 538,102 517,216 477,037
Operating Segments      
Segment Profit      
Operating income 651,675 667,670 516,287
Operating Segments | Codman Specialty Surgical      
Segment Profit      
Operating income 417,873 439,471 356,657
Operating Segments | Tissue Technologies      
Segment Profit      
Operating income 233,802 228,199 159,630
Corporate and other      
Segment Profit      
Operating income $ (398,873) $ (453,526) $ (337,160)
XML 122 R100.htm IDEA: XBRL DOCUMENT v3.22.4
SEGMENT AND GEOGRAPHIC INFORMATION (Total Revenue by Major Geographic Area) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Segment Reporting Information [Line Items]      
Total revenue, net $ 1,557,666 $ 1,542,448 $ 1,371,868
Total long-lived assets 516,776 412,686  
United States (Includes long-lived assets in Puerto Rico)      
Segment Reporting Information [Line Items]      
Total revenue, net 1,126,810 1,089,526 971,975
Total long-lived assets 440,223 339,535  
Europe      
Segment Reporting Information [Line Items]      
Total revenue, net 170,903 191,327 172,689
Total long-lived assets 60,857 55,026  
Asia Pacific      
Segment Reporting Information [Line Items]      
Total revenue, net 176,477 182,034 157,174
Total long-lived assets 12,975 11,289  
Rest of the World      
Segment Reporting Information [Line Items]      
Total revenue, net 83,476 79,561 $ 70,030
Total long-lived assets $ 2,721 $ 6,836  
XML 123 R9999.htm IDEA: XBRL DOCUMENT v3.22.4
Label Element Value
Accounting Standards Update [Extensible Enumeration] us-gaap_AccountingStandardsUpdateExtensibleList Accounting Standards Update 2016-13 [Member]
XML 124 iart-20221231_htm.xml IDEA: XBRL DOCUMENT 0000917520 2022-01-01 2022-12-31 0000917520 2022-06-30 0000917520 2023-02-21 0000917520 2021-01-01 2021-12-31 0000917520 2020-01-01 2020-12-31 0000917520 2022-12-31 0000917520 2021-12-31 0000917520 2020-12-31 0000917520 2019-12-31 0000917520 us-gaap:CommonStockMember 2019-12-31 0000917520 us-gaap:TreasuryStockMember 2019-12-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000917520 us-gaap:RetainedEarningsMember 2019-12-31 0000917520 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0000917520 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000917520 us-gaap:TreasuryStockMember 2020-01-01 2020-12-31 0000917520 2019-01-01 2019-12-31 0000917520 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-12-31 0000917520 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0000917520 us-gaap:CommonStockMember 2020-12-31 0000917520 us-gaap:TreasuryStockMember 2020-12-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000917520 us-gaap:RetainedEarningsMember 2020-12-31 0000917520 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000917520 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000917520 us-gaap:TreasuryStockMember 2021-01-01 2021-12-31 0000917520 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000917520 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2020-12-31 0000917520 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2020-12-31 0000917520 us-gaap:CommonStockMember 2021-12-31 0000917520 us-gaap:TreasuryStockMember 2021-12-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000917520 us-gaap:RetainedEarningsMember 2021-12-31 0000917520 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000917520 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000917520 us-gaap:TreasuryStockMember 2022-01-01 2022-12-31 0000917520 us-gaap:CommonStockMember 2022-12-31 0000917520 us-gaap:TreasuryStockMember 2022-12-31 0000917520 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000917520 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000917520 us-gaap:RetainedEarningsMember 2022-12-31 0000917520 us-gaap:AllowanceForCreditLossMember 2021-12-31 0000917520 us-gaap:AllowanceForCreditLossMember 2022-01-01 2022-12-31 0000917520 us-gaap:AllowanceForCreditLossMember 2022-12-31 0000917520 us-gaap:AllowanceForCreditLossMember 2020-12-31 0000917520 us-gaap:AllowanceForCreditLossMember 2021-01-01 2021-12-31 0000917520 us-gaap:AllowanceForCreditLossMember 2019-12-31 0000917520 us-gaap:AllowanceForCreditLossMember 2020-01-01 2020-12-31 0000917520 us-gaap:LandMember 2022-12-31 0000917520 us-gaap:LandMember 2021-12-31 0000917520 us-gaap:BuildingAndBuildingImprovementsMember 2022-12-31 0000917520 us-gaap:BuildingAndBuildingImprovementsMember 2021-12-31 0000917520 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2022-01-01 2022-12-31 0000917520 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2022-01-01 2022-12-31 0000917520 us-gaap:LeaseholdImprovementsMember 2022-12-31 0000917520 us-gaap:LeaseholdImprovementsMember 2021-12-31 0000917520 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-12-31 0000917520 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-12-31 0000917520 us-gaap:MachineryAndEquipmentMember 2022-12-31 0000917520 us-gaap:MachineryAndEquipmentMember 2021-12-31 0000917520 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2022-01-01 2022-12-31 0000917520 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2022-01-01 2022-12-31 0000917520 iart:DemonstrationEquipmentMember 2022-12-31 0000917520 iart:DemonstrationEquipmentMember 2021-12-31 0000917520 srt:MinimumMember iart:DemonstrationEquipmentMember 2022-01-01 2022-12-31 0000917520 srt:MaximumMember iart:DemonstrationEquipmentMember 2022-01-01 2022-12-31 0000917520 iart:InformationSystemsandHardwareMember 2022-12-31 0000917520 iart:InformationSystemsandHardwareMember 2021-12-31 0000917520 srt:MinimumMember iart:InformationSystemsandHardwareMember 2022-01-01 2022-12-31 0000917520 srt:MaximumMember iart:InformationSystemsandHardwareMember 2022-01-01 2022-12-31 0000917520 us-gaap:FurnitureAndFixturesMember 2022-12-31 0000917520 us-gaap:FurnitureAndFixturesMember 2021-12-31 0000917520 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-12-31 0000917520 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-12-31 0000917520 us-gaap:ConstructionInProgressMember 2022-12-31 0000917520 us-gaap:ConstructionInProgressMember 2021-12-31 0000917520 srt:MinimumMember 2022-01-01 2022-12-31 0000917520 srt:MaximumMember 2022-01-01 2022-12-31 0000917520 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0000917520 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0000917520 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0000917520 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0000917520 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-12-31 0000917520 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0000917520 iart:ClosureOfFacilityMember 2022-12-31 0000917520 iart:ReorganizationProjectsMember 2022-12-31 0000917520 iart:ClosureOfFacilityMember 2021-12-31 0000917520 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000917520 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000917520 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember 2020-02-04 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-02-04 0000917520 iart:CumulativeEffectPeriodOfAdoptionAdjustmentDebtDiscountReclassificationMember 2020-12-31 0000917520 iart:CumulativeEffectPeriodOfAdoptionAdjustmentDebtDiscountAmortizationAndEquityCostsReclassificationMember 2020-12-31 0000917520 iart:ReboundTherapeuticsCorporationMember 2021-12-31 0000917520 iart:ReboundTherapeuticsCorporationMember 2020-12-31 0000917520 2023-01-01 2022-12-31 0000917520 2024-01-01 2022-12-31 0000917520 2025-01-01 2022-12-31 0000917520 2026-01-01 2022-12-31 0000917520 2027-01-01 2022-12-31 0000917520 2028-01-01 2022-12-31 0000917520 iart:NeurosurgeryMember iart:CodmanSpecialtySurgicalMember 2022-01-01 2022-12-31 0000917520 iart:NeurosurgeryMember iart:CodmanSpecialtySurgicalMember 2021-01-01 2021-12-31 0000917520 iart:NeurosurgeryMember iart:CodmanSpecialtySurgicalMember 2020-01-01 2020-12-31 0000917520 iart:InstrumentsMember iart:CodmanSpecialtySurgicalMember 2022-01-01 2022-12-31 0000917520 iart:InstrumentsMember iart:CodmanSpecialtySurgicalMember 2021-01-01 2021-12-31 0000917520 iart:InstrumentsMember iart:CodmanSpecialtySurgicalMember 2020-01-01 2020-12-31 0000917520 iart:CodmanSpecialtySurgicalMember 2022-01-01 2022-12-31 0000917520 iart:CodmanSpecialtySurgicalMember 2021-01-01 2021-12-31 0000917520 iart:CodmanSpecialtySurgicalMember 2020-01-01 2020-12-31 0000917520 iart:RegenerativeSkinAndWoundMember iart:TissueTechnologiesMember 2022-01-01 2022-12-31 0000917520 iart:RegenerativeSkinAndWoundMember iart:TissueTechnologiesMember 2021-01-01 2021-12-31 0000917520 iart:RegenerativeSkinAndWoundMember iart:TissueTechnologiesMember 2020-01-01 2020-12-31 0000917520 iart:ExtremityOrthopedicsMember iart:TissueTechnologiesMember 2022-01-01 2022-12-31 0000917520 iart:ExtremityOrthopedicsMember iart:TissueTechnologiesMember 2021-01-01 2021-12-31 0000917520 iart:ExtremityOrthopedicsMember iart:TissueTechnologiesMember 2020-01-01 2020-12-31 0000917520 iart:PrivateLabelMember iart:TissueTechnologiesMember 2022-01-01 2022-12-31 0000917520 iart:PrivateLabelMember iart:TissueTechnologiesMember 2021-01-01 2021-12-31 0000917520 iart:PrivateLabelMember iart:TissueTechnologiesMember 2020-01-01 2020-12-31 0000917520 iart:TissueTechnologiesMember 2022-01-01 2022-12-31 0000917520 iart:TissueTechnologiesMember 2021-01-01 2021-12-31 0000917520 iart:TissueTechnologiesMember 2020-01-01 2020-12-31 0000917520 iart:SurgicalInnovationAssociatesIncMember 2022-12-06 2022-12-06 0000917520 iart:SurgicalInnovationAssociatesIncMember iart:RevenueBasedPerformanceMilestonesMember 2022-12-06 0000917520 iart:SurgicalInnovationAssociatesIncMember iart:FDAApprovalOfPremarketApprovalMember 2022-12-06 0000917520 iart:SurgicalInnovationAssociatesIncMember 2022-12-06 0000917520 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember iart:TraditionalWoundCareMember 2022-08-31 0000917520 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember iart:TraditionalWoundCareMember 2022-08-31 2022-08-31 0000917520 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember iart:TraditionalWoundCareMember 2022-01-01 2022-12-31 0000917520 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember iart:TraditionalWoundCareMember 2022-12-31 0000917520 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember iart:ExtremityOrthopedicsMember 2021-01-04 0000917520 iart:ConsortiumofFocusedOrthopedistsLLCMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember iart:ExtremityOrthopedicsMember 2021-01-04 2021-01-04 0000917520 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember iart:ExtremityOrthopedicsMember 2020-12-31 0000917520 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember iart:ExtremityOrthopedicsMember 2021-01-01 2021-12-31 0000917520 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember iart:ExtremityOrthopedicsMember 2022-12-31 0000917520 iart:ACellIncMember 2021-01-20 2021-01-20 0000917520 iart:ACellIncMember 2021-01-20 0000917520 iart:ACellIncMember 2021-06-30 0000917520 srt:MinimumMember iart:ACellIncMember 2021-01-20 2021-01-20 0000917520 srt:MaximumMember iart:ACellIncMember 2021-01-20 2021-01-20 0000917520 iart:ACellIncMember 2022-12-31 0000917520 iart:ACellIncMember 2021-12-31 0000917520 iart:SeniorCreditFacilityMember 2020-02-03 0000917520 us-gaap:SecuredDebtMember iart:TermLoanFacilityMember 2020-02-03 0000917520 us-gaap:RevolvingCreditFacilityMember 2020-02-03 0000917520 us-gaap:StandbyLettersOfCreditMember 2020-02-03 0000917520 iart:SwinglineLoanMember 2020-02-03 0000917520 iart:SeniorCreditFacilityMember iart:DebtCovenantPeriod3Member 2020-07-14 0000917520 iart:SeniorCreditFacilityMember iart:DebtCovenantPeriod4Member 2020-07-14 0000917520 srt:MinimumMember iart:SeniorCreditFacilityMember us-gaap:EurodollarMember 2022-01-01 2022-12-31 0000917520 srt:MaximumMember iart:SeniorCreditFacilityMember us-gaap:EurodollarMember 2022-01-01 2022-12-31 0000917520 iart:SeniorCreditFacilityMember us-gaap:FederalFundsEffectiveSwapRateMember 2022-01-01 2022-12-31 0000917520 iart:SeniorCreditFacilityMember iart:OneMonthEurodollarRateMember 2022-01-01 2022-12-31 0000917520 srt:MinimumMember iart:SeniorCreditFacilityMember 2022-01-01 2022-12-31 0000917520 srt:MaximumMember iart:SeniorCreditFacilityMember 2022-01-01 2022-12-31 0000917520 iart:SeniorCreditFacilityMember 2020-01-01 2020-03-31 0000917520 iart:SeniorCreditFacilityMember 2020-07-01 2020-09-30 0000917520 us-gaap:RevolvingCreditFacilityMember 2022-12-31 0000917520 us-gaap:RevolvingCreditFacilityMember 2021-12-31 0000917520 us-gaap:SecuredDebtMember iart:TermLoanFacilityMember 2022-12-31 0000917520 us-gaap:SecuredDebtMember iart:TermLoanFacilityMember 2021-12-31 0000917520 us-gaap:SecuredDebtMember iart:TermLoanFacilityMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0000917520 us-gaap:StandbyLettersOfCreditMember iart:SeniorCreditFacilityMember 2021-12-31 0000917520 us-gaap:StandbyLettersOfCreditMember iart:SeniorCreditFacilityMember 2022-12-31 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-02-04 2020-02-04 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-12-09 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember us-gaap:CallOptionMember 2020-02-04 2020-02-04 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2022-12-31 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2021-01-01 2021-12-31 0000917520 iart:TwoThousandTwentyFiveSeniorConvertibleNotesMember us-gaap:ConvertibleDebtMember 2022-01-01 2022-12-31 0000917520 us-gaap:FairValueInputsLevel2Member 2022-12-31 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2022-12-31 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2021-12-31 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2022-12-31 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2021-12-31 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche3Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2022-12-31 0000917520 iart:InterestRateSwapDesignatedDecember132017Tranche3Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2021-12-31 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2022-12-31 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2021-12-31 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2022-12-31 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2021-12-31 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche3Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2022-12-31 0000917520 iart:InterestRateSwapDesignatedOctober102018Tranche3Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2021-12-31 0000917520 iart:InterestRateSwapDesignatedDecember182018Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2022-12-31 0000917520 iart:InterestRateSwapDesignatedDecember182018Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2021-12-31 0000917520 iart:InterestRateSwapDesignatedDecember182018Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2022-12-31 0000917520 iart:InterestRateSwapDesignatedDecember182018Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2021-12-31 0000917520 iart:InterestRateSwapDesignatedDecember152020Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2022-12-31 0000917520 iart:InterestRateSwapDesignatedDecember152020Tranche1Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2021-12-31 0000917520 iart:InterestRateSwapDesignatedDecember152020Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2022-12-31 0000917520 iart:InterestRateSwapDesignatedDecember152020Tranche2Member us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember iart:OneMonthUSDLIBORMember 2021-12-31 0000917520 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000917520 us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:ShortMember 2017-10-02 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:LongMember 2017-10-02 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:ShortMember 2022-09-26 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:ShortMember 2022-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember 2020-12-21 0000917520 us-gaap:CrossCurrencyInterestRateContractMember 2022-01-01 2022-12-31 0000917520 iart:CrossCurrencyInterestRateSwapContractTwoMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2022-12-31 0000917520 iart:CrossCurrencyInterestRateSwapContractTwoMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2021-12-31 0000917520 iart:CrossCurrencyInterestRateSwapContractTwoMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000917520 iart:CrossCurrencyInterestRateSwapContractTwoMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000917520 iart:CrossCurrencyInterestRateSwapContractTwoMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2022-12-31 0000917520 iart:CrossCurrencyInterestRateSwapContractTwoMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2021-12-31 0000917520 iart:CrossCurrencyInterestRateSwapContractThreeMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2022-12-31 0000917520 iart:CrossCurrencyInterestRateSwapContractThreeMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2021-12-31 0000917520 iart:CrossCurrencyInterestRateSwapContractThreeMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000917520 iart:CrossCurrencyInterestRateSwapContractThreeMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000917520 iart:CrossCurrencyInterestRateSwapContractThreeMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2022-12-31 0000917520 iart:CrossCurrencyInterestRateSwapContractThreeMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2021-12-31 0000917520 iart:CrossCurrencyInterestRateSwapContractOneMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2022-12-31 0000917520 iart:CrossCurrencyInterestRateSwapContractOneMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2021-12-31 0000917520 iart:CrossCurrencyInterestRateSwapContractOneMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000917520 iart:CrossCurrencyInterestRateSwapContractOneMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000917520 iart:CrossCurrencyInterestRateSwapContractOneMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2022-12-31 0000917520 iart:CrossCurrencyInterestRateSwapContractOneMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2021-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000917520 iart:CodmanMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:ShortMember 2022-10-03 0000917520 us-gaap:CrossCurrencyInterestRateContractMember 2022-10-03 2022-10-03 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-10-04 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2022-12-31 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2021-12-31 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2022-12-31 0000917520 iart:CrossCurrencyInterestRateContractOneMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2021-12-31 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2022-12-31 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2021-12-31 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2022-12-31 0000917520 iart:CrossCurrencyInterestRateContractTwoMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2021-12-31 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2022-12-31 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2021-12-31 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2022-12-31 0000917520 iart:CrossCurrencyInterestRateContractThreeMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2021-12-31 0000917520 iart:CrossCurrencyInterestRateContractFourMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2022-12-31 0000917520 iart:CrossCurrencyInterestRateContractFourMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2021-12-31 0000917520 iart:CrossCurrencyInterestRateContractFourMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000917520 iart:CrossCurrencyInterestRateContractFourMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000917520 iart:CrossCurrencyInterestRateContractFourMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2022-12-31 0000917520 iart:CrossCurrencyInterestRateContractFourMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2021-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-05-26 0000917520 us-gaap:CrossCurrencyInterestRateContractMember 2022-05-26 2022-05-26 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-05-26 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2021-09-30 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2021-09-30 2021-09-30 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000917520 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000917520 us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000917520 us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000917520 us-gaap:OtherAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000917520 us-gaap:OtherAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000917520 iart:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000917520 us-gaap:OtherLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2021-12-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2022-01-01 2022-12-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2022-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2021-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2021-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2022-01-01 2022-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2022-12-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-12-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-12-31 0000917520 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2021-01-01 2021-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherNonoperatingIncomeExpenseMember 2021-01-01 2021-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2020-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestIncomeMember 2021-01-01 2021-12-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000917520 us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember 2021-01-01 2021-12-31 0000917520 us-gaap:CrossCurrencyInterestRateContractMember 2022-12-31 0000917520 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2020-12-31 0000917520 us-gaap:CurrencySwapMember us-gaap:NondesignatedMember 2021-06-30 0000917520 us-gaap:CurrencySwapMember us-gaap:NondesignatedMember 2021-09-30 0000917520 us-gaap:ForeignExchangeForwardMember 2022-01-01 2022-12-31 0000917520 us-gaap:ForeignExchangeForwardMember 2021-01-01 2021-12-31 0000917520 us-gaap:CurrencySwapMember 2022-01-01 2022-12-31 0000917520 us-gaap:CurrencySwapMember 2021-01-01 2021-12-31 0000917520 iart:CodmanSpecialtySurgicalMember 2020-12-31 0000917520 iart:TissueTechnologiesMember 2020-12-31 0000917520 iart:ACellIncMember iart:CodmanSpecialtySurgicalMember 2021-01-01 2021-12-31 0000917520 iart:ACellIncMember iart:TissueTechnologiesMember 2021-01-01 2021-12-31 0000917520 iart:ACellIncMember 2021-01-01 2021-12-31 0000917520 iart:CodmanSpecialtySurgicalMember 2021-12-31 0000917520 iart:TissueTechnologiesMember 2021-12-31 0000917520 iart:SurgicalInnovationAssociatesIncMember iart:CodmanSpecialtySurgicalMember 2022-01-01 2022-12-31 0000917520 iart:SurgicalInnovationAssociatesIncMember iart:TissueTechnologiesMember 2022-01-01 2022-12-31 0000917520 iart:SurgicalInnovationAssociatesIncMember 2022-01-01 2022-12-31 0000917520 iart:CodmanSpecialtySurgicalMember 2022-12-31 0000917520 iart:TissueTechnologiesMember 2022-12-31 0000917520 iart:CompletedTechnologyMember 2022-01-01 2022-12-31 0000917520 iart:CompletedTechnologyMember 2022-12-31 0000917520 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-12-31 0000917520 us-gaap:CustomerRelationshipsMember 2022-12-31 0000917520 iart:TrademarksBrandNamesMember 2022-01-01 2022-12-31 0000917520 iart:TrademarksBrandNamesMember 2022-12-31 0000917520 us-gaap:TradeNamesMember 2022-12-31 0000917520 iart:SupplierRelationShipsMember 2022-01-01 2022-12-31 0000917520 iart:SupplierRelationShipsMember 2022-12-31 0000917520 iart:AllOtherMember 2022-01-01 2022-12-31 0000917520 iart:AllOtherMember 2022-12-31 0000917520 iart:CompletedTechnologyMember 2021-01-01 2021-12-31 0000917520 iart:CompletedTechnologyMember 2021-12-31 0000917520 us-gaap:CustomerRelationshipsMember 2021-01-01 2021-12-31 0000917520 us-gaap:CustomerRelationshipsMember 2021-12-31 0000917520 iart:TrademarksBrandNamesMember 2021-01-01 2021-12-31 0000917520 iart:TrademarksBrandNamesMember 2021-12-31 0000917520 us-gaap:TradeNamesMember 2021-12-31 0000917520 iart:SupplierRelationShipsMember 2021-01-01 2021-12-31 0000917520 iart:SupplierRelationShipsMember 2021-12-31 0000917520 iart:AllOtherMember 2021-01-01 2021-12-31 0000917520 iart:AllOtherMember 2021-12-31 0000917520 us-gaap:SubsequentEventMember 2023-01-26 0000917520 us-gaap:SubsequentEventMember 2023-01-26 2023-01-26 0000917520 2022-04-26 0000917520 2022-01-12 0000917520 2022-01-12 2022-01-12 0000917520 2022-03-24 0000917520 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0000917520 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0000917520 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0000917520 us-gaap:EmployeeStockMember 2022-12-31 0000917520 us-gaap:EmployeeStockMember 2022-01-01 2022-12-31 0000917520 us-gaap:EmployeeStockMember 2021-01-01 2021-12-31 0000917520 us-gaap:EmployeeStockMember 2020-01-01 2020-12-31 0000917520 iart:TwoThousandThreePlanMember 2010-05-01 2010-05-31 0000917520 iart:TwoThousandThreePlanMember 2017-05-01 2017-05-31 0000917520 iart:TwoThousandOnePlanMember 2022-12-31 0000917520 iart:TwoThousandPlanMember 2022-12-31 0000917520 iart:TwoThousandThreePlanMember 2022-12-31 0000917520 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000917520 srt:DirectorMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000917520 iart:EmployeeMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000917520 srt:MinimumMember iart:DirectorsandCertainExecutiveOfficersMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000917520 srt:MaximumMember iart:DirectorsandCertainExecutiveOfficersMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000917520 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0000917520 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000917520 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000917520 us-gaap:EmployeeStockOptionMember 2022-12-31 0000917520 us-gaap:RestrictedStockMember 2021-12-31 0000917520 iart:PerformanceStockandContractStockMember 2021-12-31 0000917520 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0000917520 iart:PerformanceStockandContractStockMember 2022-01-01 2022-12-31 0000917520 us-gaap:RestrictedStockMember 2022-12-31 0000917520 iart:PerformanceStockandContractStockMember 2022-12-31 0000917520 iart:RestrictedStockPerformanceStockAndContractStockMember 2022-01-01 2022-12-31 0000917520 iart:RestrictedStockPerformanceStockAndContractStockMember 2021-01-01 2021-12-31 0000917520 iart:RestrictedStockPerformanceStockAndContractStockMember 2020-01-01 2020-12-31 0000917520 us-gaap:PerformanceSharesMember 2022-12-31 0000917520 iart:RestrictedStockPerformanceStockAndContractStockMember 2022-12-31 0000917520 country:FR 2022-12-31 0000917520 country:DE 2022-12-31 0000917520 2019-05-01 2019-05-31 0000917520 srt:AffiliatedEntityMember 2021-01-01 2021-12-31 0000917520 srt:AffiliatedEntityMember 2022-01-01 2022-12-31 0000917520 us-gaap:BuildingMember 2022-12-31 0000917520 us-gaap:BuildingMember 2021-12-31 0000917520 us-gaap:VehiclesMember 2022-12-31 0000917520 us-gaap:VehiclesMember 2021-12-31 0000917520 iart:RelatedPartiesMember 2022-12-31 0000917520 iart:ThirdPartiesMember 2022-12-31 0000917520 iart:FiveYearOptionLeasePeriodOneMember srt:AffiliatedEntityMember 2022-01-01 2022-12-31 0000917520 iart:FiveYearLeasePeriodTwoMember srt:AffiliatedEntityMember 2022-01-01 2022-12-31 0000917520 iart:ExtremityOrthopedicsMember 2021-01-01 2021-12-31 0000917520 us-gaap:ForeignCountryMember us-gaap:SwissFederalTaxAdministrationFTAMember 2020-12-01 2020-12-31 0000917520 us-gaap:DomesticCountryMember 2022-12-31 0000917520 us-gaap:ForeignCountryMember 2022-12-31 0000917520 us-gaap:StateAndLocalJurisdictionMember 2022-12-31 0000917520 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2021-12-31 0000917520 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2021-01-01 2021-12-31 0000917520 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2022-12-31 0000917520 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2020-12-31 0000917520 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2020-01-01 2020-12-31 0000917520 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-12-31 0000917520 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-01-01 2019-12-31 0000917520 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0000917520 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0000917520 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000917520 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-12-31 0000917520 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-12-31 0000917520 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-12-31 0000917520 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0000917520 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0000917520 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000917520 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-12-31 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2021-12-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2021-12-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2021-12-31 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2021-12-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2021-12-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:SurgicalInnovationAssociatesIncMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2021-12-31 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2022-01-01 2022-12-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2022-01-01 2022-12-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2022-01-01 2022-12-31 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2022-01-01 2022-12-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2022-01-01 2022-12-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:SurgicalInnovationAssociatesIncMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2022-01-01 2022-12-31 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2022-12-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2022-12-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2022-12-31 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2022-12-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2022-12-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:SurgicalInnovationAssociatesIncMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2022-12-31 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2020-12-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2020-12-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2020-12-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2020-12-31 0000917520 us-gaap:OtherCurrentLiabilitiesMember iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2021-01-01 2021-12-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:ArkisBioSciencesInc.Member us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2021-01-01 2021-12-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2021-01-01 2021-12-31 0000917520 us-gaap:OtherNoncurrentLiabilitiesMember iart:ACellMember us-gaap:FairValueInputsLevel3Member iart:ContingentConsiderationLiabilityMember 2021-01-01 2021-12-31 0000917520 iart:DermaSciencesMember iart:BioDEarnoutPaymentsandMedihoneyEarnoutPaymentsMember 2022-01-01 2022-12-31 0000917520 iart:DermaSciencesMember 2022-12-31 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0000917520 iart:DermaSciencesMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0000917520 iart:ArkisBioSciencesInc.Member 2019-07-29 0000917520 iart:ArkisBioSciencesInc.Member iart:MilestonePaymentOneMember 2019-07-29 0000917520 iart:ArkisBioSciencesInc.Member iart:MilestonePaymentTwoMember 2019-07-29 0000917520 iart:ArkisBioSciencesInc.Member 2022-12-31 0000917520 us-gaap:OperatingSegmentsMember iart:CodmanSpecialtySurgicalMember 2022-01-01 2022-12-31 0000917520 us-gaap:OperatingSegmentsMember iart:CodmanSpecialtySurgicalMember 2021-01-01 2021-12-31 0000917520 us-gaap:OperatingSegmentsMember iart:CodmanSpecialtySurgicalMember 2020-01-01 2020-12-31 0000917520 us-gaap:OperatingSegmentsMember iart:TissueTechnologiesMember 2022-01-01 2022-12-31 0000917520 us-gaap:OperatingSegmentsMember iart:TissueTechnologiesMember 2021-01-01 2021-12-31 0000917520 us-gaap:OperatingSegmentsMember iart:TissueTechnologiesMember 2020-01-01 2020-12-31 0000917520 us-gaap:OperatingSegmentsMember 2022-01-01 2022-12-31 0000917520 us-gaap:OperatingSegmentsMember 2021-01-01 2021-12-31 0000917520 us-gaap:OperatingSegmentsMember 2020-01-01 2020-12-31 0000917520 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-12-31 0000917520 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-12-31 0000917520 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-12-31 0000917520 country:US 2022-01-01 2022-12-31 0000917520 srt:EuropeMember 2022-01-01 2022-12-31 0000917520 srt:AsiaPacificMember 2022-01-01 2022-12-31 0000917520 iart:RestOfWorldMember 2022-01-01 2022-12-31 0000917520 country:US 2021-01-01 2021-12-31 0000917520 srt:EuropeMember 2021-01-01 2021-12-31 0000917520 srt:AsiaPacificMember 2021-01-01 2021-12-31 0000917520 iart:RestOfWorldMember 2021-01-01 2021-12-31 0000917520 country:US 2020-01-01 2020-12-31 0000917520 srt:EuropeMember 2020-01-01 2020-12-31 0000917520 srt:AsiaPacificMember 2020-01-01 2020-12-31 0000917520 iart:RestOfWorldMember 2020-01-01 2020-12-31 0000917520 country:US 2022-12-31 0000917520 srt:EuropeMember 2022-12-31 0000917520 srt:AsiaPacificMember 2022-12-31 0000917520 iart:RestOfWorldMember 2022-12-31 0000917520 country:US 2021-12-31 0000917520 srt:EuropeMember 2021-12-31 0000917520 srt:AsiaPacificMember 2021-12-31 0000917520 iart:RestOfWorldMember 2021-12-31 iso4217:USD shares iso4217:USD shares iart:Segment iart:reporting_unit pure iart:Customer iart:contingentLiability iso4217:CHF iso4217:EUR iart:renewal_option iart:liability iart:product false 2022 FY 0000917520 http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201613Member http://integralife.com/20221231#AccountingStandardUpdate202006Member P1Y P1Y P1Y P1Y P1Y P1Y 0.0135739 P6Y P10Y 0 0 0 0 0 0 10-K true 2022-12-31 --12-31 false 000-26224 INTEGRA LIFESCIENCES HOLDINGS CORP DE 51-0317849 1100 Campus Road 08540 Princeton NJ 609 275-0500 Common Stock, Par Value $.01 Per Share IART NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false 3916000000 81636066 Certain portions of the registrant’s definitive proxy statement relating to its scheduled May 12, 2023 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission, are incorporated by reference in Part III of this Annual Report on Form 10-K. 238000 PricewaterhouseCoopers LLP Florham Park, New Jersey 1557666000 1542448000 1371868000 587355000 597808000 520834000 101193000 93051000 77381000 616316000 637445000 594526000 13882000 16914000 27757000 1318746000 1345218000 1220498000 238920000 197230000 151370000 11917000 6737000 9297000 49594000 50395000 71581000 644000 41798000 0 12007000 19307000 4434000 213894000 214677000 93520000 33344000 45602000 -40372000 180550000 169075000 133892000 2.18 2.00 1.58 2.16 1.98 1.57 82997000 84698000 84650000 83516000 85485000 85228000 180550000 169075000 133892000 -17807000 -17362000 53363000 104351000 68192000 -96837000 18859000 17024000 -24442000 85492000 51168000 -72395000 7429000 6998000 4604000 75114000 40804000 -14428000 19694000 11900000 -16771000 55420000 28904000 2343000 235970000 197979000 136235000 456661000 513448000 4304000 4735000 263465000 231831000 324583000 317386000 116789000 91051000 1161498000 1153716000 311302000 311703000 148284000 84543000 1126609000 1145573000 1038881000 1013458000 45994000 56950000 57190000 16440000 3889758000 3782383000 38125000 45000000 14624000 14775000 102100000 61837000 7253000 5295000 78771000 92656000 80033000 120458000 320906000 340021000 733149000 824257000 104700000 112500000 567341000 564426000 157420000 90329000 63338000 45788000 138501000 120258000 2085355000 2097579000 0 0 15000000 15000000 0 0 0 0 0.01 0.01 240000000 240000000 90477000 89600000 905000 896000 1276977000 1264943000 6823000 4899000 362862000 234448000 10265000 -45155000 879118000 698568000 1804403000 1684804000 3889758000 3782383000 180550000 169075000 133892000 118299000 119836000 116031000 0 0 519000 0 2754000 0 -4585000 -2755000 -64138000 27725000 36210000 19590000 6845000 7030000 12076000 2816000 3834000 2955000 0 0 15415000 6813000 -2240000 -7855000 644000 41798000 0 -20304000 -2162000 951000 33905000 -7265000 -52105000 29124000 -5374000 48348000 -8612000 21143000 -1632000 2182000 -7875000 -13735000 17343000 32874000 -57512000 4274000 28000 -37000 -4438000 -14110000 -2889000 264469000 312427000 203832000 42343000 48022000 38890000 23960000 190468000 0 4742000 58000 25000000 51509000 303910000 0 11145000 3000 3657000 -4909000 -76000 7840000 -58580000 -161443000 -68073000 40750000 25500000 171500000 148550000 125500000 441000000 0 0 0 0 104248000 104248000 0 0 0 0 575000000 575000000 0 0 44563000 0 249000 24347000 125000000 0 100000000 5465000 6824000 5232000 24618000 4801000 5075000 -251953000 -98226000 121625000 -10723000 -9476000 13871000 -56787000 43282000 271255000 513448000 470166000 198911000 456661000 513448000 470166000 88735000 887000 2865000 -119943000 1213620000 -76402000 398574000 1416736000 133892000 133892000 2343000 2343000 13000 694000 694000 503000 2000 11000 526000 -1066000 -538000 4000 19397000 19401000 42539000 42539000 2060000 115724000 -15724000 100000000 -200000 -200000 89251000 893000 4914000 -235141000 1290908000 -74059000 532266000 1514867000 169075000 169075000 28904000 28904000 18000 1127000 1127000 331000 1000 15000 693000 201000 895000 2000 35981000 35983000 -63274000 -2773000 -66047000 89600000 896000 4899000 -234448000 1264943000 -45155000 698568000 1684804000 180550000 180550000 55420000 55420000 17000 1078000 1078000 859000 7000 14000 738000 -20974000 -20229000 2000 27778000 27780000 1938000 129152000 -4152000 125000000 90476000 905000 6823000 -362862000 1276977000 10265000 879118000 1804403000 BUSINESSIntegra LifeSciences Holdings Corporation (the “Company”) was incorporated in Delaware in 1989. The Company is a worldwide leader in medical technology. The Company was founded with the acquisition of an engineered collagen technology platform used to repair and regenerate tissue. Since then, Integra has developed numerous product lines from this technology for applications ranging from burn and deep tissue wounds to the repair of dura mater in the brain, as well as nerves and tendons. The Company has expanded its base regenerative technology business to include surgical instruments, neurosurgical products and advanced wound care through global acquisitions and product development to meet the evolving needs of its customers and enhance patient care. The Company sells its products directly through various sales forces and through a variety of other distribution channels. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BASIS OF PRESENTATION </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements and the accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America and conform to Regulation S-X under the Securities Exchange Act of 1934, as amended. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRINCIPLES OF CONSOLIDATION </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. See Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions and Divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for details of new subsidiaries included in the consolidation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">USE OF ESTIMATES </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements is in conformity with generally accepted accounting principles in the United States ("GAAP") which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company continues to navigate the novel coronavirus ("COVID-19") pandemic and recent variants of the virus</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as the adverse impacts to global economic conditions, supply chain and the operations, there may be impact to future estimates including, but not limited to, inventory valuations, fair value measurements, goodwill and long-lived asset impairments, the effectiveness of the Company’s hedging instruments, deferred tax valuation allowances, and allowances for doubtful accounts receivable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CASH AND CASH EQUIVALENTS </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all short-term, highly liquid investments purchased with original maturities of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TRADE ACCOUNTS RECEIVABLE AND ALLOWANCES FOR DOUBTFUL ACCOUNTS RECEIVABLE </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company grants credit to customers in the normal course of business, but generally does not require collateral or any other security to support its receivables.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the collectability of accounts receivable based on a combination of factors. The Company recognizes a provision for doubtful accounts that reflects the Company’s estimate of expected credit losses for trade accounts receivable. In circumstances where a specific customer is unable to meet its financial obligations to the Company, a provision to the allowances for doubtful accounts is recorded against amounts due to reduce the net recognized receivable to the amount that is reasonably expected to be collected. For all other customers, the Company evaluates measurement of all expected credit losses for trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company adopted this guidance on January 1, 2020 using a modified retrospective transition method which requires a cumulative-effect adjustment to the opening balance of retained earnings to be recognized on the date of adoption with no change to financial results reported in prior periods. The cumulative-effect adjustment recorded on January 1, 2020 was not material. The adoption of this ASU did not have a significant impact on the Company's consolidated financial statements and related disclosures. The Company's exposure to credit losses may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the COVID-19 pandemic and recent variants of the virus, and other customer-specific factors. Although the Company has historically not experienced significant credit losses, it is possible that there could be an adverse impact due to customer and governmental responses to the COVID-19 pandemic.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions to the allowances for doubtful accounts are recorded to selling, general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered. Provision for doubtful accounts, net of recoveries, associated with accounts receivable, included in selling, general and administrative expense, was charges of $0.2 million for the year ended December 31, 2022, recoveries of $1.1 million, and charges of $3.6 million for the years ended December 31, 2021 and 2020, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The below table shows the rollforward of the allowance for doubtful accounts for the years ended December 31, 2022, 2021 and 2020:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charged to Costs and Expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at End of Period</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(669)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,059)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(986)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,635 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,499)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,439 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Deductions primarily relates to allowance for doubtful accounts written off during the year, net of recoveries and other adjustments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INVENTORIES</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, consisting of purchased materials, direct labor and manufacturing overhead, are stated at the lower of cost, the value determined by the first-in, first-out method, or net realizable value. Inventories consisted of the following: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,088 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,528 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,323 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,897 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,583 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,386 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each balance sheet date, the Company evaluates inventories for excess quantities, obsolescence or shelf life expiration. This evaluation includes analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, a review of the shelf life expiration dates for products, as well as the feasibility of reworking or using excess or obsolete products or components in the production or assembly of other products that are not obsolete or for which there are not excess quantities in inventory. To the extent that management determines there are excess or obsolete inventory or quantities with a shelf life that is too near its expiration for the Company to reasonably expect that it can sell those products prior to their expiration, the Company adjusts the carrying value to estimated net realizable value. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes inventory costs associated with certain products prior to regulatory approval, based on management's judgment of probable economic benefit. The Company could be required to expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or delay of approval by necessary regulatory bodies or a decision by management to discontinue the related development program. No such amounts were capitalized at December 31, 2022 or 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PROPERTY, PLANT AND EQUIPMENT </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at historical cost less accumulated depreciation and any impairment charges. The Company provides for depreciation using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the lesser of the lease term or the useful life. The cost of major additions and improvements is capitalized, while maintenance and repair costs that do not improve or extend the lives of the respective assets are charged to operations as incurred. The cost of computer software developed or obtained for internal use is accounted for in accordance with the Accounting Standards Codification 350-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal-Use Software.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment balances and corresponding lives were as follows: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,512 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,032 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,292 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,495 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and production equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Demonstration equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,792 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Information systems and hardware</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,706 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,921 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641,031 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329,729)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(314,874)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,302 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,703 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense associated with property, plant and equipmen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t was $40.1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $39.4 million, and $42.1 million for the years ended December 31, 2022, 2021 and 2020, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CAPITALIZED INTEREST</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest cost on capital projects, including facilities build-out and internal use software, is capitalized and included in the cost of the project. Capitalization commences with the first expenditure for the project and continues until the project is substantially complete and ready for its intended use. When no debt is incurred specifically for a project, interest is capitalized on project expenditures using the weighted average cost of the Company's outstanding borrowings. For the years ended December 31, 2022 and 2021, respectively, the Company capitalized $1.4 million and $1.2 million of interest expense into property, plant and equipment. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ACQUISITIONS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The Company accounts for the acquisition of a business in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC Topic 805"). Amounts paid to acquire a business are allocated to the assets acquired and liabilities assumed based on their fair values at the date of acquisition. Any excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs and costs to restructure the acquired company are expensed as incurred.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration is recorded at fair value as measured on the date of acquisition. The value recorded is based on estimates of future financial projections under various potential scenarios using either a Monte Carlo simulation or the probability-weighted income approach derived from revenue estimates and probability assessment with respect to the likelihood of achieving contingent obligations. Contingent payments related to acquisitions consist of development, regulatory, and commercial milestone payments, in addition to sales-based payments, and are valued using discounted cash flow techniques. Each quarter until such contingent amounts are earned, the fair value of the liability is remeasured at each reporting period and adjusted as a component of operating expenses based on changes to the underlying assumptions. The change in the fair value of sales-based payments is based upon future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payment charges. The estimates used to determine the fair value of the contingent consideration liability are subject to significant judgment and actual results are likely to differ from the amounts originally recorded.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determi</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nes the fair value of acquired intangible assets based on detailed valuations that use certain information and assumptions provided by management. The Company allocates any excess purchase price over the fair value of the net tangible and intangible assets acquired to goodwill. Determining the fair value of these intangible assets acquired as part of a business combination requires the Company to make significant estimates. These estimates include the amount and timing of projected future cash flows, the discount rate used to discount those cash flows to present value, the assessment of the asset’s life cycle, and the consideration of legal, technical, regulatory, economic, and competitive risks. The fair value assigned to other intangible assets is determined by estimating the future cash flows of each project or technology and discounting the net cash flows back to their present values. The discount rate used is determined at the time of measurement in accordance with accepted valuation methodologies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;D has an alternative future use. The Company uses the income approach to determine the fair value of developed technology and IPR&amp;D acquired in a business combination. This approach determines fair value by estimating the after-tax cash flows attributable to the respective asset over its useful life and then discounting these after-tax cash flows back to a present value. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each product including net revenues, cost of sales, R&amp;D costs, selling and marketing costs, the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, and competitive trends impacting the asset and each cash flow stream. The Company also uses the income approach, as described above, to determine the estimated fair value of certain other identifiable intangible assets including customer relationships, trade names and business licenses. Customer relationships represent established relationships with customers, which provide a ready channel for the sale of additional products and services. Trade names represent acquired company and product names.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D acquired in a business combination is capitalized as an indefinite-lived intangible asset. Development costs incurred after the acquisition are expensed as incurred. Upon receipt of regulatory approval, the indefinite-lived intangible asset is then accounted for as a finite-lived intangible asset and amortized on a straight-line basis or accelerated basis, as appropriate, over its estimated useful life. If the research and development project is subsequently abandoned, the indefinite-lived intangible asset is charged to expense. IPR&amp;D acquired outside of a business combination is expensed immediately.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the uncertainty associated with research and development projects, there is risk that actual results will differ materially from the original cash flow projections and that the research and development project will result in a successful commercial product. The risks associated with achieving commercialization include, but are not limited to, delay or failure to obtain regulatory approvals to conduct clinical trials, delay or failure to obtain required market clearances, delays or issues with patent</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issuance, or validity and litigation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;D with no alternative future use is charged to expense at the acquisition date. Payments that would be recognized as contingent consideration in a business combination are expensed when probable in an asset acquisition. Refer to Note 4, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> and Divestitures</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for more information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GOODWILL AND OTHER INTANGIBLE ASSETS </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the cost over the fair value of net assets of acquired businesses is recorded as goodwill. Goodwill is not subject to amortization but is reviewed for impairment at the reporting unit level annually, or more frequently if impairment indicators arise. The Company's assessment of the recoverability of goodwill is based upon a comparison of the carrying value of goodwill with its estimated fair value. The Company reviews goodwill for impairment in the third quarter every year in accordance with ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC Topic 350") and whenever events or changes in circumstances indicate the carrying value of goodwill may not be recoverable. Refer to Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other Intangibles</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two reportable segments with three underlying reporting units. Refer to Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment and Geographic Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information on reportable segments. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other intangible assets include patents, trademarks, purchased technology, and supplier and customer relationships. Identifiable intangible assets are initially recorded at fair market value at the time of acquisition generally using an income or cost approach. The Company capitalizes costs incurred to renew or extend the term of recognized intangible assets and amortizes those costs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">over their expected useful lives.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests intangible assets with indefinite lives for impairment annually in the third quarter in accordance with ASC Topic 350. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of an indefinite lived intangible asset below its carrying amount. The Company tests for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of the intangible asset is less than its carrying amount. The Company may elect to bypass this qualitative evaluation and perform a quantitative test. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product rights and other definite-lived intangible assets are tested periodically for impairment in accordance with ASC 350 Topic when events or changes in circumstances indicate that an asset's carrying value may not be recoverable. The impairment testing involves comparing the carrying amount of the asset or asset group to the forecasted undiscounted future cash flows. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and impairment exists. An impairment loss is measured as the excess of the asset's carrying value over its fair value, calculated using discounted future cash flows. The computed impairment loss is recognized in the period that the impairment occurs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LONG-LIVED ASSETS </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets held and used by the Company, including property, plant and equipment, intangible assets, and leases are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets to be held and used, a recoverability test is performed using projected undiscounted net cash flows applicable to the long-lived assets. If an impairment exists, the amount of such impairment is calculated based on the estimated fair value of the asset. Impairments to long-lived assets to be disposed of are recorded based upon the difference between the carrying value and the fair value of the applicable assets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INTEGRA FOUNDATION </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may periodically make contributions to the Integra Foundation, Inc. The Integra Foundation was incorporated in 2002 exclusively for charitable, educational, and scientific purposes and qualifies under IRC 501(c)(3) as an exempt private foundation. Under its charter, the Integra Foundation engages in activities that promote health, the diagnosis and treatment of disease, and the development of medical science through grants, contributions and other appropriate means. The Integra Foundation is a separate legal entity and is not a subsidiary of the Company; therefore, its results are not included in these consolidated financial statements. The Company contributed $0.0 million, $1.2 million and $0.8 million to the Integra Foundation during the years ended December 31, 2022, 2021 and 2020, respectively. These contributions were recorded in selling, general, and administrative expense. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DERIVATIVES </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company develops, manufactures, and sells medical devices globally and its earnings and cash flows are exposed to market risk from changes in interest rates and currency exchange rates. The Company addresses these risks through a risk management program that includes the use of derivative financial instruments and operates the program pursuant to documented corporate risk management policies. All derivative financial instruments are recognized in the financial statements at fair value in accordance with the authoritative guidance. Under the guidance, for those instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation, based on the exposure being hedged. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, further, on the type of hedging relationship. The Company's derivative instruments do not subject its earnings or cash flows to material risk, and gains and losses on these derivatives generally offset losses and gains on the item being hedged. The Company has not entered into derivative transactions for speculative purposes. From time to time, the Company may enter into derivatives that are not designated as hedging instruments in order to protect itself from currency volatility due to intercompany balances. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivative instruments are recognized at the fair values as either assets or liabilities on the balance sheet. The Company determines the fair value of its derivative instruments using the framework prescribed by the authoritative guidance, by considering the estimated amount the Company would receive to sell or transfer these instruments at the reporting date and by taking into account expected forward interest rates, currency exchange rates, the creditworthiness of the counterparty for assets, and its creditworthiness for liabilities. In certain instances, the Company utilizes a discounted cash flow model to measure fair value. Generally, the Company uses inputs that include quoted prices for similar assets or liabilities in active markets, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The Company has classified all of its derivative assets and liabilities within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of its derivative instruments. The Company classifies derivatives designated as hedges in the same category as the item being hedged for cash flow presentation purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into foreign currency forward and foreign currency swap contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into other income, net, on the consolidated financial statements. Refer to Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FOREIGN CURRENCY </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All assets and liabilities of foreign subsidiaries which have a functional currency other than the U.S. dollar are translated at the rate of exchange at year-end, while elements of the income statement are translated at the average exchange rates in effect during the year. The net effect of these translation adjustments is shown as a component of accumulated other comprehensive income (loss). These currency translation adjustments are not currently adjusted for income taxes as they relate to permanent investments in non-U.S. subsidiaries. Foreign currency transaction net losses of $3.3 million, net gains of less than $0.1 million, and net losses $1.6 million are reported in other income, net in the statements of operations, for the year ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INCOME TAXES </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for by using the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period when the change is enacted. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position. Reserves are established for positions that don't meet this recognition threshold. The reserve is measured as the largest amount of benefit determined on a cumulative probability basis that the Company believes is more likely than not to be realized upon ultimate settlement of the position. These reserves are classified as long-term liabilities in the consolidated balance sheets of the Company, unless the reserves are expected to be paid in cash during the next twelve months, in which case they are classified as current liabilities. The Company also records interest and penalties accrued in relation to uncertain tax benefits as a component of income tax expense. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company believes it has identified all reasonable exposures and the reserve it has established is appropriate under the circumstances, it is possible that additional exposures exist and that exposures may be settled at amounts different than the amounts reserved. It is also possible that changes in facts and circumstances could cause the Company to either materially increase or reduce the carrying amount of its tax reserve. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to indefinitely reinvest substantially all of its foreign earnings unless there is a manner under which to remit the earnings without a material tax cost. The current provisional analysis indicates that the Company has sufficient U.S. liquidity, including borrowing capacity, to fund foreseeable U.S. cash needs without requiring the repatriation of foreign cash. One time or unusual items that may impact the ability or intent to keep the foreign earnings and cash indefinitely reinvested include significant U.S. acquisitions, loans from a foreign subsidiary and changes in tax laws. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">REVENUE RECOGNITION </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue, net, includes product sales, product royalties and other revenues, such as fees received from services. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For products shipped with FOB shipping point terms, the control of the product passes to the customer at the time of shipment. For shipments in which the control of the product is transferred when the customer receives the product, the Company recognizes revenue upon receipt by the customer. Certain products that the Company produces for private label customers have no alternative use and the Company has a right of payment for performance to date. Revenues from those products are recognized over the period that the Company manufactures these products, which is typically one month to three months. The Company uses the input method to measure the manufacturing activities completed to date, which depicts the progress of the Company's performance obligation of transferring control of goods being manufactured for private label customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and distributors, and also from inventory physically held by field sales representatives. For these types of products sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Revenues from sale of products and services are evidenced by either a contract with the customer or a valid purchase order and an invoice which includes all relevant terms of sale. For product sales, invoices are generally issued upon the transfer of control (or upon the completion of the manufacturing in the case of the private label transactions recognized over time) and are typically payable 30 days after the invoice date. The Company performs a review of each specific customer's creditworthiness and ability to pay prior to acceptance as a customer. Further, the Company performs periodic reviews of its customers' creditworthiness prospectively. Refer to Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Revenue From Contracts With Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for more information. The Company also maintains a provision for estimated returns and allowances in the same period that the related revenue is recorded. This reserve is based upon an analysis of actual credit memos issued for pricing issues or returned goods over an extended period, as well as assumptions about outstanding accounts receivable and judgment in interpreting the data.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RESEARCH AND DEVELOPMENT </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs, including salaries, depreciation, consultant and other external fees, and facility costs directly attributable to research and development activities, are expensed in the period in which they are incurred. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EMPLOYEE TERMINATION BENEFITS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have a written severance plan, and it does not offer similar termination benefits to affected employees in all restructuring initiatives. Accordingly, in situations where minimum statutory termination benefits must be paid to the affected employees, the Company records employee severance costs associated with these restructuring activities in accordance with the authoritative guidance for non-retirement post-employment benefits. Charges associated with these activities are recorded when the payment of benefits is probable and can be reasonably estimated. In all other situations where the Company pays out termination benefits, including supplemental benefits paid in excess of statutory minimum amounts and benefits offered to affected employees based on management's discretion, the Company records these termination costs in accordance with the authoritative guidance for ASC Topic 712 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Nonretirement Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ASC Topic 420 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">One-time Employee Termination Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of the recognition of charges for employee severance costs other than minimum statutory benefits depends on whether the affected employees are required to render service beyond their legal notification period in order to receive the benefits. If affected employees are required to render service beyond their legal notification period, charges are recognized over the future service period. Otherwise, charges are recognized when management has approved a specific plan and employee communication requirements have been met. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred employee termination costs on restructuring activities associated with a closure of a manufacturing facility in France and other reorganization projects in the consolidated statement of operations for the year ended December 31, 2022. In 2021, the Company incurred employee termination costs on restructuring activities associated with the closure of a manufacturing facility in France. The following table summarizes our restructuring related accrual balances included within accrued expenses and other current liabilities in the consolidated balance sheet for the year ended December 31, 2022 and 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.163%"><tr><td style="width:1.0%"/><td style="width:47.120%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.511%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.045%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, beginning of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,372 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of Goods Sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, end of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,107 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,226 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the accrual balance as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of December 31, 2022 is $2.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to the closure o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f a manufacturing facility located in France, and other reorganization projects of $3.1M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the accrual balance as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of December 31, 2021 is $10.2 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the closure o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f the manufacturing facility located in France. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">STOCK-BASED COMPENSATION </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Relevant authoritative guidance requires companies to recognize the expense related to the fair value of their stock-based compensation awards. Stock-based compensation expense for stock option awards are based on the grant date fair value using the binomial distribution model. The Company recognizes compensation expense for stock option awards, restricted stock awards, performance stock awards and contract stock awards over the requisite service period of the award. All excess tax benefits and taxes and tax deficiencies from stock-based compensation are included in provision for income taxes in the consolidated statement of operations. Refer to Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PENSION BENEFITS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains defined benefit pension plans that cover certain employees in France, Japan, Germany and Switzerland. Various factors are considered in determining the pension liability, including the number of employees expected to be paid their salary levels and years of service, the expected return on plan assets, the discount rate used to determine the benefit obligations, the timing of benefit payments and other actuarial assumptions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retirement benefit plan assumptions are reassessed on an annual basis or more frequently if changes in circumstances indicate a re-evaluation of assumptions are required. The key benefit plan assumptions are the discount rate and expected rate of return on plan assets. The discount rate is based on average rates on bonds that matched the expected cash outflows of the benefit plans. The expected rate of return is based on historical and expected returns on the various categories of plan assets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the corridor approach in measuring the amount of net periodic benefit pension cost to recognize each period. The corridor approach defers all actuarial gains and losses resulting from variances between actual results and actuarial assumptions. Those unrecognized gains and losses are amortized when the net gains and losses exceed 10% of the greater of the market-related value of plan assets or the projected benefit obligation at the beginning of the year. The amount in excess of the corridor is amortized over the average remaining service period to retirement date of active plan participants.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Compensation Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a deferred compensation plan in which certain employees of the Company may defer the payment and taxation of up to 75% of their base salary and up to 100% of bonus amounts and other eligible cash compensation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This deferred compensation is invested in funds offered under the Plan and is valued based on Level 1 measurements in the fair value hierarchy. The purpose of the plan is to retain key employees by providing them with an opportunity to defer a portion of their compensation as elected by the participant in accordance with the plan. Any amounts set aside to defray the liabilities assumed by the Company will remain the general assets of the Company until such amounts are distributed to the participants. Assets of the Company's deferred compensation plan are included in Other current assets and recorded at fair value based on their quoted market prices. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CONCENTRATION OF CREDIT RISK </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, which are held at major financial institutions, investment-grade marketable debt securities and trade receivables. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's products are sold on an uncollateralized basis and on credit terms based upon a credit risk assessment of each customer. A portion of the Company's trade receivables to customers outside the United States includes sales to foreign distributors, who then sell to government owned or supported healthcare systems. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the Company's customers accounted for 10% or more of the consolidated net sales during the years ended December 31, 2022, 2021 and 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RECENT ACCOUNTING PRONOUNCEMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Simplifying the Accounting for Income Taxes, intended to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. This guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. The Company adopted ASU 2019-12 as of January 1, 2021. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 848), and subsequent amendment to the initial guidance: ASU 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 848): Scope (collectively, “Topic 848”). Topic 848 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference London Inter-Bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. The guidance generally can be applied from March 12, 2020 through December 31, 2022. On October 5, 2022, the FASB approved an extension of the sunset date of the reference rate reform from December 31, 2022 to December 31, 2024, past LIBOR’s end date. The Company currently has contracts that are indexed to LIBOR and are continuing to evaluate the scope of impacted contracts and potential risk. The Company expects all LIBOR-based contracts to be replaced by the Secured Overnight Financing Rate (“SOFR”), which is calculated based on overnight transactions under repurchase agreements backed by Treasury securities. The Alternative Reference Rates Committee, a group of private-market participants convened by the U.S. Federal Reserve Board and the New York Federal Reserve, has recommended the use of SOFR as a more robust reference rate alternative to LIBOR. The use of SOFR as a substitute for LIBOR is, however, voluntary and may not be suitable for all market participants. There can be no assurance that the replacement rate will be economically equivalent to LIBOR, which could result in higher interest rates for us under our debt facilities. There is no guarantee that a transition from LIBOR to SOFR will not result in financial market disruptions, significant increases in benchmark rates, or our borrowing costs, any of which could have an adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt- Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40):Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The guidance simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify. The guidance also simplifies the diluted net income per share calculation in certain areas. The ASU will be effective for annual and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years using either the modified retrospective or full retrospective method. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As detailed in Note 5,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on February 4, 2020, the Company issued $575.0 million aggregate principal amount of its 0.5% Convertible Senior Notes due 2025 (the "2025 Notes"). The 2025 Notes are subject to the guidance included in ASU 2020-06. The Company adopted this guidance on January 1, 2021 using the modified retrospective approach which resulted in a cumulative-effect adjustment that increased (decreased) the following consolidated balance sheet accounts:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.518%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ADJUSTMENT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CONSOLIDATED BALANCE SHEET CLASSIFICATION</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AMOUNT<br/> (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax impact of cumulative-effect adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.6)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount reclassification</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term convertible securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity issuance costs reclassification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term convertible securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount amortization and equity costs reclassification, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained Earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net impact of cumulative-effect adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2020, the Company made an irrevocable election under the indenture to require the principal portion of its 2025 Notes to be settled in cash and any excess in shares. Following the irrevocable notice, only the amounts settled in excess of the principal will be considered in diluted earnings per share under the “if-converted” method. Upon adoption of ASU 2020-06, the Company’s 2025 Notes were reflected entirely as a liability since the embedded conversion feature will no longer be separately presented within stockholders’ equity. Additionally, from January 1, 2021, the Company is no longer incurring non-cash interest expense for the amortization of debt discount.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU 2020-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which updates various codification topics by clarifying or improving disclosure requirements to align with the regulations of the U.S. Securities and Exchange Commission (the "SEC") . The ASU has been effective for the Company for annual and interim periods beginning after January 1, 2021. The Company adopted this standard on the January 1, 2021. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU 2021-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which provides guidance to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The amendment currently has no impact to the Company as the effect will largely depend on the terms of written call options or financings issued or modified in the future. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no other recently issued accounting pronouncements that are expected to have any significant effect on the Company's financial position, results of operations or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for interest during the years ended December 31, 2022, 2021 and 2020 was $42.2 million (net of $1.4 million that was capitalized into construction in progress), $43.2 million (net of $1.2 million that was capitalized into construction in progress) and $47.3 million (net of $2.3 million that was capitalized into construction in progress), respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for income taxes, net of refunds, for the years ended December 31, 2022, 2021 and 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $35.9 million, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$49.5 million and $29.8 million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NON-CASH INVESTING AND FINANCING ACTIVITIES</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment purchases included in liabilities at December 31, 2022, 2021 and 2020 were $10.5 million, $4.7 million and $1.6 million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2021, the Company achieved its final developmental milestone which triggered a $5.0 million obligation to be paid to former shareholders of Rebound Therapeutics Corporation ("Rebound"). The Company recorded $5.0 million as an intangible asset in the consolidated balance sheet upon achieving the milestone. The remaining obligation was included in accrued liabilities at December 31, 2021 in the consolidated balance sheets. The milestone was fully paid in 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020, the Company achieved another developmental milestone which triggered a $20.0 million obligation to be paid to the former shareholders of Rebound. The Company recorded $20.0 million as an intangible asset in the consolidated balance sheet upon achieving the milestone. The milestone was paid during the fourth quarter of 2020.</span></div> BASIS OF PRESENTATION These financial statements and the accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America and conform to Regulation S-X under the Securities Exchange Act of 1934, as amended. <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRINCIPLES OF CONSOLIDATION </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. See Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions and Divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for details of new subsidiaries included in the consolidation.</span></div> USE OF ESTIMATES The preparation of consolidated financial statements is in conformity with generally accepted accounting principles in the United States ("GAAP") which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of derivative instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates. <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CASH AND CASH EQUIVALENTS </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all short-term, highly liquid investments purchased with original maturities of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TRADE ACCOUNTS RECEIVABLE AND ALLOWANCES FOR DOUBTFUL ACCOUNTS RECEIVABLE </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company grants credit to customers in the normal course of business, but generally does not require collateral or any other security to support its receivables.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the collectability of accounts receivable based on a combination of factors. The Company recognizes a provision for doubtful accounts that reflects the Company’s estimate of expected credit losses for trade accounts receivable. In circumstances where a specific customer is unable to meet its financial obligations to the Company, a provision to the allowances for doubtful accounts is recorded against amounts due to reduce the net recognized receivable to the amount that is reasonably expected to be collected. For all other customers, the Company evaluates measurement of all expected credit losses for trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company adopted this guidance on January 1, 2020 using a modified retrospective transition method which requires a cumulative-effect adjustment to the opening balance of retained earnings to be recognized on the date of adoption with no change to financial results reported in prior periods. The cumulative-effect adjustment recorded on January 1, 2020 was not material. The adoption of this ASU did not have a significant impact on the Company's consolidated financial statements and related disclosures. The Company's exposure to credit losses may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the COVID-19 pandemic and recent variants of the virus, and other customer-specific factors. Although the Company has historically not experienced significant credit losses, it is possible that there could be an adverse impact due to customer and governmental responses to the COVID-19 pandemic.</span>Provisions to the allowances for doubtful accounts are recorded to selling, general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered. 200000 -1100000 3600000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The below table shows the rollforward of the allowance for doubtful accounts for the years ended December 31, 2022, 2021 and 2020:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charged to Costs and Expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at End of Period</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(669)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,059)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(986)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,635 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,499)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,439 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Deductions primarily relates to allowance for doubtful accounts written off during the year, net of recoveries and other adjustments.</span></div> 4735000 238000 0 669000 4304000 6439000 -1059000 341000 -986000 4735000 4303000 3635000 0 1499000 6439000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INVENTORIES</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, consisting of purchased materials, direct labor and manufacturing overhead, are stated at the lower of cost, the value determined by the first-in, first-out method, or net realizable value. Inventories consisted of the following: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,088 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,528 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,323 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,897 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,583 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,386 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each balance sheet date, the Company evaluates inventories for excess quantities, obsolescence or shelf life expiration. This evaluation includes analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, a review of the shelf life expiration dates for products, as well as the feasibility of reworking or using excess or obsolete products or components in the production or assembly of other products that are not obsolete or for which there are not excess quantities in inventory. To the extent that management determines there are excess or obsolete inventory or quantities with a shelf life that is too near its expiration for the Company to reasonably expect that it can sell those products prior to their expiration, the Company adjusts the carrying value to estimated net realizable value. </span></div>The Company capitalizes inventory costs associated with certain products prior to regulatory approval, based on management's judgment of probable economic benefit. The Company could be required to expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or delay of approval by necessary regulatory bodies or a decision by management to discontinue the related development program. Inventories consisted of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,088 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,528 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,323 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,897 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,583 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,386 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 172088000 162528000 70598000 65323000 81897000 89535000 324583000 317386000 0 0 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PROPERTY, PLANT AND EQUIPMENT </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at historical cost less accumulated depreciation and any impairment charges. The Company provides for depreciation using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the lesser of the lease term or the useful life. The cost of major additions and improvements is capitalized, while maintenance and repair costs that do not improve or extend the lives of the respective assets are charged to operations as incurred. The cost of computer software developed or obtained for internal use is accounted for in accordance with the Accounting Standards Codification 350-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal-Use Software.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment balances and corresponding lives were as follows: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,512 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,032 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,292 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,495 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and production equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Demonstration equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,792 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4-5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Information systems and hardware</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,706 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,921 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1-15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,875 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641,031 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329,729)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(314,874)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,302 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,703 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div> 966000 1512000 14710000 19032000 P5Y P40Y 164292000 155495000 P1Y P20Y 181780000 183270000 P3Y P20Y 3792000 2791000 P4Y P5Y 151330000 148706000 P1Y P7Y 20286000 20921000 P1Y P15Y 103875000 94850000 641031000 626577000 329729000 314874000 311302000 311703000 40100000 39400000 42100000 CAPITALIZED INTERESTThe interest cost on capital projects, including facilities build-out and internal use software, is capitalized and included in the cost of the project. Capitalization commences with the first expenditure for the project and continues until the project is substantially complete and ready for its intended use. When no debt is incurred specifically for a project, interest is capitalized on project expenditures using the weighted average cost of the Company's outstanding borrowings. 1400000 1200000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ACQUISITIONS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The Company accounts for the acquisition of a business in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC Topic 805"). Amounts paid to acquire a business are allocated to the assets acquired and liabilities assumed based on their fair values at the date of acquisition. Any excess of the purchase price over the fair value of the net assets acquired is recorded as goodwill. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs and costs to restructure the acquired company are expensed as incurred.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration is recorded at fair value as measured on the date of acquisition. The value recorded is based on estimates of future financial projections under various potential scenarios using either a Monte Carlo simulation or the probability-weighted income approach derived from revenue estimates and probability assessment with respect to the likelihood of achieving contingent obligations. Contingent payments related to acquisitions consist of development, regulatory, and commercial milestone payments, in addition to sales-based payments, and are valued using discounted cash flow techniques. Each quarter until such contingent amounts are earned, the fair value of the liability is remeasured at each reporting period and adjusted as a component of operating expenses based on changes to the underlying assumptions. The change in the fair value of sales-based payments is based upon future revenue estimates and increases or decreases as revenue estimates or expectation of timing of payment charges. The estimates used to determine the fair value of the contingent consideration liability are subject to significant judgment and actual results are likely to differ from the amounts originally recorded.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determi</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nes the fair value of acquired intangible assets based on detailed valuations that use certain information and assumptions provided by management. The Company allocates any excess purchase price over the fair value of the net tangible and intangible assets acquired to goodwill. Determining the fair value of these intangible assets acquired as part of a business combination requires the Company to make significant estimates. These estimates include the amount and timing of projected future cash flows, the discount rate used to discount those cash flows to present value, the assessment of the asset’s life cycle, and the consideration of legal, technical, regulatory, economic, and competitive risks. The fair value assigned to other intangible assets is determined by estimating the future cash flows of each project or technology and discounting the net cash flows back to their present values. The discount rate used is determined at the time of measurement in accordance with accepted valuation methodologies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;D has an alternative future use. The Company uses the income approach to determine the fair value of developed technology and IPR&amp;D acquired in a business combination. This approach determines fair value by estimating the after-tax cash flows attributable to the respective asset over its useful life and then discounting these after-tax cash flows back to a present value. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each product including net revenues, cost of sales, R&amp;D costs, selling and marketing costs, the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, and competitive trends impacting the asset and each cash flow stream. The Company also uses the income approach, as described above, to determine the estimated fair value of certain other identifiable intangible assets including customer relationships, trade names and business licenses. Customer relationships represent established relationships with customers, which provide a ready channel for the sale of additional products and services. Trade names represent acquired company and product names.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D acquired in a business combination is capitalized as an indefinite-lived intangible asset. Development costs incurred after the acquisition are expensed as incurred. Upon receipt of regulatory approval, the indefinite-lived intangible asset is then accounted for as a finite-lived intangible asset and amortized on a straight-line basis or accelerated basis, as appropriate, over its estimated useful life. If the research and development project is subsequently abandoned, the indefinite-lived intangible asset is charged to expense. IPR&amp;D acquired outside of a business combination is expensed immediately.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the uncertainty associated with research and development projects, there is risk that actual results will differ materially from the original cash flow projections and that the research and development project will result in a successful commercial product. The risks associated with achieving commercialization include, but are not limited to, delay or failure to obtain regulatory approvals to conduct clinical trials, delay or failure to obtain required market clearances, delays or issues with patent</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issuance, or validity and litigation.</span></div>If the acquired net assets do not constitute a business under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;D with no alternative future use is charged to expense at the acquisition date. Payments that would be recognized as contingent consideration in a business combination are expensed when probable in an asset acquisition. <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GOODWILL AND OTHER INTANGIBLE ASSETS </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the cost over the fair value of net assets of acquired businesses is recorded as goodwill. Goodwill is not subject to amortization but is reviewed for impairment at the reporting unit level annually, or more frequently if impairment indicators arise. The Company's assessment of the recoverability of goodwill is based upon a comparison of the carrying value of goodwill with its estimated fair value. The Company reviews goodwill for impairment in the third quarter every year in accordance with ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC Topic 350") and whenever events or changes in circumstances indicate the carrying value of goodwill may not be recoverable. Refer to Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other Intangibles</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two reportable segments with three underlying reporting units. Refer to Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment and Geographic Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information on reportable segments. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other intangible assets include patents, trademarks, purchased technology, and supplier and customer relationships. Identifiable intangible assets are initially recorded at fair market value at the time of acquisition generally using an income or cost approach. The Company capitalizes costs incurred to renew or extend the term of recognized intangible assets and amortizes those costs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">over their expected useful lives.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests intangible assets with indefinite lives for impairment annually in the third quarter in accordance with ASC Topic 350. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of an indefinite lived intangible asset below its carrying amount. The Company tests for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of the intangible asset is less than its carrying amount. The Company may elect to bypass this qualitative evaluation and perform a quantitative test. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product rights and other definite-lived intangible assets are tested periodically for impairment in accordance with ASC 350 Topic when events or changes in circumstances indicate that an asset's carrying value may not be recoverable. The impairment testing involves comparing the carrying amount of the asset or asset group to the forecasted undiscounted future cash flows. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and impairment exists. An impairment loss is measured as the excess of the asset's carrying value over its fair value, calculated using discounted future cash flows. The computed impairment loss is recognized in the period that the impairment occurs.</span></div> 2 3 LONG-LIVED ASSETS Long-lived assets held and used by the Company, including property, plant and equipment, intangible assets, and leases are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets to be held and used, a recoverability test is performed using projected undiscounted net cash flows applicable to the long-lived assets. If an impairment exists, the amount of such impairment is calculated based on the estimated fair value of the asset. Impairments to long-lived assets to be disposed of are recorded based upon the difference between the carrying value and the fair value of the applicable assets. INTEGRA FOUNDATION The Company may periodically make contributions to the Integra Foundation, Inc. The Integra Foundation was incorporated in 2002 exclusively for charitable, educational, and scientific purposes and qualifies under IRC 501(c)(3) as an exempt private foundation. Under its charter, the Integra Foundation engages in activities that promote health, the diagnosis and treatment of disease, and the development of medical science through grants, contributions and other appropriate means. The Integra Foundation is a separate legal entity and is not a subsidiary of the Company; therefore, its results are not included in these consolidated financial statements. 0.0 1200000 800000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DERIVATIVES </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company develops, manufactures, and sells medical devices globally and its earnings and cash flows are exposed to market risk from changes in interest rates and currency exchange rates. The Company addresses these risks through a risk management program that includes the use of derivative financial instruments and operates the program pursuant to documented corporate risk management policies. All derivative financial instruments are recognized in the financial statements at fair value in accordance with the authoritative guidance. Under the guidance, for those instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation, based on the exposure being hedged. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, further, on the type of hedging relationship. The Company's derivative instruments do not subject its earnings or cash flows to material risk, and gains and losses on these derivatives generally offset losses and gains on the item being hedged. The Company has not entered into derivative transactions for speculative purposes. From time to time, the Company may enter into derivatives that are not designated as hedging instruments in order to protect itself from currency volatility due to intercompany balances. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivative instruments are recognized at the fair values as either assets or liabilities on the balance sheet. The Company determines the fair value of its derivative instruments using the framework prescribed by the authoritative guidance, by considering the estimated amount the Company would receive to sell or transfer these instruments at the reporting date and by taking into account expected forward interest rates, currency exchange rates, the creditworthiness of the counterparty for assets, and its creditworthiness for liabilities. In certain instances, the Company utilizes a discounted cash flow model to measure fair value. Generally, the Company uses inputs that include quoted prices for similar assets or liabilities in active markets, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The Company has classified all of its derivative assets and liabilities within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of its derivative instruments. The Company classifies derivatives designated as hedges in the same category as the item being hedged for cash flow presentation purposes.</span></div>The Company entered into foreign currency forward and foreign currency swap contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into other income, net, on the consolidated financial statements. FOREIGN CURRENCY All assets and liabilities of foreign subsidiaries which have a functional currency other than the U.S. dollar are translated at the rate of exchange at year-end, while elements of the income statement are translated at the average exchange rates in effect during the year. The net effect of these translation adjustments is shown as a component of accumulated other comprehensive income (loss). These currency translation adjustments are not currently adjusted for income taxes as they relate to permanent investments in non-U.S. subsidiaries. -3300000 100000 -1600000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INCOME TAXES </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for by using the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period when the change is enacted. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position. Reserves are established for positions that don't meet this recognition threshold. The reserve is measured as the largest amount of benefit determined on a cumulative probability basis that the Company believes is more likely than not to be realized upon ultimate settlement of the position. These reserves are classified as long-term liabilities in the consolidated balance sheets of the Company, unless the reserves are expected to be paid in cash during the next twelve months, in which case they are classified as current liabilities. The Company also records interest and penalties accrued in relation to uncertain tax benefits as a component of income tax expense. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company believes it has identified all reasonable exposures and the reserve it has established is appropriate under the circumstances, it is possible that additional exposures exist and that exposures may be settled at amounts different than the amounts reserved. It is also possible that changes in facts and circumstances could cause the Company to either materially increase or reduce the carrying amount of its tax reserve. </span></div>The Company continues to indefinitely reinvest substantially all of its foreign earnings unless there is a manner under which to remit the earnings without a material tax cost. The current provisional analysis indicates that the Company has sufficient U.S. liquidity, including borrowing capacity, to fund foreseeable U.S. cash needs without requiring the repatriation of foreign cash. One time or unusual items that may impact the ability or intent to keep the foreign earnings and cash indefinitely reinvested include significant U.S. acquisitions, loans from a foreign subsidiary and changes in tax laws. <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">REVENUE RECOGNITION </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue, net, includes product sales, product royalties and other revenues, such as fees received from services. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For products shipped with FOB shipping point terms, the control of the product passes to the customer at the time of shipment. For shipments in which the control of the product is transferred when the customer receives the product, the Company recognizes revenue upon receipt by the customer. Certain products that the Company produces for private label customers have no alternative use and the Company has a right of payment for performance to date. Revenues from those products are recognized over the period that the Company manufactures these products, which is typically one month to three months. The Company uses the input method to measure the manufacturing activities completed to date, which depicts the progress of the Company's performance obligation of transferring control of goods being manufactured for private label customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and distributors, and also from inventory physically held by field sales representatives. For these types of products sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Revenues from sale of products and services are evidenced by either a contract with the customer or a valid purchase order and an invoice which includes all relevant terms of sale. For product sales, invoices are generally issued upon the transfer of control (or upon the completion of the manufacturing in the case of the private label transactions recognized over time) and are typically payable 30 days after the invoice date. The Company performs a review of each specific customer's creditworthiness and ability to pay prior to acceptance as a customer. Further, the Company performs periodic reviews of its customers' creditworthiness prospectively. Refer to Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Revenue From Contracts With Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for more information. The Company also maintains a provision for estimated returns and allowances in the same period that the related revenue is recorded. This reserve is based upon an analysis of actual credit memos issued for pricing issues or returned goods over an extended period, as well as assumptions about outstanding accounts receivable and judgment in interpreting the data.</span><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Performance Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Significant Judgments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company's strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally 90 days. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract Asset and Liability</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized from the Company's private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the prepaid expenses and other current assets account in the consolidated balance sheet. Upon invoicing to the customer, the balance is recorded in trade receivable, net in the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.</span></div>Shipping and Handling FeesThe Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold. P1M P3M RESEARCH AND DEVELOPMENT Research and development costs, including salaries, depreciation, consultant and other external fees, and facility costs directly attributable to research and development activities, are expensed in the period in which they are incurred. <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EMPLOYEE TERMINATION BENEFITS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have a written severance plan, and it does not offer similar termination benefits to affected employees in all restructuring initiatives. Accordingly, in situations where minimum statutory termination benefits must be paid to the affected employees, the Company records employee severance costs associated with these restructuring activities in accordance with the authoritative guidance for non-retirement post-employment benefits. Charges associated with these activities are recorded when the payment of benefits is probable and can be reasonably estimated. In all other situations where the Company pays out termination benefits, including supplemental benefits paid in excess of statutory minimum amounts and benefits offered to affected employees based on management's discretion, the Company records these termination costs in accordance with the authoritative guidance for ASC Topic 712 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Nonretirement Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ASC Topic 420 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">One-time Employee Termination Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div>The timing of the recognition of charges for employee severance costs other than minimum statutory benefits depends on whether the affected employees are required to render service beyond their legal notification period in order to receive the benefits. If affected employees are required to render service beyond their legal notification period, charges are recognized over the future service period. Otherwise, charges are recognized when management has approved a specific plan and employee communication requirements have been met. The following table summarizes our restructuring related accrual balances included within accrued expenses and other current liabilities in the consolidated balance sheet for the year ended December 31, 2022 and 2021.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.163%"><tr><td style="width:1.0%"/><td style="width:47.120%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.511%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.045%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, beginning of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,372 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of Goods Sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,267)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, end of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,107 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,226 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 10226000 6372000 1494000 3436000 72000 288000 5582000 466000 -12267000 -336000 5107000 10226000 2000000 3100000 10200000 STOCK-BASED COMPENSATION Relevant authoritative guidance requires companies to recognize the expense related to the fair value of their stock-based compensation awards. Stock-based compensation expense for stock option awards are based on the grant date fair value using the binomial distribution model. The Company recognizes compensation expense for stock option awards, restricted stock awards, performance stock awards and contract stock awards over the requisite service period of the award. All excess tax benefits and taxes and tax deficiencies from stock-based compensation are included in provision for income taxes in the consolidated statement of operations. <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PENSION BENEFITS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains defined benefit pension plans that cover certain employees in France, Japan, Germany and Switzerland. Various factors are considered in determining the pension liability, including the number of employees expected to be paid their salary levels and years of service, the expected return on plan assets, the discount rate used to determine the benefit obligations, the timing of benefit payments and other actuarial assumptions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retirement benefit plan assumptions are reassessed on an annual basis or more frequently if changes in circumstances indicate a re-evaluation of assumptions are required. The key benefit plan assumptions are the discount rate and expected rate of return on plan assets. The discount rate is based on average rates on bonds that matched the expected cash outflows of the benefit plans. The expected rate of return is based on historical and expected returns on the various categories of plan assets. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the corridor approach in measuring the amount of net periodic benefit pension cost to recognize each period. The corridor approach defers all actuarial gains and losses resulting from variances between actual results and actuarial assumptions. Those unrecognized gains and losses are amortized when the net gains and losses exceed 10% of the greater of the market-related value of plan assets or the projected benefit obligation at the beginning of the year. The amount in excess of the corridor is amortized over the average remaining service period to retirement date of active plan participants.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Compensation Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a deferred compensation plan in which certain employees of the Company may defer the payment and taxation of up to 75% of their base salary and up to 100% of bonus amounts and other eligible cash compensation.</span></div>This deferred compensation is invested in funds offered under the Plan and is valued based on Level 1 measurements in the fair value hierarchy. The purpose of the plan is to retain key employees by providing them with an opportunity to defer a portion of their compensation as elected by the participant in accordance with the plan. Any amounts set aside to defray the liabilities assumed by the Company will remain the general assets of the Company until such amounts are distributed to the participants. Assets of the Company's deferred compensation plan are included in Other current assets and recorded at fair value based on their quoted market prices. 0.75 1 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CONCENTRATION OF CREDIT RISK </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, which are held at major financial institutions, investment-grade marketable debt securities and trade receivables. </span></div>The Company's products are sold on an uncollateralized basis and on credit terms based upon a credit risk assessment of each customer. A portion of the Company's trade receivables to customers outside the United States includes sales to foreign distributors, who then sell to government owned or supported healthcare systems. 0 0 0 0.10 0.10 0.10 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RECENT ACCOUNTING PRONOUNCEMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Simplifying the Accounting for Income Taxes, intended to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. This guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. The Company adopted ASU 2019-12 as of January 1, 2021. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 848), and subsequent amendment to the initial guidance: ASU 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 848): Scope (collectively, “Topic 848”). Topic 848 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference London Inter-Bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. The guidance generally can be applied from March 12, 2020 through December 31, 2022. On October 5, 2022, the FASB approved an extension of the sunset date of the reference rate reform from December 31, 2022 to December 31, 2024, past LIBOR’s end date. The Company currently has contracts that are indexed to LIBOR and are continuing to evaluate the scope of impacted contracts and potential risk. The Company expects all LIBOR-based contracts to be replaced by the Secured Overnight Financing Rate (“SOFR”), which is calculated based on overnight transactions under repurchase agreements backed by Treasury securities. The Alternative Reference Rates Committee, a group of private-market participants convened by the U.S. Federal Reserve Board and the New York Federal Reserve, has recommended the use of SOFR as a more robust reference rate alternative to LIBOR. The use of SOFR as a substitute for LIBOR is, however, voluntary and may not be suitable for all market participants. There can be no assurance that the replacement rate will be economically equivalent to LIBOR, which could result in higher interest rates for us under our debt facilities. There is no guarantee that a transition from LIBOR to SOFR will not result in financial market disruptions, significant increases in benchmark rates, or our borrowing costs, any of which could have an adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt- Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40):Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The guidance simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify. The guidance also simplifies the diluted net income per share calculation in certain areas. The ASU will be effective for annual and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years using either the modified retrospective or full retrospective method. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As detailed in Note 5,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on February 4, 2020, the Company issued $575.0 million aggregate principal amount of its 0.5% Convertible Senior Notes due 2025 (the "2025 Notes"). The 2025 Notes are subject to the guidance included in ASU 2020-06. The Company adopted this guidance on January 1, 2021 using the modified retrospective approach which resulted in a cumulative-effect adjustment that increased (decreased) the following consolidated balance sheet accounts:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.518%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ADJUSTMENT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CONSOLIDATED BALANCE SHEET CLASSIFICATION</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AMOUNT<br/> (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax impact of cumulative-effect adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.6)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount reclassification</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term convertible securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity issuance costs reclassification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term convertible securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount amortization and equity costs reclassification, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained Earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net impact of cumulative-effect adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2020, the Company made an irrevocable election under the indenture to require the principal portion of its 2025 Notes to be settled in cash and any excess in shares. Following the irrevocable notice, only the amounts settled in excess of the principal will be considered in diluted earnings per share under the “if-converted” method. Upon adoption of ASU 2020-06, the Company’s 2025 Notes were reflected entirely as a liability since the embedded conversion feature will no longer be separately presented within stockholders’ equity. Additionally, from January 1, 2021, the Company is no longer incurring non-cash interest expense for the amortization of debt discount.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU 2020-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which updates various codification topics by clarifying or improving disclosure requirements to align with the regulations of the U.S. Securities and Exchange Commission (the "SEC") . The ASU has been effective for the Company for annual and interim periods beginning after January 1, 2021. The Company adopted this standard on the January 1, 2021. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU 2021-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which provides guidance to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The amendment currently has no impact to the Company as the effect will largely depend on the terms of written call options or financings issued or modified in the future. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no other recently issued accounting pronouncements that are expected to have any significant effect on the Company's financial position, results of operations or cash flows.</span></div> 575000000 0.005 The Company adopted this guidance on January 1, 2021 using the modified retrospective approach which resulted in a cumulative-effect adjustment that increased (decreased) the following consolidated balance sheet accounts:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.518%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ADJUSTMENT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CONSOLIDATED BALANCE SHEET CLASSIFICATION</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AMOUNT<br/> (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax impact of cumulative-effect adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.6)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount reclassification</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term convertible securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity issuance costs reclassification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term convertible securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt discount amortization and equity costs reclassification, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained Earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net impact of cumulative-effect adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -20600000 89100000 -2500000 -2800000 -63300000 42200000 1400000 43200000 1200000 47300000 2300000 35900000 49500000 29800000 10500000 4700000 1600000 5000000 5000000 20000000 20000000 REVENUES FROM CONTRACTS WITH CUSTOMERS<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Summary of Accounting Policies on Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized upon the transfer of control of promised products or services to the customers in an amount that reflects the consideration the Company expects to receive in exchange for those products and services. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Performance Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's performance obligations consist mainly of transferring control of goods and services identified in the contracts, purchase orders, or invoices. The Company has no significant multi-element contracts with customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Significant Judgments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Usage-based royalties and licenses are estimated based on the provisions of contracts with customers and recognized in the same period that the royalty-based products are sold by the Company's strategic partners. The Company estimates and recognizes royalty revenue based upon communication with licensees, historical information, and expected sales trends. Differences between actual reported licensee sales and those that were estimated are adjusted in the period in which they become known, which is typically the following quarter. Historically, such adjustments have not been significant. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates returns, price concessions, and discount allowances using the expected value method based on historical trends and other known factors. Rebate allowances are estimated using the most likely method based on each customer contract. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's return policy, as set forth in its product catalogs and sales invoices, requires review and authorization in advance prior to the return of product. Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally 90 days. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less. The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract Asset and Liability</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized from the Company's private label business that are not invoiced to the customers as a result of recognizing revenue over time are recorded as a contract asset included in the prepaid expenses and other current assets account in the consolidated balance sheet. Upon invoicing to the customer, the balance is recorded in trade receivable, net in the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating revenues may include fees received under service agreements. Non-refundable fees received under multiple-period service agreements are recognized as revenue as the Company satisfies the performance obligations to the other party. A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarized the changes in the contract asset and liability balances for the year ended December 31, 2022:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:79.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.222%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Contract Asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract asset, January 1, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transferred to trade receivable from contract asset included<br/>     in beginning of the year contract asset </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract asset, net of transferred to trade receivables on contracts during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,122 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract asset, December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,122 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Contract Liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability, January 1, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,946 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of revenue included in beginning of year contract liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability, net of revenue recognized on contracts during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability, December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,127 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, the short-term portion of the contract liability of $7.3 million and the long-term portion of $8.8 million is included in current liabilities and other liabilities, respectively, in the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company is expected to recognize revenue of approximately $7.3 million in 2023, $4.2 million in 2024, $2.7 million in 2025, $1.1 million in 2026, $0.7 million in 2027, and $0.1 million thereafter.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Shipping and Handling Fees</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in the cost of goods sold. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Warranties</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company's medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to two years from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Taxes Collected from Customers</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disaggregated Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues disaggregated by the major sources of revenues for years-ended December 31, 2022, 2021 and 2020 (dollar amounts in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neurosurgery</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">794,017 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">802,959 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">716,339 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Instruments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225,547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,273 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Codman Specialty Surgical</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,019,564 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,025,232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">894,831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wound Reconstruction and Care</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)(3)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">406,689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392,463 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Extremity Orthopedics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Private Label</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,413 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,753 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,683 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Tissue Technologies</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">538,102 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517,216 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">477,037 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,557,666 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,542,448 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,371,868 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> On January 4, 2021, the Company completed its sale of its Extremity Orthopedics business. See Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions and Divestitures, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">for details</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> See Note 4. Acquisitions and Divestitures, for details around the ACell acquisition.</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> On August 31, 2022, the Company completed the sale of its non-core traditional wound care ("TWC") business. See Note</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Acquisitions and Divestitures</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment and Geographical Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for details of revenues based on the location of the customer.</span></div> P90D <div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarized the changes in the contract asset and liability balances for the year ended December 31, 2022:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:79.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.222%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Contract Asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract asset, January 1, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transferred to trade receivable from contract asset included<br/>     in beginning of the year contract asset </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract asset, net of transferred to trade receivables on contracts during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,122 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract asset, December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,122 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Contract Liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability, January 1, 2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,946 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of revenue included in beginning of year contract liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability, net of revenue recognized on contracts during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability, December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,127 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 11412000 11412000 10122000 10122000 11946000 5349000 9596000 -66000 16127000 7300000 8800000 7300000 4200000 2700000 1100000 700000 100000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Warranties</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company's medical devices, including monitoring systems and neurosurgical systems, are designed to operate over long periods of time. These products are sold with warranties which may extend for up to two years from the date of purchase. The warranties are not considered a separate performance obligation. The Company estimates its product warranties using the expected value method based on historical trends and other known factors. The Company includes them in accrued expenses and other current liabilities in the consolidated balance sheet.</span></div> P2Y Taxes Collected from CustomersThe Company elected to exclude from the measurement of the transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the entity from a customer. <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues disaggregated by the major sources of revenues for years-ended December 31, 2022, 2021 and 2020 (dollar amounts in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neurosurgery</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">794,017 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">802,959 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">716,339 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Instruments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225,547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,273 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Codman Specialty Surgical</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,019,564 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,025,232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">894,831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wound Reconstruction and Care</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)(3)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">406,689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392,463 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Extremity Orthopedics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Private Label</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,413 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,753 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,683 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Tissue Technologies</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">538,102 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517,216 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">477,037 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,557,666 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,542,448 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,371,868 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> On January 4, 2021, the Company completed its sale of its Extremity Orthopedics business. See Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions and Divestitures, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">for details</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> See Note 4. Acquisitions and Divestitures, for details around the ACell acquisition.</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> On August 31, 2022, the Company completed the sale of its non-core traditional wound care ("TWC") business. See Note</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Acquisitions and Divestitures</span></div> 794017000 802959000 716339000 225547000 222273000 178492000 1019564000 1025232000 894831000 406689000 392463000 293038000 0 0 78316000 131413000 124753000 105683000 538102000 517216000 477037000 1557666000 1542448000 1371868000 ACQUISITIONS AND DIVESTITURES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Surgical Innovation Associates, Inc. Acquisition</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On December 6, 2022, the Company completed its acquisition of Surgical Innovation Associates, Inc. ("SIA") for an acquisition purchase price of $51.5 million. In addition to the purchase price, the acquisition includes two separate contingent considerations payments, which are dependent on 1) achieving certain revenue-based performance milestones in 2023, 2024, and 2025 (up to $50.0 million in additional payments), as well as 2) the approval by the FDA of the Premarket Approval (“PMA”) Application for DuraSorb for certain uses by certain timing targets (up to $40.0 million in additional payments). SIA's core technology, DuraSorb, is a fully resorbable scaffold of a globally accepted polymer, which is cleared for use in hernia repair, abdominal wall, and other soft tissue reinforcement. DuraSorb sales will be reported within Integra’s Tissue Technologies segment as part of its Wound Reconstruction and Care franchise. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Assets Acquired and Liabilities Assumed at Fair Value</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The SIA Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired, and liabilities assumed in a business combination to be recognized at their fair values as of the acquisition date. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation as of December 6, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Life</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts receivable, net </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,654 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,543 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,854 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">127,397</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,044 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,044 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred Tax Liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,799 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,607 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">71,450</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">55,947</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Developed Technology</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The estimated fair value of the developed technology was determined using the multi-period excess earnings method of the income approach, which estimates value based on the present value of future economic benefits. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each product including net revenues, cost of sales, R&amp;D costs, selling and marketing costs, working capital, and contributory asset charges, the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of the asset’s life cycle, and competitive trends impacting the asset and the cash flow stream.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company used a discount rate of 18% to arrive at the present value for the acquired intangible assets to reflect the rate of return a market participant would expect to earn and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company allocated goodwill related to the SIA Acquisition to the Tissue Technologies segment. Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected revenue and cost synergies of the combined company and assembled workforce. A key factor that contributes to the recognition of goodwill, and a driver for the Company’s acquisition of SIA, is the attractive growth opportunities presented by the surgical matrix business in the breast reconstruction market. Goodwill recognized as a result of this acquisition is non-deductible for income tax purposes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Contingent Consideration</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company determines the acquisition date fair value of contingent consideration obligations based on a probability-weighted income approach derived from revenue estimates and a probability assessment with respect to the likelihood of achieving contingent obligations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined using the fair value concepts in ASC 820. The resulting most likely payouts are discounted using an appropriate effective annual interest rate. At each reporting date, the contingent consideration obligation will be revalued to estimated fair value and changes in fair value will be reflected as income or expense in the consolidated statement of operations. Changes in the fair value of the contingent considerations may result from changes in discount periods and rates and changes in the timing and amount of revenue estimates. Changes in assumptions utilized in the contingent consideration fair value estimates could result in an increase in the contingent consideration obligation and a corresponding charge to operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As part of the acquisition, the Company is required to pay to the shareholder of SIA up to $90.0 million for two separate payments, which are dependent on 1) achieving certain revenue-based performance milestones in 2023, 2024, and 2025 (up to $50.0 million in additional payments), as well as 2) the approval by the FDA of the PMA for DuraSorb for certain uses by </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">certain timing targets (up to $40.0 million in additional payments). The Company used iterations of the Monte Carlo simulation to calculate the fair value of the contingent consideration for the revenue-based milestone that considered the possible outcomes of scenarios related to each specific milestone for the revenue based performance milestone. The Company used probabilities of achieving the conditions to calculate the fair value of the contingent consideration for the PMA approval milestone. The Company estimated the fair value of the contingent consideration for the revenue based milestone to be $32.6 million at the acquisition date and $25.0 million for the PMA approval milestone.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Deferred Tax Liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Deferred tax liabilities result from identifiable intangible assets’ fair value adjustments. These adjustments create excess book basis over tax basis which is tax-effected by the statutory tax rates of applicable jurisdictions.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of non-core traditional wound care business</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 31, 2022, the Company completed its sale of its non-core traditional wound care ("TWC") business to Gentell, LLC ("Gentell") for $28.8 million, which consists of $27.8 million in cash plus $1.0 million in contingent consideration which may be received upon achieving certain revenue-based performance milestones two years after the closing date. The proceeds from the sale of the TWC business of $27.8 million is presented in the consolidated statement of cash flows net of cash transferred of $3.5 million and other transaction fees. The transaction included the sale of the Company's TWC products, such as sponges, gauze and conforming bandages, and certain advanced wound care dressings, such as supportive, calcium alginate, hydrogel, and foam dressings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The divestiture did not represent a strategic shift that had a major effect on the Company's operations and financial statements. Goodwill was allocated to the assets and liabilities divested using the relative fair value method of the TWC business to the Company's Tissue Technologies reportable business segment. In connection with the sale, the Company recognized $0.6 million as a gain from the sale of the business in the consolidated statement of operations for the year ended December 31, 2022. The transaction is subject to final working capital adjustments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the purchase and sale agreement, the Company also entered into a contract manufacturing agreement with Gentell. Under the terms of the agreement, Gentell received inventory, equipment, and tooling to manufacture certain MediHoney® and TCC-EZ® products on behalf of the Company. On the close date of this transaction, the Company transferred all inventory associated with these products to Gentell and recognized an asset of $11.1 million, as a form of a deposit for the inventory transferred, which based on the expected timing of inventory purchases, was primarily included within prepaid expenses and other current assets in the consolidated balance sheet. This deposit will be utilized by the Company on future orders placed to Gentell for such products. As of December 31, 2022, the Company had a deposit remaining of $8.3 million which is included in prepaid assets and recognized a payable due to Gentell of $2.7 million, which is included in the consolidated balance sheet within accrued expenses and other current liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of Extremity Orthopedics Business</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2021, the Company completed the sale of its Extremity Orthopedics business to Smith &amp; Nephew USD Limited ("Smith &amp; Nephew"). The transaction included the sale of the Company's upper and lower Extremity Orthopedics product portfolio, including ankle and shoulder arthroplasty and hand and wrist product lines. The Company received an aggregate purchase price of $240.0 million from Smith &amp; Nephew and concurrently paid $41.5 million to the Consortium of Focused Orthopedists, LLC ("CFO") effectively terminating the licensing agreement between Integra and CFO relating to the development of shoulder arthroplasty products. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities divested consisted of the following as of December 31, 2020 (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.111%"><tr><td style="width:1.0%"/><td style="width:68.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset - operating leases and Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,589 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,332 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,893 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,546 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,845 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets held for sale</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,104 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,440 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities held for sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,751 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The divestiture did not represent a strategic shift that had a major effect on the Company's operations and financial statements. Goodwill was allocated to the assets and liabilities divested using the relative fair value method of the Extremity Orthopedics business to the Company's Tissue Technologies reporting unit. In connection with the sale, the Company recognized a gain of $41.8 million that is presented in Gain from the sale of business in the consolidated statement of operations for the year ended December 31, 2021. The Company finalized the net working capital to Smith &amp; Nephew as of December 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also entered into a transition services agreement ("TSA") with Smit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h &amp; Nephew which requires the Company to provide certain services on behalf</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of Smith &amp; Nephew for the duration of the period subsequent to the sale of the business as defined in the TSA. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized a payable due to Smith &amp; Nephew of $2.3 million as of December 31, 2022, which is included in the consolidated balance sheet within accrued expenses and other current liabilities.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The TSA includes services such as invoicing and cash collections from customers on behalf of Smith &amp; Nephew. As of December 31, 2022, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company has concluded the majority of the transition services agreement, pending final payment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ACell, Inc. Acquisition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2021, the Company acquired ACell, Inc. (the "ACell Acquisition") for an acquisition purchase price of $306.9 million plus contingent considerations of up to $100 million, that may be payable upon achieving certain revenue-based performance milestones in 2022, 2023 and 2025. The final working capital adjustments of $1.3 million was finalized and paid as of June 30, 2021. ACell was a privately-held company that offered a portfolio of regenerative products for complex wound management, including developing and commercializing products based on MatriStem Urinary Bladder Matrix, a technology platform derived from porcine urinary bladder extracellular matrix.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed at Fair Value</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACell Acquisition has been accounted for using the acquisition method of accounting. This method requires that assets acquired and liabilities assumed in a business combination are recognized at their fair values as of the acquisition date. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the final fair values of the assets acquired and liabilities assumed at the acquisition date:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Final Valuation </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Life</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,726 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts receivable, net </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,992 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,769 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13-14 years</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right of use asset - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,465 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">408,780</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,966 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of lease liability - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,357 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liability - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,585 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">101,842</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">306,938</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the developed technology acquired was determined using the multi-period excess earnings method of the income approach, which estimates value based on the present value of future economic benefits. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each product including net revenues, cost of sales, R&amp;D costs, selling and marketing costs, the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, and competitive trends impacting the asset and each cash flow stream.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used a discount rate of 8.5% to arrive at the present value for the acquired intangible assets to reflect the rate of return a market participant would expect to earn and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated goodwill related to the ACell acquisition to the Tissue Technologies segment. Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected synergies of the combined company and assembled workforce. Goodwill recognized as a result of this acquisition is non-deductible for income tax purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the acquisition, the Company is required to make payments to the former shareholders of ACell up to $100 million based on the achievement of certain revenue-based performance milestones in 2022, 2023, and 2025. Based on revenue performance in 2022, no payment will be made for the first performance milestone. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company used iterations of the Monte Carlo simulation to calculate the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specific milestone. The Company estimated the fair value of the contingent consideration to be $23.9 million at the acquisition date. The Company recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.7 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $21.8 million in other liabilities as of December 31, 2022 and 2021, respectively, in the consolidated balance sheets of the Company. The change in the fair value of the contingent obligation was primarily as a result of changes in the timing and amount of revenue estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the acquisition date fair value of contingent consideration obligations using a Monte Carlo simulation, as well as significant unobservable inputs, reflecting the Company’s assessment of the assumptions market participants would use to value these liabilities. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined using the fair value concepts in ASC 820. The resultant most likely payouts are discounted using an appropriate effective annual interest rate. At each reporting date, the contingent consideration obligations is revalued to estimated fair value and changes in fair value will be reflected as income or expense in our consolidated statement of operations. Changes in the fair value of the contingent considerations may result from changes in discount periods and rates and changes in the timing and amount of revenue estimates. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Tax Liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities result from identifiable intangible assets’ fair value adjustments. These adjustments create excess book basis over tax basis which is tax-effected by the statutory tax rates of applicable jurisdictions.</span></div> 51500000 50000000 40000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation as of December 6, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Life</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts receivable, net </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,654 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,543 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,854 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">127,397</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,044 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,044 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred Tax Liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,799 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,607 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">71,450</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">55,947</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the final fair values of the assets acquired and liabilities assumed at the acquisition date:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Final Valuation </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Life</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,726 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts receivable, net </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,992 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,769 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13-14 years</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right of use asset - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,465 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">408,780</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">718 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,966 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of lease liability - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,357 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liability - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,585 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">101,842</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">306,938</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 4438000 1551000 2900000 1654000 10543000 75000000 P14Y 41854000 127397000 2044000 2044000 11799000 57607000 71450000 55947000 0.18 90000000 2 50000000 40000000 32600000 25000000 28800000 27800000 1000000 P2Y 27800000 3500000 600000 11100000 8300000 2700000 240000000 41500000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities divested consisted of the following as of December 31, 2020 (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.111%"><tr><td style="width:1.0%"/><td style="width:68.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset - operating leases and Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,589 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,332 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,893 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,546 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,845 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets held for sale</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,104 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,440 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability - operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities held for sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,751 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 713000 3186000 6589000 13332000 37893000 47546000 52845000 162104000 336000 539000 1767000 3440000 5669000 11751000 41800000 2300000 306900000 100000000 1300000 2726000 16469000 18299000 1498000 38992000 13769000 245000000 P13Y P14Y 94147000 9259000 7465000 148000 408780000 718000 5966000 1673000 8357000 276000 7585000 61724000 23900000 101842000 306938000 0.085 100000000 23900000 3700000 21800000 DEBT<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment to the Sixth Amended and Restated Senior Credit Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2020, the Company entered into the sixth amendment and restatement (the "February 2020 Amendment") of its Senior Credit Facility (the "Senior Credit Facility") with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent. The February 2020 Amendment extended the maturity date to February 3, 2025. The Company continues to have the aggregate principal amount of up to approximately $2.2 billion available to it through the following facilities: (i) a $877.5 million Term Loan facility, and (ii) a $1.3 billion revolving credit facility, which includes a $60 million sublimit for the issuance of standby letters of credit and a $60 million sublimit for swingline loans.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s maximum consolidated total leverage ratio in the financial covenants (as defined in the Senior Credit Facility) is the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:75.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Consolidated Total Leverage Ratio</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022 through June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2023 and the last day of each fiscal quarter thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.00 to 1.00</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Senior Credit Facility bear interest, at the Company’s option, at a rate equal to the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">the Eurodollar Rate (as defined in the amendment and restatement) in effect from time to time plus the applicable rate (ranging from 1.00% to 2.25%), or </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">the highest of:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the weighted average overnight Federal funds rate, as published by the Federal Reserve Bank of New York, plus 0.50%</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the prime lending rate of Bank of America, N.A. or</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the one-month Eurodollar Rate plus 1.00% </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable rates are based on the Company’s consolidated total leverage ratio (defined as the ratio of (a) consolidated funded indebtedness as of such date less cash that is not subject to any restriction on the use or investment thereof to (b) consolidated EBITDA (as defined by the July 2020 amendment), for the period of four consecutive fiscal quarters ending on such date).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will pay an annual commitment fee (ranging from 0.15% to 0.30%), based on the Company's consolidated total leverage ratio, on the amount available for borrowing under the revolving credit facility. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Credit Facility is collateralized by substantially all of the assets of the Company’s U.S. subsidiaries, excluding intangible assets. The Senior Credit Facility is subject to various financial and negative covenants and at December 31, 2022, the Company was in compliance with all such covenants. In connection with the February 2020 Amendment, the Company capitalized $4.6 million of financing costs in connection with modification </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Senior Credit Facility and wrote off $1.2 million of previously capitalized financing costs during the first quarter of 2020. In connection with the July 2020 amendment, the Company expensed $3.3 million of incremental financing costs in connection with the modification of the Senior Credit Facility during the third quarter of 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> no balance outstanding at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the revolving portion of the Senior Credit Facility and as of December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021, there was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$31.3 million, outstanding under the revolving portion of the Senior Credit Facility at weighted average interest rate of 1.4%. At December 31, 2022 and 2021, there was $771.3 million and $843.8 million, respectively, outstanding, under the Term Loan component of the Senior Credit Facility at weighted average interest rate of 5.6% and 1.4%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. At December 31, 2022 and 2021, there was $38.1 million and $45.0 million, respectively, of the Term Loan component of the Senior Credit Facility was classified as current on the consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of outstanding borrowings of the Senior Credit Facility's Term Loan components at December 31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $800.8 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This fair values were determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Letters of credit outstanding as of December 31, 2022 and 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> totaled $1.6 million. Ther</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e were no amounts drawn as of December 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual repayments of the Term Loan component of the Senior Credit Facility are due as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year-ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Repayment</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669,375 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future interest payments on the term loan component of the Senior Credit Facility based on current interest rates are expected to approximate $42.7 million in 2023, $39.1 million in 2024, and $3.6 million in 2025. Interest is calculated on the term loan portion of the Senior Credit Facility based on LIBOR plus the spread paid by the Company. As the revolving credit facility and Securitization Facility can be repaid at any time, no interest has been included in the calculation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outstanding balance of the revolving credit component of the Senior Credit Facility is due on February 3, 2025. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 4, 2020, the Company issued $575.0 million aggregate principal amount of its 0.5% Convertible Senior Notes due 2025 (the "2025 Notes"). The 2025 Notes will mature on August 15, 2025 and bear interest at a rate of 0.5% per annum payable semi-annually in arrears, unless earlier converted, repurchased or redeemed in accordance with the terms of the 2025 Notes. The portion of debt proceeds that was classified as equity at the time of the offering was $104.5 million. The effective interest rate implicit in the liability component was 4.2%. In connection with this offering, the Company capitalized $13.2 million of financing fees. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes are senior, unsecured obligations of the Company, and are convertible into cash and shares of its common stock based on initial conversion rate, subject to adjustment of 13.5739 shares per $1,000 principal amounts of the 2025 Notes (which represents an initial conversion price of $73.67 per share). The 2025 Notes convert only in the following circumstances: (1) if the closing price of the Company's common stock has been at least 130% of the conversion price during the period; (2) if the average trading price per $1,000 principal amount of the 2025 Notes is less than or equal to 98% of the average conversion value of the 2025 Notes during a period as defined in the indenture; (3) at any time on or after February 20, 2023; or (4) if specified corporate transactions occur. As of December 31, 2022, none of these conditions existed with respect to the 2025 Notes and as a result the 2025 Notes are classified as long term.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2020, the Company entered into the First Supplemental Indenture to the original agreement dated as of February 4, 2020 between the Company and Citibank, N.A., as trustee, governing the Company’s outstanding 2025 Notes. The Company irrevocably elected (1) to eliminate the Company’s option to choose physical settlement on any conversion of the 2025 Notes that occurs on or after the date of the First Supplemental Indenture and (2) with respect to any Combination Settlement for a conversion of the 2025 Notes, the Specified Dollar Amount that will be settled in cash per $1,000 principal amount of the 2025 Notes shall be no lower than $1,000. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Notes will have the right to require the Company to repurchase for cash all or a portion of their Notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of a fundamental change (as defined in the indenture relating to the Notes). The Company will also be required to increase the conversion rate for holders who convert their Notes in connection with certain fundamental changes occurring prior to the maturity date or following delivery by the Company of a notice of redemption. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the 2025 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of the 2025 Notes (the “hedge participants”). The cost of the call transactions was $104.2 million for the 2025 Notes. The Company received $44.5 million of proceeds from the warrant transactions for the 2025 Notes. The call transactions involved purchasing call options from the hedge participants, and the warrant transactions involved selling call options to the hedge participants with a higher strike price than the purchased call options. The initial strike price of the call transactions was $73.67, subject to anti-dilution adjustments substantially similar to those in the 2025 Notes. The initial strike price of the warrant transactions was $113.34 for the 2025 Notes, subject to customary anti-dilution adjustments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, the carrying amount of the liability was $575.0 million. The fair value of the 2025 Notes at December 31, 2022 wa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s $560.5 million.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Factors that the Company considered when estimating the fair value of the 2025 Notes included recent quoted market prices or dealer quote. The level of the 2025 Notes is considered as Level 1. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the adoption of ASU 2020-06, for both the years ended December 31, 2022 and 2021, the Company recognized only cash interest related to the contractual interest coupon on the 2025 Notes of $2.9 million. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securitization Facility</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2018, the Company entered into an accounts receivable securitization facility (the "Securitization Facility") under which accounts receivable of certain domestic subsidiaries are sold on a non-recourse basis to a special purpose entity (“SPE”), which is a bankruptcy-remote, consolidated subsidiary of the Company. Accordingly, the assets of the SPE are not available to satisfy the obligations of the Company or any of its subsidiaries. From time to time, the SPE may finance such accounts receivable with a revolving loan facility secured by a pledge of such accounts receivable. The amount of outstanding borrowings on the Securitization Facility at any one time is limited to $150.0 million. The Securitization Facility Agreement ("Securitization Agreement") governing the Securitization Facility contains certain covenants and termination events. An occurrence of an event of default or a termination event under this Securitization Agreement may give rise to the right of its counterparty to terminate this facility. As of December 31, 2022, the Company was in compliance with the covenants and none of the termination events had occurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 28, 2021, the Company entered into an amendment (the "May 2021 Amendment") of the Securitization Facility which extended the maturity date from December 21, 2021 to May 28, 2024. The May 2021 Amendment does not increase the Company’s total indebtedness.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022 and 2021, the Company had $104.7 million and $112.5 million, of outstanding borrowings under its Securitization Facility at a weighted average interest rate of 5.0% and 1.1%, respectively. The fair value of the outstanding borrowing of the Securitization Facility at December 31, 2022 was $104.9 million. These fair values were determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly, and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities.</span></div> 2200000000 877500000 1300000000 60000000 60000000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s maximum consolidated total leverage ratio in the financial covenants (as defined in the Senior Credit Facility) is the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:75.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Consolidated Total Leverage Ratio</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022 through June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2023 and the last day of each fiscal quarter thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.00 to 1.00</span></div></td></tr></table></div> 4500 4000.00 0.0100 0.0225 0.0050 0.0100 0.0015 0.0030 4600000 1200000 3300000 0 31300000 0.014 771300000 843800000 0.056 0.014 38100000 45000000 800800000 1600000 1600000 0 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual repayments of the Term Loan component of the Senior Credit Facility are due as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year-ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Repayment</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669,375 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 38125000 67500000 669375000 775000000 42700000 39100000 3600000 575000000 0.005 0.005 104500000 0.042 13200000 73.67 1.30 0.98 1000 1 104200000 44500000 73.67 113.34 575000000 560500000 2900000 2900000 150000000 104700000 112500000 0.050 0.011 104900000 DERIVATIVE INSTRUMENTS<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Hedging</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s interest rate risk relates to U.S. dollar denominated variable interest rate borrowings. The Company uses interest rate swap derivative instruments to manage earnings and cash flow exposure resulting from changes in interest rates. These interest rate swaps apply a fixed interest rate on a portion of the Company's expected LIBOR-indexed floating-rate borrowings.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held the following interest rate swaps as of December 31, 2022 and 2021 (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Hedged Item</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Designation Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Termination Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Fixed Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Asset (Liability)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1-month USD LIBOR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 13, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 1, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.201 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1-month USD LIBOR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 13, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">July 1, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.423 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,520)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1-month USD LIBOR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 13, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 1, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.313 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,421)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1-month USD LIBOR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">October 10, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">July 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,512)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1-month USD LIBOR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">October 10, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">July 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,905 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,464)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1-month USD LIBOR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">October 10, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">July 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1-month USD LIBOR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 18, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.885 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,886)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1-month USD LIBOR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 18, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.867 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,764)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1-month USD LIBOR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 15, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">July 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23,742 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1-month USD LIBOR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 15, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">July 1, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,475,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,775,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56,712 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(43,956)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has designated these derivative instruments as cash flow hedges. The Company assesses the effectiveness of these derivative instruments and has recorded the changes in the fair value of the derivative instrument designated as a cash flow hedge as unrealized gains or losses in accumulated other comprehensive income (“AOCI”), net of tax, until the hedged item affected earnings, at which point any gain or loss was reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, the Company will reclassify the remaining amount of any gain or loss on the related cash flow hedge recorded in AOCI to interest expense at that time.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Hedging</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company enters into foreign currency hedge contracts intended to protect the U.S. dollar value of certain forecasted foreign currency denominated transactions. The Company assesses the effectiveness of the contracts that are designated as hedging instruments. The changes in fair value of foreign currency cash flow hedges are recorded in AOCI, net of tax. Those amounts are subsequently reclassified to earnings from AOCI as impacted by the hedged item when the hedged item affects earnings. If the hedged forecasted transaction does not occur, or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. For contracts not designated as hedging instruments, the changes in fair value of the contracts are recognized in other income, net in the consolidated statements of operation, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of the Company’s hedging program depends, in part, on forecasts of certain activity denominated in foreign currency. The Company may experience unanticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activities during periods of currency volatility. In addition, changes in currency exchange rates related to any unhedged transactions may affect earnings and cash flows. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cross-Currency Rate Swaps</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 2, 2017, the Company entered into cross currency swap agreements to convert a notional amount of $300.0 million equivalent to 291.2 million of Swiss Francs ("CHF") denominated intercompany loans into U.S. dollars. The CHF- denominated intercompany loans were the result of the purchase of intellectual property by a subsidiary in Switzerland as part of an acquisition. On September 26, 2022, the Company amended the CHF-denominated intercompany loan to extend the termination date to September 2023 and as a result, the Company early terminated the cross-currency swap designated as cash flow hedge of an intercompany loan with aggregate notional amount of $50.0 million. Simultaneously, the Company entered into a cross-currency swap agreement to convert a notional amount of CHF 48.5 million equivalent to $49.1 million of this </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amended intercompany loan into U.S. dollars. The loss recorded by the Company upon the settlement of the swap was not material for the period. As of December 31, 2022, $49.1 million of the $300.0 million notional amount remain outstanding.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 21, 2020, the Company entered into cross-currency swap agreements to convert a notional amount of $471.6 million equivalent to 420.1 million of a CHF-denominated intercompany loan into U.S. dollars. The CHF-denominated intercompany loan was the result of an intra-entity transfer of certain intellectual property rights to a subsidiary in Switzerland completed during the fourth quarter of 2020. The intercompany loan requires quarterly payments of CHF 5.8 million plus accrued interest. As a result, the aggregate notional amount of the related cross-currency swaps will decrease by a corresponding amount.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of these cross-currency swaps is to reduce volatility of earnings and cash flows associated with changes in the foreign currency exchange rate. Under the terms of these contracts, which have been designated as cash flow hedges, the Company will make interest payments in Swiss Francs and receive interest in U.S. dollars. Upon the maturity of these contracts, the Company will pay the principal amount of the loans in Swiss Francs and receive U.S. dollars from the counterparties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held the following cross-currency rate swaps as of December 31, 2022 and 2021 (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.897%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Termination Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Notional Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Asset (Liability)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2, 2017</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.95%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,283)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.52%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 21, 2020</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 22, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,241)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.98%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420,001 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">445,821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 28, 2022</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 29, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.95%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,532 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,528)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.32%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,769)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,242)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">rd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2022, in accordance with the termination date, the Company settled cross-currency swaps designated as cash flow hedges of an intercompany loan with aggregate notional amounts of $100 million. Based on the closing exchange rates, the gain upon settlement of these swaps was approximately $1.6 million which was offset by the loss on the settlement of the intercompany loan.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 4, 2021 in accordance with the termination date, the Company settled a cross-currency swap designated as a cash flow hedge of an intercompany loan with an aggregate notional amount of $50.0 million. The gain recorded by the Company upon the settlement of the swap was not material for the period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cross-currency swaps are carried on the consolidated balance sheet at fair value, and changes in the fair values are recorded as unrealized gains or losses in AOCI. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages certain foreign exchange risks through a variety of strategies, including hedging. The Company is exposed to foreign exchange risk from its international operations through foreign currency purchases, net investments in foreign subsidiaries, and foreign currency assets and liabilities created in the normal course of business. On October 1, 2018 ,December 16, 2020 and May 26, 2022, the Company entered into cross-currency swap agreements designated as net investment hedges to partially offset the effects of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">foreign currency on foreign subsidiaries.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held the following cross-currency rate swaps designated as net investment hedges as of December 31, 2022 and 2021 (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:14.751%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Termination Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fixed Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Notional Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>Asset (Liability)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay EUR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EUR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,713 </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,503 </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.57%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay EUR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EUR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,820 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,820 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,307 </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,147 </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.19%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 16, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 16, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(792)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive USD</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 26, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 16, 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288,210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,663)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.94%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,643)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,858 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2022, the Company early settled cross-currency swaps designated as net investment hedge with an aggregate notional amount of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$250 million equivalent to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 222.3 million CHF. The original settlement date was December 16, 2027. As a result of the settlement, the Company recorded a gain of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.9 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in AOCI. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2022, the Company entered into cross-currency swap agreements designated as net investment hedge to replace these swaps with a notional amount of $300 million equivalent to 288 million CHF. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2021, in accordance with the termination date, the Company settled cross-currency swaps designated as net investment hedge with an aggregate notional amount of $52 million equivalent to 44.9 million Euros. As a result of the settlement, the Company recorded a gain of $0.1 million in AOCI.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cross-currency swaps were carried on the consolidated balance sheet at fair value and changes in the fair values were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recorded as unrealized gains or losses in AOCI. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Counterparty Credit Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages its concentration of counterparty credit risk on its derivative instruments by limiting acceptable counterparties to a group of major financial institutions with investment grade credit ratings, and by actively monitoring their credit ratings and outstanding positions on an ongoing basis. Therefore, the Company considers the credit risk of the counterparties to be low. Furthermore, none of the Company’s derivative transactions are subject to collateral or other security arrangements, and none contain provisions that depend upon the Company’s credit ratings from any credit rating agency.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Derivative Instruments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has classified all of its derivative instruments within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of the derivative instruments. The fair values of the interest rate swaps and cross-currency swaps were developed using a market approach based on publicly available market yield curves and the terms of the swap. The Company performs ongoing assessments of counterparty credit risk. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effects of Derivative Instruments on Financial Position and Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value for derivatives designated as hedging instruments in the consolidated balance sheets as of December 31, 2022 and 2021:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value as of December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Location on Balance Sheet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedges — Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,497 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,900 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,682 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,653 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total derivatives designated as hedges — Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,173 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,497 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedges — Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;text-indent:4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,738 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,859 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,608 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,366 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total derivatives designated as hedges — Liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,874 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,838 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:2.2pt">The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:2.2pt">At December 31, 2022 and 2021, the total notional amounts related to the Company’s interest rate swaps were $1.5 billion and $1.8 billion respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the effect of derivative instruments designated as cash flow hedges and net investment hedges on the accompanying consolidated statement of operations during the years ended December 31, 2022 and 2021:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.812%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance in AOCI<br/>Beginning of<br/>Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount of<br/>Gain (Loss)<br/>Recognized in<br/>AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount of Gain (Loss)<br/>Reclassified from<br/>AOCI into<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance in AOCI<br/>End of Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location in<br/>Statements of<br/>Operations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43,956)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,360)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,688)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,847 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,430 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,789 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,914)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55,965)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,351 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,859 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,527 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93,769)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,402 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,411)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43,956)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,073)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,275 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,890 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,688)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,291)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,515 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(107,133)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,192 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,024 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55,965)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2022 and 2021, the Company recorded a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gain of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$11.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and gain of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$23.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, in other income, net related to change in fair value related to the foreign currency rate tran</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">slation of the cross-currency swaps, designated as cash flow hedges, to offset the gains or losses recognized on the intercompany loans.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2022 and 2021, the Company reco</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rded gains of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$8.4 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d $9.1 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps designated as cash flow hedges.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated gain that is expected to be reclassified to other income, net from AOCI as of December 31, 2022, for the cross-currency swaps designated as cash flow hedges within the next twelve months is $4.5 million. As of December 31, 2022, the Company does not expect any gains or losses will be reclassified into earnings as a result of the discontinuance of these cash flow hedges because the original forecasted transaction will not occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated gain that is expected to be reclassified to interest income from AOCI as of December 31, 2022 for the c</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ross-currency swaps designated as net investment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hedges, within the next twelve months is $11.7 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Instruments not designated hedges:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020, the Company entered into foreign currency forward contracts, with a notional amount of $4.2 million, to mitigate the foreign exchange risk related to certain intercompany loans denominated in Canadian Dollar ("CAD"). These contracts were settled in third quarter of 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, the Company entered into a foreign currency swap, with a notional amount of $7.3 million, to mitigate the risk from fluctuations in foreign currency exchange rates associated with an intercompany loan denominated in JPY. In a foreign currency swap transaction, the Company agrees with another party to exchange, at specified intervals, the difference between one currency and another currency at a fixed exchange rate, generally set at inception, calculated by reference to an agreed upon notional amount. The notional amount of each currency is exchanged at the inception and termination of the currency swap by each party. The Company subsequently paid down a portion of this swap, bringing the notional amount down to $6.4 million. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the gains (losses) of derivative instruments not designated as hedges on the condensed consolidated statements of income, which was included in other income:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.333%"><tr><td style="width:1.0%"/><td style="width:43.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.717%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,258 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">455 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held the following interest rate swaps as of December 31, 2022 and 2021 (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Hedged Item</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Designation Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Termination Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Fixed Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Asset (Liability)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1-month USD LIBOR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 13, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 1, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.201 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1-month USD LIBOR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 13, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">July 1, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.423 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,012 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,520)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1-month USD LIBOR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">200,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 13, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 1, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.313 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,421)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1-month USD LIBOR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">October 10, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">July 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,512)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1-month USD LIBOR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">October 10, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">July 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,905 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,464)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1-month USD LIBOR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">October 10, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">July 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1-month USD LIBOR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 18, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.885 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,886)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1-month USD LIBOR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 18, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.867 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,764)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1-month USD LIBOR Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">575,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 15, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">July 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23,742 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,552 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1-month USD LIBOR Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 15, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">July 1, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,475,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,775,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56,712 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(43,956)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held the following cross-currency rate swaps as of December 31, 2022 and 2021 (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.897%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Termination Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fixed Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Notional Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Asset (Liability)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2, 2017</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.95%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,598 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,283)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.52%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 21, 2020</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 22, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,241)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.98%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420,001 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">445,821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 28, 2022</span></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 29, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.95%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,532 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,528)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.32%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,769)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,242)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company held the following cross-currency rate swaps designated as net investment hedges as of December 31, 2022 and 2021 (dollar amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:14.751%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Termination Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fixed Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Notional Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>Asset (Liability)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay EUR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EUR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,760 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,713 </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,503 </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.57%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay EUR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 3, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EUR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,820 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,820 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,307 </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,147 </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.19%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 16, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 16, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(792)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive USD</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pay CHF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 26, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 16, 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CHF</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288,210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,663)</span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" rowspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td rowspan="2" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receive U.S.$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.94%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,643)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,858 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 300000000 0.02201 0 -5268000 150000000 150000000 0.02423 5012000 -5520000 200000000 200000000 0.02313 8380000 -7421000 75000000 75000000 0.03220 1831000 -5512000 75000000 75000000 0.03199 1905000 -5464000 75000000 75000000 0.03209 1970000 -5494000 100000000 100000000 0.02885 4252000 -6886000 100000000 100000000 0.02867 4153000 -6764000 575000000 575000000 0.01415 23742000 3552000 125000000 125000000 0.01404 5467000 821000 1475000000 1775000000 56712000 -43956000 300000000 291200000 50000000 48500000 49100000 49100000 300000000 471600000 420100000 5800000 0.0195 0 145598000 0 -8283000 0.0452 0 150000000 0.0300 374137000 397137000 -4241000 41000 0.0398 420001000 445821000 0.0195 48532000 0 -3528000 0 0.0532 49142000 0 -7769000 -8242000 100000000 1600000 50000000 0 51760000 51760000 4713000 2503000 0.0257 60000000 60000000 0 38820000 38820000 4307000 2147000 0.0219 45000000 45000000 0 0 222300000 0 -792000 0.0110 0 250000000 0 288210000 0 -14663000 0 0.0194 300000000 0 -5643000 3858000 250000000 222300000 4900000 300000000 288000000 52000000 44900000 100000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value for derivatives designated as hedging instruments in the consolidated balance sheets as of December 31, 2022 and 2021:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value as of December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Location on Balance Sheet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedges — Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,497 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,900 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,682 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,653 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,373 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total derivatives designated as hedges — Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,173 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,497 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives designated as hedges — Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;text-indent:4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,738 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,859 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,608 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,366 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total derivatives designated as hedges — Liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,874 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,838 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:2.2pt">The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:2.2pt">At December 31, 2022 and 2021, the total notional amounts related to the Company’s interest rate swaps were $1.5 billion and $1.8 billion respectively.</span></div> 4497000 4900000 16682000 0 11653000 5120000 40030000 4373000 3311000 2104000 76173000 16497000 0 18187000 3528000 8283000 0 0 0 30143000 8738000 4859000 20608000 3366000 32874000 64838000 1500000000 1800000000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents the effect of derivative instruments designated as cash flow hedges and net investment hedges on the accompanying consolidated statement of operations during the years ended December 31, 2022 and 2021:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.812%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance in AOCI<br/>Beginning of<br/>Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount of<br/>Gain (Loss)<br/>Recognized in<br/>AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount of Gain (Loss)<br/>Reclassified from<br/>AOCI into<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance in AOCI<br/>End of Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location in<br/>Statements of<br/>Operations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43,956)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,360)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,688)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,847 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,430 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,789 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,914)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55,965)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,351 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,859 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,527 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Flow Hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93,769)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,402 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,411)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43,956)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,073)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,275 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,890 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,688)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income, net</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Net Investment Hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,291)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,515 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(107,133)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,192 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,024 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55,965)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div> -43956000 93308000 -7360000 56712000 -9688000 8847000 19430000 -20271000 -2321000 2196000 6789000 -6914000 -55965000 104351000 18859000 29527000 -93769000 27402000 -22411000 -43956000 -1073000 24275000 32890000 -9688000 -12291000 16515000 6545000 -2321000 -107133000 68192000 17024000 -55965000 11100000 23800000 8400000 9100000 4500000 11700000 4200000 7300000 6400000 The following table summarizes the gains (losses) of derivative instruments not designated as hedges on the condensed consolidated statements of income, which was included in other income:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.333%"><tr><td style="width:1.0%"/><td style="width:43.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.717%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.802%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency forward contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,258 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">455 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0 -174000 1258000 629000 1258000 455000 GOODWILL AND OTHER INTANGIBLE ASSETS <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The qualitative evaluation is an assessment of factors including reporting unit specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of a reporting unit is less than its carrying amount, including goodwill. The Company may elect to bypass the qualitative assessment for its three reporting units and perform a quantitative test. The assumptions used in evaluating goodwill for impairment are subject to change and are tracked against historical results by management. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative test estimates the fair value of the three reporting units using a discounted cash flow model, which incorporates significant estimates and assumptions made by management which, by their nature, are characterized by uncertainty. Inputs used to fair value the Company's reporting units are considered inputs of the fair value hierarchy. For Level 3 measurements, significant increases or decreases in long-term growth rates or discount rates in isolation or in combination could result in a significantly lower or higher fair value measurement. The key assumptions impacting the valuation included the following: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The reporting unit's financial projections, which are based on management's assessment of regional and macroeconomic variables, industry trends and market opportunities, and the Company's strategic objectives and future growth plans.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The projected terminal value for the reporting unit, which represents the present value of projected cash flows beyond the last period in the discounted cash flow analysis. The terminal value reflects the Company's assumptions related to long-term growth rates and profitability, which are based on several factors, including local and macroeconomic variables, market opportunities, and future growth plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The discount rate used to measure the present value of the projected future cash flows is set using a weighted-average cost of capital method that considers market and industry data as well as the Company's specific risk factors that are likely to be considered by a market participant. The weighted-average cost of capital is the Company's estimate of the overall after-tax rate of return required by equity and debt holders of a business enterprise. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, the Company elected to perform a qualitative analysis for its three reporting units. The Company determined, after performing the qualitative analysis, that there was no evidence that it is more likely than not that the fair value was less that the carrying amounts, therefore, it was not necessary to perform a quantitative impairment test.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill in 2022 and 2021 were as follows: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:65.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Codman Specialty Surgical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Tissue Technologies</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671,975 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,392 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932,367 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ACell Acquisition </span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,147 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,147 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,547)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,509)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,056)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,428 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,030 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013,458 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of non-core traditional wound care business</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,019)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,019)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SIA Acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,209)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,413)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656,219 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,662 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038,881 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's identifiable intangible assets were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:47.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.969%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,204,325 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(370,968)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833,357 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144,040)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,041 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks/brand names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,674)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Codman trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplier relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,041 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,071)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,697,532 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(570,923)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126,609 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;padding-right:-9pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:47.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.969%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132,954 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307,013)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825,941 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks/brand names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,468)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Codman trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplier relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,891)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,646,892 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(501,319)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145,573 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets with Indefinite Lives</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests intangible assets with indefinite lives for impairment annually in the third quarter in accordance with ASC Topic 350. Additionally, the Company may perform interim tests if an event occurs or circumstances change that could potentially reduce the fair value of a indefinite lived intangible asset below its carrying amount. The Company tests for impairment by either performing a qualitative evaluation or a quantitative test. The qualitative evaluation is an assessment of factors, including specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of the intangible asset is less than its carrying amount. The Company may elect to bypass this qualitative evaluation and perform a quantitative test. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, the Company elected to perform a qualitative analysis for its intangible asset with indefinite lives. The Company determined, after performing the qualitative analysis, that there was no evidence that it is more likely than not that the fair value was less that the carrying amounts, therefore, it was not necessary to perform a quantitative impairment test.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product rights and other definite-lived intangible assets are tested periodically for impairment in accordance with ASC Topic 360 when events or changes in circumstances indicate that an asset's carrying value may not be recoverable. The impairment testing involves comparing the carrying amount of the asset or asset group to the forecasted undiscounted future cash flows. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and impairment exists. An impairment loss is measured as the excess of the asset's carrying value over its fair value, calculated using discounted future cash flows. The computed impairment loss is recognized in the period that the impairment occurs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense (including amounts reported in cost of product revenues) for the years ended December 31, 2022, 2021 and 2020 was $78.3 million, $83.3 million and $74.5 million, respectively. </span></div>Annual amortization expense is expected to approximate $82.3 million in 2023, $81.7 million in 2024, $81.7 million in 2025, $81.5 million in 2026, $79.6 million in 2027 and $551.6 million thereafter. Amortization of product technology based intangible assets totaled $64.4 million, $66.5 million and $46.7 million for the years ended December 31, 2022, 2021 and 2020, respectively, and is presented by the Company within cost of goods sold. 3 3 3 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill in 2022 and 2021 were as follows: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:65.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Codman Specialty Surgical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Tissue Technologies</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671,975 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,392 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932,367 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ACell Acquisition </span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,147 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,147 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,547)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,509)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,056)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,428 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,030 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013,458 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of non-core traditional wound care business</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,019)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,019)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SIA Acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,209)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,413)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656,219 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,662 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038,881 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 671975000 260392000 932367000 0 94147000 94147000 -8547000 -4509000 -13056000 663428000 350030000 1013458000 0 5019000 5019000 0 41855000 41855000 -7209000 -4204000 -11413000 656219000 382662000 1038881000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's identifiable intangible assets were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:47.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.969%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,204,325 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(370,968)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833,357 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144,040)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,041 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks/brand names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,674)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Codman trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplier relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,041 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,071)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,697,532 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(570,923)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126,609 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;padding-right:-9pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:47.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.969%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132,954 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307,013)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825,941 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks/brand names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,468)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Codman trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplier relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,891)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,646,892 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(501,319)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145,573 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's identifiable intangible assets were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:47.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.969%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,204,325 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(370,968)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833,357 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144,040)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,041 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks/brand names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,674)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Codman trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplier relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,041 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,071)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,697,532 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(570,923)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126,609 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;padding-right:-9pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:47.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.969%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132,954 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307,013)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825,941 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks/brand names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,468)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Codman trade name</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,758 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplier relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,891)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,646,892 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(501,319)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145,573 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P18Y 1204325000 370968000 833357000 P12Y 193081000 144040000 49041000 P28Y 97265000 34674000 62591000 166693000 166693000 P30Y 30211000 17170000 13041000 P11Y 5957000 4071000 1886000 1697532000 570923000 1126609000 P18Y 1132954000 307013000 825941000 P12Y 211344000 142755000 68589000 P28Y 98367000 31468000 66899000 167758000 167758000 P30Y 30211000 16192000 14019000 P11Y 6258000 3891000 2367000 1646892000 501319000 1145573000 78300000 83300000 74500000 82300000 81700000 81700000 81500000 79600000 551600000 64400000 66500000 46700000 TREASURY STOCK<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022 and 2021, there were 6.8 million and 4.9 million shares of treasury stock outstanding with a cost of $362.9 million and $234.4 million, respectively, at a weighted average cost per share of $53.18 and $47.86, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 26, 2023, the Company entered into a $150 million accelerated share repurchase ("2023 ASR") and received 2.1 million shares of the Company common stock at inception of the 2023 ASR, which represented approximately 80% of the expected total shares of under the 2023 SAR. The remaining repurchase transactions are expected to be completed in the first half of 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 26 2022, the Board of Directors authorized the Company to repurchase up to $225 million of the Company’s common stock. The program allows the Company to repurchase its shares opportunistically from time to time. The repurchase authorization expires in December 2024. This stock repurchase authorization replaces the previous $225 million stock repurchase authorization, of which $100 million remained authorized at the time of its replacement, and which was otherwise set to expire on December 31, 2022. Purchases may be affected through one or more open market transactions, privately negotiated transactions, transactions structured through investment banking institutions, or a combination of the foregoing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 12, 2022, the Company entered into a $125 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">accelerated share repurchase ("2022 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASR") and received 1.48 million shares of Company common stock at inception of the 2022 ASR, which represented approximately 80% of the expected total shares under the 2022 ASR. I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n March 24, 2022, the early exercise provision was exercised by the 2022 ASR counterparty. Upon settlement on March 24, 2022, the Company received an additional 0.46 million shares determined using the volume-weighted average price of the Company's common stock during the term of the 2022 ASR.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the year ended December 31, 2021, there were no repurchases of the Company’s common stock as part of the share repurchase authorization.</span></div>On August 16, 2022, the Inflation Reduction Act of 2022 (the “Act”) was signed into law. The Act implements a new excise tax of 1% on the net share repurchases made by the company effective for share repurchases performed January 1, 2023, or after. 6800000 4900000 362900000 234400000 53.18 47.86 150000000 2100000 0.80 225000000 225000000 100000000 125000000 1480000 0.80 460000 STOCK-BASED COMPENSATION<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense - all related to employees and members of the Board of Directors - recognized under the authoritative guidance was as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,437 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,096 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,725 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,210 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,591 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total estimated tax benefit related to stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,574 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,804 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net effect on net income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,151 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,406 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,370 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EMPLOYEE STOCK PURCHASE PLAN </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the Employee Stock Purchase Plan (the “ESPP”) is to provide eligible employees of the Company with the opportunity to acquire shares of common stock at periodic intervals by means of accumulated payroll deductions. The ESPP is a non-compensatory plan. Under the ESPP, a total of 3.0 million shares of common stock are reserved for issuance. These shares will be made available either from the Company’s authorized but unissued shares of common stock or from shares of common stock reacquired by the Company as treasury stock. At December 31, 2022, 2.0 million shares remain available for purchase under the ESPP. During the years ended December 31, 2022, 2021 and 2020, the Company issued 20,780 shares, 16,948 shares and 18,284 shares under the ESPP for $1.1 million, $1.1 million and $1.1 million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EQUITY AWARD PLANS </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company had stock options, restricted stock awards, performance stock awards, contract stock awards and restricted stock unit awards outstanding under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan (the “2003 Plan”). The 2000 and 2001 Equity Incentive Plans were terminated as of February 19, 2021, and no further awards may be issued under the plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2010 and May 2017, the stockholders of the Company approved amendments to the 2003 Plan to increase by 3.5 million and 1.7 million, respectively, the number of shares of common stock that may be issued under the 2003 Plan. The Company has reserved 4.0 million shares under each of the 2000 Plan and the 2001 Plan, and 14.7 million shares under the 2003 Plan. The Plans permit the Company to grant incentive and non-qualified stock options, stock appreciation rights, restricted stock, contract stock, performance stock, or dividend equivalent rights to designated directors, officers, employees and associates of the Company. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options issued under the 2003 Plan became exercisable over specified periods, generally within four years from the date of grant for officers and employees, and within one year from the date of the grant for members of the Board of Directors. The awards generally expire eight years from the grant date for employees and from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQzZDZiZGY5NzQyZTQxMzFiY2VmNGQ0MTU1YWFmYjg5L3NlYzo0M2Q2YmRmOTc0MmU0MTMxYmNlZjRkNDE1NWFhZmI4OV8xNzIvZnJhZzpjMjJmYjdjNzU1YmQ0YzAxYWJhNTZhZDI2ZGRhZjJkOS90ZXh0cmVnaW9uOmMyMmZiN2M3NTViZDRjMDFhYmE1NmFkMjZkZGFmMmQ5XzIzMDY_22acb8fc-f2cb-409d-a273-b3b42a7cc9db">six</span> to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQzZDZiZGY5NzQyZTQxMzFiY2VmNGQ0MTU1YWFmYjg5L3NlYzo0M2Q2YmRmOTc0MmU0MTMxYmNlZjRkNDE1NWFhZmI4OV8xNzIvZnJhZzpjMjJmYjdjNzU1YmQ0YzAxYWJhNTZhZDI2ZGRhZjJkOS90ZXh0cmVnaW9uOmMyMmZiN2M3NTViZDRjMDFhYmE1NmFkMjZkZGFmMmQ5XzIzMTI_d4b35179-5c95-4990-bea5-db80dcb363e7">ten</span> for directors and certain executive officers, except in certain instances that result in accelerated vesting due to death, disability, retirement age or change in control provisions within their grant agreements. Restricted stock issued under the 2003 Plan vests ratably over specified periods, generally three years after the date of grant. The vesting of performance stock issued under the 2003 Plan is subject to service and performance conditions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values stock option grants using the binomial distribution model. Management believes that the binomial distribution model is preferable to the Black-Scholes model because it is a more flexible model that gives consideration to the impact of non-transferability and vesting provisions in valuing employee stock options. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the value of stock options granted, the Company considered that it has never paid cash dividends and does not currently intend to pay cash dividends, and thus has assumed a 0% dividend yield. Expected volatilities are based on the historical volatility of the Company’s stock price. The expected life of stock options is estimated based on historical data on exercise of stock options, post-vesting forfeitures and other factors to estimate the expected term of the stock options granted. The risk-free interest rates are derived from the U.S. Treasury yield curve in effect on the date of grant for instruments with a remaining term similar to the expected life of the options. The Company accounts for forfeitures as they occur. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions were used in the calculation of fair value:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.01%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.89%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of option from grant date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value of options granted</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$23.15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$22.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$13.03</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s stock option activity. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Contractual Term in Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Stock Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$26,970</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.63 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,772 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.82 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,635 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $3.5 million, $5.0 million and $3.2 million in expense related to stock options during the years ended December 31, 2022, 2021 and 2020, respectively. The intrinsic value of options exercised for the years ended December 31, 2022, 2021 and 2020 were $4.0 million, $11.1 million and $8.7 million, respectively. Cash received from option exercises and employee stock purchase plan was $5.5 million, $6.8 million and $5.2 million, for the years ended December 31, 2022, 2021 and 2020, respectively. The realized tax benefit from options exercised w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ere $0.6 mi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">llion, $2.2 million and $1.7 million for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, there was approximately $3.5 million of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of approximately two years. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Awards of Restricted Stock, Performance Stock and Contract Stock </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s awards of restricted stock, performance stock and contract stock for the year ended December 31, 2022. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance Stock and Contract Stock Awards</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments for performance achievement related to award target</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancellations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.63 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.88 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $24.3 million, $31.2 million and $16.4 million in expense related to such awards during the years ended December 31, 2022, 2021 and 2020, respectively. The total fair market value of shares vested and released in 2022, 2021 and 2020 was $65.0 million, $15.7 million and $17.3 million, respectively. Vested awards include shares that have been fully earned but had not been delivered as of December 31, 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance stock awards have performance features associated with them. Performance stock, restricted stock and contract stock awards generally have requisite service periods of three years. The fair value of these awards is being expensed on a straight-line basis over the vesting period. As of December 31, 2022, there were 129,399 performance stock units ("PSU's") subject to vest and be released based on 2022 performance achievement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, there was approximately $29.7 million of total unrecognized compensation costs related to unvested restricted stock, performance stock and contract stock awards. These costs are expected to be recognized over a weighted-average period of approximately two years. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, there were approximately 3.1 million shares available for grant under the 2003 Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalized into inventory, share based compensation costs of $0.6 million, $0.5 million and $0.4 million for the years ended December 31, 2022, 2021 and 2020, respectively. Such share-based compensation was recognized as cost of goods sold when related inventory was sold.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense - all related to employees and members of the Board of Directors - recognized under the authoritative guidance was as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,437 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,096 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,725 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,210 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,591 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total estimated tax benefit related to stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,574 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,804 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net effect on net income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,151 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,406 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,370 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 549000 470000 344000 1739000 1644000 1471000 25437000 34096000 17776000 27725000 36210000 19591000 10574000 13804000 6221000 17151000 22406000 13370000 3000000 2000000 20780 16948 18284 1100000 1100000 1100000 3500000 1700000 4000000 4000000 14700000 P4Y P1Y P8Y P3Y 0 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions were used in the calculation of fair value:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.01%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.89%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of option from grant date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average grant date fair value of options granted</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$23.15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$22.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$13.03</span></td></tr></table></div> 0 0 0 0.30 0.29 0.27 0.0201 0.0130 0.0089 P7Y P7Y P7Y 23.15 22.59 13.03 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s stock option activity. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Contractual Term in Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Stock Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$26,970</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.63 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,772 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.82 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,635 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1225000 45.11 P4Y3M18D 26970000 146000 65.11 155000 28.32 14000 50.68 1202000 49.63 P4Y1M20D 10772000 871000 45.82 P3Y3M18D 9635000 3500000 5000000.0 3200000 4000000 11100000 8700000 5500000 6800000 5200000 600000 2200000 1700000 3500000 P2Y <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s awards of restricted stock, performance stock and contract stock for the year ended December 31, 2022. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance Stock and Contract Stock Awards</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments for performance achievement related to award target</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancellations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.63 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.88 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 422000 58.78 442000 60.62 334000 62.88 245000 62.89 0 0 18000 60.76 34000 62.29 10000 59.88 239000 58.27 252000 59.38 483000 61.63 407000 62.88 24300000 31200000 16400000 65000000 15700000 17300000 P3Y 129399 29700000 P2Y 3100000 600000 500000 400000 RETIREMENT BENEFIT PLANS<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DEFINED BENEFIT PLANS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has various defined benefit plans which covers certain employees in France, Japan, Germany and Switzerland. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company’s defined benefit pension plans for the years ended December 31, 2022 and 2021 included the following (amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,419 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,741 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(893)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost (credit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net period benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted average assumptions were used to develop net periodic pension benefit costs and the actuarial present values of projected pension benefit obligations for the years ended December 31, 2022 and 2021, respectively:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.958%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.37 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate for cash balance plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. In 2022 and 2021, the discount rates were prescribed as the current yield on corporate bonds with an average rating of AA or AAA of equivalent currency and term to the liabilities. The expected returns on plan assets represent the average rate of return expected to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid. In developing the expected rates of return, the Company considers returns of historical market data as well as actual returns on the plan assets. Using this reference information, the long-term return expectations for each asset category are developed according to the allocation among those investment categories.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assessment is determined using projections from external financial sources, long-term historical averages, actual returns by asset class and the various asset class allocations by market.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth the change in projected benefit obligations and the change in plan assets for the years ended December 31, 2022 and 2021 and a reconciliation of the funded status at December 31, 2022 and 2021, respectively (amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.549%"><tr><td style="width:1.0%"/><td style="width:64.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.982%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.287%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change In Projected Benefit Obligations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligations, beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,869 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,419 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,822)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(390)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(586)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(655)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee contribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit payment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(999)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign currency exchange rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,810)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected benefit obligations, end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50,364</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">65,184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change In Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value, beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,914 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,863)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(633)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign currency exchange rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Plan assets at fair value, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,053</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,914</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.549%"><tr><td style="width:1.0%"/><td style="width:65.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.982%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.117%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation Of Funded Status</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,053 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,914 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,364 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unfunded benefit obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,311</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,270</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unfunded benefit obligations are included in other liabilities in the consolidated balance sheets at December 31, 2022 and 2021, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the periods ended December 31, 2022 and 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company had a net gain of $7.4 million and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $7.0 million, respectively, recognized within accumulated other comprehensive loss that has not been recognized as a component of net periodic benefit cost. The gain recognized during the period ended December 31, 2021, is primarily attributed to a change in the discount rate used to estimate the projected benefit obligation for defined benefit plans which cover certain employees in Switzerland. The combined accumulated benefit obligations for the defined benefit plans was $46.4 million and $60.3 million as of December 31, 2022 and 2021, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized gains and losses are amortized over the average remaining future service for each plan. For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses is determined by using a 10% corridor of the greater of the market value of assets or the accumulated benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior service costs/benefits for the pension plans are amortized over the average remaining future service of plan participants at the time of the plan amendment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net plan assets of the pension plans are invested in common trusts. Common trusts are classified as Level 2 in fair value hierarchy. The fair value of common trusts is valued at net asset value based on the fair values of the underlying investments of the trusts as determined by the sponsor of the trusts. The investment strategy of the Company's defined benefit plans is both to meet the liabilities of the plans as they fall due and to maximize the return on invested assets within appropriate risk profile.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The benefit plans in France and Germany had no assets at December 31, 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, no plan assets are expected to be returned to the Company in the next twelve months.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the summary of expected future benefit payments (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,045 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,050 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Next five years</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,068 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, contributions expected to be paid to the plan in 2022 is $2.6 million. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DEFINED CONTRIBUTION PLANS </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has various defined contribution savings plans that cover substantially all employees in the United States, Belgium, Canada, France, Japan, Netherlands, the U.K. and Puerto Rico. The Company matches a certain percentage of each employee’s contributions as per the provisions of the plans. Total contributions by the Company to the plans were $9.8 million, $8.8 million and $6.7 million for the years ended December 31, 2022, 2021 and 2020, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DEFERRED COMPENSATION PLAN</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a Deferred Compensation Plan in which certain employees of the Company may defer the payment and taxation of up to 75% of their base salary and up to 100% of bonus amounts and other eligible cash compensation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This deferred compensation is invested in funds offered under this plan and is valued based on Level 1 measurements in the fair value hierarchy. Assets of the Company's deferred compensation plan are included in Other current assets and recorded at fair value based on their quoted market prices. The fair value of these assets at December 31, 2022 and 2021 was $4.7 million and $3.8 million. Offsetting liabilities relating to the deferred compensation plan are included in Other liabilities.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company’s defined benefit pension plans for the years ended December 31, 2022 and 2021 included the following (amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.957%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,419 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,741 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(893)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost (credit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net period benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">915</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> Net periodic benefit costs Net periodic benefit costs Net periodic benefit costs Net periodic benefit costs Net periodic benefit costs 2419000 2741000 194000 100000 1381000 893000 -326000 -281000 -9000 -186000 0 -51000 915000 1904000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted average assumptions were used to develop net periodic pension benefit costs and the actuarial present values of projected pension benefit obligations for the years ended December 31, 2022 and 2021, respectively:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.958%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.37 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest crediting rate for cash balance plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 0.0244 0.0037 0.0361 0.0359 0.0197 0.0210 0.0100 0.0100 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth the change in projected benefit obligations and the change in plan assets for the years ended December 31, 2022 and 2021 and a reconciliation of the funded status at December 31, 2022 and 2021, respectively (amounts in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.549%"><tr><td style="width:1.0%"/><td style="width:64.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.982%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.287%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change In Projected Benefit Obligations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligations, beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,869 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,419 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gain) loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,822)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(390)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(586)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(655)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee contribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit payment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(999)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign currency exchange rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,810)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected benefit obligations, end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50,364</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">65,184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change In Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value, beginning of year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,914 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,863)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(633)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign currency exchange rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Plan assets at fair value, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,053</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,914</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 65184000 72869000 194000 100000 2419000 2741000 14822000 5044000 -390000 -586000 20000 655000 999000 917000 391000 373000 999000 2128000 1810000 2657000 50364000 65184000 39914000 37825000 -2863000 3371000 2356000 2254000 999000 917000 0 633000 998000 2128000 391000 373000 -964000 -1319000 38053000 39914000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.549%"><tr><td style="width:1.0%"/><td style="width:65.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.982%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.117%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation Of Funded Status</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,053 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,914 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,364 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unfunded benefit obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,311</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,270</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 38053000 39914000 50364000 65184000 -12311000 -25270000 7400000 7000000 46400000 60300000 0 0 0 <div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the summary of expected future benefit payments (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,045 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,050 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Next five years</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,068 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 2211000 2045000 2050000 1929000 1868000 11068000 2600000 9800000 8800000 6700000 0.75 1 4700000 3800000 LEASES AND RELATED PARTY LEASES<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases administrative, manufacturing, research and distribution facilities and vehicles through operating lease agreements. The Company has no finance leases as of December 31, 2022. Many of the Company's leases include both lease (e.g., fixed payments including rent) and non-lease components (e.g., common-area or other maintenance costs). For vehicles, the Company has elected the practical expedient to group lease and non-lease components. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most facility leases include one or more options to renew. The exercise of lease renewal options is typically at the Company's sole discretion, therefore, the majority of renewals to extend the lease terms are not included in the ROU assets and lease liabilities as they are not reasonably certain of exercise. The Company regularly evaluates renewal options and when they are reasonably certain of exercise, the renewal period is included in the lease term.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of the Company's leases do not provide an implicit rate, the Company uses a collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease expense for the year ended December 31, 2022 and 2021, was $22.6 million and $20.3 million, respectively, which includes $0.3 million, in related party operating lease expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases at December 31, 2022 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.946%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:18.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except lease term and discount rate)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,543 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,624 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,775 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,329 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,044 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,104 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years):</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased facilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased vehicles</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 years</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased facilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased vehicles</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.200%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,610 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under operating leases at December 31, 2022 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Related Parties</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third Parties</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,024 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,320 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,869 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,198 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,886 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,429 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,451 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,407 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,044 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,420 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no future minimum lease payments under finance leases at December 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Leases </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its manufacturing facility in Plainsboro, New Jersey, from a general partnership that is 50% owned by a corporation whose stockholders are trusts, whose beneficiaries include family members of the Company’s principal stockholder and former director. The term of the current lease agreement is through October 31, 2029 at an annual rate of approximately $0.3 million per year. The current lease agreement also provides (i) a 5-year renewal option for the Company to extend the lease from November 1, 2029 through October 31, 2034 at the fair market rental rate of the premises, and (ii) another 5-year renewal option to extend the lease from November 1, 2034 through October 31, 2039 at the fair market rental rate of the premises.</span></div> 1 22600000 20300000 300000 300000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases at December 31, 2022 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.946%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:18.086%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except lease term and discount rate)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,543 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,624 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,775 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,329 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,044 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,104 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years):</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased facilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased vehicles</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 years</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased facilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased vehicles</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 148284000 84543000 14624000 14775000 157420000 90329000 172044000 105104000 P16Y10M24D P10Y4M24D P2Y P2Y1M6D 0.054 0.051 0.027 0.026 <div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.200%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,610 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 17442000 15077000 72169000 12610000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under operating leases at December 31, 2022 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Related Parties</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third Parties</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,024 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,320 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,869 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,198 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,886 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,429 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,451 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,407 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,044 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,420 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 296000 20024000 20320000 296000 20869000 21165000 296000 19198000 19494000 296000 16830000 17126000 296000 15886000 16182000 542000 164622000 165164000 2022000 257429000 259451000 87407000 172044000 14624000 157420000 0 0.50 300000 P5Y November 1, 2029 through October 31, 2034 P5Y November 1, 2034 through October 31, 2039 INCOME TAXES <div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,642 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,150 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,082 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,894 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,677 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,520 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. Federal statutory rate to the Company’s effective tax rate is as follows: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:59.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in income taxes resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Excess tax benefits from stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Intercompany profit in inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Nondeductible facilitative costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Contingent Consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Research and development credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Return to provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Global intangible low-taxed income ("GILTI")</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Nondeductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">   Fair market value step up on intra-entity transfer of intellectual property</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Gain from sale of business - book to tax differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our effective tax rate was 15.6% and 21.2% of income before income taxes for the years ended December 31, 2022 and December 31, 2021, respectively. In 2022, the Company’s lower effective tax rate was driven by a $5.1 million income tax benefit related to stock compensation and a $2.4 million income tax benefit related to the filing of amended federal and state returns for prior years. In 2021, the Company's higher effective tax rate was driven in part by an $8.5 million income tax expense for nondeductible goodwill related to the sale of the Extremity Orthopedics business, offset by a $3.1 million income tax benefit related to excess tax benefits from stock compensation. In 2020, the Company’s lower worldwide effective tax rate was primarily driven by an $59.2 million income tax benefit on an intra-entity transfer of certain intellectual property, substantially completed during the fourth quarter in 2020. Excluding this transaction, the effective worldwide tax rate for 2020 was 20.2%.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2020, the Company completed an intra-entity transfer of certain intellectual property rights to one of its subsidiaries in Switzerland. While the transfer did not result in a taxable gain, the Company’s Swiss subsidiary received a step-up in tax basis based on the fair value of the transferred intellectual property rights. The Company determined the fair value using a discounted cash flow model based on expectations of revenue growth rates, royalty rates, discount rates, and useful lives of the intellectual property. The Co</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">mpany recorded a $59.2 million deferred tax benefit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in Switzerland related to the amortizable tax basis in the transferred intellectual property.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2022, the Company’s foreign operations generated a $0.4 million increase in income tax expense when compared to the same period in 2021, because of geographic and business mix of taxable earnings and losses, among other factors. The 2022 foreign effective tax rate is 15.9%, compared to 15.2% in 2021. The Company’s foreign tax rate is primarily based upon statutory rates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2021, the Company’s foreign operations generated a $63.6 million increase in income tax expense when compared to the same period in 2020, because of the intra-entity transfer of certain intellectual property in 2020, geographic and business mix of taxable earnings and losses, among other factors. The 2021 foreign effective tax rate is 15.2%, compared to (57.1)% in 2020. The Company’s foreign tax rate is primarily based upon statutory rates and is also impacted by the intra-entity transfer of certain intellectual property as described above for 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Changes to income tax laws and regulations, in any of the tax jurisdictions in which the Company operates, could impact the effective tax rate. Various governments, both U.S. and non-U.S., are increasingly focused on tax reform and revenue-raising legislation. On August 16, 2022, the Inflation Reduction Act of 2022 (the “Act”) was signed into law, the company does not expect the law to have a material impact on the company’s effective tax rate. Further, legislation in foreign jurisdictions may be enacted, in response to the base erosion and profit-sharing (BEPS) project begun by the Organization for Economic Cooperation and Development (OECD). The OECD recently finalized major reform of the international tax system with respect to implementing a global minimum tax rate. Such changes in U.S. and Non-U.S. jurisdictions could have an adverse effect on the Company’s effective tax rate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes consisted of the following: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,835 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,377 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,893 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,042 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,929 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,357 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,766 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,830)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,079)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,316)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,688)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,760)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,322 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,585)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,755)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,138)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,344 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,602 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,372)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax effects of significant temporary differences that give rise to deferred tax assets and liabilities, shown before jurisdictional netting, are presented below: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Doubtful accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,029 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Inventory related items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,084 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Accrued vacation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,042 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Accrued bonus</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,944 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,955 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,742 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,707 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,198 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalization of research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,770 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Unrealized foreign exchange gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,849 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Charitable contributions carryforward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Leases and Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,788 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,164 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,737 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,767)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Deferred tax assets after valuation allowance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,513 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,970 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Intangible and fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166,891)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152,150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Unrealized foreign exchange loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,991)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Leases and Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,975)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,658)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total deferred tax liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202,857)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169,808)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net deferred tax assets (liabilities)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,344)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,162 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 U.S. Tax Cuts and Jobs Act contained a provision which requires, for tax purposes, the capitalization and amortization of research and development expenses; effective for years beginning after December 31, 2021. The Company’s deferred tax assets increased by $20.2 million within the table above, related to the 2017 Tax Act.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, the Company had net operating loss carryforwards of $79.5 million for federal income tax purposes, $75.5 million for foreign income tax purposes and $37.9 million for state income tax purposes to offset future taxable income. The majority of the federal net operating loss carryforwards expire through 2037, while $18.6 million have an indefinite carry forward period. For foreign net operating loss carryforwards, $59.1 million will expire through 2028, while the remaining $16.4 million have an indefinite carry forward period. The state net operating loss carryforwards expire through 2036. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance relates to deferred tax assets for certain items that will be deductible for income tax purposes under very limited circumstances and for which the Company believes it will not satisfy the more likely than not threshold for realization of the associated tax benefit. In the event that the Company determines that it would be able to realize more or less than the recorded amount of net deferred tax assets, an adjustment to the deferred tax asset valuation allowance would be recorded in the period such a determination is made. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance at December 31, 2022 and 2021 primarily remained unchanged from respective prior periods; decreasing by an immaterial amount in both periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charged to Costs and Expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at End of Period</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets valuation allowance </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,069 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company has not provided deferred income taxes on unrepatriated earnings from foreign subsidiaries as they are deemed to be indefinitely reinvested unless there is a manner under which to remit the earnings with no material tax cost. Material taxes would primarily be attributable to foreign withholding taxes and local income taxes when such earnings are distributed. The Company will repatriate foreign earnings when there is no need for reinvestment overseas and no material tax cost to bring the earnings back to the United States. Reinvestment considerations would include future acquisitions, transactions, and capital expenditure plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of uncertain tax benefits is as follows: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Prior years' tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Approximately $0.7 million of the balance at December 31, 2022 relates to uncertain tax positions that, if recognized, would affect the annual effective tax rate. The Company has $0.3 million of uncertain tax positions at December 31, 2022 related to tax positions for which it is reasonably possible that the amounts could be reduced during the twelve months following December 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties relating to uncertain tax positions in income tax expense. The Company recognized a minimal benefit for the years ended December 31, 2022, 2021 and 2020. The Company had minimal interest and penalties accrued for the years ended December 31, 2022 and 2021 and 2020. </span></div>The Company files Federal income tax returns, as well as multiple state, local and foreign jurisdiction tax returns. The Company is no longer subject to examinations of its U.S. consolidated Federal income tax returns by the IRS through fiscal year 2015. Additionally, the Company is no longer subject to examinations by the IRS for fiscal year 2017. All significant state and local matters have been concluded through fiscal year 2014. All significant foreign matters have been settled through fiscal 2015. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,642 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,150 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,082 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,894 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,677 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,520 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 92642000 91150000 15082000 121252000 123527000 78438000 213894000 214677000 93520000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. Federal statutory rate to the Company’s effective tax rate is as follows: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:59.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in income taxes resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Excess tax benefits from stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Intercompany profit in inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Nondeductible facilitative costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Contingent Consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Research and development credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Return to provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Global intangible low-taxed income ("GILTI")</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Nondeductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">   Fair market value step up on intra-entity transfer of intellectual property</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Gain from sale of business - book to tax differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.210 0.210 0.210 0.001 0.019 0.012 -0.039 -0.040 -0.079 -0.024 -0.012 -0.010 0.003 -0.002 0.012 0.002 0.003 0.011 -0.020 -0.002 0.002 0.014 0.012 0.016 -0.005 -0.007 -0.023 0.028 0.007 0.025 0.018 0.009 0.024 0 0 -0.633 0 0.039 0.028 -0.004 0 0.005 0.156 0.212 -0.432 0.156 0.212 -5100000 -2400000 8500000 -3100000 59200000 0.202 59200000 400000 0.159 0.152 63600000 0.152 -0.571 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes consisted of the following: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,835 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,377 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,893 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,042 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,929 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,357 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,766 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,591)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,830)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,079)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,316)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,688)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,760)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,322 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,763 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,585)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,755)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,138)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,344 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,602 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,372)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 24201000 31938000 6184000 3835000 11377000 5029000 9893000 5042000 12553000 37929000 48357000 23766000 -11591000 -12830000 -5079000 -2316000 -3688000 -1760000 9322000 13763000 -57299000 -4585000 -2755000 -64138000 33344000 45602000 -40372000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax effects of significant temporary differences that give rise to deferred tax assets and liabilities, shown before jurisdictional netting, are presented below: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Doubtful accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,029 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Inventory related items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,084 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,319 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Accrued vacation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,042 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Accrued bonus</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,944 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,955 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,742 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,707 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,198 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalization of research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,770 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Unrealized foreign exchange gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,849 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Charitable contributions carryforward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Leases and Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,788 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,164 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,737 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,767)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Deferred tax assets after valuation allowance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,513 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,970 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Intangible and fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166,891)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152,150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Unrealized foreign exchange loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,991)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Leases and Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,975)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,658)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Total deferred tax liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202,857)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169,808)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net deferred tax assets (liabilities)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,344)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,162 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2261000 2029000 31950000 31841000 13084000 13319000 2175000 3042000 4944000 7415000 10175000 13955000 2130000 1742000 30707000 26198000 51542000 36770000 6228000 12849000 180000 206000 39788000 41371000 195164000 190737000 9651000 9767000 185513000 180970000 166891000 152150000 12991000 0 22975000 17658000 202857000 169808000 17344000 11162000 20200000 79500000 75500000 37900000 18600000 59100000 16400000 The valuation allowance at December 31, 2022 and 2021 primarily remained unchanged from respective prior periods; decreasing by an immaterial amount in both periods.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charged to Costs and Expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at End of Period</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets valuation allowance </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,069 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 15258000 -515000 71000 14672000 13825000 1444000 89000 100000 15258000 12069000 1617000 0 -139000 13825000 <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of uncertain tax benefits is as follows: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Prior years' tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 676000 702000 676000 37000 0 0 0 0 26000 0 26000 0 713000 676000 702000 700000 300000 NET INCOME PER SHARE<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net income per share was as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Dollars in thousands, except per share amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Basic net income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,075 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,892 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Diluted net income per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,550 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,075 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding — Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares for diluted earnings per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,516 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,485 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,228 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock of approximately 0.3 million and 0.1 million shares at December 31, 2022, and 2021 that are issuable through exercise of dilutive securities, respectively, and were not included in the computation of diluted net income per share because their effect would have been anti-dilutive. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the adoption of ASU 2020-06, as the principal amount of the 2025 Notes will be paid in cash and only the conversion spread is settled in shares, the Company will be utilizing the if-converted method and only includes the net number of incremental shares that would be issued upon conversion.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net income per share was as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Dollars in thousands, except per share amounts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Basic net income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,075 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,892 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Diluted net income per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,550 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,075 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding — Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares for diluted earnings per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,516 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,485 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,228 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 180550000 169075000 133892000 82997000 84698000 84650000 2.18 2.00 1.58 180550000 169075000 133892000 82997000 84698000 84650000 519000 787000 577000 83516000 85485000 85228000 2.16 1.98 1.57 300000 100000 ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in accumulated other comprehensive loss by component between December 31, 2022 and 2021 are presented in the table below, net of tax:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Items</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Items</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,981)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,893 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,067)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,155)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,429 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,807)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts reclassified from accumulated other comprehensive income, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current-period other comprehensive gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,798 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,429 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,807)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,420 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,817 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,322 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,874)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,265 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, the Company reclassified a gain of $15.0 million and a loss of $0.4 million from accumulated other comprehensive loss to other income, net and interest income, respectively.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in accumulated other comprehensive loss by component between December 31, 2022 and 2021 are presented in the table below, net of tax:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains and Losses on Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Defined Benefit Pension Items</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Items</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,981)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,893 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,067)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,155)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,429 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,807)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts reclassified from accumulated other comprehensive income, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current-period other comprehensive gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,798 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,429 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,807)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,420 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,817 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,322 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,874)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,265 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -42981000 1893000 -4067000 -45155000 80335000 7429000 -17807000 69957000 14537000 0 0 14537000 65798000 7429000 -17807000 55420000 22817000 9322000 -21874000 10265000 15000000 400000 COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for certain technology, manufacturing, distribution, and selling rights and licenses granted to the Company, the Company has agreed to pay royalties on sales of certain products that it sells. The royalty payments that the Company made under these agreements were not significant for any of the periods presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to various claims, lawsuits and proceedings in the ordinary course of the Company's business, including claims by current or former employees, distributors and competitors and with respect to its products and product liability claims, lawsuits and proceedings, some of which have been settled by the Company. In the opinion of management, such claims are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material, adverse effect on the Company's financial condition. However, it is possible that the </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company's results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues for loss contingencies when it is deemed probable that a loss has been incurred and that loss is estimable. The amounts accrued are based on the full amount of the estimated loss before considering insurance proceeds and do not include an estimate for legal fees expected to be incurred in connection with the loss contingency. The Company consistently accrues legal fees expected to be incurred in connection with loss contingencies as those fees are incurred by outside counsel as a period cost.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Contingent Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the fair value of contingent consideration during the twelve-month period ended December 31, 2022 and 2021 to reflect the change in estimate, additions, payments, transfers and the time value of money during the period. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the years ended December 31, 2022 and 2021 is as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:17.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.276%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="36" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration Liability Related to Acquisition of:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Arkis <br/> (See Note 4) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derma Sciences</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ACell Inc.<br/> (See Note 4) </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SIA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,691 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,408 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers from long-term to current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,885 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,885)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration liabilities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(846)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,885)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,215)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,845 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,050 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,700 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,607 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.528%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration Liability Related to Acquisition of:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Arkis <br/> (See Note 4) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derma Sciences</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ACell Inc.<br/> (See Note 4)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,415 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers from long-term to current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration liabilities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,691 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,408 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,800 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Derma Sciences</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assumed contingent consideration incurred by Derma Sciences, Inc. ("Derma Sciences") related to its acquisitions of BioD and the intellectual property related to Medihoney products. The Company accounted for the contingent liabilities by recording their fair value on the date of the acquisition based on a probability weighted income approach. The Company has already paid $33.3 million related to the aforementioned contingent liabilities. One contingent milestone remains which relates to net sales of Medihoney™ products exceeding certain amounts defined in the agreement between the Company and Derma Sciences. The potential maximum undiscounted payment amounts to $3.0 million. The estimated fair value as of December 31, 2022 and 2021 was $0.2 million. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Arkis BioSciences, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the acquisition of Arkis BioSciences, Inc. ("Arkis"), the Company is required to pay the former shareholders of Arkis up to $25.5 million based on the timing of certain development milestones of $10 million and commercial sales milestones of $15.5 million, respectively. The Company used a probability weighted income approach to calculate the fair value of the contingent consideration that considered the possible outcomes of scenarios related to each specified milestone. The Company estimated the fair value of the contingent consideration to be $13.1 million at the acquisition date. The estimated the fair value as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $12.9 million. The Company recorded $2.8 million in accrued expenses and other current liabilities and $10.1 million in other liabilities at </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheets of the Company.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the years ended December 31, 2022 and 2021 is as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:17.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.276%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="36" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration Liability Related to Acquisition of:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Arkis <br/> (See Note 4) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derma Sciences</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ACell Inc.<br/> (See Note 4) </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SIA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,691 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,408 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers from long-term to current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,885 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,885)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration liabilities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(846)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,885)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,215)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,845 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,050 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,700 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,607 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.528%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration Liability Related to Acquisition of:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Arkis <br/> (See Note 4) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derma Sciences</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ACell Inc.<br/> (See Note 4)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location in Financial Statements</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,415 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transfers from long-term to current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration liabilities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,691 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,408 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,800 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div> 3691000 11408000 230000 0 21800000 0 0 0 0 0 57607000 0 0 0 4885000 -4885000 0 846000 1358000 0 4885000 13215000 0 2845000 10050000 230000 0 3700000 57607000 3415000 11746000 230000 0 0 0 0 23900000 276000 -276000 0 0 0 62000 0 2100000 3691000 11408000 230000 21800000 33300000 1 3000000 200000 200000 25500000 10000000 15500000 13100000 12900000 2800000 10100000 SEGMENT AND GEOGRAPHIC INFORMATION<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company internally manages two global reportable segments and reports the results of its businesses to its chief operating decision maker. The two reportable segments and their activities are described below.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Codman Specialty Surgical segment includes (i) the Neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment and (ii) the Instruments business, which sells more than 40,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Tissue Technologies segment includes such offerings as skin and wound repair, plastics &amp; surgical reconstruction products, bone grafts, and nerve and tendon repair products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporate and other category includes (i) various executive, finance, human resource, information systems and legal functions, (ii) brand management, and (iii) share-based compensation costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating results of the various reportable segments as presented are not comparable to one another because (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions, and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the operating segment results. Net sales and profit by reportable segment for the years ended December 31, 2022, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:58.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.804%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Segment Net Sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Codman Specialty Surgical</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019,564 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025,232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894,831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Tissue Technologies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517,216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477,037 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557,666 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542,448 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371,868 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Segment Profit</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Codman Specialty Surgical</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tissue Technologies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,802 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,630 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651,675 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667,670 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,287 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,882)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,914)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,757)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398,873)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(453,526)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(337,160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,920 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,230 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,370 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not allocate any assets to the reportable segments. No asset information is reported to the chief operating decision maker and disclosed in the financial information for each segment. The Company attributes revenue to geographic areas based on the location of the customer. Total revenue, net and long-lived assets (tangible) by major geographic area are summarized below: </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:34.289%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asia Pacific</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of the World</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126,810 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,903 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557,666 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089,526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,034 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,561 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,689 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371,868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-lived assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,776 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,026 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,289 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,836 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,686 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2 2 40000 Net sales and profit by reportable segment for the years ended December 31, 2022, 2021 and 2020 are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:58.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.804%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Segment Net Sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Codman Specialty Surgical</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019,564 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025,232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894,831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Tissue Technologies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517,216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477,037 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557,666 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542,448 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371,868 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Segment Profit</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Codman Specialty Surgical</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tissue Technologies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,802 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,630 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651,675 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667,670 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,287 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,882)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,914)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,757)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398,873)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(453,526)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(337,160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,920 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,230 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,370 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1019564000 1025232000 894831000 538102000 517216000 477037000 1557666000 1542448000 1371868000 417873000 439471000 356657000 233802000 228199000 159630000 651675000 667670000 516287000 13882000 16914000 27757000 -398873000 -453526000 -337160000 238920000 197230000 151370000 Total revenue, net and long-lived assets (tangible) by major geographic area are summarized below: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:34.289%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dollars in thousands</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asia Pacific</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of the World</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126,810 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,903 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557,666 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089,526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,034 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,561 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,689 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371,868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-lived assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,975 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,776 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,026 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,289 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,836 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,686 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1126810000 170903000 176477000 83476000 1557666000 1089526000 191327000 182034000 79561000 1542448000 971975000 172689000 157174000 70030000 1371868000 440223000 60857000 12975000 2721000 516776000 339535000 55026000 11289000 6836000 412686000 EXCEL 125 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 126 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 127 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 128 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 493 598 1 false 149 0 false 13 false false R1.htm 0000001 - Document - Document and Entity Information Sheet http://integralife.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://integralife.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS CONSOLIDATED STATEMENTS OF OPERATIONS Statements 3 false false R4.htm 0000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 4 false false R5.htm 0000005 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://integralife.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 5 false false R6.htm 0000006 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://integralife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 6 false false R7.htm 0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 0000008 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Sheet http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Statements 8 false false R9.htm 0000009 - Disclosure - BUSINESS Sheet http://integralife.com/role/BUSINESS BUSINESS Notes 9 false false R10.htm 0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 0000011 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS Sheet http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERS REVENUES FROM CONTRACTS WITH CUSTOMERS Notes 11 false false R12.htm 0000012 - Disclosure - ACQUISITIONS AND DIVESTITURES Sheet http://integralife.com/role/ACQUISITIONSANDDIVESTITURES ACQUISITIONS AND DIVESTITURES Notes 12 false false R13.htm 0000013 - Disclosure - DEBT Sheet http://integralife.com/role/DEBT DEBT Notes 13 false false R14.htm 0000014 - Disclosure - DERIVATIVE INSTRUMENTS Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTS DERIVATIVE INSTRUMENTS Notes 14 false false R15.htm 0000015 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Sheet http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETS GOODWILL AND OTHER INTANGIBLE ASSETS Notes 15 false false R16.htm 0000016 - Disclosure - TREASURY STOCK Sheet http://integralife.com/role/TREASURYSTOCK TREASURY STOCK Notes 16 false false R17.htm 0000017 - Disclosure - STOCK-BASED COMPENSATION Sheet http://integralife.com/role/STOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 17 false false R18.htm 0000018 - Disclosure - RETIREMENT BENEFIT PLANS Sheet http://integralife.com/role/RETIREMENTBENEFITPLANS RETIREMENT BENEFIT PLANS Notes 18 false false R19.htm 0000019 - Disclosure - LEASES AND RELATED PARTY LEASES Sheet http://integralife.com/role/LEASESANDRELATEDPARTYLEASES LEASES AND RELATED PARTY LEASES Notes 19 false false R20.htm 0000020 - Disclosure - INCOME TAXES Sheet http://integralife.com/role/INCOMETAXES INCOME TAXES Notes 20 false false R21.htm 0000021 - Disclosure - NET INCOME PER SHARE Sheet http://integralife.com/role/NETINCOMEPERSHARE NET INCOME PER SHARE Notes 21 false false R22.htm 0000022 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Sheet http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Notes 22 false false R23.htm 0000023 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://integralife.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 23 false false R24.htm 0000024 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION Sheet http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATION SEGMENT AND GEOGRAPHIC INFORMATION Notes 24 false false R25.htm 0000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 25 false false R26.htm 0000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES 26 false false R27.htm 0000027 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables) Sheet http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSTables REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables) Tables http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERS 27 false false R28.htm 0000028 - Disclosure - ACQUISITIONS AND DIVESTITURES (Tables) Sheet http://integralife.com/role/ACQUISITIONSANDDIVESTITURESTables ACQUISITIONS AND DIVESTITURES (Tables) Tables http://integralife.com/role/ACQUISITIONSANDDIVESTITURES 28 false false R29.htm 0000029 - Disclosure - DEBT (Tables) Sheet http://integralife.com/role/DEBTTables DEBT (Tables) Tables http://integralife.com/role/DEBT 29 false false R30.htm 0000030 - Disclosure - DERIVATIVE INSTRUMENTS (Tables) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSTables DERIVATIVE INSTRUMENTS (Tables) Tables http://integralife.com/role/DERIVATIVEINSTRUMENTS 30 false false R31.htm 0000031 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Sheet http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Tables http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETS 31 false false R32.htm 0000032 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://integralife.com/role/STOCKBASEDCOMPENSATIONTables STOCK-BASED COMPENSATION (Tables) Tables http://integralife.com/role/STOCKBASEDCOMPENSATION 32 false false R33.htm 0000033 - Disclosure - RETIREMENT BENEFIT PLANS (Tables) Sheet http://integralife.com/role/RETIREMENTBENEFITPLANSTables RETIREMENT BENEFIT PLANS (Tables) Tables http://integralife.com/role/RETIREMENTBENEFITPLANS 33 false false R34.htm 0000034 - Disclosure - LEASES AND RELATED PARTY LEASES (Tables) Sheet http://integralife.com/role/LEASESANDRELATEDPARTYLEASESTables LEASES AND RELATED PARTY LEASES (Tables) Tables http://integralife.com/role/LEASESANDRELATEDPARTYLEASES 34 false false R35.htm 0000035 - Disclosure - INCOME TAXES (Tables) Sheet http://integralife.com/role/INCOMETAXESTables INCOME TAXES (Tables) Tables http://integralife.com/role/INCOMETAXES 35 false false R36.htm 0000036 - Disclosure - NET INCOME PER SHARE (Tables) Sheet http://integralife.com/role/NETINCOMEPERSHARETables NET INCOME PER SHARE (Tables) Tables http://integralife.com/role/NETINCOMEPERSHARE 36 false false R37.htm 0000037 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables) Sheet http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables) Tables http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS 37 false false R38.htm 0000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://integralife.com/role/COMMITMENTSANDCONTINGENCIESTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://integralife.com/role/COMMITMENTSANDCONTINGENCIES 38 false false R39.htm 0000039 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables) Sheet http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables SEGMENT AND GEOGRAPHIC INFORMATION (Tables) Tables http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATION 39 false false R40.htm 0000040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) Sheet http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) Details http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables 40 false false R41.htm 0000041 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Roll forward of Valuation for Doubtful Accounts (Details) Sheet http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRollforwardofValuationforDoubtfulAccountsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Roll forward of Valuation for Doubtful Accounts (Details) Details 41 false false R42.htm 0000042 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Inventories, Net) (Details) Sheet http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofInventoriesNetDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Inventories, Net) (Details) Details http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables 42 false false R43.htm 0000043 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property, Plant and Equipment Balances and Corresponding Lives) (Details) Sheet http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property, Plant and Equipment Balances and Corresponding Lives) (Details) Details http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables 43 false false R44.htm 0000044 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Restructuring Charges (Details) Sheet http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofRestructuringChargesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Restructuring Charges (Details) Details 44 false false R45.htm 0000045 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Adoption of 2020-06 (Details) Sheet http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdoptionof202006Details SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Adoption of 2020-06 (Details) Details 45 false false R46.htm 0000046 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Narrative) (Details) Sheet http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails REVENUES FROM CONTRACTS WITH CUSTOMERS (Narrative) (Details) Details http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSTables 46 false false R47.htm 0000047 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Narrative, Revenue Remaining Performance Obligation) (Details) Sheet http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeRevenueRemainingPerformanceObligationDetails REVENUES FROM CONTRACTS WITH CUSTOMERS (Narrative, Revenue Remaining Performance Obligation) (Details) Details http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSTables 47 false false R48.htm 0000048 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Schedule of Changes in Contract Assets and Liabilities) (Details) Sheet http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails REVENUES FROM CONTRACTS WITH CUSTOMERS (Schedule of Changes in Contract Assets and Liabilities) (Details) Details http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSTables 48 false false R49.htm 0000049 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Schedule of Revenues Disaggregated by Major Source) (Details) Sheet http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails REVENUES FROM CONTRACTS WITH CUSTOMERS (Schedule of Revenues Disaggregated by Major Source) (Details) Details http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSTables 49 false false R50.htm 0000050 - Disclosure - ACQUISITIONS AND DIVESTITURES - Business Acquisition, Narrative (Details) Sheet http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessAcquisitionNarrativeDetails ACQUISITIONS AND DIVESTITURES - Business Acquisition, Narrative (Details) Details 50 false false R51.htm 0000051 - Disclosure - ACQUISITIONS AND DIVESTITURES - Fair Value Acquisition SIA (Details) Sheet http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionSIADetails ACQUISITIONS AND DIVESTITURES - Fair Value Acquisition SIA (Details) Details 51 false false R52.htm 0000052 - Disclosure - ACQUISITIONS AND DIVESTITURES - Divestitures, Narrative (Details) Sheet http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails ACQUISITIONS AND DIVESTITURES - Divestitures, Narrative (Details) Details 52 false false R53.htm 0000053 - Disclosure - ACQUISITIONS AND DIVESTITURES - Assets and Liabilities Divested (Details) Sheet http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails ACQUISITIONS AND DIVESTITURES - Assets and Liabilities Divested (Details) Details 53 false false R54.htm 0000054 - Disclosure - ACQUISITIONS AND DIVESTITURES - Fair Value Acquisition ACell (Details) Sheet http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails ACQUISITIONS AND DIVESTITURES - Fair Value Acquisition ACell (Details) Details 54 false false R55.htm 0000055 - Disclosure - DEBT (Narrative) (Details) Sheet http://integralife.com/role/DEBTNarrativeDetails DEBT (Narrative) (Details) Details http://integralife.com/role/DEBTTables 55 false false R56.htm 0000056 - Disclosure - DEBT (Maximum Total Leverage Ratio Table) (Details) Sheet http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails DEBT (Maximum Total Leverage Ratio Table) (Details) Details http://integralife.com/role/DEBTTables 56 false false R57.htm 0000057 - Disclosure - DEBT (Schedule of Debt Maturity) (Details) Sheet http://integralife.com/role/DEBTScheduleofDebtMaturityDetails DEBT (Schedule of Debt Maturity) (Details) Details http://integralife.com/role/DEBTTables 57 false false R58.htm 0000058 - Disclosure - DERIVATIVE INSTRUMENTS (Schedule of Interest Rate Swap Derivatives) (Details) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails DERIVATIVE INSTRUMENTS (Schedule of Interest Rate Swap Derivatives) (Details) Details http://integralife.com/role/DERIVATIVEINSTRUMENTSTables 58 false false R59.htm 0000059 - Disclosure - DERIVATIVE INSTRUMENTS (Narrative) (Details) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails DERIVATIVE INSTRUMENTS (Narrative) (Details) Details http://integralife.com/role/DERIVATIVEINSTRUMENTSTables 59 false false R60.htm 0000060 - Disclosure - DERIVATIVE INSTRUMENTS (Schedule of Cross-Currency Swap Derivatives) (Details) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails DERIVATIVE INSTRUMENTS (Schedule of Cross-Currency Swap Derivatives) (Details) Details http://integralife.com/role/DERIVATIVEINSTRUMENTSTables 60 false false R61.htm 0000061 - Disclosure - DERIVATIVE INSTRUMENTS (Schedule of Net Investment Hedges Derivatives) (Details) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails DERIVATIVE INSTRUMENTS (Schedule of Net Investment Hedges Derivatives) (Details) Details http://integralife.com/role/DERIVATIVEINSTRUMENTSTables 61 false false R62.htm 0000062 - Disclosure - DERIVATIVE INSTRUMENTS (Fair Value of Derivative Instruments By Balance Sheet Location) (Details) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails DERIVATIVE INSTRUMENTS (Fair Value of Derivative Instruments By Balance Sheet Location) (Details) Details http://integralife.com/role/DERIVATIVEINSTRUMENTSTables 62 false false R63.htm 0000063 - Disclosure - DERIVATIVE INSTRUMENTS (Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations) (Details) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails DERIVATIVE INSTRUMENTS (Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations) (Details) Details http://integralife.com/role/DERIVATIVEINSTRUMENTSTables 63 false false R64.htm 0000064 - Disclosure - DERIVATIVE INSTRUMENTS- (Schedule of Gains and (Loss) of Derivative Instruments) (Details) Sheet http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofGainsandLossofDerivativeInstrumentsDetails DERIVATIVE INSTRUMENTS- (Schedule of Gains and (Loss) of Derivative Instruments) (Details) Details http://integralife.com/role/DERIVATIVEINSTRUMENTSTables 64 false false R65.htm 0000065 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Narrative) (Details) Sheet http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails GOODWILL AND OTHER INTANGIBLE ASSETS (Narrative) (Details) Details http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables 65 false false R66.htm 0000066 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Schedule of Changes in Carrying Amount of Goodwill) (Details) Sheet http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails GOODWILL AND OTHER INTANGIBLE ASSETS (Schedule of Changes in Carrying Amount of Goodwill) (Details) Details http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables 66 false false R67.htm 0000067 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Components of Company's Identifiable Intangible Assets) (Details) Sheet http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails GOODWILL AND OTHER INTANGIBLE ASSETS (Components of Company's Identifiable Intangible Assets) (Details) Details http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables 67 false false R68.htm 0000068 - Disclosure - TREASURY STOCK - Narrative (Details) Sheet http://integralife.com/role/TREASURYSTOCKNarrativeDetails TREASURY STOCK - Narrative (Details) Details 68 false false R69.htm 0000069 - Disclosure - STOCK-BASED COMPENSATION (Summary of Employee Stock-Based Compensation Expense) (Details) Sheet http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofEmployeeStockBasedCompensationExpenseDetails STOCK-BASED COMPENSATION (Summary of Employee Stock-Based Compensation Expense) (Details) Details http://integralife.com/role/STOCKBASEDCOMPENSATIONTables 69 false false R70.htm 0000070 - Disclosure - STOCK-BASED COMPENSATION (Narrative) (Details) Sheet http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails STOCK-BASED COMPENSATION (Narrative) (Details) Details http://integralife.com/role/STOCKBASEDCOMPENSATIONTables 70 false false R71.htm 0000071 - Disclosure - STOCK-BASED COMPENSATION (Summary of Weighted-Average Assumptions) (Details) Sheet http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofWeightedAverageAssumptionsDetails STOCK-BASED COMPENSATION (Summary of Weighted-Average Assumptions) (Details) Details http://integralife.com/role/STOCKBASEDCOMPENSATIONTables 71 false false R72.htm 0000072 - Disclosure - STOCK-BASED COMPENSATION (Summary of Stock Option Activity) (Details) Sheet http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetails STOCK-BASED COMPENSATION (Summary of Stock Option Activity) (Details) Details http://integralife.com/role/STOCKBASEDCOMPENSATIONTables 72 false false R73.htm 0000073 - Disclosure - STOCK-BASED COMPENSATION (Summary of Vested and Unvested Restricted Stock, Performance Stock, and Contract Stock) (Details) Sheet http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofVestedandUnvestedRestrictedStockPerformanceStockandContractStockDetails STOCK-BASED COMPENSATION (Summary of Vested and Unvested Restricted Stock, Performance Stock, and Contract Stock) (Details) Details http://integralife.com/role/STOCKBASEDCOMPENSATIONTables 73 false false R74.htm 0000074 - Disclosure - RETIREMENT BENEFIT PLANS (Schedule of Net Periodic Benefit Costs) (Details) Sheet http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofNetPeriodicBenefitCostsDetails RETIREMENT BENEFIT PLANS (Schedule of Net Periodic Benefit Costs) (Details) Details http://integralife.com/role/RETIREMENTBENEFITPLANSTables 74 false false R75.htm 0000075 - Disclosure - RETIREMENT BENEFIT PLANS (Schedule of Assumptions Used Periodic Benefit Cost and Actuarial Present Value) (Details) Sheet http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofAssumptionsUsedPeriodicBenefitCostandActuarialPresentValueDetails RETIREMENT BENEFIT PLANS (Schedule of Assumptions Used Periodic Benefit Cost and Actuarial Present Value) (Details) Details http://integralife.com/role/RETIREMENTBENEFITPLANSTables 75 false false R76.htm 0000076 - Disclosure - RETIREMENT BENEFIT PLANS (Schedule of Change in Benefit Obligations and Plan Assets) (Details) Sheet http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofChangeinBenefitObligationsandPlanAssetsDetails RETIREMENT BENEFIT PLANS (Schedule of Change in Benefit Obligations and Plan Assets) (Details) Details http://integralife.com/role/RETIREMENTBENEFITPLANSTables 76 false false R77.htm 0000077 - Disclosure - RETIREMENT BENEFIT PLANS (Scheduled of Funded Status) (Details) Sheet http://integralife.com/role/RETIREMENTBENEFITPLANSScheduledofFundedStatusDetails RETIREMENT BENEFIT PLANS (Scheduled of Funded Status) (Details) Details http://integralife.com/role/RETIREMENTBENEFITPLANSTables 77 false false R78.htm 0000078 - Disclosure - RETIREMENT BENEFIT PLANS (Narrative) (Details) Sheet http://integralife.com/role/RETIREMENTBENEFITPLANSNarrativeDetails RETIREMENT BENEFIT PLANS (Narrative) (Details) Details http://integralife.com/role/RETIREMENTBENEFITPLANSTables 78 false false R79.htm 0000079 - Disclosure - RETIREMENT BENEFIT PLANS (Schedule of Expected Benefit Payments and Minimum Contribution on Unfunded Plans) (Details) Sheet http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofExpectedBenefitPaymentsandMinimumContributiononUnfundedPlansDetails RETIREMENT BENEFIT PLANS (Schedule of Expected Benefit Payments and Minimum Contribution on Unfunded Plans) (Details) Details http://integralife.com/role/RETIREMENTBENEFITPLANSTables 79 false false R80.htm 0000080 - Disclosure - LEASES AND RELATED PARTY LEASES - Narrative (Details) Sheet http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails LEASES AND RELATED PARTY LEASES - Narrative (Details) Details 80 false false R81.htm 0000081 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details) Sheet http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details) Details 81 false false R82.htm 0000082 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details) Sheet http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalCashFlowInformationDetails LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details) Details 82 false false R83.htm 0000083 - Disclosure - LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases Current Period (Details) Sheet http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases Current Period (Details) Details 83 false false R84.htm 0000084 - Disclosure - INCOME TAXES (Schedule of Income Before Income Taxes) (Details) Sheet http://integralife.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesDetails INCOME TAXES (Schedule of Income Before Income Taxes) (Details) Details http://integralife.com/role/INCOMETAXESTables 84 false false R85.htm 0000085 - Disclosure - INCOME TAXES (Schedule of Effective Tax Rate Reconciliation) (Details) Sheet http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails INCOME TAXES (Schedule of Effective Tax Rate Reconciliation) (Details) Details http://integralife.com/role/INCOMETAXESTables 85 false false R86.htm 0000086 - Disclosure - INCOME TAXES (Narrative) (Details) Sheet http://integralife.com/role/INCOMETAXESNarrativeDetails INCOME TAXES (Narrative) (Details) Details http://integralife.com/role/INCOMETAXESTables 86 false false R87.htm 0000087 - Disclosure - INCOME TAXES (Schedule of Provision for Income Taxes) (Details) Sheet http://integralife.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesDetails INCOME TAXES (Schedule of Provision for Income Taxes) (Details) Details http://integralife.com/role/INCOMETAXESTables 87 false false R88.htm 0000088 - Disclosure - INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details) Sheet http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details) Details http://integralife.com/role/INCOMETAXESTables 88 false false R89.htm 0000089 - Disclosure - INCOME TAXES (Tax Valuation Allowance) (Details) Sheet http://integralife.com/role/INCOMETAXESTaxValuationAllowanceDetails INCOME TAXES (Tax Valuation Allowance) (Details) Details http://integralife.com/role/INCOMETAXESTables 89 false false R90.htm 0000090 - Disclosure - INCOME TAXES (Schedule of Uncertain Tax Benefits Reconciliation) (Details) Sheet http://integralife.com/role/INCOMETAXESScheduleofUncertainTaxBenefitsReconciliationDetails INCOME TAXES (Schedule of Uncertain Tax Benefits Reconciliation) (Details) Details http://integralife.com/role/INCOMETAXESTables 90 false false R91.htm 0000091 - Disclosure - NET INCOME PER SHARE (Basic and Diluted Net Income Per Share) (Details) Sheet http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails NET INCOME PER SHARE (Basic and Diluted Net Income Per Share) (Details) Details http://integralife.com/role/NETINCOMEPERSHARETables 91 false false R92.htm 0000092 - Disclosure - NET INCOME PER SHARE (Narrative) (Details) Sheet http://integralife.com/role/NETINCOMEPERSHARENarrativeDetails NET INCOME PER SHARE (Narrative) (Details) Details http://integralife.com/role/NETINCOMEPERSHARETables 92 false false R93.htm 0000093 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Schedule of Accumulated Other Comprehensive Income (Loss)) (Details) Sheet http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofAccumulatedOtherComprehensiveIncomeLossDetails ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Schedule of Accumulated Other Comprehensive Income (Loss)) (Details) Details http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables 93 false false R94.htm 0000094 - Disclosure - AACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Narrative) (Details) Sheet http://integralife.com/role/AACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails AACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Narrative) (Details) Details 94 false false R95.htm 0000095 - Disclosure - COMMITMENTS AND CONTINGENCIES (Fair Value Contingent Consideration) (Details) Sheet http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails COMMITMENTS AND CONTINGENCIES (Fair Value Contingent Consideration) (Details) Details http://integralife.com/role/COMMITMENTSANDCONTINGENCIESTables 95 false false R96.htm 0000096 - Disclosure - COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details) Sheet http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details) Details 96 false false R97.htm 0000097 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details) Sheet http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails COMMITMENTS AND CONTINGENCIES - Narrative (Details) Details 97 false false R98.htm 0000098 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Narrative) (Details) Sheet http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails SEGMENT AND GEOGRAPHIC INFORMATION (Narrative) (Details) Details http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables 98 false false R99.htm 0000099 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Net Sales and Profit by Reportable Segment) (Details) Sheet http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails SEGMENT AND GEOGRAPHIC INFORMATION (Net Sales and Profit by Reportable Segment) (Details) Details http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables 99 false false R100.htm 0000100 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Total Revenue by Major Geographic Area) (Details) Sheet http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails SEGMENT AND GEOGRAPHIC INFORMATION (Total Revenue by Major Geographic Area) (Details) Details http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables 100 false false R9999.htm Uncategorized Items - iart-20221231.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - iart-20221231.htm Cover 101 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 15 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DebtInstrumentConvertibleConversionRatio1, us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued, us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod, us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense - iart-20221231.htm 4 iart-20221231.htm iart-20221231.xsd iart-20221231_cal.xml iart-20221231_def.xml iart-20221231_lab.xml iart-20221231_pre.xml iart-20221231xexx103h.htm iart-20221231xexx103i.htm iart-20221231xexx103j.htm iart-20221231xexx103k.htm iart-20221231xexx103l.htm iart-20221231xexx211.htm iart-20221231xexx231.htm iart-20221231xexx311.htm iart-20221231xexx312.htm iart-20221231xexx321.htm iart-20221231xexx322.htm iart-20221231xexx33.htm iart-20221231xexx44.htm iart-20221231_g1.jpg iart-20221231_g2.jpg iart-20221231_g3.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 131 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "iart-20221231.htm": { "axisCustom": 1, "axisStandard": 44, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 1528, "http://xbrl.sec.gov/dei/2022": 37 }, "contextCount": 493, "dts": { "calculationLink": { "local": [ "iart-20221231_cal.xml" ] }, "definitionLink": { "local": [ "iart-20221231_def.xml" ] }, "inline": { "local": [ "iart-20221231.htm" ] }, "labelLink": { "local": [ "iart-20221231_lab.xml" ] }, "presentationLink": { "local": [ "iart-20221231_pre.xml" ] }, "schema": { "local": [ "iart-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 958, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 17, "http://xbrl.sec.gov/dei/2022": 4, "total": 21 }, "keyCustom": 95, "keyStandard": 503, "memberCustom": 70, "memberStandard": 77, "nsprefix": "iart", "nsuri": "http://integralife.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://integralife.com/role/DocumentandEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "10", "role": "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000100 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Total Revenue by Major Geographic Area) (Details)", "menuCat": "Details", "order": "100", "role": "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION (Total Revenue by Major Geographic Area) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS", "menuCat": "Notes", "order": "11", "role": "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERS", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - ACQUISITIONS AND DIVESTITURES", "menuCat": "Notes", "order": "12", "role": "http://integralife.com/role/ACQUISITIONSANDDIVESTITURES", "shortName": "ACQUISITIONS AND DIVESTITURES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - DEBT", "menuCat": "Notes", "order": "13", "role": "http://integralife.com/role/DEBT", "shortName": "DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - DERIVATIVE INSTRUMENTS", "menuCat": "Notes", "order": "14", "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTS", "shortName": "DERIVATIVE INSTRUMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS", "menuCat": "Notes", "order": "15", "role": "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETS", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - TREASURY STOCK", "menuCat": "Notes", "order": "16", "role": "http://integralife.com/role/TREASURYSTOCK", "shortName": "TREASURY STOCK", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - STOCK-BASED COMPENSATION", "menuCat": "Notes", "order": "17", "role": "http://integralife.com/role/STOCKBASEDCOMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - RETIREMENT BENEFIT PLANS", "menuCat": "Notes", "order": "18", "role": "http://integralife.com/role/RETIREMENTBENEFITPLANS", "shortName": "RETIREMENT BENEFIT PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - LEASES AND RELATED PARTY LEASES", "menuCat": "Notes", "order": "19", "role": "http://integralife.com/role/LEASESANDRELATEDPARTYLEASES", "shortName": "LEASES AND RELATED PARTY LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "false", "longName": "0000002 - Document - Audit Information", "menuCat": "Cover", "order": "2", "role": "http://integralife.com/role/AuditInformation", "shortName": "Audit Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - INCOME TAXES", "menuCat": "Notes", "order": "20", "role": "http://integralife.com/role/INCOMETAXES", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - NET INCOME PER SHARE", "menuCat": "Notes", "order": "21", "role": "http://integralife.com/role/NETINCOMEPERSHARE", "shortName": "NET INCOME PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)", "menuCat": "Notes", "order": "22", "role": "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "23", "role": "http://integralife.com/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION", "menuCat": "Notes", "order": "24", "role": "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATION", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "25", "role": "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:InventoryPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "menuCat": "Tables", "order": "26", "role": "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:InventoryPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)", "menuCat": "Tables", "order": "27", "role": "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSTables", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - ACQUISITIONS AND DIVESTITURES (Tables)", "menuCat": "Tables", "order": "28", "role": "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESTables", "shortName": "ACQUISITIONS AND DIVESTITURES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - DEBT (Tables)", "menuCat": "Tables", "order": "29", "role": "http://integralife.com/role/DEBTTables", "shortName": "DEBT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "menuCat": "Statements", "order": "3", "role": "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - DERIVATIVE INSTRUMENTS (Tables)", "menuCat": "Tables", "order": "30", "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSTables", "shortName": "DERIVATIVE INSTRUMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "menuCat": "Tables", "order": "31", "role": "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "menuCat": "Tables", "order": "32", "role": "http://integralife.com/role/STOCKBASEDCOMPENSATIONTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - RETIREMENT BENEFIT PLANS (Tables)", "menuCat": "Tables", "order": "33", "role": "http://integralife.com/role/RETIREMENTBENEFITPLANSTables", "shortName": "RETIREMENT BENEFIT PLANS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "iart:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - LEASES AND RELATED PARTY LEASES (Tables)", "menuCat": "Tables", "order": "34", "role": "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESTables", "shortName": "LEASES AND RELATED PARTY LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "iart:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - INCOME TAXES (Tables)", "menuCat": "Tables", "order": "35", "role": "http://integralife.com/role/INCOMETAXESTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - NET INCOME PER SHARE (Tables)", "menuCat": "Tables", "order": "36", "role": "http://integralife.com/role/NETINCOMEPERSHARETables", "shortName": "NET INCOME PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)", "menuCat": "Tables", "order": "37", "role": "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "menuCat": "Tables", "order": "38", "role": "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESTables", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables)", "menuCat": "Tables", "order": "39", "role": "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "menuCat": "Statements", "order": "4", "role": "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ProvisionForDoubtfulAccounts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)", "menuCat": "Details", "order": "40", "role": "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ProvisionForDoubtfulAccounts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i83ae2861f4a1489fa6e81d7262ab2f96_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Roll forward of Valuation for Doubtful Accounts (Details)", "menuCat": "Details", "order": "41", "role": "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRollforwardofValuationforDoubtfulAccountsDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Roll forward of Valuation for Doubtful Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i3fe44e0a022f4f34bf03594794a50963_I20191231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:InventoryPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Inventories, Net) (Details)", "menuCat": "Details", "order": "42", "role": "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofInventoriesNetDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Inventories, Net) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "us-gaap:InventoryPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property, Plant and Equipment Balances and Corresponding Lives) (Details)", "menuCat": "Details", "order": "43", "role": "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Property, Plant and Equipment Balances and Corresponding Lives) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i4b9d9ed2b94d4cd6853e13d7ede4ff8d_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Restructuring Charges (Details)", "menuCat": "Details", "order": "44", "role": "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofRestructuringChargesDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Restructuring Charges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RestructuringReserveAccrualAdjustment1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredIncomeTaxLiabilitiesNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Adoption of 2020-06 (Details)", "menuCat": "Details", "order": "45", "role": "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdoptionof202006Details", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Adoption of 2020-06 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i923e26b254024ce191a077d3ad910d88_I20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DeferredIncomeTaxLiabilitiesNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "iart:ReturnPolicyIssueOfCreditNumberOfDaysFromShipment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Narrative) (Details)", "menuCat": "Details", "order": "46", "role": "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "iart:ReturnPolicyIssueOfCreditNumberOfDaysFromShipment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i788f04f5fed04ca38e49ba6f03024c26_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Narrative, Revenue Remaining Performance Obligation) (Details)", "menuCat": "Details", "order": "47", "role": "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeRevenueRemainingPerformanceObligationDetails", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS (Narrative, Revenue Remaining Performance Obligation) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i788f04f5fed04ca38e49ba6f03024c26_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i4b9d9ed2b94d4cd6853e13d7ede4ff8d_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Schedule of Changes in Contract Assets and Liabilities) (Details)", "menuCat": "Details", "order": "48", "role": "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS (Schedule of Changes in Contract Assets and Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i4b9d9ed2b94d4cd6853e13d7ede4ff8d_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - REVENUES FROM CONTRACTS WITH CUSTOMERS (Schedule of Revenues Disaggregated by Major Source) (Details)", "menuCat": "Details", "order": "49", "role": "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails", "shortName": "REVENUES FROM CONTRACTS WITH CUSTOMERS (Schedule of Revenues Disaggregated by Major Source) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "ib05901fa55ec4ee09f5c084cb113c902_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "5", "role": "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i628706586a0345ba8883bd6d56eb2045_D20221206-20221206", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - ACQUISITIONS AND DIVESTITURES - Business Acquisition, Narrative (Details)", "menuCat": "Details", "order": "50", "role": "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessAcquisitionNarrativeDetails", "shortName": "ACQUISITIONS AND DIVESTITURES - Business Acquisition, Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i628706586a0345ba8883bd6d56eb2045_D20221206-20221206", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - ACQUISITIONS AND DIVESTITURES - Fair Value Acquisition SIA (Details)", "menuCat": "Details", "order": "51", "role": "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionSIADetails", "shortName": "ACQUISITIONS AND DIVESTITURES - Fair Value Acquisition SIA (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i547e9b738a9b4ffe8435a24e596115f8_I20221206", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - ACQUISITIONS AND DIVESTITURES - Divestitures, Narrative (Details)", "menuCat": "Details", "order": "52", "role": "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails", "shortName": "ACQUISITIONS AND DIVESTITURES - Divestitures, Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i8e90ad876dbd48bc8aa7bf8b4a53d714_D20210120-20210120", "decimals": "-5", "lang": "en-US", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i58908f12479149769863fd3b128d144e_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - ACQUISITIONS AND DIVESTITURES - Assets and Liabilities Divested (Details)", "menuCat": "Details", "order": "53", "role": "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails", "shortName": "ACQUISITIONS AND DIVESTITURES - Assets and Liabilities Divested (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i58908f12479149769863fd3b128d144e_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - ACQUISITIONS AND DIVESTITURES - Fair Value Acquisition ACell (Details)", "menuCat": "Details", "order": "54", "role": "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "shortName": "ACQUISITIONS AND DIVESTITURES - Fair Value Acquisition ACell (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i4eab553affa54f9fb01f97a61e3c4a4c_I20210120", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:SecuredDebtCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - DEBT (Narrative) (Details)", "menuCat": "Details", "order": "55", "role": "http://integralife.com/role/DEBTNarrativeDetails", "shortName": "DEBT (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-5", "lang": "en-US", "name": "iart:InterestPaymentsYearOne", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i2429c77787c540b481af5ad54734a36f_I20200714", "decimals": "INF", "first": true, "lang": "en-US", "name": "iart:DebtInstrumentCovenantMaximumLeverageRatio", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - DEBT (Maximum Total Leverage Ratio Table) (Details)", "menuCat": "Details", "order": "56", "role": "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails", "shortName": "DEBT (Maximum Total Leverage Ratio Table) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i2429c77787c540b481af5ad54734a36f_I20200714", "decimals": "INF", "first": true, "lang": "en-US", "name": "iart:DebtInstrumentCovenantMaximumLeverageRatio", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - DEBT (Schedule of Debt Maturity) (Details)", "menuCat": "Details", "order": "57", "role": "http://integralife.com/role/DEBTScheduleofDebtMaturityDetails", "shortName": "DEBT (Schedule of Debt Maturity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "idb5285f5cc45407cbdd753e2c83bf644_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - DERIVATIVE INSTRUMENTS (Schedule of Interest Rate Swap Derivatives) (Details)", "menuCat": "Details", "order": "58", "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails", "shortName": "DERIVATIVE INSTRUMENTS (Schedule of Interest Rate Swap Derivatives) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i0437592feca04863946089d86b4469ac_I20221231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - DERIVATIVE INSTRUMENTS (Narrative) (Details)", "menuCat": "Details", "order": "59", "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "shortName": "DERIVATIVE INSTRUMENTS (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "id9344740008a49528124058c2083bc1e_I20201231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "6", "role": "http://integralife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i4ed0c764a1ef48f18d31ec981995213b_I20201221", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - DERIVATIVE INSTRUMENTS (Schedule of Cross-Currency Swap Derivatives) (Details)", "menuCat": "Details", "order": "60", "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "shortName": "DERIVATIVE INSTRUMENTS (Schedule of Cross-Currency Swap Derivatives) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i7523d880d9374a2481b72ce4679376f9_I20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i4ed0c764a1ef48f18d31ec981995213b_I20201221", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - DERIVATIVE INSTRUMENTS (Schedule of Net Investment Hedges Derivatives) (Details)", "menuCat": "Details", "order": "61", "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails", "shortName": "DERIVATIVE INSTRUMENTS (Schedule of Net Investment Hedges Derivatives) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "if061f0c8b11a4b0e9af9f2d1b0096dfc_I20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i4ed0c764a1ef48f18d31ec981995213b_I20201221", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - DERIVATIVE INSTRUMENTS (Fair Value of Derivative Instruments By Balance Sheet Location) (Details)", "menuCat": "Details", "order": "62", "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "shortName": "DERIVATIVE INSTRUMENTS (Fair Value of Derivative Instruments By Balance Sheet Location) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i29f1ed4692244fb883cb0925404db697_I20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i4b9d9ed2b94d4cd6853e13d7ede4ff8d_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - DERIVATIVE INSTRUMENTS (Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations) (Details)", "menuCat": "Details", "order": "63", "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "shortName": "DERIVATIVE INSTRUMENTS (Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "ib305e15ed1f0490ea6032f84d1419429_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000064 - Disclosure - DERIVATIVE INSTRUMENTS- (Schedule of Gains and (Loss) of Derivative Instruments) (Details)", "menuCat": "Details", "order": "64", "role": "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofGainsandLossofDerivativeInstrumentsDetails", "shortName": "DERIVATIVE INSTRUMENTS- (Schedule of Gains and (Loss) of Derivative Instruments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportingUnits", "reportCount": 1, "unitRef": "reporting_unit", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000065 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Narrative) (Details)", "menuCat": "Details", "order": "65", "role": "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AdjustmentForAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i4b9d9ed2b94d4cd6853e13d7ede4ff8d_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000066 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Schedule of Changes in Carrying Amount of Goodwill) (Details)", "menuCat": "Details", "order": "66", "role": "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Schedule of Changes in Carrying Amount of Goodwill) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "iart:CostOfDefiniteAndIndefiniteLivedIntangibleAssetsGrossExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000067 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Components of Company's Identifiable Intangible Assets) (Details)", "menuCat": "Details", "order": "67", "role": "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Components of Company's Identifiable Intangible Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "iart:CostOfDefiniteAndIndefiniteLivedIntangibleAssetsGrossExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockCommonShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000068 - Disclosure - TREASURY STOCK - Narrative (Details)", "menuCat": "Details", "order": "68", "role": "http://integralife.com/role/TREASURYSTOCKNarrativeDetails", "shortName": "TREASURY STOCK - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockCommonShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000069 - Disclosure - STOCK-BASED COMPENSATION (Summary of Employee Stock-Based Compensation Expense) (Details)", "menuCat": "Details", "order": "69", "role": "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofEmployeeStockBasedCompensationExpenseDetails", "shortName": "STOCK-BASED COMPENSATION (Summary of Employee Stock-Based Compensation Expense) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "7", "role": "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000070 - Disclosure - STOCK-BASED COMPENSATION (Narrative) (Details)", "menuCat": "Details", "order": "70", "role": "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "shortName": "STOCK-BASED COMPENSATION (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000071 - Disclosure - STOCK-BASED COMPENSATION (Summary of Weighted-Average Assumptions) (Details)", "menuCat": "Details", "order": "71", "role": "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofWeightedAverageAssumptionsDetails", "shortName": "STOCK-BASED COMPENSATION (Summary of Weighted-Average Assumptions) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "2", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i4b9d9ed2b94d4cd6853e13d7ede4ff8d_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000072 - Disclosure - STOCK-BASED COMPENSATION (Summary of Stock Option Activity) (Details)", "menuCat": "Details", "order": "72", "role": "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetails", "shortName": "STOCK-BASED COMPENSATION (Summary of Stock Option Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i74db8baf10424ff7a6207881e5bae34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000073 - Disclosure - STOCK-BASED COMPENSATION (Summary of Vested and Unvested Restricted Stock, Performance Stock, and Contract Stock) (Details)", "menuCat": "Details", "order": "73", "role": "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofVestedandUnvestedRestrictedStockPerformanceStockandContractStockDetails", "shortName": "STOCK-BASED COMPENSATION (Summary of Vested and Unvested Restricted Stock, Performance Stock, and Contract Stock) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i74db8baf10424ff7a6207881e5bae34e_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000074 - Disclosure - RETIREMENT BENEFIT PLANS (Schedule of Net Periodic Benefit Costs) (Details)", "menuCat": "Details", "order": "74", "role": "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofNetPeriodicBenefitCostsDetails", "shortName": "RETIREMENT BENEFIT PLANS (Schedule of Net Periodic Benefit Costs) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000075 - Disclosure - RETIREMENT BENEFIT PLANS (Schedule of Assumptions Used Periodic Benefit Cost and Actuarial Present Value) (Details)", "menuCat": "Details", "order": "75", "role": "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofAssumptionsUsedPeriodicBenefitCostandActuarialPresentValueDetails", "shortName": "RETIREMENT BENEFIT PLANS (Schedule of Assumptions Used Periodic Benefit Cost and Actuarial Present Value) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfNetFundedStatusTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i4b9d9ed2b94d4cd6853e13d7ede4ff8d_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanBenefitObligation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000076 - Disclosure - RETIREMENT BENEFIT PLANS (Schedule of Change in Benefit Obligations and Plan Assets) (Details)", "menuCat": "Details", "order": "76", "role": "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofChangeinBenefitObligationsandPlanAssetsDetails", "shortName": "RETIREMENT BENEFIT PLANS (Schedule of Change in Benefit Obligations and Plan Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanActuarialGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfNetFundedStatusTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000077 - Disclosure - RETIREMENT BENEFIT PLANS (Scheduled of Funded Status) (Details)", "menuCat": "Details", "order": "77", "role": "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduledofFundedStatusDetails", "shortName": "RETIREMENT BENEFIT PLANS (Scheduled of Funded Status) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfNetFundedStatusTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFundedStatusOfPlan", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000078 - Disclosure - RETIREMENT BENEFIT PLANS (Narrative) (Details)", "menuCat": "Details", "order": "78", "role": "http://integralife.com/role/RETIREMENTBENEFITPLANSNarrativeDetails", "shortName": "RETIREMENT BENEFIT PLANS (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000079 - Disclosure - RETIREMENT BENEFIT PLANS (Schedule of Expected Benefit Payments and Minimum Contribution on Unfunded Plans) (Details)", "menuCat": "Details", "order": "79", "role": "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofExpectedBenefitPaymentsandMinimumContributiononUnfundedPlansDetails", "shortName": "RETIREMENT BENEFIT PLANS (Schedule of Expected Benefit Payments and Minimum Contribution on Unfunded Plans) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "ieb43d094e8824032961a8ec85d76affb_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "menuCat": "Statements", "order": "8", "role": "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "ieb43d094e8824032961a8ec85d76affb_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "iart:LesseeOperatingLeaseNumberOfRenewalOptions", "reportCount": 1, "unique": true, "unitRef": "renewal_option", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000080 - Disclosure - LEASES AND RELATED PARTY LEASES - Narrative (Details)", "menuCat": "Details", "order": "80", "role": "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails", "shortName": "LEASES AND RELATED PARTY LEASES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "iart:LesseeOperatingLeaseNumberOfRenewalOptions", "reportCount": 1, "unique": true, "unitRef": "renewal_option", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "iart:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000081 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details)", "menuCat": "Details", "order": "81", "role": "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails", "shortName": "LEASES AND RELATED PARTY LEASES - Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "iart:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i4686279af17c417cbe3854bacf4ca2d8_I20221231", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "iart:CashFlowLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000082 - Disclosure - LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details)", "menuCat": "Details", "order": "82", "role": "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalCashFlowInformationDetails", "shortName": "LEASES AND RELATED PARTY LEASES - Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "iart:CashFlowLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000083 - Disclosure - LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases Current Period (Details)", "menuCat": "Details", "order": "83", "role": "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails", "shortName": "LEASES AND RELATED PARTY LEASES - Future Minimum Lease Payment Under Operating Leases Current Period (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000084 - Disclosure - INCOME TAXES (Schedule of Income Before Income Taxes) (Details)", "menuCat": "Details", "order": "84", "role": "http://integralife.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesDetails", "shortName": "INCOME TAXES (Schedule of Income Before Income Taxes) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000085 - Disclosure - INCOME TAXES (Schedule of Effective Tax Rate Reconciliation) (Details)", "menuCat": "Details", "order": "85", "role": "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails", "shortName": "INCOME TAXES (Schedule of Effective Tax Rate Reconciliation) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000086 - Disclosure - INCOME TAXES (Narrative) (Details)", "menuCat": "Details", "order": "86", "role": "http://integralife.com/role/INCOMETAXESNarrativeDetails", "shortName": "INCOME TAXES (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000087 - Disclosure - INCOME TAXES (Schedule of Provision for Income Taxes) (Details)", "menuCat": "Details", "order": "87", "role": "http://integralife.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesDetails", "shortName": "INCOME TAXES (Schedule of Provision for Income Taxes) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000088 - Disclosure - INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details)", "menuCat": "Details", "order": "88", "role": "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails", "shortName": "INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i5c0443956aba4287a79da88ad2b1f789_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "icbb5085d40924d08b32a44ed38777fa8_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000089 - Disclosure - INCOME TAXES (Tax Valuation Allowance) (Details)", "menuCat": "Details", "order": "89", "role": "http://integralife.com/role/INCOMETAXESTaxValuationAllowanceDetails", "shortName": "INCOME TAXES (Tax Valuation Allowance) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i16e2c6f764c8440b9b5484c3e0a26c87_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - BUSINESS", "menuCat": "Notes", "order": "9", "role": "http://integralife.com/role/BUSINESS", "shortName": "BUSINESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i4b9d9ed2b94d4cd6853e13d7ede4ff8d_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000090 - Disclosure - INCOME TAXES (Schedule of Uncertain Tax Benefits Reconciliation) (Details)", "menuCat": "Details", "order": "90", "role": "http://integralife.com/role/INCOMETAXESScheduleofUncertainTaxBenefitsReconciliationDetails", "shortName": "INCOME TAXES (Schedule of Uncertain Tax Benefits Reconciliation) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "ib4ed22898bc64d24b7765e593f891985_I20191231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000091 - Disclosure - NET INCOME PER SHARE (Basic and Diluted Net Income Per Share) (Details)", "menuCat": "Details", "order": "91", "role": "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails", "shortName": "NET INCOME PER SHARE (Basic and Diluted Net Income Per Share) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000092 - Disclosure - NET INCOME PER SHARE (Narrative) (Details)", "menuCat": "Details", "order": "92", "role": "http://integralife.com/role/NETINCOMEPERSHARENarrativeDetails", "shortName": "NET INCOME PER SHARE (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i4b9d9ed2b94d4cd6853e13d7ede4ff8d_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000093 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Schedule of Accumulated Other Comprehensive Income (Loss)) (Details)", "menuCat": "Details", "order": "93", "role": "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofAccumulatedOtherComprehensiveIncomeLossDetails", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Schedule of Accumulated Other Comprehensive Income (Loss)) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherNonoperatingIncomeExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000094 - Disclosure - AACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Narrative) (Details)", "menuCat": "Details", "order": "94", "role": "http://integralife.com/role/AACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails", "shortName": "AACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i787ac1d1d9ba4a389460945f21e1be91_D20220101-20221231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherNonoperatingIncomeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i9c2f742f6e864e72a554afa2da3a8c66_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000095 - Disclosure - COMMITMENTS AND CONTINGENCIES (Fair Value Contingent Consideration) (Details)", "menuCat": "Details", "order": "95", "role": "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Fair Value Contingent Consideration) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i68a223d9d7454456aa04f06027515378_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "iart:FairValueMeasurementwithUnobservableInputsReconciliationLiabilityTransfersFromLongTermtoCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "ibae60ef4e8d8432b944c8e3b719f35a7_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000096 - Disclosure - COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details)", "menuCat": "Details", "order": "96", "role": "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "shortName": "COMMITMENTS AND CONTINGENCIES - Fair Value Contingent Consideration, Balance Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R97": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "icf69e67cb3914b7097e58795099a96dc_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "iart:BusinessCombinationContingentConsiderationNumberOfLiabilities", "reportCount": 1, "unique": true, "unitRef": "liability", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000097 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)", "menuCat": "Details", "order": "97", "role": "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "icf69e67cb3914b7097e58795099a96dc_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "iart:BusinessCombinationContingentConsiderationNumberOfLiabilities", "reportCount": 1, "unique": true, "unitRef": "liability", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000098 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Narrative) (Details)", "menuCat": "Details", "order": "98", "role": "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i6f0d2ae3ba1f445db46d7d3d48fcf5d9_D20220101-20221231", "decimals": "INF", "lang": "en-US", "name": "iart:SegmentReportingInformationNumberOfProductsOffered", "reportCount": 1, "unique": true, "unitRef": "product", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i912f32710efe4b489b6f6444b9fa8ba4_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000099 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Net Sales and Profit by Reportable Segment) (Details)", "menuCat": "Details", "order": "99", "role": "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails", "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION (Net Sales and Profit by Reportable Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "iart-20221231.htm", "contextRef": "i8beb115769fa4bde80a56f0d62b90c05_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9999": { "firstAnchor": null, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - iart-20221231.htm", "menuCat": "Cover", "order": "101", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - iart-20221231.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 149, "tag": { "country_DE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GERMANY", "terseLabel": "GERMANY" } } }, "localname": "DE", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "country_FR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FRANCE", "terseLabel": "FRANCE" } } }, "localname": "FR", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States (Includes long-lived assets in Puerto Rico)" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r932", "r933", "r934" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/AuditInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r932", "r933", "r934" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r932", "r933", "r934" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r932", "r933", "r934" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r935" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r930" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r929" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r929" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r929" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r936" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r929" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r929" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r929" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Smaller Reporting Company" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r929" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r937" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r932", "r933", "r934" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r928" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r931" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://integralife.com/role/DocumentandEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "iart_ACellIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ACell, Inc.", "label": "ACell, Inc. [Member]", "terseLabel": "ACell, Inc." } } }, "localname": "ACellIncMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "xbrltype": "domainItemType" }, "iart_ACellMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ACell", "label": "ACell [Member]", "terseLabel": "ACell" } } }, "localname": "ACellMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "iart_AcceleratedShareRepurchasesAdditionalSharesReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accelerated Share Repurchases, Additional Shares Received", "label": "Accelerated Share Repurchases, Additional Shares Received", "terseLabel": "Accelerated share repurchases, additional shares received" } } }, "localname": "AcceleratedShareRepurchasesAdditionalSharesReceived", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "xbrltype": "sharesItemType" }, "iart_AcceleratedShareRepurchasesPercentageOfExpectedTotalRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accelerated Share Repurchases, Percentage Of Expected Total Repurchased", "label": "Accelerated Share Repurchases, Percentage Of Expected Total Repurchased", "terseLabel": "Accelerated share repurchases, percentage of expected total repurchased" } } }, "localname": "AcceleratedShareRepurchasesPercentageOfExpectedTotalRepurchased", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "xbrltype": "percentItemType" }, "iart_AcceleratedShareRepurchasesSharesReceivedAtInception": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accelerated Share Repurchases. Shares Received at Inception", "label": "Accelerated Share Repurchases. Shares Received at Inception", "terseLabel": "Accelerated share repurchases, shares received at inception" } } }, "localname": "AcceleratedShareRepurchasesSharesReceivedAtInception", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "xbrltype": "sharesItemType" }, "iart_AccruedExpensesAndOtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued expenses and other current liabilities.", "label": "Accrued Expenses And Other Current Liabilities [Member]", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilitiesMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "xbrltype": "domainItemType" }, "iart_AccumulatedOtherComprehensiveIncomeLossRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]", "label": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossRollForward", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "iart_AllOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All Other [Member]", "label": "All Other [Member]", "terseLabel": "All other" } } }, "localname": "AllOtherMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "iart_AmortizationOfDebtIssuanceCostsAndDebtRefinancedFees": { "auth_ref": [], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization Of Debt Issuance Costs And Debt Refinanced Fees", "label": "Amortization Of Debt Issuance Costs And Debt Refinanced Fees", "terseLabel": "Amortization of debt issuance costs and expenses associated with debt refinancing" } } }, "localname": "AmortizationOfDebtIssuanceCostsAndDebtRefinancedFees", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "iart_AnnualRateOfLeaseAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Annual rate of lease agreement.", "label": "Annual Rate Of Lease Agreement", "terseLabel": "Annual rate of lease agreement" } } }, "localname": "AnnualRateOfLeaseAgreement", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_ArkisBioSciencesInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arkis BioSciences Inc. [Member]", "label": "Arkis BioSciences Inc. [Member]", "terseLabel": "Arkis" } } }, "localname": "ArkisBioSciencesInc.Member", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_AssetAcquisitionDevelopmentMilestonePaymentToBePaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Development Milestone Payment", "label": "Asset Acquisition, Development Milestone Payment To Be Paid", "terseLabel": "Asset Acquisition, Development Milestone Payment To Be Paid" } } }, "localname": "AssetAcquisitionDevelopmentMilestonePaymentToBePaid", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets And Liabilities, Lessee [Table Text Block]", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Supplemental Balance Sheet Information" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESTables" ], "xbrltype": "textBlockItemType" }, "iart_AuditInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Audit Information", "label": "Audit Information [Abstract]" } } }, "localname": "AuditInformationAbstract", "nsuri": "http://integralife.com/20221231", "xbrltype": "stringItemType" }, "iart_BioDEarnoutPaymentsandMedihoneyEarnoutPaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BioD Earnout Payments and Medihoney Earnout Payments [Member]", "label": "BioD Earnout Payments and Medihoney Earnout Payments [Member]", "terseLabel": "BioD Earnout Payments and Medihoney Earnout Payments" } } }, "localname": "BioDEarnoutPaymentsandMedihoneyEarnoutPaymentsMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_BusinessAcquisitionNumberOfContingentLiabilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Acquisition, Number Of Contingent Liabilities", "label": "Business Acquisition, Number Of Contingent Liabilities", "terseLabel": "Business Acquisition, number of payments" } } }, "localname": "BusinessAcquisitionNumberOfContingentLiabilities", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessAcquisitionNarrativeDetails" ], "xbrltype": "integerItemType" }, "iart_BusinessCombinationContingentConsiderationNumberOfLiabilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration, Number Of Liabilities", "label": "Business Combination, Contingent Consideration, Number Of Liabilities", "terseLabel": "Number of liabilities" } } }, "localname": "BusinessCombinationContingentConsiderationNumberOfLiabilities", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "integerItemType" }, "iart_BusinessCombinationIntangibleAssetAcquiredDiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Intangible Asset Acquired, Discount Rate", "label": "Business Combination, Intangible Asset Acquired, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "BusinessCombinationIntangibleAssetAcquiredDiscountRate", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessAcquisitionNarrativeDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails" ], "xbrltype": "percentItemType" }, "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses": { "auth_ref": [], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses", "terseLabel": "Accrued expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails" ], "xbrltype": "monetaryItemType" }, "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesCurrentPortionOfLeaseLiabilityOperatingLeases": { "auth_ref": [], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Current Portion of Lease Liability, Operating Leases", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Current Portion of Lease Liability, Operating Leases", "terseLabel": "Current portion of lease liability - operating leases" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesCurrentPortionOfLeaseLiabilityOperatingLeases", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails" ], "xbrltype": "monetaryItemType" }, "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiabilityOperatingLeases": { "auth_ref": [], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Lease Liability, Operating Leases", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Lease Liability, Operating Leases", "terseLabel": "Lease liability - operating leases" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLeaseLiabilityOperatingLeases", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails" ], "xbrltype": "monetaryItemType" }, "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssetOperatingLeases": { "auth_ref": [], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails": { "order": 4.0, "parentTag": "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Asset, Operating Leases", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Right of Use Asset, Operating Leases", "terseLabel": "Right of use asset - operating leases" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssetOperatingLeases", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails" ], "xbrltype": "monetaryItemType" }, "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill": { "auth_ref": [], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired Including Goodwill", "totalLabel": "Total assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionSIADetails" ], "xbrltype": "monetaryItemType" }, "iart_BusinessCombinationWorkingCapitalAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Working Capital Adjustment", "label": "Business Combination, Working Capital Adjustment", "terseLabel": "Working capital adjustment" } } }, "localname": "BusinessCombinationWorkingCapitalAdjustment", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_CashFlowLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Flow, Lessee [Abstract]", "label": "Cash Flow, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashFlowLesseeAbstract", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "iart_CashFlowLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Flow, Lessee [Table Text Block]", "label": "Cash Flow, Lessee [Table Text Block]", "terseLabel": "Supplemental Cash Flow Information" } } }, "localname": "CashFlowLesseeTableTextBlock", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESTables" ], "xbrltype": "textBlockItemType" }, "iart_ChangeInContractWithCustomerAssetRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change In Contract With Customer, Asset [Roll Forward]", "label": "Change In Contract With Customer, Asset [Roll Forward]", "terseLabel": "Contract Asset" } } }, "localname": "ChangeInContractWithCustomerAssetRollForward", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "iart_ChangeInContractWithCustomerLiabilityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change In Contract With Customer, Liability [Roll Forward]", "label": "Change In Contract With Customer, Liability [Roll Forward]", "terseLabel": "Contract Liability" } } }, "localname": "ChangeInContractWithCustomerLiabilityRollForward", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "iart_CharitableContributions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Charitable contributions", "label": "Charitable contributions", "terseLabel": "Contributions to Integra Foundation" } } }, "localname": "CharitableContributions", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_ClosureOfFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Closure of Facility", "label": "Closure of Facility [Member]", "terseLabel": "Closure of Facility" } } }, "localname": "ClosureOfFacilityMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_CodmanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Codman [Member]", "label": "Codman [Member]", "terseLabel": "Codman" } } }, "localname": "CodmanMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_CodmanSpecialtySurgicalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Codman Specialty Surgical [Member]", "label": "Codman Specialty Surgical [Member]", "terseLabel": "Codman Specialty Surgical" } } }, "localname": "CodmanSpecialtySurgicalMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "iart_CompletedTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Completed technology.", "label": "Completed Technology [Member]", "terseLabel": "Completed technology" } } }, "localname": "CompletedTechnologyMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "iart_ConcentrationRiskNumberofCustomersOverBenchmark": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration Risk, Number of Customers Over Benchmark", "label": "Concentration Risk, Number of Customers Over Benchmark", "terseLabel": "Concentration risk, number of customers over benchmark" } } }, "localname": "ConcentrationRiskNumberofCustomersOverBenchmark", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "integerItemType" }, "iart_ConcentrationRiskThresholdPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration Risk, Threshold Percentage", "label": "Concentration Risk, Threshold Percentage", "terseLabel": "Concentration risk, threshold percentage" } } }, "localname": "ConcentrationRiskThresholdPercentage", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "percentItemType" }, "iart_ConsortiumofFocusedOrthopedistsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consortium of Focused Orthopedists, LLC [Member]", "label": "Consortium of Focused Orthopedists, LLC [Member]", "terseLabel": "Consortium of Focused Orthopedists, LLC" } } }, "localname": "ConsortiumofFocusedOrthopedistsLLCMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_ContingentConsiderationLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Consideration Liability [Member]", "label": "Contingent Consideration Liability [Member]", "terseLabel": "Contingent Consideration Liability" } } }, "localname": "ContingentConsiderationLiabilityMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "iart_ContractWithCustomerAssetNetOfReclassifiedToReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Asset, Net Of Reclassified To Receivable", "label": "Contract With Customer, Asset, Net Of Reclassified To Receivable", "terseLabel": "Contract asset, net of transferred to trade receivables on contracts during the period" } } }, "localname": "ContractWithCustomerAssetNetOfReclassifiedToReceivable", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "iart_ContractWithCustomerLiabilityIncreaseFromForeignCurrencyTranslation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Increase From Foreign Currency Translation", "label": "Contract With Customer, Liability, Increase From Foreign Currency Translation", "terseLabel": "Foreign currency translation" } } }, "localname": "ContractWithCustomerLiabilityIncreaseFromForeignCurrencyTranslation", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "iart_ContractWithCustomerLiabilityNetOfRevenueRecognizedAndForeignCurrencyTranslation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Net Of Revenue Recognized And Foreign Currency Translation", "label": "Contract With Customer, Liability, Net Of Revenue Recognized And Foreign Currency Translation", "terseLabel": "Contract liability, net of revenue recognized on contracts during the period" } } }, "localname": "ContractWithCustomerLiabilityNetOfRevenueRecognizedAndForeignCurrencyTranslation", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "iart_CostOfDefiniteAndIndefiniteLivedIntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "calculation": { "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails": { "order": 1.0, "parentTag": "iart_DefiniteAndIndefiniteLivedIntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost Of Definite And Indefinite Lived Intangible Assets Gross Excluding Goodwill.", "label": "Cost Of Definite And Indefinite Lived Intangible Assets Gross Excluding Goodwill", "terseLabel": "Cost" } } }, "localname": "CostOfDefiniteAndIndefiniteLivedIntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "iart_CrossCurrencyInterestRateContractFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cross Currency Interest Rate Contract Four [Member]", "label": "Cross Currency Interest Rate Contract Four [Member]", "terseLabel": "Cross-Currency Interest Rate Swap Four" } } }, "localname": "CrossCurrencyInterestRateContractFourMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_CrossCurrencyInterestRateContractOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cross Currency Interest Rate Contract One [Member]", "label": "Cross Currency Interest Rate Contract One [Member]", "terseLabel": "Cross-Currency Interest Rate Swap One" } } }, "localname": "CrossCurrencyInterestRateContractOneMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_CrossCurrencyInterestRateContractThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cross Currency Interest Rate Contract Three [Member]", "label": "Cross Currency Interest Rate Contract Three [Member]", "terseLabel": "Cross-Currency Interest Rate Swap Three" } } }, "localname": "CrossCurrencyInterestRateContractThreeMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_CrossCurrencyInterestRateContractTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cross Currency Interest Rate Contract Two [Member]", "label": "Cross Currency Interest Rate Contract Two [Member]", "terseLabel": "Cross-Currency Interest Rate Swap Two" } } }, "localname": "CrossCurrencyInterestRateContractTwoMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_CrossCurrencyInterestRateSwapContractOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cross Currency Interest Rate Swap, Contract One", "label": "Cross Currency Interest Rate Swap, Contract One [Member]", "terseLabel": "Cross Currency Interest Rate Swap, Contract One" } } }, "localname": "CrossCurrencyInterestRateSwapContractOneMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_CrossCurrencyInterestRateSwapContractThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cross Currency Interest Rate Swap, Contract Three", "label": "Cross Currency Interest Rate Swap, Contract Three [Member]", "terseLabel": "Cross Currency Interest Rate Swap, Contract Three" } } }, "localname": "CrossCurrencyInterestRateSwapContractThreeMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_CrossCurrencyInterestRateSwapContractTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cross Currency Interest Rate Swap, Contract Two", "label": "Cross Currency Interest Rate Swap, Contract Two [Member]", "terseLabel": "Cross Currency Interest Rate Swap, Contract Two" } } }, "localname": "CrossCurrencyInterestRateSwapContractTwoMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_CumulativeEffectPeriodOfAdoptionAdjustmentDebtDiscountAmortizationAndEquityCostsReclassificationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cumulative Effect, Period of Adoption, Adjustment, Debt Discount Amortization and Equity Costs Reclassification", "label": "Cumulative Effect, Period of Adoption, Adjustment, Debt Discount Amortization and Equity Costs Reclassification [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment, Debt Discount Amortization and Equity Costs Reclassification" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentDebtDiscountAmortizationAndEquityCostsReclassificationMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdoptionof202006Details" ], "xbrltype": "domainItemType" }, "iart_CumulativeEffectPeriodOfAdoptionAdjustmentDebtDiscountReclassificationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cumulative Effect, Period of Adoption, Adjustment, Debt Discount Reclassification", "label": "Cumulative Effect, Period of Adoption, Adjustment, Debt Discount Reclassification [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment, Debt Discount Reclassification" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentDebtDiscountReclassificationMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdoptionof202006Details" ], "xbrltype": "domainItemType" }, "iart_DebtCovenantPeriod3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Covenant Period 3 [Member]", "label": "Debt Covenant Period 3 [Member]", "terseLabel": "September 30, 2022 through June 30, 2023" } } }, "localname": "DebtCovenantPeriod3Member", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails" ], "xbrltype": "domainItemType" }, "iart_DebtCovenantPeriod4Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Covenant Period 4 [Member]", "label": "Debt Covenant Period 4 [Member]", "terseLabel": "September 30, 2023 and the last day of each fiscal quarter thereafter" } } }, "localname": "DebtCovenantPeriod4Member", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails" ], "xbrltype": "domainItemType" }, "iart_DebtCovenantPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Covenant Period [Axis]", "label": "Debt Covenant Period [Axis]", "terseLabel": "Debt Covenant Period [Axis]" } } }, "localname": "DebtCovenantPeriodAxis", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails" ], "xbrltype": "stringItemType" }, "iart_DebtCovenantPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Debt Covenant Period [Axis]", "label": "Debt Covenant Period [Domain]", "terseLabel": "Debt Covenant Period [Domain]" } } }, "localname": "DebtCovenantPeriodDomain", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails" ], "xbrltype": "domainItemType" }, "iart_DebtInstrumentCombinationSettlementForDebtConversionMinimumSettledInCashPerPrincipalAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Combination Settlement For Debt Conversion, Minimum Settled In Cash Per Principal Amount", "label": "Debt Instrument, Combination Settlement For Debt Conversion, Minimum Settled In Cash Per Principal Amount", "terseLabel": "Combination settlement for debt conversion, minimum settled in cash per principal amount" } } }, "localname": "DebtInstrumentCombinationSettlementForDebtConversionMinimumSettledInCashPerPrincipalAmount", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_DebtInstrumentCovenantMaximumLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Maximum Leverage Ratio", "label": "Debt Instrument, Covenant, Maximum Leverage Ratio", "terseLabel": "Debt Instrument, Covenant, Maximum Leverage Ratio" } } }, "localname": "DebtInstrumentCovenantMaximumLeverageRatio", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails" ], "xbrltype": "pureItemType" }, "iart_DebtInstrumentMaximumAverageConversionValueOfNotes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Maximum Average Conversion Value Of Notes", "label": "Debt Instrument, Maximum Average Conversion Value Of Notes", "terseLabel": "Maximum average conversion value of notes" } } }, "localname": "DebtInstrumentMaximumAverageConversionValueOfNotes", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "percentItemType" }, "iart_DebtInstrumentMaximumSellingPriceOfCommonStockOfTheConversionPriceDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Maximum Selling Price Of Common Stock Of The Conversion Price During Period", "label": "Debt Instrument, Maximum Selling Price Of Common Stock Of The Conversion Price During Period", "terseLabel": "Maximum selling price of the company's common stock of the conversion price" } } }, "localname": "DebtInstrumentMaximumSellingPriceOfCommonStockOfTheConversionPriceDuringPeriod", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "percentItemType" }, "iart_DebtWeightedAverageInterestRateFromSecuritization": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt, Weighted Average Interest Rate, From Securitization", "label": "Debt, Weighted Average Interest Rate, From Securitization", "terseLabel": "Security facility, weighted average interest rate" } } }, "localname": "DebtWeightedAverageInterestRateFromSecuritization", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "percentItemType" }, "iart_DeferredTaxAssetIncreaseDueTo2017TaxAct": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Asset, Increase Due To 2017 Tax Act", "label": "Deferred Tax Asset, Increase Due To 2017 Tax Act", "terseLabel": "Deferred tax asset, increase" } } }, "localname": "DeferredTaxAssetIncreaseDueTo2017TaxAct", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_DeferredTaxAssetsLeasesAndOther": { "auth_ref": [], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 12.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Leases And Other", "label": "Deferred Tax Assets, Leases And Other", "terseLabel": "Leases and Other" } } }, "localname": "DeferredTaxAssetsLeasesAndOther", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "iart_DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsEmployeeVacation": { "auth_ref": [], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Vacation", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Vacation", "terseLabel": "Accrued vacation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsEmployeeVacation", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "iart_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsCapitalizedResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 9.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Tax Deferred Expense, Reserves And Accruals, Capitalized Research And Development", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves And Accruals, Capitalized Research And Development", "terseLabel": "Capitalization of research and development expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsCapitalizedResearchAndDevelopment", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "iart_DeferredTaxLiabilitiesLeasesAndOther": { "auth_ref": [], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Leases And Other", "label": "Deferred Tax Liabilities, Leases And Other", "negatedLabel": "Leases and Other" } } }, "localname": "DeferredTaxLiabilitiesLeasesAndOther", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "iart_DeferredTaxLiabilitiesUnrealizedForeignExchangeLoss": { "auth_ref": [], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Unrealized Foreign Exchange Loss", "label": "Deferred Tax Liabilities, Unrealized Foreign Exchange Loss", "negatedTerseLabel": "Unrealized foreign exchange loss" } } }, "localname": "DeferredTaxLiabilitiesUnrealizedForeignExchangeLoss", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "iart_DefinedBenefitPlanBenefitObligationPremiumsPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Benefit Obligation, Premiums Paid", "label": "Defined Benefit Plan, Benefit Obligation, Premiums Paid", "negatedTerseLabel": "Premiums paid" } } }, "localname": "DefinedBenefitPlanBenefitObligationPremiumsPaid", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofChangeinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "iart_DefinedBenefitPlanDeferPaymentAndTaxationBaseSalaryPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Defer Payment And Taxation, Base Salary, Percentage", "label": "Defined Benefit Plan, Defer Payment And Taxation, Base Salary, Percentage", "terseLabel": "Defer payment and taxation, base salary, percentage (up to)" } } }, "localname": "DefinedBenefitPlanDeferPaymentAndTaxationBaseSalaryPercentage", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "percentItemType" }, "iart_DefinedBenefitPlanDeferPaymentAndTaxationBonusAndOtherCompensationPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Defer Payment And Taxation, Bonus And Other Compensation, Percentage", "label": "Defined Benefit Plan, Defer Payment And Taxation, Bonus And Other Compensation, Percentage", "terseLabel": "Defer payment and taxation, bonus and other eligible cash compensation, percentage (up to)" } } }, "localname": "DefinedBenefitPlanDeferPaymentAndTaxationBonusAndOtherCompensationPercentage", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "percentItemType" }, "iart_DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag", "label": "DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag", "terseLabel": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income Not Disclosed Flag" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofNetPeriodicBenefitCostsDetails" ], "xbrltype": "stringItemType" }, "iart_DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfPriorServiceCostCreditStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfPriorServiceCostCreditStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag", "label": "DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfPriorServiceCostCreditStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag", "terseLabel": "DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfPriorServiceCostCreditStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfPriorServiceCostCreditStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofNetPeriodicBenefitCostsDetails" ], "xbrltype": "stringItemType" }, "iart_DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag", "label": "DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag", "terseLabel": "DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofNetPeriodicBenefitCostsDetails" ], "xbrltype": "stringItemType" }, "iart_DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag", "label": "DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag", "terseLabel": "DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofNetPeriodicBenefitCostsDetails" ], "xbrltype": "stringItemType" }, "iart_DefinedBenefitPlanNetPeriodicBenefitCostCreditSettlementGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DefinedBenefitPlanNetPeriodicBenefitCostCreditSettlementGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag", "label": "DefinedBenefitPlanNetPeriodicBenefitCostCreditSettlementGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag", "terseLabel": "DefinedBenefitPlanNetPeriodicBenefitCostCreditSettlementGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditSettlementGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofNetPeriodicBenefitCostsDetails" ], "xbrltype": "stringItemType" }, "iart_DefinedBenefitPlanPlanAssetsPremiumsPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Plan Assets, Premiums Paid", "label": "Defined Benefit Plan, Plan Assets, Premiums Paid", "negatedLabel": "Premiums paid" } } }, "localname": "DefinedBenefitPlanPlanAssetsPremiumsPaid", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofChangeinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "iart_DefiniteAndIndefiniteLivedIntangibleAssetsNetExcludingGoodwill": { "auth_ref": [], "calculation": { "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Definite And Indefinite Lived Intangible Assets Net Excluding Goodwill.", "label": "Definite And Indefinite Lived Intangible Assets Net Excluding Goodwill", "totalLabel": "Net" } } }, "localname": "DefiniteAndIndefiniteLivedIntangibleAssetsNetExcludingGoodwill", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "iart_DemonstrationEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Demonstration Equipment", "label": "Demonstration Equipment [Member]", "terseLabel": "Demonstration equipment" } } }, "localname": "DemonstrationEquipmentMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails" ], "xbrltype": "domainItemType" }, "iart_DerivativeNotionalAmountTerminated": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derivative, Notional Amount, Terminated", "label": "Derivative, Notional Amount, Terminated", "terseLabel": "Derivative, notional amount, terminated" } } }, "localname": "DerivativeNotionalAmountTerminated", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_DermaSciencesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derma Sciences [Member]", "label": "Derma Sciences [Member]", "terseLabel": "Derma Sciences" } } }, "localname": "DermaSciencesMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_DirectorsandCertainExecutiveOfficersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Directors and Certain Executive Officers [Member]", "label": "Directors and Certain Executive Officers [Member]", "terseLabel": "Directors and Certain Executive Officers" } } }, "localname": "DirectorsandCertainExecutiveOfficersMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_DiscontinuedOperationContinuingInvolvementPrepaidAsset": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Discontinued Operation, Continuing Involvement, Prepaid Asset", "label": "Discontinued Operation, Continuing Involvement, Prepaid Asset", "terseLabel": "Discontinued operation, continuing involvement, prepaid asset" } } }, "localname": "DiscontinuedOperationContinuingInvolvementPrepaidAsset", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_DiscontinuedOperationContinuingInvolvementPrepaidAssetsCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Discontinued Operation, Continuing Involvement, Prepaid Expenses, Current Assets", "label": "Discontinued Operation, Continuing Involvement, Prepaid Assets , Current", "terseLabel": "Inventory purchase, prepaid expenses and other current assets" } } }, "localname": "DiscontinuedOperationContinuingInvolvementPrepaidAssetsCurrent", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_DisposalGroupIncludingDiscontinuedOperationConsiderationContingentConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Contingent Consideration", "label": "Disposal Group, Including Discontinued Operation, Consideration, Contingent Consideration", "terseLabel": "Sale of business, contingent consideration" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationContingentConsideration", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_DisposalGroupIncludingDiscontinuedOperationConsiderationContingentConsiderationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Contingent Consideration, Period", "label": "Disposal Group, Including Discontinued Operation, Consideration, Contingent Consideration, Period", "terseLabel": "Period for revenue based performance milestone" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationContingentConsiderationPeriod", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails" ], "xbrltype": "durationItemType" }, "iart_DisposalGroupIncludingDiscontinuedOperationLeaseLiabilityCurrent": { "auth_ref": [], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Lease Liability, Current", "label": "Disposal Group, Including Discontinued Operation, Lease Liability, Current", "terseLabel": "Current portion of lease liability - operating leases" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationLeaseLiabilityCurrent", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails" ], "xbrltype": "monetaryItemType" }, "iart_DisposalGroupIncludingDiscontinuedOperationLeaseLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Lease Liability, Noncurrent", "label": "Disposal Group, Including Discontinued Operation, Lease Liability, Noncurrent", "terseLabel": "Lease liability - operating leases" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationLeaseLiabilityNoncurrent", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails" ], "xbrltype": "monetaryItemType" }, "iart_DisposalGroupIncludingDiscontinuedOperationPaymentRelatedToContractTermination": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Payment Related To Contract Termination", "label": "Disposal Group, Including Discontinued Operation, Payment Related To Contract Termination", "terseLabel": "Sale of extremity orthopedics business, payment for terminating license agreement" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPaymentRelatedToContractTermination", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_DisposalGroupIncludingDiscontinuedOperationRightOfUseAssetOperatingLeasesAndOtherAssets": { "auth_ref": [], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Right of Use Asset Operating Leases and Other Assets", "label": "Disposal Group, Including Discontinued Operation, Right of Use Asset Operating Leases and Other Assets", "terseLabel": "Right of use asset-operating leases and Other assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationRightOfUseAssetOperatingLeasesAndOtherAssets", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails" ], "xbrltype": "monetaryItemType" }, "iart_DisposalGroupIncludingDiscontinuedOperationTransitionalSupplyAgreementPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Transitional Supply Agreement, Payable", "label": "Disposal Group, Including Discontinued Operation, Transitional Supply Agreement, Payable", "terseLabel": "Transitional supply agreement, payable" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationTransitionalSupplyAgreementPayable", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_EffectiveForeignIncomeTaxRateReconciliationContinuingOperations": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Foreign Income Tax Rate Reconciliation, Continuing Operations", "label": "Effective Foreign Income Tax Rate Reconciliation, Continuing Operations", "terseLabel": "Effective foreign income tax rate" } } }, "localname": "EffectiveForeignIncomeTaxRateReconciliationContinuingOperations", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "percentItemType" }, "iart_EffectiveIncomeTaxRateReconciliationAssetsHeldForSaleOutsideBasisDifferencePercent": { "auth_ref": [], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Assets Held-For-Sale, Outside Basis Difference, Percent", "label": "Effective Income Tax Rate Reconciliation, Assets Held-For-Sale, Outside Basis Difference, Percent", "terseLabel": "Gain from sale of business - book to tax differences" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAssetsHeldForSaleOutsideBasisDifferencePercent", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "iart_EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent": { "auth_ref": [], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Contingent Consideration, Percent", "label": "Effective Income Tax Rate Reconciliation, Contingent Consideration, Percent", "terseLabel": "Contingent Consideration" } } }, "localname": "EffectiveIncomeTaxRateReconciliationContingentConsiderationPercent", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "iart_EffectiveIncomeTaxRateReconciliationDeductionIntercompanyInventoryPercent": { "auth_ref": [], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails": { "order": 10.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Deduction, Intercompany Inventory, Percent", "label": "Effective Income Tax Rate Reconciliation, Deduction, Intercompany Inventory, Percent", "terseLabel": "Intercompany profit in inventory" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDeductionIntercompanyInventoryPercent", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "iart_EffectiveIncomeTaxRateReconciliationDeferredIncomeTaxBenefitTransferIntraEntityIntellectualPropertyAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Deferred Income Tax Benefit, Transfer Intra-Entity Intellectual Property, Amount", "label": "Effective Income Tax Rate Reconciliation, Deferred Income Tax Benefit, Transfer Intra-Entity Intellectual Property, Amount", "terseLabel": "Deferred income tax benefit, transfer intra-entity intellectual property, amount" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDeferredIncomeTaxBenefitTransferIntraEntityIntellectualPropertyAmount", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_EffectiveIncomeTaxRateReconciliationIncomeTaxBenefitTransferIntraEntityIntellectualPropertyAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Income Tax Benefit, Transfer Intra-Entity Intellectual Property, Amount", "label": "Effective Income Tax Rate Reconciliation, Income Tax Benefit, Transfer Intra-Entity Intellectual Property, Amount", "terseLabel": "Income tax benefit, transfer intra-entity intellectual property, amount" } } }, "localname": "EffectiveIncomeTaxRateReconciliationIncomeTaxBenefitTransferIntraEntityIntellectualPropertyAmount", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent": { "auth_ref": [], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails": { "order": 8.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Percent", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation, Percent", "terseLabel": "Nondeductible executive compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "iart_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalandProfessionalPercent": { "auth_ref": [], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails": { "order": 11.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Legal and Professional, Percent", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Legal and Professional, Percent", "terseLabel": "Nondeductible facilitative costs" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalandProfessionalPercent", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "iart_EffectiveIncomeTaxRateReconciliationTransferIntraEntityIntellectualPropertyRateDifferentialOnFMVStepUpPercent": { "auth_ref": [], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails": { "order": 12.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Transfer Intra-Entity Intellectual Property, Rate Differential On FMV Step-Up, Percent", "label": "Effective Income Tax Rate Reconciliation, Transfer Intra-Entity Intellectual Property, Rate Differential On FMV Step-Up, Percent", "terseLabel": "Fair market value step up on intra-entity transfer of intellectual property" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTransferIntraEntityIntellectualPropertyRateDifferentialOnFMVStepUpPercent", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "iart_EffectiveWorldwideIncomeTaxRateReconciliationPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Worldwide Income Tax Rate Reconciliation, Percent", "label": "Effective Worldwide Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective worldwide tax rate" } } }, "localname": "EffectiveWorldwideIncomeTaxRateReconciliationPercent", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "percentItemType" }, "iart_EmployeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee [Member]", "label": "Employee [Member]", "terseLabel": "Employee" } } }, "localname": "EmployeeMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_EmployeeStockPurchasePlanProceeds": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds received from employees in connection with the employee stock purchase plan.", "label": "Employee Stock Purchase Plan Proceeds", "terseLabel": "ESPP proceeds received" } } }, "localname": "EmployeeStockPurchasePlanProceeds", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_ExtremityOrthopedicsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extremity Orthopedics [Member]", "label": "Extremity Orthopedics [Member]", "terseLabel": "Extremity Orthopedics" } } }, "localname": "ExtremityOrthopedicsMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails", "http://integralife.com/role/INCOMETAXESNarrativeDetails", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "xbrltype": "domainItemType" }, "iart_FDAApprovalOfPremarketApprovalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "FDA Approval Of Premarket Approval", "label": "FDA Approval Of Premarket Approval [Member]", "terseLabel": "FDA Approval Of Premarket Approval" } } }, "localname": "FDAApprovalOfPremarketApprovalMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessAcquisitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_FairValueMeasurementwithUnobservableInputsReconciliationLiabilityTransfersFromLongTermtoCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers From Long-Term to Current", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers From Long-Term to Current", "terseLabel": "Transfers from long-term to current portion" } } }, "localname": "FairValueMeasurementwithUnobservableInputsReconciliationLiabilityTransfersFromLongTermtoCurrent", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "iart_FiveYearLeasePeriodTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Five Year Lease Period Two", "label": "Five Year Lease Period Two [Member]", "terseLabel": "Five Year Option Lease From November 1, 2034 Through October 31, 2039" } } }, "localname": "FiveYearLeasePeriodTwoMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_FiveYearOptionLeasePeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Five Year Option Lease Period One", "label": "Five Year Option Lease Period One [Member]", "terseLabel": "Five Year Option Lease From November 1, 2029 Through October 31, 2034" } } }, "localname": "FiveYearOptionLeasePeriodOneMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_FoundationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foundation [Policy Text Block].", "label": "Foundation [Policy Text Block]", "terseLabel": "Integra Foundation" } } }, "localname": "FoundationPolicyTextBlock", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "iart_GainLossOnDispositionOfPropertyPlantEquipmentAndConstructionInProgress": { "auth_ref": [], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (Loss) On Disposition Of Property Plant Equipment And Construction In-Progress", "label": "Gain (Loss) On Disposition Of Property Plant Equipment And Construction In-Progress", "negatedLabel": "Loss (Gain) on disposal of property and equipment and construction in-progress" } } }, "localname": "GainLossOnDispositionOfPropertyPlantEquipmentAndConstructionInProgress", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "iart_IncomeTaxLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income Tax [Line Items]", "label": "Income Tax [Line Items]", "terseLabel": "Income Tax [Line Items]" } } }, "localname": "IncomeTaxLineItems", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "stringItemType" }, "iart_IncomeTaxTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income Tax [Table]", "label": "Income Tax [Table]", "terseLabel": "Income Tax [Table]" } } }, "localname": "IncomeTaxTable", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "stringItemType" }, "iart_IncreaseInAuthorizedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The increase in the number of authorized shares under the Plan.", "label": "Increase In Authorized Shares", "terseLabel": "Increase in authorized shares (in shares)" } } }, "localname": "IncreaseInAuthorizedShares", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "iart_InformationSystemsandHardwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information Systems and Hardware [Member]", "label": "Information Systems and Hardware [Member]", "terseLabel": "Information systems and hardware" } } }, "localname": "InformationSystemsandHardwareMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails" ], "xbrltype": "domainItemType" }, "iart_InstrumentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Instruments [Member]", "label": "Instruments [Member]", "terseLabel": "Instruments" } } }, "localname": "InstrumentsMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "xbrltype": "domainItemType" }, "iart_IntercompanyLoanQuarterlyPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intercompany Loan, Quarterly Payment", "label": "Intercompany Loan, Quarterly Payment", "terseLabel": "Intercompany loan, quarterly payment" } } }, "localname": "IntercompanyLoanQuarterlyPayment", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_InterestPaymentsYearOne": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest Payments, Year One", "label": "Interest Payments, Year One", "terseLabel": "Interest payments, year one" } } }, "localname": "InterestPaymentsYearOne", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_InterestPaymentsYearThree": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest Payments, Year Three", "label": "Interest Payments, Year Three", "terseLabel": "Interest payments, year three" } } }, "localname": "InterestPaymentsYearThree", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_InterestPaymentsYearTwo": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest Payments, Year Two", "label": "Interest Payments, Year Two", "terseLabel": "Interest payments, year two" } } }, "localname": "InterestPaymentsYearTwo", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_InterestRateSwapDesignatedDecember132017Tranche1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Swap Designated December 13, 2017 Tranche 1 [Member]", "label": "Interest Rate Swap Designated December 13, 2017 Tranche 1 [Member]", "terseLabel": "Interest Rate Swap Designated December 13, 2017 Tranche 1" } } }, "localname": "InterestRateSwapDesignatedDecember132017Tranche1Member", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_InterestRateSwapDesignatedDecember132017Tranche2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Swap Designated December 13, 2017 Tranche 2 [Member]", "label": "Interest Rate Swap Designated December 13, 2017 Tranche 2 [Member]", "terseLabel": "Interest Rate Swap Designated December 13, 2017 Tranche 2" } } }, "localname": "InterestRateSwapDesignatedDecember132017Tranche2Member", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_InterestRateSwapDesignatedDecember132017Tranche3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Swap Designated December 13, 2017 Tranche 3 [Member]", "label": "Interest Rate Swap Designated December 13, 2017 Tranche 3 [Member]", "terseLabel": "Interest Rate Swap Designated December 13, 2017 Tranche 3" } } }, "localname": "InterestRateSwapDesignatedDecember132017Tranche3Member", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_InterestRateSwapDesignatedDecember152020Tranche1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Swap Designated December 15, 2020 Tranche 1", "label": "Interest Rate Swap Designated December 15, 2020 Tranche 1 [Member]", "terseLabel": "Interest Rate Swap Designated December 15, 2020 Tranche 1" } } }, "localname": "InterestRateSwapDesignatedDecember152020Tranche1Member", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_InterestRateSwapDesignatedDecember152020Tranche2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Swap Designated December 15, 2020 Tranche 2", "label": "Interest Rate Swap Designated December 15, 2020 Tranche 2 [Member]", "terseLabel": "Interest Rate Swap Designated December 15, 2020 Tranche 2" } } }, "localname": "InterestRateSwapDesignatedDecember152020Tranche2Member", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_InterestRateSwapDesignatedDecember182018Tranche1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Swap Designated December 18, 2018 Tranche 1 [Member]", "label": "Interest Rate Swap Designated December 18, 2018 Tranche 1 [Member]", "terseLabel": "Interest Rate Swap Designated December 18, 2018 Tranche 1" } } }, "localname": "InterestRateSwapDesignatedDecember182018Tranche1Member", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_InterestRateSwapDesignatedDecember182018Tranche2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Swap Designated December 18, 2018 Tranche 2 [Member]", "label": "Interest Rate Swap Designated December 18, 2018 Tranche 2 [Member]", "terseLabel": "Interest Rate Swap Designated December 18, 2018 Tranche 2" } } }, "localname": "InterestRateSwapDesignatedDecember182018Tranche2Member", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_InterestRateSwapDesignatedOctober102018Tranche1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Swap Designated October 10, 2018 Tranche 1 [Member]", "label": "Interest Rate Swap Designated October 10, 2018 Tranche 1 [Member]", "terseLabel": "Interest Rate Swap Designated October 10, 2018 Tranche 1" } } }, "localname": "InterestRateSwapDesignatedOctober102018Tranche1Member", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_InterestRateSwapDesignatedOctober102018Tranche2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Swap Designated October 10, 2018 Tranche 2 [Member]", "label": "Interest Rate Swap Designated October 10, 2018 Tranche 2 [Member]", "terseLabel": "Interest Rate Swap Designated October 10, 2018 Tranche 2" } } }, "localname": "InterestRateSwapDesignatedOctober102018Tranche2Member", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_InterestRateSwapDesignatedOctober102018Tranche3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Swap Designated October 10, 2018 Tranche 3 [Member]", "label": "Interest Rate Swap Designated October 10, 2018 Tranche 3 [Member]", "terseLabel": "Interest Rate Swap Designated October 10, 2018 Tranche 3" } } }, "localname": "InterestRateSwapDesignatedOctober102018Tranche3Member", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_InventoryCapitalizedExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventory, Capitalized Expenses", "label": "Inventory, Capitalized Expenses", "terseLabel": "Inventory, capitalized expenses" } } }, "localname": "InventoryCapitalizedExpenses", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_LesseeOperatingLeaseNumberOfRenewalOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Number Of Renewal Options", "label": "Lessee, Operating Lease, Number Of Renewal Options", "terseLabel": "Number of renewal options (or more)" } } }, "localname": "LesseeOperatingLeaseNumberOfRenewalOptions", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "xbrltype": "integerItemType" }, "iart_MilestonePaymentOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Payment One [Member]", "label": "Milestone Payment One [Member]", "terseLabel": "Milestone Payment One" } } }, "localname": "MilestonePaymentOneMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_MilestonePaymentTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Payment Two [Member]", "label": "Milestone Payment Two [Member]", "terseLabel": "Milestone Payment Two" } } }, "localname": "MilestonePaymentTwoMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_NeurosurgeryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Neurosurgery [Member]", "label": "Neurosurgery [Member]", "terseLabel": "Neurosurgery" } } }, "localname": "NeurosurgeryMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "xbrltype": "domainItemType" }, "iart_NoncashLeaseExpense": { "auth_ref": [], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash Lease Expense", "label": "Noncash Lease Expense", "terseLabel": "Non-cash lease expense" } } }, "localname": "NoncashLeaseExpense", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "iart_NoncashOrPartNoncashInProcessResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash Or Part Noncash, In Process Research And Development", "label": "Noncash Or Part Noncash, In Process Research And Development", "terseLabel": "Non-cash in-process research and development expense" } } }, "localname": "NoncashOrPartNoncashInProcessResearchAndDevelopment", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "iart_OneMonthEurodollarRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Month Eurodollar Rate [Member]", "label": "One Month Eurodollar Rate [Member]", "terseLabel": "One-Month Eurodollar Rate" } } }, "localname": "OneMonthEurodollarRateMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_OneMonthUSDLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Month USD LIBOR [Member]", "label": "One Month USD LIBOR [Member]", "terseLabel": "1-month USD LIBOR Loan" } } }, "localname": "OneMonthUSDLIBORMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails" ], "xbrltype": "domainItemType" }, "iart_OptionToExtendLeaseYears": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Option to extend lease, years.", "label": "Option To Extend Lease, Years", "terseLabel": "Option to extend lease, years" } } }, "localname": "OptionToExtendLeaseYears", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "xbrltype": "durationItemType" }, "iart_PaymentsForOptionIndexToIssuersEquity": { "auth_ref": [], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Options Indexed to Issuer's Equity", "label": "Payments For Option Index To Issuers Equity", "negatedLabel": "Purchase of option hedge on convertible notes", "verboseLabel": "Cost of call transactions" } } }, "localname": "PaymentsForOptionIndexToIssuersEquity", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_PaymentsForProceedsFromBusinessAcquisitions": { "auth_ref": [], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For (Proceeds From) Business Acquisitions", "label": "Payments For (Proceeds From) Business Acquisitions", "negatedTerseLabel": "Cash paid for business acquisitions, net of cash acquired" } } }, "localname": "PaymentsForProceedsFromBusinessAcquisitions", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "iart_PaymentsToAcquireInProcessResearchAndDevelopmentAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire In Process Research And Development And Intangible Assets", "label": "Payments To Acquire In Process Research And Development And Intangible Assets", "negatedLabel": "Acquired in-process research and development and intangibles" } } }, "localname": "PaymentsToAcquireInProcessResearchAndDevelopmentAndIntangibleAssets", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "iart_PercentOfManufacturingFacilityOwnedByCorporationWhoseShareholdersAreTrustsWhoseBeneficiariesIncludeFamilyMembersOfCompanysFormerDirector": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percent Of Manufacturing Facility Owned By Corporation Whose Shareholders Are Trusts, Whose Beneficiaries Include Family Members Of Company's Former Director", "label": "Percent Of Manufacturing Facility Owned By Corporation Whose Shareholders Are Trusts, Whose Beneficiaries Include Family Members Of Company's Former Director", "terseLabel": "Percent of manufacturing facility owned by corporation whose shareholders are trusts whose beneficiaries include family members of company's former director" } } }, "localname": "PercentOfManufacturingFacilityOwnedByCorporationWhoseShareholdersAreTrustsWhoseBeneficiariesIncludeFamilyMembersOfCompanysFormerDirector", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "xbrltype": "percentItemType" }, "iart_PerformanceStockandContractStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Stock and Contract Stock [Member]", "label": "Performance Stock and Contract Stock [Member]", "terseLabel": "Performance Stock and Contract Stock Awards" } } }, "localname": "PerformanceStockandContractStockMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofVestedandUnvestedRestrictedStockPerformanceStockandContractStockDetails" ], "xbrltype": "domainItemType" }, "iart_PrivateLabelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private Label [Member]", "label": "Private Label [Member]", "terseLabel": "Private Label" } } }, "localname": "PrivateLabelMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "xbrltype": "domainItemType" }, "iart_ReboundTherapeuticsCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rebound Therapeutics Corporation [Member]", "label": "Rebound Therapeutics Corporation [Member]", "terseLabel": "Rebound" } } }, "localname": "ReboundTherapeuticsCorporationMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_RegenerativeSkinAndWoundMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regenerative Skin And Wound [Member]", "label": "Regenerative Skin And Wound [Member]", "terseLabel": "Wound Reconstruction and Care" } } }, "localname": "RegenerativeSkinAndWoundMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "xbrltype": "domainItemType" }, "iart_RelatedPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Parties [Member]", "label": "Related Parties [Member]", "terseLabel": "Related Parties" } } }, "localname": "RelatedPartiesMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails" ], "xbrltype": "domainItemType" }, "iart_ReorganizationProjectsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reorganization Projects", "label": "Reorganization Projects [Member]", "terseLabel": "Reorganization Projects" } } }, "localname": "ReorganizationProjectsMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_RestOfWorldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenues from rest of the world.", "label": "Rest Of World [Member]", "terseLabel": "Rest of the World" } } }, "localname": "RestOfWorldMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "iart_RestrictedStockPerformanceStockAndContractStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock, performance stock and contract stock member", "label": "Restricted Stock, Performance Stock, And Contract Stock [Member]", "terseLabel": "Restricted Stock, Performance Stock and Contract Stock" } } }, "localname": "RestrictedStockPerformanceStockAndContractStockMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_ReturnPolicyIssueOfCreditNumberOfDaysFromShipment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Return Policy, Issue of Credit, Number of Days from Shipment", "label": "Return Policy, Issue Of Credit, Number Of Days From Shipment", "terseLabel": "Number of days from shipment to issue a credit on returned goods" } } }, "localname": "ReturnPolicyIssueOfCreditNumberOfDaysFromShipment", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "xbrltype": "durationItemType" }, "iart_RevenueBasedPerformanceMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue Based Performance Milestones", "label": "Revenue Based Performance Milestones [Member]", "terseLabel": "Revenue Based Performance Milestones" } } }, "localname": "RevenueBasedPerformanceMilestonesMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessAcquisitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_RevenueFromContractWithCustomerProductsShippedWithNoAlternativeUseAndRightOfPaymentForPerformanceManufacturingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue From Contract With Customer, Products Shipped With No Alternative Use And Right Of Payment For Performance, Manufacturing Period", "label": "Revenue From Contract With Customer, Products Shipped With No Alternative Use And Right Of Payment For Performance, Manufacturing Period", "terseLabel": "Manufacturing period for products shipped with no alternative use and right of payment for performance" } } }, "localname": "RevenueFromContractWithCustomerProductsShippedWithNoAlternativeUseAndRightOfPaymentForPerformanceManufacturingPeriod", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "durationItemType" }, "iart_RevenueProductWarrantyPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue, Product Warranty Period", "label": "Revenue, Product Warranty Period", "terseLabel": "Product warranty period (up to)" } } }, "localname": "RevenueProductWarrantyPeriod", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "xbrltype": "durationItemType" }, "iart_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right Of Use Asset Obtained In Exchange For Lease Liability [Abstract]", "label": "Right Of Use Asset Obtained In Exchange For Lease Liability [Abstract]", "terseLabel": "ROU assets obtained in exchange for lease liabilities:" } } }, "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "iart_SecuredLongTermDebtSecuritizationProgram": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Secured Long-Term Debt, Securitization Program", "label": "Secured Long-Term Debt, Securitization Program", "terseLabel": "Secured long-term debt, securitization program" } } }, "localname": "SecuredLongTermDebtSecuritizationProgram", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_SecuredLongTermDebtSecuritizationProgramNoncurrent": { "auth_ref": [], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Secured Long-Term Debt, Securitization Program, Noncurrent", "label": "Secured Long-Term Debt, Securitization Program, Noncurrent", "terseLabel": "Long-term borrowings under securitization facility" } } }, "localname": "SecuredLongTermDebtSecuritizationProgramNoncurrent", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "iart_SecuritizationFacilityFairValueOfAmountOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Securitization Facility, Fair Value Of Amount Outstanding", "label": "Securitization Facility, Fair Value Of Amount Outstanding", "terseLabel": "Securitization facility, fair value of amount outstanding" } } }, "localname": "SecuritizationFacilityFairValueOfAmountOutstanding", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_SegmentReportingInformationNumberOfProductsOffered": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of products sold by a segment", "label": "Segment Reporting Information, Number Of Products Offered", "terseLabel": "Number of products offered (more than)" } } }, "localname": "SegmentReportingInformationNumberOfProductsOffered", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails" ], "xbrltype": "integerItemType" }, "iart_SeniorCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Credit Facility.", "label": "Senior Credit Facility [Member]", "terseLabel": "Senior Credit Facility" } } }, "localname": "SeniorCreditFacilityMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails", "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAdjustmentsforPerformanceAchievementShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Adjustments for Performance Achievement, Shares", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Adjustments for Performance Achievement, Shares", "negatedTerseLabel": "Adjustments for performance achievement related to award target (in shares)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAdjustmentsforPerformanceAchievementShares", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofVestedandUnvestedRestrictedStockPerformanceStockandContractStockDetails" ], "xbrltype": "sharesItemType" }, "iart_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAdjustmentsforPerformanceAchievementWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Adjustments for Performance Achievement, Weighted Average Grant Date Fair Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Adjustments for Performance Achievement, Weighted Average Grant Date Fair Value", "terseLabel": "Adjustments for performance achievement related to award target (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAdjustmentsforPerformanceAchievementWeightedAverageGrantDateFairValue", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofVestedandUnvestedRestrictedStockPerformanceStockandContractStockDetails" ], "xbrltype": "perShareItemType" }, "iart_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchasedPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased, Percent", "label": "Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased, Percent", "terseLabel": "Accelerated share repurchases, percentage of expected total repurchased" } } }, "localname": "StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchasedPercent", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "xbrltype": "percentItemType" }, "iart_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary Of Significant Accounting Policies [Line Items]", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "iart_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary Of Significant Accounting Policies [Table]", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "iart_SupplierRelationShipsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplier Relation Ships [Member]", "label": "Supplier Relation Ships [Member]", "terseLabel": "Supplier relationships" } } }, "localname": "SupplierRelationShipsMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "iart_SurgicalInnovationAssociatesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Surgical Innovation Associates Inc", "label": "Surgical Innovation Associates Inc [Member]", "terseLabel": "Surgical Innovation Association Inc" } } }, "localname": "SurgicalInnovationAssociatesIncMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessAcquisitionNarrativeDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionSIADetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "xbrltype": "domainItemType" }, "iart_SwinglineLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Swingline Loan [Member]", "label": "Swingline Loan [Member]", "terseLabel": "Swingline Loan" } } }, "localname": "SwinglineLoanMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_TermLoanFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan Facility [Member]", "label": "Term Loan Facility [Member]", "terseLabel": "Term Loan Facility" } } }, "localname": "TermLoanFacilityMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_ThirdPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Parties [Member]", "label": "Third Parties [Member]", "verboseLabel": "Third Parties" } } }, "localname": "ThirdPartiesMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails" ], "xbrltype": "domainItemType" }, "iart_TissueTechnologiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tissue Technologies [Member]", "label": "Tissue Technologies [Member]", "terseLabel": "Tissue Technologies" } } }, "localname": "TissueTechnologiesMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "iart_TrademarksBrandNamesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trademarks Brand Names.", "label": "Trademarks Brand Names [Member]", "terseLabel": "Trademarks/brand names" } } }, "localname": "TrademarksBrandNamesMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "iart_TraditionalWoundCareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Traditional Wound Care", "label": "Traditional Wound Care [Member]", "terseLabel": "Traditional Wound Care" } } }, "localname": "TraditionalWoundCareMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_TransferorsInterestsInTransferredFinancialAssetsMaximumInvestmentLimit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Transferor's Interests In Transferred Financial Assets, Maximum Investment Limit", "label": "Transferor's Interests In Transferred Financial Assets, Maximum Investment Limit", "terseLabel": "Securitization facility, outstanding borrowings, maximum limit" } } }, "localname": "TransferorsInterestsInTransferredFinancialAssetsMaximumInvestmentLimit", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "iart_TwoThousandOnePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand One Plan [Member]", "label": "Two Thousand One Plan [Member]", "terseLabel": "2001 Plan" } } }, "localname": "TwoThousandOnePlanMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_TwoThousandPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Plan [Member]", "label": "Two Thousand Plan [Member]", "terseLabel": "2000 Plan" } } }, "localname": "TwoThousandPlanMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_TwoThousandThreePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand three Plan [Member]", "label": "Two Thousand Three Plan [Member]", "terseLabel": "2003 Plan" } } }, "localname": "TwoThousandThreePlanMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_TwoThousandTwentyFiveSeniorConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Twenty Five Senior Convertible Notes [Member]", "label": "Two Thousand Twenty Five Senior Convertible Notes [Member]", "terseLabel": "2025 Notes" } } }, "localname": "TwoThousandTwentyFiveSeniorConvertibleNotesMember", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "iart_UnrecognizedTaxBenefitsIncreasesDuringPeriodAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unrecognized Tax Benefits, Increases During Period [Abstract]", "label": "Unrecognized Tax Benefits, Increases During Period [Abstract]", "terseLabel": "Gross increases:" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesDuringPeriodAbstract", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofUncertainTaxBenefitsReconciliationDetails" ], "xbrltype": "stringItemType" }, "iart_UnrecognizedTaxBenefitsReductionsResultingFromOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unrecognized Tax Benefits, Reductions Resulting From Other", "label": "Unrecognized Tax Benefits, Reductions Resulting From Other", "negatedTerseLabel": "Other" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromOther", "nsuri": "http://integralife.com/20221231", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofUncertainTaxBenefitsReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r878", "r999", "r1056", "r1057", "r1059" ], "lang": { "en-us": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Entity" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r345", "r399", "r411", "r412", "r413", "r414", "r415", "r417", "r421", "r485", "r486", "r487", "r488", "r490", "r491", "r493", "r495", "r496", "r991", "r992" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r345", "r399", "r411", "r412", "r413", "r414", "r415", "r417", "r421", "r485", "r486", "r487", "r488", "r490", "r491", "r493", "r495", "r496", "r991", "r992" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r342", "r343", "r501", "r529", "r884", "r886" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r291", "r356", "r363", "r369", "r441", "r681", "r682", "r683", "r711", "r712", "r749", "r752", "r754", "r755", "r802" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdoptionof202006Details", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r291", "r356", "r363", "r369", "r441", "r681", "r682", "r683", "r711", "r712", "r749", "r752", "r754", "r755", "r802" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdoptionof202006Details", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r291", "r356", "r363", "r369", "r441", "r681", "r682", "r683", "r711", "r712", "r749", "r752", "r754", "r755", "r802" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdoptionof202006Details", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r970" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Director" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r480", "r481", "r482", "r483", "r638", "r812", "r844", "r879", "r880", "r902", "r917", "r927", "r993", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r480", "r481", "r482", "r483", "r638", "r812", "r844", "r879", "r880", "r902", "r917", "r927", "r993", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r423", "r815", "r904", "r925", "r988", "r989", "r996", "r1068" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r423", "r815", "r904", "r925", "r988", "r989", "r996", "r1068" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r480", "r481", "r482", "r483", "r587", "r638", "r670", "r671", "r672", "r811", "r812", "r844", "r879", "r880", "r902", "r917", "r927", "r985", "r993", "r1063", "r1064", "r1065", "r1066", "r1067" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r480", "r481", "r482", "r483", "r587", "r638", "r670", "r671", "r672", "r811", "r812", "r844", "r879", "r880", "r902", "r917", "r927", "r985", "r993", "r1063", "r1064", "r1065", "r1066", "r1067" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r342", "r343", "r501", "r529", "r885", "r886" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r424", "r425", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r905", "r926", "r996" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r424", "r425", "r864", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r905", "r926", "r996" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r970", "r1058" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRollforwardofValuationforDoubtfulAccountsDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r346", "r347", "r348", "r351", "r352" ], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRollforwardofValuationforDoubtfulAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "Derivative Instruments, Gain (Loss) [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt": { "auth_ref": [ "r159" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement.", "label": "Accelerated Share Repurchases, Settlement (Payment) or Receipt", "terseLabel": "Accelerated share repurchase program, receipt (payment)" } } }, "localname": "AcceleratedShareRepurchasesSettlementPaymentOrReceipt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r289", "r290", "r291", "r292", "r293", "r357", "r358", "r359", "r435", "r436", "r438", "r439", "r440", "r441", "r442", "r443", "r681", "r682", "r683", "r711", "r712", "r727", "r728", "r729", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r779", "r780", "r784", "r785", "r786", "r799", "r800", "r801", "r802", "r803", "r804", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r964" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible Enumeration]", "terseLabel": "Accounting Standards Update [Extensible List]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r15", "r32" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "terseLabel": "Accounts payable, trade" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "auth_ref": [ "r972" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Accounts Receivable, Allowance for Credit Loss" } } }, "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r429", "r430" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Trade accounts receivable, net of allowances of $4,304 and $4,735" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionExpense": { "auth_ref": [ "r896", "r987" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.", "label": "Accretion Expense", "terseLabel": "Accretion of bond issuance discount" } } }, "localname": "AccretionExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r47", "r52", "r220", "r944", "r945", "r946" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Defined Benefit Pension Items" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r129", "r302" ], "calculation": { "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r318", "r327", "r328", "r735", "r887", "r944" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Gains and Losses on Derivatives" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/AACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails", "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/AACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails", "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r49", "r51", "r52", "r310", "r839", "r852", "r856" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r326", "r327", "r771", "r772", "r773", "r774", "r775", "r776" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/AACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails", "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r48", "r52", "r220", "r804", "r847", "r848", "r944", "r945", "r946", "r961", "r962", "r963" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income", "verboseLabel": "Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofAccumulatedOtherComprehensiveIncomeLossDetails", "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r45", "r52", "r220", "r327", "r328", "r772", "r773", "r774", "r775", "r776", "r944" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Items" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Weighted Average Life" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionSIADetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r24", "r924" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdoptionof202006Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r24" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r681", "r682", "r683", "r961", "r962", "r963", "r1047" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r83", "r120" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "verboseLabel": "Amortization expense" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": { "auth_ref": [ "r146" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.", "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt", "terseLabel": "Share repurchase and equity component of the convertible note issuance, net" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r189", "r190", "r641" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r674" ], "calculation": { "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofEmployeeStockBasedCompensationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "netLabel": "Share-based compensation expense recognized", "terseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofEmployeeStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "calculation": { "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofEmployeeStockBasedCompensationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Expense, after Tax", "totalLabel": "Net effect on net income" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofEmployeeStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForCreditLossMember": { "auth_ref": [ "r956", "r957", "r958", "r959", "r960" ], "lang": { "en-us": { "role": { "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]", "terseLabel": "SEC Schedule, 12-09, Allowance, Credit Loss" } } }, "localname": "AllowanceForCreditLossMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRollforwardofValuationforDoubtfulAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r311", "r433", "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Trade accounts receivable, allowances" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r57", "r520", "r782", "r949" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Incremental financing cost expense" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r83", "r113", "r120" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "negatedLabel": "Amortization", "verboseLabel": "Intangible asset amortization" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Shares excluded from computation as their effect would be antidilutive (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/NETINCOMEPERSHARENarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r1041" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r1041" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r263", "r276", "r306", "r338", "r407", "r413", "r419", "r437", "r485", "r486", "r488", "r489", "r490", "r492", "r494", "r496", "r497", "r733", "r737", "r761", "r924", "r991", "r992", "r1060" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r297", "r314", "r338", "r437", "r485", "r486", "r488", "r489", "r490", "r492", "r494", "r496", "r497", "r733", "r737", "r761", "r924", "r991", "r992", "r1060" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r8", "r131", "r295", "r296" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "totalLabel": "Total assets held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r645", "r646", "r647", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r669", "r670", "r671", "r672", "r673" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "verboseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofVestedandUnvestedRestrictedStockPerformanceStockandContractStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r228", "r232" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis Of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Buildings and building improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Leased facilities" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r726", "r915", "r916" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessAcquisitionNarrativeDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionSIADetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r203", "r204", "r726", "r915", "r916" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessAcquisitionNarrativeDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionSIADetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessAcquisitionNarrativeDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionSIADetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r732", "r948" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in fair value of contingent consideration and others" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r213" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to)" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessAcquisitionNarrativeDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r210", "r211", "r731" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration, cash payments due upon achievement of certain revenue-based performance milestones (up to)", "verboseLabel": "Contingent consideration, liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessAcquisitionNarrativeDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r210", "r212" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Business combination, contingent consideration, liability, current" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r210", "r212" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Business combination, contingent consideration, liability, noncurrent" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r206" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionSIADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability": { "auth_ref": [ "r205", "r206" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionSIADetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": { "auth_ref": [ "r206" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails": { "order": 6.0, "parentTag": "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets", "totalLabel": "Total current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionSIADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r206" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionSIADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r206" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Trade accounts receivable, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionSIADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": { "auth_ref": [ "r206" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionSIADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r206" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionSIADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": { "auth_ref": [ "r206" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails": { "order": 3.0, "parentTag": "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets", "terseLabel": "Deferred tax assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r206" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "terseLabel": "Deferred tax liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionSIADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r205", "r206" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails": { "order": 2.0, "parentTag": "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionSIADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r205", "r206" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventories, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionSIADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r206" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "totalLabel": "Total liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionSIADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "auth_ref": [ "r206" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "terseLabel": "Other long-term liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r206" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails": { "order": 7.0, "parentTag": "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r205", "r206" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails": { "order": 5.0, "parentTag": "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r206" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionSIADetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r14", "r92", "r104" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "BUSINESS" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/BUSINESS" ], "xbrltype": "textBlockItemType" }, "us-gaap_CallOptionMember": { "auth_ref": [ "r858", "r859", "r860", "r861", "r862", "r863" ], "lang": { "en-us": { "role": { "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option.", "label": "Call Option [Member]", "terseLabel": "Call Option" } } }, "localname": "CallOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r88", "r89", "r90" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Property and equipment purchases included in liabilities" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r85", "r300", "r882" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash And Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r79", "r85", "r91" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r79", "r255" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashDivestedFromDeconsolidation": { "auth_ref": [ "r72" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.", "label": "Cash Divested from Deconsolidation", "terseLabel": "Cash divested from deconsolidation" } } }, "localname": "CashDivestedFromDeconsolidation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging", "verboseLabel": "Cash Flow Hedges" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r307", "r308", "r309", "r338", "r372", "r376", "r378", "r380", "r388", "r389", "r437", "r485", "r488", "r489", "r490", "r496", "r497", "r527", "r528", "r530", "r531", "r532", "r761", "r881", "r938", "r951", "r965" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r160", "r161", "r162", "r163" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Warrant strike price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r140", "r478", "r479", "r866", "r990" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r961", "r962", "r1047" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized shares (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r23", "r924" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock; $0.01 par value; 240,000 authorized shares; 90,477 and 89,600 issued at December\u00a031, 2022 and 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r53", "r322", "r324", "r331", "r835", "r841" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income, net of tax" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r67", "r330", "r834", "r840" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r99", "r100", "r253", "r254", "r427", "r865" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r99", "r100", "r253", "r254", "r427", "r857", "r865" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r99", "r100", "r253", "r254", "r427", "r865", "r1069" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r273", "r392" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration Of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r99", "r100", "r253", "r254", "r427", "r865" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r218", "r889" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles Of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction-in-progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessAcquisitionNarrativeDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessAcquisitionNarrativeDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r995" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of Changes in Contract Assets and Contract Liabilities" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r536", "r538", "r559" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "periodEndLabel": "Contract asset, End of Period", "periodStartLabel": "Contract asset, Beginning of period" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetReclassifiedToReceivable": { "auth_ref": [ "r903" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time from transfer to receivable due to right to consideration becoming unconditional.", "label": "Contract with Customer, Asset, Reclassified to Receivable", "negatedTerseLabel": "Transferred to trade receivable from contract asset included in beginning of the year contract asset" } } }, "localname": "ContractWithCustomerAssetReclassifiedToReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r536", "r537", "r559" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Contract liability, End of Period", "periodStartLabel": "Contract liability, Beginning of Period" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r536", "r537", "r559" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Contract liabilities", "verboseLabel": "Short-term portion of contract liability" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r536", "r537", "r559" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Long-term portion of contract liability" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r560" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "negatedLabel": "Recognition of revenue included in beginning of year contract liability" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofChangesinContractAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r19", "r266", "r278" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible Debt", "terseLabel": "Convertible debt" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r145", "r498", "r499", "r510", "r511", "r512", "r516", "r517", "r518", "r519", "r520", "r897", "r898", "r899", "r900", "r901" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Debt" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtNoncurrent": { "auth_ref": [ "r39" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.", "label": "Convertible Debt, Noncurrent", "terseLabel": "Long-term convertible securities" } } }, "localname": "ConvertibleDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS", "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdoptionof202006Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r108", "r412", "r413", "r414", "r415", "r421", "r969" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate and other" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r60", "r815" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSoldAmortization": { "auth_ref": [ "r947" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.", "label": "Cost, Amortization", "terseLabel": "Amortization of product technology" } } }, "localname": "CostOfGoodsAndServicesSoldAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofEmployeeStockBasedCompensationExpenseDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofRestructuringChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r58" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": { "auth_ref": [ "r136", "r137", "r139" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.", "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]", "terseLabel": "Employee Termination Benefits" } } }, "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CrossCurrencyInterestRateContractMember": { "auth_ref": [ "r998", "r1045" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.", "label": "Cross Currency Interest Rate Contract [Member]", "terseLabel": "Cross-Currency Interest Rate Swap", "verboseLabel": "Cross-currency swap" } } }, "localname": "CrossCurrencyInterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrencySwapMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.", "label": "Currency Swap [Member]", "terseLabel": "Currency Swap" } } }, "localname": "CurrencySwapMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofGainsandLossofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r954", "r1037", "r1039" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r954", "r1037" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r201", "r706", "r716", "r954" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r954", "r1037", "r1039" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r98", "r427" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer Relationships", "verboseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r149", "r337", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r514", "r521", "r522", "r524" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "DEBT" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBT" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r17", "r18", "r19", "r264", "r266", "r275", "r345", "r498", "r499", "r500", "r501", "r502", "r504", "r510", "r511", "r512", "r513", "r515", "r516", "r517", "r518", "r519", "r520", "r783", "r897", "r898", "r899", "r900", "r901", "r952" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails", "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Interest rates available to the company at its option" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": { "auth_ref": [ "r147" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.", "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component", "terseLabel": "Debt proceeds, classified as equity at time of offering" } } }, "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r148", "r500" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "verboseLabel": "Initial conversion price (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r38", "r153", "r154", "r156", "r500" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "verboseLabel": "Initial conversion rate" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r258", "r260", "r498", "r783", "r898", "r899" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Convertible notes, aggregate principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r512", "r760", "r898", "r899" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Fair value" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r37", "r258", "r526", "r783" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r37", "r499" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt, interest rate", "verboseLabel": "Convertible notes, interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails", "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r39", "r345", "r498", "r499", "r500", "r501", "r502", "r504", "r510", "r511", "r512", "r513", "r515", "r516", "r517", "r518", "r519", "r520", "r783", "r897", "r898", "r899", "r900", "r901", "r952" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails", "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Redemption price, percentage" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r39", "r153", "r155", "r156", "r157", "r257", "r258", "r260", "r272", "r345", "r498", "r499", "r500", "r501", "r502", "r504", "r510", "r511", "r512", "r513", "r515", "r516", "r517", "r518", "r519", "r520", "r523", "r783", "r897", "r898", "r899", "r900", "r901", "r952" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTMaximumTotalLeverageRatioTableDetails", "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtWeightedAverageInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of debt outstanding.", "label": "Debt, Weighted Average Interest Rate", "terseLabel": "Weighted average interest rate on debt" } } }, "localname": "DebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredCompensationPlanAssets": { "auth_ref": [ "r939" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.", "label": "Deferred Compensation Plan Assets", "terseLabel": "Deferred compensation plan, fair value of assets" } } }, "localname": "DeferredCompensationPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r954", "r1038", "r1039" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r259" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Capitalized incremental financing costs" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r201", "r954", "r1038" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r689", "r690" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets, net" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r83", "r201", "r707", "r715", "r716", "r954" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://integralife.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Total deferred", "verboseLabel": "Deferred income tax (benefit) provision" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://integralife.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r20", "r21", "r265", "r274", "r701" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r689", "r690" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liabilities", "verboseLabel": "Deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdoptionof202006Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r954", "r1038", "r1039" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards": { "auth_ref": [ "r199", "r1036" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 11.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.", "label": "Deferred Tax Assets, Charitable Contribution Carryforwards", "terseLabel": "Charitable contributions carryforward" } } }, "localname": "DeferredTaxAssetsCharitableContributionCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "auth_ref": [ "r199", "r1036" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.", "label": "Deferred Tax Assets, Deferred Income", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredTaxAssetsDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r702" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross [Abstract]", "terseLabel": "Assets:" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r199", "r1036" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "Deferred Tax Assets, Inventory", "terseLabel": "Inventory related items" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r1035" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Total net deferred tax assets (liabilities)" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r1035" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Deferred tax assets after valuation allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r199", "r1036" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration", "terseLabel": "Operating loss carryforwards, not subject to expiration" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "terseLabel": "Operating loss carryforwards, subject to expiration" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r198", "r199", "r1036" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "verboseLabel": "Tax credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses": { "auth_ref": [ "r199", "r1036" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee bonuses.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Bonuses", "terseLabel": "Accrued bonus" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r199", "r1036" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "terseLabel": "Stock compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "auth_ref": [ "r199", "r1036" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.", "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Doubtful accounts" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses": { "auth_ref": [ "r199", "r1036" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 10.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.", "label": "Deferred Tax Assets, Unrealized Currency Losses", "terseLabel": "Unrealized foreign exchange gain" } } }, "localname": "DeferredTaxAssetsUnrealizedCurrencyLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r703" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r192", "r1035" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "totalLabel": "Total net deferred tax assets (liabilities)" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": { "auth_ref": [ "r199", "r1036" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets", "negatedLabel": "Intangible and fixed assets" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": { "auth_ref": [ "r596" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.", "label": "Defined Benefit Plan, Accumulated Benefit Obligation", "terseLabel": "Accumulated benefit obligation" } } }, "localname": "DefinedBenefitPlanAccumulatedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax": { "auth_ref": [ "r52", "r608" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax", "terseLabel": "Gain (loss) recognized within accumulated other comprehensive loss" } } }, "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "auth_ref": [ "r578", "r913" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "terseLabel": "Actual return on plan assets" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofChangeinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "auth_ref": [ "r571" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "negatedTerseLabel": "Actuarial (gain) loss" } } }, "localname": "DefinedBenefitPlanActuarialGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofChangeinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r564", "r603", "r628", "r913", "r914" ], "calculation": { "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofNetPeriodicBenefitCostsDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedTerseLabel": "Recognized actuarial losses" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r564", "r604", "r629", "r913", "r914" ], "calculation": { "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofNetPeriodicBenefitCostsDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "terseLabel": "Amortization of prior service cost (credit)" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssetsExpectedToBeReturnedToEmployerAmount": { "auth_ref": [ "r288" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of defined benefit plan asset expected to be returned to employer within one year or operating cycle, if longer, following current fiscal year.", "label": "Defined Benefit Plan, Plan Assets, Expected to be Returned to Employer, Amount", "terseLabel": "Plan assets expected to be returned next twelve months" } } }, "localname": "DefinedBenefitPlanAssetsExpectedToBeReturnedToEmployerAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "auth_ref": [ "r610" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofAssumptionsUsedPeriodicBenefitCostandActuarialPresentValueDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "auth_ref": [ "r612", "r633" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets", "terseLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofAssumptionsUsedPeriodicBenefitCostandActuarialPresentValueDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": { "auth_ref": [ "r611" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase", "terseLabel": "Rate of compensation increase" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofAssumptionsUsedPeriodicBenefitCostandActuarialPresentValueDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate": { "auth_ref": [ "r613" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average interest crediting rate used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate", "terseLabel": "Interest crediting rate for cash balance plans" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofAssumptionsUsedPeriodicBenefitCostandActuarialPresentValueDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "auth_ref": [ "r566" ], "calculation": { "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduledofFundedStatusDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation", "periodEndLabel": "Projected benefit obligations, end of year", "periodStartLabel": "Projected benefit obligations, beginning of year", "terseLabel": "Benefit obligations" } } }, "localname": "DefinedBenefitPlanBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduledofFundedStatusDetails", "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofChangeinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "auth_ref": [ "r573", "r636" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "negatedTerseLabel": "Benefit payment" } } }, "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofChangeinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": { "auth_ref": [ "r570" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation.", "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant", "terseLabel": "Employee contribution" } } }, "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofChangeinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "terseLabel": "Change In Projected Benefit Obligations" } } }, "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofChangeinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "terseLabel": "Change In Plan Assets" } } }, "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofChangeinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r580", "r590", "r632", "r911", "r912", "r913", "r914" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "netLabel": "Employer contributions" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofChangeinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "auth_ref": [ "r597" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "terseLabel": "Next five years" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofExpectedBenefitPaymentsandMinimumContributiononUnfundedPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "auth_ref": [ "r597" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "terseLabel": "2023" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofExpectedBenefitPaymentsandMinimumContributiononUnfundedPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "auth_ref": [ "r597" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "terseLabel": "2027" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofExpectedBenefitPaymentsandMinimumContributiononUnfundedPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "auth_ref": [ "r597" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "terseLabel": "2026" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofExpectedBenefitPaymentsandMinimumContributiononUnfundedPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "auth_ref": [ "r597" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "terseLabel": "2025" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofExpectedBenefitPaymentsandMinimumContributiononUnfundedPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "auth_ref": [ "r597" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "terseLabel": "2024" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofExpectedBenefitPaymentsandMinimumContributiononUnfundedPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": { "auth_ref": [ "r598", "r914" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year", "terseLabel": "Contributions expected to be paid to plan" } } }, "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r564", "r602", "r627", "r913", "r914" ], "calculation": { "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofNetPeriodicBenefitCostsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "auth_ref": [ "r577", "r588", "r590", "r591", "r911", "r912", "r913" ], "calculation": { "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduledofFundedStatusDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.", "label": "Defined Benefit Plan, Plan Assets, Amount", "periodEndLabel": "Plan assets at fair value, end of year", "periodStartLabel": "Plan assets at fair value, beginning of year", "terseLabel": "Benefit plans, assets", "verboseLabel": "Fair value of plan assets" } } }, "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSNarrativeDetails", "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduledofFundedStatusDetails", "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofChangeinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "auth_ref": [ "r572" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "negatedTerseLabel": "Effect of foreign currency exchange rates" } } }, "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofChangeinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "auth_ref": [ "r563", "r586", "r913" ], "calculation": { "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduledofFundedStatusDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "negatedTotalLabel": "Unfunded benefit obligations" } } }, "localname": "DefinedBenefitPlanFundedStatusOfPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduledofFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlanAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan [Abstract]", "terseLabel": "Reconciliation Of Funded Status" } } }, "localname": "DefinedBenefitPlanFundedStatusOfPlanAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduledofFundedStatusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r564", "r569", "r601", "r626", "r913", "r914" ], "calculation": { "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofNetPeriodicBenefitCostsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost", "verboseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofChangeinBenefitObligationsandPlanAssetsDetails", "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r599", "r624", "r913", "r914" ], "calculation": { "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofNetPeriodicBenefitCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Net period benefit cost" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAmendments": { "auth_ref": [ "r574" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment", "terseLabel": "Plan amendments" } } }, "localname": "DefinedBenefitPlanPlanAmendments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofChangeinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "auth_ref": [ "r582", "r1001" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "negatedTerseLabel": "Benefits paid" } } }, "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofChangeinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": { "auth_ref": [ "r581" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant", "terseLabel": "Employee contributions" } } }, "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofChangeinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r579" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Effect of foreign currency exchange rates" } } }, "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofChangeinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": { "auth_ref": [ "r565", "r606", "r631" ], "calculation": { "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofNetPeriodicBenefitCostsDetails": { "order": 6.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement", "negatedTerseLabel": "Settlements" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r567", "r600", "r625", "r913", "r914" ], "calculation": { "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofNetPeriodicBenefitCostsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost", "verboseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofChangeinBenefitObligationsandPlanAssetsDetails", "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofNetPeriodicBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": { "auth_ref": [ "r568" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement", "negatedTerseLabel": "Plan settlements" } } }, "localname": "DefinedBenefitPlanSettlementsBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofChangeinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "auth_ref": [ "r585" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "negatedLabel": "Plan settlements" } } }, "localname": "DefinedBenefitPlanSettlementsPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSScheduleofChangeinBenefitObligationsandPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r637" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Total contributions made" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r83", "r127" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]", "verboseLabel": "Derivative, Name [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofGainsandLossofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r44", "r230", "r261", "r315", "r886" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "terseLabel": "Total derivatives designated as hedges \u2014 Assets", "verboseLabel": "Derivative fair value" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r44", "r230", "r261", "r315", "r886" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "terseLabel": "Total derivatives designated as hedges \u2014 Liabilities" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "auth_ref": [ "r760" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives.", "label": "Derivative, Fair Value, Net", "terseLabel": "Fair Value Asset (Liability)", "verboseLabel": "Estimated Fair Value" } } }, "localname": "DerivativeFairValueOfDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "terseLabel": "Fixed Rate", "verboseLabel": "Fixed Interest Rate" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r229", "r231", "r235", "r237", "r886" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]", "verboseLabel": "Derivative, by Nature [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofGainsandLossofDerivativeInstrumentsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r248", "r745" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "DERIVATIVE INSTRUMENTS" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r226", "r229", "r235" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r226", "r229", "r235", "r237", "r241", "r242", "r743" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofGainsandLossofDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofGainsandLossofDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r234", "r1044" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "terseLabel": "Derivative instruments not designated as hedging instruments, gain (loss), net" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofGainsandLossofDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r1042", "r1043" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "netLabel": "Notional Amount", "terseLabel": "Aggregate Notional Amount", "verboseLabel": "Notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r221", "r222", "r223", "r226", "r227", "r233", "r235", "r238", "r240", "r242", "r745" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r221", "r222", "r226", "r227", "r239", "r344" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivatives" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DilutiveSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]", "terseLabel": "Effect of dilutive securities:" } } }, "localname": "DilutiveSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r558", "r904", "r905", "r906", "r907", "r908", "r909", "r910" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r996" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r644", "r676", "r677", "r679", "r685", "r918" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r125", "r132" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations" } } }, "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable": { "auth_ref": [ "r0", "r1", "r8", "r131" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable", "terseLabel": "Disposal group, payable recognized" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities": { "auth_ref": [ "r0", "r1", "r8", "r131" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities", "terseLabel": "Accrued compensation" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Sale of business, disposition price" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets": { "auth_ref": [ "r0", "r1", "r8", "r131" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails": { "order": 7.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as deferred tax assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Assets", "terseLabel": "Deferred tax assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities": { "auth_ref": [ "r0", "r1", "r8", "r131" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities", "terseLabel": "Deferred tax liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": { "auth_ref": [ "r0", "r1", "r8", "r131" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails": { "order": 5.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Goodwill", "terseLabel": "Goodwill" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": { "auth_ref": [ "r0", "r1", "r8", "r131" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Intangible Assets", "terseLabel": "Intangible assets, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": { "auth_ref": [ "r0", "r1", "r8", "r131" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Inventory", "terseLabel": "Inventories" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": { "auth_ref": [ "r0", "r1", "r8", "r131" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "auth_ref": [ "r0", "r1", "r8", "r126", "r131" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": { "auth_ref": [ "r0", "r1", "r8", "r131" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails": { "order": 6.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r915", "r916" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails", "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r332", "r361", "r362", "r363", "r364", "r365", "r370", "r372", "r378", "r379", "r380", "r384", "r755", "r756", "r836", "r842", "r892" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "netLabel": "Basic net income per common share (in dollars per share)", "verboseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "verboseLabel": "Basic net income per share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r332", "r361", "r362", "r363", "r364", "r365", "r372", "r378", "r379", "r380", "r384", "r755", "r756", "r836", "r842", "r892" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "netLabel": "Diluted net income per common share (in dollars per share)", "verboseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "verboseLabel": "Diluted net income per share:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r381", "r382", "r383", "r385" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET INCOME PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/NETINCOMEPERSHARE" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r770" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r692" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate", "totalLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails", "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]", "terseLabel": "Increase (decrease) in income taxes resulting from:" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r340", "r692", "r718" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r1032", "r1040" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Foreign operations" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent": { "auth_ref": [ "r1032" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI).", "label": "Effective Income Tax Rate Reconciliation, GILTI, Percent", "terseLabel": "Global intangible low-taxed income (\"GILTI\")" } } }, "localname": "EffectiveIncomeTaxRateReconciliationGiltiPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r1032", "r1040" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": { "auth_ref": [ "r1032", "r1040" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails": { "order": 13.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.", "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent", "terseLabel": "Return to provision" } } }, "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "auth_ref": [ "r1031", "r1032" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount", "negatedTerseLabel": "Effective income tax reconciliation, tax benefit, excess stock-based compensation deductions" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "auth_ref": [ "r1031", "r1032" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails": { "order": 14.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent", "terseLabel": "Excess tax benefits from stock compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r1032", "r1040" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State income taxes, net of federal tax benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r1032", "r1040" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails": { "order": 9.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "negatedTerseLabel": "Research and development credit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofEffectiveTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r675" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Amount Capitalized", "terseLabel": "Capitalized share-based compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofEmployeeStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r678" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized compensation costs related to unvested awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r678" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average period for cost recognition, in years" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r674" ], "calculation": { "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofEmployeeStockBasedCompensationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "terseLabel": "Total estimated tax benefit related to stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofEmployeeStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": { "auth_ref": [ "r680" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit", "terseLabel": "Tax benefit realized from stock options exercised" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Employee Stock Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r152", "r291", "r326", "r327", "r328", "r353", "r354", "r355", "r358", "r366", "r368", "r387", "r441", "r534", "r681", "r682", "r683", "r711", "r712", "r754", "r771", "r772", "r773", "r774", "r775", "r776", "r804", "r847", "r848", "r849" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/AACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails", "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofAccumulatedOtherComprehensiveIncomeLossDetails", "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EurodollarMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.", "label": "Eurodollar [Member]", "terseLabel": "Eurodollar Rate" } } }, "localname": "EurodollarMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExtendedProductWarrantyPolicy": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for extended product warranties and other guarantee contracts including the methodology for measuring the liability.", "label": "Extended Product Warranty, Policy [Policy Text Block]", "terseLabel": "Product Warranties" } } }, "localname": "ExtendedProductWarrantyPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r512", "r590", "r591", "r592", "r593", "r594", "r595", "r758", "r808", "r809", "r810", "r898", "r899", "r911", "r912", "r913" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r512", "r590", "r595", "r758", "r809", "r898", "r899", "r911", "r912", "r913" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "verboseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r512", "r590", "r591", "r592", "r593", "r594", "r595", "r758", "r810", "r898", "r899", "r911", "r912", "r913" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r249", "r252" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r249", "r252" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of Contingent Consideration" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r759" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "negatedLabel": "Change in fair value of contingent consideration liabilities", "verboseLabel": "Change in fair value of contingent consideration liabilities" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": { "auth_ref": [ "r250" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases", "terseLabel": "Additions" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r249" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance, End of Period", "periodStartLabel": "Balance, Beginning of Period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r512", "r590", "r591", "r592", "r593", "r594", "r595", "r808", "r809", "r810", "r898", "r899", "r911", "r912", "r913" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r228", "r233", "r241" ], "lang": { "en-us": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "auth_ref": [ "r1046" ], "lang": { "en-us": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.", "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]", "terseLabel": "Overnight Federal Funds Rate" } } }, "localname": "FederalFundsEffectiveSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r797" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, to be Paid", "terseLabel": "Future minimum lease payments, finance leases" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Weighted Average Life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r304", "r464" ], "calculation": { "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails": { "order": 2.0, "parentTag": "iart_DefiniteAndIndefiniteLivedIntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "Expected annual amortization expense, thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r121" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "Expected annual amortization expense, 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r121" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "Expected annual amortization expense, 2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r121" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "Expected annual amortization expense, 2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r121" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "Expected annual amortization expense, 2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r121" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "Expected annual amortization expense, 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r461", "r463", "r464", "r466", "r816", "r820" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r114", "r119" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign Tax Authority" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "auth_ref": [ "r1049", "r1050" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Realized", "terseLabel": "Foreign currency transaction gain (loss)" } } }, "localname": "ForeignCurrencyTransactionGainLossRealized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r778" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign Currency Forward Contract" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofGainsandLossofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignPlanMember": { "auth_ref": [ "r1002", "r1003", "r1004" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Foreign Plan [Member]", "terseLabel": "Foreign Plan" } } }, "localname": "ForeignPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture, fixtures, and office equipment" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r229" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "terseLabel": "Gain (loss) recognized in other income" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfBusiness": { "auth_ref": [ "r736", "r949" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.", "label": "Gain (Loss) on Disposition of Business", "negatedTerseLabel": "Gain from the sale of businesses", "terseLabel": "Gain from sale of businesses" } } }, "localname": "GainLossOnSaleOfBusiness", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails", "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r303", "r449", "r833", "r895", "r924", "r973", "r980" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails": { "order": 1.0, "parentTag": "iart_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredIncludingGoodwill", "weight": 1.0 }, "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "End of period", "periodStartLabel": "Beginning of period", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionSIADetails", "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r451", "r895" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill acquisition" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETS" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r111", "r117" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill And Other Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r455" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency translation" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "auth_ref": [ "r453", "r895" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Written off Related to Sale of Business Unit", "negatedTerseLabel": "Sale of non-core traditional wound care business" } } }, "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r226", "r743" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r949", "r984" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-Lived", "terseLabel": "Non-cash impairment charges" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r339", "r717" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "United States operations" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r55", "r262", "r268", "r283", "r407", "r412", "r418", "r421", "r837", "r894" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://integralife.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://integralife.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r339", "r717" ], "calculation": { "http://integralife.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign operations" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofIncomeBeforeIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r915", "r916" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails", "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r1", "r2", "r3", "r4", "r5", "r6", "r7", "r9", "r10", "r11", "r12", "r132", "r133" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r467", "r471" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofEmployeeStockBasedCompensationExpenseDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofRestructuringChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofEmployeeStockBasedCompensationExpenseDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofRestructuringChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r195" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r195" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r340", "r693", "r699", "r705", "r713", "r719", "r723", "r724", "r725" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXES" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "auth_ref": [ "r1033" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.", "label": "Income Tax Examination, Penalties and Interest Accrued", "terseLabel": "Penalties and interest accrued" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r341", "r367", "r368", "r405", "r691", "r714", "r721", "r843" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://integralife.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision (benefit) for income taxes", "totalLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://integralife.com/role/INCOMETAXESScheduleofProvisionforIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r325", "r687", "r688", "r699", "r700", "r704", "r708" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationDispositionOfBusiness": { "auth_ref": [ "r1032" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation.", "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Amount", "terseLabel": "Tax expense related to sale of business" } } }, "localname": "IncomeTaxReconciliationDispositionOfBusiness", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r1032" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "terseLabel": "Effective income tax rate reconciliation, foreign income tax rate differential, increase (decrease), amount" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r1032" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount", "negatedTerseLabel": "Excess tax benefits from stock compensation" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": { "auth_ref": [ "r1032" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount", "negatedTerseLabel": "Effective Income Tax rate reconciliation, prior year income taxes, amount" } } }, "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r80", "r87" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r82" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable, accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r82" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r813", "r948" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Contract liabilities" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r82" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Other non-current liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r82" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other non-current assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r82" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "auth_ref": [ "r194" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase reasonably possible in the next twelve months for the unrecognized tax benefit.", "label": "Increase in Unrecognized Tax Benefits is Reasonably Possible", "terseLabel": "Increase in unrecognized tax benefits is reasonably possible" } } }, "localname": "IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r373", "r374", "r375", "r380", "r643" ], "calculation": { "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Stock options and restricted stock (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r462", "r465" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r116", "r122" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r112", "r118" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestCapitalizationPolicyPolicyTextBlock": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for interest capitalization.", "label": "Interest Capitalization, Policy [Policy Text Block]", "terseLabel": "Capitalized Interest" } } }, "localname": "InterestCapitalizationPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestCostsCapitalizedAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest costs capitalized disclosed as an adjusting item to interest costs incurred.", "label": "Interest Costs Capitalized Adjustment", "terseLabel": "Interest expense capitalized into property, plant, and equipment" } } }, "localname": "InterestCostsCapitalizedAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r259", "r270", "r329", "r401", "r781" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r66", "r519", "r900", "r901" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Cash interest" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which reported facts about interest income have been included.", "label": "Interest Income [Member]", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r950" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidCapitalized": { "auth_ref": [ "r888", "r950" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest capitalized, classified as investing activity.", "label": "Interest Paid, Capitalized, Investing Activities", "terseLabel": "Interest paid, capitalized into construction in progress" } } }, "localname": "InterestPaidCapitalized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r243" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "terseLabel": "Gain (loss) estimated to be reclassified to earnings during next twelve months" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r922" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "netLabel": "Interest rate swap" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r940" ], "calculation": { "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofInventoriesNetDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "verboseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofInventoriesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r313", "r883", "r924" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofInventoriesNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net", "totalLabel": "Total inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofInventoriesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r299", "r312", "r386", "r446", "r447", "r448", "r814", "r890" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r942" ], "calculation": { "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofInventoriesNetDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "verboseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofInventoriesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r941" ], "calculation": { "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofInventoriesNetDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "verboseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofInventoriesNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r63", "r400" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "negatedTerseLabel": "Interest income", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/AACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails", "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r997" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r1054" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]", "terseLabel": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r1054" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]", "terseLabel": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r792" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r1055" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Operating Lease Maturities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r797" ], "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r797" ], "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r797" ], "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r797" ], "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r797" ], "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r797" ], "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r797" ], "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r797" ], "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r791" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee, Operating Lease, Option to Extend", "terseLabel": "Period for extended lease" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r798" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES AND RELATED PARTY LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASES" ], "xbrltype": "textBlockItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of credit outstanding" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r34", "r338", "r437", "r485", "r486", "r488", "r489", "r490", "r492", "r494", "r496", "r497", "r734", "r737", "r738", "r761", "r893", "r991", "r1060", "r1061" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r28", "r267", "r280", "r924", "r953", "r971", "r1048" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r36", "r298", "r338", "r437", "r485", "r486", "r488", "r489", "r490", "r492", "r494", "r496", "r497", "r734", "r737", "r738", "r761", "r924", "r991", "r1060", "r1061" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r8", "r131", "r295", "r296" ], "calculation": { "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "totalLabel": "Total liabilities held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESAssetsandLiabilitiesDivestedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r19", "r266", "r275" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-Term Line of Credit", "terseLabel": "Line of credit facility outstanding" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Line of credit, commitment fee percentage" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": { "auth_ref": [ "r760" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of the amount outstanding under the credit facility.", "label": "Line of Credit Facility, Fair Value of Amount Outstanding", "terseLabel": "Line of credit facility, fair value of amount outstanding" } } }, "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r33" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates an ownership position in, or purchase of, a security.", "label": "Long [Member]", "terseLabel": "Long" } } }, "localname": "LongMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r19", "r266", "r278", "r511", "r525", "r898", "r899" ], "calculation": { "http://integralife.com/role/DEBTScheduleofDebtMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "totalLabel": "Principal Repayment" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTScheduleofDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r143", "r345", "r516" ], "calculation": { "http://integralife.com/role/DEBTScheduleofDebtMaturityDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTScheduleofDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r143", "r345", "r516" ], "calculation": { "http://integralife.com/role/DEBTScheduleofDebtMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTScheduleofDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r143", "r345", "r516" ], "calculation": { "http://integralife.com/role/DEBTScheduleofDebtMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTScheduleofDebtMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r39", "r144" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery and production equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "auth_ref": [ "r13", "r214" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "terseLabel": "ACQUISITIONS AND DIVESTITURES" } } }, "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURES" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r335" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r335" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r79", "r81", "r84" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r56", "r84", "r269", "r282", "r296", "r320", "r323", "r328", "r338", "r357", "r361", "r362", "r363", "r364", "r367", "r368", "r377", "r407", "r412", "r418", "r421", "r437", "r485", "r486", "r488", "r489", "r490", "r492", "r494", "r496", "r497", "r756", "r761", "r894", "r991" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedging", "verboseLabel": "Net Investment Hedges" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdoptionof202006Details" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r93", "r289", "r290", "r291", "r292", "r293", "r356", "r357", "r358", "r359", "r360", "r363", "r369", "r384", "r435", "r436", "r438", "r439", "r440", "r441", "r442", "r443", "r681", "r682", "r683", "r709", "r710", "r711", "r712", "r727", "r728", "r729", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r779", "r780", "r784", "r785", "r786", "r787", "r799", "r800", "r801", "r802", "r803", "r804", "r817", "r818", "r819", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdoptionof202006Details" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r425" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Total long-lived assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r968" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportingUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.", "label": "Number of Reporting Units", "terseLabel": "Number of reporting units" } } }, "localname": "NumberOfReportingUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r52", "r54" ], "calculation": { "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "terseLabel": "Other comprehensive gain (loss)" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r407", "r412", "r418", "r421", "r894" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating income", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r1053" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r789" ], "calculation": { "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r789" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "netLabel": "Less: Current lease liabilities", "terseLabel": "Current portion of lease liability - operating leases", "verboseLabel": "Current lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r789" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "netLabel": "Long-term lease liabilities", "terseLabel": "Lease liability - operating leases", "verboseLabel": "Non-current lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r790", "r793" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r788" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right of use asset - operating leases", "verboseLabel": "ROU assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r796", "r923" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r795", "r923" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r198" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r411", "r412", "r413", "r414", "r415", "r421" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OptionIndexedToIssuersEquityEquityAxis": { "auth_ref": [ "r151", "r244", "r245", "r247" ], "lang": { "en-us": { "role": { "documentation": "Information by type of options indexed to an issuer's equity.", "label": "Option Indexed to Issuer's Equity [Axis]", "terseLabel": "Option Indexed to Issuer's Equity [Axis]" } } }, "localname": "OptionIndexedToIssuersEquityEquityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityStrikePrice1": { "auth_ref": [ "r150", "r246" ], "lang": { "en-us": { "role": { "documentation": "Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.", "label": "Option Indexed to Issuer's Equity, Strike Price", "verboseLabel": "Initial strike price (in dollars per share)" } } }, "localname": "OptionIndexedToIssuersEquityStrikePrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.", "label": "Option Indexed to Issuer's Equity, Type [Domain]", "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]" } } }, "localname": "OptionIndexedToIssuersEquityTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r228", "r241" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r305" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesBeforeTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax [Abstract]", "terseLabel": "Unrealized gain (loss) on derivatives" } } }, "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesBeforeTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent": { "auth_ref": [ "r216", "r217", "r219" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent", "terseLabel": "Change in foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent": { "auth_ref": [ "r216", "r217", "r219" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive gain (loss), before tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive (loss) income, before tax:" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent": { "auth_ref": [ "r317" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax, Parent", "totalLabel": "Unrealized gain (loss) on derivatives" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r316", "r317", "r739", "r740", "r744" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "netLabel": "Gain (loss) recorded in AOCL, change in fair value", "terseLabel": "Unrealized derivative gain (loss) arising during period", "verboseLabel": "Amount\u00a0of Gain (Loss) Recognized\u00a0in AOCI" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r317", "r319" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "verboseLabel": "Amount\u00a0of\u00a0Gain\u00a0(Loss) Reclassified from AOCI into Earnings" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r317", "r319", "r741" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Less: Reclassification adjustments for gain (loss) included in net income" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r742" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Other comprehensive income (loss), net investment hedge, gain (loss), reclassification, before tax" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r216", "r217", "r219", "r321", "r324" ], "calculation": { "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofAccumulatedOtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive gain (loss), net of tax", "verboseLabel": "Other comprehensive loss, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofAccumulatedOtherComprehensiveIncomeLossDetails", "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": { "auth_ref": [ "r46", "r49", "r168" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax", "terseLabel": "Defined benefit pension plan - net gain (loss) arising during period" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r50", "r326", "r330", "r691", "r720", "r722", "r771", "r774", "r776", "r834", "r840" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Tax", "negatedTerseLabel": "Income tax (expense) benefit related to items in other comprehensive gain (loss)" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Accrued Expenses and Other Current Liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherDepreciationAndAmortization": { "auth_ref": [ "r61", "r83", "r127" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.", "label": "Other Depreciation and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "OtherDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesMember": { "auth_ref": [ "r228", "r241" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other liabilities.", "label": "Other Liabilities [Member]", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r40" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationBalanceInformationDetails", "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESFairValueContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r65" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/AACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails", "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other income, net" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r78" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "terseLabel": "Payment for contingent consideration" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities": { "auth_ref": [], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net cash outflow or inflow from derivative instruments during the period, which are classified as investing activities, excluding those designated as hedging instruments.", "label": "Payments for (Proceeds from) Derivative Instrument, Investing Activities", "negatedTerseLabel": "Net proceeds (payments) on swaps designated as net investment hedges" } } }, "localname": "PaymentsForProceedsFromDerivativeInstrumentInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r75" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Purchase of treasury stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r77" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r334" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedTerseLabel": "Cash taxes paid in net equity settlement" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r70", "r730" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Payments to acquire business" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessAcquisitionNarrativeDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r71" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r587", "r589", "r595", "r614", "r616", "r617", "r618", "r619", "r620", "r634", "r635", "r637", "r639", "r913" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "RETIREMENT BENEFIT PLANS" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANS" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementPlansPolicy": { "auth_ref": [ "r169", "r174", "r175", "r176", "r177" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.", "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]", "terseLabel": "Pension Benefits" } } }, "localname": "PensionAndOtherPostretirementPlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Shares Units" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PositionAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by position taken for a security.", "label": "Position [Axis]", "terseLabel": "Position [Axis]" } } }, "localname": "PositionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PositionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates position taken for a security.", "label": "Position [Domain]", "terseLabel": "Position [Domain]" } } }, "localname": "PositionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockNoParValue": { "auth_ref": [ "r22", "r994" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, No Par Value", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized shares (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r22", "r924" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred Stock; no par value; 15,000 authorized shares; none outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r943" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSFairValueofDerivativeInstrumentsByBalanceSheetLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r74" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from convertible notes issuance" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r68" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from sale of business" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESDivestituresNarrativeDetails", "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "auth_ref": [ "r74" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.", "label": "Proceeds from Issuance of Secured Debt", "terseLabel": "Proceeds from borrowings of long-term indebtedness" } } }, "localname": "ProceedsFromIssuanceOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r73", "r187" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "terseLabel": "Cash received from option exercises and employee stock purchase plan" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r73" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from sale of stock purchase warrants", "verboseLabel": "Proceeds from warrant transactions" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r69" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sales of property and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r73", "r187" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercised stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment by Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r128", "r301" ], "calculation": { "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r130", "r281", "r838", "r924" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r130", "r867", "r868" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant And Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property, Plant and Equipment Balances and Corresponding Lives" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Useful Lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r333", "r445" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "negatedTerseLabel": "Provision (recoveries) for doubtful accounts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r52", "r54" ], "calculation": { "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "terseLabel": "Less: Amounts reclassified from accumulated other comprehensive income, net" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/AACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/AACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/AACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Uncertain Tax Benefits [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofUncertainTaxBenefitsReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r615", "r805", "r806" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r615", "r805", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r1059" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfSecuredDebt": { "auth_ref": [ "r76" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.", "label": "Repayments of Secured Debt", "negatedLabel": "Payments on debt" } } }, "localname": "RepaymentsOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r191" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofEmployeeStockBasedCompensationExpenseDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofRestructuringChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research And Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock Awards" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofVestedandUnvestedRestrictedStockPerformanceStockandContractStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r83", "r473", "r475", "r986" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Charges:" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofRestructuringChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r469", "r470", "r475", "r476" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofRestructuringChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r470", "r474" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Balance, end of the year", "periodStartLabel": "Balance, beginning of the year", "terseLabel": "Restructuring costs" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofRestructuringChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "auth_ref": [ "r470", "r476" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.", "label": "Restructuring Reserve, Accrual Adjustment", "terseLabel": "Payments and other adjustments" } } }, "localname": "RestructuringReserveAccrualAdjustment1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofRestructuringChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofRestructuringChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r25", "r158", "r279", "r851", "r856", "r924" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdoptionof202006Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r291", "r353", "r354", "r355", "r358", "r366", "r368", "r441", "r681", "r682", "r683", "r711", "r712", "r754", "r847", "r849" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanSponsorLocationAxis": { "auth_ref": [ "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r610", "r611", "r612", "r613", "r615", "r618", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r1002", "r1003", "r1004" ], "lang": { "en-us": { "role": { "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Axis]", "terseLabel": "Retirement Plan Sponsor Location [Axis]" } } }, "localname": "RetirementPlanSponsorLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanSponsorLocationDomain": { "auth_ref": [ "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r610", "r611", "r612", "r613", "r615", "r618", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r1002", "r1003", "r1004" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Domain]", "terseLabel": "Retirement Plan Sponsor Location [Domain]" } } }, "localname": "RetirementPlanSponsorLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r398", "r399", "r411", "r416", "r417", "r423", "r424", "r427", "r557", "r558", "r815" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "netLabel": "Total revenue", "terseLabel": "Total revenue, net", "verboseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r562", "r891" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition", "verboseLabel": "Revenue Recognition and Shipping and Handling Fees" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r539", "r540", "r541", "r542", "r543", "r544", "r547", "r548", "r561", "r562" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "REVENUES FROM CONTRACTS WITH CUSTOMERS" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERS" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r545" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Performance obligations expected to be satisfied" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeDetails", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeRevenueRemainingPerformanceObligationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeRevenueRemainingPerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Performance obligations expected to be satisfied, expected timing" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeRevenueRemainingPerformanceObligationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeRevenueRemainingPerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSNarrativeRevenueRemainingPerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueTransactionPriceMeasurementTaxExclusionPolicyTextBlock": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for election to exclude from measurement of transaction price tax assessed by governmental authority that are both imposed on and concurrent with specific revenue-producing transaction, and collected from customer. Includes, but is not limited to, sales, use, value-added and excise tax.", "label": "Revenue, Transaction Price Measurement, Tax Exclusion [Policy Text Block]", "terseLabel": "Taxes Collected from Customers" } } }, "localname": "RevenueTransactionPriceMeasurementTaxExclusionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r794", "r923" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r427", "r967" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Sales Revenue, Net" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r52", "r1051", "r1052" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Changes in Accumulated Other Comprehensive Loss" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "auth_ref": [ "r609" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "terseLabel": "Schedule of Weighted Average Assumptions Used" } } }, "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r913", "r1000" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]", "terseLabel": "Schedule of Benefit Obligations and Plan Assets" } } }, "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r203", "r204", "r726" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESBusinessAcquisitionNarrativeDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails", "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionSIADetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Summary Of Employee Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Provision for Income Taxes" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r39", "r153", "r155", "r156", "r157", "r257", "r258", "r260", "r272", "r898", "r900", "r955" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt Maximum Leverage Ratios" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r169", "r170", "r171", "r172", "r173" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r229", "r235", "r743" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Effect of Derivative Instruments Designated as Cash Flow Hedges on Statements of Operations" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Summary of Fair Value in Balance Sheet for Derivatives Designated as Hedging Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r221", "r222", "r223", "r226", "r227", "r233", "r235", "r238", "r240" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r1", "r2", "r3", "r4", "r5", "r6", "r7", "r9", "r10", "r11", "r12", "r132", "r133" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Schedule of Major Classes of Assets and Liabilities Held For Sale" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r966" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Basic And Diluted Net Income Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/NETINCOMEPERSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r185", "r188" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofEmployeeStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "terseLabel": "Schedule of Expected Benefit Payments" } } }, "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r114", "r119" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Components of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r895" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails", "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r895", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Changes in Carrying Amount of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r954" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of Income (Loss) Before Income Taxes" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r122", "r123" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Components of Indefinite-Lived Intangible Assets" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r16", "r29", "r30", "r31" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "verboseLabel": "Schedule of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of Contractual Repayments of Debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Schedule of Net Periodic Benefit Costs" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetFundedStatusTableTextBlock": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of net funded status of pension plans and/or other employee benefit plans.", "label": "Schedule of Net Funded Status [Table Text Block]", "terseLabel": "Schedule of Funded Status" } } }, "localname": "ScheduleOfNetFundedStatusTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/RETIREMENTBENEFITPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r93", "r94", "r96", "r97" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]", "terseLabel": "Schedule of Impact on Statement of Operations" } } }, "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule of Operating Leased Assets [Table]", "terseLabel": "Schedule of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESFutureMinimumLeasePaymentUnderOperatingLeasesCurrentPeriodDetails", "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r234", "r1044" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "terseLabel": "Derivatives Not Designated as Hedging Instruments" } } }, "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule of Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPropertyPlantandEquipmentBalancesandCorrespondingLivesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r469", "r470", "r471", "r472", "r475", "r476", "r477" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofRestructuringChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r134", "r135", "r138" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Restructuring and Related Costs" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r59", "r109" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Schedule of Geographic Revenue, by Area" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r105", "r106", "r107", "r111" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r105", "r106", "r107", "r111" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Net Sales and Profit, by Segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r179", "r180", "r182" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Activity [Table Text Block]", "verboseLabel": "Summary Of Restricted Stock, Performance Stock, and Contract Stock Activity" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r640", "r642", "r645", "r646", "r647", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r669", "r670", "r671", "r672", "r673" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-Based Compensation, Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofVestedandUnvestedRestrictedStockPerformanceStockandContractStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r178", "r180", "r182" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "verboseLabel": "Summary Of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "verboseLabel": "Summary Of Weighted-Average Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r921", "r1034" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Schedule of Uncertain Tax Benefits Reconciliation" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtCurrent": { "auth_ref": [ "r17", "r264", "r277" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "Secured Debt, Current", "terseLabel": "Current portion of borrowings under senior credit facility", "verboseLabel": "Term loan component of senior credit facility, classified as current" } } }, "localname": "SecuredDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS", "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SecuredLongTermDebt": { "auth_ref": [ "r39" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.", "label": "Secured Long-Term Debt, Noncurrent", "terseLabel": "Long-term borrowings under senior credit facility" } } }, "localname": "SecuredLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r395", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r421", "r427", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r472", "r477", "r895", "r1068" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r395", "r396", "r397", "r407", "r410", "r415", "r419", "r420", "r421", "r422", "r423", "r426", "r427", "r428" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "SEGMENT AND GEOGRAPHIC INFORMATION" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTotalRevenuebyMajorGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting Information, Operating Income (Loss) [Abstract]", "terseLabel": "Segment Net Sales" } } }, "localname": "SegmentReportingInformationOperatingIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingInformationProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting Information, Profit (Loss) [Abstract]", "terseLabel": "Segment Profit" } } }, "localname": "SegmentReportingInformationProfitLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r62" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofEmployeeStockBasedCompensationExpenseDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofRestructuringChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r82" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r918" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "terseLabel": "Requisite service periods of performance stock, restricted stock and contract stock awards, in years" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r918" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r662" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Cancellations (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofVestedandUnvestedRestrictedStockPerformanceStockandContractStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r662" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Cancellations (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofVestedandUnvestedRestrictedStockPerformanceStockandContractStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r660" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofVestedandUnvestedRestrictedStockPerformanceStockandContractStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r660" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofVestedandUnvestedRestrictedStockPerformanceStockandContractStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r657", "r658" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested at end of year (in shares)", "periodStartLabel": "Unvested at beginning of year (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofVestedandUnvestedRestrictedStockPerformanceStockandContractStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofVestedandUnvestedRestrictedStockPerformanceStockandContractStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r657", "r658" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested at end of year (in dollars per share)", "periodStartLabel": "Unvested at beginning of year (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofVestedandUnvestedRestrictedStockPerformanceStockandContractStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value Per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofVestedandUnvestedRestrictedStockPerformanceStockandContractStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r661" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Released (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofVestedandUnvestedRestrictedStockPerformanceStockandContractStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r664" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Fair value of shares vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r661" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Released (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofVestedandUnvestedRestrictedStockPerformanceStockandContractStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r671" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r672" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r670" ], "lang": { "en-us": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofVestedandUnvestedRestrictedStockPerformanceStockandContractStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r920" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Common stock reserved for issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for purchase (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r651" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at end of year (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r651" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Exercisable at end of year (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r664" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value, options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r655" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited or Expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r1012" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r663" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value of options granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofWeightedAverageAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r186" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r649", "r650" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of year (in shares)", "periodStartLabel": "Outstanding at beginning of year (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r649", "r650" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Outstanding at end of year (in dollars per share)", "periodStartLabel": "Weighted Average Exercise Price, Outstanding at beginning of year (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r665" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested or expected to vest at end of year (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "terseLabel": "Shares issued (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r645", "r646", "r647", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r669", "r670", "r671", "r672", "r673" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofVestedandUnvestedRestrictedStockPerformanceStockandContractStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r655" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Forfeited or Expired (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r653" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r648", "r667", "r668", "r669", "r670", "r673", "r684", "r685" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r919" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Expiration period, in years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r669" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life of option from grant date" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofWeightedAverageAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r186" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercisable at end of year" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Contractual Term in Years, Exercisable at end of year" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Contractual Term in Years, Outstanding at end of year" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance, End of Period (in shares)", "periodStartLabel": "Balance, Beginning of Period (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates the sale of a borrowed security or written option.", "label": "Short [Member]", "terseLabel": "Short" } } }, "localname": "ShortMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DERIVATIVEINSTRUMENTSNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofCrossCurrencySwapDerivativesDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofNetInvestmentHedgesDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r92", "r336" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_StandbyLettersOfCreditMember": { "auth_ref": [ "r142", "r215", "r284", "r484" ], "lang": { "en-us": { "role": { "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.", "label": "Standby Letters of Credit [Member]", "terseLabel": "Standby Letters of Credit" } } }, "localname": "StandbyLettersOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and Local Jurisdiction" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r294", "r395", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r421", "r427", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r468", "r472", "r477", "r895", "r1068" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "http://integralife.com/role/REVENUESFROMCONTRACTSWITHCUSTOMERSScheduleofRevenuesDisaggregatedbyMajorSourceDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails", "http://integralife.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNetSalesandProfitbyReportableSegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r307", "r308", "r309", "r338", "r372", "r376", "r378", "r380", "r388", "r389", "r437", "r485", "r488", "r489", "r490", "r496", "r497", "r527", "r528", "r530", "r531", "r532", "r761", "r881", "r938", "r951", "r965" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACQUISITIONSANDDIVESTITURESFairValueAcquisitionACellDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r42", "r152", "r291", "r326", "r327", "r328", "r353", "r354", "r355", "r358", "r366", "r368", "r387", "r441", "r534", "r681", "r682", "r683", "r711", "r712", "r754", "r771", "r772", "r773", "r774", "r775", "r776", "r804", "r847", "r848", "r849" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/AACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSNarrativeDetails", "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofAccumulatedOtherComprehensiveIncomeLossDetails", "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r353", "r354", "r355", "r387", "r815" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r22", "r23", "r152", "r158" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock through employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r22", "r23", "r152", "r158" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock for vesting of share-based awards, net of shares withheld for taxes (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r22", "r23", "r152", "r158", "r654" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r22", "r23", "r152", "r158" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock through employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r22", "r23", "r158", "r181" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock for vesting of share-based awards, net of shares withheld for taxes" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock repurchase program, authorized amount (up to)" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Remaining amount under share repurchase" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r22", "r23", "r152", "r158" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedTerseLabel": "Accelerated shares repurchased (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r22", "r23", "r152", "r158" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Accelerated shares repurchased" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r23", "r26", "r27", "r110", "r924", "r953", "r971", "r1048" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance, End of Period", "periodStartLabel": "Balance, Beginning of Period", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSScheduleofAccumulatedOtherComprehensiveIncomeLossDetails", "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS", "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://integralife.com/role/DERIVATIVEINSTRUMENTSEffectofDerivativeInstrumentsDesignatedCashFlowHedgesonStatementsofOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]", "terseLabel": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r777", "r807" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r777", "r807" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r777", "r807" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.", "label": "Summary of Valuation Allowance [Table Text Block]", "terseLabel": "Summary of Valuation Allowance" } } }, "localname": "SummaryOfValuationAllowanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESTables", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SwissFederalTaxAdministrationFTAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of Switzerland.", "label": "Swiss Federal Tax Administration (FTA) [Member]", "terseLabel": "Switzerland" } } }, "localname": "SwissFederalTaxAdministrationFTAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Text Block [Abstract]" } } }, "localname": "TextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r285", "r286", "r287", "r431", "r432", "r434" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Trade Accounts Receivable And Allowances For Doubtful Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "verboseLabel": "Codman trade name" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSComponentsofCompanysIdentifiableIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "terseLabel": "Treasury stock, average cost per share (in dollars per share)" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "terseLabel": "Treasury stock outstanding (in shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockCommonValue": { "auth_ref": [ "r43", "r160", "r163" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Value", "terseLabel": "Treasury stock" } } }, "localname": "TreasuryStockCommonValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r41", "r160" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r41", "r160" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "negatedPeriodEndLabel": "Balance, End of Period, Treasury Stock (in shares)", "negatedPeriodStartLabel": "Balance, Beginning of Period, Treasury Stock (in shares)", "terseLabel": "Treasury stock, at cost; shares (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r23", "r152", "r158" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Accelerated share repurchases, shares received at inception" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/TREASURYSTOCKNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockTextBlock": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Treasury Stock [Text Block]", "terseLabel": "TREASURY STOCK" } } }, "localname": "TreasuryStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/TREASURYSTOCK" ], "xbrltype": "textBlockItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r41", "r160", "r163" ], "calculation": { "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost; 6,823 and 4,899 shares at December\u00a031, 2022 and 2021, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r469", "r470", "r475", "r476" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r686", "r695" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Balance, end of year", "periodStartLabel": "Balance, beginning of year" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofUncertainTaxBenefitsReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r694" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Penalties and interest expense" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r697" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Current year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofUncertainTaxBenefitsReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r696" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Prior years' tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESScheduleofUncertainTaxBenefitsReconciliationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r698" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r101", "r102", "r103", "r390", "r391", "r393", "r394" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use Of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Valuation Allowance [Line Items]", "terseLabel": "Valuation Allowance [Line Items]" } } }, "localname": "ValuationAllowanceLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESTaxValuationAllowanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": { "auth_ref": [ "r956", "r957", "r958", "r959", "r960" ], "lang": { "en-us": { "role": { "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.", "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset" } } }, "localname": "ValuationAllowanceOfDeferredTaxAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESTaxValuationAllowanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowanceTable": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "A listing of an entity's valuation allowances to reduce deferred tax assets to amounts which it is more likely than not will not be realized, including a description of the deferred tax assets for which the valuation allowance has been recorded and the amount of the valuation allowance.", "label": "Valuation Allowance [Table]", "terseLabel": "Valuation Allowance [Table]" } } }, "localname": "ValuationAllowanceTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESTaxValuationAllowanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r346", "r352" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Balance at End of Period", "periodStartLabel": "Balance at Beginning of Period" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESTaxValuationAllowanceDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRollforwardofValuationforDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r349" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "terseLabel": "Charged to Costs and Expenses" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESTaxValuationAllowanceDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRollforwardofValuationforDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": { "auth_ref": [ "r350" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account", "terseLabel": "Other" } } }, "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESTaxValuationAllowanceDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRollforwardofValuationforDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r351" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedTerseLabel": "Deductions" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESTaxValuationAllowanceDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRollforwardofValuationforDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r346", "r347", "r348", "r351", "r352" ], "lang": { "en-us": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESTaxValuationAllowanceDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRollforwardofValuationforDoubtfulAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r346", "r347", "r348", "r351", "r352" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/INCOMETAXESTaxValuationAllowanceDetails", "http://integralife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRollforwardofValuationforDoubtfulAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails", "http://integralife.com/role/DERIVATIVEINSTRUMENTSScheduleofInterestRateSwapDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VehiclesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment used primarily for road transportation.", "label": "Vehicles [Member]", "terseLabel": "Leased vehicles" } } }, "localname": "VehiclesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/LEASESANDRELATEDPARTYLEASESSupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r371", "r380" ], "calculation": { "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average common shares for diluted earnings per share (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average common shares outstanding (See Note 13):" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r370", "r380" ], "calculation": { "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average common shares outstanding - Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://integralife.com/role/NETINCOMEPERSHAREBasicandDilutedNetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.", "label": "Write off of Deferred Debt Issuance Cost", "terseLabel": "Previously capitalized financing costs, written-off" } } }, "localname": "WriteOffOfDeferredDebtIssuanceCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://integralife.com/role/DEBTNarrativeDetails" ], "xbrltype": "monetaryItemType" } }, "unitCount": 13 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1000": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1001": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1002": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1003": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1004": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1005": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1006": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1007": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1008": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1009": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1010": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1011": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1012": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1013": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1014": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1015": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1016": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1017": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1018": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1019": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1020": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1021": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1022": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1023": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1024": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1025": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1026": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1027": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1028": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1029": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1030": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1031": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1032": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1033": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1034": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1035": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1036": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1037": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1038": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1039": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1040": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1041": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1042": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1043": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1044": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1045": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(6)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1046": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1047": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1048": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1049": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1050": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1051": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1052": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1053": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1054": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1055": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1056": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1057": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1058": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1059": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1060": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1061": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1062": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1063": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1064": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1065": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1066": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1067": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1068": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1069": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=2122178", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907907&loc=d3e12803-110250", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466103&loc=SL6014347-161799", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "63", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=126970277&loc=d3e23176-110880", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405686&loc=d3e22802-112653", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/subtopic&trid=2208821", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r214": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90193-114008", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90198-114008", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r248": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org/topic&trid=2229140", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(t)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "32", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919569&loc=SL82860478-203043", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "https://asc.fasb.org/topic&trid=2134417", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r685": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r725": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r778": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r798": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r818": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r819": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r820": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r821": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r822": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r823": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r824": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r825": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r826": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r827": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r828": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r829": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r830": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r831": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r832": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r833": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r834": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r835": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r837": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r838": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r839": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r840": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r841": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r842": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r843": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r844": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r845": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r846": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r847": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r848": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r849": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r850": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r851": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r852": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r853": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r854": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r855": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r856": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r857": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r858": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column B)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r859": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column C)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r860": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column D)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r861": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column E)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r862": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column F)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r863": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r864": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r865": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r866": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r867": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r868": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r869": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r870": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r871": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r872": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r873": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r874": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r875": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r876": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r877": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r878": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r879": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r880": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r881": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r882": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r883": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r884": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r885": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r886": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r887": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r888": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r889": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r890": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r891": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r892": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r893": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r894": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r895": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r896": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r897": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r898": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r899": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r900": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r901": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r902": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r903": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r904": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r905": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r906": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r907": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r908": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r909": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r910": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r911": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r912": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r913": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r914": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r915": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r916": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r917": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r918": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r919": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r920": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r921": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r922": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r923": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r924": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r925": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r926": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r927": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r928": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r929": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r930": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r931": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r932": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r933": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r934": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r935": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r936": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r937": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r938": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r939": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r940": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r941": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r942": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r943": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r944": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r945": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r946": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r947": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(2))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r948": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r949": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r950": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r951": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r952": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r953": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r954": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r955": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r956": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r957": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r958": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r959": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e725-108305", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r960": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r961": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r962": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r963": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r964": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r965": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r966": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r967": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r968": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r969": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e765-108305", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r970": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r971": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r972": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r973": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r974": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r975": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r976": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r977": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r978": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r979": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r980": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r981": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r982": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r983": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r984": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r985": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r986": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r987": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r988": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r989": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r990": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r991": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r992": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r993": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r994": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r995": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r996": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r997": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r998": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r999": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" } }, "version": "2.2" } ZIP 132 0000917520-23-000015-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000917520-23-000015-xbrl.zip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

  •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�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end

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